PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA				HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA			FACTORS THAT PROMPTED FAMILIES TO FILE MEDICAL MALPRACTICE CLAIMS FOLLOWING PERINATAL INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMATION; CARE	Objective. - To identify self-reported reasons that prompt families to file malpractice claims following perinatal injuries. Design. - Families were interviewed by telephone using a questionnaire that contained structured and open-ended questions. Participants. - Mothers of infants who had experienced permanent injuries or deaths and had closed malpractice claims in Florida between 1986 and August 1989 were interviewed. Questionnaires were completed by 127 (35%) of a total of 368 such families. Outcome Measures. - Reasons prompting families to file and families' descriptions of medical events, advice from acquaintances, and the quality of physician-family communication. Results. - Families volunteered numerous reasons for filing: advised by knowledgeable acquaintances (33% of respondents), recognized cover-up (24%), needed money (24%), recognized that their child would have no future (23%), needed information (20%), and decided to seek revenge or protect others from harm (19%). Over one third of all families indicated that they were told by medical personnel prior to filing that the care provided had caused their children's injuries. Families expressed dissatisfaction with physician-patient communication. Families believed that physicians would not listen (13% of sample), would not talk openly (32%), attempted to mislead them (48%), or did not warn about long-term neurodevelopmental problems (70%). Conclusion. - Families give many reasons for filing a claim. Obtaining money may not be the only goal for some families who file suit.	VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37240; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN 37240; VANDERBILT UNIV,INST PUBL POLICY STUDIES,CTR HLTH POLICY,NASHVILLE,TN 37240; VANDERBILT UNIV,DEPT ECON,NASHVILLE,TN 37240	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University				Clayton, Ellen/0000-0002-0308-4110				ALDRICH J, 1975, AM J POLIT SCI, V19, P571, DOI 10.2307/2110547; [Anonymous], 1986, COSTS COMPENSATION P; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1985, MED MALPRACTICE THEO; FADEN RR, 1981, MED CARE, V19, P718, DOI 10.1097/00005650-198107000-00003; Felstiner William L. F., 1980, LAW SOC REV, V15, P631; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; KASTELER J, 1976, J HEALTH SOC BEHAV, V17, P328, DOI 10.2307/2136711; Katz J., 1984, SILENT WORLD DOCTOR; KORSCH BM, 1968, PEDIATRICS, V42, P855; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Kruse J, 1988, Fam Med, V20, P422; Kubler-Ross E., 1969, DEATH DYING; LAVERY JP, 1988, OBSTET GYNECOL, V71, P138; MARTIN CJ, 1987, STAT MED, V6, P613, DOI 10.1002/sim.4780060510; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; SLOAN FA, 1991, LAW CONTEMP PROBL, V54, P131, DOI 10.2307/1191857; SLOAN FA, 1990, LAW SOC REV, V24, P601; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WHITCHERALAGNA S, 1989, W J MED, V150, P356; Wolf S M, 1988, Law Med Health Care, V16, P197; 1991, DHHS PHS911232 US DE; 1990, BESTS REV PROPERTY C, V91, P42; 1987, MED MALPRACTICE CHAR; 1990, COST MED PROFESSIONA; 1969, PROFESSIONAL LIABILI, P980; 1990, BESTS REV PROPERTY C, V91, P117; 1989, MED LIABILITY ITS IM, P1; 1977, MED INSURANCE FEASIB; 1990, PATIENTS DOCTORS LAW	36	323	325	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1359	1363		10.1001/jama.267.10.1359	http://dx.doi.org/10.1001/jama.267.10.1359			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740858				2022-12-24	WOS:A1992HG67800029
J	KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD				KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD			SSN6-TUP1 IS A GENERAL REPRESSOR OF TRANSCRIPTION IN YEAST	CELL			English	Article							UPSTREAM ACTIVATION SITE; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CATABOLITE REPRESSION; INVERTASE SYNTHESIS; GLUCOSE REPRESSION; S-CEREVISIAE; GENETIC INTERACTIONS; ALPHA-2 PRODUCT; CYC1 GENE	The homeodomain protein alpha-2 and the SRF-like protein Mcm1 are required to establish cell type in the yeast Saccharomyces cerevisiae. Together, these regulatory proteins recognize a specific DNA operator, marking a set of genes for transcriptional repression. In this paper, we show that occupancy of the operator by alpha-2-Mcm1 is not sufficient to bring about repression. Rather, repression is effected only when Ssn6 (a TPR protein) and Tup1 (a beta-transducin repeat protein) are also present in the cell. We show that Ssn6 represses transcription when brought to a promoter by a bacterial DNA-binding domain and that Tup1 is required for this repression. Based on these and other results, we propose that Ssn6-Tup1 is a general repressor of transcription in yeast, recruited to target promoters by a variety of sequence-specific DNA-binding proteins.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	University of California System; University of California San Francisco; Columbia University; Columbia University	KELEHER, CA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Alberts B., 2017, MOL BIOL CELL; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1, P495; AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CARLSON M, 1984, GENETICS, V107, P19; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EBINA Y, 1983, J BIOL CHEM, V258, P3258; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRIGGS DW, 1992, IN PRESS P NATL ACAD; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMONTT JF, 1980, GENETICS, V94, P899; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller J.H., 1972, EXPT MOL GENETICS; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NEIGEBORN L, 1987, GENETICS, V115, P247; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHAMHART DHJ, 1975, J BACTERIOL, V121, P747, DOI 10.1128/JB.121.3.747-752.1975; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW P E, 1990, New Biologist, V2, P111; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARK HC, 1980, GENETICS, V94, P921; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; TRUMBLY RJ, 1986, J BACTERIOL, V166, P1123, DOI 10.1128/jb.166.3.1123-1127.1986; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WILSON KL, 1984, MOL CELL BIOL, V4, P2420, DOI 10.1128/MCB.4.11.2420; WILSON KL, 1985, P NATL ACAD SCI USA, V83, P2536; WRIGHT RM, 1990, MOL CELL BIOL, V10, P1297, DOI 10.1128/MCB.10.3.1297; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F	72	587	598	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					709	719		10.1016/0092-8674(92)90146-4	http://dx.doi.org/10.1016/0092-8674(92)90146-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739976				2022-12-24	WOS:A1992HF44000011
J	TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y				TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y			DISAPPEARANCE OF THYROTROPIN-BLOCKING ANTIBODIES AND SPONTANEOUS-RECOVERY FROM HYPOTHYROIDISM IN AUTOIMMUNE-THYROIDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING INHIBITOR IMMUNOGLOBULINS; PRIMARY MYXEDEMA; HASHIMOTOS-THYROIDITIS; GOITROUS HYPOTHYROIDISM; RECEPTOR ANTIBODY; GRAVES-DISEASE; CELLS; GROWTH; FRTL-5; INVITRO	Background. Hypothyroidism may result from the production of antibodies that block the actions of thyrotropin. How often these thyrotropin-blocking antibodies are a cause of hypothyroidism and whether their production may cease, causing hypothyroidism to disappear, have not been extensively studied. Methods. We determined the frequency with which thyrotropin-blocking antibodies were present in 172 hypothyroid patients with goitrous autoimmune thyroiditis (Hashimoto's disease) and 64 hypothyroid patients with atrophic autoimmune thyroiditis (idiopathic primary hypothyroidism). For 6 to 11 years we then followed 21 of these patients who were found to have thyrotropin-blocking antibodies. They received levothyroxine therapy for 3.5 to 8 years, after which it was discontinued. At frequent intervals during this time we measured the patients' serum concentrations of thyroxine, triiodothyronine, thyrotropin, and thyrotropin-blocking antibodies (measured as immunoglobulins that inhibit thyrotropin binding and immunoglobulins that inhibit thyrotropin bioactivity). Results. Thyrotropin-blocking antibodies were detected in 9 percent of the patients with goitrous autoimmune thyroiditis and in 25 percent of those with atrophic autoimmune thyroiditis. Among the 21 patients studied serially while receiving levothyroxine, thyrotropin-blocking antibodies disappeared in 15 (group 1), 7 of whom had goiter initially, and persisted in 6 (group 2), none of whom had goiter initially. Levothyroxine therapy was subsequently discontinued in these 21 patients. Six of those in group 1 (four with goiter) remained euthyroid (mean follow-up after discontinuation of therapy, 2.1 years), and nine became hypothyroid again within 3 months. All six patients in group 2 remained hypothyroid. Conclusions. Hypothyroidism in some patients with autoimmune thyroiditis may be due to thyrotropin-blocking antibodies. The production of thyrotropin-blocking antibodies may subside, producing remissions of hypothyroidism. Chronic autoimmune thyroiditis may therefore cause transient as well as permanent hypothyroidism.			TAKASU, N (corresponding author), SHINSHU UNIV,SCH MED,DEPT GERONTOL ENDOCRINOL & METAB,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							AMINO N, 1977, ANN INTERN MED, V87, P155, DOI 10.7326/0003-4819-87-2-155; ARIKAWA K, 1985, J CLIN ENDOCR METAB, V60, P953, DOI 10.1210/jcem-60-5-953; BASTENIE PA, 1985, AM J MED, V79, P91, DOI 10.1016/0002-9343(85)90551-0; BUCHANAN WW, 1965, ARCH INTERN MED, V115, P411, DOI 10.1001/archinte.1965.03860160037006; CARLSON HE, 1980, ARCH INTERN MED, V140, P1675, DOI 10.1001/archinte.1980.00330230122034; CHIOVATO L, 1990, J CLIN ENDOCR METAB, V71, P40, DOI 10.1210/jcem-71-1-40; CHO BY, 1989, ACTA ENDOCRINOL-COP, V120, P99, DOI 10.1530/acta.0.1200099; ENDO K, 1978, J CLIN ENDOCR METAB, V46, P734, DOI 10.1210/jcem-46-5-734; Greerspan FS, 1991, BASIC CLIN ENDOCRINO, P188; HASHIM FA, 1986, CLIN ENDOCRINOL, V25, P275, DOI 10.1111/j.1365-2265.1986.tb01692.x; HOW J, 1980, LANCET, V2, P427; IIDA Y, 1987, J CLIN ENDOCR METAB, V64, P124, DOI 10.1210/jcem-64-1-124; KONISHI J, 1985, ANN INTERN MED, V103, P26, DOI 10.7326/0003-4819-103-1-26; KONISHI J, 1983, J CLIN ENDOCR METAB, V57, P544, DOI 10.1210/jcem-57-3-544; KRAIEM Z, 1987, CLIN ENDOCRINOL, V27, P409, DOI 10.1111/j.1365-2265.1987.tb01168.x; MATSUURA N, 1980, NEW ENGL J MED, V303, P738, DOI 10.1056/NEJM198009253031306; MORI T, 1987, ENDOCRINOL JAPON, V34, P237; NIKOLAI TF, 1989, AM J MED SCI, V297, P18, DOI 10.1097/00000441-198901000-00005; OCHI Y, 1976, ENDOCRINOL JAPON, V23, P183; OKAMURA K, 1978, ACTA ENDOCRINOL-COP, V88, P703, DOI 10.1530/acta.0.0880703; OKAMURA K, 1988, J CLIN ENDOCR METAB, V67, P720, DOI 10.1210/jcem-67-4-720; OKAMURA K, 1990, ACTA ENDOCRINOL-COP, V122, P107, DOI 10.1530/acta.0.1220107; SATO K, 1990, J CLIN ENDOCR METAB, V71, P855, DOI 10.1210/jcem-71-4-855; SATO K, 1988, CLIN ENDOCRINOL, V29, P231, DOI 10.1111/j.1365-2265.1988.tb01220.x; Smith B R, 1981, Methods Enzymol, V74 Pt C, P405; STEEL NR, 1984, BRIT MED J, V288, P1559, DOI 10.1136/bmj.288.6430.1559; TAJIRI J, 1986, J CLIN ENDOCR METAB, V63, P412, DOI 10.1210/jcem-63-2-412; TAKASU N, 1990, CLIN ENDOCRINOL, V33, P687, DOI 10.1111/j.1365-2265.1990.tb03906.x; TAKASU N, 1978, EUR J BIOCHEM, V90, P131, DOI 10.1111/j.1432-1033.1978.tb12583.x; TAKASU N, 1984, J ENDOCRINOL, V101, P189, DOI 10.1677/joe.0.1010189; TAKASU N, 1987, J CLIN ENDOCR METAB, V64, P239, DOI 10.1210/jcem-64-2-239; TAKASU N, 1990, LANCET, V336, P1084, DOI 10.1016/0140-6736(90)92567-2; TAKASU N, 1984, J CLIN ENDOCR METAB, V59, P142, DOI 10.1210/jcem-59-1-142; TAMAI H, 1990, CLIN ENDOCRINOL, V33, P699, DOI 10.1111/j.1365-2265.1990.tb03907.x; TAMAKI H, 1990, J CLIN ENDOCR METAB, V71, P1382, DOI 10.1210/jcem-71-5-1382; TANAKA H, 1987, ENDOCRINOL JAPON, V34, P689; TOKUDA Y, 1988, J CLIN ENDOCR METAB, V67, P251, DOI 10.1210/jcem-67-2-251; WERNER SC, 1978, THYROID, P843; YAMAMOTO M, 1983, ACTA ENDOCRINOL-COP, V102, P531, DOI 10.1530/acta.0.1020531; YAMAMOTO T, 1978, ANN INTERN MED, V88, P808, DOI 10.7326/0003-4819-88-6-808; YOSHINARI M, 1983, BRIT MED J, V287, P720, DOI 10.1136/bmj.287.6394.720	41	102	105	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					513	518		10.1056/NEJM199202203260803	http://dx.doi.org/10.1056/NEJM199202203260803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1732791				2022-12-24	WOS:A1992HD65800003
J	SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P				SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P			RESISTANCE TO ERYTHROMYCIN IN GROUP-A STREPTOCOCCI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-HEMOLYTIC STREPTOCOCCI; PYOGENES; LINCOSAMIDES; PHARYNGITIS; ANTIBIOTICS; INFECTIONS; PENICILLIN; MACROLIDES; PATTERN; ADULTS	Background. The use of erythromycin in Finland nearly tripled from 1979 to 1989. In 1988, we observed an unusually high frequency of resistance to erythromycin in group A streptococci in one geographic region. Because routine testing does not detect the sensitivity of these organisms to antibiotics, we initiated a national study to evaluate the extent of this resistance. Methods. We studied 272 isolates of group A streptococci obtained from blood cultures from 1988 through 1990. In 1990 we collected from six regional laboratories 3087 consecutive isolates from throat swabs and 1349 isolates from pus samples. Resistance was indicated by growth on blood agar containing 2-mu-g of erythromycin per milliliter after incubation in 5 percent carbon dioxide. We also evaluated the clinical importance of erythromycin resistance in a retrospective study of consecutive patients with pharyngitis. Results. The frequency of resistance to erythromycin in group A streptococci from blood cultures increased from 4 percent in 1988 to 24 percent in 1990. From January to December 1990, the frequency of resistance in isolates from throat swabs increased from 7 percent to 20 percent, and resistance in isolates from pus increased from 11 percent to 31 percent. In four communities within 50 km of each other, the frequency of erythromycin resistance ranged from 2 to 5 percent to 26 to 44 percent. Several distinct DNA restriction profiles and serotypes were found among resistant isolates from the same area, suggesting a multiclonal origin. The treatment of pharyngitis with erythromycin failed in 9 of 19 patients infected with erythromycin-resistant group A streptococci, as compared with 1 of 26 patients with erythromycin-susceptible isolates (47 percent vs. 4 percent, P = 0.008). Conclusions. In Finland since 1988 there has been a rapid and substantial increase in resistance to erythromycin in group A streptococci. The extent of this resistance is particularly serious since there are only a few alternative antibiotics available for peroral treatment of group A streptococcal infections.	NATL INST PUBL HLTH, OULU REG INST, OULU, FINLAND; NATL INST PUBL HLTH, DEPT BACTERIOL, OULU, FINLAND; UMEA UNIV, DEPT CLIN MICROBIOL, S-90187 UMEA, SWEDEN; HLTH CTR, Pargas, FINLAND; HLTH CTR, POYTYA, FINLAND; KUOPIO UNIV HOSP, DEPT CLIN MICROBIOL, KUOPIO, FINLAND; AURORA HOSP, SF-00250 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; SEINAJOKI CENT HOSP, SEINAJOKI, FINLAND; SOCIAL INSURANCE INST, SOCIAL SECUR RES INST, HELSINKI, FINLAND	Umea University; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Seinajoki Central Hospital	SEPPALA, H (corresponding author), NATL INST PUBL HLTH, ANTIMICROBIAL RES UNIT, POB 57, SF-20521 TURKU, FINLAND.		Huovinen, Pentti/C-1917-2009					[Anonymous], 1991, LANCET, V337, P651; BORZANI M, 1989, J CHEMOTHERAPY, V1, P35, DOI 10.1080/1120009X.1989.11738861; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; COL NF, 1987, REV INFECT DIS, V9, pS232; DIXON JMS, 1974, J INFECT DIS, V130, P351, DOI 10.1093/infdis/130.4.351; Fernandes P. B., 1987, Antimicrobic Newsletter, V4, P25, DOI 10.1016/0738-1751(87)90002-5; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; GUNN BA, 1977, J CLIN MICROBIOL, V5, P650; HOLMSTROM L, 1990, SCAND J INFECT DIS, V22, P179, DOI 10.3109/00365549009037900; HORAUD T, 1985, J ANTIMICROB CHEMOTH, V16, P111, DOI 10.1093/jac/16.suppl_A.111; HUOVINEN P, 1989, ANN INTERN MED, V110, P612, DOI 10.7326/0003-4819-110-8-612; ISTRE GR, 1981, ANTIMICROB AGENTS CH, V20, P244, DOI 10.1128/AAC.20.2.244; JARVINEN H, 1989, LANCET, V1, P1022; KAPLAN EL, 1991, EUR J CLIN MICROBIOL, V10, P55, DOI 10.1007/BF01964407; KOMAROFF AL, 1983, SCIENCE, V222, P927, DOI 10.1126/science.6415813; MAKELA PH, 1989, FINN MED J, V44, P419; MALMBORG AS, 1986, J ANTIMICROB CHEMOTH, V18, P293, DOI 10.1093/jac/18.3.293; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MAXTED WR, 1972, STREPTOCOCCI STREPTO, P256; MIYAMOTO Y, 1978, ANTIMICROB AGENTS CH, V13, P399, DOI 10.1128/AAC.13.3.399; PHILLIPS G, 1990, J ANTIMICROB CHEMOTH, V25, P723, DOI 10.1093/jac/25.4.723; SCOTT RJD, 1989, EPIDEMIOL INFECT, V102, P85, DOI 10.1017/S095026880002971X; SKJOLD SA, 1987, J INFECT DIS, V155, P1145, DOI 10.1093/infdis/155.6.1145; SPENCER RC, 1989, LANCET, V1, P168; STINGEMORE N, 1989, MED J AUSTRALIA, V150, P626, DOI 10.5694/j.1326-5377.1989.tb136725.x; TRALLERO EP, 1989, LANCET, V2, P444; WEISBLUM B, 1985, J ANTIMICROB CHEMOTH, V16, P63, DOI 10.1093/jac/16.suppl_A.63; WITTLER RR, 1990, AM J DIS CHILD, V144, P587, DOI 10.1001/archpedi.1990.02150290081033; ZACKRISSON G, 1988, SCAND J INFECT DIS, V20, P419, DOI 10.3109/00365548809032478; 1990, NLN PUBLICATION, V30; 1990, FINNISH STATISTICS M; 1982, NLN PUBLICATION, V8; 1986, NLN PUBLICATION, V14; 1990, ANTIMICROBIAL SUSCEP, V10	35	295	298	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					292	297		10.1056/NEJM199201303260503	http://dx.doi.org/10.1056/NEJM199201303260503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728733				2022-12-24	WOS:A1992HA99100003
J	WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB				WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB			PROGNOSTIC IMPORTANCE OF SOCIAL AND ECONOMIC-RESOURCES AMONG MEDICALLY TREATED PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; SMOKING CESSATION; HEART-DISEASE; A BEHAVIOR; SUPPORT; MORTALITY; SURVIVAL; STRESS; DEATH; EDUCATION	Objective. - To evaluate the hypothesis that diminished social and economic resources impact adversely on cardiovascular mortality in patients with coronary artery disease. Design. - Inception cohort study of patients undergoing cardiac catheterization from 1974 through 1980 and followed up through 1989. Setting. - Tertiary care university medical center. Patients. - Consecutive sample of 1965 medically treated patients with stenosis 75% or greater of at least one major coronary artery. Five hundred patients were not enrolled due to logistic problems; 33 refused; 64 had missing data on key medical variables. The final study population included 1368 patients, 82% male, with a median age of 52 years. Main Outcome Measure. - Survival time until cardiovascular death. Results. - Independent of all known baseline invasive and noninvasive medical prognostic factors, patients with annual household incomes of $40 000 or more had an unadjusted 5-year survival of 0.91, compared with 0.76 in patients with incomes of $10 000 or less (Cox model adjusted hazard ratio, 1.9; 95% confidence interval, 1.57 to 2.32; P = .002). Similarly, unmarried patients without a confidant had an unadjusted 5-year survival rate of 0.50, compared with 0.82 in patients who were married, had a confidant, or both (adjusted hazard ratio, 3.34; 95% confidence interval, 1.84 to 6.20; P < .0001). Conclusions. - Low levels of social and economic resources identify an important high-risk group among medically treated patients with coronary artery disease, independent of important medical prognostic factors. Additional study will be required to see if interventions to increase these resources improve prognosis.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,DURHAM,NC 27710	Duke University	WILLIAMS, RB (corresponding author), DUKE UNIV,MED CTR,DEPT PSYCHIAT,BEHAV MED RES CTR,POB 3926,DURHAM,NC 27710, USA.			Hlatky, Mark/0000-0003-4686-9441; Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, P01HL036587] Funding Source: NIH RePORTER; AHRQ HHS [HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-17670, P01 HL036587, HL-36587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAREFOOT JC, 1989, AM J CARDIOL, V64, P427, DOI 10.1016/0002-9149(89)90416-5; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHANDRA V, 1983, AM J EPIDEMIOL, V117, P320, DOI 10.1093/oxfordjournals.aje.a113544; Cohen S., 1985, SOCIAL SUPPORT HLTH, P3; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DOLISZNY KM, 1989, CIRCULATION, V80, P410; FLEMING R, 1982, J HUM STRESS, V8, P14, DOI 10.1080/0097840X.1982.9936110; FRASURESMITH N, 1985, PSYCHOSOM MED, V47, P431, DOI 10.1097/00006842-198509000-00003; GIANNETTI VJ, 1985, SOC SCI MED, V20, P241, DOI 10.1016/0277-9536(85)90237-0; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; House J.S., 1985, SOCIAL SUPPORT HLTH, P83, DOI DOI 10.1016/0883-0355(88)90010-9; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; Kaplan B H, 1977, Med Care, V15, P47, DOI 10.1097/00005650-197705001-00006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1989, CIRCULATION S2, V80, P409; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUBERMAN W, 1983, J CHRON DIS, V36, P151, DOI 10.1016/0021-9681(83)90089-9; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WIKLUND I, 1988, AM J EPIDEMIOL, V128, P786, DOI 10.1093/oxfordjournals.aje.a115032; WILLIAMS CA, 1985, AM J PUBLIC HEALTH, V75, P483, DOI 10.2105/AJPH.75.5.483; WILLIAMS RB, 1988, PSYCHOSOM MED, V50, P139, DOI 10.1097/00006842-198803000-00004	32	408	413	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					520	524		10.1001/jama.267.4.520	http://dx.doi.org/10.1001/jama.267.4.520			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729574				2022-12-24	WOS:A1992GZ43900027
J	BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT				BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT			CHRONIC CHLAMYDIA-TRACHOMATIS INFECTIONS IN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MONOCLONAL-ANTIBODIES; CONJUNCTIVITIS; CELLS	Objective. - To study the natural history of Chlamydia trachomatis infections in infants. Design. - Bacteriologic and serologic study of an inception cohort. Setting. - University of Washington Medical Center, Seattle. Participants. - Twenty-two infants with C trachomatis infections either not treated early in life or recurring after antimicrobial treatment. Main Outcome Measures. - Persistence of infection in various anatomic sites, antibody responses to specific serovars (serologic variants) of C trachomatis, and serovars of isolates from mothers and infants. Results. - The cumulative proportion of infants still infected at the age of 1 year was 35%. Infection persisted in the conjunctiva, nasopharynx, and oropharynx in one child for as long as 866 days (28.5 months), when she was cured by treatment. In none of the infants did serologic tests suggest acquisition of infection other than at birth. Isolates of C trachomatis from mothers and their respective infants were always of the same serovar. Conclusions. - Many infants infected with C trachomatis at birth remain infected for months or years in the absence of specific antimicrobial therapy. Such infections may be confused with those acquired by sexual abuse.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BELL, TA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.		, Holmes/K-6215-2019		NEI NIH HHS [EY-00219] Funding Source: Medline; NIAID NIH HHS [AI-16222, AI-12192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016222, P01AI012192] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES RC, 1985, J CLIN MICROBIOL, V22, P609, DOI 10.1128/JCM.22.4.609-613.1985; Freedman A, 1966, Trans Ophthalmol Soc U K, V86, P313; FUSTER CD, 1987, PEDIATRICS, V79, P235; HAMMERSCHLAG MR, 1982, PEDIATR INFECT DIS J, V1, P395, DOI 10.1097/00006454-198211000-00007; KUO CC, 1972, J INFECT DIS, V125, P665, DOI 10.1093/infdis/125.6.665; LEE ET, 1980, STATISTICAL METHODS, P127; MARDH PA, 1987, LANCET, V1, P804; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; MORDHORST CH, 1978, JAMA-J AM MED ASSOC, V239, P1765, DOI 10.1001/jama.239.17.1765; MORDHORST CH, 1971, AM J OPHTHALMOL, V71, P861, DOI 10.1016/0002-9394(71)90256-X; REES E, 1977, BRIT J VENER DIS, V53, P173; RETTIG PH, 1985, PEDIATR INFECT DIS, V3, P95; SANDSTROM I, 1988, ACTA PAEDIATR SCAND, V77, P207, DOI 10.1111/j.1651-2227.1988.tb10631.x; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; SCHACHTER J, 1987, NEW ENGL J MED, V316, P1023; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STENBERG K, 1986, LANCET, V2, P1278; Wang S., 1977, NONGONOCOCCAL URETHR, P237; WANG SP, 1985, J INFECT DIS, V152, P791, DOI 10.1093/infdis/152.4.791; WENTWORT.BB, 1974, APPL MICROBIOL, V27, P912, DOI 10.1128/AEM.27.5.912-916.1974; YODER BL, 1981, J CLIN MICROBIOL, V13, P1036, DOI 10.1128/JCM.13.6.1036-1039.1981; 1982, MMWR S2, V31, pS33	22	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					400	402		10.1001/jama.267.3.400	http://dx.doi.org/10.1001/jama.267.3.400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727964				2022-12-24	WOS:A1992GY43700039
J	SLATER, AFG; CERAMI, A				SLATER, AFG; CERAMI, A			INHIBITION BY CHLOROQUINE OF A NOVEL HEME POLYMERASE ENZYME-ACTIVITY IN MALARIA TROPHOZOITES	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; FERRIPROTOPORPHYRIN-IX; ANTIMALARIAL ACTIVITY; MECHANISM; HEMOZOIN; PIGMENT; PH	THE incidence of human malaria has increased during the past 20 years; 270 million people are now estimated to be infected with the parasite 1. An important contribution to this increase has been the appearance of malaria organisms resistant to quinoline-containing antimalarials such as chloroquine and quinine 2. These drugs accumulate in the acid food vacuoles of the intraerythrocytic-stage malaria parasite 3-5, although the mechanism of their specific toxicity in this organelle is uncertain. The primary function of the food vacuole is the proteolysis of ingested red cell haemoglobin 6,7 to provide the growing parasite with essential amino acids. Haemoglobin breakdown in the food vacuole releases haem, which if soluble can damage biological membranes 8 and inhibit a variety of enzymes 9-10. Rather than degrading or excreting the haem, the parasite has evolved a novel pathway for its detoxification by incorporating it into an insoluble crystalline material called haemozoin or malaria pigment 11. These crystals form in the food vacuole of the parasite concomitant with haemoglobin degradation, where they remain until the infected red cell bursts. The structure of haemozoin comprises a polymer of haems linked between the central ferric ion of one haem and a carboxylate side-group oxygen of another 12. This structure does not form spontaneously from either free haem or haemoglobin under physiological conditions 12-14, and the biochemistry of its formation is unclear. Here we report the identification and characterization of a haem polymerase enzyme activity from extracts of Plasmodium falciparum trophozoites, and show that this enzyme is inhibited by quinoline-containing drugs such as chloroquine and quinine. This provides a possible explanation for the highly stage-specific anti-malarial properties of these drugs.			SLATER, AFG (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GINSBURG H, 1989, BIOCHEM PHARMACOL, V38, P2645, DOI 10.1016/0006-2952(89)90550-9; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; KROGSTAD DJ, 1986, BIOCHEM PHARMACOL, V35, P547, DOI 10.1016/0006-2952(86)90345-X; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; LEMBERG R, 1949, HEMATIN COMPOUNDS BI; Peters W, 1987, CHEMOTHERAPY DRUG RE; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; WARHURST DC, 1987, ANN TROP MED PARASIT, V81, P65, DOI 10.1080/00034983.1987.11812093; WARHURST DC, 1981, BIOCHEM PHARMACOL, V30, P3323, DOI 10.1016/0006-2952(81)90606-7; WHITE NJ, 1981, LANCET, V2, P1069, DOI 10.1016/S0140-6736(81)91275-7; YA Z, 1986, J PARASITOL, V72, P830, DOI 10.2307/3281830; YAMADA KA, 1979, EXP PARASITOL, V48, P61, DOI 10.1016/0014-4894(79)90055-9; YASUHARA T, 1991, BIOCHEM BIOPH RES CO, V178, P95, DOI 10.1016/0006-291X(91)91784-A; YAYON A, 1984, J PROTOZOOL, V31, P367, DOI 10.1111/j.1550-7408.1984.tb02981.x; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; 1990, WHO TECHNICAL REPORT, V805	28	528	534	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					167	169		10.1038/355167a0	http://dx.doi.org/10.1038/355167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729651				2022-12-24	WOS:A1992GY62900060
J	PAMER, EG; HARTY, JT; BEVAN, MJ				PAMER, EG; HARTY, JT; BEVAN, MJ			PRECISE PREDICTION OF A DOMINANT CLASS-I MHC-RESTRICTED EPITOPE OF LISTERIA-MONOCYTOGENES	NATURE			English	Article							LYMPHOCYTES-T; CELLS; HEMOLYSIN; EXPRESSION; IMMUNITY; GROWTH; DETERMINANT; INFECTION; VIRULENCE; PEPTIDE	Listeria monocytogenes is a Gram-positive bacterium which grows in the cytoplasm of eukaryotic cells and can cause severe disease in immunocompromised individuals 1,2. In murine systems CD8+ T lymphocytes have been shown to be important effectors of acquired protective immunity against L. monocytogenes 3-5. Class I MHC restricted CD8+ cytotoxic T lymphocytes (CTL), which lyse J774 macrophage-like targets infected with L. monocytogenes, are induced following in vivo injection of live organisms. Natural peptide epitopes derived from L. monocytogenes can be acid-extracted from heavily infected BALB/c spleens and detected by CTL. A CTL clone, B9, derived from a (BALB/c x C57BL/6)F1 (H-2dxb) mouse, recognizes one of these natural epitopes in an H-2K(d)-restricted fashion. B9 also recognizes P815 (H-2d) mastocytoma cells transfected with the listeriolysin gene. To identify the region of the listeriolysin recognized by CTL we used the H-2K(d) peptide-binding motif described by Rammensee and colleagues 6 to synthesize 11 nonamer peptides. One of these peptides, listeriolysin 91-99, was recognized very efficiently by B9. This represents the first identified class I MHC-restricted epitope of bacteria and demonstrates the utility of the allele-specific motif for predicting CTL epitopes.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	PAMER, EG (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT IMMUNOL, SEATTLE, WA 98195 USA.			Harty, John/0000-0001-7266-2802	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080619, R01AI019335, R01AI039031, R01AI046653] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI046653-05, R01 AI039031-11, R01 AI046653, R01 AI039031, R01 AI019335-19, R01 AI080619, R01 AI019335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BERCHE P, 1987, J IMMUNOL, V139, P3813; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BRUNT LM, 1990, J IMMUNOL, V145, P3540; DELIBERO G, 1986, J IMMUNOL, V137, P2688; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; MARGET W, 1988, INFECTION, V16, pS175, DOI 10.1007/BF01639744; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PINE L, 1987, J CLIN MICROBIOL, V25, P2247, DOI 10.1128/JCM.25.11.2247-2251.1987; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAFLEY SA, 1991, J IMMUNOL, V146, P3604; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VANBLEEK GM, 1990, NATURE, V348, P213	26	398	430	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					852	855		10.1038/353852a0	http://dx.doi.org/10.1038/353852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719425	Green Accepted			2022-12-24	WOS:A1991GM73200062
J	CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE				CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE			PHOSPHORYLATION OF THE R-DOMAIN BY CAMP-DEPENDENT PROTEIN-KINASE REGULATES THE CFTR CHLORIDE CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; AIRWAY EPITHELIA; TRANSPORT; EXPRESSION; IDENTIFICATION; INACTIVATION; MECHANISMS; PP60C-SRC; TYROSINE	CFTR, the protein associated with cystic fibrosis, is phosphorylated on serine residues in response to cAMP agonists. Serines 660, 737, 795, and 813 were identified as in vivo targets for phosphorylation by protein kinase A. The SPQ fluorescence assay revealed that mutagenesis of any one of these sites did not affect Cl- channel activity. Indeed, concomitant mutagenesis of three of the four sites still resulted in cAMP-responsive Cl- channel activity. However, mutagenesis of all four sites abolished the response. One interpretation of these results is that the CFTR Cl- channel is blocked by the R domain and that phosphorylation on serines by protein kinase A electrostatically repels the domain, allowing passage of Cl-. The four phosphorylation events appear to be degenerate: no one site is essential for channel activity, and, at least in the case of serine 660, phosphorylation at one site alone is sufficient for regulation of Cl- channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED & PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa	CHENG, SH (corresponding author), GENZYME CORP,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869; Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BERGER HA, 1991, IN PRESS J CLIN INVE; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1988, MOL CELL BIOL, V6, P1562; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ESPINO PC, 1990, ONCOGENE, V5, P283; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1059; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J., 1989, MOL CLONING LAB MANU; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHANG B, 1991, J BIOL CHEM, V266, P990	34	577	586	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					1027	1036		10.1016/0092-8674(91)90446-6	http://dx.doi.org/10.1016/0092-8674(91)90446-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716180				2022-12-24	WOS:A1991GE46000019
J	TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW			PHOSPHORYLATION-REGULATED CL- CHANNEL IN CHO CELLS STABLY EXPRESSING THE CYSTIC-FIBROSIS GENE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; CAMP; TOXIN	A CYCLIC AMP-stimulated chloride conductance appears when the cystic fibrosis gene is expressed in non-epithelial cells by infection with recombinant viruses 1,2. Cyclic AMP-stimulated conductance in this system is mediated by the same ohmic, low-conductance Cl- channel as in human secretory epithelia 2-4, but control of this channel by phosphorylation has not been directly demonstrated. Here we report the appearance of the low-conductance Cl- channel in Chinese hamster ovary cells after stable transfection with the cystic fibrosis gene. The channel is regulated on-cell by membrane-permeant analogues of cAMP and off-cell by protein kinases A and C and by alkaline phosphatase. These results are further evidence that the cystic fibrosis transmembrane regulator is a Cl- channel which can be activated by specific phosphorylation events and inactivated by dephosphorylation; they reveal an unsuspected synergism between converging kinase regulatory pathways.	MCGILL UNIV, DEPT PHYSIOL, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	McGill University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; CHANG EB, 1985, AM J PHYSIOL, V249, pC356, DOI 10.1152/ajpcell.1985.249.3.C356; COHEN P, 1989, REV BIOCH, V58, P453; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HERSCHELER J, 1987, EUR J BIOCHEM, V165, P261; JAHR H, 1988, EUR J BIOCHEM, V178, P535; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LACERDA AE, 1988, NATURE, V335, P245; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O	20	527	539	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					628	631		10.1038/352628a0	http://dx.doi.org/10.1038/352628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1714039				2022-12-24	WOS:A1991GB21100058
J	PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M				PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M			INCREASED RISK OF MYELODYSPLASIA AND LEUKEMIA AFTER ETOPOSIDE, CISPLATIN, AND BLEOMYCIN FOR GERM-CELL TUMORS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; THERAPY-RELATED LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DISSEMINATED TESTICULAR CANCER; NON-HODGKINS LYMPHOMA; ALKYLATING-AGENTS; COMBINATION CHEMOTHERAPY; OVARIAN-CARCINOMA; CYTO-TOXICITY; SOLID TUMORS	Among the cytostatic drugs only the alkylating agents have been firmly established as being leukaemogenic. This report describes 4 cases of acute myeloid leukaemia and 1 of myelodysplasia occurring in a cohort of 212 patients with germ-cell tumours treated with etoposide, cisplatin, and bleomycin. The mean cumulative risk of leukaemic complications was 4.7% (SE 2.3) 5.7 years after start of etoposide-containing chemotherapy, and, compared with the risk in the general population, the relative risk of overt leukaemia was 336 (95% Cl 92-861). No leukaemias were detected in a previous cohort of 127 patients with germ-cell tumours treated with cisplatin, bleomycin, and vinblastine. The increased risk of leukaemia was most probably due to etoposide alone or in combination with cisplatin or bleomycin, since other published work has also not revealed an excess of leukaemias among patients with germ-cell tumours treated with only cisplatin, bleomycin, and vinblastine. The risk of leukaemia was dose related since all 5 patients with leukaemic complications were among the 82 who had received a cumulative dose of more than 2000 mg/m2 etoposide, whereas no leukaemias were observed among 130 patients who had received up to 2000 mg/m2 (p = 0.004). 3 of the leukaemic patients had balanced chromosome translocations affecting bands 11q23 and 21q22. These translocations, and perhaps also other balanced aberrations, seem to be characteristic of myelodysplasia and acute leukaemia occurring after therapy with cytostatic agents acting on DNA-topoisomerase II.	STATE SERUM INST,DEPT BIOSTAT,COPENHAGEN,DENMARK; RIGSHOSP,DEPT ONCOL ONK,DK-2100 COPENHAGEN,DENMARK; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN,DENMARK	Statens Serum Institut; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	PEDERSENBJERGAARD, J (corresponding author), RIGSHOSP,DEPT HAEMATOL L4132,9 BLEGDAMSVEJ,DK-2100 COPENHAGEN,DENMARK.		Daugaard, Gedske/AAD-4009-2019	Daugaard, Gedske/0000-0002-9618-9180				ANDERSSON M, 1990, CANCER, V65, P2460, DOI 10.1002/1097-0142(19900601)65:11<2460::AID-CNCR2820651110>3.0.CO;2-S; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BASSETT WB, 1986, J CLIN ONCOL, V4, P614; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CHAMBERS SK, 1989, CANCER, V64, P2459, DOI 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; EDER JP, 1987, J CLIN INVEST, V79, P1524, DOI 10.1172/JCI112983; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; GREENE MH, 1982, NEW ENGL J MED, V307, P1416, DOI 10.1056/NEJM198212023072302; GREENE MH, 1983, CANCER RES, V43, P1891; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KANTARJIAN HM, 1986, CANCER, V58, P924, DOI 10.1002/1097-0142(19860815)58:4<924::AID-CNCR2820580420>3.0.CO;2-Y; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KAUFMANN SH, 1991, CANCER RES, V51, P1129; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; OZOLS RF, 1988, J CLIN ONCOL, V6, P1031, DOI 10.1200/JCO.1988.6.6.1031; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; PEDERSENBJERGAARD J, 1991, BLOOD, V78, P1147; PEDERSENBJERGAARD J, 1985, BLOOD, V66, P1393; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PEDERSENBJERGAARD J, 1985, ANN INTERN MED, V103, P195, DOI 10.7326/0003-4819-103-2-195; PEDERSENBJERGAARD J, 1980, CANCER-AM CANCER SOC, V45, P19, DOI 10.1002/1097-0142(19800101)45:1<19::AID-CNCR2820450106>3.0.CO;2-L; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; POMMIER Y, 1988, CANCER RES, V48, P512; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; RUBIN CM, 1990, BLOOD, V76, P2594; TAN KB, 1987, P NATL ACAD SCI USA, V84, P7668, DOI 10.1073/pnas.84.21.7668; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VANIMHOFF GW, 1986, CANCER, V57, P984, DOI 10.1002/1097-0142(19860301)57:5<984::AID-CNCR2820570518>3.0.CO;2-H; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	36	316	318	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					359	363		10.1016/0140-6736(91)90490-G	http://dx.doi.org/10.1016/0140-6736(91)90490-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1713639				2022-12-24	WOS:A1991GA60700015
J	NIGHTINGALE, SL				NIGHTINGALE, SL			IMPRINTING OF ORAL SOLID DOSAGE FORM-DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0515, V56, P22370	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-24	WOS:A1991FU89600003
J	FELLER, DC; DELACRUZ, VF				FELLER, DC; DELACRUZ, VF			IDENTIFYING ANTIGENIC T-CELL SITES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RECOGNITION; PREDICTION; SEQUENCE				FELLER, DC (corresponding author), MEDLMMUNE INC, 19 FIRSTFIELD RD, GAITHERSBURG, MD 20878 USA.							BERZOFSKY JA, 1988, J CLIN INVEST, V82, P1811, DOI 10.1172/JCI113796; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; GREY HM, 1985, IMMUNOL TODAY, V6, P101, DOI 10.1016/0167-5699(85)90025-8; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHBARD JB, IN PRESS ANN REV IMM; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SPOUGE JL, 1987, J IMMUNOL, V138, P204; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	17	68	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					720	721		10.1038/349720a0	http://dx.doi.org/10.1038/349720a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1705016				2022-12-24	WOS:A1991EY62700056
J	CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL				CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL			INABILITY OF MALARIA VACCINE TO INDUCE ANTIBODIES TO A PROTECTIVE EPITOPE WITHIN ITS SEQUENCE	SCIENCE			English	Article							PLASMODIUM-VIVAX; CIRCUMSPOROZOITE PROTEIN; IMMUNODOMINANT EPITOPE; MONOCLONAL-ANTIBODIES; PEPTIDE-SYNTHESIS; FALCIPARUM; ANTIGEN; SPOROZOITES; INFECTION; EFFICACY	Saimiri monkeys immunized with a recombinant protein containing 20 copies of the nine amino acid repeat of the Plasmodium vivax circumsporozoite (CS) protein developed high concentrations of antibodies to the repeat sequence and to sporozoites, but were not protected against challenge. After intravenous injection of an immunoglobulin G3 monoclonal antibody (NVS3) against irradiated P. vivax sporozoites, four of six monkeys were protected against sporozoite-induced malaria, and the remaining two animals took significantly longer to become parasitemic. Epitope mapping demonstrated that NVS3 recognizes only four (AGDR) of the nine amino acids within the repeat region of the P. vivax CS protein. The monkeys immunized with (DRA(D)(A)GQPAG)20 did not produce antibodies to the protective epitope AGDR. Thus, determination of the fine specificity of protective immune responses may be critical to the construction of successful subunit vaccines.	USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD 20889; CTR DIS CONTROL,MALARIA BRANCH,ATLANTA,GA 30333	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								ALVING CR, UNPUB; ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; BALLOU WR, 1987, LANCET, V1, P1277; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, IN PRESS J IMMUNOL; COLLINS WE, 1989, AM J TROP MED HYG, V40, P455, DOI 10.4269/ajtmh.1989.40.455; COLLINS WE, 1986, AM J TROP MED HYG, V35, P56, DOI 10.4269/ajtmh.1986.35.56; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GORDON DM, 1990, AM J TROP MED HYG, V42, P527, DOI 10.4269/ajtmh.1990.42.527; HALL T, 1984, J IMMUNOL, V132, P2059; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HJELM H, 1976, IMMUNOADSORBENTS PRO, P51; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLET P, 1988, AM J TROP MED HYG, V38, P340; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; RICKMAN LS, 1990, CLIN RES, V38, pA352; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336	25	88	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					668	671		10.1126/science.1704150	http://dx.doi.org/10.1126/science.1704150			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1704150				2022-12-24	WOS:A1991EW39900044
J	MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J				MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J			ACTIVITY AND DISTRIBUTION OF BINDING-SITES IN BRAIN OF A NONPEPTIDE SUBSTANCE-P (NK1) RECEPTOR ANTAGONIST	SCIENCE			English	Article							LOCUS COERULEUS NEURONS; SPINAL-CORD; RAT; RELEASE; EXCITATION; NIGRA	CP-96,345, a nonpeptide substance P antagonist, is selective for the tachykinin NK1 receptor. The compound binds to a single population of sites in guinea pig brain and potently inhibits substance P-induced excitation of locus ceruleus neurons. CP-96,345 should be a useful tool for studying the action of substance P in the central nervous system.			MCLEAN, S (corresponding author), PFIZER INC,CENT RES DIV,DEPT NEUROSCI,GROTON,CT 06340, USA.							BANNON MJ, 1986, BRAIN RES, V381, P393, DOI 10.1016/0006-8993(86)90097-1; CHEESEMAN HJ, 1983, EUR J PHARMACOL, V94, P93, DOI 10.1016/0014-2999(83)90445-4; DAM TV, 1986, PEPTIDES, V7, P855, DOI 10.1016/0196-9781(86)90106-3; DAVIES J, 1976, BRAIN RES, V107, P623, DOI 10.1016/0006-8993(76)90150-5; DEUTCH AY, 1985, PEPTIDES, V6, P113, DOI 10.1016/0196-9781(85)90143-3; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; ELLIOTT PJ, 1986, BRAIN RES, V385, P379, DOI 10.1016/0006-8993(86)91087-5; GRAY EG, 1962, J ANAT, V96, P79; GUYENET PG, 1977, BRAIN RES, V136, P178, DOI 10.1016/0006-8993(77)90144-5; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HENRY JL, 1976, BRAIN RES, V114, P439, DOI 10.1016/0006-8993(76)90965-3; INNIS RB, 1985, BRAIN RES, V335, P381, DOI 10.1016/0006-8993(85)90499-8; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LOWE J, UNPUB; LUNBERG JM, 1984, ACTA PHYSL SCAND, V120, P217; OTSUKA M, 1976, NATURE, V264, P83, DOI 10.1038/264083a0; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; RANDIC M, 1977, BRAIN RES, V128, P164, DOI 10.1016/0006-8993(77)90245-1; REGOLI D, 1987, LIFE SCI, V40, P109, DOI 10.1016/0024-3205(87)90349-3; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; TAKANO Y, 1985, LIFE SCI, V37, P2507, DOI 10.1016/0024-3205(85)90608-3; TITELER M, 1987, BIOCHEM PHARMACOL, V36, P3265, DOI 10.1016/0006-2952(87)90643-5; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0	25	206	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					437	439		10.1126/science.1703324	http://dx.doi.org/10.1126/science.1703324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703324				2022-12-24	WOS:A1991EU50400044
J	REABAN, ME; GRIFFIN, JA				REABAN, ME; GRIFFIN, JA			INDUCTION OF RNA-STABILIZED DNA CONFORMERS BY TRANSCRIPTION OF AN IMMUNOGLOBULIN SWITCH REGION	NATURE			English	Article									BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT MOLEC BIOL,RIDGEFIELD,CT 06877	Boehringer Ingelheim	REABAN, ME (corresponding author), UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294, USA.							COLLIER DA, 1988, J BIOL CHEM, V263, P7397; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; LUTZKER SG, 1989, MOBILE DNA; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; STANTON LW, 1982, NUCLEIC ACIDS RES, V10, P5993, DOI 10.1093/nar/10.19.5993; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	11	205	208	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 22	1990	348	6299					342	344		10.1038/348342a0	http://dx.doi.org/10.1038/348342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ955	1701219				2022-12-24	WOS:A1990EJ95500063
J	FLANAGAN, JG; LEDER, P				FLANAGAN, JG; LEDER, P			THE KIT LIGAND - A CELL-SURFACE MOLECULE ALTERED IN STEEL MUTANT FIBROBLASTS	CELL			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	FLANAGAN, JG (corresponding author), HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Flanagan, John/AAM-2995-2020					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Fernley H.N., 1971, ENZYMES, V4, P417; FUJITA J, 1988, BLOOD, V72, P463; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HARLOW E, 1988, ANTIBODIES LABORATOR; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JEMMERSON R, 1983, HUMAN ALKALINE PHOSP, P105; KARASUYAMA H, 1988, J EXP MED, V167, P1377, DOI 10.1084/jem.167.4.1377; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LANDRETH KS, 1984, J IMMUNOL, V132, P2724; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NAKAYAMA H, 1988, DEVELOPMENT, V102, P107; NOCKA, IN PRESS EMBO J; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1984, AM J MED GENET, V18, P621, DOI 10.1002/ajmg.1320180410; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZOELLNER HFA, 1989, J HISTOCHEM CYTOCHEM, V37, P1893, DOI 10.1177/37.12.2584695; 1990, CELL, V63	42	764	818	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					185	194		10.1016/0092-8674(90)90299-T	http://dx.doi.org/10.1016/0092-8674(90)90299-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698555				2022-12-24	WOS:A1990EB46100019
J	WRIGHT, SD; RAMOS, RA; TOBIAS, PS; ULEVITCH, RJ; MATHISON, JC				WRIGHT, SD; RAMOS, RA; TOBIAS, PS; ULEVITCH, RJ; MATHISON, JC			CD14, A RECEPTOR FOR COMPLEXES OF LIPOPOLYSACCHARIDE (LPS) AND LPS BINDING-PROTEIN	SCIENCE			English	Article									SCRIPPS CLIN & RES FDN,RES INST,DEPT IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute	WRIGHT, SD (corresponding author), ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Ulevitch, Richard J/Q-3393-2017		NIAID NIH HHS [AI 15136, AI 22003, AI 24775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775, R01AI015136, R01AI022003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHMUN RA, 1987, BLOOD, V69, P886; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; DESCH CE, 1989, LYMPHOKINE RES, V8, P141; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FERRERO E, 1988, NUCLEIC ACIDS RES, V16, P4173, DOI 10.1093/nar/16.9.4173; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HAZIOT A, 1988, J IMMUNOL, V141, P547; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MICHL J, 1979, J EXP MED, V150, P607, DOI 10.1084/jem.150.3.607; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SIMMONS DL, 1989, BLOOD, V73, P284; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TODD RF, 1982, HYBRIDOMA, V1, P329, DOI 10.1089/hyb.1.1982.1.329; ULEVITCH RJ, UNPUB; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; WRIGHT S, UNPUB; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1990, J IMMUNOL, V144, P2566; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	27	3546	3689	2	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 21	1990	249	4975					1431	1433		10.1126/science.1698311	http://dx.doi.org/10.1126/science.1698311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ451	1698311				2022-12-24	WOS:A1990DZ45100044
J	GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S				GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S			INTRODUCTION OF INTERSUBUNIT DISULFIDE BONDS IN THE MEMBRANE-DISTAL REGION OF THE INFLUENZA HEMAGGLUTININ ABOLISHES MEMBRANE-FUSION ACTIVITY	CELL			English	Article							MIDDLE-T ANTIGEN; VIRUS HEMAGGLUTININ; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; PH OPTIMUM; EXPRESSION; ACTIVATION; GLYCOPROTEIN; CLEAVAGE; PROTEINS	Influenza virus hemagglutinin (HA) mediates viral entry into cells by a low pH-induced membrane fusion event in endosomes. A number of structural changes occur throughout the length of HA at the pH of fusion. To probe their significance and their necessity for fusion activity, we have prepared a site-directed mutant HA containing novel intersubunit disulfide bonds designed to cross-link covalently the membrane-distal domains of the trimer. These mutations inhibited the low pH-induced conformational changes and prevented HA-mediated membrane fusion; conditions that reduced the novel disulfide bonds restored membrane fusion activity. We conclude that structural rearrangements in the membrane distal region of the HA are required for membrane fusion activity.	GENET INST,CAMBRIDGE,MA 02140; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Johns Hopkins University; Harvard University; Harvard University; Howard Hughes Medical Institute	GODLEY, L (corresponding author), NATL INST MED RES,MILL HILL,LONDON NW7 1AA,ENGLAND.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013654] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13654] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDDELL CR, 1984, BRIT J PHARMACOL, V82, P397, DOI 10.1111/j.1476-5381.1984.tb10775.x; BELSHAM GJ, 1986, VIRUS RES, V4, P157, DOI 10.1016/0168-1702(86)90039-0; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; JACKSON DC, 1985, VIROLOGY, V145, P72, DOI 10.1016/0042-6822(85)90202-8; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; PABO CO, 1986, BIOCHEMISTRY-US, V25, P5987, DOI 10.1021/bi00368a023; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEINHAUER DA, 1991, VIROLOGY, V184, P445, DOI 10.1016/0042-6822(91)90867-B; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WEBSTER RG, 1983, VIROLOGY, V126, P587, DOI 10.1016/S0042-6822(83)80015-4; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILSON IA, 1981, NATURE, V289, P368; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983	38	155	159	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					635	645		10.1016/0092-8674(92)90140-8	http://dx.doi.org/10.1016/0092-8674(92)90140-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739972				2022-12-24	WOS:A1992HF44000005
J	IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP				IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP			PRIMARY STRUCTURE OF DYSTROPHIN-ASSOCIATED GLYCOPROTEINS LINKING DYSTROPHIN TO THE EXTRACELLULAR-MATRIX	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LAMININ-BINDING-PROTEIN; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; CELL-MEMBRANES; SURFACE; SEQUENCE; CHANNEL; LOCUS	The primary sequence of two components of the dystrophin-glycoprotein complex has been established by complementary DNA cloning. The transmembrane 43K and extracellular 156K dystrophin-associated glyco proteins (DAGs) are encoded by a single messenger RNA and the extracellular 156K DAG binds laminin. Thus, the 156K DAG is a new laminin-binding glycoprotein which may provide a linkage between the sarcolemma and extracellular matrix. These results support the hypothesis that the dramatic reduction in the 156K DAG in Duchenne muscular dystrophy leads to a loss of a linkage between the sarcolemma and extracellular matrix and that this may render muscle fibres more susceptible to necrosis.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV TEXAS,SW MED CTR,BIOPOLYMER FACIL HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ervasti, James/AAZ-4786-2020	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BONILLA E, 1986, NEUROLOGY, V36, P171; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CLEGG DO, 1988, J CELL BIOL, V107, P699, DOI 10.1083/jcb.107.2.699; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GORKA J, 1989, PEPTIDE RES, V2, P1; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UTRNER PR, 1991, J CELL BIOL, V115, P1701; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0	36	1122	1143	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					696	702		10.1038/355696a0	http://dx.doi.org/10.1038/355696a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741056				2022-12-24	WOS:A1992HE60400053
J	WRIGHT, JW				WRIGHT, JW			PERSISTENT TYMPANIC MEMBRANE PERFORATION FROM VENTILATION TUBES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WRIGHT, JW (corresponding author), EAR INST INDIANA,INDIANAPOLIS,IN 46256, USA.							TOS M, 1990, OTOLARYNGOLOGY, pCH22	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734091				2022-12-24	WOS:A1992HD15500039
J	MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH				MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH			DIABETES IN PRISON - CAN GOOD DIABETIC CARE BE ACHIEVED	BRITISH MEDICAL JOURNAL			English	Article								Objective - To investigate the clinical characteristics and metabolic control of diabetic patients given structured diabetic care in prison. Design - Survey of diabetic men serving prison sentences during a 22 month period in a large British prison. Setting - HM Prison, Walton, Liverpool. Subjects - 42 male diabetic prisoners, of whom 23 had insulin dependent and 19 non-insulin dependent diabetes. Main outcome measures - Episodes of diabetic instability, glycated haemoglobin concentrations, body mass index. Results - No serious diabetic instability occurred. Between the initial assessment by the visiting consultant diabetologist and a second assessment 10 weeks later glycated haemoglobin concentrations had fallen from 10.8 (SD 2.9)% to 9.8 (2.4)% (p < 0.05) in prisoners with insulin dependent diabetes and from 8.7 (1.9)% to 7.6 (1.2)% (p < 0.05) in those with non-insulin dependent diabetes. Good glycaemic control continued, a mean glycated haemoglobin concentration of 7.6 (1.5)% being recorded in seven men remaining in prison for six to 18 months. Mean body mass index (weight (kg)/(height (m))2) did not change during the study (insulin dependent prisoners 23.3 (SD 2.1), non-insulin dependent prisoners 27.9 (3.8)). Conclusions - Good diabetic metabolic control is usual in prison, probably due to the rigid dietary regimen, no alcohol, and compliance with treatment. Many younger men had defaulted from their home diabetic clinics, and imprisonment allowed screening for diabetic complications and reassessment of treatment. Structured diabetic care should be offered in all prisons.	HM PRISON,LIVERPOOL,ENGLAND		MACFARLANE, IA (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; FISKEN RA, 1990, CLIN CHIM ACTA, V191, P79, DOI 10.1016/0009-8981(90)90060-6; GARROW JS, 1979, BRIT MED J, V2, P1171, DOI 10.1136/bmj.2.6199.1171; GILL GV, 1989, BRIT MED J, V298, P221, DOI 10.1136/bmj.298.6668.221; HOME P, 1984, BRIT MED J, V289, P713, DOI 10.1136/bmj.289.6447.713; SHACKLED, 1988, LANCET, V2, P1402; SMITH R, 1991, BRIT MED J, V302, P550; SMITH R, 1988, BRIT MED J, V297, P89; SMITH R, 1991, BRIT MED J, V302, P64, DOI 10.1136/bmj.302.6768.64; Smith Richard, 1984, PRISON HLTH CARE; 1988, BALANCE, P5; 1985, PRISON MED; 1985, LANCET, V2, P755	13	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					152	155		10.1136/bmj.304.6820.152	http://dx.doi.org/10.1136/bmj.304.6820.152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737159	Green Published, Bronze			2022-12-24	WOS:A1992HA97900020
J	JONES, R; LYDEARD, S				JONES, R; LYDEARD, S			IRRITABLE-BOWEL-SYNDROME IN THE GENERAL-POPULATION	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; PSYCHOSOCIAL FACTORS; SYMPTOMS; DYSFUNCTION; DYSPEPSIA; PREVALENCE; DISORDERS; DIAGNOSIS; BEHAVIOR	Objective - To determine the prevalence of symptoms compatible with a clinical diagnosis of irritable bowel syndrome in the general population. Design - Validated postal questionnaire sent to 2280 subjects randomly selected in 10 year age bands from the lists of eight general practitioners. The Manning criteria were used to define irritable bowel syndrome. Setting - Urban population in Southampton and mixed urban-rural population in Andover, Hampshire. Results - A response of 71% yielded 1620 questionnaires for analysis, of which 412 (25%) reported more than six episodes of abdominal pain in the preceding year, with 350 (22%) reporting symptoms consistent with the diagnosis of irritable bowel syndrome. The male: female ratio was 1:1.38. More subjects with irritable bowel syndrome had constipation and diarrhoea and 35% with the syndrome reported rectal bleeding compared with an overall prevalence of 20%. Other symptoms and conditions including heartburn, dyspepsia, flushing, palpitations, migraine, and urinary symptoms were significantly more common in the group with irritable bowel syndrome. Abdominal pain in childhood was more common in the subjects with irritable bowel syndrome (12%) than without (3%). One third of the group with irritable bowel syndrome had sought medical advice during the study period (male: female ratio 1:1.21); consultation behaviour was influenced by age and the presence of associated symptoms, varied considerably among patients registered with different general practitioners, and was poorly correlated with symptom severity. Conclusion - Symptoms consistent with a diagnosis of irritable bowel syndrome are present in almost one quarter of the general population and tend to be associated with a number of other complaints and conditions, some of which may reflect smooth muscle dysfunction.	UNIV SOUTHAMPTON,PRIMARY MED CARE,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								Bordie A K, 1972, J Indian Med Assoc, V58, P451; DENT OF, 1986, DIS COLON RECTUM, V29, P243, DOI 10.1007/BF02553027; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; GOUDY WJ, 1976, 3 IOW AGR HOM EC EXP; HEATON KW, 1991, GUT, V32, P73, DOI 10.1136/gut.32.1.73; INGHAM JG, 1979, J EPIDEMIOL COMMUN H, V33, P191, DOI 10.1136/jech.33.3.191; ISGAR B, 1983, GUT, V24, P190, DOI 10.1136/gut.24.3.190; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MACDONALD L, 1986, FAM PRACT, V3, P80, DOI 10.1093/fampra/3.2.80; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MENDIS BLJ, 1983, CEYLON MED J, V27, P171; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SMITH RC, 1991, GASTROENTEROLOGY, V100, P591, DOI 10.1016/0016-5085(91)80002-Q; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; Thompson, 1989, INTERPRETATION SYMPT; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHORWELL PJ, 1986, GUT, V27, P1014, DOI 10.1136/gut.27.9.1014; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37	25	496	513	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					87	90		10.1136/bmj.304.6819.87	http://dx.doi.org/10.1136/bmj.304.6819.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737146	Green Published, Bronze			2022-12-24	WOS:A1992HA17100022
J	WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL			SOMATOSTATIN STIMULATES CA2+-ACTIVATED K+ CHANNELS THROUGH PROTEIN DEPHOSPHORYLATION	NATURE			English	Article							PITUITARY CELL-LINE; VASOACTIVE INTESTINAL PEPTIDE; AMP-INDEPENDENT ACTIONS; INTRACELLULAR FREE CALCIUM; PERTUSSIS TOXIN BLOCKS; CYCLIC-AMP; TUMOR-CELLS; GH3 CELLS; POTASSIUM CONDUCTANCE; PROLACTIN SECRETION	THE neuropeptide somatostatin inhibits secretion from electrically excitable cells in the pituitary, pancreas, gut and brain 1. In mammalian pituitary tumour cells somatostatin inhibits secretion through two distinct pertussis toxin-sensitive mechanisms 2-5. One involves inhibition of adenylyl cyclase 6, the other an unidentified cyclic AMP-independent mechanism that reduces Ca2+ influx 7,8 by increasing membrane conductance to potassium 9,10. Here we demonstrate that the predominant electrophysiological effect of somatostatin on metabolically intact pituitary tumour cells is a large, sustained increase in the activity of the large-conductance Ca2+- and voltage-activated K+ channels (BK). This action of somatostatin does not involve direct effects of Ca2+, cAMP or G proteins on the channels. Our results indicate instead that somatostatin stimulates BK channel activity through protein dephosphorylation.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709; UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System								ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1541, DOI 10.1210/endo-113-5-1541; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1551, DOI 10.1210/endo-113-5-1551; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1988, J BIOL CHEM, V263, P226; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LECHLEITER JD, 1988, NEURON, V1, P27; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LUINI A, 1986, J NEUROSCI, V6, P3128; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; PATEL YC, 1990, METABOLISM, V39, P1, DOI 10.1016/0026-0495(90)90196-J; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; REINHART PH, IN PRESS J NEUROSCI; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P591, DOI 10.1113/jphysiol.1987.sp016509; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHLEGEL W, 1984, CELL CALCIUM, V5, P223, DOI 10.1016/0143-4160(84)90038-1; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMASHITA N, 1988, P NATL ACAD SCI USA, V85, P4924, DOI 10.1073/pnas.85.13.4924; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	39	257	258	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					570	573		10.1038/351570a0	http://dx.doi.org/10.1038/351570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710783				2022-12-24	WOS:A1991FR03400060
J	EARLE, K; WALKER, J; HILL, C; VIBERTI, G				EARLE, K; WALKER, J; HILL, C; VIBERTI, G			FAMILIAL CLUSTERING OF CARDIOVASCULAR-DISEASE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES AND NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; CORONARY-ARTERY DISEASE; INDEPENDENT RISK FACTOR; HEART-DISEASE; BLOOD-PRESSURE; RENAL-DISEASE; MELLITUS; HISTORY; HYPERTENSION; GROWTH	Background. Patients who have insulin-dependent diabetes mellitus and nephropathy have an excess of cardiovascular disease. Familial factors may in part account for this phenomenon. Methods. We identified 61 white patients under 65 years of age with insulin-dependent diabetes who had nephropathy, and then matched them with 61 diabetic patients without nephropathy. We determined the prevalence of cardiovascular disease in the parents of these patients with use of information obtained from death certificates or from the World Health Organization questionnaire for cardiovascular disease. Results. The rates of ascertainment of information were 96 percent (n = 117) for the parents of diabetic patients with nephropathy and 95 percent (n = 116) for the parents of patients without nephropathy. Cardiovascular disease was more often a direct cause of death among the parents of diabetic patients with nephropathy (40 percent vs. 22 percent, P < 0.03), and the combined morbidity and mortality from cardiovascular disease in this group was greater than that in the parents of diabetic patients without nephropathy (31 percent vs. 14 percent, P < 0.01). The age-adjusted and sex-adjusted relative risk of cardiovascular disease in this group of parents was 2.9 (95 percent confidence interval, 1.5 to 5.5; P < 0.001). Moreover, a paternal history of cardiovascular disease was associated with a significantly increased risk of nephropathy in the diabetic patient after the analysis was adjusted for age, sex, and duration of diabetes (odds ratio, 3.2; 95 percent confidence interval, 1.3 to 7.9; P < 0.01). Among the diabetic patients with nephropathy, those who had a cardiovascular event were much more likely to have a family history of cardiovascular disease (odds ratio, 6.2; 95 percent confidence interval, 2.0 to 19.0; P < 0.005) than those who had not had such an event. Conclusions. Among patients with insulin-dependent diabetes, a parental history of cardiovascular disease is significantly associated with the development of nephropathy and, among those with nephropathy, increases the likelihood of cardiovascular disease.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,4TH FLOOR HUNTS HOUSE,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CAMBIEN F, 1980, REV EPIDEMIOL SANTE, V28, P21; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CARR SJ, 1989, EUR J CLIN INVEST, V19, P101, DOI 10.1111/j.1365-2362.1989.tb00203.x; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; HASSTEDT SJ, 1988, AM J HUM GENET, V43, P14; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JONES SL, 1990, HYPERTENSION, V15, P570, DOI 10.1161/01.HYP.15.6.570; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KOSCHINSKY T, 1987, DIABETES METAB, V13, P318; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAMBERTON RP, 1984, DIABETES, V33, P125, DOI 10.2337/diabetes.33.2.125; LI LK, 1990, KIDNEY INT, V37, P199; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MORGAN DB, 1986, J HYPERTENS, V4, P609, DOI 10.1097/00004872-198610000-00014; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; NORGAARD K, 1991, DIABETOLOGIA, V34, P370, DOI 10.1007/BF00405012; PETTITT DJ, 1990, DIABETOLOGIA, V33, P438, DOI 10.1007/BF00404096; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WALKER JD, 1990, BRIT MED J, V301, P635, DOI 10.1136/bmj.301.6753.635; YAP L, 1989, J HYPERTENS, V7, P667, DOI 10.1097/00004872-198908000-00011	35	203	206	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					673	677		10.1056/NEJM199203053261005	http://dx.doi.org/10.1056/NEJM199203053261005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736105				2022-12-24	WOS:A1992HG11700005
J	LISTERNICK, R; FRISONE, L; SILVERMAN, BL				LISTERNICK, R; FRISONE, L; SILVERMAN, BL			DELAYED DIAGNOSIS OF INFANTS WITH ABNORMAL NEONATAL SCREENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL HYPOTHYROIDISM; NEWBORN	Objective. - To identify infants who were diagnosed clinically with a condition that previously had been detected by a state neonatal screening program, but who had failed to receive medical attention in a timely fashion. Design. - A descriptive case series of infants over a 2-year period from 1989 to 1991. Setting. - An academically affiliated tertiary care pediatric hospital, a major referral center for children with abnormal results on state neonatal screening tests. Patients. - All patients who (1) had a diagnosis suspected clinically, (2) had confirmation of disease, and (3) were subsequently found to have had abnormal screening results. Main Outcome Measures. - Age at clinical diagnosis, morbidity due to delay in diagnosis, and postnatal medical follow-up. Results. -Ten children were identified, three with 21-hydroxylase deficiency and seven with a hemoglobinopathy. In each case, the screening program had clear documentation that the office of the physician of record had received prompt telephone communication of the abnormal results. The mean age at clinical diagnosis was 32 days for the children with 21-hydroxylase deficiency and 215 days for those with sickle cell anemia, substantially longer than is mandated by proper neonatal screening practice. Potentially life-threatening complications of the underlying disease were present in six children. Conclusions. - A significant number of neonates who have metabolic disorders appropriately identified by a neonatal screening test may fail to receive timely treatment. Consideration should be given to implementing a system of directly contacting the parents of all presumptive positive cases by the state screening program.	NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV HEMATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV ENDOCRINOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	LISTERNICK, R (corresponding author), NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,DIV GEN ACAD & EMERGENCY PEDIAT,CHICAGO,IL 60614, USA.							ALLEN DB, 1988, AM J DIS CHILD, V142, P232, DOI 10.1001/archpedi.1988.02150020134049; BOWLING FG, 1986, J INHERIT METAB DIS, V9, P99, DOI 10.1007/BF01813911; FRANKENB.WK, 1974, PEDIATRICS, V54, P612; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GROVER R, 1986, AM J PUBLIC HEALTH, V76, P1236, DOI 10.2105/AJPH.76.10.1236; Guthrie R., 1964, PHENYLKETONURIA DETE; HOLTZMAN C, 1986, PEDIATRICS, V78, P553; PANG S, 1988, PEDIATRICS, V81, P866; Pearson H A, 1986, Adv Pediatr, V33, P381; TUERCK JM, 1987, AM J PUBLIC HEALTH, V77, P1528, DOI 10.2105/AJPH.77.12.1528; Weatherall DJ, 1981, THALASSEMIA SYNDROME; 1984, J PEDIATR, V104, P539; 1990, OVERVIEW NEWBORN SCR	13	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1095	1099		10.1001/jama.267.8.1095	http://dx.doi.org/10.1001/jama.267.8.1095			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735927				2022-12-24	WOS:A1992HE39100025
J	MCNAGNY, SE; PARKER, RM				MCNAGNY, SE; PARKER, RM			HIGH PREVALENCE OF RECENT COCAINE USE AND THE UNRELIABILITY OF PATIENT SELF-REPORT IN AN INNER-CITY WALK-IN CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG-ABUSE; SPECIFICITY; PREGNANCY	Objective. - To determine the prevalence of recent cocaine use and the reliability of patient self-reported cocaine use. Design. - A survey with blinded comparison to a criterion standard. Setting. - Walk-in clinic of a large public hospital in metropolitan Atlanta, Ga. Participants. -Male patients, aged 18 to 39 years, presenting to the triage desk for immediate care during weekdays. Of the 415 eligible men who agreed to participate (acceptance rate, 82%), the average age was 29.5 years, 91.6% were black, and 89% were uninsured. Intervention. - None. Main Outcome Measures. - Comparison of self-reported illicit drug use with results from urinary immunoassays for benzoylecgonine, a major cocaine metabolite. Determination of which drug history questions produce the most accurate responses using anonymous urine testing as the criterion standard. Results. - Thirty-nine percent of patients tested positive for the presence of benzoylecgonine and were statistically more likely to be older, black, and have a prior history of sexually transmitted disease (P<.01). Seventy-two percent of men with positive urinary assays denied illicit drug use in the 3 days prior to sampling. When queried with several formats, subjects with positive urine assays were more likely to admit to "any illegal drug" use (87.5%) than to the more specific "any form of cocaine" use (60.6%) within the prior year (P<.0001). Conclusions. - These results underscore the magnitude of cocaine abuse among black, inner-city men. Patient self-report of illicit drug use is highly inaccurate. Accuracy of self-report may be increased by asking less specific questions.			MCNAGNY, SE (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,GLENN MEM BLDG,69 BUTLER ST,ATLANTA,GA 30322, USA.		Parker, Ruth M/S-4583-2017	Parker, Ruth M/0000-0001-9685-6396				ALLEN LV, 1981, CLIN TOXICOL, V18, P1043, DOI 10.3109/15563658108990335; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CONE DJ, 1989, J FORENSIC SCI, V34, P415; CONE EJ, 1989, J FORENSIC SCI, V34, P32; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DEAN A, 1990, EPI INFO, V5; FISCHMAN MW, 1985, JANAL TOXICOL, V9, P241; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; Johnson B D, 1989, NIDA Res Monogr, V95, P326; KAKU DA, 1990, ANN INTERN MED, V113, P821, DOI 10.7326/0003-4819-113-11-821; MCNAGNY SE, IN PRESS J INFECT DI; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; WELCH RD, 1991, ANN EMERG MED, V20, P154, DOI 10.1016/S0196-0644(05)81215-6; 1989, MMWR, V38, P780; 1991, ADM911839 US DEP HLT; 1991, ADM911788 US DEP HLT; 1988, FED REG         0401, V53, P11970	20	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1106	1108		10.1001/jama.267.8.1106	http://dx.doi.org/10.1001/jama.267.8.1106			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1735928				2022-12-24	WOS:A1992HE39100027
J	ELSADR, W; CAPPS, L				ELSADR, W; CAPPS, L			THE CHALLENGE OF MINORITY RECRUITMENT IN CLINICAL-TRIALS FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; RANDOMIZED TRIAL; DOUBLE-BLIND; PENTAMIDINE; ZIDOVUDINE; INFECTION; EFFICACY; THERAPY		COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University	ELSADR, W (corresponding author), HARLEM HOSP MED CTR,DIV INFECT DIS,ROOM 3107,506 LENOX AVE,NEW YORK,NY 10037, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095029] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-95029] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; CONTE JE, 1990, ANN INTERN MED, V113, P203, DOI 10.7326/0003-4819-113-3-203; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; FAUCI AS, 1989, ACAD MED, V64, P115, DOI 10.1097/00001888-198903000-00002; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; HAMILTON JD, IN PRESS N ENGL J ME; HOO GWS, 1990, ANN INTERN MED, V113, P195, DOI 10.7326/0003-4819-113-3-195; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEVINE RJ, 1986, ETHICS REGULATIONS C, P67; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MOSER M, 1982, CLIN PHARMACOL THER, V32, P307, DOI 10.1038/clpt.1982.165; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SMITH WM, 1964, ANN INTERN MED, V61, P829, DOI 10.7326/0003-4819-61-5-829; SVENSSON CK, 1989, JAMA-J AM MED ASSOC, V261, P263, DOI 10.1001/jama.261.2.263; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALLE T, 1985, CLIN PHARMACOL THER, V38, P509, DOI 10.1038/clpt.1985.216; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1990, MMWR, V39, P81; 1982, BR J CLIN PHARM, V14, P97; 1979, JAMA-J AM MED ASSOC, V242, P2562	26	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					954	957		10.1001/jama.267.7.954	http://dx.doi.org/10.1001/jama.267.7.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734108				2022-12-24	WOS:A1992HD15500029
J	SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G				SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G			PLASMA-CHOLESTEROL CONCENTRATION AND MORTALITY - THE WHITEHALL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL SERUM-CHOLESTEROL; FOLLOW-UP; CANCER MORTALITY; RISK-FACTORS; DENSITY-LIPOPROTEIN; COLON CANCER; CARDIOVASCULAR-DISEASE; 7 COUNTRIES; DEATH	Objective. - To examine the relationship between plasma cholesterol concentration and mortality from major causes of death. Design. - Cohort study. Setting. - Civil service offices in London, England. Participants. - There were 17 718 male civil servants aged 40 through 64 years at the time of study entry between 1967 and 1969. Main Outcome Measure. - Mortality from major cause groups. Results. - There were 4022 deaths in the cohort over the 18 years of follow-up. Total mortality increased with cholesterol level, although mortality in the small group with very low cholesterol levels (5% of study population) was nonsignificantly higher (P > .5) than that of the remainder of the lowest quintile cholesterol group. Coronary heart disease mortality increased with increasing cholesterol concentration from the lowest levels (P < .001 for trend). The cancer mortality rate in the group below the fifth centile of the cholesterol distribution was higher than in the remainder of the cohort for lung (P < .001), pancreas (P = .05), liver (P = .09), and all smoking-related cancers (P = .02). Only for lung cancer was there a consistent inverse trend with cholesterol level (P < .01). Rates of mortality due to non-neoplastic respiratory disease were inversely related to cholesterol level (P < .001). Health state at the time of examination and socioeconomic position were related to cholesterol concentration-subjects in lower employment grades, with disease at baseline, with a history of recent unexplained weight loss, or who had been widowed had lower initial cholesterol levels. These associations largely accounted for the relationships between cholesterol level and noncardiovascular mortality. Conclusions. - The inverse associations between plasma cholesterol concentration and mortality from certain causes of death seen in cohort studies could be because the participants with low cholesterol levels possess other characteristics that place them at an elevated risk of death.			SMITH, GD (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; BOTTIGER LE, 1982, ACTA MED SCAND, V211, P437; BUDD D, 1986, CANCER, V58, P1361, DOI 10.1002/1097-0142(19860915)58:6<1361::AID-CNCR2820580630>3.0.CO;2-S; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FISER RH, 1972, J INFECT DIS, V125, P54, DOI 10.1093/infdis/125.1.54; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GERHARDSSON M, 1986, INT J EPIDEMIOL, V15, P155, DOI 10.1093/ije/15.2.155; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; HAMMOND EC, 1966, EPIDEMIOLOGICAL APPR, P127; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JOHANSEN H, 1987, CAN MED ASSOC J, V136, P823; JOHANSSON BW, 1973, EARLY PHASES CORONAR, P314; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KERTTULA Y, 1988, ANN CLIN RES, V20, P184; KEYS A, 1985, AM J EPIDEMIOL, V121, P870, DOI 10.1093/oxfordjournals.aje.a114057; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; MARMOT MG, 1984, LANCET, V1, P1003; MORRIS DL, 1983, CANCER-AM CANCER SOC, V52, P1754, DOI 10.1002/1097-0142(19831101)52:9<1754::AID-CNCR2820520933>3.0.CO;2-J; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NEATON JD, IN PRESS ARCH INTERN; NEUGUT AI, 1989, INT J EPIDEMIOL, V4, P798; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PETERSSON B, 1984, AM J MED, V77, P418, DOI 10.1016/0002-9343(84)90096-2; PETERSSON B, 1983, KLIN WOCHENSCHR, V63, P795; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REID DD, 1974, LANCET, V1, P469; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; SMITH GD, IN PRESS BMJ; SMITH GD, IN PRESS AM J EPIDEM; STEMMERMANN GN, 1981, J NATL CANCER I, V67, P1179; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; THOMAS CB, 1982, JOHNS HOPKINS MED J, V150, P89; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VITOLS S, 1985, LANCET, V2, P1150; WALD NJ, 1989, BRIT J CANCER, V59, P936, DOI 10.1038/bjc.1989.198; WALLACE RB, 1982, J NATL CANCER I, V68, P915; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3; YAARI S, 1981, LANCET, V1, P1011; 1982, JAMA-J AM MED ASSOC, V248, P2853	72	255	258	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					70	76		10.1001/jama.267.1.70	http://dx.doi.org/10.1001/jama.267.1.70			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727199				2022-12-24	WOS:A1992GW84800026
J	KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK				KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK			CLONING OF CDNA FOR THE GLUTAMATE-BINDING SUBUNIT OF AN NMDA RECEPTOR COMPLEX	NATURE			English	Article							FUNCTIONAL EXPRESSION; PROTEIN; FAMILY; HOMOLOGY; SEQUENCE; BRAIN; SHOWS	THE amino acids L-glutamic and L-aspartic acids form the most widespread excitatory transmitter network in mammalian brain 1,2. The excitation produced by L-glutamic acid is important in the early development of the nervous system 3,4, Synaptic plasticity and memory formation 5-6, seizures 7,8 and neuronal degeneration 9,10. The receptors activated by L-glutamic acid are a target for therapeutic intervention in neurodegenerative diseases, brain ischaemia and epilepsy. There are two types of receptors for the excitatory amino acids, those that lead to the opening of cation-selective channels and those that activate phospholipase C (ref. 11). The receptors activating ion channels are NMDA (N-methyl-D-aspartate) and kainate/AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive receptors. The complementary DNAs for the kainate/AMPA receptor 12,13 and for the metabotropic receptor 14 have been cloned. We report here on the isolation and characterization of a protein complex of four major proteins that represents an intact complex of the NMDA receptor ion channel and on the cloning of the cDNA for one ot the subunits of this receptor complex, the glutamate-binding protein.	UNIV KANSAS,DEPT PHARMACOL & TOXICOL,2099 CONSTANT AVE,W CAMPUS,LAWRENCE,KS 66047; UNIV KANSAS,CTR BIOMED RES,LAWRENCE,KS 66047	University of Kansas; University of Kansas								BALAZS R, 1988, NEUROSCI LETT, V87, P80, DOI 10.1016/0304-3940(88)90149-8; CHAPMAN AG, 1987, EUR J PHARMACOL, V139, P91, DOI 10.1016/0014-2999(87)90501-2; CHEN JW, 1988, J BIOL CHEM, V263, P417; CHOI DW, 1987, J NEUROSCI, V7, P369; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; EATON MJ, 1990, J BIOL CHEM, V265, P16196; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEAN DW, 1988, NEUROPHARMACOLOGY, V27, P557; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, IN PRESS BRAIN RES; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEYER JM, 1977, BIOCHEMISTRY-US, V16, P1158, DOI 10.1021/bi00625a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WEILOCH T, 1985, SCIENCE, V230, P681	32	153	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					70	73		10.1038/354070a0	http://dx.doi.org/10.1038/354070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719427				2022-12-24	WOS:A1991GN82900060
J	BANCHEREAU, J; ROUSSET, F				BANCHEREAU, J; ROUSSET, F			GROWING HUMAN LYMPHOCYTES-B IN THE CD40 SYSTEM	NATURE			English	Article							CELLS				BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.							BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	9	182	192	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					678	679		10.1038/353678a0	http://dx.doi.org/10.1038/353678a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1717852				2022-12-24	WOS:A1991GK67200077
J	TREZISE, AEO; BUCHWALD, M				TREZISE, AEO; BUCHWALD, M			INVIVO CELL-SPECIFIC EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							IDENTIFICATION; GENE	CYSTIC fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 1-3. The principal manifestations of CF include increased concentration of Cl- in exocrine gland secretions 4,5, pancreatic insufficiency, chronic lung disease, intestinal blockage and malabsorption of fat 5,6, and male and female infertility 7. Insight into the function of CFTR can be gained by correlating its cell-specific expression with the physiology of those cells and with CF pathology. Determination of CFTR messenger RNA in rat tissues by in situ hybridization shows that it is specifically expressed in the ductal cells of the pancreas and the salivary glands. In the intestine, decreasing gradients of expression of the CFTR gene are observed on both the crypt-villus and the proximal-distal axes. This expression is consistent with CFTR being responsible for bidirectional Cl- transport, secretion in the intestinal crypts 8 and reabsorption in the salivary gland ducts 4, and suggests that in these tissues CFTR functions as a regulated Cl- channel. In the lung, a broad band of hybridization includes the mucosa and submucosa of the bronchi and bronchioles. In the testis, CFTR expression is regulated during the cycle of the seminiferous epithelium. Post-meiotic expression is maximal in the round spermatids of stages VII and VIII, suggesting that CFTR plays a critical role in spermatogenesis and that deficiency of this function contributes to CF male infertility.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BURGMAN SM, 1984, CYSTIC FIBROSIS, P323; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; QUINTON PM, 1990, FASEB J, V4, P1709; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Taussig LM, 1984, CYSTIC FIBROSIS, P338; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054	13	322	329	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					434	437		10.1038/353434a0	http://dx.doi.org/10.1038/353434a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1716739				2022-12-24	WOS:A1991GH60600058
J	COEN, ES; MEYEROWITZ, EM				COEN, ES; MEYEROWITZ, EM			THE WAR OF THE WHORLS - GENETIC INTERACTIONS CONTROLLING FLOWER DEVELOPMENT	NATURE			English	Review							ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; MORPHOGENESIS	The analysis of mutations affecting flower structure has led to the identification of some of the genes that direct flower development. Cloning of these genes has allowed the formulation of molecular models of how floral meristem and organ identity may be specified, and has shown that the distantly related flowering plants Arabidopsis thaliana and Antirrhinum majus use homologous mechanisms in floral pattern formation.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; JOHN INNES INST, DEPT GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND	California Institute of Technology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Meyerowitz, Elliot M/A-7118-2009					BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, PLANT MOL CELL BIOL, V5, P57; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT S1, V112, P157; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Stubbe H, 1966, GENETIK ZYTOLOGIE AN; Weberling F, 1989, MORPHOLOGY FLOWERS I; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	27	2124	2497	28	480	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					31	37		10.1038/353031a0	http://dx.doi.org/10.1038/353031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715520				2022-12-24	WOS:A1991GD80500048
J	RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA				RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA			IDENTIFICATION OF SPIROCHETES RELATED TO TREPONEMA-PALLIDUM IN NECROTIZING ULCERATIVE GINGIVITIS AND CHRONIC PERIODONTITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHAGEDENIS BIOTYPE REITER; MONOCLONAL-ANTIBODY; NICHOLS; SERUM; POLYPEPTIDES; DIAGNOSIS; PERTENUE; PROTEINS; DISEASE	Background. Spirochetes are commonly associated with periodontal disease, but it is not known whether these treponemes are pathogenic or merely opportunistic. We sought to determine whether spirochetes present in periodontal disease share antigens thought to be unique to spirochetes that are known pathogens. Methods. We examined dental plaque from 24 healthy subjects, from ulcerative sites in 17 patients with ulcerative gingivitis, and from areas of involvement in 19 patients with chronic periodontitis, using an immunocytochemical technique with monoclonal antibodies against pathogen-specific determinants on 47-kd and 37-kd molecules from Treponema pallidum subspecies pallidum. Serum was tested against T pallidum by immunoblotting and by serologic assays for syphilis. Results. Spirochetes with a pathogen-specific epitope on a 47-kd molecule were not found in plaque samples from any of the 24 healthy subjects, but they were identified in plaque samples from 11 of 17 patients with ulcerative gingivitis (P < 0.001) and from 10 of 19 patients with periodontitis (P < 0.01). Monoclonal antibodies directed against a 37-kd molecule reacted with spirochetes in plaque samples from 1 of 14 controls, from all 11 patients with gingivitis from whom samples could be obtained (P < 0.001), and from 14 of 19 patients with periodontitis (P < 0.001). Five of 18 normal subjects had IgG against 47-kd and 37-kd molecules, but none had IgG against 14-kd or 12-kd molecules from T. pallidum subspecies pallidum. Among 19 patients with ulcerative gingivitis, IgG was identified against 47-kd molecules in 15, against 37-kd molecules in 12, against 14-kd molecules in 4, and against 12-kd molecules in 15. Conclusions. The spirochetes found in dental plaque from patients with ulcerative gingivitis or chronic periodontitis have antigens that are thought to be unique to pathogenic treponemes. This close antigenic relation suggests that T. pallidum or a closely related organism may be involved in the pathogenesis of periodontal disease.	USN,DENT RES INST,GREAT LAKES,IL 60088; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; OREGON HLTH SCI UNIV,SCH DENT,DEPT PERIODONTOL,PORTLAND,OR 97201	United States Department of Defense; United States Navy; University of Washington; University of Washington Seattle; Oregon Health & Science University	RIVIERE, GR (corresponding author), OREGON HLTH SCI UNIV,SCH DENT,DEPT PEDIAT DENT,611 SW CAMPUS DR,PORTLAND,OR 97201, USA.				NIAID NIH HHS [AI-18988] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018988] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKERZANDER SA, 1983, INFECT IMMUN, V42, P634, DOI 10.1128/IAI.42.2.634-638.1983; BAKERZANDER SA, 1985, J INFECT DIS, V15, P264; BARRON SL, 1991, ORAL MICROBIOL IMMUN, V6, P97, DOI 10.1111/j.1399-302X.1991.tb00458.x; BLANCO DR, 1986, J IMMUNOL, V137, P2031; COURTOIS GJ, 1983, J PERIODONTOL, V54, P671, DOI 10.1902/jop.1983.54.11.671; HANFF PA, 1982, J IMMUNOL, V129, P1287; HOOK EW, 1985, J CLIN MICROBIOL, V22, P241, DOI 10.1128/JCM.22.2.241-244.1985; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JACOBS PA, 1982, J MOL CATAL, V17, P145, DOI 10.1016/0304-5102(82)85026-8; JOHNSON BD, 1986, J PERIODONTOL, V57, P141, DOI 10.1902/jop.1986.57.3.141; JONES SA, 1984, J EXP MED, V160, P1404, DOI 10.1084/jem.160.5.1404; KORNMAN KS, 1987, J PERIODONTAL RES, V22, P192, DOI 10.1111/j.1600-0765.1987.tb01566.x; LAI CH, 1986, J CLIN PERIODONTOL, V13, P752, DOI 10.1111/j.1600-051X.1986.tb00878.x; LINDHE J, 1980, J PERIODONTOL, V51, P264, DOI 10.1902/jop.1980.51.5.264; LISTGARTEN M. A., 1965, ARCH ORAL BIOL, V10, P127, DOI 10.1016/0003-9969(65)90064-6; LISTGARTEN MA, 1965, J PERIODONTOL, V36, P328, DOI 10.1902/jop.1965.36.4.328; LISTGARTEN MA, 1976, J PERIODONTOL, V47, P1, DOI 10.1902/jop.1976.47.1.1; LISTGARTEN MA, 1967, J PERIODONTOL, V38, P379, DOI 10.1902/jop.1967.38.5.379; Loesche W J, 1988, Adv Dent Res, V2, P275; LOESCHE WJ, 1981, HOST PARASITE INTERA, P62; LUKEHART SA, 1985, J IMMUNOL, V134, P585; RADOLF JD, 1988, INFECT IMMUN, V56, P1825, DOI 10.1128/IAI.56.7.1825-1828.1988; RADOLF JD, 1986, INFECT IMMUN, V54, P626, DOI 10.1128/IAI.54.3.626-634.1986; TEW JG, 1985, J PERIODONTAL RES, V20, P580, DOI 10.1111/j.1600-0765.1985.tb00842.x; THORNBURG RW, 1983, INFECT IMMUN, V42, P623, DOI 10.1128/IAI.42.2.623-627.1983; Umemoto T, 1988, Adv Dent Res, V2, P292; 1969, MANUAL TESTS SYPHILI, P15	27	66	68	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					539	543		10.1056/NEJM199108223250803	http://dx.doi.org/10.1056/NEJM199108223250803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1713299	Bronze			2022-12-24	WOS:A1991GB44700003
J	VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B				VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B			STRUCTURAL DETERMINANTS OF ION FLOW THROUGH RECOMBINANT GLUTAMATE RECEPTOR CHANNELS	SCIENCE			English	Article								Functional glutamate receptors (GluRs) were transiently expressed in cultured mammalian cells from cloned complementary DNAs encoding GluR-A, -B, -C, or -D polypeptides. The steady-state current-voltage (I-V) relations of glutamate- and kainate-induced currents through homomeric channels fell into two classes: channels composed of either the GluR-A, -C, and -D subunits showed doubly rectifying I-V curves, and channels composed of the GluR-B subunits displayed simple outward rectification. The presence of GluR-B subunits in heteromeric GluRs determined the I-V behavior of the resulting channels. Site-directed mutagenesis identified a single amino acid difference (glutamine to arginine) in the putative transmembrane segment TM2 responsible for subunit-specific I-V relationships. The properties of heteromeric wild-type and mutant GluRs revealed that the dominance of GluR-B is due to the arginine residue in the TM2 region.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, W-6900 HEIDELBERG 1, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ADAMS PR, 1975, BRIT J PHARMACOL, V53, P308, DOI 10.1111/j.1476-5381.1975.tb07364.x; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONAS P, IN PRESS J PHYSL LON; JONAS P, UNPUB; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MONGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEHER E, 1975, P NATL ACAD SCI USA, V72, P2140, DOI 10.1073/pnas.72.6.2140; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHERIDAN RE, 1975, P NATL ACAD SCI USA, V72, P3496, DOI 10.1073/pnas.72.9.3496; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012	23	718	729	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1715	1718		10.1126/science.1710829	http://dx.doi.org/10.1126/science.1710829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710829				2022-12-24	WOS:A1991FT11400049
J	BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM				BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM			PARENTAL IMPRINTING OF THE MOUSE H19 GENE	NATURE			English	Article							EXPRESSION; EVOLUTION; RNA	THE mouse H19 gene encodes one of the most abundant RNAs in the developing mouse embryo 1. It is expressed at the blastocyst stage of development, and accumulates to high levels in tissues of endodermal and mesodermal origin (H. Kim, unpublished result). After birth the gene is repressed in all tissues except skeletal muscle. It lacks a common open reading frame in the 2.5-kilobase RNA, but has considerable nucleotide sequence similarity between the genes of rodents and humans 2,3. Expression of the gene in transgenic mice results in late prenatal lethality, suggesting that the dosage of its gene product is strictly controlled 4. The H19 gene maps to the distal segment of mouse chromosome 7, in a region that is parentally imprinted 5, a process by which genes are differentially expressed on the maternal and paternal chromosomes. We have now used an RNase protection assay that can distinguish between H19 alleles in four subspecies of Mus, to demonstrate that the H19 gene is parentally imprinted, with the active copy derived from the mother. This assay will be of general use in assaying allele-specific gene expression.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	BARTOLOMEI, MS (corresponding author), PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BONHOMME F, 1984, BIOCHEM GENET, V22, P275, DOI 10.1007/BF00484229; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, IN PRESS GENES DEV; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVISSON MT, 1988, MOUSE NEWS LETT, V81, P12; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAMMER MF, 1989, P NATL ACAD SCI USA, V86, P3261, DOI 10.1073/pnas.86.9.3261; LYON MF, 1988, AM J HUM GENET, V42, P8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	23	969	997	1	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					153	155		10.1038/351153a0	http://dx.doi.org/10.1038/351153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709450				2022-12-24	WOS:A1991FL03500053
J	VALLANCE, P; MONCADA, S				VALLANCE, P; MONCADA, S			HYPERDYNAMIC CIRCULATION IN CIRRHOSIS - A ROLE FOR NITRIC-OXIDE	LANCET			English	Article							L-ARGININE; ENDOTOXIN; INVIVO; BLOOD	Hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors are features of cirrhosis. These cardiovascular changes might be the result of increased synthesis of a vasodilator. Nitric oxide (NO), a potent vasodilator, is synthesised in and released from peripheral blood-vessels in man. Studies in animals indicate that bacterial endotoxin and cytokines induce NO synthase expression in vessel walls, with sustained NO release and consequent hypotension. Endotoxaemia is a common feature of cirrhosis; persistent induction of NO synthase may account for the associated haemodynamic changes.	WELLCOME RES LABS, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories								AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; BENDTSEN F, 1990, J HEPATOL, V10, P198, DOI 10.1016/0168-8278(90)90052-S; BOSCH J, 1988, KIDNEY LIVER DISEASE, P286; BOURGOIGNIE JJ, 1988, KIDNEY LIVER DISEASE, P486; BURTON GA, 1990, BRIT J PHARMACOL, V99, P364, DOI 10.1111/j.1476-5381.1990.tb14709.x; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; FONG YM, 1990, J CLIN INVEST, V85, P1896, DOI 10.1172/JCI114651; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LINTRUP J, 1966, ACTA MED SCAND, V179, P13; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MIYASE S, 1990, Gastroenterologia Japonica, V25, P356; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADLOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; SCHRIER RW, 1988, KIDNEY LIVER DISEASE, P265; SHEARMAN DJC, 1989, DISEASES GASTROINTES, P795; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TOLINS JP, 1990, AM J PHYSIOL, V258, pH655, DOI 10.1152/ajpheart.1990.258.3.H655; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1989, LANCET, V2, P997; WYKE RJ, 1989, BAILLIERE CLIN GASTR, V3, P187, DOI 10.1016/0950-3528(89)90052-3; YOMOTA M, 1989, J BIOCHEM BIOPH METH, V18, P97	27	580	603	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	1991	337	8744					776	778		10.1016/0140-6736(91)91384-7	http://dx.doi.org/10.1016/0140-6736(91)91384-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1706450				2022-12-24	WOS:A1991FD88400015
J	GOODALL, J				GOODALL, J			HELPING A CHILD TO UNDERSTAND HER OWN TESTICULAR FEMINIZATION	LANCET			English	Editorial Material								Children do not think as adults do. They would therefore be less worried than adults are about a diagnosis with serious or ominous implications, yet they are commonly left uninformed until someone judges that they are old enough to understand. For most, this means delivery of painful information during the very vulnerable teenage years. A better approach is to unfold the trust stage by stage, matching simple statements to the child's conceptual growth until the personal implication are finally realised as part of a maturing process. Use of this approach for a child with testicular feminisation is described.	N STAFFORDSHIRE HOSP,DEPT PAEDIAT,STOKE ON TRENT,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								BEADLE M, 1972, CHILDS MIND; BRANDON J, 1977, BRIT J SOC WORK, V7, P335; EISER C, 1983, CHILD CARE HLTH DEV, V9, P233, DOI 10.1111/j.1365-2214.1983.tb00320.x; GOODALL J, 1987, J ROY SOC HEALTH, V107, P224, DOI 10.1177/146642408710700606; Goodenough F. L., 1963, GOODENOUGH HARRIS DR; SPINETTA J, 1980, PSYCHOL ASPECTS CHIL	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					33	35		10.1016/0140-6736(91)93344-9	http://dx.doi.org/10.1016/0140-6736(91)93344-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EQ604	1702173				2022-12-24	WOS:A1991EQ60400018
J	MERLUZZI, VJ; HARGRAVE, KD; LABADIA, M; GROZINGER, K; SKOOG, M; WU, JC; SHIH, CK; ECKNER, K; HATTOX, S; ADAMS, J; ROSEHTHAL, AS; FAANES, R; ECKNER, RJ; KOUP, RA; SULLIVAN, JL				MERLUZZI, VJ; HARGRAVE, KD; LABADIA, M; GROZINGER, K; SKOOG, M; WU, JC; SHIH, CK; ECKNER, K; HATTOX, S; ADAMS, J; ROSEHTHAL, AS; FAANES, R; ECKNER, RJ; KOUP, RA; SULLIVAN, JL			INHIBITION OF HIV-1 REPLICATION BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR	SCIENCE			English	Article									UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT & MED,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	MERLUZZI, VJ (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042257] Funding Source: NIH RePORTER; NHLBI NIH HHS [HB 67027, HL 42257] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENVENISTE RE, 1975, SCIENCE, V190, P886, DOI 10.1126/science.52892; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HO DD, 1989, NEW ENGL J MED, V321, P1622; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, UNPUB; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; Moore M., COMMUNICATION; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SARMA PS, 1971, VIROLOGY, V44, P137, DOI 10.1016/0042-6822(71)90160-7; SINGER RH, 1989, BLOOD, V74, P2295; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SULLIVAN JM, UNPUB, P61901; TOJI L, 1969, P NATL ACAD SCI USA, V63, P871, DOI 10.1073/pnas.63.3.871; YARCHOAN R, 1986, LANCET, V1, P575	23	788	834	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 7	1990	250	4986					1411	1413		10.1126/science.1701568	http://dx.doi.org/10.1126/science.1701568			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL843	1701568				2022-12-24	WOS:A1990EL84300043
J	GREGORY, RJ; CHENG, SH; RICH, DP; MARSHALL, J; PAUL, S; HEHIR, K; OSTEDGAARD, L; KLINGER, KW; WELSH, MJ; SMITH, AE				GREGORY, RJ; CHENG, SH; RICH, DP; MARSHALL, J; PAUL, S; HEHIR, K; OSTEDGAARD, L; KLINGER, KW; WELSH, MJ; SMITH, AE			EXPRESSION AND CHARACTERIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article									GENZYME CORP,1 MP RD,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; IG LABS INC,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; University of Iowa; Howard Hughes Medical Institute; University of Iowa			Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Marshall, John/0000-0003-1361-2869; Ostedgaard, Lynda/0000-0001-7717-3442				Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; MOLE SE, 1985, J VIROL, V54, P703, DOI 10.1128/JVI.54.3.703-710.1985; Murikami H., 1980, P NATL ACAD SCI USA, V77, P3464; NASH B, 1984, J BIOL CHEM, V259, P678; QUINTON PM, 1989, CLIN CHEM, V35, P726; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J., 1989, MOL CLONING LAB MANU; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WURZNER R, 1980, J IMMUN METHS, V126, P231	33	334	361	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					382	386		10.1038/347382a0	http://dx.doi.org/10.1038/347382a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699127				2022-12-24	WOS:A1990EA56400063
J	NADEL, AS; GREEN, JK; HOLMES, LB; FRIGOLETTO, FD; BENACERRAF, BR				NADEL, AS; GREEN, JK; HOLMES, LB; FRIGOLETTO, FD; BENACERRAF, BR			ABSENCE OF NEED FOR AMNIOCENTESIS IN PATIENTS WITH ELEVATED LEVELS OF MATERNAL SERUM ALPHA-FETOPROTEIN AND NORMAL ULTRASONOGRAPHIC EXAMINATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BRIGHAM & WOMENS HOSP,DEPT NEWBORN MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	NADEL, AS (corresponding author), BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024560] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24560] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS MJ, 1984, AM J OBSTET GYNECOL, V148, P241, DOI 10.1016/S0002-9378(84)80062-9; AULA P, 1978, AM J DIS CHILD, V132, P984, DOI 10.1001/archpedi.1978.02120350048008; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P584; DRUGAN A, 1988, OBSTET GYNECOL, V72, P627; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Milunsky A., 1986, GENETIC DISORDERS FE, P453; NELSON K, 1989, NEW ENGL J MED, V320, P19, DOI 10.1056/NEJM198901053200104; NICOLAIDES KH, 1986, LANCET, V2, P72; NORIO R, 1988, POPULATION STRUCTURE, P600; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; RICHARDS DS, 1988, OBSTET GYNECOL, V71, P203; Romero R., 1988, PRENATAL DIAGNOSIS C; SIMPSON JL, 1989, MATERNAL FETAL MED P, P78; TABOR A, 1986, LANCET, V1, P1287; VANDENHOF MC, 1990, AM J OBSTET GYNECOL, V162, P322, DOI 10.1016/0002-9378(90)90378-K; Weinstein MC, 1980, CLIN DECISION ANAL	16	79	84	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 30	1990	323	9					557	561		10.1056/NEJM199008303230901	http://dx.doi.org/10.1056/NEJM199008303230901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DW219	1696358				2022-12-24	WOS:A1990DW21900001
J	PATERSON, Y; ENGLANDER, SW; RODER, H				PATERSON, Y; ENGLANDER, SW; RODER, H			AN ANTIBODY-BINDING SITE ON CYTOCHROME-C DEFINED BY HYDROGEN-EXCHANGE AND 2-DIMENSIONAL NMR	SCIENCE			English	Article									UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	PATERSON, Y (corresponding author), UNIV PENN, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA.		Roder, Heinrich/B-3455-2009	Roder, Heinrich/0000-0003-1860-2491; Paterson, Yvonne/0000-0002-9406-4958	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035926, R01GM031847] Funding Source: NIH RePORTER; NCRR NIH HHS [S07-RR-05415-28] Funding Source: Medline; NIGMS NIH HHS [GM 31847, R01 GM031847, GM 35926] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANGLISTER J, 1989, BIOCHEMISTRY-US, V28, P3360, DOI 10.1021/bi00434a035; ANGLISTER J, 1988, BIOCHEMISTRY-US, V27, P717, DOI 10.1021/bi00402a034; ANGLISTER J, 1987, BIOCHEMISTRY-US, V26, P6058, DOI 10.1021/bi00393a017; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BRANDT P, 1987, BIOCHEMISTRY-US, V26, P3156, DOI 10.1021/bi00385a032; BURNENS A, 1987, SCIENCE, V235, P780, DOI 10.1126/science.2433768; BUSHNELL GW, IN PRESS J MOL BIOL; CARBONE FR, 1985, J IMMUNOL, V135, P2609; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1985, COMPUT CHEM, V9, P1, DOI 10.1016/0097-8485(85)80011-5; COOPER HM, 1987, J BIOL CHEM, V262, P11591; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; ENGLANDER JJ, 1987, BIOCHEMISTRY-US, V26, P1846, DOI 10.1021/bi00381a009; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FENG Y, 1989, BIOCHEMISTRY-US, V28, P195, DOI 10.1021/bi00427a027; GOETZE AM, 1978, BIOCHEMISTRY-US, V17, P1733, DOI 10.1021/bi00602a023; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; JEMMERSON R, 1986, BIOTECHNIQUES, V4, P1818; KOOISTRA DA, 1978, BIOCHEMISTRY-US, V17, P345, DOI 10.1021/bi00595a024; KUWAJIMA K, 1983, J MOL BIOL, V169, P299, DOI 10.1016/S0022-2836(83)80185-5; LOUIE G, 1988, J MOL BIOL, V201, P765, DOI 10.1016/0022-2836(88)90473-1; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; NAGAYAMA K, 1980, J MAGN RESON, V40, P321, DOI 10.1016/0022-2364(80)90255-3; O'Donnell T. J., 1981, Computer Graphics, V15, P133, DOI 10.1145/965161.806799; OERTLE M, 1989, EUR J BIOCHEM, V182, P699, DOI 10.1111/j.1432-1033.1989.tb14881.x; PATERSON Y, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P177; RODER H, UNPUB; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; WAND AJ, 1989, BIOCHEMISTRY-US, V28, P186, DOI 10.1021/bi00427a026; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1100, DOI 10.1021/bi00353a024; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; Wuthrich K., 1986, NMR PROTEINS NUCL AC	42	169	174	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 17	1990	249	4970					755	759		10.1126/science.1697101	http://dx.doi.org/10.1126/science.1697101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV088	1697101	Green Accepted			2022-12-24	WOS:A1990DV08800024
J	KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE				KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE			THE NATURAL-HISTORY OF ELECTROCARDIOGRAPHIC PREEXCITATION IN MEN - THE MANITOBA FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						PREEXCITATION SYNDROMES; ELECTROCARDIOGRAPHY; ARRHYTHMIA; WOLFF-PARKINSON-WHITE SYNDROME; CORONARY DISEASE	PARKINSON-WHITE SYNDROME; POPULATION	Objective: To examine the natural history of preexcitation occurring on the routine electrocardiogram (ECG). Design: A longitudinal cohort study of 3983 originally healthy men followed prospectively for 40 years. Setting: Free-living (community-dwelling) study members residing predominantly in Canada. Participants: Nineteen male study members with preexcitation occurring during routine examination in the 40-year follow-up of the Manitoba Follow-up Study. Measurements: Routinely requested clinical examinations and ECGs, supplemented by information supplied by the study member or his physician. Main Results: Ten study members were found to have preexcitation at enrollment, for a prevalence of 2.5 per 1000 (95% CI, 1.2 to 4.6). A delta wave was first detected during follow-up in an additional nine study members. Seventeen of 19 study members did not have the delta wave at some later time, and preexcitation was intermittently present in most of these members. Over time there was a loss of preexcitation, with 15 of 19 study members no longer exhibiting a delta wave by the end of follow-up. Five of 11 study members with symptoms had physician confirmation of an arrhythmia. Fourteen study members remain alive, and none of the five deaths was attributed to preexcitation. Conclusions: Preexcitation found on routine ECG in our originally healthy male study group did not confer excess morbidity or mortality, even in those study members who developed symptomatic arrhythmias. Most preexcitation was intermittent and disappeared over time.	MANITOBA FOLLOW UP STUDY, 148-770 BANNATYNE AVE, WINNIPEG R3E 0W3, MANITOBA, CANADA									AVERILL KH, 1960, AM J CARDIOL, V6, P108, DOI 10.1016/0002-9149(60)90041-2; BERKMAN NL, 1968, NEW ENGL J MED, V278, P492, DOI 10.1056/NEJM196802292780906; FLEISS JL, 1981, STAT METHODS RATES P, P237; FLENSTED.E, 1969, ACTA MED SCAND, V186, P65; GALLAGHER JJ, 1978, PROG CARDIOVASC DIS, V20, P285, DOI 10.1016/0033-0620(78)90015-4; GUIZE L, 1985, ANN MED INTERNE, V136, P474; HISS RG, 1962, CIRCULATION, V25, P947, DOI 10.1161/01.CIR.25.6.947; HURST JW, 1986, HEART, P415; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1989, NEW ENGL J MED, V320, P1230; KLEIN GJ, 1983, AM J CARDIOL, V52, P292, DOI 10.1016/0002-9149(83)90125-X; KOSSMANN CE, 1967, CIRCULATION, V35, P583, DOI 10.1161/01.CIR.35.3.583; MATHEWSON FAL, 1960, CIRCULATION, V21, P196, DOI 10.1161/01.CIR.21.2.196; MUNGER TM, 1990, CIRCULATION, V82, P317; Prineas R., 1982, MINNESOTA CODE MANUA; PROUDFIT WL, 1989, CLEV CLIN J MED, V56, P601, DOI 10.3949/ccjm.56.6.601; REED JC, 1947, AM HEART J, V33, P701; SEARS GA, 1962, CAN MED ASSOC J, V87, P1213; SMITH RF, 1964, CIRCULATION, V29, P672, DOI 10.1161/01.CIR.29.5.672; SORIA R, 1989, ARCH MAL COEUR VAISS, V82, P331; WELLENS HJJ, 1983, MOD CONC CARDIOV DIS, V52, P53; Wilson FN, 1915, ARCH INTERN MED, V16, P1008; Wolff L, 1930, AM HEART J, V5, P685, DOI 10.1016/S0002-8703(30)90086-5	23	65	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					456	460		10.7326/0003-4819-116-6-456	http://dx.doi.org/10.7326/0003-4819-116-6-456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739235				2022-12-24	WOS:A1992HJ59800004
J	BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ				BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ			SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN	NATURE			English	Article							HUMAN ALPHA-THROMBIN; PROTEIN; RNA; SEQUENCES; INVITRO; LIGANDS; GENOME	APTAMERS 1 are double-stranded DNA or single-stranded RNA molecules that bind specific molecular targets. Large randomly generated populations can be enriched in aptamers by in vitro selection and polymerase chain reaction 1-11. But so far single-stranded DNA has not been investigated for aptamer properties, nor has a target protein been considered that does not interact physiologically with nucleic acid. Here we describe the isolation of single-stranded DNA aptamers to the protease thrombin of the blood coagulation cascade and report binding affinities in the range 25-200 nM. Sequence data from 32 thrombin aptamers, selected from a pool of DNA containing 60 nucleotides of random sequence, displayed a highly conserved 14-17-base region. Several of these aptamers at nanomolar concentrations inhibited thrombin-catalysed fibrin-clot formation in vitro using either purified fibrinogen or human plasma.	GILEAD SCI INC,346 LAKESIDE DR,FOSTER CITY,CA 94404	Gilead Sciences								BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GREEN R, 1990, NATURE, V347, P467; HULTMAN T, 1988, NUCLEOS NUCLEOT, V7, P629, DOI 10.1080/07328318808056299; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	15	2017	2304	30	1173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					564	566		10.1038/355564a0	http://dx.doi.org/10.1038/355564a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741036				2022-12-24	WOS:A1992HC52600065
J	STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS				STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS			POTABLE WATER AS A CAUSE OF SPORADIC CASES OF COMMUNITY-ACQUIRED LEGIONNAIRES-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEGIONELLA-PNEUMOPHILA CONTAMINATION; DISTRIBUTION-SYSTEMS; PNEUMONIA; PREVALENCE	Background. The environmental sources of sporadic, community-acquired legionnaires' disease are largely unknown, and culturing of water sources after identification of a case is currently not recommended. We conducted a prospective study of sporadic cases of community-acquired legionnaires' disease to determine whether the environmental reservoirs could be identified. Methods. We cultured samples of potable water obtained from sources to which each of 20 patients with culture-confirmed, community-acquired legionnaires' disease had been exposed during the two weeks before the onset of symptoms. Monoclonal-antibody subtyping and restriction-endonuclease analysis were performed on the legionella isolates recovered from both the patients and the associated environmental cultures. Results. For 8 of the 20 patients, isolates of Legionella pneumophila with identical subtypes were identified in cultures from both the patient and the potable water to which the patient had been exposed. The environmental reservoirs linked to the infections were the water supplies of two private residences, two nursing homes, two hospital outpatient clinics, and an industrial plant. Conclusions. Potable-water supplies that harbor L. pneumophila are an important source of community-acquired legionnaires' disease. Future studies should include attempts to identify the environmental sources of this infection.	VET AFFAIRS MED CTR, INFECT DIS SECT, UNIV DR C, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; UNIV LAVAL, QUEBEC CITY G1K 7P4, QUEBEC, CANADA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Stanford University								[Anonymous], 1985, CAN MED ASSOC J, V132, P160; ARNOW PM, 1985, J INFECT DIS, V152, P145, DOI 10.1093/infdis/152.1.145; AUBERTIN J, 1987, INFECTION, V15, P328, DOI 10.1007/BF01647732; BATES JH, 1989, CHEST, V95, pS194, DOI 10.1378/chest.95.3_Supplement.194S; BEST M, 1983, LANCET, V2, P307; CHERRY WB, 1978, J CLIN MICROBIOL, V8, P329; EZZEDDINE H, 1989, J HOSP INFECT, V13, P121, DOI 10.1016/0195-6701(89)90018-2; FALCO V, 1991, CHEST, V100, P1007, DOI 10.1378/chest.100.4.1007; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FIELDS BS, 1984, APPL ENVIRON MICROB, V47, P467, DOI 10.1128/AEM.47.3.467-471.1984; FISHERHOCH SP, 1981, LANCET, V1, P932; FRIISMOLLER A, 1986, SCAND J INFECT DIS, V18, P321, DOI 10.3109/00365548609032343; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; KLIMEK JJ, 1983, AM J INFECT CONTROL, V11, P79, DOI 10.1016/0196-6553(83)90117-7; LEE TC, 1988, ARCH ENVIRON HEALTH, V43, P59, DOI 10.1080/00039896.1988.9934375; MACFARLANE JT, 1982, LANCET, V2, P255; MUDER RR, 1983, JAMA-J AM MED ASSOC, V249, P3184, DOI 10.1001/jama.249.23.3184; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; MURACA PW, 1988, AM IND HYG ASSOC J, V49, P584, DOI 10.1202/0002-8894(1988)049&lt;0584:LDITWE&gt;2.0.CO;2; MURACA PW, 1990, INFECT CONT HOSP EP, V11, P79, DOI 10.1086/646126; REDD SC, 1987, JAMA-J AM MED ASSOC, V257, P1221, DOI 10.1001/jama.257.9.1221; REDD SC, 1987, JAMA-J AM MED ASSOC, V2, P274; RUF B, 1989, LUNG, V167, P11, DOI 10.1007/BF02714926; STOUT JE, 1985, APPL ENVIRON MICROB, V49, P221, DOI 10.1128/AEM.49.1.221-228.1985; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P2595; SYNDER MB, 1990, J INFECT DIS, V162, P127, DOI 10.1093/infdis/162.1.127; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; Vickers R M, 1987, Semin Respir Infect, V2, P274; VICKERS RM, 1987, INFECT CONT HOSP EP, V8, P357, DOI 10.1017/S0195941700067412; VICKERS RM, IN PRESS J CLIN MICR; WADOWSKY RM, 1985, APPL ENVIRON MICROB, V49, P1197, DOI 10.1128/AEM.49.5.1197-1205.1985; WITHERELL LE, 1988, J AM WATER WORKS ASS, V80, P87	32	122	127	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					151	155		10.1056/NEJM199201163260302	http://dx.doi.org/10.1056/NEJM199201163260302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727545				2022-12-24	WOS:A1992GZ21300002
J	PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA				PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA			EFFECT OF FAST TRACK ADMISSION FOR ACUTE MYOCARDIAL-INFARCTION ON DELAY TO THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; GENERAL-PRACTITIONER; CARE UNIT; STREPTOKINASE; THERAPY; REDUCTION; PATIENT; POLICY; TIME	Objective - To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. Design - Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. Setting - Major accident and emergency, cardiac and trauma centre. Subjects - 359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. Main outcome measures - Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. Results - 248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. 95% (79/83) of patients treated with thrombolysis after fast track admission had the diagnosis confirmed by electrocardiography and enzyme analysis. The median delay from hospital admission to thrombolytic treatment fell from 93 minutes in 1987-8 to 49 minutes in fast track patients (p < 0.001). Delay in admission to the cardiac care unit was reduced by 47% for fast track patients (median 60 minutes in 1987-8 v 32 minutes in 1990, p < 0.001) and by 25% for all patients (60 minutes v 45 minutes, p < 0.001). Conclusion - This fast track system requires no additional staff or equipment, and it halves in-hospital delay to thrombolytic treatment without affecting the accuracy of diagnosis among patients requiring thrombolysis.	ROYAL INFIRM, DEPT CARDIOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh				Fox, Keith/0000-0002-0140-2752				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BURNS JMA, 1989, BRIT HEART J, V61, P322; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FOX KAA, 1990, BMJ-BRIT MED J, V300, P867, DOI 10.1136/bmj.300.6728.867; KNABB RM, 1987, J NUCL MED, V28, P1563; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MCNEILL AJ, 1991, Q J MED, V79, P487; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; PELL A C H, 1990, Health Bulletin (Edinburgh), V48, P225; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RIDKER P, 1990, Journal of the American College of Cardiology, V15, p167A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SHEEHAN FH, 1983, AM J CARDIOL, V52, P431, DOI 10.1016/0002-9149(83)90002-4; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILCOX RG, 1988, LANCET, V2, P525	22	99	97	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					83	87		10.1136/bmj.304.6819.83	http://dx.doi.org/10.1136/bmj.304.6819.83			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737145	Green Published, Bronze			2022-12-24	WOS:A1992HA17100021
J	PEI, D; ULRICH, HD; SCHULTZ, PG				PEI, D; ULRICH, HD; SCHULTZ, PG			A COMBINATORIAL APPROACH TOWARD DNA RECOGNITION	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; SEQUENCE-SPECIFIC CLEAVAGE; SITE-SPECIFIC CLEAVAGE; DUPLEX DNA; PLASMID DNA; LIGANDS; NUCLEASE; POLYMERASE; MOLECULES; INVITRO	A combinatorial approach has been used to identify individual RNA molecules from a large population of sequences that bind a 16-base pair homopurine-homopyrimidine DNA sequence through triple-helix formation. Fourteen of the seventeen clones selected contained stretches of pyrimidines highly homologous to the target DNA sequence (T.AT and C+.GC). In addition, these RNA molecules contained hairpin loops, interior loops, and nonstandard base triplets [C+(or C).AT, U.GC, G.GC, and A.AT] at various positions. Affinity cleavage experiments confirmed the ability of selected sequences to bind specifically to the target DNA. Systematic variation in both the target DNA sequence and buffer components should provide increased insight into the molecular interactions required for triple-helix-mediated recognition of natural DNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Pei, Dehua/P-4594-2016	Pei, Dehua/0000-0002-2057-6934; Ulrich, Helle D./0000-0003-0431-2223	NIGMS NIH HHS [R01GM41679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; KAISER R, 1991, NATURE, V350, P656, DOI 10.1038/350656d0; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LIPSETT MN, 1963, BIOCHEM BIOPH RES CO, V11, P224, DOI 10.1016/0006-291X(63)90338-3; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MILLER JH, 1966, P NATL ACAD SCI USA, V55, P1201, DOI 10.1073/pnas.55.5.1201; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MUAIYAMA T, 1968, TETRAHEDRON LETT, V56, P5907; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI DF, UNPUB; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WU TF, 1989, NUCLEIC ACIDS RES, V17, P3501, DOI 10.1093/nar/17.9.3501	40	58	66	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1408	1411		10.1126/science.1716784	http://dx.doi.org/10.1126/science.1716784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716784				2022-12-24	WOS:A1991GF85100038
J	ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ				ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ			DEMONSTRATION THAT CFTR IS A CHLORIDE CHANNEL BY ALTERATION OF ITS ANION SELECTIVITY	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; ION CHANNEL; PATCH-CLAMP; TRANSPORT; IDENTIFICATION; EXPRESSION; CELLS; CAMP	Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) generates adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, indicating that CFTR is either a chloride channel or a chloride channel regulator. To distinguish between these possibilities, basic amino acids in the putative transmembrane domains were mutated. The sequence of anion selectivity of cAMP-regulated channels in cells containing either endogenous or recombinant CFTR was bromide > chloride > iodide > fluoride. Mutation of the lysines at positions 95 or 335 to acidic amino acids converted the selectivity sequence to iodide > bromide > chloride > fluoride. These data indicate that CFTR is a cAMP-regulated chloride channel and that lysines 95 and 335 determine anion selectivity.	GENZYME CORP,FRAMINGHAM,MA 01701; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, IN PRESS P NATL ACAD; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CARSON MR, 1989, AM J PHYSIOL, V257, pL259, DOI 10.1152/ajplung.1989.257.4.L259; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DIAMOND G, 1991, AM ASS CANCER RES A, V33; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRZELCZAK Z, 1990, Journal of Cell Biology, V111, p310A; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; OSTEDGAARD LS, UNPUB; QUINTON PM, 1989, ANN NY ACAD SCI, V574, P438; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	36	990	1007	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					202	205		10.1126/science.1712984	http://dx.doi.org/10.1126/science.1712984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712984				2022-12-24	WOS:A1991FW16000039
J	MCARDLE, CS; HOLE, D				MCARDLE, CS; HOLE, D			IMPACT OF VARIABILITY AMONG SURGEONS ON POSTOPERATIVE MORBIDITY AND MORTALITY AND ULTIMATE SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE-BOWEL-CANCER; LOCAL RECURRENCE	Objective - To assess the differences among surgeons in postoperative complications, postoperative mortality, and survival in patients undergoing surgery for colorectal cancer. Design - Prospective study of patients with colorectal cancer managed by one of 13 consultant surgeons, none of whom had a special interest in colorectal surgery. Setting - Royal Infirmary, Glasgow. Patients - 645 sequential patients with colorectal cancer presenting over the six years from 1974 to 1979. Main outcome measures - Postoperative complications, postoperative mortality (within 30 days), and survival (up to 10 years); predictive factors for postoperative mortality and survival; and relative hazard rate ratios for individual surgeons. Results - The proportion of patients undergoing apparently curative resection varied among surgeons from 40% to 76%; overall postoperative mortality varied from 8% to 30%. After curative resection postoperative mortality varied from 0% to 20%, local recurrence from 0% to 21%, and the rate of anastomotic leak from 0% to 25%. Survival at 10 years in patients who underwent curative resection varied from 20% to 63%, two year survival in those who underwent palliative resection varied from 7% to 32%, and median survival in those who underwent palliative diversion varied from one to eight months. The hazard rate ratios among individual surgeons, taking into account the identified risk factors, varied from 0.56 to 2.03, from 0.17 to 1.92, and from 0.57 to 1.50 for curative resection, palliative resection, and palliative diversion, respectively. Conclusion - There were significant variations in patient outcome among surgeons after surgery for colorectal cancer; such differences compromise survival. A considerable improvement in overall survival might be achieved if such surgery were undertaken by surgeons with a special interest in colorectal surgery or surgical oncology.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20,SCOTLAND		MCARDLE, CS (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT SURG,GLASGOW G31 2ER,SCOTLAND.							AUSOBSKY JR, 1985, ANN ROY COLL SURG, V67, P159; Breslow NE, 1987, SCI PUBLICATION INT, V2; Buck N, 1987, REPORT CONFIDENTIAL; COX DR, 1972, J R STAT SOC B, V34, P187; FIELDING LP, 1980, BRIT MED J, V281, P411, DOI 10.1136/bmj.281.6237.411; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCARDLE CS, 1990, BRIT J SURG, V77, P280, DOI 10.1002/bjs.1800770314; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; SHANDALL A, 1985, BRIT J SURG, V72, P606, DOI 10.1002/bjs.1800720808	10	474	479	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1501	1505		10.1136/bmj.302.6791.1501	http://dx.doi.org/10.1136/bmj.302.6791.1501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1713087	Green Published, Bronze			2022-12-24	WOS:A1991FT50500021
J	PYLE, AM; CECH, TR				PYLE, AM; CECH, TR			RIBOZYME RECOGNITION OF RNA BY TERTIARY INTERACTIONS WITH SPECIFIC RIBOSE 2'-OH GROUPS	NATURE			English	Article							TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; KINETICS; BINDING; TEMPERATURE; SUBSTRATE; SELECTION	SHORTENED forms of the group I intron from Tetrahymena catalyse sequence-specific cleavage of exogenous oligonucleotide substrates 1, 2. The association between RNA enzyme (ribozyme) and substrate is mediated by pairing between an internal guide sequence on the ribozyme and a complementary sequence on the substrate 1, 3, 4. RNA substrates and cleavage products associate with a binding energy greater than that of base-pairing by approximately 4 kcal-mol-1 (at 42-degrees-C), whereas DNA associates with an energy around that expected for base-pairing 5-9. It has been proposed that the difference in binding affinity is due to specific 2'-OH groups on an RNA substrate forming stabilizing tertiary interactions with the core of the ribozxyme, or that the RNA.RNA helix formed upon association of an RNA substrate and the ribozyme might be more stable than an RNA.DNA helix of the same sequence 6. To differentiate between these two models, chimaeric oligonucleotides containing deoxynucleotide residues at successive positions along the chain were synthesized, and their equilibrium binding constants for association with the ribozyme were measured directly by a new gel electrophoresis technique 5. We report here that most of the extra binding energy can be accounted for by discrete RNA-ribozyme interactions, the 2'-OH group on the sugar residue three nucleotides from the cleavage site contributing the most interaction energy. Thus, in addition to the well documented binding of RNA to RNA by base-pairing 10-14, 2'-OH groups within a duplex can also mediate association between RNA molecules.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, CELL, V50, P951, DOI 10.1016/0092-8674(87)90522-8; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DIX DB, 1986, J BIOL CHEM, V261, P112; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NELSON JW, 1982, BIOCHEMISTRY-US, V21, P5289, DOI 10.1021/bi00264a026; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WU T, 1989, NUCLEIC ACIDS RES, V9, P3501; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	31	184	189	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					628	631		10.1038/350628a0	http://dx.doi.org/10.1038/350628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1708111				2022-12-24	WOS:A1991FH11200066
J	OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			CHARACTERIZATION OF 2 85KD PROTEINS THAT ASSOCIATE WITH RECEPTOR TYROSINE KINASES, MIDDLE-T/PP60C-SRC COMPLEXES, AND PI3-KINASE	CELL			English	Article							MIDDLE-T-ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-II; PHOSPHATIDYLINOSITOL KINASE; PDGF RECEPTOR; SEQUENCE-ANALYSIS; MESSENGER-RNAS; BOVINE BRAIN; INOSITOL 3-PHOSPHATE; HEMATOPOIETIC-CELLS	Affinity-purified bovine brain phosphatidylinositol 3-kinase (PI3-kinase) contains two major proteins of 85 and 110 kd. Amino acid sequence analysis and cDNA cloning reveals two related 85 kd proteins (p85-alpha and p85-beta), which both contain one SH3 and two SH2 regions (src homology regions). When expressed, these 85 kd proteins bind to and are substrates for tyrosine-phosphorylated receptor kinases and the polyoma virus middle-T antigen/pp60c-src complex, but lack PI3-kinase activity. However, an antiserum raised against p85-beta immunoprecipitates PI3-kinase activity. The active PI3-kinase complex containing p85-alpha or p85-beta and the 110 kd protein binds to PDGF but not EGF receptors. p85-alpha and p85-beta may mediate specific PI3-kinase interactions with a subset of tyrosine kinases.	UNIV COLL & MIDDLX SCH MED,DEPT CHEM PATHOL,LONDON,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	University of London; University College London; European Molecular Biology Laboratory (EMBL)	OTSU, M (corresponding author), LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON,ENGLAND.		Hsuan, Justin/C-8825-2009; Parker, Peter j/D-5192-2013	Hsuan, Justin/0000-0001-6083-7564; Fry, Michael/0000-0001-8518-1370; parker, peter/0000-0002-6218-2933; Ruiz Larrea, Fernanda/0000-0001-5610-7745				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COHEN B, 1990, MOL CELL BIOL, V87, P4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSTOVA J, 1989, NUCLEIC ACIDS RES, V17, P1427, DOI 10.1093/nar/17.4.1427; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACDONALD ML, 1985, P NATL ACAD SCI USA, V82, P3993, DOI 10.1073/pnas.82.12.3993; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P499, DOI 10.1093/nar/12.1Part2.499; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STOCKWELL PA, 1987, COMPUT APPL BIOSCI, V3, P37; SUGANO S, 1985, MOL CELL BIOL, V5, P2399, DOI 10.1128/MCB.5.9.2399; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; Summers MD, 1987, MANUAL METHODS BACUL; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; ULUG ET, 1990, J VIROL, V64, P3995; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	114	734	824	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					91	104		10.1016/0092-8674(91)90411-Q	http://dx.doi.org/10.1016/0092-8674(91)90411-Q			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707345	Bronze			2022-12-24	WOS:A1991FF77300012
J	BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F				BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F			LONG-TERM HUMAN B-CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40	SCIENCE			English	Article							ACTIVATION; GROWTH; PROLIFERATION; MONOCYTES; RECEPTOR; ANTIGEN; BP35	CD40 is a 45- to 50-kilodalton transmembrane glycoprotein expressed on B lymphocytes, epithelial cells, and some carcinoma cell lines. Human resting B lymphocytes entered a state of sustained proliferation when incubated with both the mouse fibroblastic Ltk- cell line that had been transfected with the human Fc receptor (Fc-gamma-RII/CDw32) and monoclonal antibodies to CD40. In combination with interleukin-4, factor-dependent long-term normal human B cell lines were generated that were consistently negative for Epstein-Barr viral infection. Thus, cross-linking of CD40 is likely to represent an important phenomenon in the clonal expansion of B cells.			BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE.		De Paoli, Paolo/AAG-2586-2021	De Paoli, Paolo/0000-0002-9502-1781				BANCHEREAU J, UNPUB; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DEFRANCE T, 1990, CYTOKINES B LYMPHOCY, P65; KANEOKA H, 1983, J IMMUNOL, V131, P158; LEFKOVITS I, 1985, LIMITING DILUTION AN, P81; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PELTZ GA, 1988, J IMMUNOL, V141, P1891; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROUSSET F, UNPUB; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPITS H, 1987, J IMMUNOL, V139, P1142; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAX WJM, 1984, J IMMUNOL, V133, P1185; TISCH R, 1988, IMMUNOL TODAY, V9, P145, DOI 10.1016/0167-5699(88)91202-9; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818	22	620	685	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					70	72		10.1126/science.1702555	http://dx.doi.org/10.1126/science.1702555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702555				2022-12-24	WOS:A1991EQ60300028
J	GOULD, KL; MORENO, S; TONKS, NK; NURSE, P				GOULD, KL; MORENO, S; TONKS, NK; NURSE, P			COMPLEMENTATION OF THE MITOTIC ACTIVATOR, P80CDC25, BY A HUMAN PROTEIN-TYROSINE PHOSPHATASE	SCIENCE			English	Article									UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GOULD, KL (corresponding author), UNIV OXFORD, DEPT BIOCHEM, MICROBIOL UNIT, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 3QU, ENGLAND.		Moreno, Sergio/K-3671-2014	Moreno, Sergio/0000-0002-8039-1413; Gould, Kathleen/0000-0002-3810-4070				COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, IN PRESS P NATL ACAD; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FANTES PA, 1981, J BACTERIOL, V146, P746, DOI 10.1128/JB.146.2.746-754.1981; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, UNPUB; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY CJ, UNPUB; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9	34	188	200	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	1990	250	4987					1573	1576		10.1126/science.1703321	http://dx.doi.org/10.1126/science.1703321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM931	1703321				2022-12-24	WOS:A1990EM93100041
J	WAKUI, M; OSIPCHUK, YV; PETERSEN, OH				WAKUI, M; OSIPCHUK, YV; PETERSEN, OH			RECEPTOR-ACTIVATED CYTOPLASMIC CA2+ SPIKING MEDIATED BY INOSITOL TRISPHOSPHATE IS DUE TO CA2+-INDUCED CA2+ RELEASE	CELL			English	Article									UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAUCH P, 1986, J MEMBRANE BIOL, V94, P99, DOI 10.1007/BF01871191; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PETERSEN OH, 1989, CELL CALCIUM, V10, P375, DOI 10.1016/0143-4160(89)90063-8; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAYLOR CW, 1986, BIOCHEM J, V238, P765, DOI 10.1042/bj2380765; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	46	258	260	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 30	1990	63	5					1025	1032		10.1016/0092-8674(90)90505-9	http://dx.doi.org/10.1016/0092-8674(90)90505-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701691				2022-12-24	WOS:A1990EL75900017
J	RICH, DP; ANDERSON, MP; GREGORY, RJ; CHENG, SH; PAUL, S; JEFFERSON, DM; MCCANN, JD; KLINGER, KW; SMITH, AE; WELSH, MJ				RICH, DP; ANDERSON, MP; GREGORY, RJ; CHENG, SH; PAUL, S; JEFFERSON, DM; MCCANN, JD; KLINGER, KW; SMITH, AE; WELSH, MJ			EXPRESSION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CORRECTS DEFECTIVE CHLORIDE CHANNEL REGULATION IN CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS	NATURE			English	Article									UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701; IG LABS INC,FRAMINGHAM,MA 01701; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; NEW ENGLAND MED CTR,DEPT PEDIAT,BOSTON,MA 02111; NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Sanofi-Aventis; Genzyme Corporation; Tufts University; Tufts Medical Center; Tufts Medical Center			Cheng, Seng H/AAC-6564-2022	Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAO AC, 1990, J MEMBRANE BIOL, V113, P193, DOI 10.1007/BF01870071; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; CLIFF WH, 1989, PED PULM S, V4, P45; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fields BN, 1985, VIROLOGY, P685; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JEFFERSON DM, IN PRESS AM J PHYSL; KEEREM BS, 1989, SCIENCE, V245, P1073; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LI M, 1990, AM J PHYSIOL, V259, pC295, DOI 10.1152/ajpcell.1990.259.2.C295; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAM SJ, 1989, P NATL ACAD SCI USA, V86, P10166, DOI 10.1073/pnas.86.24.10166; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; VERKMAN AS, 1989, ANAL BIOCHEM, V178, P355, DOI 10.1016/0003-2697(89)90652-0; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WELSH MJ, 1985, J MEMBRANE BIOL, V88, P149, DOI 10.1007/BF01868429	35	586	623	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					358	363		10.1038/347358a0	http://dx.doi.org/10.1038/347358a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699126				2022-12-24	WOS:A1990EA56400053
J	DRUMM, ML; POPE, HA; CLIFF, WH; ROMMENS, JM; MARVIN, SA; TSUI, LC; COLLINS, FS; FRIZZELL, RA; WILSON, JM				DRUMM, ML; POPE, HA; CLIFF, WH; ROMMENS, JM; MARVIN, SA; TSUI, LC; COLLINS, FS; FRIZZELL, RA; WILSON, JM			CORRECTION OF THE CYSTIC-FIBROSIS DEFECT INVITRO BY RETROVIRUS-MEDIATED GENE-TRANSFER	CELL			English	Article									UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35233; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Howard Hughes Medical Institute; University of Michigan System; University of Michigan	DRUMM, ML (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Tsui, Lap-chee/A-1081-2010; Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131	NIDDK NIH HHS [DK41330, DK38518, DK08260] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041330, F32DK008260, P01DK038518] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOAT TF, 1976, ARCH BIOCHEM BIOPHYS, V177, P95, DOI 10.1016/0003-9861(76)90419-7; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM B, 1990, IN PRESS P NATL ACAD; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TAUSSIG LM, 1984, CYSTIC FIBROSIS, P1; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; 1990, AM J HUM GENET, V47, P359	30	562	593	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 21	1990	62	6					1227	1233		10.1016/0092-8674(90)90398-X	http://dx.doi.org/10.1016/0092-8674(90)90398-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EA117	1698126	Green Published			2022-12-24	WOS:A1990EA11700019
J	DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A				DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A			ANTIGEN ANALOG MAJOR HISTOCOMPATIBILITY COMPLEXES ACT AS ANTAGONISTS OF THE T-CELL RECEPTOR	CELL			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; IMMUNOGENIC PEPTIDES; MHC BINDING; ACTIVATION; MOLECULES; IA; COMPETITION; SPECIFICITY; RECOGNITION	A novel mechanism for inhibition of T cell responses is described. Using the recognition of the influenza hemagglutinin (HA) 307-319 peptide in the context of DR1 class II major histocompatibility complex molecules, we have found that nonstimulatory analogs of the HA peptide preferentially inhibit HA-specific T cells in inhibition of antigen presentation assays. This antigen-specific effect could be generalized to another DR1-restricted peptide, Tetanus toxoid 830-843. Direct binding and cellular experiments indicated that the mechanism responsible was distinct from competition for binding to DRI molecules. Likewise, negative signaling and induction of T cell tolerance could also be excluded as effector mechanisms. Thus, the most likely mechanism for this effect is engagement of antigen-specific T cell receptors by DR1-peptide analog complexes, which results in antigen-specific competitive blocking of T cell responses by virtue of their capacity to compete with DR1-antigen complexes for binding to the T cell receptor.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037	La Jolla Institute for Immunology	DEMAGISTRIS, MT (corresponding author), CYTEL,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022		NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI28197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GRAY HM, 1989, CLIN IMMUNOL IMMUNOP, V53, pS47; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARDING CV, 1988, IMMUNOL REV, V106, P77, DOI 10.1111/j.1600-065X.1988.tb00774.x; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KURATA A, 1990, J IMMUNOL, V144, P4526; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LAMONT AG, 1990, J IMMUNOL, V144, P2493; LEIGHTON J, 1991, J IMMUNOL, V147, P198; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PROUST JJ, 1991, EUR J IMMUNOL, V21, P335, DOI 10.1002/eji.1830210214; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Sette A, 1991, Semin Immunol, V3, P195; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1	40	504	516	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					625	634		10.1016/0092-8674(92)90139-4	http://dx.doi.org/10.1016/0092-8674(92)90139-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739971				2022-12-24	WOS:A1992HF44000004
J	NEWMAN, AJ; NORMAN, C				NEWMAN, AJ; NORMAN, C			U5 SNRNA INTERACTS WITH EXON SEQUENCES AT 5' AND 3' SPLICE SITES	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; COMPENSATORY BASE CHANGE; II CATALYTIC INTRONS; U1 SNRNA; U2 SNRNP; CLEAVAGE SITE; TACTAAC BOX; 2'-OME RNA; YEAST	U5 snRNA is an essential pre-mRNA splicing factor whose function remains enigmatic. Specific mutations in a conserved single-stranded loop sequence in yeast U5 snRNA can activate cleavage of G1 --> A mutant pre-mRNAs at aberrant 5' splice sites and facilitate processing of dead-end lariat intermediates to mRNA. Activation of aberrant 5' cleavage sites involves base pairing between U5 snRNA and nucleotides upstream of the cleavage site. Processing of dead-end lariat intermediates to mRNA correlates with base pairing between U5 and the first two bases in exon 2. The loop sequence in U5 snRNA may therefore be intimately involved in the transesterification reactions at 5' and 3' splice sites. This pattern of interactions is strikingly reminiscent of exon recognition events in group II self-splicing introns and is consistent with the notion that U5 snRNA may be related to a specific functional domain from a group II-like self-splicing ancestral intron.			NEWMAN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; MICHEL F, 1987, COLD SPRING HARB SYM, V52, P201, DOI 10.1101/SQB.1987.052.01.025; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TYSTRAUSS E, 1991, GENE DEV, V5, P629; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	56	335	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					743	754		10.1016/0092-8674(92)90149-7	http://dx.doi.org/10.1016/0092-8674(92)90149-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739979				2022-12-24	WOS:A1992HF44000014
J	LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S				LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S			PREDICTORS OF MORTALITY AMONG HIV-INFECTED WOMEN IN KIGALI, RWANDA	ANNALS OF INTERNAL MEDICINE			English	Article						RWANDA; AFRICA; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; WOMENS HEALTH SERVICES	HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL CASE-DEFINITION; SUB-SAHARAN AFRICA; NUTRITIONAL-STATUS; LATENCY PERIOD; HOMOSEXUAL MEN; SURVIVAL-TIME; BISEXUAL MEN; RISK-FACTORS; AIDS	Objective: To better characterize the natural history of disease due to human immunodeficiency virus (HIV) infection in African women. Design: Prospective cohort study over a 2-year follow-up period. Participants: A total of 460 HIV-seropositive women and a comparison cohort of HIV-seronegative women recruited from prenatal and pediatric clinics in Kigali, Rwanda in 1988. Measurements: Clinical signs and symptoms of HIV disease, AIDS, and mortality. Main Results: Follow-up data at 2 years were available for 93% of women who were still alive. At enrollment, many seropositive women reported symptoms listed in the World Health Organization (WHO) clinical case definition of AIDS, but these were nonspecific and often improved over time. The 2-year mortality among HIV-infected women by Kaplan-Meier survival analysis was 7% (95% Cl, 5% to 10%) overall, and 21% (Cl, 8% to 34%) for the 40 women who fulfilled the WHO case definition of AIDS at entry. In comparison, the 2-year mortality in women not infected with HIV was only 0.3% (Cl, 0% to 7%). Independent baseline predictors of mortality in seropositive women by Cox proportional hazards modeling were, in order of descending risk factor prevalence: a body mass index of 21 kg/m2 or less (relative hazard, 2.3; Cl, 1.1 to 4.8), low income (relative hazard, 2.3; Cl, 1.1 to 4.5), an erythrocyte sedimentation rate exceeding 60 mm/h (relative hazard, 4.9; Cl, 2.2 to 10.9), chronic diarrhea (relative hazard, 2.6; Cl, 1.1 to 5.7), a history of herpes zoster (relative hazard 5.3; Cl, 2.5 to 11.4), and oral candida (relative hazard, 7.3; Cl, 1.6 to 33.3). Human immunodeficiency virus disease was the cause of death in 38 of the 39 HIV-positive women who died, but only 25 met the WHO definition of AIDS before death. Conclusions: Human immunodeficiency virus disease now accounts for 90% of all deaths among child-bearing urban Rwandan women. Many symptomatic seropositive patients may show some clinical improvement and should not be denied routine medical care. Easily diagnosed signs and symptoms and inexpensive laboratory tests can be used in Africa to identify those patients with a particularly good or bad prognosis.	PROJET SAN FRANCISCO, KIGALI, RWANDA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94131 USA; RWANDAN NATL AIDS PROGRAM, KIGALI, RWANDA; CTR HOSP KIGALI, KIGALI, RWANDA; MINIST HLTH KIGALI, KIGALI, RWANDA	University of California System; University of California San Francisco	LINDAN, CP (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, 74 NEW MONTGOMERY ST, SUITE 600, SAN FRANCISCO, CA 94105 USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [A123980] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ANZALA A, 1991, 6 INT C AIDS FLOR, P103; BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1988, BRIT MED BULL, V44, P183, DOI 10.1093/oxfordjournals.bmb.a072240; CHIN J, 1989, B WORLD HEALTH ORGAN, V67, P1; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; GILKS CF, 1991, BRIT MED J, V303, P1189, DOI 10.1136/bmj.303.6811.1189; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HEBERT JR, 1988, MED HYPOTHESES, V27, P51, DOI 10.1016/0306-9877(88)90083-7; HEBERT JR, 1990, J SUBST ABUSE TREAT, V7, P161; HESSOL NA, 1990, J ACQ IMMUN DEF SYND, V3, P1078; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; HUNTER SS, 1990, SOC SCI MED, V31, P681, DOI 10.1016/0277-9536(90)90250-V; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LEFRERE JJ, 1989, AIDS, V3, P603, DOI 10.1097/00002030-198909000-00008; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; LUCAS SB, 1987, ADV MED, V23, P102; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MCLEOD DT, 1990, RESP MED, V84, P225, DOI 10.1016/S0954-6111(08)80039-X; MELBYE M, 1987, LANCET, V1, P728; MELBYE M, 1986, LANCET, V2, P1113; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULLER O, 1990, LANCET, V335, P236, DOI 10.1016/0140-6736(90)90339-7; MURRAY HW, 1989, AM J MED, V86, P533, DOI 10.1016/0002-9343(89)90380-X; NELSON JA, 1990, AIDS, V4, P1, DOI 10.1097/00002030-199001000-00001; NGALY B, 1990, J ACQ IMMUN DEF SYND, V3, P430; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; PALLANGYO KJ, 1987, LANCET, V2, P972; PHAIR J, 1991, 6 INT C AIDS FLOR; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VANDEPERRE P, 1989, LANCET, V1, P941; VANDEPERRE P, 1987, AIDS, V1, P207; VANGRIENSVEN GJP, 1990, AM J EPIDEMIOL, V132, P203; WENGER JD, 1988, J GEN INTERN MED, V3, P464, DOI 10.1007/BF02595923; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1989, DRAFT REPORT INFORMA; 1987, MMWR S, V36, pS3; 1986, WEEKLY EPIDEMIOL REC, V61, P69; REPORTED AIDS CASES	56	139	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					320	328		10.7326/0003-4819-116-4-320	http://dx.doi.org/10.7326/0003-4819-116-4-320			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733389				2022-12-24	WOS:A1992HD54600010
J	SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC				SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC			MEASLES HERD-IMMUNITY - THE ASSOCIATION OF ATTACK RATES WITH IMMUNIZATION RATES IN PRESCHOOL-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES	Objective. - To examine the association between incidence of measles and immunization coverage among preschool-age children. Design. - An ecological study in which measles incidence was compared with immunization coverage among census tracts. The independent effects of race and population density were controlled for. Setting. - A recent measles outbreak in Milwaukee, Wis. immunization coverage data were estimated from a retrospective, school-based survey of Milwaukee grade school students. Patients. - One thousand eleven persons (less-than-or-equal-to 17 years) who had confirmed measles from September 1989 through June 1990. Main Outcome Measures. - Confirmed measles cases grouped by census tract, corresponding census tract preoutbreak immunization coverage, racial breakdown, and population density. Results. - Census tracts stratified into four levels, with mean immunization rates of 50.4%, 60.2%, 69.9%, and 81.0%, had respective median attack rates of 11.6, 5.0, 1.7, and 0.0 cases per 1000 persons (P < .01). The association between immunization coverage and measles attack rate remained significant even after controlling for race and population density. Conclusions. - Modest improvements in low levels of immunization coverage among 2-year-olds confer substantial protection against measles outbreaks. Coverage of 80% or less may be sufficient to prevent sustained measles outbreaks in an urban community.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,DATA MANAGEMENT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	SCHLENKER, TL (corresponding author), MILWAUKEE HLTH DEPT,841 N BROADWAY,MILWAUKEE,WI 53202, USA.							BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; EMERSON JD, 1983, UNDERSTANDING ROBUST, P33; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; Hedrich AW, 1933, AM J HYG, V17, P613, DOI 10.1093/oxfordjournals.aje.a117929; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hollander M., 1973, NONPARAMETRIC STAT, P114; INMAN RL, 1979, TECHNOMETRICS, V21, P499; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P314; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MASSEY DS, 1989, DEMOGRAPHY, V26, P373, DOI 10.2307/2061599; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Schlenker T, 1990, Wis Med J, V89, P403; SENCER DJ, 1967, PUBLIC HEALTH REP, V82, P253, DOI 10.2307/4592985; THACKER SB, 1991, AM J EPIDEMIOL, V133, P517, DOI 10.1093/oxfordjournals.aje.a115923; 1987, MMWR, V36, P45; 1990, MMWR, V39, P317; 1991, MEASLES EPIDEMIC PRO; 1985, PHC802243 US DEP COM; 1989, MMWR, V38, P1; 1990, MMWR, V39, P353; 1991, MMWR, V40, P93; 1991, MMWR, V40, P36	23	69	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					823	826		10.1001/jama.267.6.823	http://dx.doi.org/10.1001/jama.267.6.823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732654				2022-12-24	WOS:A1992HC48400027
J	DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG				DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG			PHOSPHORYLATION OF INITIATION FACTOR-2-ALPHA BY PROTEIN-KINASE GCN2 MEDIATES GENE-SPECIFIC TRANSLATIONAL CONTROL OF GCN4 IN YEAST	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; DOUBLE-STRANDED-RNA; POLYPEPTIDE-CHAIN INITIATION; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FACTOR-II; MESSENGER-RNA; FACTOR EIF-2; START-SITE; EXPRESSION	We show that phosphorylation of the a subunit of eukaryotic translation initiation factor 2 (eIF-2) by the protein kinase GCN2 mediates translational control of the yeast transcriptional activator GCN4. In vitro, GCN2 specifically phosphorylates the alpha-subunit of rabbit or yeast eIF-2. In vivo, phosphorylation of eIF-2-alpha increases in response to amino acid starvation, which is dependent on GCN2. Substitution of Ser-51 with alanine eliminates phosphorylation of eIF-2-alpha by GCN2 in vivo and in vitro and abolishes increased expression of GCN4 and amino acid biosynthetic genes under its control in amino acid-starved cells. The Asp-51 substitution mimics the phosphorylated state and derepresses GCN4 in the absence of GCN2. Thus, an established mechanism for regulating total protein synthesis in mammalian cells mediates gene-specific translational control in yeast.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	DEVER, TE (corresponding author), NICHHD, MOLEC GENET LOWER EUKARYOTES SECT, BETHESDA, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032263] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32263] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ERNST H, 1987, J BIOL CHEM, V262, P1206; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; HANNIG EM, 1990, GENETICS, V126, P549; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LONDON IM, 1987, ENZYMES, V18, P359; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MESSENGUY F, 1976, EUR J BIOCHEM, V67, P335, DOI 10.1111/j.1432-1033.1976.tb10696.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; NIEDERBERGER P, 1983, J GEN MICROBIOL, V129, P2571; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SIKORSKI RS, 1989, GENETICS, V122, P19; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	47	593	606	2	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					585	596		10.1016/0092-8674(92)90193-G	http://dx.doi.org/10.1016/0092-8674(92)90193-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739968				2022-12-24	WOS:A1992HD39800017
J	HUNTER, CP; WOOD, WB				HUNTER, CP; WOOD, WB			EVIDENCE FROM MOSAIC ANALYSIS OF THE MASCULINIZING GENE HER-1 FOR CELL-INTERACTIONS IN C-ELEGANS SEX DETERMINATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; POLARITY GENE; DROSOPHILA; HERMAPHRODITE; INHIBITOR; LINEAGES; NEMATODE; EVENTS	SEX in Caenorhabditis elegans is determined by a regulatory cascade of seven interacting autosomal genes controlled by three X-linked genes in response to the X chromosome-to-autosome (X/A) ratio 1,2. XX animals (high X/A) develop as self-fertile hermaphrodites, and XO animals (low X/A) develop as males. The activity of the first gene in the sex-determining cascade, her-1, is required for male sexual development 3. XO her-1 loss-of-function mutants develop as self-fertile hermaphrodites, whereas XX her-1 gain-of-function mutants develop as masculinized intersexes 4. By genetic mosaic analysis using a fused free duplication linking her-1 to a cell-autonomous marker gene, we show here that her-1 expression in a sexually dimorphic cell is neither necessary nor sufficient for that cell to adopt a male fate. Our results suggest that her-1 is expressed in many, possibly all, cells and that its gene product can function non-autonomously through cell interactions to determine male sexual development.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder								AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; Cigarroa FG, 1989, GROWTH FACTORS, V1, P179, DOI 10.3109/08977198909029127; DONIACH T, 1986, GENETICS, V114, P53; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HERMAN RK, 1976, GENETICS, V83, P91; HODGKIN J, 1984, Journal of Embryology and Experimental Morphology, V83, P103; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; HUNTER CP, 1990, THESIS U COLORADO; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; MOHLER J, 1988, GENETICS, V120, P1061; OBRIEN SJ, 1990, GENETIC MAPS, V5; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; PATEK CE, 1991, DEVELOPMENT, V113, P311; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; SCHEDIN P, 1988, THESIS U COLORADO; SCHEDIN P, 1991, DEVELOPMENT, V112, P833; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRENT C, 1988, GENETICS, V120, P145; VILLENEUVE AM, 1990, GENETICS, V124, P91; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	32	74	80	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					551	555		10.1038/355551a0	http://dx.doi.org/10.1038/355551a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741033				2022-12-24	WOS:A1992HC52600061
J	HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE				HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE			STABILITY OF ESSENTIAL DRUGS DURING SHIPMENT TO THE TROPICS	BRITISH MEDICAL JOURNAL			English	Article							SOLID-PHASE; DECOMPOSITION; DEGRADATION; KINETICS	Objective - To determine whether present methods of international transport of essential drugs by sea adversely affect their quality. Design - Controlled longitudinal study of drug shipments sent by sea from Unicef in Copenhagen to Lagos; to Mombasa and by land to Kampala; and to Bangkok. 11 essential drugs were stored in four locations on board the ships. Setting - Main shipping routes from Unicef, Copenhagen, to tropical countries. Main outcome measures - Temperature and relative humidity in the test packs during the journey. Amount of active ingredient in the drugs before and after shipment. Results - Temperatures recorded within the test packs range from -3.5-degrees-C to 42.4-degrees-C and were 3-12-degrees-C higher than the ambient temperature. Relative humidity within the packs ranged from 20% to 88%. Differences between the locations on board were negligible. Ergometrine injection, methylergometrine injection, and retinol capsules lost 1.5-5.8% of their activity. Ampoules of ergometrine showed a large variation in the amount of active ingredient after shipment, with three of 80 samples having concentrations 60% below those stated. Ampicillin, benzylpenicillin, phenoxymethylpenicillin, and tetracycline were not affected by transport. Conclusions - Drugs were exposed to a much higher temperature and humidity than is recommended by the manufacturer, especially in tropical harbours and during inland transport. Except for ergometrine and methylergometrine the transport would not affect clinical effectiveness.	UNICEF,DIV SUPPLY,DK-2100 COPENHAGEN,DENMARK; MED PROD AGCY,CHEM LABS,S-75125 UPPSALA,SWEDEN	Medical Products Agency	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.							Abu Reid I, 1990, INT PHARM J, V4, P6; ALKER GJA, 1988, LANCET, V2, P393; [Anonymous], 1986, WHOPHARM86529; BECKER G, 1983, PHARM ZEITUNG, V15, P794; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; HOGERZEIL HV, 1991, WHODAP911; LONGLAND PW, 1987, PHARM J, P147; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P47; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P55; PIKAL MJ, 1977, J PHARM SCI, V66, P1312, DOI 10.1002/jps.2600660927; SMALLENBROEK H, 1983, STABILITY DRUGS TROP; YORK P, 1977, PHARMAZIE, V32, P101; 1990, WHOMCH907; 1990, ESSENTIAL DRUGS PRIC; 1990, WHO TECH REP SER, V790	15	38	39	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					210	212		10.1136/bmj.304.6821.210	http://dx.doi.org/10.1136/bmj.304.6821.210			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739795	Green Published, Bronze			2022-12-24	WOS:A1992HA98000021
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - SWIMMING - THE HAZARDS OF TAKING A DIP	BRITISH MEDICAL JOURNAL			English	Article											WALKER, A (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,LONDON W2 1NY,ENGLAND.							BALARAJAN R, 1991, BRIT MED J, V303, P144; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; DUNLOP JM, 1991, BRIT MED J, V302, P671, DOI 10.1136/bmj.302.6778.671; HALL C, 1990, RUNNING WATER; MORRIS J, 1991, WATER B, V465, P7; PIKE EB, 1991, 2736MP WAT RES CTR D; PIKE EB, 1990, 2518MP WAT RES CTR D; WHEELER D, 1990, LAB PRACT, V39, P19; 1959, J HYGIENE, V57, P435; 1990, POLLUTION BEACHES 4T; 1991, WATER INFORMATION WA; 1991, BATHING WATER QUALIT; 1990, TOXIC BLUE GREEN ALG	13	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					242	245		10.1136/bmj.304.6821.242	http://dx.doi.org/10.1136/bmj.304.6821.242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739802	Green Published, Bronze			2022-12-24	WOS:A1992HA98000031
J	ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW				ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW			A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEINS; DYNAMICS; PACKING	THE hydrophobic cores of proteins are generally well packed, with few cavities 1,2. Mutations in which a bulky buried residue such as leucine or phenylalanine is replaced with a small residue such as alanine can create cavities in the core of a protein (our unpublished results). The sizes and shapes of such cavities can vary substantially depending on factors such as local geometry, whether or not a cavity already exists at the site of substitution, and the degree to which the protein structure relaxes to occupy the space vacated by the substituted residue. We show by crystallographic and thermodynamic analysis that the cavity created by the replacement Leu 99 --> Ala in T4 lysozyme is large enough to bind benzene and that ligand binding increases the melting temperature of the protein by 6.0-degrees-C at Ph 3.0. Benzene does not, however, bind to the cavity created by the Phe 153 --> Ala replacement. The results show that cavities can be engineered in proteins and suggest that such cavities might be tailored to bind specific ligands. The binding of benzene at an internal site 7 angstrom from the molecular surface also illustrates the dynamic nature of proteins, even in crystals.	UNIV OREGON,HOWARD HUGHES MED INST,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CAMPBELL ID, 1975, PROC R SOC SER B-BIO, V189, P503, DOI 10.1098/rspb.1975.0070; CONNOLLY ML, 1986, INT J PEPT PROT RES, V28, P360; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; Eisenberg H, 1976, Adv Protein Chem, V30, P101, DOI 10.1016/S0065-3233(08)60479-9; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; HERMANS J, 1961, J AM CHEM SOC, V83, P3283, DOI 10.1021/ja01476a025; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; KRETSINGER RH, 1968, J MOL BIOL, V31, P305, DOI 10.1016/0022-2836(68)90446-4; LAKOWICZ JR, 1966, BIOCHEMISTRY-US, V21, P287; LUMRY RW, 1975, C INT CNRS LEAU SYST, V246, P53; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SNYDER GH, 1976, BIOCHEMISTRY-US, V15, P2275, DOI 10.1021/bi00656a005; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7	23	240	242	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					371	373		10.1038/355371a0	http://dx.doi.org/10.1038/355371a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731252				2022-12-24	WOS:A1992HA59100075
J	WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C				WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C			DIURNAL-VARIATION IN INCIDENCE OF STROKE - OXFORDSHIRE COMMUNITY STROKE PROJECT	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN CARDIAC DEATH; ACUTE CEREBROVASCULAR-DISEASE; CIRCADIAN VARIATION; MYOCARDIAL-INFARCTION; ISCHEMIC STROKE; MORNING INCREASE; ONSET; FREQUENCY; REGISTRY	Objective - To determine whether diurnal variation occurs in the onset of stroke. Design - Community based study over four years. Setting - Oxfordshire, United Kingdom. Subjects - 105 000 people, of whom 675 had a first ever stroke. 545 had a cerebral infarction, 66 had primary intracerebral haemorrhage, 33 had subarachnoid haemorrhage, and in 31 the type of stroke was not known. Main outcome measures - Time of stroke and degree of activity at onset. Results - In the 578 patients for whom it was known whether onset occurred while asleep or awake, the proportion with onset during sleep was 25% (135/545) for cerebral infarction, 17% (11/66) for primary intracerebral haemorrhage, and 0% (0/33) for subarachnoid haemorrhage. This difference persisted if patients in whom it was not known whether they were asleep or awake at onset were classed as asleep. For all stroke types together there was a significant (chi-2 = 218.7, p < 0.001) diurnal variation with a morning peak between 0800 and 1000, which persisted even after allowing for strokes first noted on waking by redistributing the hour of onset through the preceding eight hours (chi-2 = 47, p < 0.001). A significant diurnal variation was also found in the onset of cerebral infarction (peak 0800-1000, chi-2 = 208.4, p < 0.001). Fewer patients had other forms of stroke and the diurnal variations for primary intracerebral haemorrhage (peak 1000-1200) and subarachnoid haemorrhage (peaks 0800-1000 and 1800-2000) were not significant. There seemed to be a second smaller peak for all types of stroke. Conclusions - All types of stroke are most likely to occur after waking in the morning. The cause of the circadian variation requires further study.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND; ST JAMES UNIV HOSP, DEPT NEUROL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	University of Edinburgh; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Saint James's University Hospital			sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				AGNOLI A, 1975, REV NEUROL, V131, P597; ALLEN CMC, 1983, Q J MED, V52, P515; ANDREOTTI F, 1988, BRIT HEART J, V59, P99; ARBOIX A, 1990, STROKE, V21, P826, DOI 10.1161/str.21.5.826a; ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CAPLAN LR, 1983, STROKE, V14, P530, DOI 10.1161/01.STR.14.4.530; COLANTONIO D, 1989, AM J CARDIOL, V64, P403, DOI 10.1016/0002-9149(89)90548-1; FREEDMAN LS, 1979, J EPIDEMIOL COMMUN H, V33, P223, DOI 10.1136/jech.33.3.223; GARDNER MJ, 1989, STATISTICS CONFIDENC; HERDERSCHEE D, 1991, CEREBROVASC DIS, V1, P165, DOI 10.1159/000108835; KUBOTA K, 1987, STROKE, V18, P812, DOI 10.1161/str.18.4.812b; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MARSH EE, 1990, ARCH NEUROL-CHICAGO, V47, P1178, DOI 10.1001/archneur.1990.00530110032012; MARSHALL J, 1977, STROKE, V8, P230, DOI 10.1161/01.STR.8.2.230; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Olivares L, 1973, STROKE, V4, P773, DOI 10.1161/01.STR.4.5.773; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TORVIK A, 1976, STROKE, V7, P255, DOI 10.1161/01.STR.7.3.255; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; WILLICH SN, 1989, DEUT MED WOCHENSCHR, V114, P613, DOI 10.1055/s-2008-1066644; WINDT C, 1988, J NEUROL NEUROSUR PS, V51, P109	28	117	119	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					155	157		10.1136/bmj.304.6820.155	http://dx.doi.org/10.1136/bmj.304.6820.155			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737160	Green Published, Bronze			2022-12-24	WOS:A1992HA97900021
J	LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM				LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM			A CHIMERIC 11-BETA-HYDROXYLASE ALDOSTERONE SYNTHASE GENE CAUSES GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM AND HUMAN HYPERTENSION	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DNA; CLONING; IDENTIFICATION; 18-OXOCORTISOL; POLYMORPHISMS; CDNA; RNA	GLUCOCORTICOID-REMEDIABLE aldosteronism (GRA), an autosomal dominant disorder, is characterized by hypertension with variable hyperaldosteronism 1,2 and by high levels of the abnormal adrenal steroids 18-oxocortisol and 18-hydroxycortisol 3-5, which are all under control of adrenocorticotropic hormone and suppressible by glucocorticoids 6. These abnormalities could result from ectopic expression of aldosterone synthase, which is normally expressed only in adrenal glomerulosa, in the adrenal fasciculata. Genes encoding aldosterone synthase 7-9 and steroid 11-beta-hydroxylase 7 (expressed in both adrenal fasciculata and glomerulosa), which are 95% identical 7 and lie on chromosome 8q (refs 7, 10), are therefore candidate genes for GRA. Here we demonstrate complete linkage of GRA in a large kindred to a gene duplication arising from unequal crossing over, fusing the 5' regulatory region of 11-beta-hydroxylase to the coding sequences of aldosterone synthase (maximum lod score 5.23 for complete linkage, odds ratio of 170,000:1). This mutation can account for all the physiological abnormalities of GRA. Our result represents the demonstration of a mutation causing hypertension in otherwise phenotypically normal animals or humans.	BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; VET AFFAIRS HOSP,BRONX,NY 10468	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	LIFTON, RP (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,SUITE 6200,SALT LAKE CITY,UT 84132, USA.							BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; CHU MD, 1982, J BIOL CHEM, V257, P2218; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOMEZSANCHEZ CE, 1984, J CLIN ENDOCR METAB, V59, P1022, DOI 10.1210/jcem-59-5-1022; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; MORNET E, 1989, J BIOL CHEM, V264, P20961; NEW MI, 1967, J CLIN ENDOCR METAB, V27, P300, DOI 10.1210/jcem-27-2-300; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PICKERING GW, 1990, HYPERTENSION PATHOPH, P18; PLATT ROBERT, 1967, P9; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; ULICK S, 1991, J STEROID BIOCHEM, V38, P59, DOI 10.1016/0960-0760(91)90401-P; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1983, J BIOL CHEM, V258, P5498; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436	21	928	943	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					262	265		10.1038/355262a0	http://dx.doi.org/10.1038/355262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731223				2022-12-24	WOS:A1992GZ69400071
J	PILGRIM, JA; STANSFELD, S; MARMOT, M				PILGRIM, JA; STANSFELD, S; MARMOT, M			LOW BLOOD-PRESSURE, LOW MOOD	BRITISH MEDICAL JOURNAL			English	Article							GENERAL HEALTH QUESTIONNAIRE; HYPERTENSION; DEPRESSION; HOSTILITY	Objective - To determine whether a set of physical symptoms is associated with low blood pressure and to investigate the possible role of psychological factors in their occurrence. Design - Analysis of data collected by questionnaire and physical screening from the first phase of the Whitehall II study, a cohort study of an employed population. Setting - 23 civil service departments in London. Subjects - 10314 male and female London based civil servants aged between 35 and 55. Main outcome measures - Symptoms of dizziness-giddiness and unexplained tiredness; psychological functioning as measured by the 30 item general health questionnaire in which the response "no more than usual" to an item about disease was scored as indicating chronic illness. Results - Dizziness-giddiness in men and unexplained tiredness in both men and women were significantly related to low systolic blood pressure. There was a highly significant inverse relation between general health questionnaire score and systolic blood pressure for both men and women, which persisted after controlling for potentially confounding variables, including age, body mass index, drug treatment, physical illness, and exercise. This association of low blood pressure with physical symptoms was no longer significant when general health questionnaire score was controlled for. Conclusions - There seems a strong relation between low systolic blood pressure and minor psychological dysfunction. Associated physical symptoms seem to be secondary to the primary disturbance in mental state.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, ACAD DEPT PSYCHIAT, LONDON, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London	PILGRIM, JA (corresponding author), UCL, UNIV COLL & MIDDLESEX SCH MED, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; COCHRANE R, 1973, J PSYCHOSOM RES, V17, P215, DOI 10.1016/0022-3999(73)90026-3; Dembroski T M, 1978, J Behav Med, V1, P159, DOI 10.1007/BF00846637; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; GOODCHILD ME, 1985, BRIT J PSYCHIAT, V146, P55, DOI 10.1192/bjp.146.1.55; HUPPERT FA, 1988, PSYCHOL MED, V18, P1001, DOI 10.1017/S0033291700009922; MANN AH, 1977, PSYCHOL MED, V7, P653, DOI 10.1017/S0033291700006309; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; NAKAGAWARA M, 1987, PSYCHIAT RES, V21, P85, DOI 10.1016/0165-1781(87)90065-5; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; RABKIN JG, 1983, AM J PSYCHIAT, V140, P1072; ROBBINS JM, 1982, SOC SCI MED, V16, P27, DOI 10.1016/0277-9536(82)90420-8; STANSFELD S, IN PRESS PSYCHOL MED; WESSELY S, 1990, BMJ-BRIT MED J, V301, P18; 1967, RECOMMENDATIONS HUMA	16	120	121	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					75	78		10.1136/bmj.304.6819.75	http://dx.doi.org/10.1136/bmj.304.6819.75			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737142	Bronze, Green Published			2022-12-24	WOS:A1992HA17100018
J	WITKE, W; SCHLEICHER, M; NOEGEL, AA				WITKE, W; SCHLEICHER, M; NOEGEL, AA			REDUNDANCY IN THE MICROFILAMENT SYSTEM - ABNORMAL-DEVELOPMENT OF DICTYOSTELIUM CELLS LACKING 2 F-ACTIN CROSS-LINKING PROTEINS	CELL			English	Article							MYOSIN HEAVY-CHAIN; SITE-A-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; BINDING PROTEINS; ALPHA-ACTININ; HOMOLOGOUS RECOMBINATION; CHEMOTACTIC STIMULATION; GELATION FACTOR; DISCOIDEUM; AGGREGATION	We generated by gene disruption Dictyostelium cells that lacked both the F-actin cross-linking proteins, alpha-actinin and gelation factor. Several major cell functions, such as growth, chemotaxis, phagocytosis, and pinocytosis, were apparently unaltered. However, in all double mutants, development was greatly impaired. After formation of aggregates, cells were very rarely able to form fruiting bodies. This ability was rescued when mutant and wild-type strains were mixed in a ratio of 70 to 30. The developmental program in the mutant was not arrested, since the expression pattern of early and late genes remained unchanged. Development of the mutant was rendered normal when a functional actin-actinin gene was introduced and expressed, showing the morphogenetic defect to be due to the absence of the two F-actin cross-linking proteins. These findings suggest the existence of a functional network allowing mutual complementation of certain actin-binding proteins.			WITKE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BERTHOLDT G, 1985, CELL DIFFER DEV, V16, P187, DOI 10.1016/0045-6039(85)90516-0; BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BRAY D, 1989, NATURE, V338, P203, DOI 10.1038/338203a0; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; CONDEELIS J, 1981, NATURE, V292, P161; COUKELL MB, 1975, MOL GEN GENET, V142, P119, DOI 10.1007/BF00266094; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FECHHEIMER M, 1982, CELL MOTIL CYTOSKEL, V2, P287, DOI 10.1002/cm.970020308; GERISCH G, 1991, ANNU REV PHYSIOL, V53, P607, DOI 10.1146/annurev.physiol.53.1.607; GERISCH G, 1981, J CELL SCI, V52, P1; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HARRINGTON BJ, 1968, APPL MICROBIOL, V16, P106, DOI 10.1128/AEM.16.1.106-113.1968; JERMYN KA, 1991, DEVELOPMENT, V111, P779; KAY RR, 1989, DEVELOPMENT S, P81; KNECHT DA, 1988, DEV BIOL, V128, P178, DOI 10.1016/0012-1606(88)90280-1; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1033; LANGANGER G, 1983, MIKROSKOPIE, V40, P237; LODISH HF, 1982, DEV DICTYOSTELIUM DI, P325; Loomis W F, 1978, Birth Defects Orig Artic Ser, V14, P497; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOEGEL A, 1985, EMBO J, V4, P3805, DOI 10.1002/j.1460-2075.1985.tb04151.x; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; Noegel AA, 1991, CURR OPIN CELL BIOL, V3, P18, DOI 10.1016/0955-0674(91)90161-Q; PETERS DJM, 1988, DEV BIOL, V128, P158, DOI 10.1016/0012-1606(88)90278-3; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; SCHLEICHER M, 1988, DEV GENET, V9, P521, DOI 10.1002/dvg.1020090428; SPUDICH JA, 1989, CELL REGUL, V1, P1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; VOGEL G, 1987, METHOD CELL BIOL, V28, P129; WALLACE JS, 1984, CELL DIFFER DEV, V14, P205, DOI 10.1016/0045-6039(84)90047-2; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WEBER AT, 1971, DEV BIOL, V26, P606, DOI 10.1016/0012-1606(71)90143-6; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1991, NOVEL CALCIUM BINDIN, P321; YANAGISAWA K, 1967, EXP CELL RES, V46, P328, DOI 10.1016/0014-4827(67)90070-5	58	135	137	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					53	62		10.1016/0092-8674(92)90205-Q	http://dx.doi.org/10.1016/0092-8674(92)90205-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732064				2022-12-24	WOS:A1992GZ58300008
J	SCHUMAN, EM; MADISON, DV				SCHUMAN, EM; MADISON, DV			A REQUIREMENT FOR THE INTERCELLULAR MESSENGER NITRIC-OXIDE IN LONG-TERM POTENTIATION	SCIENCE			English	Article							RELAXING FACTOR; L-ARGININE; SYNAPTIC TRANSMISSION; HIPPOCAMPAL SLICES; DIVALENT-CATIONS; RAT HIPPOCAMPUS; CENTRAL NEURONS; CA1 NEURONS; ENHANCEMENT; ACTIVATION	Long-term potentiation (LTP) of synaptic transmission is a widely studied model of neuronal plasticity. The induction of LTP is known to require processes in the postsynaptic neuron, while experimental evidence suggests that the expression of LTP may occur in the presynaptic terminal. This has led to speculation that a retrograde messenger travels from the post- to the presynaptic cell during induction of LTP. Extracellular application or postsynaptic injection of two inhibitors of nitric oxide synthase, N-nitro-L-arginine or N(G)-methyl-L-arginine, blocks LTP. Extracellular application of hemoglobin, which binds nitric oxide, also attenuates LTP. These findings suggest that nitric oxide liberated from postsynaptic neurons may travel back to presynaptic terminals to cause LTP expression.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Schuman, Erin M/D-6204-2011					ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARINAGA M, 1990, SCIENCE, V248, P1603, DOI 10.1126/science.1973002; BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1990, NATURE, V346, P698, DOI 10.1038/346698a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1989, J BIOL CHEM, V264, P8455; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DOLPHIN AC, 1982, NEUROSCIENCE, V20, P279; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GOH JW, 1989, SCIENCE, V244, P980, DOI 10.1126/science.2543072; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KENNEDY MB, 1988, NATURE, V335, P770, DOI 10.1038/335770a0; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; ODELL TJ, IN PRESS P NATL ACAD; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SCHUMAN E, UNPUB; SCHUMAN E M, 1991, Society for Neuroscience Abstracts, V17, P2; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STEVENS CF, 1988, NATURE, V336, P308, DOI 10.1038/336308a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YUI Y, 1991, J BIOL CHEM, V244, P3714	49	981	1000	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1991	254	5037					1503	1506		10.1126/science.1720572	http://dx.doi.org/10.1126/science.1720572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720572				2022-12-24	WOS:A1991GT90300039
J	WALKER, RM				WALKER, RM			DNR IN THE OR - RESUSCITATION AS AN OPERATIVE RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETHICAL CHALLENGE; CARDIAC-ARREST; ANESTHESIA; WITNESSES; CARE	Should do-not-resuscitate (DNR) orders be routinely rescinded when terminally ill patients undergo palliative surgery? If so, patients will be forced to balance the benefits of palliative surgery against the risks of unwanted resuscitation. If physicians are required to honor intraoperative DNR orders, they may feel unacceptably restrained from correcting adverse effects for which they feel responsible. This dilemma has been overlooked by DNR policies. This article argues for the permissibility of honoring intraoperative DNR orders. The patient's right to refuse treatment outweighs physicians' concerns about professional scrutiny over intraoperative deaths. Physicians' moral concerns about hastening patient death are important but may be assuaged by (1) emphasizing patients' acceptance of operative mortality risk; (2) viewing matters as analogous to surgery on Jehovah's Witnesses who refuse lifesaving transfusion; (3) viewing the patient's intraoperative death as a double effect, that is, an unintended negative effect that is linked to the performance of a good act (palliation); and (4) distinguishing this from assisted suicide.			WALKER, RM (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV MED ETH & HUMANITIES, 12901 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BENSON KT, 1989, ANESTH ANALG, V69, P647; CANTOR NL, 1987, LEGAL FRONTIERS DEAT; COHEN MM, 1988, JAMA-J AM MED ASSOC, V260, P2859, DOI 10.1001/jama.260.19.2859; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; DIXON JL, 1981, JAMA-J AM MED ASSOC, V246, P2471, DOI 10.1001/jama.246.21.2471; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; FRADER J, 1988, NEONATAL ANESTHESIA, pCH12; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GILLON R, 1986, BRIT MED J, V292, P193, DOI 10.1136/bmj.292.6514.193; HARRIS TJB, 1983, ANAESTHESIA, V38, P989, DOI 10.1111/j.1365-2044.1983.tb12031.x; Katz J., 1984, SILENT WORLD DOCTOR; KEATS AS, 1983, COMPLICATIONS ANESTH, pCH1; LEDERER DH, 1987, HASTINGS CENT REP, V17, P18, DOI 10.2307/3563178; LONGO WE, 1988, DIS COLON RECTUM, V31, P842, DOI 10.1007/BF02554846; MAY W, 1978, ENCY BIOETHICS, P316; MCGRATH PC, 1989, ANN SURG, V209, P284, DOI 10.1097/00000658-198903000-00006; MEISEL A, 1986, CRIT CARE MED, V14, P239, DOI 10.1097/00003246-198603000-00016; Miles S., 1988, PROTOCOLS ELECTIVE U; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; OLSSON GL, 1988, ACTA ANAESTH SCAND, V32, P653, DOI 10.1111/j.1399-6576.1988.tb02804.x; PEATFIELD RC, 1977, LANCET, V1, P1223; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SCOTT NB, 1988, BRIT J SURG, V75, P299; THOMAS JM, 1983, CAN MED ASSOC J, V128, P1153; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1991, ACCREDITATION MANUAL, P77; 1987, GUIDELINES TERMINATI; 1985, CONN MED, V49, P367	30	63	64	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2407	2412		10.1001/jama.266.17.2407	http://dx.doi.org/10.1001/jama.266.17.2407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1717723				2022-12-24	WOS:A1991GM79000028
J	REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP				REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP			MUTATIONS IN THE CHANNEL DOMAIN ALTER DESENSITIZATION OF A NEURONAL NICOTINIC RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; ACETYLCHOLINE-RECEPTOR; H-3 CHLORPROMAZINE; ION CHANNEL; DELTA-SUBUNIT; NONCOMPETITIVE BLOCKERS; ACTIVATED CHANNELS; AMINO-ACIDS; SUPERFAMILY; TRANSPORT	A VARIETY of ligand-gated ion channels undergo a fast activation process after the rapid application of agonist and also a slower transition towards desensitized or inactivated closed channel states when exposure to agonist is prolonged 1-5. Desensitization involves at least two distinct closed states in the acetylcholine receptor, each with an affinity for agonists higher than those of the resting or active conformations 1-5. Here we investigate how structural elements could be involved in the desensitization of the acetylcholine-gated ion channel from the chick brain alpha-bungarotoxin sensitive homo-oligomeric alpha-7 receptor 6,7, using site-directed mutagenesis and expression in Xenopus oocytes. Mutations of the highly conserved leucine 247 residue 8,9 from the uncharged MII segment of alpha-7 suppress inhibition by the open-channel blocker QX-222 (ref. 10), indicating that this residue, like others from MII (refs 11-22), faces the lumen of the channel. But, unexpectedly, the same mutations decrease the rate of desensitization of the response, increase the apparent affinity for acetylcholine and abolish current rectification. Moreover, unlike wild-type alpha-7, which has channels with a single conductance level, the leucine-to-threonine mutant has an additional conducting state active at low acetylcholine concentrations. It is possible that mutation of Leu 247 renders conductive one of the high-affinity desensitized states of the receptor.	UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,FAC MED,DEPT PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva	REVAH, F (corresponding author), INST PASTEUR,CNRS,UNITE RECH ASSOCIEE D1284,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			Mulle, Christophe/0000-0003-2709-6615				Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P5452, DOI 10.1021/bi00292a029; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P281, DOI 10.1111/j.1432-1033.1979.tb12894.x; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; [No title captured]	25	461	474	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					846	849		10.1038/353846a0	http://dx.doi.org/10.1038/353846a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719423				2022-12-24	WOS:A1991GM73200060
J	STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL				STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL			NEUTRALIZATION OF DIVERGENT HIV-1 ISOLATES BY CONFORMATION-DEPENDENT HUMAN-ANTIBODIES TO GP120	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; HTLV-III/LAV; CD4 RECEPTOR; CHIMPANZEES; INFECTION; IDENTIFICATION; DETERMINANT; RETROVIRUS; SEQUENCE	The spectrum of human immunodeficiency virus type 1 (HIV-1) isolates neutralized by antibodies from HIV-1-infected humans is broader than the spectrum of isolates neutralized by sera from animals immunized with purified gp120 subunits. This broader neutralization was due, in part, to the presence of antibodies to conserved gp120 conformational epitopes. Purified conformation-dependent gp120-specific human antibodies neutralized a wider range of virus isolates than human antibodies directed to linear determinants in gp120 and were also responsible for the majority of the gp120-specific CD4-blocking activity of HIV-1-infected human sera. A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.			STEIMER, KS (corresponding author), CHIRON CORP,EMERYVILLE,CA 94608, USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575				ARTHUR LO, 1987, P NATL ACAD SCI USA, V84, P8583, DOI 10.1073/pnas.84.23.8583; BARR PJ, 1987, VACCINE, V5, P90, DOI 10.1016/0264-410X(87)90053-3; BARR PJ, 1987, S MOL CELLULAR BIOL, V43, P205; BERKOWER I, 1989, J EXP MED, V170, P1681, DOI 10.1084/jem.170.5.1681; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOUDSMIT J, 1989, AIDS, V3, pS119, DOI 10.1097/00002030-198901001-00017; HAIGWOOD NL, 1991, VACCINES, V91, P51; HAIGWOOD NL, 1990, VACCINES, V90, P31; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; Means G.E., 1971, CHEM MODIFICATION PR; MYERS G, 1990, HUMAN RETROVIRUSES A; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PRINCE AM, 1987, J INFECT DIS, V156, P268, DOI 10.1093/infdis/156.2.268; PROFY AT, 1990, J IMMUNOL, V144, P4641; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3; ROBEY WG, 1986, P NATL ACAD SCI USA, V83, P7023, DOI 10.1073/pnas.83.18.7023; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SARIN PS, 1986, SCIENCE, V232, P1135, DOI 10.1126/science.3010464; SCANDELLA CJ, UNPUB; STEIMER KS, 1988, VACCINES, V88, P347; STEIMER KS, 1987, VACCINES, V87, P236; STEIMER KS, IN PRESS AIDS RES RE, V2; WEISS RA, 1986, NATURE, V324, P572, DOI 10.1038/324572a0	36	253	259	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					105	108		10.1126/science.1718036	http://dx.doi.org/10.1126/science.1718036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718036				2022-12-24	WOS:A1991GH60500039
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			REEXAMINATION OF THE FOLDING OF BPTI - PREDOMINANCE OF NATIVE INTERMEDIATES	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; STRUCTURAL CHARACTERIZATION; DISULFIDE BOND; RIBONUCLEASE-A; CYTOCHROME-C; PROTEIN; NMR; EXCHANGE; PATHWAY; ENERGETICS	Bovine pancreatic trypsin inhibitor (BPTI) continues to be the only protein for which a detailed pathway of folding has been described. Previous studies led to the conclusion that nonnative states are well populated in the oxidative folding of BPTI. This conclusion has broadly influenced efforts to understand protein folding. The population of intermediates present during the folding of BPTI has been reexamined by modern separation techniques. It was found that all well-populated folding intermediates contain only native disulfide bonds. These data emphasize the importance of native protein structure for understanding protein folding.	MIT,DEPT PHYS,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 05927] Funding Source: Medline; NIGMS NIH HHS [GM 41307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CREIGHTON TE, 1974, J MOL BIOL, V87, P603, DOI 10.1016/0022-2836(74)90106-5; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; CREIGHTON TE, 1975, J MOL BIOL, V96, P777, DOI 10.1016/0022-2836(75)90152-7; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P3, DOI 10.1016/0959-440X(91)90003-C; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; GOLDENBERG DP, 1985, BIOPOLYMERS, V24, P167, DOI 10.1002/bip.360240114; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, IN PRESS PROTEINS; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; MCCOY LF, 1980, BIOCHEMISTRY-US, V19, P4738, DOI 10.1021/bi00562a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STALEY JP, UNPUB; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1980, NATURE, V286, P630, DOI 10.1038/286630a0; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JG, UNPUB; WEISSMAN JS, 1982, J MOL BIOL, V155, P347; YAGISAWA S, 1989, BIOCHEM J, V263, P985, DOI 10.1042/bj2630985	46	513	518	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1386	1393		10.1126/science.1716783	http://dx.doi.org/10.1126/science.1716783			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716783				2022-12-24	WOS:A1991GF85100032
J	GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF				GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF			ENHANCEMENT OF THE GLUTAMATE RESPONSE BY CAMP-DEPENDENT PROTEIN-KINASE IN HIPPOCAMPAL-NEURONS	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; RECEPTOR DESENSITIZATION; CHANNELS; MODULATION; QUISQUALATE; FORSKOLIN; KAINATE; CELLS; CONDUCTANCES	Receptor channels activated by glutamate, an excitatory neurotransmitter in the mammalian brain, are involved in processes such as long-term potentiation and excitotoxicity. Studies of glutamate receptor channels expressed in cultured hippocampal pyramidal neurons reveal that these channels are subject to neuromodulatory regulation through the adenylate cyclase cascade. The whole-cell current response to glutamate and kainate [a non-NMDA (N-methyl-D-aspartate) receptor agonist] was enhanced by forskolin, an activator of adenylate cyclase. Single-channel analysis revealed that an adenosine 3',5'-monophosphate-dependent protein kinase (PKA) increases the opening frequency and the mean open time of the non-NMDA-type glutamate receptor channels. Analysis of synaptic events indicated that forskolin, acting through PKA, increased the amplitude and decay time of spontaneous excitatory postsynaptic currents.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; YALE UNIV, NEUROSCI PROGRAM, NEW HAVEN, CT 06510 USA	Salk Institute; Rockefeller University; Yale University				Nairn, Angus/0000-0002-7075-0195				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2100, DOI 10.1021/bi00681a009; CATTERALL WA, 1990, ADV SEC MESS PHOSPH, V24, P30; CHENG HC, 1986, J BIOL CHEM, V261, P989; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Kaczmarek L. K., 1987, NEUROMODULATION; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; LANDFIELD PW, 1988, LONG TERM POTENTIATI; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; MARKRAM H, 1990, NEUROSCI LETT, V113, P62, DOI 10.1016/0304-3940(90)90495-U; MODY I, 1988, NEUROSCI LETT, V93, P73, DOI 10.1016/0304-3940(88)90015-8; PIN JP, 1989, EUR J PHARM-MOLEC PH, V172, P81, DOI 10.1016/0922-4106(89)90047-3; RASSENDREN FA, 1989, NEUROSCI LETT, V99, P333, DOI 10.1016/0304-3940(89)90469-2; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WATANABE K, 1987, NEUROSCI LETT, V78, P211, DOI 10.1016/0304-3940(87)90635-5; WEINBERG CB, 1979, P NATL ACAD SCI USA, V76, P504, DOI 10.1073/pnas.76.1.504; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	25	383	392	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1135	1138		10.1126/science.1716001	http://dx.doi.org/10.1126/science.1716001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1716001				2022-12-24	WOS:A1991GD80800031
J	COHEN, S; TYRRELL, DAJ; SMITH, AP				COHEN, S; TYRRELL, DAJ; SMITH, AP			PSYCHOLOGICAL STRESS AND SUSCEPTIBILITY TO THE COMMON COLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTEERS; INFECTION	Background. It is not known whether psychological stress suppresses host resistance to infection. To investigate this issue, we prospectively studied the relation between psychological stress and the frequency of documented clinical colds among subjects intentionally exposed to respiratory viruses. Methods. After completing questionnaires assessing degrees of psychological stress, 394 healthy subjects were given nasal drops containing one of five respiratory viruses (rhinovirus type 2, 9, or 14, respiratory syncytial virus, or coronavirus type 229E), and an additional 26 were given saline nasal drops. The subjects were then quarantined and monitored for the development of evidence of infection and symptoms. Clinical colds were defined as clinical symptoms in the presence of an infection verified by the isolation of virus or by an increase in the virus-specific antibody titer. Results. The rates of both respiratory infection (P < 0.005) and clinical colds (P < 0.02) increased in a dose-response manner with increases in the degree of psychological stress. Infection rates ranged from approximately 74 percent to approximately 90 percent, according to levels of psychological stress, and the incidence of clinical colds ranged from approximately 27 percent to 47 percent. These effects were not altered when we controlled for age, sex, education, allergic status, weight, the season, the number of subjects housed together, the infectious status of subjects sharing the same housing, and virus-specific antibody status at base line (before challenge). Moreover, the associations observed were similar for all five challenge viruses. Several potential stress-illness mediators, including smoking, alcohol consumption, exercise, diet, quality of sleep, white-cell counts, and total immunoglobulin levels, did not explain the association between stress and illness. Similarly, controls for personality variables (self-esteem, personal control, and introversion-extraversion) failed to alter our findings. Conclusions. Psychological stress was associated in a dose-response manner with an increased risk of acute infectious respiratory illness, and this risk was attributable to increased rates of infection rather than to an increased frequency of symptoms after infection.	UNIV WALES COLL CARDIFF,HLTH PSYCHOL RES UNIT,CARDIFF CF1 1XL,S GLAM,WALES; MRC,COMMON COLD UNIT,SALISBURY,ENGLAND	Cardiff University	COHEN, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Smith, Andrew P/B-2192-2010; Winwood, Peter/A-6363-2008	Smith, Andrew/0000-0001-8805-8028; Cohen, Sheldon/0000-0003-2248-4600	NIAID NIH HHS [AI23072] Funding Source: Medline; NIMH NIH HHS [MH00721] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023072] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ader R., 1981, PSYCHONEUROIMMUNOLOG, V1st ed.; Afifi A.A., 1984, COMPUTER AIDED MULTI; ALEXANDER R W, 1956, Stud Med, V4, P61; BARCLAY WS, 1987, J VIROL METHODS, V15, P53, DOI 10.1016/0166-0934(87)90048-6; BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27; BOYCE WT, 1977, PEDIATRICS, V60, P609; BROADBENT DE, 1984, J PSYCHOSOM RES, V28, P511, DOI 10.1016/0022-3999(84)90085-0; CALABRESE JR, 1987, AM J PSYCHIAT, V144, P1123; CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410; CLUFF LE, 1966, ARCH INTERN MED, V117, P159, DOI 10.1001/archinte.117.2.159; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; COHEN S, 1988, SOCIAL PSYCHOL HLTH, P31; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FELTEN SY, 1987, J NEUROSCI RES, V18, P37, DOI 10.1002/jnr.490180108; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921; GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389, DOI 10.1093/oxfordjournals.aje.a114409; Henderson, 1981, NEUROSIS SOCIAL ENV; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; KIECOLT-GLASER J K, 1988, Brain Behavior and Immunity, V2, P67, DOI 10.1016/0889-1591(88)90007-4; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; Laudenslager ML, 1987, VIRUSES IMMUNITY MEN, P391; Lazarus R.S., 1984, STRESS APPRAISAL COP; MEYER RJ, 1962, PEDIATRICS, V29, P539; MORAHAN PS, 1989, NAT IMMUN, P557; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; TOTMAN R, 1980, J PSYCHOSOM RES, V24, P155, DOI 10.1016/0022-3999(80)90037-9; Tyrrell DAJ, 1988, LAB DIAGNOSIS INFECT, V2, P723; ZEVON MA, 1982, J PERS SOC PSYCHOL, V43, P111, DOI 10.1037/0022-3514.43.1.111	34	1151	1166	4	185	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					606	612		10.1056/NEJM199108293250903	http://dx.doi.org/10.1056/NEJM199108293250903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC328	1713648				2022-12-24	WOS:A1991GC32800003
J	DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L				DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L			SPECIFIC INTERACTION BETWEEN HPV-16 E1-E4 AND CYTOKERATINS RESULTS IN COLLAPSE OF THE EPITHELIAL-CELL INTERMEDIATE FILAMENT NETWORK	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAMES; HUMAN KERATINOCYTES; VACCINIA VIRUS; PROTEINS; E4; IDENTIFICATION; TRANSFORMATION; L1; CYTOSKELETON	THE human papillomaviruses (HPV) are associated specifically with epithelial lesions, ranging from benign warts to invasive carcinoma (for review, see refs 1, 2). The virus encodes three late proteins, which are produced only in terminally differentiating keratinocytes, two of which are structural components of the virion 3. The third, E1-E4, is derived primarily from the E4 open reading frame, which represents a region of maximal divergence between different HPV types 4,5. E1-E4 does not seem to be a component of the virus particle or to be needed for transformation in vitro 6,7, but accumulates in the cytoplasm 5,8-10, where in certain benign lesions it can comprise 20-30% of total cell protein 4,10. We show here that expression of the HPV-16 E1-E4 protein in human keratinocytes (the natural host cell for HPV infection) results in the total collapse of the cytokeratin matrix. Tubulin and actin networks are unaffected by E1-E4, as are the nuclear lamins.			DOORBAR, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREITBURD F, 1987, CANCER CELL, V5, P115; Broker T.R., 1986, CANCER CELL, V4, P17; BROWN DR, 1988, VIROLOGY, V165, P262, DOI 10.1016/0042-6822(88)90680-0; BROWNE HM, 1988, J GEN VIROL, V69, P1263, DOI 10.1099/0022-1317-69-6-1263; CRUM CP, 1990, VIROLOGY, V178, P238, DOI 10.1016/0042-6822(90)90399-C; DOORBAR J, 1988, EMBO J, V7, P825, DOI 10.1002/j.1460-2075.1988.tb02881.x; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; DOORBAR J, 1989, VIROLOGY, V172, P51, DOI 10.1016/0042-6822(89)90106-2; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Eckert B S, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P403; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HILLER G, 1979, VIROLOGY, V98, P142, DOI 10.1016/0042-6822(79)90533-6; Lane E B, 1990, Semin Cancer Biol, V1, P165; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MACKETT M, 1985, DNA CLONING PRACTICA, V2; MCLEAN CS, 1990, J CLIN PATHOL, V43, P488, DOI 10.1136/jcp.43.6.488; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHYY TT, 1989, J CELL BIOL, V108, P997, DOI 10.1083/jcb.108.3.997; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZURHAUSEN H, 1990, PAPOVAVIRIDAE	27	227	237	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					824	827		10.1038/352824a0	http://dx.doi.org/10.1038/352824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715519				2022-12-24	WOS:A1991GC96400067
J	CHAUDHARY, PM; RONINSON, IB				CHAUDHARY, PM; RONINSON, IB			EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS	CELL			English	Article							BONE-MARROW-CELLS; RESISTANCE GENE; ANTIGENIC ANALYSIS; PROGENITOR CELLS; CFU-S; RHODAMINE-123 FLUORESCENCE; MONOCLONAL-ANTIBODY; TUMOR-CELLS; RAT-LIVER; PURIFICATION	Hematopoietic stem cells show reduced staining with a mitochondrial fluorescent dye, rhodamine 123 (Rh123), which was supposed to indicate decreased mitochondrial activity in these cells. Rhl23 and several other fluorescent dyes are substrates for transport mediated by P-glycoprotein (P-gp), an efflux pump responsible for multidrug resistance in tumor cells. We have found that staining of human bone marrow cells with fluorescent dyes is potentiated by P-gp inhibitors and inversely correlated with P-gp expression. P-gp is expressed in practically all hematopoietic progenitor cells, including long-term culture-initiating cells. The highest levels of P-gp among the progenitors are associated with cells displaying characteristics of pluripotent stem cells. These results have implications for stem cell purification and bone marrow resistance to cancer chemotherapy.			CHAUDHARY, PM (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.		Chaudhary, Preet/E-1970-2018; Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [CA-40333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333, R01CA040333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERENSON RJ, 1991, BLOOD, V77, P1717; BERTONCELLO I, 1985, EXP HEMATOL, V13, P999; BRANDT J, 1988, J CLIN INVEST, V82, P1017, DOI 10.1172/JCI113658; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; FORD JM, 1990, PHARMACOL REV, V42, P155; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; GELLER RB, 1990, BRIT J HAEMATOL, V76, P340, DOI 10.1111/j.1365-2141.1990.tb06365.x; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAUGHLAND RP, 1989, MOL PROBES HDB FLUOR; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KASTAN MB, 1990, BLOOD, V75, P1947; LALANDE ME, 1981, P NATL ACAD SCI-BIOL, V78, P363, DOI 10.1073/pnas.78.1.363; LAMPIDIS TJ, 1985, CANCER RES, V45, P2626; MCCARTHY KF, 1990, INT J CELL CLONING, V8, P184, DOI 10.1002/stem.5530080305; MULDER AH, 1987, EXP HEMATOL, V15, P99; NEYFAKH AA, 1989, EXP CELL RES, V185, P496, DOI 10.1016/0014-4827(89)90318-2; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PALLAVICINI MG, 1985, EXP HEMATOL, V13, P1173; Pirker R, 1989, Cancer Commun, V1, P141; PLOEMACHER RE, 1988, J CELL PHYSIOL, V136, P531, DOI 10.1002/jcp.1041360320; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SHUDO N, 1990, CANCER RES, V50, P3055; SKIYSMS D, 1985, DOMSYIV VRLL MOL HRN, V11, P117; SNFTRED TH, 1986, NLOOF, V67, P842; SNFTRED TH, 1986, NLOOF, V68, P1030; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SROUR EF, 1991, CYTOMETRY, V12, P179, DOI 10.1002/cyto.990120213; STRAUSS LC, 1986, EXP HEMATOL, V14, P878; SUGAWARA I, 1988, CANCER RES, V48, P1926; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VANDERSLUIJS JP, 1990, EXP HEMATOL, V18, P893; VISSER JWM, 1990, EXP HEMATOL, V18, P248	47	926	966	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					85	94		10.1016/0092-8674(91)90141-K	http://dx.doi.org/10.1016/0092-8674(91)90141-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712673				2022-12-24	WOS:A1991FW91300011
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBILITY OF YERSINIA-ENTEROCOLITICA BACTEREMIA DUE TO TRANSFUSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, MMWR, V40, P176	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-24	WOS:A1991FU89600005
J	HOLLMANN, M; HARTLEY, M; HEINEMANN, S				HOLLMANN, M; HARTLEY, M; HEINEMANN, S			CA2+ PERMEABILITY OF KA-AMPA GATED GLUTAMATE RECEPTOR CHANNELS DEPENDS ON SUBUNIT COMPOSITION	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; EXCITATORY AMINO-ACIDS; XENOPUS-LAEVIS OOCYTES; ACTIVATED CHANNELS; DIVALENT-CATIONS; STRIATAL NEURONS; CHLORIDE CURRENT; CALCIUM; CULTURE	NMDA (N-methyl-D-aspartate) receptors and non-NMDA receptors represent the two major classes of ion channel-linked glutamate receptors. Unlike the NMDA receptor channels, non-NMDA receptor channels have usually been thought to conduct monovalent cations only. Non-NMDA receptor ion channels that can be gated by kainic acid (KA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) are formed by the glutamate receptor subunits GluR1, GluR2, and GluR3. These subunits were expressed in various combinations in Xenopus oocytes so that their permeability to divalent cations could be studied. At physiological resting potentials, KA and AMPA elicited inward calcium currents in oocytes expressing GluR1, GluR3, and GluR1 plus GluR3. In contrast, oocytes expressing GluR1 plus GluR2 or GluR3 plus GluR2 showed no such permeability. Thus, in neurons expressing certain KA-AMPA receptor subunits, glutamate may trigger calcium-dependent intracellular events by activating non-NMDA receptors.			HOLLMANN, M (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.			Hollmann, Michael/0000-0001-8000-7787	NINDS NIH HHS [NS28709-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, UNPUB; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1987, J NEUROSCI, V7, P3230; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MONAGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; MURPHY SN, 1989, J PHARMACOL EXP THER, V249, P184; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P1097, DOI 10.1152/jn.1989.61.6.1097; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; RANDLE JCR, 1988, MOL CELL BIOCHEM, V80, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275	35	1295	1321	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					851	853		10.1126/science.1709304	http://dx.doi.org/10.1126/science.1709304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709304				2022-12-24	WOS:A1991FL12300049
J	DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB				DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB			PRESENCE OF AN SH2 DOMAIN IN THE ACTIN-BINDING PROTEIN TENSIN	SCIENCE			English	Article							SMOOTH-MUSCLE VINCULIN; PHOSPHOLIPASE C-II; TYROSINE KINASES; FOCAL ADHESIONS; ALPHA-ACTININ; SARCOMA-VIRUS; CELLS; PHOSPHORYLATION; SIMILARITY; INVITRO	The molecular cloning of the complementary DNA coding for a 90-kilodalton fragment of tensin, an actin-binding component of focal contacts and other submembraneous cytoskeletal structures, is reported. The derived amino acid sequence revealed the presence of a Src homology 2 (SH2) domain. This domain is shared by a number of signal transduction proteins including nonreceptor tyrosine kinases such as Abl, Fps, Src, and Src family members, the transforming protein Crk, phospholipase C-gamma-l, PI-3 (phosphatidylinositol) kinase, and guanosine triphosphatase-activating protein (GAP). Like the SH2 domain found in Src, Crk, and Abl, the SH2 domain of tensin bound specifically to a number of phosphotyrosine-containing proteins from v-src-transformed cells. Tensin was also found to be phosphorylated on tyrosine residues. These findings suggest that by possessing both actin-binding and phosphotyrosine-binding activities and being itself a target for tyrosine kinases, tensin may link signal transduction pathways with the cytoskeleton.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT BIOPHYS,BALTIMORE,MD 21218	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Johns Hopkins University				Druker, Brian/0000-0001-8331-8206	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022289, R01GM038318] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38318, GM 22289] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Burridge K, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P587; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTLER JAV, UNPUB; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS RR, 1984, J BIOL CHEM, V259, P3916; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; KELLIE S, 1985, EXP CELL RES, V160, P259, DOI 10.1016/0014-4827(85)90174-0; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P669; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LIN S, 1989, SPRINGER SERIES BIOP, V3, P341; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Marston F. A. O., 1987, DNA CLONING, P59; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RISINGER M A, 1988, Journal of Cell Biology, V107, p256A; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SMITH DB, 1990, CURRENT PROTOCOLS MO; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; WILKINS JA, 1987, J CELL BIOL, V106, pA130	42	217	218	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					712	715		10.1126/science.1708917	http://dx.doi.org/10.1126/science.1708917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708917				2022-12-24	WOS:A1991FK18500051
J	SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL				SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL			RECOMBINANT VIRUS-VACCINE INDUCED SIV-SPECIFIC CD8+ CYTOTOXIC LYMPHOCYTES-T	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; AIDS; CELLS; PROTECTION; INDIVIDUALS; REPLICATION; INFECTION; SEQUENCE; INVITRO; MACAQUE	Evidence indicates that cytotoxic T lymphocytes (CTLs) may be important in containing the spread of the human immunodeficiency virus (HIV) in the infected host. Although the use of recombinant viruses has been proposed as an approach to elicit protective immunity against HIV, the ability of recombinant viral constructs to elicit CD8+ CTL responses in higher primates has never been demonstrated. A live recombinant virus, vaccinia-simian immunodeficiency virus of macaques (SIV(mac)), was used to determine whether such a genetically restricted, T lymphocyte-mediated antiviral response could be generated in a primate. Vaccinia-SIV(mac) vaccination elicited an SIV(mac) Gag-specific, CD8+ CTL response in rhesus monkeys. These CTLs recognized a peptide fragment that spans residues 171 to 195 of the Gag protein. The rhesus monkey major histocompatibility complex (MHC) class I gene product restricting this CTL response was defined. Both the vaccinated and SIV(mac)-infected monkeys that shared this MHC class I gene product developed CTLs with the same Gag epitope specificity. These findings support the use of recombinant virus vaccines for the prevention of HIV infections in humans.	HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772; APPL BIOTECHNOL INC,CAMBRIDGE,MA 02142	Harvard University					NATIONAL CANCER INSTITUTE [R01CA050139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020729, R37AI020729] Funding Source: NIH RePORTER; NCI NIH HHS [CA50139] Funding Source: Medline; NIAID NIH HHS [AI26507, AI20729] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ada GF, 1990, SEMIN VIROL SER, V1, P3; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; FRANCHINI G, 1987, NATURE, V328, P539, DOI 10.1038/328539a0; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MAZZARA G, UNPUB; MCLAUGHLINTAYLOR E, 1988, J GEN VIROL, V69, P1731, DOI 10.1099/0022-1317-69-7-1731; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLER MD, IN PRESS VACCINES 91; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROOK AH, 1987, J IMMUNOL, V138, P1064; Shen L., UNPUB; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WATANABE M, 1990, J VIROL, V64, P656, DOI 10.1128/JVI.64.2.656-663.1990; YAMAMOTO H, 1990, J IMMUNOL, V145, P3740; YAMAMOTO H, 1990, J IMMUNOL, V144, P3385; ZAGURY D, 1988, NATURE, V332, P728, DOI 10.1038/332728a0; ZARLING JM, 1987, J IMMUNOL, V139, P988	30	90	94	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					440	443		10.1126/science.1708168	http://dx.doi.org/10.1126/science.1708168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1708168				2022-12-24	WOS:A1991FH10300043
J	ANDERSON, JB; GRANT, JBF				ANDERSON, JB; GRANT, JBF			POSTOPERATIVE RETENTION OF URINE - A PROSPECTIVE URODYNAMIC STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORPHINE; INHIBITION; ANALGESIA; DETRUSOR; NALOXONE; REFLEX	Objective-To investigate the cause of post-operative retention of urine in elderly men. Design-Prospective study. Setting-Northern General Hospital, Sheffield. Patients-32 consecutive men (median age 73, range 55-85) referred to the urology department who were unable to pass urine either within 48 hours after operation and required catheterisation (23) or after removal of a catheter inserted at the initial operation (nine). Intervention-Intermittent self catheterisation. Main outcome measures-Urological investigation by medium fill and voiding cystometry within four weeks after operation, and minimum follow up three months thereafter. Results-6 patients resumed normal voiding before urodynamic assessment, three proceeded straight to prostatectomy, and one was unfit for self catheterisation. Of 22 men who underwent urodynamic investigation, only five had bladder outflow obstruction, who subsequently had successful prostatectomy; 15 showed either a low pressure-low flow system (seven) or complete detrusor failure (eight) and two showed pelvic parasympathetic nerve damage. With intermittent self catheterisation spontaneous voiding returned in all but one man within a median of 8 weeks (range 6-32 weeks). Recovery of bladder function took significantly longer in men with detrusor failure than in those with an underactive bladder (median 10 weeks (range 6-32 weeks) upsilon-median 8 weeks (range 6-8 weeks); p = 0.05). Three months later all patients had re-established their own normal voiding pattern with minimal residual urine on ultrasonography and satisfactory flow rates. Conclusions-Postoperative urinary retention in elderly men is not an indication for prostatectomy; a normal pattern of micturition can be re-established by intermittent self catheterisation in most men.	NO GEN HOSP, DEPT UROL, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	Northern General Hospital								CAMPBELL ED, 1972, DIS COLON RECTUM, V15, P69, DOI 10.1007/BF02587676; Craigen A A, 1969, J R Coll Gen Pract, V18, P226; DOYLE PT, 1976, BRIT J UROL, V48, P329, DOI 10.1111/j.1464-410X.1976.tb06645.x; DRAY A, 1984, J PHARMACOL EXP THER, V231, P254; DRAY A, 1988, ANESTHESIOLOGY, V68, P323, DOI 10.1097/00000542-198803000-00001; DURANT PAC, 1988, ANESTHESIOLOGY, V68, P325, DOI 10.1097/00000542-198803000-00002; ELLIS H, 1987, LECTURE NOTES GENERA, P362; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; GOSLING JA, 1977, J UROLOGY, V118, P302, DOI 10.1016/S0022-5347(17)57981-1; HASKELL DL, 1974, ARCH SURG-CHICAGO, V109, P378; HISAMITSU T, 1984, BRAIN RES, V298, P51, DOI 10.1016/0006-8993(84)91146-6; HODSMAN NBA, 1988, BRIT J SURG, V75, P212, DOI 10.1002/bjs.1800750307; LEVENTHAL A, 1978, Surgery Gynecology and Obstetrics, V146, P347; MARSHALL V, 1988, CLIN SCI SURGEONS, P552; MITCHELL JP, 1986, HAMILTON BAILEYS EME, P507; MURRAY KHA, 1982, BRIT J UROL, V54, P638, DOI 10.1111/j.1464-410X.1982.tb13614.x; PETERSEN TK, 1982, BRIT J ANAESTH, V54, P1175, DOI 10.1093/bja/54.11.1175; PETROS JG, 1990, AM J SURG, V159, P374, DOI 10.1016/S0002-9610(05)81274-7; SANDYK R, 1986, UROLOGY, V27, P79, DOI 10.1016/0090-4295(86)90215-3; STALLARD S, 1988, BRIT J SURG, V75, P1141, DOI 10.1002/bjs.1800751128; TAMMELA T, 1986, SCAND J UROL NEPHROL, V20, P197, DOI 10.3109/00365598609024494; TREIGER P, 1950, AM J SURG, V80, P195, DOI 10.1016/0002-9610(50)90529-0; VAIDYANATHAN S, 1981, J UROLOGY, V126, P500, DOI 10.1016/S0022-5347(17)54596-6; VIRTANEN R, 1982, ACTA ANAESTH SCAND, V26, P297, DOI 10.1111/j.1399-6576.1982.tb01770.x; WALTS LF, 1985, CLIN ORTHOP RELAT R, V194, P280; 1990, BR J OBSTET GYNAE S6, V97	26	39	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1991	302	6781					894	896		10.1136/bmj.302.6781.894	http://dx.doi.org/10.1136/bmj.302.6781.894			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1709058	Green Published, Bronze			2022-12-24	WOS:A1991FG42100028
J	WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J				WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J			TUMOR ANGIOGENESIS AND METASTASIS - CORRELATION IN INVASIVE BREAST-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRENEOPLASTIC LESIONS; GROWTH-FACTOR; MARKER; NEOVASCULARIZATION; VESSELS; CANCER; CELLS; MELANOMA; MEMBRANE; BIOLOGY	Background. Experimental evidence suggests that the growth of a tumor beyond a certain size requires angiogenesis, which may also permit metastasis. To investigate how tumor angiogenesis correlates with metastases in breast carcinoma, we counted microvessels (capillaries and venules) and graded the density of microvessels within the initial invasive carcinomas of 49 patients (30 with metastases and 19 without). Methods. Using light microscopy, we highlighted the vessels by staining their endothelial cells immunocytochemically for factor VIII. The microvessels were carefully counted (per 200 x field), and their density was graded (1 to 4+), in the most active areas of neovascularization, without knowledge of the outcome in the patient, the presence or absence of metastases, or any other pertinent variable. Results. Both microvessel counts and density grades correlated with metastatic disease. The mean (+/- SD) count and grade in the patients with metastases were 101 +/- 49.3 and 2.95 +/- 1.00 vessels, respectively. The corresponding values in the patients without metastases were significantly lower - 45 +/- 21.1 and 1.38 +/- 0.82 (P = 0.003 and P less-than-or-equal-to 0.001, respectively). For each 10-microvessel increase in the count per 200 x field, there was a 1.59-fold increase in the risk of metastasis (95 percent confidence interval, 1.19 to 2.12; P = 0.003). The microvessel count and density grade also correlated with distant metastases. For each 10-microvessel increase in the vessel count per 200 x field, there was a 1.17-fold increase in the risk of distant metastasis (95 percent confidence interval, 1.02 to 1.34; P = 0.029). Conclusions. The number of microvessels per 200 x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both). Assessment of tumor angiogenesis may therefore prove valuable in selecting patients with early breast carcinoma for aggressive therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	WEIDNER, N (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-37395-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037395, R01CA037395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X; BREM SS, 1977, SCIENCE, V195, P880, DOI 10.1126/science.402692; CHODAK GW, 1980, ANN SURG, V192, P762, DOI 10.1097/00000658-198012000-00012; Cox DR., 1970, ANAL BINARY DATA; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Folkman J., 1987, THROMB DIATH HAEMO, P583; FOLKMAN J, 1989, NATURE, P339; HERLYN M, 1987, LAB INVEST, V56, P461; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; JENSEN HM, 1987, ANGIOGENESIS MECHANI, P155; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; LIOTTA LA, 1974, CANCER RES, V34, P997; LIOTTA LA, 1976, CANCER RES, V36, P889; MOSCATELLI D, 1981, J CELL BIOL, V91, pA201; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; NICHOLSON GL, 1979, SCI AM, V240, P66; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; POLVERINI PJ, 1984, LAB INVEST, V51, P635; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SMITH SS, 1970, CAN J OPHTHALMOLOGY, V5, P175; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; WEISS L, 1976, FUNDAMENTAL ASPECTS, P51; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	29	4984	5620	5	331	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					1	8		10.1056/NEJM199101033240101	http://dx.doi.org/10.1056/NEJM199101033240101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1701519	Bronze			2022-12-24	WOS:A1991EQ50300001
J	MISHIRO, S; HOSHI, Y; TAKEDA, K; YOSHIKAWA, A; GOTANDA, T; TAKAHASHI, K; AKAHANE, Y; YOSHIZAWA, H; OKAMOTO, H; TSUDA, F; PETERSON, DA; MUCHMORE, E				MISHIRO, S; HOSHI, Y; TAKEDA, K; YOSHIKAWA, A; GOTANDA, T; TAKAHASHI, K; AKAHANE, Y; YOSHIZAWA, H; OKAMOTO, H; TSUDA, F; PETERSON, DA; MUCHMORE, E			NON-A, NON-B HEPATITIS SPECIFIC ANTIBODIES DIRECTED AT HOST-DERIVED EPITOPE - IMPLICATION FOR AN AUTOIMMUNE PROCESS	LANCET			English	Article									JAPANESE RED CROSS, CTR BLOOD, SAITAMA, JAPAN; YAMANASHI MED COLL, DEPT INTERNAL MED 1, YAMANASHI, JAPAN; HIROSHIMA UNIV, SCH MED, DEPT HYG, HIROSHIMA 730, JAPAN; JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; ABBOTT LABS, N CHICAGO, IL 60064 USA; KITASATO INST, IMMUNOL SECT, TOKYO 108, JAPAN; HAMAMATSU UNIV, SCH MED, DEPT PUBL HLTH, HAMAMATSU, SHIZUOKA 43131, JAPAN; NYU MED CTR, EXPTL MED & SURG PRIMATES LAB, NEW YORK, NY 10016 USA	Japanese Red Cross Medical Center; University of Yamanashi; Hiroshima University; Jichi Medical University; Abbott Laboratories; Kitasato University; Hamamatsu University School of Medicine; New York University	MISHIRO, S (corresponding author), INST IMMUNOL, KORAKU 1-1-10, BUNKYO KU, TOKYO, JAPAN.		Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; HOFFNAGLE JH, 1973, LANCET, V2, P869; HUYNH TV, 1985, DNA CLONING, V1; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MIYAMURA T, 1990, P NATL ACAD SCI USA, V87, P983, DOI 10.1073/pnas.87.3.983; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; SHIMIZU YK, 1979, SCIENCE, V205, P197, DOI 10.1126/science.451589; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; THEILMANN L, 1990, LANCET, V335, P1345; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIZAWA H, 1980, GASTROENTEROLOGY, V79, P512; 883109225	19	213	217	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	1990	336	8728					1400	1403		10.1016/0140-6736(90)93101-T	http://dx.doi.org/10.1016/0140-6736(90)93101-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL851	1701012				2022-12-24	WOS:A1990EL85100004
J	ALFA, CE; DUCOMMUN, B; BEACH, D; HYAMS, JS				ALFA, CE; DUCOMMUN, B; BEACH, D; HYAMS, JS			DISTINCT NUCLEAR AND SPINDLE POLE BODY POPULATIONS OF CYCLIN-CDC2 IN FISSION YEAST	NATURE			English	Article									UNIV LONDON UNIV COLL,DEPT BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND; HOWARD HUGHES MED INST,COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of London; University College London; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				Alfa C. E., 1989, J CELL SCI S, V12, P9; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DAVIDSE LC, 1986, ANNU REV PHYTOPATHOL, V24, P43, DOI 10.1146/annurev.py.24.090186.000355; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, J CELL SCI, V96, P683; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HAGAN IM, 1988, THESIS U LONDON; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HYAMS JS, 1978, J CELL BIOL, V78, P401, DOI 10.1083/jcb.78.2.401; KING SM, 1982, CAN J MICROBIOL, V28, P261, DOI 10.1139/m82-036; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; UMESONO K, 1983, CURR GENET, V7, P123, DOI 10.1007/BF00365637; WALKER GM, 1982, J GEN MICROBIOL, V128, P61	21	186	186	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 18	1990	347	6294					680	682		10.1038/347680a0	http://dx.doi.org/10.1038/347680a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED620	1699136				2022-12-24	WOS:A1990ED62000058
J	CHESTER, AH; ONEIL, GS; MONCADA, S; TADJKARIMI, S; YACOUB, MH				CHESTER, AH; ONEIL, GS; MONCADA, S; TADJKARIMI, S; YACOUB, MH			LOW BASAL AND STIMULATED RELEASE OF NITRIC-OXIDE IN ATHEROSCLEROTIC EPICARDIAL CORONARY-ARTERIES	LANCET			English	Article									HAREFIELD HOSP,NATL HEART & LUNG INST,THORAC & CARDIAC SURG UNIT,HAREFIELD UB9 6JH,MIDDX,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; GlaxoSmithKline; Wellcome Research Laboratories								AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P349, DOI 10.1016/0033-0620(88)90003-5; BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; CHESTER AH, IN PRESS INT J CARDI; CHRISTIE MI, 1989, BRIT J PHARMACOL, V98, P397, DOI 10.1111/j.1476-5381.1989.tb12610.x; COLER J, 1989, BRIT J PHARMACOL, V97, P639; CROSSMAN DC, 1989, CIRCULATION, V80, P475, DOI 10.1161/01.CIR.80.3.475; FELETOU M, 1988, BRIT J PHARMACOL, V93, P515, DOI 10.1111/j.1476-5381.1988.tb10306.x; FORSTERMANN U, 1988, CIRC RES, V62, P185, DOI 10.1161/01.RES.62.2.185; GRIFFITH TM, 1984, J PHYSIOL-LONDON, V351, P13, DOI 10.1113/jphysiol.1984.sp015228; HABIB JB, 1986, CIRC RES, V58, P305, DOI 10.1161/01.RES.58.2.305; IP JH, 1989, CURR OPIN CARDIOL, V4, P772, DOI 10.1097/00001573-198912000-00002; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; PALMER RMJ, 1987, NATURE, V327, P525; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SCHOEFFTER P, 1988, BRIT J PHARMACOL, V95, P531, DOI 10.1111/j.1476-5381.1988.tb11674.x; THOM S, 1987, CLIN SCI, V73, P547, DOI 10.1042/cs0730547; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1989, LANCET, V2, P997; WHITTLE BJR, 1989, BRIT J PHARMACOL, V98, P646, DOI 10.1111/j.1476-5381.1989.tb12639.x	20	257	268	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 13	1990	336	8720					897	900		10.1016/0140-6736(90)92269-N	http://dx.doi.org/10.1016/0140-6736(90)92269-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC456	1699098				2022-12-24	WOS:A1990EC45600003
J	STANDAERT, RF; GALAT, A; VERDINE, GL; SCHREIBER, SL				STANDAERT, RF; GALAT, A; VERDINE, GL; SCHREIBER, SL			MOLECULAR-CLONING AND OVEREXPRESSION OF THE HUMAN FK506-BINDING PROTEIN FKBP	NATURE			English	Article									HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138	Harvard University			Standaert, Robert F./AAI-1532-2021; Standaert, Robert F/D-9467-2013	Standaert, Robert F/0000-0002-5684-1322				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FASMAN GD, 1989, PRACTICAL HDB BIOCH, P80; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; INNIS MA, 1990, PCR PROTOCOLS; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STARZL TE, 1989, LANCET, V2, P1000; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; SWAIN CG, 1980, J CHEM INF COMP SCI, V20, P47, DOI 10.1021/ci60021a011; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094	36	311	356	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 16	1990	346	6285					671	674		10.1038/346671a0	http://dx.doi.org/10.1038/346671a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU728	1696686				2022-12-24	WOS:A1990DU72800067
J	TSE, A; HILLE, B				TSE, A; HILLE, B			GNRH-INDUCED CA2+ OSCILLATIONS AND RHYTHMIC HYPERPOLARIZATIONS OF PITUITARY GONADOTROPES	SCIENCE			English	Article							MEMBRANE CURRENTS; CA-2+ TRANSIENTS; K+ CHANNELS; LH-RELEASE; HORMONE; RAT; CELLS	Secretion of gonadotropic hormones from pituitary gonadotropes in response to gonadotropin-releasing hormone (GnRH) is essential for regulation of reproductive potential. Gonadotropes from male rats exhibited an unusual form of cellular excitation that resulted from periodic membrane hyperpolarization. GnRH induced an oscillatory release of intracellular Ca2+ via a guanosine triphosphate (GTP) binding protein-coupled phosphoinositide pathway and hyperpolarized the gonadotrope periodically by opening apamin-sensitive Ca2+-activated K+ (SK) channels. Each hyperpolarization was terminated by firing of a few action potentials that may result from removal of inactivation from voltage-gated Na+ and Ca2+ channels.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Tse, Amy/C-3142-2013	Tse, Amy/0000-0002-0847-7466				BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOSMA MM, UNPUB; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHEN C, 1989, NEUROCHEM INT, V15, P265, DOI 10.1016/0197-0186(89)90132-0; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; CROXTON TL, 1989, METHOD ENZYMOL, V168, P145; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; MASON WT, 1985, NEUROENDOCRINOLOGY, V41, P258, DOI 10.1159/000124186; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PALADE P, 1989, MOL PHARMACOL, V36, P673; PFAFFINGER P, 1988, J NEUROSCI, V8, P3343; PFAFFINGER PJ, 1988, NEURON, V1, P477, DOI 10.1016/0896-6273(88)90178-X; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; POULSEN JH, 1976, NATURE, V263, P156, DOI 10.1038/263156a0; RIVIER JE, 1978, LIFE SCI, V23, P869, DOI 10.1016/0024-3205(78)90522-2; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; SMITH CE, 1987, FEBS LETT, V225, P247, DOI 10.1016/0014-5793(87)81167-5; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STOJILKOVIC SS, 1990, P NATL ACAD SCI USA, V87, P8855, DOI 10.1073/pnas.87.22.8855; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, UNPUB	28	163	164	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					462	464		10.1126/science.1734523	http://dx.doi.org/10.1126/science.1734523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734523				2022-12-24	WOS:A1992HA59000040
J	WARBURG, A; MILLER, LH				WARBURG, A; MILLER, LH			SPOROGONIC DEVELOPMENT OF A MALARIA PARASITE INVITRO	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; PLASMODIUM; MOSQUITO; CULTURE	The sporogonic cycle of the avian malaria parasite Plasmodium gallinaceum was completed in vitro. Ookinetes (motile zygotes) were seeded onto a murine basement membrane-like gel (Matrigel) in coculture with Drosophila melanogaster cells (Schneider's L2). Transformation into oocysts as well as subsequent growth and differentiation were observed in parasites attached to Matrigel and depended on the presence of L2 cells. Sporozoites were first observed on day 10 in culture. Specific circumsporozoite protein antigenicity was identified in mature oocysts and in sporozoites. It is now possible to follow the entire life cycle of Plasmodium in vitro.			WARBURG, A (corresponding author), NIAID,PARASIT DIS LAB,MALARIA SECT,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Warburg, Alon/ABE-9946-2020	Warburg, Alon/0000-0001-7929-3114				CHAO J, 1964, AM J TROP MED HYG, V13, P181, DOI 10.4269/ajtmh.1964.13.181; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; HOLLINGDALE MR, 1987, IN VITRO METHODS PAR, P180; KAUSHAL DC, 1983, MOL BIOCHEM PARASIT, V8, P53, DOI 10.1016/0166-6851(83)90034-8; KLEINMAN HK, 1987, ANAL BIOCHEM, V166, P1, DOI 10.1016/0003-2697(87)90538-0; KLEINMAN HK, IN PRESS CELLULAR AS; KRETTLI AU, 1988, PARASITE IMMUNOL, V10, P523, DOI 10.1111/j.1365-3024.1988.tb00240.x; LUNSTRUM GP, 1988, J BIOL CHEM, V263, P18318; MELHORN H, 1980, PROTISTOLOGICA, V16, P135; MONS B, 1990, PARASITOL TODAY, V6, P3, DOI 10.1016/0169-4758(90)90377-G; PONNUDURAI T, 1987, IN VITRO METHODS PAR, P153; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEIDER I, 1980, MALARIA, V2, P235; SINDEN RE, 1984, EXPERIENTIA, V40, P1330, DOI 10.1007/BF01951886; SINDEN RE, 1985, PARASITOLOGY, V91, P227, DOI 10.1017/S0031182000057334; TERZAKIS JA, 1967, J CELL BIOL, V34, P311, DOI 10.1083/jcb.34.1.311; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERBERG JP, 1977, B WORLD HEALTH ORGAN, V55, P377; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WARBURG A, UNPUB; 1963, AM TYPE CULTURE COLL	21	59	64	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					448	450		10.1126/science.1734521	http://dx.doi.org/10.1126/science.1734521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734521				2022-12-24	WOS:A1992HA59000035
J	FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC				FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC			SEQUENCE OF CHANGES IN BODY-COMPOSITION INDUCED BY TESTOSTERONE AND REVERSAL OF CHANGES AFTER DRUG IS STOPPED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MASS	Objective. -To study the changes in body composition produced by large doses of testosterone and reversal of changes when the drug is discontinued. Design. - Weekly injections of testosterone enanthate were given to young adult male volunteers for 12 weeks. Repeated assays of lean body mass (LBM) by potassium 40 counting were made during this period and at intervals during the ensuing 5 to 6 months. Participants and Setting. - Subjects who were living on their own, who were known to be free of significant disease, and who volunteered as controls for a study of patients with neuromuscular disease. Assays were done in the Clinical Research Center. Main Outcome Measures. - Changes in body weight, LBM, and (by subtraction) body fat. Results. - Testosterone treatment produced a progressive increase in LBM and a progressive decrease in body fat. Body composition reverted slowly toward normal when the injections were stopped; thus, the effects of testosterone lingered for some time. The magnitude of the observed changes in LBM was in keeping with the change in urinary creatinine excretion reported for these same subjects. Conclusion. - Testosterone is a powerful anabolic agent that also serves to reduce body fat content.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester				Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [RR-00044] Funding Source: Medline; NICHD NIH HHS [HD-18454] Funding Source: Medline; NINDS NIH HHS [NS-22099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K06HD018454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022099] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOIA JF, 1981, METABOLISM, V30, P1076, DOI 10.1016/0026-0495(81)90050-0; Forbes G, 1987, HUMAN BODY COMPOSITI; FORBES GB, 1991, J APPL PHYSIOL, V70, P994, DOI 10.1152/jappl.1991.70.3.994; FORBES GB, 1986, BRIT J NUTR, V56, P1, DOI 10.1079/BJN19860080; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FORBES GB, 1985, FED PROC, V44, P343; FORBES GB, 1982, DIET EXERCISE SYNERG, P75; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; HASSAGER C, 1989, MATURITAS, V4, P305; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; WELLE S, IN PRESS J CLIN ENDO; WILMORE JH, 1983, MED SCI SPORT EXER, V15, P21	12	84	85	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					397	399		10.1001/jama.267.3.397	http://dx.doi.org/10.1001/jama.267.3.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727963				2022-12-24	WOS:A1992GY43700038
J	GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D				GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D			PREVALENCE OF TUBERCULIN POSITIVITY AND SKIN-TEST ANERGY IN HIV-1-SEROPOSITIVE AND HIV-1-SERONEGATIVE INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS-INFECTION; AIDS	Objectives. - To identify differences in purified protein derivative (PPD) tuberculin positivity and skin test anergy rates by human immunodeficiency virus (HIV) serostatus, CD4+ lymphocyte count, and other risk factors in intravenous drug users (IVDUs); and to evaluate the appropriateness of the Centers for Disease Control (CDC)-recommended definition for a positive PPD tuberculin skin test result in HIV-1-seropositive patients. Design. - Nested case-control and cross-sectional analyses. Setting. - Community-based cohort of IVDUs. Patients. - Two hundred sixty HIV-1-seropositive and -seronegative IVDUs, drawn from an unselected cohort, were skin-tested for sensitivity to PPD tuberculin, mumps, and Candida antigens using the Mantoux method. Outcome Measures. - Positivity to PPD tuberculin, skin test anergy. Results. - Even using the CDC definition of an induration 5 mm or greater in diameter in HIV-1 seropositives, this group was substantially less likely to be PPD tuberculin positive than HIV-1 seronegatives (13.8% vs 25.2%; P = .02). In the HIV-1 seropositives the relative odds of being PPD positive varied depending on whether 10 mm or greater (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.2 to 0.7), 5 mm or greater (OR, 0.5; 95% CI, 0.2 to 0.9), or 2 mm or greater (OR, 0.7; 95% CI, 0.4 to 1.3) was used to define a positive test result. The mean diameter induration in the HIV-1-seropositive group was 2.6 mm vs 5.4 mm in the seronegative group (P =.005). Skin test anergy (to mumps and Candida) appeared to explain the differential. Anergy was substantially higher in the HIV-1 seropositive group and increased as the CD4+ lymphocyte count fell (chi-2 for linear trend, 24.5; P < .0001). An inverse linear trend for PPD positivity and CD4+ lymphocyte count was also observed (chi-2 for trend, 6.1; P = .01). In multivariate analyses, being 35 years of age or older and being HIV-1 seronegative were significantly associated with PPD positivity, while history of previous police arrest was of borderline significance. Only HIV-1 seropositivity was significantly associated with anergy. Conclusions. - These findings show that CDC-recommended definition of an induration 5 mm or greater in diameter for PPD tuberculin positivity in HIV-1 seropositives significantly underestimates the "true" infection rate (using the PPD positivity rate in HIV-1 seronegatives as the criterion standard). A definition of 2 mm or greater would appear to be a better cutoff for reducing misclassification in HIV-1 seropositives. This study also confirms that delayed-type hypersensitivity is seriously depressed in HIV-1 seropositive IVDUs and that anergy testing is mandatory to properly assess a negative PPD test result.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	Johns Hopkins University	GRAHAM, NMH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 624 N BROADWAY, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04334, DA 05664] Funding Source: Medline; PHS HHS [CCU300466-10] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRX D, 1989, 5TH P INT C AIDS MON; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P638; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; NOLAN CM, 1988, 4TH INT C AIDS STOCK, P313; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SELIK RM, 1987, AIDS, V1, P175; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; Vlahov D, 1991, NIDA Res Monogr, V109, P75; 1991, MMWR, V40, P27; 1989, MMWR, V34, P236; 1990, MMWR, V39, P153; 1990, MMWR, V39, P1	19	188	191	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					369	373		10.1001/jama.267.3.369	http://dx.doi.org/10.1001/jama.267.3.369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727959				2022-12-24	WOS:A1992GY43700033
J	HIRSCHMANN, JV				HIRSCHMANN, JV			NORMAL BODY-TEMPERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HIRSCHMANN, JV (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DOWNTON JH, 1987, AGE AGEING, V16, P41, DOI 10.1093/ageing/16.1.41; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1945, GASTROENTEROLOGY, V5, P326; MELLETTE HC, 1951, J APPL PHYSIOL, V3, P65; WEIZMAN ED, 1982, NEUROBIOL AGING, V3, P299	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					414	414						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727969				2022-12-24	WOS:A1992GY43700045
J	AMOS, A; BOSTOCK, Y				AMOS, A; BOSTOCK, Y			FOR DEBATE - POLICY ON CIGARETTE ADVERTISING AND COVERAGE OF SMOKING AND HEALTH IN EUROPEAN WOMENS MAGAZINES	BRITISH MEDICAL JOURNAL			English	Article											AMOS, A (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							AITKEN PP, 1990, BRIT J ADDICT, V85, P399; AITKEN PP, 1991, BRIT J ADDICT, V86, P383; AITKEN PP, 1987, BRIT J ADDICT, V82, P615; Amos A, 1990, World Health Forum, V11, P416; AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; AMOS A, 1991, HLTH ED J, V50, P26; AMOS A, 1991, PUTTING WOMEN PICTUR; BAAM R, 1990, ROKEN WELBESCHOUWD; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; Charlton A., 1986, HLTH ED J, V45, P75; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; EARNSTER VL, 1985, NY STATE J MED, V85, P335; GODDARD E, 1990, SMOKING SECONDARY SC; GODDARD E, 1987, SMOKING SECONDARY SC; JACOBSON B, 1988, BEATING LADYKILLERS; JACOBSON B, 1985, SMOKE GETS YOUR EYES; LOCK S, 1990, BRIT MED J, V301, P1405, DOI 10.1136/bmj.301.6766.1405; NUTBEAM D, 1988, PLANNING SMOKE FREE; ROGERS D, 1987, TOBACCO REPORTER FEB, P8; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1990, 7TH P WORLD C TOB HL, P765; 1990, IT CAN BE DONE SMOKE; 1983, TOBACCO REPORTER APR, P44; 1989, NATIONAL READERSHIP; 1987, EUROPE CANCER SURVEY; 1987, SMOKE FREE EUROPE 5; 1986, SCOTTISH HLTH STATIS; 1989, HLTH TOBACCO; 1989, SMOKING WISH STOP FI	29	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					99	101		10.1136/bmj.304.6819.99	http://dx.doi.org/10.1136/bmj.304.6819.99			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA171	1737152	Green Published, Bronze			2022-12-24	WOS:A1992HA17100028
J	RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO				RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO			ALCOHOL-CONSUMPTION AND ITS RELATION TO CARDIOVASCULAR RISK-FACTORS IN BRITISH WOMEN	BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN SUBFRACTIONS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CHOLESTEROL; MORTALITY; ETHANOL; SMOKING; GLUCOSE; LIPIDS; MEN	Objective - To examine the relation between alcohol consumption and risk factors for coronary heart disease in women. Design - Cross sectional study of a stratified random sample of the population grouped into five categories of habitual alcohol consumption. Setting - People registered with general practitioners at two large health centres in east Bristol, England. Subjects - 1048 women aged 25-69 years. Main outcome measures - Fasting plasma concentrations of insulin, total cholesterol, total triglycerides, and high density lipoprotein cholesterol, including its subfractions HDL2 and HDL3, and body mass index. Results - Compared with non-drinkers women consuming a moderate amount of alcohol (1-20 g/day) had lower plasma concentrations of triglycerides, by 0.19 mmol/l (95% confidence interval 0.07 to 0.5); cholesterol, by 0.4 mmol/l (0.19 to 0.61); and insulin, by 1.4 mU/l (0.43 to 1.97) and a lower body mass index, by 1.2 kg/m2 (0.43 to 1.97). They also had higher concentrations of high density lipoprotein cholesterol, by 0-09 mmol/l (0.03 to 0.15); HDL2 cholesterol by 0.05 mmol/l (-0.02 to 0.10) and HDL3 cholesterol, by 0.06 mmol/l (0.06 to 0.11). All these were independent of body mass index, smoking habits, and taking oral contraceptives. Conclusions - Moderate alcohol consumption is associated with lower levels of cardiovascular risk factors in women. Insulin may have a central role.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND	University of Bristol	RAZAY, G (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BELFRAGE P, 1977, EUR J CLIN INVEST, V7, P127, DOI 10.1111/j.1365-2362.1977.tb01584.x; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DIETSCHY JM, 1974, J LIPID RES, V15, P508; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; FEHILY AM, 1988, EUR J CLIN NUTR, V42, P405; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HENNEKENS CH, 1987, CIRCULATION, V76, P501; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; MARMOT MG, 1981, LANCET, V1, P580; METZ R, 1969, DIABETES, V18, P517, DOI 10.2337/diab.18.8.517; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; OETTLE GJ, 1987, AM J CLIN NUTR, V45, P86, DOI 10.1093/ajcn/45.1.86; OHLER G, 1982, INT J OBES S1, V6, P137; PATEL DG, 1979, METABOLISM, V28, P85, DOI 10.1016/0026-0495(79)90173-2; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P121; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEINER G, 1986, AM J CARDIOL, V57, P27; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; THORNTON J, 1983, LANCET, V2, P819; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; 1989, REFERENCE MANUAL REL	33	94	95	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					80	83		10.1136/bmj.304.6819.80	http://dx.doi.org/10.1136/bmj.304.6819.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737144	Green Published, Bronze			2022-12-24	WOS:A1992HA17100020
J	SUMNERS, D; KELSEY, M; CHAIT, I				SUMNERS, D; KELSEY, M; CHAIT, I			PSYCHOLOGICAL-ASPECTS OF LOWER URINARY-TRACT INFECTIONS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							URETHRAL SYNDROME	Objective - To determine whether women with the urethral syndrome can be distinguished from those with urinary tract infection by case notes, clinical symptoms, or psychiatric state. Design - Longitudinal survey of consecutive women presenting with dysuria and frequency. Setting - General practice and community. Subjects - 58 patients with the urethral syndrome and 44 patients with a urinary tract infection, mean age 39.9 years. Main outcome measures - Results of analysis of serial midstream urine specimens, patients' self rated physical symptoms and responses to 60 item general health questionnaire at presentation and after resolution of symptoms, and results of psychiatric assessment with the clinical psychiatric interview. Results - 4 of 42 patients with a urinary tract infection had recently changed sexual partner compared with none of 58 with the urethral syndrome. Dysuria and nocturia were more common in patients with urinary tract infections than those with the urethral syndrome (mean (SD) score for dysuria 5-37 (2.39) v 4.57 (2.13), p < 0.05; nocturia in 39/44 (88%) patients v 40/58 (69%), chi-2 = 5.5, p < 0.02). Both groups showed transient high levels of distress which resolved with the physical symptoms, but no psychiatric difference distinguished them. Conclusion - The urethral syndrome is not associated with increased psychiatric morbidity.	WHITTINGTON HOSP,LONDON N19 5NF,ENGLAND; ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	SUMNERS, D (corresponding author), NAPSBURY HOSP,LONDON AL2 1AA,HERTS,ENGLAND.							BORCHAM P, 1984, J R SOC MED, V77, P111; BROOKS D, 1978, BACTERIOLOGICAL EXAM, P39; BRUMFITT W, 1991, BRIT MED J, V303, P1, DOI 10.1136/bmj.303.6793.1; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; FROST D, 1981, BRIT J PSYCHIAT, V138, P292; FRY J, 1980, COMMON DISEASES THEI; GALLAGHER DJ, 1965, BMJ-BRIT MED J, V1, P622, DOI 10.1136/bmj.1.5435.622; GOLDBERG DP, 1970, BRIT J PREV SOC MED, V24, P18; Goldberg DP., 1972, DETECTION PSYCHIATRI; GRAY LA, 1956, JAMA-J AM MED ASSOC, V162, P1361, DOI 10.1001/jama.1956.02970320009003; MASON E, 1977, J IRISH MED ASSOC, V70, P335; ODOWD TC, 1984, BMJ, V288, P208; REES DLP, 1977, BRIT J UROL, V49, P651, DOI 10.1111/j.1464-410X.1977.tb04547.x; SCHMIDT RA, 1985, UROL CLIN N AM, V12, P349; SCOTTI RJ, 1984, CLIN OBSTET GYNECOL, V27, P515, DOI 10.1097/00003081-198406000-00025; WATERS WE, 1969, BR J PREV SOC MED, V23, P293; 1979, BMJ, V2, P717	18	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					17	19		10.1136/bmj.304.6818.17	http://dx.doi.org/10.1136/bmj.304.6818.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734984	Green Published, Bronze			2022-12-24	WOS:A1992GY90900026
J	KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM				KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM			EOSINOPHILIA-MYALGIA-SYNDROME IN L-TRYPTOPHAN-EXPOSED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INGESTION	Objectives. - To study the incidence of eosinophilia-myalgia syndrome, the risk factors associated with the syndrome, and the clinical spectrum of illness associated with L-tryptophan use in an exposed population. Design. - Retrospective cohort and nested case-control studies of risk factors for eosinophilia-myalgia syndrome using inpatient and outpatient chart reviews, telephone interviews, and in-person patient interviews. Descriptive study of clinical course of L-tryptophan users. Setting. - Office practice of one psychiatrist based in a small city (population 43 467) in South Carolina. Patients. - Eligible subjects were all patients from the practice who used L-tryptophan during the 1989 study interval. Of these, 418 (87%) were interviewed. Main Outcome Measures. - Clinical spectrum of illness associated with L-tryptophan use, including definite and possible cases of eosinophilia-myalgia syndrome. Results. - Among the 418 interviewed L-tryptophan users, we identified 47 definite cases (11%) and 68 possible cases (16%) of eosinophilia-myalgia syndrome, most of which involved patients who were using one retail brand of L-tryptophan (brand A). Among the 157 brand A users, we identified 45 definite cases (29%) and 36 possible cases (23%) of eosinophilia-myalgia syndrome, and the risk for the syndrome increased as the brand A dose increased. Fifty percent (19 of 38) of those using more than 4000 mg/day developed definite eosinophilia-myalgia syndrome, and 84% (32 of 38) developed either definite or possible eosinophilia-myalgia syndrome. On multivariate analysis, risk for definite eosinophilia-myalgia syndrome was associated with brand A dose and age of the patient; however, gender, race, and use of other medications were not associated with the syndrome. Conclusions. - These results suggest that many people exposed to the agent causing eosinophilia-myalgia syndrome may develop illness, and dose of presumably contaminated L-tryptophan is the single most important predictor of eosinophilia-myalgia syndrome. The broad range of signs and symptoms reported by patients using L-tryptophan illustrates that a strict case definition may identify only about half of those affected.	S CAROLINA DEPT HLTH & ENVIRONM CONTROL, DIV DIS CONTROL & EPIDEMIOL, COLUMBIA, SC USA		KAMB, ML (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD NE, MAIL STOP E-02, ATLANTA, GA 30333 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MIETTINEN OS, 1972, AM J EPIDEMIOL, V96, P168, DOI 10.1093/oxfordjournals.aje.a121443; NORIEGA AR, 1982, LANCET, V2, P697; POOLE L, 1977, SOME COMMON BASIC PR; Rosner B, 1982, FUNDAMENTALS BIOSTAT; SERRANORIOS M, 1984, TOXIC OIL SYNDROME M, P53; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; 1990, PHYSICIANS DESK REFE; 1989, MMWR, V38, P785; 1990, MMWR, V39, P589	19	100	101	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					77	82		10.1001/jama.267.1.77	http://dx.doi.org/10.1001/jama.267.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727200				2022-12-24	WOS:A1992GW84800027
J	POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF				POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF			DIRECT ACCESS TO SERUM MACROMOLECULES BY INTRAERYTHROCYTIC MALARIA PARASITES	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; TRANSPORT; MEMBRANE; PROTEIN; CULTURE	TRAFFICKING pathways in malaria-infected erythrocytes are complex because the internal parasite is separated from the serum by the erythrocyte and parasitophorous vacuolar membranes 1. Intraerythrocytic Plasmodium falciparum parasites can endocytose dextrans, protein A and an IgG2a antibody. Here we show that these macromolecules do not cross the erythrocyte or parasitophorous vacuolar membranes, but rather gain direct access to the aqueous space surrounding the parasite through a parasitophorous duct. Evidence for this structure includes visualization of membranes that are continuous between the parasitophorous vacuolar and erythrocyte membranes, and surface labelling of the parasite with fluorescent macromolecules under conditions that block endocytosis. The parasite can internalize by fluid-phase endocytosis macromolecules from the aqueous compartment surrounding it. Thus, surface antigens on trophozoites and schizonts should be considered as targets for antibody-directed parasiticidal agents.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL & CELL BIOL, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	Jefferson University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; BARNWELL JW, 1990, BLOOD CELLS, V16, P379; ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9; GREEN TJ, 1985, AM J TROP MED HYG, V34, P24, DOI 10.4269/ajtmh.1985.34.24; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; HOWARD RJ, 1987, J CELL BIOL, V104, P1269, DOI 10.1083/jcb.104.5.1269; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; HUNTER J A, 1991, Biophysical Journal, V59, p442A; JENSEN JB, 1982, SCIENCE, V216, P1230, DOI 10.1126/science.7043736; JEPSEN S, 1983, SCAND J IMMUNOL, V18, P567, DOI 10.1111/j.1365-3083.1983.tb00893.x; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAYLOR DW, 1987, MOL BIOCHEM PARASIT, V25, P165, DOI 10.1016/0166-6851(87)90005-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERSCHAFT PH, 1987, BIOCHIM BIOPHYS ACTA, V901, P1, DOI 10.1016/0005-2736(87)90250-1	17	193	194	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					73	75		10.1038/353073a0	http://dx.doi.org/10.1038/353073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715521				2022-12-24	WOS:A1991GD80500061
J	PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON				PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON			BCR SEQUENCES ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE BIND TO THE ABL-SH2 REGULATORY DOMAIN IN A NON-PHOSPHOTYROSINE-DEPENDENT MANNER	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; C-ABL; PHILADELPHIA-CHROMOSOME; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; FUSED TRANSCRIPT; PHOSPHOLIPASE-C; LYMPHOID-CELLS	BCR-ABL is a chimeric oncogene implicated in the pathogenesis of Philadelphia chromosome-positive human leukemias. BCR first exon sequences specifically activate the tyrosine kinase and transforming potential of BCR-ABL. We have tested the hypothesis that activation of BCR-ABL may involve direct interaction between BCR sequences and the tyrosine kinase regulatory domains of ABL. Full-length c-BCR as well as BCR sequences retained in BCR-ABL bind specifically to the SH2 domain of ABL. The binding domain has been localized within the first exon of BCR and consists of at least two SH2-binding sites. This domain is essential for BCR-ABL-mediated transformation. Phosphoserine/phosphothreonine but not phosphotyrosine residues on BCR are required for interaction with the ABL SH2 domain. These findings extend the range of potential SH2-protein interactions in growth control pathways and suggest a function for SH2 domains in the activation of the BCR-ABL oncogene as well as a role for BCR in cellular signaling pathways.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	PENDERGAST, AM (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.			Pendergast, Ann Marie/0000-0002-1250-6880; Muller, Alexander/0000-0001-7854-6933				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1991, IN PRESS ONCOGENE; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUO K, 1900, MOL CELL BIOL, V10, P5305; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOTSN MG, 1990, P NSYL SVSF DVI UD, V87, P8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; Pendergast A M, 1987, Baillieres Clin Haematol, V1, P1001, DOI 10.1016/S0950-3536(87)80036-7; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; Summers MD, 1987, MANUAL METHODS BACUL; TIMMONS MS, 1989, ONCOGENE, V4, P559; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	55	325	339	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					161	171		10.1016/0092-8674(91)90148-R	http://dx.doi.org/10.1016/0092-8674(91)90148-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712671				2022-12-24	WOS:A1991FW91300018
J	VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A				VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A			ACCELERATION OF ACTIVATION AND INACTIVATION BY THE BETA SUBUNIT OF THE SKELETAL-MUSCLE CALCIUM-CHANNEL	NATURE			English	Article							DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; MAMMALIAN-CELLS; MESSENGER-RNA; CDNA CLONING; ALPHA-1-SUBUNIT; RESOLUTION; INDUCTION; EXISTENCE; CURRENTS	THE L-type voltage-dependent calcium channel is an important link in excitation-contraction coupling of muscle cells 1 (reviewed in refs 2 and 3). The channel has two functional characteristics: calcium permeation and receptor sites for calcium antagonists. In skeletal muscle the channel is a complex of five subunits, alpha-1, alpha-2, beta, gamma and delta (ref. 4). Complementary DNAs to these subunits have been cloned and their amino-acid sequences deduced 5-8. The skeletal muscle alpha-1 subunit cDNA expressed in L cells manifests as specific calcium-ion permeation, as well as sensitivity to the three classes of organic calcium-channel blockers 9,10. We report here that coexpression of the alpha-1 subunit with other subunits results in significant changes in dihydropyridine binding and gating properties. The available number of drug receptor sites increases 10-fold with an alpha-1-beta combination, whereas the affinity of the dihydropyridine binding site remains unchanged. Also, the presence of the beta-subunit accelerates activation and inactivation kinetics of the calcium-channel current.	UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati				LORY, philippe/0000-0002-1638-7604				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAFFREY JM, 1989, J NEUROSCI, V9, P3443; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; Janis R.A., 1987, ADV DRUG RES, V16, P309; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PRAGNELL M, 1985, NATURE, V314, P747; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sambrook J., 1989, MOL CLONING LAB MANU; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1	28	270	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					159	162		10.1038/352159a0	http://dx.doi.org/10.1038/352159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1712427				2022-12-24	WOS:A1991FW09700058
J	WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB				WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB			2ND-TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS AND THE RISK OF SUBSEQUENT FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; PREGNANCIES; OUTCOMES; VALUES	Background. The finding of an elevated level of maternal serum alpha-fetoprotein during the second trimester of pregnancy may indicate that the fetus has died or is about to die. It is uncertain, however, whether the finding is associated with an increased risk of fetal death later in gestation independent of known causes of elevation, such as the presence of neural-tube defects or multiple gestation. Methods. To address this question, we performed a case-control study of 612 women whose pregnancies ended in fetal death and 2501 women who gave birth to live infants, using reports from California vital statistics for 1987. All the women had singleton pregnancies and alpha-fetoprotein screening in the second trimester. Results. Women with elevated levels of serum alpha-fetoprotein in the second trimester of pregnancy had an increased risk of fetal death, and the risk was increased until term. Women with the highest levels of serum alpha-fetoprotein - greater-than-or-equal-to 3.0 times the median value - had a very high risk of fetal death (odds ratio, 10.4; 95 percent confidence interval, 4.9 to 22.0) as compared with women who had normal levels of alpha-fetoprotein. Maternal serum alpha-fetoprotein levels that were 2.0 to 2.9 times the median were also associated with an elevated risk of fetal death (odds ratio, 2.4; 95 percent confidence interval, 1.7 to 3.4). Elevated levels of alpha-fetoprotein were especially likely to be associated with fetal death in cases in which maternal hypertension or placental infarction was also present. Conclusions. An unexplained elevated level of maternal serum alpha-fetoprotein in the second trimester of pregnancy is associated with an increased risk of subsequent fetal death, up to four to five months after alpha-fetoprotein screening.	UNIV CALIF BERKELEY,SCH PUBL HLTH,WARREN HALL,BERKELEY,CA 94720; CALIF DEPT HLTH SERV,GENET DIS BRANCH,CALIF ALPHA FETOPROT SCREENING PROGRAM,BERKELEY,CA 94704; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; California Department of Health Care Services; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Waller, Dorothy/0000-0003-2211-4773				ADAMS MJ, 1984, AM J OBSTET GYNECOL, V148, P241, DOI 10.1016/S0002-9378(84)80062-9; ANDERSON GD, 1986, OBSTETRICS NORMAL PR, P819; Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BAULD R, 1974, ARCH DIS CHILD, V49, P782, DOI 10.1136/adc.49.10.782; BENNETT MJ, 1979, AM J OBSTET GYNECOL, V135, P545, DOI 10.1016/0002-9378(79)90449-6; BERKELEY AS, 1983, AM J OBSTET GYNECOL, V146, P859, DOI 10.1016/0002-9378(83)91091-8; BOYD PA, 1986, PRENATAL DIAG, V6, P369, DOI 10.1002/pd.1970060505; BROCK DJH, 1979, LANCET, V1, P1281; BURTON BK, 1988, OBSTET GYNECOL, V72, P709; BYRNE J, 1986, AM J MED GENET, V25, P327, DOI 10.1002/ajmg.1320250219; CRANDALL BF, 1983, WESTERN J MED, V138, P524; DAVENPORT DM, 1983, AM J OBSTET GYNECOL, V146, P657, DOI 10.1016/0002-9378(83)91008-6; EVANS MI, 1988, OBSTET GYNECOL, V72, P342; FAROOQUI MO, 1973, OBSTET GYNECOL SURV, V28, P144; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MILUNSKY A, 1989, AM J OBSTET GYNECOL, V161, P291, DOI 10.1016/0002-9378(89)90501-2; MOORE TR, 1989, AM J OBSTET GYNECOL, V160, P1075, DOI 10.1016/0002-9378(89)90164-6; NELSON LH, 1987, AM J OBSTET GYNECOL, V157, P572, DOI 10.1016/S0002-9378(87)80009-1; ROBINSON L, 1989, OBSTET GYNECOL, V74, P17; SALAFIA CM, 1988, AM J OBSTET GYNECOL, V158, P1064, DOI 10.1016/0002-9378(88)90220-7; SEPPALA M, 1976, LANCET, V2, P123; SEPPALA M, 1972, BMJ-BRIT MED J, V4, P769, DOI 10.1136/bmj.4.5843.769; SIMPSON JL, 1987, AM J OBSTET GYNECOL, V156, P852, DOI 10.1016/0002-9378(87)90341-3; SIMPSON JL, 1986, OBSTETRICS NORMAL PR, P651; WARBURTON D, 1964, AM J HUM GENET, V16, P1; 1977, LANCET, V1, P1323	27	71	71	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					6	10		10.1056/NEJM199107043250102	http://dx.doi.org/10.1056/NEJM199107043250102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710779				2022-12-24	WOS:A1991FU34200002
J	ASHBY, M; STOFFELL, B				ASHBY, M; STOFFELL, B			THERAPEUTIC RATIO AND DEFINED PHASES - PROPOSAL OF ETHICAL FRAMEWORK FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS		ROYAL ADELAIDE HOSP,PALLIAT MED,ADELAIDE,SA 5006,AUSTRALIA; FLINDERS UNIV,MED CTR,MED ETH UNIT,BEDFORD PK,SA 5042,AUSTRALIA	Royal Adelaide Hospital; Flinders University South Australia								AHRONHEIM JC, 1990, LANCET, P278; BLACK D, 1990, BRIT MED J, V300, P1321, DOI 10.1136/bmj.300.6735.1321; CASSIDY S, 1986, J ROY SOC MED, V79, P717; GILHOOLY MLM, 1988, PALLIATIVE MED, V2, P64; Glover J, 1977, CAUSING DEATH SAVING; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIRSCHFIELD MJ, 1989, PALLIATIVE MED, V4, P25; JONES A, 1980, CLIN RADIOL, V31, P121, DOI 10.1016/S0009-9260(80)80135-8; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; LUNT B, 1987, PALLIATIVE MED, V1, P136; MITCHELL JRA, 1979, BRIT MED J, V1, P1523, DOI 10.1136/bmj.1.6177.1523; Rachels J, 1986, END LIFE; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SMITH T, 1988, BRIT MED J, V297, P438, DOI 10.1136/bmj.297.6646.438; STOLL BA, 1990, J MED ETHICS, V16, P71, DOI 10.1136/jme.16.2.71; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; TIMOTHY AR, 1988, BRIT MED J, V297, P471, DOI 10.1136/bmj.297.6646.471; 1989, LANCET, V1, P476	18	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1322	1324		10.1136/bmj.302.6788.1322	http://dx.doi.org/10.1136/bmj.302.6788.1322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1711907	Green Published, Bronze			2022-12-24	WOS:A1991FQ44400024
J	KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T				KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T			SH2 AND SH3 DOMAINS - ELEMENTS THAT CONTROL INTERACTIONS OF CYTOPLASMIC SIGNALING PROTEINS	SCIENCE			English	Article							ROUS-SARCOMA VIRUS; GROWTH-FACTOR RECEPTOR; AMINO-TERMINAL DOMAIN; TYROSINE KINASE GENE; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL KINASE; SRC GENE; PDGF RECEPTOR; EGF RECEPTOR; REGULATES INTERACTIONS	Src homology (SH) regions 2 and 3 are noncatalytic domains that are conserved among a series of cytoplasmic signaling proteins regulated by receptor protein-tyrosine kinases, including phospholipase C-gamma, Ras GTPase (guanosine triphosphatase)-activating protein, and Src-like tyrosine kinases. The SH2 domains of these signaling proteins bind tyrosine phosphorylated polypeptides, implicated in normal signaling and cellular transformation. Tyrosine phosphorylation acts as a switch to induce the binding of SH2 domains, thereby mediating the formation of heteromeric protein complexes at or near the plasma membrane. The formation of these complexes is likely to control the activation of signal transduction pathways by tyrosine kinases. The SH3 domain is a distinct motif that, together with SH2, may modulate interactions with the cytoskeleton and membrane. Some signaling and transforming proteins contain SH2 and SH3 domains unattached to any known catalytic element. These noncatalytic proteins may serve as adaptors to link tyrosine kinases to specific target proteins. These observations suggest that SH2 and SH3 domains participate in the control of intracellular responses to growth factor stimulation.	UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Moran, Michael/GYD-3631-2022; Pawson, Tony J/E-4578-2013					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1987, J VIROL, V61, P1893, DOI 10.1128/JVI.61.6.1893-1900.1987; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO J, 1988, NATURE, V343, P377; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, COMMUNICATION; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1990, ANNU REV BIOCHEM, V61, P121; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM JW, 1990, J BIOL CHEM, V265, P3940; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH C, UNPUB; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KRIZ R, 1990, CIBA F SYMP, V150, P112; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTSU M, COMMUNICATION; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PELICCI G, COMMUNICATION; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REICHMAN CT, COMMUNICATION; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROTTAPEL R, IN PRESS MOL CELL BI; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	131	1859	1969	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					668	674		10.1126/science.1708916	http://dx.doi.org/10.1126/science.1708916			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708916				2022-12-24	WOS:A1991FK18500038
J	IRVING, BA; WEISS, A				IRVING, BA; WEISS, A			THE CYTOPLASMIC DOMAIN OF THE T-CELL RECEPTOR ZETA-CHAIN IS SUFFICIENT TO COUPLE TO RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS	CELL			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; LYMPHOCYTE-T; TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHATES; SURFACE MOLECULES; CD3 COMPLEX; ACTIVATION; EXPRESSION; PROTEIN	The function of the T cell antigen receptor (TCR) invariant chains, CD3-gamma, delta, epsilon, and zeta, is poorly understood. Evidence suggests that CD3 couples receptor ligand binding to intracellular signaling events. To examine the role of the CD3-zeta-chain in TCR-mediated signal transduction, a chimeric protein linking the extracellular and transmembrane domains of CD8 to the cytoplasmic domain of the zeta-chain was constructed. The CD8/zeta-chimera is expressed independently of the TCR and is capable of transducing signals that, by criteria of early and late activation, are indistinguishable from those generated by the intact TCR. These data indicate that CD8/zeta can activate the appropriate signal transduction pathways in the absence of CD3-gamma, delta, and epsilon, and suggest that the role of CD3-zeta is to couple the TCR to intracellular signal transduction mechanisms.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	IRVING, BA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Frank S J, 1990, Semin Immunol, V2, P89; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GOLDSMITH MA, 1988, IMMUNOL TODAY, V9, P220, DOI 10.1016/0167-5699(88)91219-4; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KLAUSNER R D, 1989, New Biologist, V1, P3; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER N, 1986, J ORG CHEM, V51, P263, DOI 10.1021/jo00352a032; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TESTI R, 1989, J IMMUNOL, V142, P1854; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	728	795	4	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					891	901		10.1016/0092-8674(91)90314-O	http://dx.doi.org/10.1016/0092-8674(91)90314-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705867				2022-12-24	WOS:A1991FA94000007
J	SCOTT, JK; SMITH, GP				SCOTT, JK; SMITH, GP			SEARCHING FOR PEPTIDE LIGANDS WITH AN EPITOPE LIBRARY	SCIENCE			English	Article									UNIV MISSOURI,DIV BIOL SCI,TUCKER HALL,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT MED,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CWIRLA SE, IN PRESS P NATL ACAD; DAY LA, 1969, J MOL BIOL, V39, P265, DOI 10.1016/0022-2836(69)90316-7; DELACRUZ VF, 1988, J BIOL CHEM, V263, P4318; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GEYSEN HM, 1986, CIBA F S, V119, P131; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LATHE R, 1984, DNA CELL BIOL, V3, P174; LIN TC, 1980, J BIOL CHEM, V215, P10331; Maniatis T., 1982, MOL CLONING; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NER SS, 1988, BIOTECHNIQUES, V6, P408; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RICHARDS FF, 1975, SCIENCE, V187, P130, DOI 10.1126/science.46122; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, ADV GENE TECHNOLOGY, P224; SMITH GP, 1988, VIROLOGY, V167, P156, DOI 10.1016/0042-6822(88)90065-7; SMITH GP, 1987, VECTORS SURVEY MOL C, P61; SUTRA EA, 1989, J BIOL CHEM, V264, P15721; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; WICKNER W, 1975, P NATL ACAD SCI USA, V72, P4749, DOI 10.1073/pnas.72.12.4749	23	1835	2882	3	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 27	1990	249	4967					386	390		10.1126/science.1696028	http://dx.doi.org/10.1126/science.1696028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ702	1696028				2022-12-24	WOS:A1990DQ70200033
J	TANAKA, M; LAI, JS; HERR, W				TANAKA, M; LAI, JS; HERR, W			PROMOTER-SELECTIVE ACTIVATION DOMAINS IN OCT-1 AND OCT-2 DIRECT DIFFERENTIAL ACTIVATION OF AN SNRNA AND MESSENGER-RNA PROMOTER	CELL			English	Article							BINDING PROTEIN OCT-1; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; POLYMERASE-II; SV40 ENHANCER; DNA-BINDING; POU DOMAIN; OCTAMER MOTIF; HELA-CELLS; B-CELLS	The promoter specificity of transcriptional activators is generally thought to be conferred by the specificity of the DNA-binding domain, which brings the activation domain to the appropriate promoter sequence. We show here, however, that Oct-1 and Oct-2 can differentially activate transcription not through DNA binding specificity but instead through the use of promoter-selective activation domains. These distinct activation domains lead to stimulation of the U2 small nuclear RNA promoter by Oct-1 and an mRNA promoter by Oct-2. An Oct-2 variant, called Oct-2B, differs from Oct-2 by an Oct-1 -related C-terminal extension that results from alternative splicing. This variant gains the ability to activate the U2 small nuclear RNA promoter. Thus, the promoter selectivity of a transcriptional activator can be changed, in this case by alternative splicing, without affecting its DNA binding specificity.	SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	TANAKA, M (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA 13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GERTSER T, 1990, EMBO J, V9, P1635; GODING CR, 1989, VIROLOGY, V173, P363; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HSIEH CL, 1990, GENOMICS, V6, P666, DOI 10.1016/0888-7543(90)90502-L; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x	54	206	207	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					755	767		10.1016/0092-8674(92)90150-B	http://dx.doi.org/10.1016/0092-8674(92)90150-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739980				2022-12-24	WOS:A1992HF44000015
J	MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ				MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ			STRUCTURAL BASIS OF LATENCY IN PLASMINOGEN-ACTIVATOR INHIBITOR-1	NATURE			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; SERPINS; ALPHA-1-ANTITRYPSIN; MODEL; ANTITHROMBIN; PLAKALBUMIN; REFINEMENT; OVALBUMIN; MUTANTS	HuMAN plasminogen activator inhibitor-1 (PAI-1) 1,2 is the fast-acting inhibitor of tissue plasminogen activator and urokinase 3 and is a member of the serpin family of protease inhibitors 4. Serpins normally form complexes with their target proteases that dissociate very slowly as cleaved species and then fold into a highly stable inactive state 5 in which the residues that flank the scissile bond (P1 and P1'; ref. 6) are separated by about 70 angstrom (refs 7-9). PAI-1 also spontaneously folds into a stable 10 inactive state without cleavage; this state is termed 'latent' because inhibitory activity can be restored through denaturation and renaturation 2,10. Here we report the structure of intact latent PAI-1 determined by single-crystal X-ray diffraction to 2.6 angstrom resolution. The three-dimensional structure reveals that residues on the N-terminal side of the primary recognition site are inserted as a central strand of the largest beta-sheet, in positions similar to the corresponding residues in the cleaved form of the serpin alpha-1-proteinase inhibitor (alpha-1-PI) 7. Residues C-terminal to the recognition site occupy positions on the surface of the molecule distinct from those of the corresponding residues in cleaved serpins 7-9 or in the intact inactive serpin homologue, ovalbumin 11, and its cleavage product, plakal-bumin 12. The structure of latent PAI-1 is similar to one formed after cleavage in other serpins, and the stability of both latent PAI-1 and cleaved serpins may be derived from the same structural features 13,14.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA; PFIZER INC, DIV CENT RES, DEPT MOLEC GENET & PROT CHEM, GROTON, CT 06340 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Brookhaven National Laboratory; Pfizer; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1969, ACTA CRYSTALL B-STRU, VB 25, P2571, DOI 10.1107/S0567740869006091; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE AE, 1990, BIOCHIM BIOPHYS ACTA, V1037, P16, DOI 10.1016/0167-4838(90)90096-X; GOLDSMITH EJ, 1991, PROTEINS, V9, P225, DOI 10.1002/prot.340090308; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JONES TA, 1991, VERSION 54; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1979, J BIOL CHEM, V254, P5317; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; MUNCH M, IN PRESS EMBO J; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PAPAMOKOS E, 1982, J MOL BIOL, V158, P515, DOI 10.1016/0022-2836(82)90212-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WRIGHT HT, 1990, J MOL BIOL, V213, P513	33	536	551	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					270	273		10.1038/355270a0	http://dx.doi.org/10.1038/355270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731226				2022-12-24	WOS:A1992GZ69400074
J	SNOWDEN, RJ; HAMMETT, ST				SNOWDEN, RJ; HAMMETT, ST			SUBTRACTIVE AND DIVISIVE ADAPTATION IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							SPATIAL-FREQUENCY; CORTICAL-NEURONS; STRIATE CORTEX; INHIBITION; ORIENTATION; CAT; CONTRAST; SPECIFICITY; SELECTIVITY; CELLS	SENSORY systems can adapt to the conditions imposed on them 1. In the visual system, adapting to a pattern increases the threshold of the ability to see that pattern, and reduces the perceived contrast of the pattern above threshold 2-4. Most neurons of the striate cortex reduce their responsiveness after being stimulated for some time by a high-contrast pattern 5-7. Such an effect may lie behind these psychophysical adaptation phenomena 2-4. These adaptation effects have been reported to be confined to patterns of similar orientation, which is understandable in that the visual neurons that adapt are only excited by a small range of orientations 8. Neurophysiological evidence suggests that neurons with different orientation preferences have inhibitory interconnections 9-13. It is therefore of interest to explore the possible effects of these connections on perception. Here we show that adapting to a horizontal pattern can reduce the perceived contrast of a vertical test pattern more than a horizontal test pattern. These 'cross-orientation' effects are modelled by a division-like process, whereas the more normal 'similar-orientation' effects are modelled by a subtractive process.			SNOWDEN, RJ (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,POB 901,CARDIFF CF1 3YG,WALES.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BENEVENTO LA, 1972, NATURE-NEW BIOL, V238, P124, DOI 10.1038/newbio238124a0; BLAKEMORE C, 1971, J PHYSIOL-LONDON, V213, P157, DOI 10.1113/jphysiol.1971.sp009374; BLAKEMORE C, 1973, VISION RES, V13, P1915, DOI 10.1016/0042-6989(73)90063-1; BLAKEMORE CB, 1971, SCIENCE, V166, P245; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; DEALY RS, 1974, J PHYSIOL-LONDON, V241, P261, DOI 10.1113/jphysiol.1974.sp010652; DEAN AF, 1980, J PHYSIOL-LONDON, V308, P84; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; Gibson JJ, 1937, J EXP PSYCHOL, V20, P453, DOI 10.1037/h0059826; GILINSKY AS, 1968, J OPT SOC AM, V58, P13, DOI 10.1364/JOSA.58.000013; GREENLEE MW, 1988, VISION RES, V28, P1303, DOI 10.1016/0042-6989(88)90061-2; HEELEY DW, 1979, VISION RES, V29, P1229; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MOLLON J, 1974, New Scientist, V61, P479; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; RAMOA AS, 1986, NATURE, V321, P237, DOI 10.1038/321237a0; SILLITO AM, 1979, TRENDS NEUROSCI, V2, P196, DOI 10.1016/0166-2236(79)90078-X; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOLHURST DJ, 1981, EXP BRAIN RES, V41, P414	24	49	49	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					248	250		10.1038/355248a0	http://dx.doi.org/10.1038/355248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731220				2022-12-24	WOS:A1992GZ69400066
J	HISS, J; ARENSBURG, B				HISS, J; ARENSBURG, B			SUFFOCATION FROM MISUSE OF GAS MASKS DURING THE GULF WAR	BRITISH MEDICAL JOURNAL			English	Article									TEL AVIV UNIV,SACKLER SCH MED,DEPT ANAT & ANTHROPOL,TEL AVIV,ISRAEL; L GREENBERG NATL INST FORENS MED,TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine								Di Maio D.J., 1989, FORENSIC PATHOLOGY, P207; POLSON CJ, 1985, ESSENTIALS FORENSIC, P449	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					92	92		10.1136/bmj.304.6819.92	http://dx.doi.org/10.1136/bmj.304.6819.92			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737149	Bronze, Green Published			2022-12-24	WOS:A1992HA17100025
J	COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E				COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E			POINT MUTATIONS IN HUMAN KERATIN-14 GENES OF EPIDERMOLYSIS-BULLOSA SIMPLEX PATIENTS - GENETIC AND FUNCTIONAL ANALYSES	CELL			English	Article							INTERMEDIATE FILAMENT PROTEINS; TERMINAL DIFFERENTIATION; CULTURED FIBROBLASTS; EPIDERMAL KERATIN; WEBER-COCKAYNE; LAMIN-A; EXPRESSION; CELLS; DOMINANT; SEQUENCE	Previously we demonstrated that transgenic mice expressing mutant basal epidermal keratin genes exhibited a phenotype resembling a group of autosomal dominant human skin disorders known as epidermolysis bullosa simplex (EBS). EBS diseases affect approximately 1: 50,000 and are of unknown etiology, although all subtypes exhibit blistering arising from basal cell cytolysis. We now demonstrate that two patients with spontaneous cases of Dowling-Meara EBS have point mutations in a critical region in one (K14) of two basal keratin genes. To demonstrate function, we engineered one of these point mutations in a cloned human K14 cDNA, and showed that a K14 with an Arg-125 --> Cys mutation disrupted keratin network formation in transfected keratinocytes and perturbed filament assembly in vitro. Since we had previously shown that keratin network perturbation is an essential component of EBS diseases, these data suggest that the basis for the phenotype in this patients resides in this point mutation.	UNIV TEXAS,DEPT DERMATOL,HOUSTON,TX 77030; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT DERMATOL,CHICAGO,IL 60614	University of Texas System; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	COULOMBE, PA (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, IN PRESS J CELL BIOL; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FINE JD, 1985, ARCH DERMATOL, V121, P1292, DOI 10.1001/archderm.121.10.1292; FINE JD, 1989, PEDIATR DERMATOL, V6, P1, DOI 10.1111/j.1525-1470.1989.tb00256.x; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1983, P NATL ACAD SCI-BIOL, V80, P5857, DOI 10.1073/pnas.80.19.5857; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; HANEKE E, 1982, J INVEST DERMATOL, V78, P219, DOI 10.1111/1523-1747.ep12506502; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1971, DERMATOLOGY GENERAL, P621; QUAXJEUKEN YEFM, 1983, P NATL ACAD SCI-BIOL, V80, P3548, DOI 10.1073/pnas.80.12.3548; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SAVTCHENKO ES, 1988, MOL BIOL EVOL, V5, P97; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUN TT, 1978, J BIOL CHEM, V253, P2053; TOWBIN H, 1979, P NATL ACAD SCI USA, V81, P4683; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; [No title captured]	50	548	555	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1301	1311		10.1016/0092-8674(91)90051-Y	http://dx.doi.org/10.1016/0092-8674(91)90051-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717157				2022-12-24	WOS:A1991GG55200023
J	LEWIS, M; FAED, MJW; HOWIE, PW				LEWIS, M; FAED, MJW; HOWIE, PW			SCREENING FOR DOWNS-SYNDROME BASED ON INDIVIDUAL RISK	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; CHORIONIC-GONADOTROPIN; PREGNANCY; ABNORMALITIES	Objective - To evaluate the effectiveness of biochemical screening of individual pregnancies for Down's syndrome risk. Design - Retrospective determination of risk. Setting - Obstetric and cytogenetic services in Tayside, Scotland. Subjects - 3436 pregnant women who had screening for neural tube defects in the second trimester during November 1988 to March 1990 and whose pregnancies were dated by ultrasonography. Three women with pregnancies associated with Down's syndrome reported later in 1990. Main outcome measures - Individual risk calculated from age at estimated date of delivery; chorionic gonadotrophin and a fetoprotein concentrations in serum samples obtained at precisely determined gestational ages in second trimester. Results of karyotype determination and outcome of pregnancy. Results - During November 1988 to March 1990 karyotypes were determined for 5% of pregnancies for reasons of maternal age and genetic history and one of the eight affected fetuses was detected. Individual risk could not be calculated for 347 pregnancies, but screening on this basis would have detected five of the cases and required screening in 194 out of 3089 (6.3%) pregnancies; all three affected pregnancies reported later in 1990 would also have been detected, giving a success rate of 73% (95% confidence interval 39% to 94%). The age distribution of women according to individual risk suggests that women over 35 would be screened effectively. Conclusion - Screening based on individual risk would use resources more effectively than screening based on maternal age and genetic history without affecting detection rates in older women.			LEWIS, M (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND.							BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHRISTIE AD, 1980, THESIS U DUNDEE DUND; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MANCINI G, 1991, PRENATAL DIAG, V11, P245, DOI 10.1002/pd.1970110406; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; STEVENSON JD, 1987, ANN CLIN BIOCHEM, V24, P411, DOI 10.1177/000456328702400411; SUCHY SF, 1990, OBSTET GYNECOL, V76, P20; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1989, OBSTETRICS, P269; WALKER EM, 1988, BRIT J OBSTET GYNAEC, V95, P659, DOI 10.1111/j.1471-0528.1988.tb06526.x	13	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					551	553		10.1136/bmj.303.6802.551	http://dx.doi.org/10.1136/bmj.303.6802.551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1717087	Bronze, Green Published			2022-12-24	WOS:A1991GE94800022
J	LINCHAO, S; COHEN, SN				LINCHAO, S; COHEN, SN			THE RATE OF PROCESSING AND DEGRADATION OF ANTISENSE RNAI REGULATES THE REPLICATION OF COIE1-TYPE PLASMIDS INVIVO	CELL			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; PRIMER TRANSCRIPT; RIBONUCLEASE-E; DNA-REPLICATION; COPY-NUMBER; PMB1 REPLICATION; RIBOSOMAL-RNA; GROWTH-RATE; STABILITY	We show that the rate of degradation of RNAI, an antisense repressor of the replication primer RNAII, is a key element of control in the replication of ColE1-type plasmids in vivo. Cleavage of RNAI by RNAase E, a ribosomal RNA-processing enzyme encoded or controlled by the rne (also known as ams) locus, relieves repression by endonucleolytically converting RNAI to a very rapidly decaying product, pRNAl-5. A 5' triphosphate-terminated homolog of pRNAI-5 is degraded slowly and consequently inhibits replication. Nucleotide substitutions within the RNAase E cleavage sequence alter RNAI half-life and plasmid copy number, changing also the incompatibility phenotype. RNAI variants lacking the sequence cleaved by RNAase E are eliminated by growth rate-dependent degradation, resulting in growth-responsive control of plasmid replication and copy number.	STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University	LINCHAO, S (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CABELLO F, 1976, NATURE, V259, P285, DOI 10.1038/259285a0; CESARENI G, 1985, TRENDS BIOCHEM SCI, V10, P303, DOI 10.1016/0968-0004(85)90168-9; CESARENI G, 1984, EMBO J, V3, P1365, DOI 10.1002/j.1460-2075.1984.tb01978.x; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; DOOLEY TP, 1985, J MOL BIOL, V186, P87, DOI 10.1016/0022-2836(85)90259-1; ELBLE RC, 1983, MECHANISMS DNA REPLI, P303; FITZWATER T, 1988, EMBO J, V7, P3289, DOI 10.1002/j.1460-2075.1988.tb03196.x; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; JAURIN B, 1982, EMBO J, V1, P875, DOI 10.1002/j.1460-2075.1982.tb01263.x; KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LACATENA RM, 1984, CELL, V37, P1009, DOI 10.1016/0092-8674(84)90435-5; LACATENA RM, 1983, J MOL BIOL, V170, P635, DOI 10.1016/S0022-2836(83)80125-9; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; Maniatis T., 1982, MOL CLONING; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; MASUKATA H, 1984, CELL, V36, P513, DOI 10.1016/0092-8674(84)90244-7; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MELEFORS O, 1988, CELL, V52, P893, DOI 10.1016/0092-8674(88)90431-X; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NUGENT ME, 1986, J GEN MICROBIOL, V132, P1021; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; RAY BK, 1982, EUR J BIOCHEM, V125, P283, DOI 10.1111/j.1432-1033.1982.tb06680.x; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SZEBERENYI J, 1983, J MOL BIOL, V168, P525, DOI 10.1016/S0022-2836(83)80300-3; TAMM J, 1985, P NATL ACAD SCI USA, V82, P2257, DOI 10.1073/pnas.82.8.2257; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WONG EM, 1985, CELL, V42, P959, DOI 10.1016/0092-8674(85)90292-2	60	188	190	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1233	1242		10.1016/0092-8674(91)90018-T	http://dx.doi.org/10.1016/0092-8674(91)90018-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712252				2022-12-24	WOS:A1991FU89900015
J	HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G				HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G			SYMPATHETIC REGULATION OF CARDIAC CALCIUM CURRENT IS DUE EXCLUSIVELY TO CAMP-DEPENDENT PHOSPHORYLATION	NATURE			English	Article							G-PROTEIN; ION CHANNELS; SINGLE CELLS; ACETYLCHOLINE; HEART; STIMULATION; MYOCYTES; MODULATION; KINASE; ANALOG	THE positive inotropic effect of the sympathetic nervous system on the heart is partly mediated by an increase in the voltage-gated Ca2+ current (I(Ca)). This increase is generally attributed to beta-adrenergic receptor-stimulated cyclic AMP-dependent phosphorylation of the Ca2+ channel 1,2. It has been suggested that cAMP-dependent phosphorylation cannot explain all the effects of beta-adrenergic agonists on I(Ca) and that a parallel membrane-delimited pathway involving the 'direct' action of the G protein G(s) also stimulates I(Ca) (refs 3-7). A precedent exists for such a membrane-delimited pathway in the activation of a K+ channel by acetylcholine in heart 1,8. A membrane-delimited pathway for stimulation of I(Ca) might be important in rapid beat-to-beat regulation of contraction by the sympathetic nervous system 9, because isoproterenol may produce a biphasic increase in I(Ca) with the rapid phase (tau = 150 ms) putatively mediated by the direct pathway and the slow phase (tau = 35 s) by cAMP-dependent phosphorylation. Here we report that in frog, rat, and guinea pig ventricular myocytes I(Ca) increases slowly and monophasically in response to isoproterenol. The increase is completely blocked by inhibitors of cAMP-dependent phosphorylation. Furthermore, the time course of the increase in I(Ca) closely parallels the increase in contractile force produced by sympathetic nerve stimulation. These data refute earlier suggestions that regulation of Ca2+ channels by the sympathetic nervous system involves or requires a direct G-protein pathway.	UNIV PARIS 11, INSERM, U241, PHYSIOL CELLULAIRE CARDIAQUE LAB, F-91405 ORSAY, FRANCE; UNIV VIRGINIA, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Virginia	HARTZELL, HC (corresponding author), EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA.		Fischmeister, Rodolphe/L-6061-2018; MERY, Pierre-François/C-5903-2019	Fischmeister, Rodolphe/0000-0003-2086-9865; Mery, Pierre-Francois/0000-0001-6214-5422				BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARTZELL HC, 1987, MOL PHARMACOL, V32, P639; HARTZELL HC, 1991, BIOPHYS J, V59, P551; HUTTER OF, 1956, J GEN PHYSIOL, V39, P715, DOI 10.1085/jgp.39.5.715; IMOTO Y, 1988, AM J PHYSIOL, V255, pH722, DOI 10.1152/ajpheart.1988.255.4.H722; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; MERY PF, 1991, BIOPHYS J, V59, P551; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; PELZER S, 1990, AM J PHYSIOL, V259, pH264, DOI 10.1152/ajpheart.1990.259.1.H264; SHUBA YM, 1990, J PHYSIOL-LONDON, V424, P205, DOI 10.1113/jphysiol.1990.sp018063; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; SPEAR JF, 1979, CIRC RES, V44, P75, DOI 10.1161/01.RES.44.1.75; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	22	214	214	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1991	351	6327					573	576		10.1038/351573a0	http://dx.doi.org/10.1038/351573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710784				2022-12-24	WOS:A1991FR03400061
J	AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH				AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH			IDENTIFICATION INSITU AND PHYLOGENY OF UNCULTURED BACTERIAL ENDOSYMBIONTS	NATURE			English	Article							PARAMECIUM-CAUDATUM; HOLOSPORA-ELEGANS; OBTUSA; PROBES; FORMS; CELLS; DNA	THE use of Koch's technique to isolate bacteria in pure cultures has enabled thousands of bacterial species to be characterized. But for the many microorganisms that have never been cultivated, DNA amplification in vitro using the polymerase chain reaction is now making their genes accessible 1-3. Here we use this technique to study bacteria of the genus Holospora, which live in ciliates 4 and whose phylogenetic relationship has remained unknown because they are impossible to cultivate. Species of Holospora are highly infectious 5-7 and live in the nuclei of their specific host cells: H. elegans and H. undulata infect micronuclei of Paramecium caudatum 8, whereas H. obtusa infects the macronucleus in other strains of the same host species 9; Holospora species have a common developmental cycle 10-13. We have amplified, cloned and sequenced gene fragments encoding ribosomal RNA of H. obtusa. The phylogenetic position of H. obtusa in the alpha-group of Proteobacteria was determined by 16S rRNA sequence analysis. The sequences were then used to design species- as well as genus-specific rRNA hybridization probes, which enabled us to detect and differentiate individual cells of the endosymbionts in situ. The large amount of rRNA in the cells indicates a high physiological activity of the endosymbionts in the host nuclei.	UNIV MUNSTER,INST ZOOL,W-4400 MUNSTER,GERMANY	University of Munster	AMANN, R (corresponding author), TECH UNIV MUNICH,LEHRSTUHL MIKROBIOL,ARCISSTR 21,W-8000 MUNICH 2,GERMANY.		Amann, Rudolf I/C-6534-2014	Amann, Rudolf I/0000-0002-0846-7372				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; DRYDEN SC, 1990, NUCLEIC ACIDS RES, V18, P7267, DOI 10.1093/nar/18.24.7267; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; FUJISHIMA M, 1990, ZOOL SCI, V7, P849; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P720, DOI 10.1128/jb.170.2.720-726.1988; GORTZ HD, 1990, J BACTERIOL, V172, P5664; GORTZ HD, 1980, PROTISTOLOGICA, V16, P591; GORTZ HD, 1989, J GEN MICROBIOL, V135, P3079; GORTZ HD, 1986, INT REV CYTOL, V102, P169, DOI 10.1016/S0074-7696(08)61275-9; GROMOV BV, 1981, INT J SYST BACTERIOL, V31, P348, DOI 10.1099/00207713-31-3-348; Hafkine M. -W., 1890, ANN I PASTEUR, V4, P148; Holt, 1984, BERGEYS MANUAL SYSTE, P795; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OSSIPOV D V, 1975, Acta Protozoologica, V14, P263; PREER JR, 1984, INT J SYST BACTERIOL, V32, P140; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHMIDT HJ, 1987, MICROBIOS, V49, P189; SCHMIDT HJ, 1985, MICROBIOS, V4, P165; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782, DOI 10.1128/AEM.56.3.782-787.1990; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	287	295	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					161	164		10.1038/351161a0	http://dx.doi.org/10.1038/351161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709451				2022-12-24	WOS:A1991FL03500056
J	IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S				IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S			REPLACEMENT OF DONOR LYMPHOID-TISSUE IN SMALL-BOWEL TRANSPLANTS	LANCET			English	Note								The presence of recipient lymphocytes in grafts is thought to equate with rejection. Thus, we wished to follow the fate of lymphocytes after transplant of the small bowel. Three complete small-bowel transplants, two with the liver from the same donor also transplanted, were done successfully. Patients were immunosuppressed with FK 506. 5 to 11% of lymphocytes in the recipients' peripheral blood were of donor origin during the early postoperative period when there were no clinical signs of graft-versus-host disease. However, donor cells were no longer detectable after 12 to 54 days. Serial biopsy specimens of the grafted small bowel showed progressive replacement of lymphocytes in the lamina propria by those of the recipient's HLA phenotype. Lymphoid repopulation was complete after 10 to 12 weeks but the epithelial cells of the intestine remained those of the donor. The patients are on enteral alimentation after 5, 6, and 8 months with histopathologically normal or nearly normal intestines. Re-examination of assumptions about the rejection of intestinal grafts and strategies for its prevention are required following these observations.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARK CLI, 1990, TRANSPLANT P, V22, P2460; FUNG JJ, 1989, CLIN TRANSPLANT, V3, P316; FUNG JJ, 1985, HUM IMMUNOL, V14, P287, DOI 10.1016/0198-8859(85)90236-8; GOUW ASH, 1987, TRANSPLANTATION, V43, P291, DOI 10.1097/00007890-198702000-00025; GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A; MARKUS PM, IN PRESS TRANSPLANTA; MONCHIK GJ, 1971, SURGERY, V70, P693; MURASE N, IN PRESS SURGERY; STARZL TE, 1962, AM J SURG, V103, P219, DOI 10.1016/0002-9610(62)90491-9; TZAKIS AG, 1991, TRANSPLANT P, V23, P924	10	156	158	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					818	819		10.1016/0140-6736(91)92517-6	http://dx.doi.org/10.1016/0140-6736(91)92517-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1707470	Green Accepted			2022-12-24	WOS:A1991FF22800005
J	ZSEBO, KM; WILLIAMS, DA; GEISSLER, EN; BROUDY, VC; MARTIN, FH; ATKINS, HL; HSU, RY; BIRKETT, NC; OKINO, KH; MURDOCK, DC; JACOBSEN, FW; LANGLEY, KE; SMITH, KA; TAKEISHI, T; CATTANACH, BM; GALLI, SJ; SUGGS, SV				ZSEBO, KM; WILLIAMS, DA; GEISSLER, EN; BROUDY, VC; MARTIN, FH; ATKINS, HL; HSU, RY; BIRKETT, NC; OKINO, KH; MURDOCK, DC; JACOBSEN, FW; LANGLEY, KE; SMITH, KA; TAKEISHI, T; CATTANACH, BM; GALLI, SJ; SUGGS, SV			STEM-CELL FACTOR IS ENCODED AT THE SI-LOCUS OF THE MOUSE AND IS THE LIGAND FOR THE C-KIT TYROSINE KINASE RECEPTOR	CELL			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; UNIV WASHINGTON,DEPT HEMATOL,SEATTLE,WA 98195; MRC,RADIOBIOL UNIT,CHILTON,ENGLAND	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle	ZSEBO, KM (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI022674, R37AI023990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045311] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23990, AI22674] Funding Source: Medline; NIGMS NIH HHS [GM45311] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUCHOWSKI A, 1984, CANCER BIOCHEM BIOPH, V7, P175; ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; ANDRE C, 1989, ONCOGENE, V4, P1047; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BERNSTEIN SE, 1968, ANN NY ACAD SCI, V149, P475, DOI 10.1111/j.1749-6632.1968.tb15186.x; BERNSTEIN SE, 1970, AM J SURG, V119, P448, DOI 10.1016/0002-9610(70)90148-0; BOSSELMAN RA, 1989, J VIROL, V63, P2680, DOI 10.1128/JVI.63.6.2680-2689.1989; CATTANACH BM, 1988, MOUSE NEWS LETT, V80, P156; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; EBBE S, 1973, BLOOD, V42, P865, DOI 10.1182/blood.V42.6.865.865; EBBE S, 1973, BLOOD, V42, P857, DOI 10.1182/blood.V42.6.857.857; EVANS EP, 1990, MOUSE GENOME, V86, P230; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED W, 1973, BRIT J HAEMATOL, V24, P643, DOI 10.1111/j.1365-2141.1973.tb01690.x; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GALLI SJ, 1987, BLOOD, V69, P1661; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GEISSLER EN, 1988, P NATL ACAD SCI USA, V85, P9635, DOI 10.1073/pnas.85.24.9635; GEISSLER EN, 1983, EXP HEMATOL, V11, P461; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HARRISON DE, 1972, RADIAT RES, V52, P553, DOI 10.2307/3573514; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JARBOE DJ, 1989, J IMMUNOL, V7, P2418; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KITAMURA Y, 1989, MAST CELL BASOPHIL D, P229; LALLEY PA, 1978, P NATL ACAD SCI USA, V75, P2382, DOI 10.1073/pnas.75.5.2382; LALLEY PA, 1978, NATURE, V274, P160, DOI 10.1038/274160a0; LERNER C, 1990, EXP HEMATOL, V18, P114; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MANIATIS T, 1982, MOL CLONING LABORATO, P188; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT JD, 1983, MOL CELL BIOL, V3, P1266, DOI 10.1128/MCB.3.7.1266; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAYLOR SL, 1984, SOMAT CELL MOLEC GEN, V10, P531, DOI 10.1007/BF01534857; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1810; PLOEMACHER RE, 1986, EXP HEMATOL, V14, P9; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RIOS M, 1990, Experimental Hematology (Charlottesville), V18, P568; RUSCETTI FW, 1976, P SOC EXP BIOL MED, V152, P398; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1949, GENETICS, V34, P708; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI AY, 1983, SOMAT CELL GENET, V9, P391, DOI 10.1007/BF01539146; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; Silvers W.K., 1979, COAT COLORS MICE, P206; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; WOLF NS, 1974, CELL TISSUE KINET, V7, P89, DOI 10.1111/j.1365-2184.1974.tb00402.x; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	66	1354	1404	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					213	224		10.1016/0092-8674(90)90302-U	http://dx.doi.org/10.1016/0092-8674(90)90302-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698556				2022-12-24	WOS:A1990EB46100022
J	HOFFMANN, I; BIRNSTIEL, ML				HOFFMANN, I; BIRNSTIEL, ML			CELL CYCLE-DEPENDENT REGULATION OF HISTONE PRECURSOR MESSENGER-RNA PROCESSING BY MODULATION OF U7 SNRNA ACCESSIBILITY	NATURE			English	Article											HOFFMANN, I (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.							BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; COTTEN M, 1988, EMBO J, V7, P801, DOI 10.1002/j.1460-2075.1988.tb02878.x; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; GEORGIEV O, 1985, EMBO J, V4, P481, DOI 10.1002/j.1460-2075.1985.tb03654.x; GICK O, 1987, P NATL ACAD SCI USA, V84, P8937, DOI 10.1073/pnas.84.24.8937; GICK O, 1986, EMBO J, V5, P1319, DOI 10.1002/j.1460-2075.1986.tb04362.x; GILMARTIN GM, 1988, MOL CELL BIOL, V8, P1076, DOI 10.1128/MCB.8.3.1076; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; STRUB K, 1986, EMBO J, V5, P1675, DOI 10.1002/j.1460-2075.1986.tb04411.x; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345	18	24	24	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 16	1990	346	6285					665	668		10.1038/346665a0	http://dx.doi.org/10.1038/346665a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU728	1696685				2022-12-24	WOS:A1990DU72800065
J	FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG				FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG			THE NONTRANSMEMBRANE TYROSINE PHOSPHATASE PTP-1B LOCALIZES TO THE ENDOPLASMIC-RETICULUM VIA ITS 35 AMINO-ACID C-TERMINAL SEQUENCE	CELL			English	Article							HUMAN-PLACENTA; PROTEIN-KINASE; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; KIDNEY-CELLS; EXPRESSION; RECEPTOR; GENE; PURIFICATION; ANTIBODIES	We report the first intracellular characterization of an endogenous nontransmembrane protein tyrosine phosphatase (PTP). Using affinity-purified polyclonal antibodies, we have identified PTP-1B as a 50 kd serine phosphoprotein in immunoprecipitation and immunoblotting assays. Surprisingly, indirect immunofluorescence experiments indicate that PTP-1B is localized predominantly i n the endoplasmic reticulum (ER). Subcellular fractionation is consistent with this localization and establishes that PTP-IB is tightly associated with microsomal membranes, with its phosphatase domain oriented towards the cytoplasm. The C-terminal 35 amino acids of PTP-1B are both necessary and sufficient for targeting to the ER. The finding of a tyrosine phosphatase on the ER suggests new possibilities for cellular events controlled by tyrosine phosphorylation.			FRANGIONI, JV (corresponding author), BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE SK, 1991, BIOCHIM BIOPHYS ACTA, V1061, P26, DOI 10.1016/0005-2736(91)90264-9; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0	55	546	561	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					545	560		10.1016/0092-8674(92)90190-N	http://dx.doi.org/10.1016/0092-8674(92)90190-N			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739967				2022-12-24	WOS:A1992HD39800014
J	DEMELKER, RA				DEMELKER, RA			DIAGNOSTIC-VALUE OF MICROTYMPANOMETRY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; PRESCHOOL-CHILDREN; EFFUSION; EAR; IDENTIFICATION; TYMPANOMETRY; MANAGEMENT	Objective - To determine the reliability, validity, and feasibility of a new hand held microtympanometer. Design - Comparison of microtympanometry by two independent observations of a general practitioner and a nurse, and against a validated reference instrument. Setting - Primary care health centre of a school for the deaf in the United States. Subjects - 111 schoolchildren receiving a regular check up. Main outcome measures - Tympanometry with the Grason Stadler 28, classified with a slightly modified Jerger's classification. Results - Interobserver reliability was 0.95 (Cohen's X). Results of microtympanometry were highly comparable with results of the reference instrument (likelihood ratio of positive results, 161.2). Conclusions - The microtympanometer could be used in general practice: it is hand held, child friendly, easy to handle, and accurate.			DEMELKER, RA (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,3511 ZC UTRECHT,NETHERLANDS.							BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; BLUESTONE CD, 1979, ANN OTO RHINOL LARYN, V88, P13, DOI 10.1177/00034894790880S503; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BURKE P, 1989, J ROY COLL GEN PRACT, V39, P377; CANTEKIN EI, 1977, ANN OTO RHINOL LARYN, V86, P16, DOI 10.1177/00034894770864S202; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CASSELBRANT ML, 1985, LARYNGOSCOPE, V95, P428; Chalmers D., 1989, OTITIS MEDIA EFFUSIO; DEMELKER RA, 1988, FAM PRACT, V5, P307, DOI 10.1093/fampra/5.4.307; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; GARDNER MJ, 1989, STATISTICS CONFIDENC; GATES GA, 1986, ANN OTO RHINOL LARYN, V95, P46, DOI 10.1177/000348948609500110; KARMA PH, 1988, RECENT ADV OTITIS ME; KELSEY JL, 1986, METHODS OBSERVATIONA; MARGOLIS RH, 1989, INT J AUDITORY COMMU, V26, P197; REVES R, 1985, BMJ-BRIT MED J, V290, P1953, DOI 10.1136/bmj.290.6486.1953; Sackett D.L., 1985, CLIN EPIDEMIOLOGY BA; VANDELISDONK EH, 1990, ZIEKTEN HUISARTSPRAK; WAZEN JJ, 1988, ANN RHINOL LARY S133, V97, P20; WILMOT JF, 1988, J ROY COLL GEN PRACT, V38, P149; ZIELHUIS G A, 1989, Scandinavian Journal of Primary Health Care, V7, P33, DOI 10.3109/02813438909103668; ZIELHUIS GA, 1990, CLIN OTOLARYNGOL, V15, P147, DOI 10.1111/j.1365-2273.1990.tb00448.x; 1990, LANCET, V336, P23	23	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					96	98		10.1136/bmj.304.6819.96	http://dx.doi.org/10.1136/bmj.304.6819.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737151	Bronze, Green Published			2022-12-24	WOS:A1992HA17100027
J	WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH				WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH			STRATEGIES FOR THE GLOBAL ERADICATION OF POLIOMYELITIS BY THE YEAR 2000	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TYPE-3 POLIOVIRUS; VACCINE STRAIN; VIRUS; EXCRETION; RECEPTOR; WORLD		PAN AMER HLTH ORG, WASHINGTON, DC USA; WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND; WHO, OFF ASSISTANT DIRECTOR GEN, CH-1211 GENEVA 27, SWITZERLAND	Pan American Health Organization; World Health Organization; World Health Organization	WRIGHT, PF (corresponding author), VANDERBILT UNIV, DEPT PEDIAT, DIV INFECT DIS, NASHVILLE, TN 37232 USA.							ALMOND JW, 1987, ANNU REV MICROBIOL, V41, P153; ALMOND JW, 1990, B WORLD HEALTH ORGAN, V68, P545; [Anonymous], 1990, WKLY EPIDEMIOL REC, V65, P5; [Anonymous], 1990, WHOEPICDSPOLIO901; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CHUMAKOV KM, 1991, P NATL ACAD SCI USA, V88, P199, DOI 10.1073/pnas.88.1.199; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; DORVAL BL, 1989, BIOCHEM BIOPH RES CO, V159, P1177, DOI 10.1016/0006-291X(89)92234-1; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; FENNER F, 1988, SMALLPOX ITE ERADICA; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P69, DOI 10.1111/j.1749-6632.1989.tb27359.x; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KOHARA M, 1988, J VIROL, V62, P2828, DOI 10.1128/JVI.62.8.2828-2835.1988; LEMON SM, 1991, PROG MED VIROL, V38, P42; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; 1991, WKLY B, V6, P38; 1988, WHO WHA4128 RES, P26; 1989, WHO WHA4232 RES, P33; 1985, B PAN AM HLTH ORGAN, V19, P213; 1990, MMWR-MORBID MORTAL W, V39, P557	30	89	90	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1774	1779		10.1056/NEJM199112193252504	http://dx.doi.org/10.1056/NEJM199112193252504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1719418				2022-12-24	WOS:A1991GV73900004
J	KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K				KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K			CYCLES OF PROGRESSIVE REALIGNMENT OF GRNA WITH MESSENGER-RNA IN RNA EDITING	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; KINETOPLASTID MITOCHONDRIA; CYTOCHROME-OXIDASE; SUBUNIT-III; ORGANIZATION; MINICIRCLES; TRANSCRIPT; DOMAINS; REGION	We characterized numerous partially edited NADH dehydrogenase 7 and ATPase 6 cDNAs. Most of these have a stretch of incompletely edited sequence at the junction of mature and unedited sequences. The characteristics of the junctions suggest editing of sites multiple times and that editing within each junction does not proceed precisely 3' to 5'. Analyses of gRNAs and corresponding junction sequences predict a series of progressively more stable, but incompletely base-paired, interactions in the junction region. The predicted interactions suggest that the gRNA is progressively realigned with the mRNA being edited. We suggest that gRNA interactions with the mRNA result in regions of lower thermodynamic stability that are selected for editing, thus driving toward the most stable structure, the complete gRNA/mRNA duplex.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,SEATTLE,WA 98109, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014102, R37AI014102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14102] Funding Source: Medline; NIGMS NIH HHS [GM42188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1989, MOL BIOL RNA, P187; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART KS, 1990, TRENDS BIOL SCI, V16, P68; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	27	80	83	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					537	546		10.1016/0092-8674(91)90528-7	http://dx.doi.org/10.1016/0092-8674(91)90528-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1718605				2022-12-24	WOS:A1991GN66400010
J	PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H				PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H			LOWER RECEPTOR AVIDITY REQUIRED FOR THYMIC CLONAL DELETION THAN FOR EFFECTOR T-CELL FUNCTION	NATURE			English	Article							BONE-MARROW CHIMERAS; TRANSGENIC MICE; ANTIGEN RECEPTOR; TOLERANCE; SELECTION; ANTIBODY; COMPLEX; ANERGY; GENES	CLONAL deletion in the thymus plays a major part in T-cell tolerance to self antigens 1-3. But the mechanism of negative selection, its fine specificity and the threshold of affinity and avidity remains unknown. We have now examined these aspects of negative selection with mice expressing a transgenic T-cell receptor with specificity for lymphocytic choriomeningitis virus (LCMV) glycoprotein in association with the class I H-2D(b) molecule. These mice were rendered tolerant to LCMV by neonatal infection with mutant LCMVs bearing point mutations in the T-cell epitope recognized by the transgenic T-cell receptor (ref. 4). Variant LCMVs were also tested for their ability to elicit antiviral responses in transgenic mice in vivo and in vitro. Comparison in vivo revealed that a low-avidity receptor interaction, which was unable to induce effector T cells in the periphery, was still sufficient for clonal deletion in the thymus.			PIRCHER, H (corresponding author), UNIV HOSP ZURICH,INST PATHOL,CH-8091 ZURICH,SWITZERLAND.							AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PULLEN AM, 1989, J IMMUNOL, V142, P3033; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	18	264	269	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					482	485		10.1038/351482a0	http://dx.doi.org/10.1038/351482a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710780				2022-12-24	WOS:A1991FP75800056
J	ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC				ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC			3-DIMENSIONAL STRUCTURES OF ACIDIC AND BASIC FIBROBLAST GROWTH-FACTORS	SCIENCE			English	Article							TRYPSIN-INHIBITOR KUNITZ; MACROMOLECULAR CRYSTALLOGRAPHY; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; SEQUENCE; INTERLEUKIN-1-BETA; REFINEMENT; PROGRAMS; SYSTEM; GENE	Members of the fibroblast growth factor (FGF) family of proteins stimulate the proliferation and differentiation of a variety of cell types through receptor-mediated pathways. The three-dimensional structures of two members of this family, bovine acidic FGF and human basic FGF, have been crystallographically determined. These structures contain 12 antiparallel beta-strands organized into a folding pattern with approximate threefold internal symmetry. Topologically equivalent folds have been previously observed for soybean trypsin inhibitor and interleukins-1-beta and -1-alpha. The locations of sequences implicated in receptor and heparin binding by FGF are presented. These sites include beta-sheet strand 10, which is adjacent to the site of an extended sequence insertion in several oncogene proteins of the FGF family, and which shows sequence conservation among the FGF family and interleukin-1-beta.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; Amgen								BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOX GM, 1988, J BIOL CHEM, V263, P18452; FOX GM, UNPUB; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARICS I, 1989, ONCOGENE, V4, P335; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VEERAPANDIAN B, UNPUB; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	39	357	383	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					90	93		10.1126/science.1702556	http://dx.doi.org/10.1126/science.1702556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702556				2022-12-24	WOS:A1991EQ60300035
J	BAEKKESKOV, S; AANSTOOT, HJ; CHRISTGAU, S; REETZ, A; SOLIMENA, M; CASCALHO, M; FOLLI, F; RICHTEROLESEN, H; CAMILLI, PD				BAEKKESKOV, S; AANSTOOT, HJ; CHRISTGAU, S; REETZ, A; SOLIMENA, M; CASCALHO, M; FOLLI, F; RICHTEROLESEN, H; CAMILLI, PD			IDENTIFICATION OF THE 64K AUTOANTIGEN IN INSULIN-DEPENDENT DIABETES AS THE GABA-SYNTHESIZING ENZYME GLUTAMIC-ACID DECARBOXYLASE	NATURE			English	Article									UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University; Novo Nordisk; Hagedorn Research Institute	BAEKKESKOV, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MICROBIOL IMMUNOL, SAN FRANCISCO, CA 94143 USA.		Solimena, Michele/E-1275-2011; folli, franco/J-2795-2018; Solimena, Michele/GVS-5990-2022	folli, franco/0000-0001-9824-5222; Baekkeskov, Steinunn/0000-0003-0878-3188; Aanstoot, Henk-Jan/0000-0002-5534-1633; Cascalho, Marilia/0000-0002-2695-3921				ALBERS RW, 1959, J BIOL CHEM, V234, P926; AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1989, DIABETES, V38, P1133, DOI 10.2337/diabetes.38.9.1133; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1981, P NATL ACAD SCI-BIOL, V78, P6456, DOI 10.1073/pnas.78.10.6456; BAEKKESKOV S, 1986, IMMUNOLOGY ENDOCRINE, P73; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHRISTIE MR, 1990, J BIOL CHEM, V265, P376; COOKE A, 1990, CURR TOP MICROBIOL, V164, P125; DECAMILLI P, 1990, REV PHYSL, V52, P625; GARRY DJ, 1988, J HISTOCHEM CYTOCHEM, V36, P573, DOI 10.1177/36.6.2896676; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JULIEN JF, 1990, J NEUROCHEM, V54, P703, DOI 10.1111/j.1471-4159.1990.tb01928.x; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; Mugnaini E, 1985, HDB CHEM NEUROANATOM, P436; OERTEL WH, 1980, BRAIN RES BULL, V5, P713, DOI 10.1016/0361-9230(80)90117-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; PASSARIELLO N, 1982, J CLIN ENDOCR METAB, V54, P1145, DOI 10.1210/jcem-54-6-1145; REUSENSBILLEN B, 1984, CELL TISSUE RES, V235, P503, DOI 10.1007/BF00226946; ROBBINS MS, 1981, DIABETES, V30, P168, DOI 10.2337/diabetes.30.2.168; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SIGURDSSON E, 1990, CURR TOP MICROBIOL, V164, P143; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; [No title captured]	35	1467	1529	4	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 13	1990	347	6289					151	156		10.1038/347151a0	http://dx.doi.org/10.1038/347151a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DY352	1697648				2022-12-24	WOS:A1990DY35200051
J	GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM				GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM			PEDESTRIAN AND HYPOTHERMIA DEATHS AMONG NATIVE-AMERICANS IN NEW-MEXICO - BETWEEN BAR AND HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; INDIANS; MORTALITY; INJURY; ABUSE	Objective. - To determine the nature of excess injury mortality among Native Americans in New Mexico. Design. - Retrospective review of death certificates for deaths from unintentional injuries. Setting. - The state of New Mexico. Subjects. - New Mexico residents who died of unintentional injuries between January 1, 1980, and December 31, 1989. Main Outcome Measure. - Cause-specific mortality rates. Results. - Over half of the excess mortality from all unintentional injuries among Native Americans resulted from hypothermia and from pedestrian-motor vehicle crashes. New Mexico Native Americans were nearly eight times more likely to die in pedestrian-motor vehicle crashes and were 30 times more likely to die of hypothermia compared with other New Mexico residents. At death, 90% of those Native Americans tested were highly intoxicated (median blood alcohol concentrations of 0.24 and 0.18 mg/dL for pedestrian and hypothermia deaths, respectively). Despite the fact that most Native Americans in New Mexico live on reservations, most deaths occurred at off-reservation sites in border towns and on roads leading back to the reservation. Conclusions. - The possession and sale of alcohol is illegal on many Native American reservations. This policy forces Native Americans who want to drink to travel long distances to obtain alcohol. These data suggest that this policy is also the likely explanation for the markedly increased risk of death from hypothermia and pedestrian-motor vehicle crashes in this population.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD SERV,ATLANTA,GA 30333; LOVELACE FDN MED EDUC & RES,ALBUQUERQUE,NM	Centers for Disease Control & Prevention - USA; Lovelace Respiratory Research Institute	GALLAHER, MM (corresponding author), NEW MEXICO DEPT HLTH,OFF EPIDEMIOL,POB 26110,1190 ST FRANCIS DR,SANTA FE,NM 87502, USA.		Duran, Bonnie m/A-3029-2009					BAILAR JC, 1964, BIOMETRICS, V20, P639; BAKER SP, 1974, AM J PUBLIC HEALTH, V64, P319; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DEAN AG, 1990, WORLD PROCESSING DAT; FLEISS JL, 1981, STATISTICAL METHODS, P244; GALLAHER MM, 1989, JAMA-J AM MED ASSOC, V262, P2243; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; MAY P A, 1977, Plains Anthropologist, V22, P223; May P. A, 1977, AM INDIAN LAW REV, V5, P217; MAY PA, 1986, J STUD ALCOHOL, V47, P187, DOI 10.15288/jsa.1986.47.187; MAY PA, 1988, J STUD ALCOHOL, V49, P324, DOI 10.15288/jsa.1988.49.324; MAY PA, 1982, INT J ADDICT, V17, P1185, DOI 10.3109/10826088209056349; MAY PA, 1989, MOTOR VEHICLE CRASHE, P207; OLSON JS, 1984, NATIVE AM 20TH CENTU, P186; OLSON S, 1985, ALCOHOL AM TAKING AC, P2; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; SEWELL CM, 1989, WESTERN J MED, V150, P708; SMART RG, 1979, J STUD ALCOHOL, V40, P908, DOI 10.15288/jsa.1979.40.908; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WOODHOUSE P, 1989, LANCET, V2, P1201; 1988, MMMWR, V37, P780; 1980, INT CLASSIFICATION D, V1; 1982, MMWR, V31, P669; 1988, PHS0218547 HLTH HUM; 1990, INJURIES AM INDIANS; 1983, MMWR, V32, P46; 1943, 16TH CENSUS US 1940, V2; 1981, PC801B33 US BUR CENS	28	58	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1345	1348		10.1001/jama.267.10.1345	http://dx.doi.org/10.1001/jama.267.10.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740855				2022-12-24	WOS:A1992HG67800026
J	DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH				DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH			EFFICACY AND RISKS OF MORICIZINE IN INDUCIBLE SUSTAINED VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; ETHMOZINE; ARRHYTHMIAS; ELECTROPHYSIOLOGY; HYDROCHLORIDE; PROARRHYTHMIA; FIBRILLATION; FLECAINIDE; ENCAINIDE; SAFETY	Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life-threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.	NW MEM HOSP, 250 E SUPER ST, WESLEY PAVILLION, SUITE 524, CHICAGO, IL 60611 USA; ST FRANCIS HOSP, MED CTR, ROSLYN, NY USA; LENOX HILL HOSP, NEW YORK, NY 10021 USA	Northwestern Memorial Hospital; Northwell Health								[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1990, AM J CARDIOL, V65, pD15; CALVO R, 1985, CLIN PHARMACOL THER, V37, P186; DOHERTY JU, 1984, CIRCULATION, V70, P440; DORIAN P, 1986, AM HEART J, V112, P327, DOI 10.1016/0002-8703(86)90270-X; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; HERRE JM, 1990, ANN INTERN MED, V113, P671, DOI 10.7326/0003-4819-113-9-671; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE45, DOI 10.1016/0002-9149(87)90201-3; KAVANAGH KM, 1991, J AM COLL CARDIOL, V17, P391, DOI 10.1016/S0735-1097(10)80104-4; LEVINE JH, 1989, CIRCULATION, V80, P1063, DOI 10.1161/01.CIR.80.4.1063; MANN DE, 1984, J AM COLL CARDIOL, V3, P537; MANN DE, 1984, AM HEART J, V107, P674, DOI 10.1016/0002-8703(84)90314-4; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIURA DS, 1986, AM HEART J, V111, P661, DOI 10.1016/0002-8703(86)90095-5; MORGANROTH J, 1984, AM J CARDIOL, V53, pB89, DOI 10.1016/0002-9149(84)90509-5; MORGANROTH J, 1990, AM J CARDIOL, V65, pD26; MORGANROTH J, 1989, AM J CARDIOL, V63, P172, DOI 10.1016/0002-9149(89)90280-4; PODRID PJ, 1987, AM J CARDIOL, V59, pE38, DOI 10.1016/0002-9149(87)90200-1; PODRID PJ, 1984, J CARDIOVASC PHARM, V65, P313; PRATT CM, 1989, AM HEART J, V118, P433, DOI 10.1016/0002-8703(89)90254-8; PRATT CM, 1986, CIRCULATION, V73, P718, DOI 10.1161/01.CIR.73.4.718; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WYNDHAM CRC, 1987, AM J CARDIOL, V60, pF67	24	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					375	381		10.7326/0003-4819-116-5-375	http://dx.doi.org/10.7326/0003-4819-116-5-375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736770				2022-12-24	WOS:A1992HF26800005
J	STEIN, D; NUSSLEINVOLHARD, C				STEIN, D; NUSSLEINVOLHARD, C			MULTIPLE EXTRACELLULAR ACTIVITIES IN DROSOPHILA EGG PERIVITELLINE FLUID ARE REQUIRED FOR ESTABLISHMENT OF EMBRYONIC DORSAL-VENTRAL POLARITY	CELL			English	Article							FEMALE STERILE MUTATIONS; DNA-BINDING SUBUNIT; TOLL GENE-PRODUCT; NF-KAPPA-B; SERINE PROTEASE; REL ONCOGENE; TRANSMEMBRANE PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; MELANOGASTER	Twelve maternal effect genes (the dorsal group and cactus) are required for the establishment of the embryonic dorsal-ventral axis in the Drosophila embryo. Embryonic dorsal-ventral polarity is defined within the perivitelline compartment surrounding the embryo by the ventral formation of a ligand for the Toll receptor. Here, by transplantation of perivitelline fluid we demonstrate the presence of three separate activities present in the perivitelline fluid that can restore dorsal-ventral polarity to mutant easter, snake, and spatzle embryos, respectively. These activities are not capable of defining the polarity of the dorsal-ventral axis; instead they restore structures according to the intrinsic dorsal-ventral polarity of the mutant embryos. They appear to be involved in the ventral formation of a ligand for the Toll protein. This process requires serine proteolytic activity; the infection of serine protease inhibitors into the perivitelline space of wild-type embryos results in the formation of dorsalized embryos.			STEIN, D (corresponding author), MAX PLANCK ENTWICKLUNGSBIOL,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1984, PATTERN FORMATION, P269; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DOYLE HJ, 1986, NATURE, V323, P76, DOI 10.1038/323076a0; ERDELYI M, 1989, GENETICS, V122, P111; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; IP YT, 1991, CELL, V64, P439; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; Poulson D. F., 1950, BIOL DROSOPHILA, P168; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; Sonnenblick B., 1950, BIOL DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wieschaus E., 1986, P199; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	53	104	105	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					429	440		10.1016/0092-8674(92)90181-B	http://dx.doi.org/10.1016/0092-8674(92)90181-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739964				2022-12-24	WOS:A1992HD39800005
J	WACHTER, RM				WACHTER, RM			AIDS, ACTIVISM, AND THE POLITICS OF HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOVEMENT				WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; Annas George J, 1989, Villanova Law Rev, V34, P771; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Bayer R., 1991, PRIVATE ACTS SOCIAL; BENNETT JT, 1990, HLTH RES CHARITIES I; Blumberg Rhoda Lois, 1984, CIVIL RIGHTS 1960S F; CHASE M, 1989, WALL STREET J   0919, pA3; COLAIACO JA, 1988, ML KING APOSTLE MILI; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Dowd Maureen, 1991, NEW YORK TIMES  0302, P7; FINTOR L, 1991, J NATL CANCER I, V83, P528, DOI 10.1093/jnci/83.8.528; FOX P, 1989, MILBANK Q, V67, P58, DOI 10.2307/3350070; Fuchs V., 1974, WHO SHALL LIVE; GROSS J, 1991, NY TIMES        0107, pA12; GROSSMAN H, 1990, NY TIMES        0819, V3, P13; HAMILTON PA, 1982, HLTH CARE CONSUMERIS; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; KOLATA G, 1990, NY TIMES, pA1; KOLATA G, 1991, NY TIMES        0716, pB6; KOLATA G, 1991, NY TIMES        0728, P13; KOLATA G, 1990, NY TIMES        0519, pA8; KRAMER L, 1990, OUTWEEK MAGAZIN 0314, P36; KRAMER L, 1989, REPROTS HOLOCAUST MA; KRAUTHAMMER C, 1990, TIME            0625, P80; LEO J, 1990, US NEWS WORLD R 0205, P18; LITTLE M, 1970, BY ANY MEANS NECESSA; MASTERSONALLEN S, 1990, INT J HEALTH SERV, V20, P485, DOI 10.2190/ATLC-AX39-M5EX-BYHF; McIntosh H, 1990, J Natl Cancer Inst, V82, P730, DOI 10.1093/jnci/82.9.730; ROTHMAN DJ, 1990, HEALTH AFFAIR, V9, P123, DOI 10.1377/hlthaff.9.3.123; Salholz E., 1990, NEWSWEEK        0312, P20; Shilts R., 1987, BAND PLAYED POLITICS; SPIERS HR, 1989, HASTINGS CENT REP, V19, P34, DOI 10.2307/3561987; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STRICKAND SP, 1979, POLITICS HLTH, P75; THOMPSON D, 1990, TIME            0122, P24; Wachter Robert M., 1991, FRAGILE COALITION SC; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1991, MMWR, V40, P358; 1990, FED REGISTER, V55, P20856	39	60	61	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					128	133		10.1056/NEJM199201093260209	http://dx.doi.org/10.1056/NEJM199201093260209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY045	1727220				2022-12-24	WOS:A1992GY04500009
J	PETROS, A; BENNETT, D; VALLANCE, P				PETROS, A; BENNETT, D; VALLANCE, P			EFFECT OF NITRIC-OXIDE SYNTHASE INHIBITORS ON HYPOTENSION IN PATIENTS WITH SEPTIC SHOCK	LANCET			English	Note							L-ARGININE; ENDOTOXIN; TONE	Hypotension during septic shock, which may reflect increased synthesis of the potent vasodilator nitric oxide (NO), is often refractory to vasoconstrictors. We describe the effects of NO synthase inhibition in two patients with life-threatening septic shock in whom conventional therapy had failed to restore blood pressure. N(G)-monomethyl-L-arginine (L-NMMA) caused dose-dependent increases in blood pressure and systemic vascular resistance in both patients, and a similar effect was observed in the second patient after treatment with N(G)-nitro-L-arginine methyl ester (L-NAME). These findings indicate that NO synthase induction contributes to the pathogenesis of septic shock, and that inhibition of NO synthase may represent a novel therapeutic option.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS THERAPY UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London								GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; JOULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; VALLANCE P, 1989, LANCET, V2, P997; WRIGHT CE, IN PRESS CARDIOVASC	10	804	831	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1557	1558		10.1016/0140-6736(91)92376-D	http://dx.doi.org/10.1016/0140-6736(91)92376-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1720856				2022-12-24	WOS:A1991GW03600007
J	KIM, J; CHEONG, C; MOORE, PB				KIM, J; CHEONG, C; MOORE, PB			TETRAMERIZATION OF AN RNA OLIGONUCLEOTIDE CONTAINING A GGGG SEQUENCE	NATURE			English	Article							5'-GUANOSINE MONOPHOSPHATE; FIBER DIFFRACTION; TELOMERIC DNA; X-RAY; MODEL; ACID	POLY rG can form four-stranded helices 1. The Hoogsteen-paired quartets of G residues on which such structures depend are so stable that they will form in 5'-GMP solutions, provided that Na+ or K+ are present (see for example, refs 2-4). Telomeric DNA sequences, which are G-rich, adopt four-stranded antiparallel G-quartet conformations in vitro 5,6, and parallel tetramerization of G-rich sequences may be involved in meiosis 7,8. Here we show that RNAs containing short runs of Gs can also tetramerize. A 19-base oligonucleotide derived from the 5S RNA of Escherichia coli (strand III), 5'GCCGAUGGUAGUGUGGGGU3', forms a K+-stabilized tetrameric aggregate that depends on the G residues at its 3' end. This complex is so stable that it would be surprising if similar structures do not occur in nature.			KIM, J (corresponding author), YALE UNIV, DEPT CHEM, 225 PROSPECT ST, NEW HAVEN, CT 06511 USA.		Cheong, Chaejoon/GWC-3135-2022					BORZO M, 1980, J AM CHEM SOC, V102, P1124, DOI 10.1021/ja00523a032; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; MOORE PB, 1988, METHOD ENZYMOL, V164, P158; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; STUDENCKI AB, 1981, THESIS U ILLINOIS; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	12	137	144	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					331	332		10.1038/351331a0	http://dx.doi.org/10.1038/351331a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	1709723				2022-12-24	WOS:A1991FM97600066
J	BLOOMFIELD, SA				BLOOMFIELD, SA			2 TYPES OF ORIENTATION-SENSITIVE RESPONSES OF AMACRINE CELLS IN THE MAMMALIAN RETINA	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; STRUCTURAL BASIS; ORGANIZATION; SELECTIVITY; CORTEX	NEURONS sensitive to the orientation of light stimuli exist throughout the mammalian visual system 1-3, suggesting that this spatial feature is a fundamental cue used by the brain to decipher visual information. The most peripheral neurons known to show orientation sensitivity are the retinal ganglion cells. Considerable morphological 4,5 and pharmacological 6-10 data suggest that the orientation sensitivity of ganglion cells is formed, at least partly, by the amacrine cells, which are laterally oriented interneurons presynaptic to the ganglion cells in the inner plexiform layer. So far there have been few studies of the responses of amacrine cells to oriented visual stimuli and their role in forming orientation-sensitive responses in the retina remains unclear. Here I report the novel finding of a population of amacrine cells in the rabbit retina which are orientation-sensitive. These amacrine cells can be divided into two subtypes, whose orientation sensitivity is manufactured by two distinct mechanisms. The orientation sensitivity of the first subtype of amacrine cell is formed from the interactions of excitatory, centre-receptive field synaptic inputs and inhibitory inputs of opposite polarity, whereas that for cells of the second subtype seems to be the product of a marked asymmetry in their dendritic arbors.			BLOOMFIELD, SA (corresponding author), NYU MED CTR,DEPT OPHTHALMOL,550 1ST AVE,NEW YORK,NY 10016, USA.				NEI NIH HHS [R01 EY007360] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007360] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1969, J NEUROPHYSIOL, V32, P424, DOI 10.1152/jn.1969.32.3.424; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; BLOOMFIELD SA, 1982, J COMP NEUROL, V208, P288, DOI 10.1002/cne.902080306; BLOOMFIELD SA, 1986, J NEUROSCI, V6, P1; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P257, DOI 10.1113/jphysiol.1978.sp012232; DOWLING JE, 1968, PROC R SOC SER B-BIO, V170, P205, DOI 10.1098/rspb.1968.0034; DUBIN MW, 1970, J COMP NEUROL, V140, P479, DOI 10.1002/cne.901400406; ELIAS SA, 1980, BRAIN RES, V196, P365; FAMGLIETTI EV, 1989, NEUROBIOLOGY INNER R, P169; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; FERSTER D, 1987, TRENDS NEUROSCI, V10, P487, DOI 10.1016/0166-2236(87)90126-3; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Hughes A., 1985, PROGR RETINAL RES, V4, P243; LEVENTHAL AG, 1983, J COMP NEUROL, V220, P465, DOI 10.1002/cne.902200408; LEVICK WR, 1967, J PHYSIOL-LONDON, V188, P285, DOI 10.1113/jphysiol.1967.sp008140; LEVICK WR, 1982, J PHYSIOL-LONDON, V329, P243, DOI 10.1113/jphysiol.1982.sp014301; MARIANI AP, 1982, NATURE, V298, P654, DOI 10.1038/298654a0; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; MILLER RF, 1979, NEUROSCIENCES 4TH ST, P227; VIDYASAGAR TR, 1982, EXP BRAIN RES, V46, P157; WYATT HJ, 1976, SCIENCE, V191, P204, DOI 10.1126/science.1857	24	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					347	350		10.1038/350347a0	http://dx.doi.org/10.1038/350347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1706822				2022-12-24	WOS:A1991FD83800095
J	PARRY, N; FOX, G; ROWLANDS, D; BROWN, F; FRY, E; ACHARYA, R; LOGAN, D; STUART, D				PARRY, N; FOX, G; ROWLANDS, D; BROWN, F; FRY, E; ACHARYA, R; LOGAN, D; STUART, D			STRUCTURAL AND SEROLOGICAL EVIDENCE FOR A NOVEL MECHANISM OF ANTIGENIC VARIATION IN FOOT-AND-MOUTH-DISEASE VIRUS	NATURE			English	Article									LAB MOLEC BIOPHYS,REX RICHARDS BLDG,S PARKS RD,OXFORD OX1 3QU,ENGLAND; WELLCOME BIOTECH,DEPT VIROL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; GlaxoSmithKline			Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Stuart, David/0000-0002-3426-4210; Fry, Elizabeth/0000-0001-9754-5303				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BADGER J, 1988, P NATL ACAD SCI USA, V85, P3304, DOI 10.1073/pnas.85.10.3304; BARNETT PV, 1989, J GEN VIROL, V70, P1483, DOI 10.1099/0022-1317-70-6-1483; BAXT B, 1980, VIROLOGY, V104, P42, DOI 10.1016/0042-6822(80)90364-5; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BOLWELL C, 1989, J GEN VIROL, V70, P59, DOI 10.1099/0022-1317-70-1-59; BOLWELL C, 1989, J GEN VIROL, V70, P45, DOI 10.1099/0022-1317-70-1-45; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; FOX G, 1987, J MOL BIOL, V196, P591, DOI 10.1016/0022-2836(87)90035-0; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MATEU MG, 1987, VIRUS RES, V8, P261, DOI 10.1016/0168-1702(87)90020-7; MCCAHON D, 1989, J GEN VIROL, V70, P639, DOI 10.1099/0022-1317-70-3-639; MCCULLOUGH KC, 1985, J IMMUNOL METHODS, V82, P91, DOI 10.1016/0022-1759(85)90228-5; MONOD J, 1965, BIOCHEMISTRY-US, V5, P365; OULDRIDGE EJ, 1984, J GEN VIROL, V65, P203, DOI 10.1099/0022-1317-65-1-203; PARRY NR, 1989, J GEN VIROL, V70, P1493, DOI 10.1099/0022-1317-70-6-1493; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; SUROVOI AY, 1989, J BIOORGANIC CHEM, V14, P527; THOMAS AAM, 1988, J VIROL, V62, P2782, DOI 10.1128/JVI.62.8.2782-2789.1988	26	189	197	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 11	1990	347	6293					569	572		10.1038/347569a0	http://dx.doi.org/10.1038/347569a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC454	1699132				2022-12-24	WOS:A1990EC45400058
J	FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A				FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A			OSTEOPENIA IN MEN WITH A HISTORY OF DELAYED PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL CONTENT; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; DUAL PHOTON-ABSORPTIOMETRY; ALKALINE-PHOSPHATASE; PHYSICAL-ACTIVITY; TOTAL-BODY; DENSITY; OSTEOPOROSIS; WOMEN; MASS	Background and Methods. The effect of delayed puberty on peak bone mineral density in men is unknown. To determine whether such a delay reduces normal peak bone density and leads to osteopenia during adulthood, we measured radial bone mineral density by single-photon absorptiometry and spinal bone mineral density by dual-energy x-ray absorptiometry in 23 men who had a history of constitutionally delayed puberty and 21 men who underwent normal puberty. Their mean ages were 26 and 24 years, respectively. The groups were matched for other factors known to affect bone mass. Results. The mean (+/- SD) radial bone mineral density was significantly lower in the men with a history of delayed puberty than in the normal men (0.73 +/- 0.07 vs. 0.80 +/- 0.05 g per square centimeter; P < 0.0002). Spinal bone mineral density was also significantly lower in the men with delayed puberty than in the normal men (1.03 +/- 0.10 vs. 1.13 +/- 0.11 g per square centimeter; P < 0.003). Radial bone density was at least 1 SD below the mean value for the normal men in 15 of the 23 men with a history of delayed puberty, and spinal bone density was similarly decreased in 10 of the 23. Conclusions. Adult men with a history of constitutionally delayed puberty have decreased radial and spinal bone mineral density. These findings suggest that the timing of puberty is an important determinant of peak bone density in men. Because the peak bone mineral density achieved during young adulthood is a major determinant of bone density in later life, men in whom puberty was delayed may be at increased risk for osteoporotic fractures when they are older.	MASSACHUSETTS GEN HOSP,DEPT MED,NEUROENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	FINKELSTEIN, JS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BULFINCH 3,BOSTON,MA 02114, USA.		Finkelstein, Joel/M-6463-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD021204, R01HD021204] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NICHD NIH HHS [HD-21204] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; COOPER DS, 1979, J CLIN INVEST, V64, P1669, DOI 10.1172/JCI109629; DHUPER S, 1990, J CLIN ENDOCR METAB, V71, P1083, DOI 10.1210/jcem-71-5-1083; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; FINKELSTEIN JS, 1990, TESTOSTERONE ACTION, P204; FORESTA C, 1983, HORM METAB RES, V15, P56, DOI 10.1055/s-2007-1018630; GARDSELL P, 1990, BONE, V11, P229, DOI 10.1016/8756-3282(90)90074-9; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GORDON M, 1982, J PEDIATR-US, V101, P477, DOI 10.1016/S0022-3476(82)80093-0; GOTFREDSEN A, 1985, J COMPUT ASSIST TOMO, V9, P631, DOI 10.1097/00004728-198505000-00072; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; GREENSPAN SL, 1986, ANN INTERN MED, V104, P77; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; HALIOUA L, 1989, AM J CLIN NUTR, V49, P534, DOI 10.1093/ajcn/49.3.534; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANDERS B, 1988, J BONE MINER RES, V3, P145; KELLY PJ, 1990, J BONE MINER RES, V5, P1169; KELLY TL, 1988, J CLIN ENDOCR METAB, V67, P839, DOI 10.1210/jcem-67-4-839; KRABBE S, 1984, ACTA PAEDIATR SCAND, V73, P745, DOI 10.1111/j.1651-2227.1984.tb17769.x; KRABBE S, 1979, ARCH DIS CHILD, V54, P950, DOI 10.1136/adc.54.12.950; KRABBE S, 1980, ACTA PAEDIATR SCAND, V69, P49, DOI 10.1111/j.1651-2227.1980.tb07028.x; LARSEN PR, 1973, J CLIN ENDOCR METAB, V37, P177, DOI 10.1210/jcem-37-2-177; LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247, DOI 10.1210/jcem-66-6-1247; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MAZESS RB, 1988, ARTHRITIS RHEUM-US, V31, P891, DOI 10.1002/art.1780310710; MAZESS RB, 1974, DHEW NIH75683 PUBL, P228; OTT SM, 1990, J CLIN ENDOCR METAB, V71, pA1082; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSENFIELD RL, 1990, J CLIN ENDOCR METAB, V70, P559, DOI 10.1210/jcem-70-3-559; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104; WARREN MP, 1986, NEW ENGL J MED, V315, P905	40	330	334	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					600	604		10.1056/NEJM199202273260904	http://dx.doi.org/10.1056/NEJM199202273260904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734250				2022-12-24	WOS:A1992HF63300004
J	GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R				GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R			A 2-COMPONENT REGULATORY SYSTEM FOR SELF NON-SELF RECOGNITION IN USTILAGO-MAYDIS	CELL			English	Article							DNA-BINDING SPECIFICITY; MATING-TYPE LOCUS; AMINO-ACID; HOMEODOMAIN; GENE; ORGANIZATION; ALPHA-2	In U. maydis the multiallelic b locus controls sexual and pathogenic development. In the b locus a gene coding for a regulatory protein had been identified, and it was suggested that the interaction of two b polypeptides specified by different alleles programs sexual development in this fungus. We now demonstrate the existence of a second regulatory gene in the b locus. We term this gene bW and refer to the former as the bE gene. Both genes exist in many alleles. Although unrelated in primary sequence, both genes are similar in their overall organization. The gene products display allele-specific variability in their N-terminal domains, show a high degree of sequence conservation in the C-terminal domains, and contain a homeodomain-related motif. Genetic evidence is provided to show that the pair of bE and bW polypeptides encoded by different b alleles is the key regulatory species.			GILLISSEN, B (corresponding author), INST GENBIOL FORSCH BERLIN GMBH,IHNESTR 63,W-1000 BERLIN 33,GERMANY.			Gillissen, Bernhard/0000-0002-1815-2091				Ballance DJ, 1991, MOL IND MYCOLOGY SYS, P1; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLKER M, 1992, IN PRESS CELL, V68; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINNEY M, 1990, CELL, V60, P5, DOI 10.1016/0092-8674(90)90708-M; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMER JE, 1987, MOL CELL BIOL, V7, P2352, DOI 10.1128/MCB.7.7.2352; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P1384; MAY G, 1991, GENETICS, V128, P529; MUTASA ES, 1990, CURR GENET, V18, P223, DOI 10.1007/BF00318385; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; TREISMAN J, 1989, CELL, V59, P553; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; ULLRICH RC, 1991, IN PRESS GENETIC ENG, V13; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; [No title captured]	37	263	272	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					647	657		10.1016/0092-8674(92)90141-X	http://dx.doi.org/10.1016/0092-8674(92)90141-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739973	hybrid			2022-12-24	WOS:A1992HF44000006
J	WALSH, C; CEPKO, CL				WALSH, C; CEPKO, CL			WIDESPREAD DISPERSION OF NEURONAL CLONES ACROSS FUNCTIONAL REGIONS OF THE CEREBRAL-CORTEX	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; CELL LINEAGE; SOMATOSENSORY CORTEX; MIGRATION PATTERNS; CORTICAL BARRELS; NERVOUS-SYSTEM; RAT; RETROVIRUS; HINDBRAIN; NEOCORTEX	The cerebral cortex of the mammalian brain has expanded rapidly during the course of evolution and acquired structurally distinguishable areas devoted to separate functions. In some brain regions, topographic restrictions to cell intermixing occur during embryonic development. As a means of examining experimentally whether such restrictions occur during formation of functional subdivisions in the rat neocortex, clonally related neocortical cells were marked by retroviral-mediated transfer of a histochemical marker gene. Clonal boundaries were determined by infection of the developing brain with a library of genetically distinct viruses and amplification of single viral genomes by the polymerase chain reaction. Many clonally related neurons in the cerebral cortex became widely dispersed across functional areas of the cortex. Specification of cortical areas therefore occurs after neurogenesis.	HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Walsh, Christopher/0000-0002-0156-2238	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023021] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23021] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1990, EXP NEUROL, V107, P36, DOI 10.1016/0014-4886(90)90061-V; ALTMAN J, 1991, NEOCORTICAL DEV; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BARBE MF, 1991, J NEUROSCI, V11, P519; BAYER SA, 1991, J COMP NEUROL, V307, P487, DOI 10.1002/cne.903070311; BERRY M, 1965, J ANAT, V99, P691; CEPKO CL, 1990, COLD SH Q B, V55, P265; CEPKO CL, 1989, NEUROMETHODS MOL NEU, V16; COOPER M W, 1989, Society for Neuroscience Abstracts, V15, P808; CRANDELL JE, 1991, EXP NEUROL, V239, P185; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; FIELDSBERRY S, IN PRESS P NATL ACAD; FISHELL G, 1990, DEV BIOL, V141, P70, DOI 10.1016/0012-1606(90)90102-O; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROST DO, 1985, NATURE, V317, P162, DOI 10.1038/317162a0; GASSER UE, 1990, P NATL ACAD SCI USA, V87, P4543, DOI 10.1073/pnas.87.12.4543; GOLDOWITZ D, 1987, DEV BRAIN RES, V35, P1, DOI 10.1016/0165-3806(87)90002-2; GROVE E A, 1991, Society for Neuroscience Abstracts, V17, P11; HOGG RV, 1978, INTRO MATH STATISTIC, P96; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; KRUSHEL L A, 1989, Society for Neuroscience Abstracts, V15, P598; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PARNAVELAS J G, 1990, Society for Neuroscience Abstracts, V16, P1272; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1974, NATURE, V250, P31, DOI 10.1038/250031a0; RYDER E F, 1988, Society for Neuroscience Abstracts, V14, P892; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, UNPUB; WALSH C, 1991, EXPERIENTIA, V46, P940; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WONGRILEY MTT, 1980, P NATL ACAD SCI-BIOL, V77, P2333, DOI 10.1073/pnas.77.4.2333; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; 1972, ANAT REC, V166, P257	53	444	452	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					434	440		10.1126/science.1734520	http://dx.doi.org/10.1126/science.1734520			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734520				2022-12-24	WOS:A1992HA59000031
J	DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M				DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M			ALTERED CHLORIDE-ION CHANNEL KINETICS ASSOCIATED WITH THE DELTA-F508 CYSTIC-FIBROSIS MUTATION	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; EXPRESSION; GENE; CL; IDENTIFICATION; TRANSPORT; MEMBRANE	CYSTIC fibrosis is associated with a defect in epithelial chloride ion transport (reviewed in refs 1, 2) which is caused by mutations in a membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator) 3. Heterologous expression of CFTR produces cyclicAMP-sensitive Cl--channel activity 4-7. Deletion of phenylalanine at amino-acid position 508 in CFTR (DELTA-F508 CFTR) is the most common mutation in cystic fibrosis 8. It has been proposed that this mutation prevents glycoprotein maturation and its transport to its normal cellular location 9. We have expressed both CFIR and DELTA-F508 CFTR in Vero cells using recombinant vaccinia virus. Although far less DELTA-F508 CFTR reached the plasma membrane than normal CFTR, sufficient DELTA-F508 CFTR was expressed at the plasma membrane to permit functional analysis. DELTA-F508 CFIR expression induced a reduced activity of the cAMP-activated Cl- channel, with conductance, anion selectivity and open-time kinetics similar to those of CFIR, but with much greater closed times, resulting in a large decrease of open probability. The DELTA-F508 mutation thus seems to have two major consequences, an abnormal translocation of the CFTR protein which limits membrane insertion, and an abnormal function in mediating Cl- transport.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; CHAMPIGNY G, 1990, FEBS LETT, V259, P263, DOI 10.1016/0014-5793(90)80024-D; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DREINHOFER J, 1988, BIOCHIM BIOPHYS ACTA, V946, P135, DOI 10.1016/0005-2736(88)90466-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EDWARDS G, 1990, TRENDS PHARMACOL SCI, V11, P417, DOI 10.1016/0165-6147(90)90149-3; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAZDUNSKI M, 1982, ANNU REV PHYSIOL, V44, P463, DOI 10.1146/annurev.ph.44.030182.002335; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P673; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	23	594	671	1	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					526	528		10.1038/354526a0	http://dx.doi.org/10.1038/354526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1722027				2022-12-24	WOS:A1991GW75100015
J	HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH				HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH			GENERATION AND USE OF SYNTHETIC PEPTIDE COMBINATORIAL LIBRARIES FOR BASIC RESEARCH AND DRUG DISCOVERY	NATURE			English	Article							SOLID-PHASE SYNTHESIS; ANTIGENIC DETERMINANT; LIGANDS; PROTEIN; ACID	EXISTING methods for the synthesis and screening of large numbers of peptides are limited by their inability to generate and screen the requisite number (millions) of individual peptides 1-4 and/or their inability to generate unmodified free peptides in quantities able to interact in solution 4-8. We have circumvented these limitations by developing synthetic peptide combinatorial libraries composed of mixtures of free peptides in quantities which can be used directly in virtually all existing assay systems. The screening of these heterogeneous libraries, along with an iterative selection and synthesis process, permits the systematic identification of optimal peptide ligands. Starting with a library composed of more than 34 million hexa-peptides, we present here the precise identification of an antigenic determinant recognized by a monoclonal antibody as well as the straightforward development of new potent antimicrobial peptides.			HOUGHTEN, RA (corresponding author), TORREY PINES INST MOLEC STUDIES,3550 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Abrams, William R/A-5782-2008					APPEL JR, 1990, J IMMUNOL, V144, P976; BLONDELLE S E, 1991, Peptide Research, V4, P12; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Cuervo J H, 1988, Pept Res, V1, P81; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GISIN BF, 1972, ANAL CHIM ACTA, V58, P248, DOI 10.1016/S0003-2670(00)86882-8; HOUGHTEN R, 1986, Patent No. 4631211; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTEN RA, 1988, VACCINES 88, P9; HOUGHTEN RA, 1987, PEPTIDE CHEM, P769; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PINILLA C, 1991, PEPTIDES 1990, P860; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	25	1121	1447	4	104	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					84	86		10.1038/354084a0	http://dx.doi.org/10.1038/354084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719428				2022-12-24	WOS:A1991GN82900065
J	FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR				FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR			NUCLEAR-ASSOCIATION OF A T-CELL TRANSCRIPTION FACTOR BLOCKED BY FK-506 AND CYCLOSPORINE-A	NATURE			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; GEL-ELECTROPHORESIS; NEUROSPORA-CRASSA; MACROLIDES FK-506; CYCLOPHILIN; ACTIVATION	CYCLOSPORIN A and FK506 inhibit T- and B-cell activation and other processes essential to an effective immune response 1-3. In T lymphocytes these drugs disrupt an unknown step in the transmission of signals from the T-cell antigen receptor to cytokine genes that coordinate the immune response 4-6. The putative intracellular receptors for FK506 and cyclosporin are cis-trans prolyl isomerases 7-11. Binding of the drug inhibits isomerase activity 8,10,11, but studies with other prolyl isomerase inhibitors 12 and analysis of cyclosporin-resistant mutants in yeast suggest that the effects of the drug result from the formation of an inhibitory complex between the drug and isomerase 13,14, and not from inhibition of isomerase activity. A transcription factor, NF-AT, which is essential for early T-cell gene activation, seems to be a specific target of cyclosporin A and FK506 action because transcription directed by this protein is blocked in T cells treated with these drugs, with little or no effect on other transcription factors such as AP-1 and NF-kappa-B (refs 15-17). Here we demonstrate that NF-AT is formed when a signal from the antigen receptor induces a pre-existing cytoplasmic subunit to translocate to the nucleus and combine with a newly synthesized nuclear subunit of NF-AT. FK506 and cyclosporin A block translocation of the cytoplasmic component without affecting synthesis of the nuclear subunit.			FLANAGAN, WM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOHMAN R J, 1990, New Biologist, V2, P663; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	34	1030	1063	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					803	807		10.1038/352803a0	http://dx.doi.org/10.1038/352803a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715516				2022-12-24	WOS:A1991GC96400060
J	BANDARA, LR; LATHANGUE, NB				BANDARA, LR; LATHANGUE, NB			ADENOVIRUS-E1A PREVENTS THE RETINOBLASTOMA GENE-PRODUCT FROM COMPLEXING WITH A CELLULAR TRANSCRIPTION FACTOR	NATURE			English	Article							E1A PROTEINS; DIFFERENTIATION; DOMAINS	THE transforming proteins of several DNA tumour viruses, including adenovirus E1a and simian virus 40 large T antigen, complex with the retinoblastoma (Rb) tumour-suppressor gene product 1,2. This requires regions in these viral proteins necessary for transformation and is thought to inactivate the growth-suppressing properties of the Rb protein by disrupting its interaction with cellular targets 3. Indeed, regions of Rb required to form a complex with E1a and large T antigen are often mutated in transformed cells 4. The level at which the Rb protein regulates proliferation is unknown, although one possibility is transcription. We have previously characterized a sequence-specific transcription factor, DRTF1, the activity of which is downregulated as embryonal carcinoma stem cells differentiate. DRTF1 is found in several discrete protein complexes (a, b and c) which are of different sizes but have the same DNA specificity 5,6. We now show that one of these also contains the Rb protein and, further, that the adenovirus E1a protein causes the dissociation of the Rb protein from this complex. This requires conserved regions 1 and 2 of E1a that are known to be required for efficient transformation 7. These results demonstrate that the Rb protein forms a complex with a DNA-bound transcription factor, and suggests that the Rb protein might act by regulating transcription.			BANDARA, LR (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1984, EMBO J, V3, P267, DOI 10.1002/j.1460-2075.1984.tb01796.x; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; TASSIOS P T, 1990, New Biologist, V2, P1123; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	13	426	438	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					494	497		10.1038/351494a0	http://dx.doi.org/10.1038/351494a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710781				2022-12-24	WOS:A1991FP75800060
J	VACHER, J; TILGHMAN, SM				VACHER, J; TILGHMAN, SM			DOMINANT NEGATIVE REGULATION OF THE MOUSE ALPHA-FETOPROTEIN GENE IN ADULT LIVER	SCIENCE			English	Article											VACHER, J (corresponding author), PRINCETON UNIV, DEPT BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.				NATIONAL CANCER INSTITUTE [R37CA044976] Funding Source: NIH RePORTER; NCI NIH HHS [CA44976] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; MARIANI BD, 1988, P NATL ACAD SCI USA, V85, P3029, DOI 10.1073/pnas.85.9.3029; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; OLSSON M, 1977, J EXP MED, V145, P819, DOI 10.1084/jem.145.4.819; OTSURU A, 1988, CANCER, V62, P1105, DOI 10.1002/1097-0142(19880915)62:6<1105::AID-CNCR2820620613>3.0.CO;2-Z; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLIARD AM, 1986, J CELL BIOL, V103, P777, DOI 10.1083/jcb.103.3.777; SCOTT RW, 1983, MOL CELL BIOL, V3, P1295, DOI 10.1128/MCB.3.7.1295; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VACHER J, UNPUB; VOGT TF, 1987, SCIENCE, V236, P301, DOI 10.1126/science.2436297; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	32	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1732	1735		10.1126/science.1702902	http://dx.doi.org/10.1126/science.1702902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	1702902				2022-12-24	WOS:A1990EN92000048
J	BENTLEY, GA; BOULOT, G; RIOTTOT, MM; POLJAK, RJ				BENTLEY, GA; BOULOT, G; RIOTTOT, MM; POLJAK, RJ			3-DIMENSIONAL STRUCTURE OF AN IDIOTOPE ANTI-IDIOTOPE COMPLEX	NATURE			English	Article											BENTLEY, GA (corresponding author), INST PASTEUR, DEPT IMMUNOL, CNRS, URA 359, UNITE IMMUNOL STRUCT, F-75724 PARIS 15, FRANCE.		Bentley, Graham/B-3623-2011					AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1987, J MOL BIOL, V194, P577, DOI 10.1016/0022-2836(87)90685-1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COLMAN PM, 1976, CRYSTALLOGRAPHIC COM, P248; ERLANGER BF, 1989, IMMUNOL TODAY, V10, P151, DOI 10.1016/0167-5699(89)90170-9; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABAT EA, 1984, BIOL IDIOTYPES, P3; LOHSS F, 1953, Z NATURFORSCH B, V8, P625; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; OUDIN J, 1963, CR HEBD ACAD SCI, V257, P805; ROITT IM, 1981, LANCET, V1, P1041; SACKS DL, 1983, SPRINGER SEMIN IMMUN, V6, P79, DOI 10.1007/BF01857368; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SLATER RJ, 1955, J EXP MED, V101, P85, DOI 10.1084/jem.101.1.85; SOBOTTKA SE, 1984, NUCL INSTRUM METH A, V220, P575, DOI 10.1016/0167-5087(84)90325-9; SOUCHON H, 1990, J MOL IMMUN, V27, P429; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TULIP WR, 1989, COLD SPRING HARB SYM, V54, P257; Urbain J, 1981, Contemp Top Mol Immunol, V8, P113; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287	29	250	254	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	1990	348	6298					254	257		10.1038/348254a0	http://dx.doi.org/10.1038/348254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700305				2022-12-24	WOS:A1990EH79600064
J	GAMBLE, JR; SKINNER, MP; BERNDT, MC; VADAS, MA				GAMBLE, JR; SKINNER, MP; BERNDT, MC; VADAS, MA			PREVENTION OF ACTIVATED NEUTROPHIL ADHESION TO ENDOTHELIUM BY SOLUBLE ADHESION PROTEIN-GMP140	SCIENCE			English	Article									INST MED & VET SCI,DIV HUMAN IMMUNOL,FROME RD,ADELAIDE,SA 5000,AUSTRALIA; WESTMEAD HOSP,THROMBOSIS & CARDIOVASC DIS RES CTR,DEPT MED,WESTMEAD,NSW 2006,AUSTRALIA	Institute Medical & Veterinary Science Australia; University of Sydney			Vadas, Mathew/R-1378-2019; Berndt, Michael C/D-5580-2012					ANDERSON DC, 1986, J IMMUNOL, V137, P15; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BUYON JP, 1988, J IMMUNOL, V140, P3156; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GAMBLE JR, 1989, P NATL ACAD SCI USA, V86, P7169, DOI 10.1073/pnas.86.18.7169; GAMBLE JR, 1988, J IMMUNOL METHODS, V109, P175, DOI 10.1016/0022-1759(88)90240-2; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GAMBLE JR, UNPUB; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; SAEGUSA Y, 1988, J IMMUNOL, V141, P4140; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH WW, UNPUB; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	37	258	278	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 27	1990	249	4967					414	417						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ702	1696029				2022-12-24	WOS:A1990DQ70200042
J	LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ				LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ			INVASION OF THE CENTRAL-NERVOUS-SYSTEM BY BORRELIA-BURGDORFERI IN ACUTE DISSEMINATED INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYME-DISEASE; MANIFESTATIONS; POLYMERASE; DIAGNOSIS; DNA	Objective. - To determine central nervous system (CNS) involvement in acutely disseminated Borrelia burgdorferi infection by measurement of borrelia-specific DNA using the polymerase chain-reaction (PCR) assay and to compare the results of this with standard serological tests. Design. - Prospective study with laboratory investigators blinded to clinical data. Setting. - Multicenter office practice with a central reference laboratory. Patients. - Cerebrospinal fluid (CSF) was collected from 12 patients with acute disseminated Lyme borreliosis with less than 2 weeks of active disease. The normal control specimens came from 16 patients whose CSF samples had been sent to the clinical laboratory for tests unrelated to the present study. Main Outcome Measures. - Clinical evidence of disease and laboratory abnormalities. Results. - Eight of the 12 patients (four of six with multiple areas of erythema migrans and four of six with cranial neuritis without erythema migrans) had B burgdorferi-specific DNA in their CSF. Among the 12 patients studied, nine had acute cranial neuritis and six had multiple erythema migrans lesions. Just four of the eight who were found to have spirochetal DNA in their CSF had complaints suggestive of CNS infection. In three of the PCR-positive CSF samples, no other abnormalities were noted. None of 16 samples from controls were positive in the PCR assay. Conclusion. - B burgdorferi can invade the CNS early in the course of infection. Careful consideration should be given to choosing antibiotics that achieve adequate CSF levels in patients with disseminated infection.	PHELPS MEM HOSP CTR, DEPT INFECT DIS, TARRYTOWN, NY USA; SUNY DOWNSTATE MED CTR, DEPT IMMUNOL, BROOKLYN, NY 11203 USA; MIDELFORT CLIN, DEPT NEUROL, EAU CLAIRE, WI USA; SUNY DOWNSTATE MED CTR, DEPT MICROBIOL, BROOKLYN, NY 11203 USA; DANBURY HOSP, DEPT INFECT DIS, DANBURY, CT 06810 USA	Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LUFT, BJ (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, T-15 080, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021	Dattwyler, Raymond/0000-0002-1983-1301; Luft, Benjamin/0000-0001-9008-7004				BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CHEN K, 1989, FEMS MICROBIOL LETT, V57, P19, DOI 10.1016/S0378-1097(97)00476-X; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GASSMANN GS, 1989, NUCLEIC ACIDS RES, V17, P3590, DOI 10.1093/nar/17.9.3590; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HUPPERTZ HI, 1989, EUR J PEDIATR, V148, P428, DOI 10.1007/BF00595904; JAULHAC B, 1991, NEW ENGL J MED, V324, P1440; LUFT BJ, 1990, CURR CLIN TOP INFECT, V10, P56; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STIERNSTEDT G, 1988, ANN NY ACAD SCI, V539, P46, DOI 10.1111/j.1749-6632.1988.tb31837.x; WILSKE B, 1986, J INFECT DIS, V153, P304, DOI 10.1093/infdis/153.2.304	18	149	150	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1364	1367		10.1001/jama.267.10.1364	http://dx.doi.org/10.1001/jama.267.10.1364			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740859				2022-12-24	WOS:A1992HG67800030
J	LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA				LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA			A PROSPECTIVE-STUDY OF BENIGN BREAST DISEASE AND THE RISK OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LESIONS; WOMEN	Objective. - To examine the relation between proliferative benign breast disease with and without atypical hyperplasia and the subsequent risk of breast cancer. Design. - Case-control study nested within a prospective cohort study. Median follow-up after breast biopsy was 8 years (25th to 75th percentile, 5 to 14 years). Participants. - Selected from a prospective cohort of 121 700 US registered nurses followed up from 1976 to 1986. Cases were women with breast cancer who had a prior biopsy for benign breast disease. Controls were randomly selected and matched on year of biopsy and year of birth from among women in the cohort who had a benign breast biopsy but who did not develop breast cancer. Included in the analysis were 121 cases and 488 controls. Main Outcome Measure. - Development of breast cancer. Results. - Slides from the first benign breast biopsy were reviewed by two breast pathologists blinded to the outcome, The multiply adjusted relative risks (RRs) for breast cancer, relative to women with no proliferative disease, were 1.6 for proliferative disease without atypia (95% confidence interval [Cl], 1.0 to 2.5) and 3.7 for atypical hyperplasia (95% Cl, 2.1 to 6.8). Breast cancer risk was more strongly associated with atypical hyperplasia among premenopausal women (RR = 5.9; 95% Cl, 2.9 to 13.2) than postmenopausal women (RR = 2.3; 95% CI, 0.9 to 5.9), but the association of breast cancer risk with proliferative disease without atypia did not differ across menopausal status. Conclusion. - These results confirm the marked increase in breast cancer risk among women with atypical hyperplasia, particularly in premenopausal women, and suggest that these women should be encouraged to undergo frequent breast cancer screening.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	LONDON, SJ (corresponding author), UNIV SO CALIF, SCH MED, DEPT PREVENT MED, 1420 SAN PABLO ST, PMB B306, LOS ANGELES, CA 90033 USA.		London, Stephanie/C-3734-2019; Colditz, Graham/A-3963-2009	London, Stephanie/0000-0003-4911-5290; Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R01CA046475, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356, CA 09001, CA 46475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, Arch Pathol Lab Med, V110, P171; BLACK MM, 1972, CANCER, V29, P338, DOI 10.1002/1097-0142(197202)29:2&lt;338::AID-CNCR2820290212&gt;3.0.CO;2-U; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DONNELLY PK, 1975, MAYO CLIN PROC, V50, P650; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; FOOTE FW, 1945, ANN SURG, V121, P197, DOI 10.1097/00000658-194502000-00009; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KODLIN D, 1977, CANCER, V39, P2603, DOI 10.1002/1097-0142(197706)39:6<2603::AID-CNCR2820390645>3.0.CO;2-T; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	14	373	384	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					941	944		10.1001/jama.267.7.941	http://dx.doi.org/10.1001/jama.267.7.941			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734106				2022-12-24	WOS:A1992HD15500026
J	HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD				HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD			INTEGRIN MODULATING FACTOR-I - A LIPID THAT ALTERS THE FUNCTION OF LEUKOCYTE INTEGRINS	CELL			English	Article							FATTY-ACID DEFICIENCY; INCREASED SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; HUMAN-NEUTROPHILS; CELL-ADHESION; POLYMORPHONUCLEAR LEUKOCYTES; COMPLEMENT RECEPTORS; TRANSIENT ADHESION; GLYCOPROTEIN-IIIA; HUMAN-MONOCYTES	The avidity of integrin CR3 (also known as alpha(M)beta-2, Mac-1, Mo-1, and CD11b/CD18) may be reversibly altered without changes in the number of cell surface receptors. Here we describe a molecule termed integrin modulating factor (IMF-1), which controls CR3 avidity. Addition of IMF-1 to polymorphonuclear leukocytes (PMNs) or to purified CR3 causes enhanced binding of ligand. IMF-1 is not present in resting PMNs, but stimulation of cells results in a transient rise in IMF-1 content that parallels a transient rise in CR3 activity. We suggest that PMNs control adhesivity by controlling synthesis of IMF-1, which then acts as an allosteric activator of leukocyte integrins. IMF-1 is an acidic, amphiphilic molecule of M(r) 340 +/- 16 that does not contain ester, phosphate, amide, sialic acid, or glycosidic or vicinal hydroxyl functionalities, but does contain a carbon-carbon double bond. These results suggest that IMF-1 is an unsaturated fatty acid or an isoprenoid acid.			HERMANOWSKIVOSATKA, A (corresponding author), ROCKEFELLER UNIV, NEW YORK, NY 10021 USA.		van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830	NIAID NIH HHS [AI24775, AI22003] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022003, P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BUYON JP, 1988, J IMMUNOL, V140, P3156; CHAN KFJ, 1989, J BIOL CHEM, V264, P18632; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DANA N, 1986, J IMMUNOL, V137, P3259; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; Guindon Y, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P554; GYLLENHAMMAR H, 1988, LIPIDS, V23, P89, DOI 10.1007/BF02535286; HARLAN JM, 1985, BLOOD, V66, P167; HENSON PM, 1988, INFLAMMATION BASIC P, P363; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LEFKOWITH JB, 1988, J IMMUNOL, V140, P228; LEFKOWITH JB, 1991, J BIOL CHEM, V266, P1071; LINDSTROM P, 1988, J CLIN LAB IMMUNOL, V25, P77; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; NEURGEBAUER KM, 1991, NATURE, V350, P68; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PATARROYO M, 1989, SCAND J IMMUNOL, V30, P129, DOI 10.1111/j.1365-3083.1989.tb01197.x; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHREINER GF, 1989, J IMMUNOL, V143, P3192; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Spaethe S.M., 1988, CELLULAR MOL ASPECTS, P153; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; TODD RF, 1988, HEMATOL ONCOL CLIN N, V2, P13; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WALSH CE, 1981, J BIOL CHEM, V256, P7228; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1990, LEUKOCYTE ADHESION MOLECULES, P190; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876	61	155	156	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					341	352		10.1016/0092-8674(92)90475-R	http://dx.doi.org/10.1016/0092-8674(92)90475-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733503				2022-12-24	WOS:A1992HB35300013
J	FRANZUSOFF, A; LAUZE, E; HOWELL, KE				FRANZUSOFF, A; LAUZE, E; HOWELL, KE			IMMUNOISOLATION OF SEC7P-COATED TRANSPORT VESICLES FROM THE YEAST SECRETORY PATHWAY	NATURE			English	Article							PROTEIN-TRANSPORT; VESICULAR INTERMEDIATE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; MEMBRANE; RECONSTITUTION; COMPLEX; EVENTS; STACK	THE transport of proteins destined for post-endoplasmic reticulum locations in the secretory pathway is Mediated by small vesicuLar carriers 1-3. Transport vesicles have been generated in cell-free assays from the yeast Saccharomyces cerevisiae, and mammalian systems 4-14. Yeast genes encoding cytosolic components that participate in vesicular traffic were first identified from the collection of conditional-lethal sec (secretory) mutants 15-17. Mutations in the yeast SEC7 gene disrupt protein transport in the secretory pathway at the nonpermissive temperature 18. The SEC7 gene product is a phosphoprotein of relative molecular mass 230,000 that functions from the cytoplasmic aspect of intracellular membranes 19,20. We report that in a yeast cell-free transport assay, the introduction of antibodies to Sec7 protein (Sec7p) results in the accumulation of transport vesicles. These vesicles are retrieved with Sec7p-specific antibodies by immuno-isolation for biochemical and electron microscopic characterization. Sec7p on the surface of the accumulated transport vesicles, in combination with previous genetic and biochemical studies 18,20, implicate Sec7p as part of a (non-clathrin) vesicle coat. This Sec7p-containing coat structure is proposed to be essential for vesicle budding at multiple stages in the yeast secretory pathway.			FRANZUSOFF, A (corresponding author), UNIV COLORADO, SCH MED, DEPT CELLULAR & STRUCT BIOL, BOX B-111, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HOWELL KE, 1989, METHOD CELL BIOL, V31, P265; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1991, TRENDS CELL BIOL, V114, P219; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PAULIK M, 1988, J BIOL CHEM, V263, P17738; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WARREN G, 1990, NATURE, V345, P382, DOI 10.1038/345382a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	27	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					173	175		10.1038/355173a0	http://dx.doi.org/10.1038/355173a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729652				2022-12-24	WOS:A1992GY62900062
J	NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH				NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH			SODIUM-CHANNEL DENSITY IN HYPOMYELINATED BRAIN INCREASED BY MYELIN BASIC-PROTEIN GENE DELETION	NATURE			English	Article							ACTION-POTENTIAL CONDUCTION; DYSMYELINATING MUTANT MICE; CENTRAL NERVOUS-SYSTEM; SHIVERER MOUSE; OPTIC-NERVE; RAT; EXPRESSION; DIFFERENTIATION; GLYCOPROTEIN; DEFICIENT	TROPHIC control over the expression and membrane distribution of voltage-dependent ion channels is one of the principal organizing events underlying the maturation of excitable cells. The myelin sheath is a major structural determinant of regional ion channel topography in central axons 1,2, but the exact molecular signals that mediate local interactions between the oligodendrocyte and axolemma are not known. We have found that large caliber fibre pathways in the brain of the mutant mouse shiverer (shi, gene on chromosome 18), whose developmental fate of myelination is averted by deletion of five exons in the myelin basic protein gene 3-5, have a striking excess of sodium channels. As cytoplasmic membranes of shiverer oligodendroglia still adhere to axons 6-8, the evidence indicates that myelin basic protein or a myelin basic protein-dependent glial transmembrane signal associated with compact myelin formation, rather than a simple glial-axon contact inhibition or an intrinsic genetic program of neuronal differentiation, could be critical in downregulating sodium channel density in axons. Here we use the shiverer mutant to show that mature central nervous system projection neurons with large caliber unmyelinated fibres sustain functional excitability by increasing sodium channel density. This axon plasticity, triggered by the absence of a single glial protein, contributes to the unexpectedly mild degree of neurological impairment in the mutant brain without myelin, and may be a potentially inducible mechanism determining the recovery of function from dysmyelinating disease.	BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University	NOEBELS, JL (corresponding author), BAYLOR UNIV,INST MOLEC GENET,DEPT NEUROL,DIV NEUROSCI,NEUROPHYSIOL SECT,DEV NEUROGENET LAB,HOUSTON,TX 77030, USA.		Marcom, Paul/M-4516-2019; Marcom, Paul/AAE-4761-2020	Marcom, Paul/0000-0001-5302-6368; Noebels, Jeffrey/0000-0002-2887-0839				BARRES BA, 1989, NEURON, V2, P1375, DOI 10.1016/0896-6273(89)90076-7; BIRD TD, 1978, J NEUROCHEM, V31, P387, DOI 10.1111/j.1471-4159.1978.tb12479.x; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHIU SY, 1987, J PHYSIOL-LONDON, V391, P631, DOI 10.1113/jphysiol.1987.sp016760; FRAIL DE, 1985, J NEUROCHEM, V45, P1071, DOI 10.1111/j.1471-4159.1985.tb05525.x; HODGKIN A, 1975, PHILOS T ROY SOC B, V270, P297, DOI 10.1098/rstb.1975.0010; INOUE Y, 1981, BRAIN RES, V219, P85, DOI 10.1016/0006-8993(81)90269-9; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LIDOW MS, 1988, BRAIN RES, V459, P105, DOI 10.1016/0006-8993(88)90290-9; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; MOURRE C, 1988, BRAIN RES, V448, P128, DOI 10.1016/0006-8993(88)91109-2; OFFARD J, 1989, NEURON, V2, P1447; PRIVAT AC, 1979, NEUROSCI LETT, V142, P107; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; ROSENBLUTH J, 1981, BRAIN RES, V208, P283, DOI 10.1016/0006-8993(81)90558-8; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P1060; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHEEDLO HJ, 1987, BRAIN RES, V415, P105, DOI 10.1016/0006-8993(87)90273-3; SMITH KJ, 1980, NATURE, V286, P154, DOI 10.1038/286154a0; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; SORG BA, 1987, J NEUROCHEM, V49, P1146, DOI 10.1111/j.1471-4159.1987.tb10005.x; STUMER W, 1987, EUR BIOPHYS J, V14, P131; WAXMAN SG, 1990, J NEUROCYTOL, V19, P11, DOI 10.1007/BF01188436; WAXMAN SG, 1989, P NATL ACAD SCI USA, V86, P1406, DOI 10.1073/pnas.86.4.1406; Waxman SG, 1987, PROG BRAIN RES <D>, V71, P121; WISNIEWSKI HM, 1976, J NEUROPATH EXP NEUR, V35, P327, DOI 10.1097/00005072-197605000-00063	30	55	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					431	434		10.1038/352431a0	http://dx.doi.org/10.1038/352431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1713650				2022-12-24	WOS:A1991FZ34600065
J	SOLDATI, T; PERRIARD, JC				SOLDATI, T; PERRIARD, JC			INTRACOMPARTMENTAL SORTING OF ESSENTIAL MYOSIN LIGHT-CHAINS - MOLECULAR DISSECTION AND INVIVO MONITORING BY EPITOPE TAGGING	CELL			English	Article							SMOOTH MUSCLE ACTIN; FUNCTIONAL DOMAINS; CELL-SURFACE; LIVING CELLS; ER PROTEINS; FIBROBLASTS; EXPRESSION; ANTIBODIES; TRANSPORT; DIFFERENTIATION	The isoprotein-specific intracompartmental sorting of the three essential myosin light chains (LCs), the skeletal muscle LC-1f and LC-3f and the nonmuscle LC-3nm, was investigated. Epitope tagging was used to monitor the intracellular localization to different cytoskeletal structures of the exogenously introduced constructs in adult rat cardiomyocytes (ARCs), which exhibit both stress fibers and regenerating myofibrils. LC-1f and LC-3f bind almost exclusively to the sarcomeric myosin heavy chain (MHC) with high affinity, while the LC-3nm interacts with stress fibers and sarcomeres equally well. Sorting appears to be directed by a hierarchical order of different affinities. Domain mapping by deletion and by construction of a LC-1f/3nm chimera suggests that the LCs are composed of three functionally distinct domains: a basal MHC binding site in the C-terminus; the central part, modulating the preferential interaction with MHC isoforms; and the isoprotein-specific N-terminus of the essential LC, which is probably not involved in the sorting process.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			SOLDATI, Thierry/U-6494-2019; SOLDATI, Thierry/A-2902-2009	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; EPPENBERGER ME, 1988, DEV BIOL, V130, P1, DOI 10.1016/0012-1606(88)90408-3; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GAUTHIER GF, 1990, J CELL BIOL, V110, P693, DOI 10.1083/jcb.110.3.693; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KREIS TE, 1980, CELL, V22, P555, DOI 10.1016/0092-8674(80)90365-7; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAMSON G, 1989, DEV BIOL, V132, P62, DOI 10.1016/0012-1606(89)90204-2; LENNETTE DA, 1978, AM J CLIN PATHOL, V69, P647; MCKENNA N, 1985, J CELL BIOL, V100, P292, DOI 10.1083/jcb.100.1.292; MITTAL B, 1987, J CELL BIOL, V105, P1753, DOI 10.1083/jcb.105.4.1753; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; SANGER JM, 1986, J CELL BIOL, V102, P2053, DOI 10.1083/jcb.102.6.2053; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; YEE JK, 1987, GENE, V53, P97, DOI 10.1016/0378-1119(87)90096-5	37	80	81	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					277	289		10.1016/0092-8674(91)90618-9	http://dx.doi.org/10.1016/0092-8674(91)90618-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713129	Green Published			2022-12-24	WOS:A1991FY71200009
J	SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD				SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD			TRKB ENCODES A FUNCTIONAL RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 BUT NOT NERVE GROWTH-FACTOR	CELL			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; GENE-TRANSFER; PROTO-ONCOGENE; FACTOR FAMILY; EXPRESSION; IDENTIFICATION; GANGLIA; DIFFERENTIATION	A variety of findings seem to functionally link brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), while distinguishing both of these factors from the third member of the neurotrophin family, nerve growth factor (NGF). Here we demonstrate that all three of these neuronal survival molecules bind similarly to the low affinity NGF receptor, but that BDNF and NT-3, unlike NGF, do not act via the high affinity NGF receptor. However, both BDNF and NT-3, but not NGF, bind to full-length and truncated forms of a receptor-like tyrosine kinase, trkB, for which no ligand had previously been identified. In addition to binding BDNF and NT-3, trkB can mediate functional responses to both of these neurotrophins when it is expressed in PC12 cells, although BDNF appears to be the more effective ligand. Thus trkB encodes an essential component of a functional receptor for BDNF and NT-3, but not for NGF. Further evidence predicts the existence of additional functional receptors for the neurotrophins.			SQUINTO, SP (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAISONPIERRE PC, 1991, IN PRESS GENOMICS; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1991, IN PRESS P NATL ACAD; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMANN A, 1978, J SUPRAMOL STR CELL, V9, P351, DOI 10.1002/jss.400090306	48	772	801	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					885	893		10.1016/0092-8674(91)90395-F	http://dx.doi.org/10.1016/0092-8674(91)90395-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710174				2022-12-24	WOS:A1991FP51600018
J	SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL				SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL			PEPTIDE SELECTION BY MHC CLASS-I MOLECULES	NATURE			English	Article							TOXIC LYMPHOCYTES-T; H-2-DEFICIENT LYMPHOMA VARIANTS; ASSOCIATION; DETERMINANT; RECOGNIZE; PROTEINS; CELLS; HLA	SYNTHETIC peptides have been used to sensitize target cells and thereby screen for epitopes recognized by T cells 1-7. Most epitopes of cytotoxic T lymphocytes can be mimicked by synthetic peptides of 12-15 amino acids 8. Although in specific cases, truncations of peptides improves sensitization of target cells 8,9, no optimum length for binding to major histocompatibility complex (MHC) class I molecules has been defined. We have now analysed synthetic peptide captured by empty MHC class I molecules of the mutant cell line RMA-S. We found that class I molecules preferentially bound short peptides (nine amino acids) and selectively bound these peptides even when they were a minor component in a mixture of longer peptides. These results may help to explain the difference in size restriction of T-cell epitopes between experiments with synthetic peptides and those with naturally processed peptides 10-12.	NETHERLANDS CANC INST,DEPT IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	SCHUMACHER, TNM (corresponding author), NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Neefjes, Jacques J.C./H-8780-2017; Schumacher, Ton/Y-2432-2019	Neefjes, Jacques J.C./0000-0001-6763-2211; Schumacher, Ton/0000-0003-0517-8804; Kast, W Martin/0000-0003-2321-3159				BJORKMAN PJ, 1990, REV BIOCH, V59, P253; ELLIOTT T, 1990, NATURE, V348, P195, DOI 10.1038/348195a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOTCH F, 1988, J EXP MED, V186, P2057; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KAST WM, IN PRESS P NATN ACAD; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PHILLIPS DR, 1970, BIOCHEM BIOPH RES CO, V40, P284, DOI 10.1016/0006-291X(70)91007-7; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213	26	276	305	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					703	706		10.1038/350703a0	http://dx.doi.org/10.1038/350703a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1708852				2022-12-24	WOS:A1991FJ13000059
J	HECKEL, JL; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL				HECKEL, JL; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL			NEONATAL BLEEDING IN TRANSGENIC MICE EXPRESSING UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	CELL			English	Article									UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University System of Ohio; University of Cincinnati; University of Pennsylvania; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	HECKEL, JL (corresponding author), CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229, USA.			Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R01HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635, R29CA044611] Funding Source: NIH RePORTER; NCI NIH HHS [CA38635, CA44611] Funding Source: Medline; NICHD NIH HHS [HD09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADDIEGO JE, 1974, J PEDIATR, V85, P807; AOKI N, 1989, BLOOD REV, V3, P11, DOI 10.1016/0268-960X(89)90021-0; AOKI N, 1980, BLOOD, V55, P483; AOKI N, 1979, J CLIN INVEST, V63, P877, DOI 10.1172/JCI109387; AZNAR J, 1984, THROMB HAEMOSTASIS, V52, P196; BAEHNER ROBERT L., 1966, N ENGL J MED, V275, P524, DOI 10.1056/NEJM196609082751003; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BELL SM, 1990, J BIOL CHEM, V265, P1333; BOOTH NA, 1983, BLOOD, V61, P267; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; CRABTREE GR, 1981, J BIOL CHEM, V256, P9718; DANO K, 1985, ADV CANCER RES, V44, P149; DAS PC, 1969, BRIT J HAEMATOL, V17, P431, DOI 10.1111/j.1365-2141.1969.tb01391.x; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; EICHELBERGER MR, 1986, PEDIATR SURG, P145; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCIS RB, 1989, BLUT, V59, P1, DOI 10.1007/BF00320240; FRIEZNERDEGEN S, 1987, BIOCHEMISTRY-US, V26, P8270; GIROLAMI A, 1986, ACTA HAEMATOL-BASEL, V75, P54, DOI 10.1159/000206083; GRALNICK HR, 1973, BRIT J HAEMATOL, V24, P89, DOI 10.1111/j.1365-2141.1973.tb05730.x; IMAOKA S, 1986, CANCER-AM CANCER SOC, V58, P1736, DOI 10.1002/1097-0142(19861015)58:8<1736::AID-CNCR2820580825>3.0.CO;2-8; KAZAMA M, 1981, THROMB RES, V21, P517, DOI 10.1016/0049-3848(81)90154-7; KLUFT C, 1987, J CLIN INVEST, V80, P1391, DOI 10.1172/JCI113217; KORDICH L, 1985, THROMB RES, V40, P645, DOI 10.1016/0049-3848(85)90302-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MILES LA, 1982, BLOOD, V59, P1246; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, P137; PELLMAN CM, 1966, J UROLOGY, V96, P375, DOI 10.1016/S0022-5347(17)63273-7; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANE DC, 1989, AM J HEMATOL, V31, P53, DOI 10.1002/ajh.2830310111; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; TAGNON HJ, 1952, CANCER, V5, P9, DOI 10.1002/1097-0142(195201)5:1<9::AID-CNCR2820050104>3.0.CO;2-S; Van Slyck E J, 1989, Henry Ford Hosp Med J, V37, P33	40	175	197	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 10	1990	62	3					447	456		10.1016/0092-8674(90)90010-C	http://dx.doi.org/10.1016/0092-8674(90)90010-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DU445	1696178				2022-12-24	WOS:A1990DU44500007
J	HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS				HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS			WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review						WEGENERS GRANULOMATOSIS; CYCLOPHOSPHAMIDE; GLUCOCORTICOIDS; GLOMERULONEPHRITIS; DRUG TOXICITY	CONTROLLED CLINICAL-TRIAL; RHEUMATOID-ARTHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; LUPUS NEPHRITIS; ANTICYTOPLASMIC AUTOANTIBODIES; INTRAVENOUS CYCLOPHOSPHAMIDE; IMMUNODIAGNOSTIC VALUE; PULSE METHOTREXATE; THERAPY; DIAGNOSIS	Objective: To prospectively study the clinical features, pathophysiology, treatment, and prognosis of Wegener granulomatosis. Design: Of the 180 patients with Wegener granulomatosis referred to the National Institute of Allergy and Infectious Diseases during the past 24 years, 158 have been followed for 6 months to 24 years (a total of 1229 patient-years). Measurements: Characteristics of clinical presentation, surgical pathology, course of illness, laboratory and radiographic findings, and the results of medical and surgical treatment have been recorded in a computer-based information retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Main Results: Men and women were equally represented; 97% of patients were white, and 85% were more than 19 years of age. The mean period of follow-up was 8 years. One hundred and thirty-three patients (84%) received "standard" therapy with daily low-dose cyclophosphamide and glucocorticoids. Eight (5.0%) received only low-dose cyclophosphamide. Six (4.0%) never received cyclophosphamide and were treated with other cytotoxic agents and glucocorticoids. Ten patients (6.0%) were treated with only glucocorticoids. Ninety-one percent of patients experienced marked improvement, and 75% achieved complete remission. Fifty percent of remissions were associated with one or more relapses. Of 99 patients followed for > 5 years, 44% had remissions of > 5 years duration. Thirteen percent of patients died of Wegener granulomatosis, treatment-related causes, or both. Almost all patients had serious morbidity from irreversible features of their disease (86%) or side effects of treatment (42%). Conclusions: The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids. Nonetheless, disease- and treatment-related morbidity is often profound. Alternative forms of therapy have not yet achieved the high rates of remission induction and successful maintenance that have been reported with daily cyclophosphamide treatment. Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.			HOFFMAN, GS (corresponding author), NIH, BLDG 10, ROOM 11B12, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; ANTONOVYCH TT, 1989, MODERN PATHOL, V2, P349; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BALTARO RJ, 1991, AM REV RESPIR DIS, V143, P275, DOI 10.1164/ajrccm/143.2.275; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; DEVANEY KO, 1990, AM J SURG PATHOL, V14, P555, DOI 10.1097/00000478-199006000-00006; ESPINOZA LR, 1986, J AM ACAD DERMATOL, V15, P508, DOI 10.1016/S0190-9622(86)70202-8; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; HAMDY H, 1987, ARTHRITIS RHEUM, V30, P361, DOI 10.1002/art.1780300401; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; HOFFMAN GS, 1991, AM REV RESPIR DIS, V143, P401, DOI 10.1164/ajrccm/143.2.401; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P132, DOI 10.1007/BF02205561; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LEAVITT RY, 1988, ARTHRITIS RHEUM, V31, P1073, DOI 10.1002/art.1780310822; LUDEMANN J, 1990, NETH J MED, V36, P157; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PINCHING AJ, 1983, Q J MED, V52, P435; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; SESSOMS SL, 1984, CLIN EXP RHEUMATOL, V2, P247; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEPPAT D, 1989, KLIN WOCHENSCHR, V67, P666, DOI 10.1007/BF01718027; TERVAERT JWC, 1990, LANCET, V336, P709; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P315, DOI 10.1097/00000478-199104000-00001; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P1112, DOI 10.1097/00000478-199012000-00003; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1990, NETH J MED, V36, P169; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WATANABE T, 1981, JPN J NEPHROL, V23, P921; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36; Wegener F, 1936, VERHANDLUNGEN DTSCH, V29, P202; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WEINSTEIN A, 1985, AM J MED, V79, P331, DOI 10.1016/0002-9343(85)90312-2; WEISS MA, 1984, HUM PATHOL, V15, P943, DOI 10.1016/S0046-8177(84)80124-0; WEST BC, 1987, ANN INTERN MED, V106, P840, DOI 10.7326/0003-4819-106-6-840; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	45	2182	2276	4	47	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					488	498		10.7326/0003-4819-116-6-488	http://dx.doi.org/10.7326/0003-4819-116-6-488			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739240				2022-12-24	WOS:A1992HJ59800010
J	FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF				FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF			A CDNA-ENCODING RAP74, A GENERAL INITIATION-FACTOR FOR TRANSCRIPTION BY RNA POLYMERASE-II	NATURE			English	Article							ACCURATE INITIATION; PROTEINS; BINDING; PROMOTER	RAP30/74 (also known as TFIIF (refs 1, 2), beta-gamma (ref. 3) and FC (ref. 4)) is one of several general factors required for initiation by RNA polymerase II (reviewed in refs 5-7). The small RAP30 subunit of RAP30/74 binds directly to polymerase and appears structurally and functionally homologous to bacterial sigma factors in their RNA polymerase-binding region 8-10. RAP30/74 or recombinant RAP30 suppresses nonspecific binding of RNA polymerase II to DNA (refs 10, 11) and is required for RNA polymerase II to assemble stably into a preinitiation complex containing promoter DNA and the general factors TFIID, TFIIA and TFIIB (refs 2, 12, 13); both RAP30 and RAP74 are physical components of the preinitiation complex 2. A complementary DNA encoding human RAP30 has been isolated 8, and here we report the isolation of a cDNA encoding human RAP74. RAP30 and RAP74 produced in Escherichia coli can be used in place of natural human RAP30/74 to direct accurate transcription initiation by RNA polymerase II in vitro.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,AGR EXPT STN,E LANSING,MI 48824; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	Michigan State University; Michigan State University; Michigan State University AgBioResearch; University of Toronto; University of Toronto								BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAJIMA S, NUCLEIC ACIDS RES, V18, P4843; KILLEEN MT, IN PRESS MOL CELL BI; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0	28	91	92	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					464	467		10.1038/355464a0	http://dx.doi.org/10.1038/355464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734284				2022-12-24	WOS:A1992HB53000075
J	RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D				RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D			NOVEL NADPH-BINDING DOMAIN REVEALED BY THE CRYSTAL-STRUCTURE OF ALDOSE REDUCTASE	NATURE			English	Article							X-RAY; PROTEIN; EVOLUTION; MUSCLE; CDNAS; FORMS; GENE	ALDOSE reductase is the first enzyme in the polyol pathway and catalyses the NADPH-dependent reduction Of D-glucose to D-sorbitol. Under normal physiological conditions aldose reductase participates in osmoregulation 1, but under hyperglycaemic conditions it contributes to the onset and development of severe complications in diabetes 2. Here we present the crystal structure of pig lens aldose reductase refined to an R-factor of 0.232 at 2.5-angstrom resolution. It exhibits a single domain folded in an eight-stranded parallel alpha/beta-barrel, similar to that in triose phosphate isomerase 3 and a score of other enzymes. Hence, aldose reductase does not possess the expected canonical dinucleotide-binding domain 4. Crystallographic analysis of the binding of 2'-monophosphoadenosine-5'-diphosphoribose, which competitively inhibits NADPH binding reveals that it binds into a cleft located at the C-terminal end of the strands of the alpha/beta-barrel. This represents a new type of binding for nicotinamide adenine dinucleotide coenzymes.	CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,15 RUE R DESCARTES,F-67084 STRASBOURG,FRANCE; BIOSTRUCT SA,ALGORITHMES,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV STRASBOURG 1,INST CHIM,CHIM ORGAN BIOL LAB,F-67008 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Favier, Frederique/B-3090-2013	Favier, Frederique/0000-0003-3249-997X; Podjarny, Alberto/0000-0002-7685-1077				ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHUNG S, 1989, J BIOL CHEM, V264, P14775; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DVORNIK D, 1987, ALDOSE REDUCTASE INH; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FUJII Y, 1990, J BIOL CHEM, V266, P9914; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; Nishimura C, 1989, Prog Clin Biol Res, V290, P211; OECHSNER U, 1988, FEBS LETT, V238, P123, DOI 10.1016/0014-5793(88)80240-0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	30	192	199	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					469	472		10.1038/355469a0	http://dx.doi.org/10.1038/355469a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734286				2022-12-24	WOS:A1992HB53000077
J	CONTI, VR; KRONENBERG, MW				CONTI, VR; KRONENBERG, MW			FOLLOW-UP AFTER CORONARY-ARTERY BYPASS-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CONTI, VR (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550, USA.							WEINER DA, 1991, J AM COLL CARDIOL, V18, P343, DOI 10.1016/0735-1097(91)90584-V	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					568	569						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729582				2022-12-24	WOS:A1992GZ43900038
J	BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y				BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y			RELATION OF FETAL AND INFANT GROWTH TO PLASMA-FIBRINOGEN AND FACTOR-VII CONCENTRATIONS IN ADULT LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; RISK	Objective - To determine whether reduced fetal and infant growth are associated with higher plasma fibrinogen and factor VII concentrations in adult life. Design - Follow up study of men born during 1920-30 whose weights at birth and at 1 year had been recorded by health visitors, and men born during 1935-43 whose size at birth had been measured in detail. Setting - Hertfordshire and Preston, England. Subjects - 591 men born in east Hertfordshire who still lived there and 148 men born in Preston who still lived in or close to the city. Main outcome measures - Plasma fibrinogen and factor VII concentrations. Results - Among men in Hertfordshire mean plasma fibrinogen and factor VII concentrations fell with increasing weight at 1 year (from 3.21 g/l in men of less-than-or-equal-to 18 lb to 2-93 g/l in men of greater-than-or-equal-to 27 lb and from 122% of standard to 103%; p < 0.001, p < 0.005 respectively). The trends were independent of cigarette smoking, alcohol consumption, body mass index, and social class. Neither plasma fibrinogen nor factor VII concentration was related to birth weight. In men in Preston, however, fibrinogen concentration fell progressively as the ratio of placental weight to birth weight decreased (p = 0.01). Conclusions - Reduced growth in fetal life and infancy is strongly related to high plasma concentrations of the haemostatic factors fibrinogen and factor VII. This may be a persisting response to impaired liver development during a critical early period.	NORTHWICK PK HOSP & CLIN RES CTR, MRC, EPIDEMIOL & MED CARE UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON S09 4XY, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ANDREW M, 1990, AM J PEDIAT HEMATOL, V12, P95; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, IN PRESS PAEDIATR PE; BROZOVIC M, 1977, BRIT MED BULL, V33, P231, DOI 10.1093/oxfordjournals.bmb.a071441; BROZOVIC M, 1974, BRIT J HAEMATOL, V28, P381, DOI 10.1111/j.1365-2141.1974.tb00819.x; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DUBOS R, 1966, PEDIATRICS, V38, P789; GRUENWALD P, 1963, BIOL NEONATORUM, V5, P215; GUREWICH V, 1976, THROMB HAEMOSTASIS, V36, P605; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOLMES GE, 1977, AM J DIS CHILD, V131, P1078, DOI 10.1001/archpedi.1977.02120230024003; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1987, THROMB DIATH HAEMO, P37; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VILLAR J, 1984, PEDIATRICS, V74, P783; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	25	198	203	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1992	304	6820					148	152		10.1136/bmj.304.6820.148	http://dx.doi.org/10.1136/bmj.304.6820.148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737158	Green Published, Bronze			2022-12-24	WOS:A1992HA97900019
J	NIGHTINGALE, ST				NIGHTINGALE, ST			3 ADDITIONAL DRUGS AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, ST (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-24	WOS:A1992GY43700004
J	VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA				VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA			CASE AND SURVIVAL DEFINITIONS IN OUT-OF-HOSPITAL CARDIAC-ARREST - EFFECT ON SURVIVAL RATE CALCULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESUSCITATION; DEATH	Objective. - To determine the effect of different case and survival definitions of out-of-hospital cardiac arrest on survival rate calculations. Design. - A 22-month case series of nontraumatic, out-of-hospital cardiac arrests. Setting. - Southwestern city (population, 400000; area, 390 km2) with a two-tiered emergency response system consisting of emergency medical technicians and paramedics. Patients. - A consecutive sample of 372 patients found without palpable pulse or spontaneous respiration. Main Outcome Measures. - Survival rate after cardiac arrest was calculated using three case definitions of arrest and two definitions of survival. Results. - Twenty percent of all patients survived to hospital admission and 6% survived to hospital discharge. Twenty-six percent of adults whose collapse was witnessed survived to hospital admission, and 10% survived to hospital discharge. Patients whose collapse was witnessed and who experienced initial ventricular fibrillation survived to hospital admission in 38% and to hospital discharge in 15% of cases. Conclusions. - The survival rate after out-of-hospital cardiac arrest varies widely depending on the case and survival definitions selected. To facilitate intersystem comparison and assessment of interventions designed to improve outcome, the Utstein Consensus Conference recommended that case and survival definitions should be adopted by all prehospital emergency systems.	ARIZONA EMERGENCY MED RES CTR,TUCSON,AZ; UNIV ARIZONA,COLL MED,CARDIOL SECT,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MATH,TUCSON,AZ 85721	University of Arizona; University of Arizona				Spaite, Daniel/0000-0003-2601-6476				COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Colton T., 1974, STAT MED, P128; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DAWSONSAUNDERS E, 1990, BASIC CLIN BIOSTATIS, P148; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; HUNT RC, 1989, AM J EMERG MED, V7, P68, DOI 10.1016/0735-6757(89)90089-2; PANTRIDG.JF, 1967, LANCET, V2, P271; VALENZUELA TD, 1989, ANN EMERG MED, V18, P573, DOI 10.1016/S0196-0644(89)80847-9; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1	12	52	52	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					272	274		10.1001/jama.267.2.272	http://dx.doi.org/10.1001/jama.267.2.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727526				2022-12-24	WOS:A1992GY04600033
J	PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ				PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ			HUMAN-IMMUNODEFICIENCY-VIRUS GENETIC-VARIATION THAT CAN ESCAPE CYTOTOXIC T-CELL RECOGNITION	NATURE			English	Article							TOXIC LYMPHOCYTES-T; PERIPHERAL-BLOOD; INFECTED INDIVIDUALS; SEROPOSITIVE INDIVIDUALS; REVERSE-TRANSCRIPTASE; SYNTHETIC PEPTIDES; HOMOSEXUAL MEN; HIV-1; REPLICATION; SELECTION	In a longitudinal study of HIV seropositive patients, there were fluctuations in the specificity of cytotoxic T cells for the virus. This was matched by variability in proviral gag DNA epitope sequences in the lymphocytes of these patients. Some of these viral variants are not recognized by autologous T cells. Accumulation of such mutations in T-cell antigenic targets would provide a mechanism for immune escape.	IMMULOGIC, PALO ALTO, CA 94304 USA; CHURCHILL HOSP, OXFORD HAEMOPHILIA CTR, OXFORD OX3 7LV, ENGLAND		PHILLIPS, RE (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		Nixon, Douglas/AAU-5734-2020	Nixon, Douglas/0000-0002-2801-1786; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BOLOGNESI DP, 1989, AIDS, V3, pS111, DOI 10.1097/00002030-198901001-00016; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BROLIDEN PA, 1989, CLIN EXP IMMUNOL, V76, P216; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOSMALIN A, 1990, P NATL ACAD SCI USA, V87, P2344, DOI 10.1073/pnas.87.6.2344; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JOLY P, 1989, J IMMUNOL, V143, P2193; KABAT E, 1979, NIH802008 DHEW PUBL; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOUP RA, 1989, BLOOD, V73, P1909; Maniatis T., 1982, MOL CLONING; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; MYERS G, 1990, HUMAN RETROVIRUSES A; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHEARER GM, 1984, J CLIN INVEST, V74, P496, DOI 10.1172/JCI111447; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STEEL CM, 1988, LANCET, V1, P1185; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7	43	960	973	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					453	459		10.1038/354453a0	http://dx.doi.org/10.1038/354453a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1721107	Bronze			2022-12-24	WOS:A1991GV07800051
J	SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M				SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M			NUCLEAR TARGETING OF THE TRANSCRIPTION FACTOR PTF1 IS MEDIATED BY A PROTEIN SUBUNIT THAT DOES NOT BIND TO THE PTF1 COGNATE SEQUENCE	CELL			English	Article							NF-KAPPA-B; DNA-BINDING; GLUCOCORTICOID RECEPTOR; XENOPUS OOCYTES; DORSAL PROTEIN; ACTIVATION; GENES; TRANSACTIVATOR; LOCALIZATION; POLYMERASE	The pancreas-specific transcription factor PTF1 is a heterooligomer that exists as two variants, alpha and beta, both of which bind DNA. The nucleus contains exclusively alpha while the cytoplasm contains both forms. alpha and beta differ in protein composition. Reconstitution of alpha in vitro requires, in addition to the DNA-binding subunits common to both forms, a 75 kd glycosylated protein that apparently does not bind DNA. Here we show that this protein is essential for targeting PTF1 to the nucleus. Upon injection into frog oocytes, alpha is translocated quantitatively to the nucleus while beta remains in the Cytoplasm. However, if beta is coinjected with purified 75 kd protein or a particular size fraction of pancreatic MRNA, it can be converted to alpha and imported into the nucleus.			SOMMER, L (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PETRUCCO S, 1990, MOL CELL BIOL, V10, P254, DOI 10.1128/MCB.10.1.254; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH PJ, 1988, ANAL BIOCHEM, V169, P390, DOI 10.1016/0003-2697(88)90301-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	35	51	52	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					987	994		10.1016/0092-8674(91)90371-5	http://dx.doi.org/10.1016/0092-8674(91)90371-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720355				2022-12-24	WOS:A1991GT75500017
J	STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA				STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA			RESISTANCE TO DDI AND SENSITIVITY TO AZT INDUCED BY A MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE AZT; THERAPY; DNA; SUSCEPTIBILITIES; MUTAGENESIS; TYPE-1; AGENTS; AIDS	Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of the reverse transcriptase coding region revealed a mutation associated with reduced sensitivity to ddI. When this mutation was present in the same genome as a mutation known to confer AZT resistance, the isolates showed increased sensitivity to AZT. Analysis of HIV-1 variants confirmed that the ddI resistance mutation alone conferred ddI and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT resistance mutation. The use of combination therapy for HIV-1 disease may prevent drug-resistant isolates from emerging.	DUKE UNIV,MED CTR,DURHAM,NC 27710; MAINE MED CTR,PORTLAND,ME 04102; WELLCOME RES LABS,DIV MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND	Duke University; Maine Medical Center; GlaxoSmithKline; Wellcome Research Laboratories	STCLAIR, MH (corresponding author), BURROUGHS WELLCOME CO,DIV VIROL,RES TRIANGLE PK,NC 27709, USA.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BACH MC, 1990, NEW ENGL J MED, V323, P275; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CANN AJ, 1988, ONCOGENE, V3, P123; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; KELLAM P, UNPUB; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROCOANCOURT D, 1990, J VIROL, V64, P2660; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	25	718	737	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1557	1559		10.1126/science.1716788	http://dx.doi.org/10.1126/science.1716788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716788				2022-12-24	WOS:A1991GG65100046
J	VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH				VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH			IMPAIRMENTS, DISABILITIES, AND HANDICAPS OF VERY PRETERM AND VERY-LOW-BIRTH-WEIGHT INFANTS AT 5 YEARS OF AGE	LANCET			English	Article							BIRTH-WEIGHT INFANTS; NEONATAL INTENSIVE-CARE; PERIVENTRICULAR-INTRAVENTRICULAR HEMORRHAGE; NATIONAL COLLABORATIVE SURVEY; FOLLOW-UP; GESTATIONAL-AGE; NETHERLANDS; MORTALITY; MORBIDITY; RESIDENTS	The Project On Preterm and Small for gestational age infants (POPS) was started in the Netherlands in 1983 to investigate the relation between prenatal/perinatal factors and mortality/morbidity in very preterm and very-low-birthweight infants. Of the 1338 liveborn infants (< 32 weeks and/or < 1500 g) 966 were enrolled in the five-year (chronological age) follow-up programme; 96% of these children were assessed during a home visit. The overall outcome was expressed as impairments, disabilities, and handicaps according to World Health Organisation criteria. Of the assessed children, 13% had a disability and 14% were handicapped, which are much higher frequencies than those found in the general population. Handicaps were due mainly to abnormalities of neuromotor function, mental development, or language and speech development. Compared with the handicap frequency in the same cohort at two years of age, a more favourable outcome at five years of age was seen in 10%, and a less favourable outcome in 7% of the children. The findings show that most of those high-risk children survived without handicap or serious disability at preschool age.	UNIV HOSP LEIDEN, DEPT PAEDIAT, NEONATAL UNIT, POB 9600, 2300 RC LEIDEN, NETHERLANDS; TNO, INST PREVENT HLTH CARE, 2313 AD LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC								AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; BAUCHNER H, 1988, PEDIATR CLIN N AM, V35, P1207; BEGANOVIC N, 1988, ARCH DIS CHILD, V63, P66, DOI 10.1136/adc.63.1.66; DENOUDEN L, 1990, NEUROPEDIATRICS, V21, P66, DOI 10.1055/s-2008-1071463; EHRENHAFT PM, 1989, OBSTET GYNECOL, V74, P528; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HORWOOD SP, 1982, PEDIATRICS, V69, P613; HUNT JV, 1988, PEDIATRICS, V82, P596; JOHNSON M A, 1987, Canadian Medical Association Journal, V136, P1157; KITCHEN WH, 1987, J PEDIATR-US, V110, P283, DOI 10.1016/S0022-3476(87)80174-9; KITCHEN WH, 1982, SEMIN PERINATOL, V6, P373; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; PIEKKALA P, 1988, NEUROPEDIATRICS, V19, P33, DOI 10.1055/s-2008-1052398; POWELL TG, 1986, LANCET, V1, P539; ROSS G, 1985, PEDIATRICS, V76, P885; SAIGAL S, 1982, J PEDIATR-US, V100, P606, DOI 10.1016/S0022-3476(82)80767-1; TOUWEN BCL, 1986, EUR J PEDIATR, V145, P460, DOI 10.1007/BF02429042; van de Bor M, 1988, Paediatr Perinat Epidemiol, V2, P328; VANDEBOR M, 1987, J PERINAT MED, V15, P333, DOI 10.1515/jpme.1987.15.4.333; VANDEBOR M, 1988, NEUROPEDIATRICS, V19, P183, DOI 10.1055/s-2008-1052442; VANDEBOR M, 1989, PEDIATRICS, V83, P915; VANDERAA DMC, 1989, THESIS STATE U LEIDE, P185; VANDERAA DMV, 1991, EUR J OBSTET GYN R B, V39, P87, DOI 10.1016/0028-2243(91)90069-W; VANDERAA DMV, 1991, PAEDIATR PERINAT EP, V5, P11; VANDERAA DMZ, 1990, NEUROPEDIATRICS, V21, P62; VANDERAA TMZ, 1989, LANCET, V1, P253; VERLOOVEVANHORICK SP, 1988, PEDIATRICS, V81, P404; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VERLOOVEVANHORICK SP, 1989, EUR J PEDIATR, V149, P197, DOI 10.1007/BF01958281; Walther F J, 1989, Paediatr Perinat Epidemiol, V3, P53, DOI 10.1111/j.1365-3016.1989.tb00369.x; WIERENGA H, 1990, EARLY HUM DEV, V23, P15, DOI 10.1016/0378-3782(90)90125-3; 1990, LICHAMELIJKE BEPERKI, P67; 1990, MANAGEMENT GROUP OXF, P15; 1980, INT CLASSIFICATION I, P207	35	177	178	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					33	36		10.1016/0140-6736(91)90015-H	http://dx.doi.org/10.1016/0140-6736(91)90015-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1711644				2022-12-24	WOS:A1991FV29600014
J	FAUSTMAN, D; COE, C				FAUSTMAN, D; COE, C			PREVENTION OF XENOGRAFT REJECTION BY MASKING DONOR HLA CLASS-I ANTIGENS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ISLET ALLOGRAFT SURVIVAL; T-CELL RECEPTORS; AUTOIMMUNE ENCEPHALOMYELITIS; MONOCLONAL-ANTIBODY; RENAL-ALLOGRAFTS; ADHESION; INVIVO; MICE; PROLONGATION	Destruction of target cells by cytotoxic T lymphocytes requires the presence of HLA (human lymphocyte antigen) class I antigens on the target cells for adhesion as well as for triggering of the antigen-specific T cell receptor. Rejection of xenogeneic human pancreatic islets and liver was circumvented by masking, before transplantation, donor antigens with F(ab')2 antibody fragments to HLA class I or tissue-specific epitopes. This strategy eliminated the need for recipient immunosuppression and allowed islet xenograft survival beyond 200 days, as demonstrated functionally by C peptide secretion as well as by histology. These in vivo observations are consistent with the importance of donor HLA class I in eliciting graft rejection and have potential applicability to the successful transplantation of other HLA class I-bearing donor tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOITARD C, 1988, P NATL ACAD SCI USA, V85, P9719, DOI 10.1073/pnas.85.24.9719; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL IL, 1989, P NATL ACAD SCI USA, V86, P4282, DOI 10.1073/pnas.86.11.4282; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; FABRE JW, 1975, TRANSPLANTATION, V20, P269; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FRENCH ME, 1972, TRANSPLANT REV-DENMA, V13, P115; GOODFELLOW PN, 1976, TRANSPLANTATION, V22, P595, DOI 10.1097/00007890-197612000-00009; KRENSKY AM, 1983, J IMMUNOL, V131, P611; LACY PE, 1979, SCIENCE, V204, P312, DOI 10.1126/science.107588; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARON R, 1983, J IMMUNOL, V131, P2316; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; VIVES M, 1990, IMMUNOLOGY DIABETES, P5; Wang Y, 1987, DIABETES, V36, P535, DOI 10.2337/diabetes.36.4.535; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	26	107	146	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1700	1702		10.1126/science.1710828	http://dx.doi.org/10.1126/science.1710828			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710828				2022-12-24	WOS:A1991FT11400044
J	CHOI, YW; KAPPLER, JW; MARRACK, P				CHOI, YW; KAPPLER, JW; MARRACK, P			A SUPERANTIGEN ENCODED IN THE OPEN READING FRAME OF THE 3' LONG TERMINAL REPEAT OF MOUSE MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECOGNITION; GENE-PRODUCTS; MLS-LOCUS; REGION; EXPRESSION; RECEPTOR; SEQUENCE; TOLERANCE; ANTIGENS	Mice express a collection of superantigens, which bind to class II major histocompatibility proteins and interact with T cells bearing particular V-beta chains as part of their alpha-beta-receptors. These superantigens have been suggested to be encoded by exogenous or endogenous mouse mammary tumour viruses. One such superantigen is now shown to be encoded in the open reading frame of the long terminal repeat of a mammary tumour virus, a gene of previously unknown function.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, YW (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DEPT MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE AM, 1988, J IMMUNOL, V141, P1369; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CROUSE CA, 1989, VIRUS RES, V12, P123, DOI 10.1016/0168-1702(89)90059-2; DICKSON C, 1981, NATURE, V291, P511, DOI 10.1038/291511a0; DONEHOWER LA, 1983, J VIROL, V45, P941, DOI 10.1128/JVI.45.3.941-949.1983; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KING LB, 1990, J IMMUNOL, V144, P3218; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T, 1989, DECONTAMINATION DILU; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTINEZ C, 1964, NATURE, V203, P1199; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; RACEVSKIS J, 1984, J VIROL, V51, P604, DOI 10.1128/JVI.51.3.604-610.1984; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SQUARTINI F, 1970, CANCER RES, V30, P2069; TOMONARI K, IN PRESS IMMUNOGENET; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEISS R, 1985, RNA TUMOR VIRUSES, P582; WHITE J, 1989, J IMMUNOL, V143, P1822; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	52	414	419	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					203	207		10.1038/350203a0	http://dx.doi.org/10.1038/350203a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706480				2022-12-24	WOS:A1991FC77900046
J	ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			GENERATION OF CAMP-ACTIVATED CHLORIDE CURRENTS BY EXPRESSION OF CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS HETEROZYGOTES; RECOMBINANT VACCINIA VIRUS; DEPENDENT PROTEIN-KINASE; ATP SYNTHASE; AIRWAY CELLS; CHANNELS; IDENTIFICATION; EPITHELIUM; TRANSPORT; SYSTEM	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis. In order to evaluate its function, CFTR was expressed in HeLa, Chinese hamster ovary (CHO), and NIH 3T3 fibroblast cells, and anion permeability was assessed with a fluorescence microscopic assay and the whole-cell patch-clamp technique. Adenosine 3',5'-monophosphate (cAMP) increased anion permeability and chloride currents in cells expressing CFTR, but not in cells expressing a mutant CFTR (DELTA-F508) or in nontransfected cells. The simplest interpretation of these observations is that CFTR is itself a cAMP-activated chloride channel. The alternative interpretation, that CFTR directly or indirectly regulates chloride channels, requires that these cells have endogenous cryptic, chloride channels that are stimulated by cAMP only in the presence of CFTR.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation				Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				ANDERSON M P, 1990, Journal of Cell Biology, V111, p63A; ANDERSON MW, UNPUB; BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; BOAT TF, 1989, METABOLIC BASIS INHE; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAO AC, 1990, J MEMBRANE BIOL, V113, P193, DOI 10.1007/BF01870071; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CRYSTAL RA, 1990, PEDIATR PULM S, V5, P59; CULLEN JJ, 1987, J CLIN INVEST, V79, P73, DOI 10.1172/JCI112811; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ERLICH HA, 1989, PRC TECHNOLOGY PRINC; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANRAHAN JW, 1989, BICARBONATE CHLORIDE; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JEFFERSON DM, 1990, AM J PHYSIOL, V249, pL496; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN PY, 1987, J BIOL CHEM, V262, P15345; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; MASTROCOLA T, 1990, LIFE SCI, V46, P1661, DOI 10.1016/0024-3205(90)90381-Z; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JL, UNPUB; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1989, SCIENCE, V245, P1073; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	43	536	546	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					679	682		10.1126/science.1704151	http://dx.doi.org/10.1126/science.1704151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	EW399	1704151				2022-12-24	WOS:A1991EW39900047
J	NISHIBE, S; WAHL, MI; HERNANDEZSOTOMAYOR, SMT; TONKS, NK; RHEE, SG; CARPENTER, G				NISHIBE, S; WAHL, MI; HERNANDEZSOTOMAYOR, SMT; TONKS, NK; RHEE, SG; CARPENTER, G			INCREASE OF THE CATALYTIC ACTIVITY OF PHOSPHOLIPASE C-GAMMA-1 BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article									VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL CANCER INSTITUTE [P01CA043720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720] Funding Source: Medline; NIGMS NIH HHS [GMO7347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; HERNANDEZSOTOMA.SM, UNPUB; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, UNPUB; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RYU SH, 1987, J BIOL CHEM, V262, P12511; SUH PG, 1988, J BIOL CHEM, V263, P14497; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, CANCER CELL-MON REV, V1, P101; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0	25	663	679	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1253	1256		10.1126/science.1700866	http://dx.doi.org/10.1126/science.1700866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700866				2022-12-24	WOS:A1990EK72300036
J	MATSUI, Y; ZSEBO, KM; HOGAN, BLM				MATSUI, Y; ZSEBO, KM; HOGAN, BLM			EMBRYONIC EXPRESSION OF A HEMATOPOIETIC GROWTH-FACTOR ENCODED BY THE SI LOCUS AND THE LIGAND FOR C-KIT	NATURE			English	Article									VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Vanderbilt University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREEN MC, 1989, GENETICS VARIANTS ST, P333; JESSELL TM, 1989, CIBA F SYMP, V144, P255; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PELTON RW, 1989, DEVELOPMENT, V106, P759; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Silvers W.K., 1979, COAT COLORS MICE, P206; SZEBO KM, 1990, CELL, V63, P195; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	19	491	497	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 18	1990	347	6294					667	669		10.1038/347667a0	http://dx.doi.org/10.1038/347667a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED620	1699134				2022-12-24	WOS:A1990ED62000053
J	BAILLEUL, B; SURANI, MA; WHITE, S; BARTON, SC; BROWN, K; BLESSING, M; JORCANO, J; BALMAIN, A				BAILLEUL, B; SURANI, MA; WHITE, S; BARTON, SC; BROWN, K; BLESSING, M; JORCANO, J; BALMAIN, A			SKIN HYPERKERATOSIS AND PAPILLOMA FORMATION IN TRANSGENIC MICE EXPRESSING A RAS ONCOGENE FROM A SUPRABASAL KERATIN PROMOTER	CELL			English	Article									BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT MOLEC EMBRYOL,CAMBRIDGE CB2 4AT,ENGLAND; UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND; GERMAN CANC RES CTR,DEPT CELL & TUMOR BIOL,W-6900 HEIDELBERG,GERMANY; CIUDAD UNIV MADRID,INST PRYMA,CTR INVEST ENERGET MEDIOAMBIENTALES & TECHNOL,E-29040 MADRID,SPAIN	Beatson Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Glasgow; Helmholtz Association; German Cancer Research Center (DKFZ); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas				Surani, Azim/0000-0002-8640-4318				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALLEN N D, 1987, P217; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Argyris T S, 1982, Carcinog Compr Surv, V7, P43; BAILLEUL B, 1988, NUCLEIC ACIDS RES, V16, P359, DOI 10.1093/nar/16.1.359; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BURNS FJ, 1976, CANCER RES, V36, P1422; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COHEN S, 1962, J BIOL CHEM, V237, P1555; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DOTTO GP, 1985, NATURE, V318, P472; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; Fuchs E., 1988, ADV CELL CULT, V6; GIUDICE GJ, 1987, CELL, V48, P453, DOI 10.1016/0092-8674(87)90196-6; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; GRONER B, 1987, TRENDS GENET, V3, P306, DOI 10.1016/0168-9525(87)90276-9; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HECKER E, 1982, CARCINOGENESIS COMPR, V7; HOWELEVANS W, 1958, Q J MED, V27, P413; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEHNERT ME, 1984, EMBO J, V3, P3279, DOI 10.1002/j.1460-2075.1984.tb02290.x; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORGAN JR, 1987, SCIENCE, V237, P1476; MORRIS RJ, 1986, CANCER RES, V46, P3061; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NEWBOLD RF, 1981, CARCINOGENESIS, V2, P243, DOI 10.1093/carcin/2.3.243; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RHODES JA, 1986, P NATL ACAD SCI USA, V83, P3844, DOI 10.1073/pnas.83.11.3844; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SCHWEIZER J, 1988, CELL TISSUE RES, V253, P221; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEWART TA, 1984, CELL, V38, P6227; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YESUDIAN P, 1980, BRIT J DERMATOL, V102, P597, DOI 10.1111/j.1365-2133.1980.tb07662.x; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	66	249	257	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 24	1990	62	4					697	708		10.1016/0092-8674(90)90115-U	http://dx.doi.org/10.1016/0092-8674(90)90115-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DW306	1696852				2022-12-24	WOS:A1990DW30600010
J	CONTENTE, S; KENYON, K; RIMOLDI, D; FRIEDMAN, RM				CONTENTE, S; KENYON, K; RIMOLDI, D; FRIEDMAN, RM			EXPRESSION OF GENE-RRG IS ASSOCIATED WITH REVERSION OF NIH 3T3 TRANSFORMED BY LTR-C-H-RAS	SCIENCE			English	Article											CONTENTE, S (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Contente, Sara/0000-0002-8099-2817	NCI NIH HHS [R01 CA 37351-04A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Blair D G, 1981, Haematol Blood Transfus, V26, P460; BOS JL, 1989, CANCER RES, V49, P4682; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CONTENTE S, UNPUB; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HAND PH, 1987, J NATL CANCER I, V79, P59; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; SAMID D, 1985, BIOCHEM BIOPH RES CO, V126, P509, DOI 10.1016/0006-291X(85)90635-7; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TANAKA T, 1986, CANCER RES, V46, P1465; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1	27	234	243	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 17	1990	249	4970					796	798		10.1126/science.1697103	http://dx.doi.org/10.1126/science.1697103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV088	1697103				2022-12-24	WOS:A1990DV08800037
J	LIN, AY; DEVAUX, B; GREEN, A; SAGERSTROM, C; ELLIOTT, JF; DAVIS, MM				LIN, AY; DEVAUX, B; GREEN, A; SAGERSTROM, C; ELLIOTT, JF; DAVIS, MM			EXPRESSION OF T-CELL ANTIGEN RECEPTOR HETERODIMERS IN A LIPID-LINKED FORM	SCIENCE			English	Article									STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Davis, Mark/0000-0001-6868-657X				ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN AL, UNPUB; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PATTEN PA, UNPUB; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REINHERZ E, COMMUNICATION; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WETTSTEIN DA, UNPUB	34	240	274	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 10	1990	249	4969					677	679		10.1126/science.1696397	http://dx.doi.org/10.1126/science.1696397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT796	1696397				2022-12-24	WOS:A1990DT79600046
J	LEE, SP; NICHOLLS, JF; PARK, HZ				LEE, SP; NICHOLLS, JF; PARK, HZ			BILIARY SLUDGE AS A CAUSE OF ACUTE-PANCREATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECURRENT PANCREATITIS; GALLBLADDER; PATHOGENESIS; SYSTEM; STONES; BILE	Background. In about 20 to 40 percent of cases of acute pancreatitis, no cause can be found, and these are labeled idiopathic. In this study, we sought to determine the frequency with which patients with acute idiopathic pancreatitis have biliary sludge, a suspension of cholesterol monohydrate crystals or calcium bilirubinate granules that is found predominantly in the gallbladder. Methods. Between 1980 and 1988, we prospectively studied 86 patients who had acute pancreatitis. In patients with no known cause of pancreatitis and no ultrasonographic evidence of gallstones or dilatation of the biliary ducts, we determined how often biliary sludge was present and its subsequent fate by repeated microscopical examinations of bile samples and abdominal ultrasonography. The outcome of patients treated by cholecystectomy or papillotomy was compared with that of untreated patients. Results. The pancreatitis was considered idiopathic in 31 of the 86 patients (36 percent), of whom 23 had microscopical evidence of biliary sludge. Biliary sludge was detected by ultrasonography in only 11 of the 23 patients (48 percent). The sludge detected by ultrasonography was composed of calcium bilirubinate granules in 10 and cholesterol monohydrate crystals in 1 (P = 0.003). Calcium bilirubinate granules were found more frequently in men (nine men vs. four women, P < 0.001). Of the 21 patients in whom biliary sludge was the only finding (2 patients also had dilated bile ducts when restudied), the 6 treated by cholecystectomy and the 4 treated by papillotomy had fewer recurrences of acute pancreatitis during follow-up (up to seven years) than the 11 untreated patients (P = 0.011). The presence of biliary sludge appeared to increase the likelihood of recurrent attacks of pancreatitis (P = 0.020). Conclusions. Biliary sludge is an underestimated cause of acute idiopathic pancreatitis.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND	University of Washington; University of Washington Seattle; University of Auckland								ACOSTA JM, 1980, SURGERY, V88, P118; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; DIMAGNO EP, 1987, HDB GASTROINTESTINAL, P176; FREUND H, 1976, ARCH SURG-CHICAGO, V111, P1106; GOODMAN AJ, 1985, GUT, V26, P125, DOI 10.1136/gut.26.2.125; HOLZBACH RT, 1983, GASTROENTEROLOGY, V84, P1055; HOUSSIN D, 1983, SURG GYNECOL OBSTET, V157, P20; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1987, AM J PHYSIOL, V252, pG374, DOI 10.1152/ajpgi.1987.252.3.G374; LEE SP, 1986, GASTROENTEROLOGY, V90, P677, DOI 10.1016/0016-5085(86)91123-6; LEE SP, 1990, HEPATOLOGY, V12, pS200; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1988, GASTROENTEROLOGY, V95, P1160, DOI 10.1016/0016-5085(88)90218-1; MAYER AD, 1984, BRIT J SURG, V71, P905; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; Mittelstaedt CA, 1987, ABDOMINAL ULTRASOUND; NEOPTOLEMOS JP, 1988, BRIT J SURG, V75, P450, DOI 10.1002/bjs.1800750517; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SHIFFMAN M L, 1990, Gastroenterology, V98, pA262; SOERGEL KH, 1989, GASTROINTESTINAL DIS, P1814; TRAPNELL JE, 1975, BRIT MED J, V2, P179, DOI 10.1136/bmj.2.5964.179; VENU RP, 1989, DIGEST DIS SCI, V34, P56, DOI 10.1007/BF01536154	25	382	393	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					589	593		10.1056/NEJM199202273260902	http://dx.doi.org/10.1056/NEJM199202273260902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734248				2022-12-24	WOS:A1992HF63300002
J	NOVACK, AH				NOVACK, AH			ANTIMICROBIAL TREATMENT OF THE UMBILICAL-CORD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIAL-COLONIZATION; CARE REGIMENS				NOVACK, AH (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.							BARRETT FF, 1979, J PEDIATR-US, V94, P796, DOI 10.1016/S0022-3476(79)80159-6; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; GLADSTONE IM, 1988, CLIN PEDIATR, V27, P127, DOI 10.1177/000992288802700302; SPECK WT, 1980, CHEMOTHERAPY, V26, P372, DOI 10.1159/000237929; SPECK WT, 1977, AM J DIS CHILD, V131, P1005, DOI 10.1001/archpedi.1977.02120220071012	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734090				2022-12-24	WOS:A1992HD15500038
J	YIP, R; SCANLON, K; TROWBRIDGE, F				YIP, R; SCANLON, K; TROWBRIDGE, F			IMPROVING GROWTH STATUS OF ASIAN REFUGEE CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; PHYSICAL GROWTH; BIRTH-WEIGHT; HEIGHT	Objective. - To analyze the trend and pattern of the nutrition status of Southeast Asian refugee children and other low-income children in the United States. Design. - Descriptive analysis of the growth data from the Pediatric Nutrition Surveillance System of the Centers for Disease Control, Atlanta, Ga, from 1980 through 1989. Subjects. - Children under 5 years of age from low-income families enrolled in public health clinics in 12 selected states. Measurements and Main Results. - Asian refugee children experienced a progressive and significant decline in the prevalence of low birth weight, low height-for-age, and low weight-for-age, while these nutritional indexes remained stable for low-income white, black, and Hispanic children. By 1989, the growth status of Asian children was near that of other ethnic groups. Conclusions. - The marked improvement of growth status among Asian refugee children over a short period suggests that the poor growth status often observed among recently immigrated Asian children is primarily related to nutritional and health factors, rather than genetic factors. In assessing the growth of Asian or immigrant children, it would be helpful to take their family and early childhood background into account.			YIP, R (corresponding author), CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,MAIL STOP K-26,ATLANTA,GA 30333, USA.							BALDWIN LM, 1988, AM J DIS CHILD, V142, P526, DOI 10.1001/archpedi.1988.02150050064033; BINKIN NJ, 1988, PEDIATRICS, V82, P828; DAVIES DP, 1988, LINEAR GROWTH RETARD, P75; DEWEY KG, 1986, AM J PUBLIC HEALTH, V76, P806, DOI 10.2105/AJPH.76.7.806; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; GAYLE HD, 1988, PUBLIC HEALTH REP, V103, P143; GRAITCEN PL, 1988, LANCET, V2, P297; HABICHT JP, 1974, LANCET, V1, P611; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; KELLER W, 1988, LINEAR GROWTH RETARD, P17; LI DK, 1990, AM J PUBLIC HEALTH, V80, P685, DOI 10.2105/AJPH.80.6.685; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P198; OLNESS K, 1984, AM J DIS CHILD, V138, P544, DOI 10.1001/archpedi.1984.02140440028006; PECK RE, 1981, AM J PUBLIC HEALTH, V71, P1144, DOI 10.2105/AJPH.71.10.1144; ROUJIA C, 1989, J TROP PEDIATRICS, V35, P255, DOI 10.1093/tropej/35.5.255; SCHUMACHER LB, 1987, PEDIATRICS, V80, P861; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; YIP R, 1991, PEDIATRICS, V87, P688; YIP R, 1989, 14TH P INT C NUTR SE; 1979, MMWR, V28, P386; 1983, CDC838295 US DEP HLT	23	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					937	940		10.1001/jama.267.7.937	http://dx.doi.org/10.1001/jama.267.7.937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734105				2022-12-24	WOS:A1992HD15500025
J	WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA				WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA			THE IMPACT OF A PHYSICIANS WARNING ON RECOVERY AFTER ALCOHOLISM-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE; PREVALENCE; DRINKING; IDENTIFICATION; INTERVENTION; RECOGNITION	Objective. - To study whether alcoholic workers had seen physicians during the year they were identified by their company, whether they recalled physicians' warnings about drinking, and whether such warnings affected outcomes 2 years later. Design. - Workers were interviewed at intake and 2 years later: subgroups who did and did not see physicians and who did and did not recall warnings were compared. Setting. - A company-union employee assistance program. Participants. - Two hundred problem drinkers, newly identified on the job, predominantly male, blue-collar workers. Outcomes. - Drinking, drunkenness, average daily alcohol consumption, and impairment score. Results. - Among the 200 participants, 74% saw physicians in the index year; only 22% recalled warnings. Recall of a warning was associated with liver disease' continued drinking while ill, supervisors' job warnings, older age, and marijuana use. Two years later, those warned were more likely to be abstaining, and sober, and were less impaired. Conclusions. - Recalling a physician's warning at intake into alcoholism treatment was associated with better prognosis 2 years later. However, among this group of employees whose drinking was serious enough to be identified on the job, fewer than a quarter recalled physicians' warnings, even though more than three quarters had seen physicians in the year preceding intake.	BOSTON UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215	Boston University; Boston University	WALSH, DC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Coffman, Gerald/0000-0002-0044-6219; Levenson, Suzette/0000-0002-1979-2373; Heeren, Timothy/0000-0001-5643-3559	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006461] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA06461] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armor D. J., 1976, ALCOHOLISM TREATMENT; BELL J, 1988, MED J AUSTRALIA, V149, P351, DOI 10.5694/j.1326-5377.1988.tb120666.x; BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BOWEN OR, 1988, JAMA-J AM MED ASSOC, V260, P2267, DOI 10.1001/jama.260.15.2267; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CLARK WD, 1981, AM J MED, V71, P275, DOI 10.1016/0002-9343(81)90129-7; CLEARY PD, 1988, AM J MED, V85, P466; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GREEN J R, 1965, Med J Aust, V1, P465; HINGSON R, 1982, J STUD ALCOHOL, V43, P273, DOI 10.15288/jsa.1982.43.273; KAMEROW DB, 1986, JAMA-J AM MED ASSOC, V255, P2054, DOI 10.1001/jama.255.15.2054; KISSIN B, 1977, TREATMENT REHABILITA, P53; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; LEWIS DC, 1983, B NEW YORK ACAD MED, V59, P181; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MULFORD HA, 1977, J STUD ALCOHOL, V38, P21; PRICE J, 1988, MED J AUSTRALIA, V149, P345, DOI 10.5694/j.1326-5377.1988.tb120663.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROHMAN ME, 1987, AM J DRUG ALCOHOL AB, V131, P199; ROLLNICK S, 1987, AUST DRUG ALCOHOL RE, V6, P341; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; TRICE HM, 1973, ALCOHOLISM PROGR RES, P359; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WEST LJ, 1984, ANN INTERN MED, V100, P405, DOI 10.7326/0003-4819-100-3-405; 1980, DIAGNOSTIC STATISTIC; 1987, PHS6TH ALC DRUG AB M	29	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					663	667		10.1001/jama.267.5.663	http://dx.doi.org/10.1001/jama.267.5.663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731132				2022-12-24	WOS:A1992HB35400022
J	AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ				AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ			THE PREVALENCE OF ULCERATED PLAQUES IN THE AORTIC-ARCH IN PATIENTS WITH STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; INFARCTION; COMPLICATION; EMBOLISM; BYPASS	Background and Methods. The cause of cerebral infarction is obscure in up to 40 percent of patients with this disorder who are studied prospectively. In this investigation, we determined the frequency of ulcerated plaques in the aortic arch and explored the part they may play in the formation of cerebral emboli. Using an autopsy data bank, we studied the prevalence of ulcerated plaques in the aortic arch in 500 consecutive patients with cerebrovascular and other neurologic diseases who were studied at autopsy. Results. Ulcerated plaques were present in 26 percent of the 239 patients with cerebrovascular disease but in only 5 percent of the 261 patients with other neurologic diseases (P < 0.001). After we controlled for age and heart weight, the adjusted rates were 16.9 percent and 5.1 percent, respectively (adjusted odds ratio, 4.0; 95 percent confidence interval, 2.1 to 7.8; P < 0.001). Among the patients with cerebrovascular disease, the prevalence of ulcerated plaques in the aortic arch was 28 percent in the 183 patients with cerebral infarcts and 20 percent in the 56 patients with brain hemorrhage. The prevalence of ulcerated plaques was 61 percent among the 28 patients with no known cause of cerebral infarction, as compared with 22 percent among the 155 patients with a known cause of cerebral infarction (P < 0.001). After adjustment for covariates, the prevalence was 57.8 percent among patients with no known cause of cerebral infarction and 20.2 percent among those with a known cause (adjusted odds ratio, 5.7; 95 percent confidence interval, 2.4 to 13.6; P < 0.001). The presence of ulcerated plaques in the aortic arch was not correlated with the presence of extracranial internal-carotid-artery stenosis, suggesting that these were two independent risk factors for stroke. Conclusions. Ulcerated plaques in the aortic arch may play a part in causing cerebral infarction, especially in patients in whom cerebral infarction has no known cause.	HOP LA PITIE SALPETRIERE, NEUROPATHOL R ESCOUROLLE LAB, F-75651 PARIS 13, FRANCE; UNIV PARIS 06, F-75230 PARIS 05, FRANCE; INSERM, U169, F-94800 VILLEJUIF, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	AMARENCO, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, christophe/B-4015-2009; Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; 				BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1978, NEUROLOGY, V28, P1206, DOI 10.1212/WNL.28.12.1206; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; ESCOUROLLE R, 1976, J NEUROL SCI, V28, P103, DOI 10.1016/0022-510X(76)90051-4; ESCOUROLLE R, 1966, REV PRATICIEN, V16, P749; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; FISHER CM, 1965, J NEUROPATH EXP NEUR, V24, P455, DOI 10.1097/00005072-196507000-00007; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LHERMITTE F, 1966, REV NEUROL-FRANCE, V115, P641; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MILLIKAN C, 1990, STROKE, V21, P1251, DOI 10.1161/01.STR.21.9.1251; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CEN, P368; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WINTER WJ, 1957, ARCH PATHOL, V64, P137; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; 1972, NEW ENGL J MED, V286, P1146; 1990, SAS USERS GUIDE STAT, V1	34	450	461	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					221	225		10.1056/NEJM199201233260402	http://dx.doi.org/10.1056/NEJM199201233260402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1727976				2022-12-24	WOS:A1992HA43100002
J	RUTTIMANN, S; CLEMENCON, D; DUBACH, UC				RUTTIMANN, S; CLEMENCON, D; DUBACH, UC			USEFULNESS OF COMPLETE BLOOD COUNTS AS A CASE-FINDING TOOL IN MEDICAL OUTPATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD CELL COUNT; AMBULATORY CARE; DIAGNOSTIC TESTS, ROUTINE; COST-BENEFIT ANALYSIS; PATIENT CARE MANAGEMENT		Objective: To determine the usefulness of routine complete blood counts as a case-finding tool in medical outpatients. Design: Prospective evaluation in a consecutive, unselected cohort. Setting: A university-based outpatient clinic providing primary and referral care in general internal medicine. Patients: A total of 595 patients (mean age [+/- SD], 40 +/- 15 years) making their initial clinic visit. Intervention: A complete blood count was done in all patients. Components of the complete blood count that were not indicated for diagnostic or management purposes at the initial visit were classified as routine tests. Main Outcome Measures: The number and nature of new diagnoses leading to new patient management; the number of additional visits and diagnostic tests precipitated by positive results. Main Results: Of the 2378 tests done, 1540 (65%) were routine tests. The percentages of abnormal test results for the four hematologic test components were as follows: leukocyte count, 7.6%; hemoglobin, 5.8%; mean corpuscular volume (MCV) of red blood cells, 7.9%; and platelet count, 4.5%. In only three patients (0.5%) was a new diagnosis made that led to a new management strategy (treatment of iron deficiency). Further work-up was unprofitable in 14 patients (2.4%). Two additional visits were necessary because of abnormal results on routine tests. No abnormality-associated clinical disease developed during a 15-month follow-up period in patients with unexplained abnormal results on routine hematologic tests. Conclusions: The routine complete blood count has limited usefulness as a case-finding tool and has a minimal effect on care in middle-aged medical outpatients.			RUTTIMANN, S (corresponding author), KANTONSSPITAL,DEPT INTERNAL MED,CH-4031 BASEL,SWITZERLAND.							DELAHUNT B, 1980, NEW ZEAL MED J, V92, P431; FRYE EB, 1987, J GEN INTERN MED, V2, P373, DOI 10.1007/BF02596360; KAPLAN EB, 1985, JAMA-J AM MED ASSOC, V253, P3576, DOI 10.1001/jama.253.24.3576; PANZER RJ, 1987, J GEN INTERN MED, V2, P365, DOI 10.1007/BF02596179; RICH EC, 1983, JAMA-J AM MED ASSOC, V249, P633; SACKETT DL, 1975, LANCET, V2, P357; SCHNEIDERMAN LJ, 1972, ARCH INTERN MED, V129, P88, DOI 10.1001/archinte.129.1.88; SHAPIRO MF, 1987, ANN INTERN MED, V106, P65, DOI 10.7326/0003-4819-106-1-65	8	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					44	50						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727094				2022-12-24	WOS:A1992GX15700007
J	STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T				STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T			THE LYMPHOCYTE-B ADHESION MOLECULE CD22 INTERACTS WITH LEUKOCYTE COMMON ANTIGEN CD45RO ON T-CELLS AND ALPHA-2-6 SIALYLTRANSFERASE, CD75, ON B-CELLS	CELL			English	Article							MONOCLONAL-ANTIBODIES; COGNATE INTERACTIONS; MEMBRANE-PROTEIN; IMMUNE-SYSTEM; SIALYL-LEX; RECEPTOR; ACTIVATION; CDNA; DIFFERENTIATION; EXPRESSION	Functional maturation of B lymphocytes correlates with expression of the B lineage-specific cell surface glycoprotein CD22. Two CD22 polypeptides have been characterized and suggested to play a role in B cell-B cell interaction as well as in B cell adhesion to monocytes. In this work we provide evidence that CD22 is directly involved in the cognate interaction between B and T cells. One of the two CD22 polypeptides, CD22-beta, interacts with a specific ligand on a subpopulation of CD4+ T cells. Our results suggest that the T cell ligand of CD22 is CD45RO, an isoform of the leukocyte common antigen class of phosphotyrosine phosphatases associated with the helper T cell phenotype. We further demonstrate that CD22 recognizes a second ligand, CD75, expressed predominantly on activated B cells and shown to be a cell surface alpha-2-6 sialytransferase.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP E, BOSTON, MA 02129 USA; BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Harvard University; Harvard Medical School; Bristol-Myers Squibb	STAMENKOVIC, I (corresponding author), MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA.		Sgroi, Dennis/AAV-2487-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], PROG IMMUNOL, DOI DOI 10.1016/B978-0-12-057550-3.50033-8; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUMIAN EL, 1989, LEUKOCYTE TYPING 4, P75; BARTLETT WC, 1990, J IMMUNOL, V145, P3956; BARTLETT WC, 1989, J IMMUNOL, V143, P1745; BOUE DR, 1988, J IMMUNOL, V140, P192; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSTEIN BK, 1989, LEUKOCYTE TYPING 4, P110; GOLAY JT, 1985, J IMMUNOL, V135, P3795; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KISHIMOTO T, 1985, ANNU REV IMMUNOL, V3, P133, DOI 10.1146/annurev.iy.03.040185.001025; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1986, P NATL ACAD SCI USA, V83, P6080, DOI 10.1073/pnas.83.16.6080; LAMMERS G, 1988, J BIOCH, V256, P623; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MORIMOTO C, 1986, J IMMUNOL, V137, P3247; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PULIDO R, 1989, J IMMUNOL, V143, P1930; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SANDERS VM, 1986, J IMMUNOL, V137, P2395; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SCHWARTZALBIEZ R, 1989, LEUKOCYTE TYPING 4, P65; SCHWINZER R, 1989, LEUKOCYTE TYPING, V4, P628; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; STROSS WP, 1989, LEUKOCYTE TYPING, V4, P615; SWAIN SL, 1987, IMMUNOL REV, V99, P263, DOI 10.1111/j.1600-065X.1987.tb01180.x; TAIARA S, 1986, J IMMUNOL, V137, P2448; TEDDER TF, 1985, J IMMUNOL, V135, P973; TERRY LA, 1988, IMMUNOLOGY, V64, P331; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VITETTA ES, 1987, IMMUNOL REV, V99, P193, DOI 10.1111/j.1600-065X.1987.tb01178.x; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WHALEN BJ, 1988, J IMMUNOL, V141, P2230; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WONG JT, 1989, J IMMUNOL, V143, P3404; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	60	370	400	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1133	1144		10.1016/0092-8674(91)90036-X	http://dx.doi.org/10.1016/0092-8674(91)90036-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717156				2022-12-24	WOS:A1991GG55200008
J	COBB, N; ETZEL, RA				COBB, N; ETZEL, RA			UNINTENTIONAL CARBON-MONOXIDE RELATED DEATHS IN THE UNITED-STATES, 1979 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MORTALITY; ARRHYTHMIAS; EXPOSURE; ANGINA	Objective.-To describe the epidemiology of recent unintentional carbon monoxide poisoning deaths in the United States. Design.-Descriptive analysis of carbon monoxide-related deaths in the United States from 1979 through 1988, based on death certificate reports compiled by the National Center for Health Statistics. Population Studied.-All US deaths, 1979 through 1988. Results.-We reviewed data from 56 133 death certificates that contained codes implicating carbon monoxide as a contributing cause of death. Of these, 25 889 were suicides, 21 0 were homicides, 15 523 were associated with severe burns or house fires, and 11 547 were classified as unintentional. The number of unintentional deaths decreased steadily by about 63 deaths per year, from 1513 in 1979 to 878 in 1988. The highest death rates occurred in winter and among males, blacks, the elderly, and residents of northern states. Motor vehicle exhaust gas caused 6552 (57%) of the unintentional deaths; 5432 (83%) of these were associated with stationary automobiles. Conclusions.-The rate of unintentional death from carbon monoxide poisoning is decreasing. This may be attributable to improvements in automobile pollution control systems and improved safety of cooking and heating appliances. Prevention programs should target young drivers, males, and the elderly.			COBB, N (corresponding author), CTR DIS CONTROL, CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976				ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ANDERSON EW, 1973, ANN INTERN MED, V79, P46, DOI 10.7326/0003-4819-79-1-46; DAVIES DM, 1980, ENVIRON RES, V21, P197, DOI 10.1016/0013-9351(80)90022-5; GITTELSOHN A, 1979, AM J PUBLIC HEALTH, V69, P680, DOI 10.2105/AJPH.69.7.680; GLASSER JH, 1981, AM J PUBLIC HEALTH, V71, P231, DOI 10.2105/AJPH.71.3.231; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P793, DOI 10.1001/jama.247.6.793; QUARLES J, 1990, NEW CLEAN AIR ACT GU; SCHAPLOWSKY AF, 1974, J ENV HLTH, V36, P569; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; STERN FB, 1988, AM J EPIDEMIOL, V128, P1276, DOI 10.1093/oxfordjournals.aje.a115081; THOM SR, 1989, J TOXICOL-CLIN TOXIC, V27, P141; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337; 1980, PHS801260 US DEP HLT; 1989, ASHRAE621989 AM SOC; 1979, UNDERLYING CAUSE DEA; 1991, MMWR, V40, P154; 1991, EPA450491004 PUBL	18	218	222	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					659	663		10.1001/jama.266.5.659	http://dx.doi.org/10.1001/jama.266.5.659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	1712865				2022-12-24	WOS:A1991FZ14000023
J	STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C				STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C			STAUFEN, A GENE REQUIRED TO LOCALIZE MATERNAL RNAS IN THE DROSOPHILA EGG	CELL			English	Article							POLAR GRANULES; EFFECT MUTATIONS; ANTEROPOSTERIOR POLARITY; BICOID PROTEIN; EMBRYO; PATTERN; MELANOGASTER; SEGMENTATION; VASA; EXPRESSION	The posterior group gene staufen is required both for the localization of maternal determinants to the posterior pole of the Drosophila egg and for bicoid RNA to localize correctly to the anterior pole. We report the cloning and sequencing of staufen and show that staufen protein is one of the first molecules to localize to the posterior pole of the oocyte, perhaps in association with oskar RNA. Once localized, staufen is found in the polar granules and is required to hold other polar granule components at the posterior pole. By the time the egg is laid, staufen protein is also concentrated at the anterior pole, in the same region as bicoid RNA.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,W-7400 TUBINGEN,GERMANY	Max Planck Society			St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301				AKAM M, 1987, DEVELOPMENT, V101, P1; BERG CA, 1991, GENETICS, V127, P515; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COUNCE SJ, 1963, J MORPHOL, V112, P129, DOI 10.1002/jmor.1051120203; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUNCAN IM, 1982, GENETICS, V102, P49; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King R. C., 1970, OVARIAN DEV DROSOPHI; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHMANN R, 1991, IN PRESS DEVELOPMENT; LEPTIN M, 1990, DEVELOPMENT, V110, P73; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9	49	524	529	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					51	63		10.1016/0092-8674(91)90138-O	http://dx.doi.org/10.1016/0092-8674(91)90138-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712672				2022-12-24	WOS:A1991FW91300008
J	YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU				YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU			A CLASS-III TRANSCRIPTION FACTOR COMPOSED OF RNA	SCIENCE			English	Article							POLYMERASE-III; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; PURIFICATION; RECOGNITION; COMPLEXES; SEQUENCES; REQUIRES; REGION; SIGNAL	It is generally assumed that the machinery that transcribes genes is composed entirely of polypeptides. However, in vitro transcription by silkworm RNA polymerase III requires a transcription factor that is not a polypeptide. This component, TFIIIR, is distinct from the previously identified transcription components: RNA polymerase III, and the accessory factors TFIIIA, TFIIIB, TFIIIC, and TFIIID. The newly discovered TFIIIR is a macromolecule that appears to be composed of RNA. It is resistant to heat, detergent, phenol, protease, and deoxyribonuclease, but it is sensitive to alkali and ribonuclease.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA; UNIV PARMA, INST SCI BIOCHIM, I-43100 PARMA, ITALY	University of Oregon; University of Oregon; University of Oregon; University of Parma					NIGMS NIH HHS [GM 32851, GM 07413, GM 25388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388, R01GM032851] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DUNSTAN H, UNPUB; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HEINS JN, 1967, J BIOL CHEM, V242, P1016; HUANG DD, 1984, SCIENCE, V225, P1482, DOI 10.1126/science.6206568; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; MORTON DG, 1982, MOL CELL BIOL, V2, P1524, DOI 10.1128/MCB.2.12.1524; MOWRY KL, 1988, TRENDS BIOCHEM SCI, V13, P447, DOI 10.1016/0968-0004(88)90220-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PACE NR, 1987, MOL BIOL RNA NEW PER, P17; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANIUK PJ, 1988, MOL BIOL RNA, P123; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SMITH TW, UNPUB; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; SPRAGUE KU, 1987, RNA POLYM REGULATION, P195; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUZUKI Y, 1974, J MOL BIOL, V88, P393, DOI 10.1016/0022-2836(74)90490-2; TANIUCHI H, 1966, J BIOL CHEM, V241, P4366; TOMIZAWA J, 1987, MOL BIOL RNA NEW PER, P249; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	43	48	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					542	546		10.1126/science.1708526	http://dx.doi.org/10.1126/science.1708526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708526				2022-12-24	WOS:A1991FJ12700039
J	BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D				BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D			ALTERED TYROSINE-527 PHOSPHORYLATION AND MITOTIC ACTIVATION OF P60C-SRC	NATURE			English	Article							OVEREXPRESSED PP60C-SRC; PROTEIN-KINASE; MITOSIS; TRANSFORMATION; SITES; ENTRY	The tyrosine kinase activity of p60c-src, the protein of the c-src gene, increase during mitosis 1,2; this may be important in initiating at least some of the cellular changes that occur during this phase of the cell cycle. Although there is evidence that p60c-src is phosphorylated at several sites during mitosis, phosphorylation in vitro does not increase its kinase activity 2,3. We now report that this kinase activity of a p60c-src mutant with residue tyrosine 527 changed to phenylanine does not change during the cell cycle, suggesting that changes in the phosphorylation state of this residue may be responsible for the activation of p60c-src at mitosis. Although changes in phosphorylation at Tyr527 cannot be detected with the wild-type protein we find that phosphorylation at Tyr527 of a mutant with reduced kinase activity decreased threefold during mitosis. On the basis of these results we suggest that activation of p60c-src at mitosis results from decreased phosphorylation on Tyr 527, and that p60c-src may be or may activate the kinase that phosphorylates Tyr 527.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; CORNELL UNIV,DEPT PATHOL,ITHACA,NY 14853	Cornell University; Cornell University				Kmiecik, Thomas/0000-0002-1367-443X				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; 1987, TP007 MILL INT; 1987, TP006 MILL INT	17	121	122	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					172	175		10.1038/349172a0	http://dx.doi.org/10.1038/349172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1702522				2022-12-24	WOS:A1991ER41800064
J	KALINKE, U; ARNOLD, B; HAMMERLING, GJ				KALINKE, U; ARNOLD, B; HAMMERLING, GJ			STRONG XENOGENEIC HLA RESPONSE IN TRANSGENIC MICE AFTER INTRODUCING AN ALPHA-3 DOMAIN INTO HLA-B27	NATURE			English	Article											KALINKE, U (corresponding author), GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.			Kalinke, Ulrich/0000-0003-0503-9564				ALTER BJ, 1990, J EXP MED, V171, P333, DOI 10.1084/jem.171.1.333; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; COPPIN HL, 1986, J IMMUNOL, V137, P2168; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DILL O, 1988, P NATL ACAD SCI USA, V85, P5664, DOI 10.1073/pnas.85.15.5664; DUTTON RW, 1978, IMMUNOL REV, V42, P20, DOI 10.1111/j.1600-065X.1978.tb00257.x; ENGELHARD VH, 1978, P NATL ACAD SCI USA, V75, P5688, DOI 10.1073/pnas.75.11.5688; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HAMMERLING GJ, 1989, EUR J IMMUNOL, V19, P599, DOI 10.1002/eji.1830190404; HINES DL, 1976, TRANSPLANTATION, V21, P375, DOI 10.1097/00007890-197605000-00003; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; KIEVITS F, 1989, P NATL ACAD SCI USA, V86, P617, DOI 10.1073/pnas.86.2.617; KOLLER BH, 1985, J IMMUNOL, V134, P2727; KRIMPENFORT P, 1987, EMBO J, V6, P1673, DOI 10.1002/j.1460-2075.1987.tb02416.x; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAZIARZ RT, 1988, J IMMUNOL, V140, P4372; OZATO K, 1983, P NATL ACAD SCI-BIOL, V80, P2040, DOI 10.1073/pnas.80.7.2040; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAMBERG NL, 1989, EUR J IMMUNOL, V19, P2349, DOI 10.1002/eji.1830191225; SHIMONKEVITZ R, 1985, J IMMUNOL, V135, P892; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; WIDMER MB, 1972, J EXP MED, V135, P1204, DOI 10.1084/jem.135.5.1204; WILSON DB, 1971, J EXP MED, V134, P857, DOI 10.1084/jem.134.4.857	29	97	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 13	1990	348	6302					642	644		10.1038/348642a0	http://dx.doi.org/10.1038/348642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM760	1701221				2022-12-24	WOS:A1990EM76000063
J	GLINIAK, BC; ROHRSCHNEIDER, LR				GLINIAK, BC; ROHRSCHNEIDER, LR			EXPRESSION OF THE M-CSF RECEPTOR IS CONTROLLED POSTTRANSCRIPTIONALLY BY THE DOMINANT ACTIONS OF GM-CSF OR MULTI-CSF	CELL			English	Article											GLINIAK, BC (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA020551, R01CA040987] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40987, CA 20551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BURGESS AW, 1980, INT J CANCER, V26, P647, DOI 10.1002/ijc.2910260517; BURGESS AW, 1977, EXPT HEMATOLOGY TODA, P135; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEXTER TM, 1980, J EXP MED, V152, P1026; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DONAHUE RE, 1986, NATURE, V321, P872, DOI 10.1038/321872a0; ETTENSOHN CA, 1990, SCIENCE, V248, P1115, DOI 10.1126/science.2188366; ETTENSOHN CA, 1988, DEV BIOL, V125, P396, DOI 10.1016/0012-1606(88)90220-5; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HAPEL AJ, 1984, BLOOD, V64, P786; HOLMES KL, 1988, IMMUNOL TODAY, V9, P344, DOI 10.1016/0167-5699(88)91335-7; IKEBUCHI K, 1988, P NATL ACAD SCI USA, V85, P3445, DOI 10.1073/pnas.85.10.3445; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOIKE K, 1986, BLOOD, V67, P859; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; Maniatis T., 1982, MOL CLONING; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1984, HEMOPOIETIC COLONIES; METCALF D, 1989, MOL CONTROL BLOOD CE; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; OGAWA M, 1983, BLOOD, V61, P823; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SXHULER GD, 1988, CELL, V55, P1115; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WILLIAMS DE, 1987, EXP HEMATOL, V15, P243; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	52	124	125	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 30	1990	63	5					1073	1083		10.1016/0092-8674(90)90510-L	http://dx.doi.org/10.1016/0092-8674(90)90510-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701692				2022-12-24	WOS:A1990EL75900022
J	GARRY, RF; FERMIN, CD; HART, DJ; ALEXANDER, SS; DONEHOWER, LA; HONG, LZ				GARRY, RF; FERMIN, CD; HART, DJ; ALEXANDER, SS; DONEHOWER, LA; HONG, LZ			DETECTION OF A HUMAN INTRACISTERNAL A-TYPE RETROVIRAL PARTICLE ANTIGENICALLY RELATED TO HIV	SCIENCE			English	Article									CAMBRIDGE BIOTECH CORP,ROCKVILLE,MD 20850; TULANE UNIV,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112; BAYLOR UNIV,DIV MOLEC VIROL,HOUSTON,TX 77030	Tulane University; Baylor University	GARRY, RF (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NEW ORLEANS,LA 70112, USA.			Garry, Robert/0000-0002-5683-3250	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022720, R01AI028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000712] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22720, AI 28048] Funding Source: Medline; NIDCD NIH HHS [DC 00712] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALEXANDER S, UNPUB; CALARCO PG, 1973, NATURE-NEW BIOL, V243, P91; CIAMPOLILLO A, 1989, LANCET, V1, P1096; CRAWFORD TB, 1980, SCIENCE, V207, P997, DOI 10.1126/science.6153243; DUVIC M, 1987, J AM ACAD DERMATOL, V17, P656, DOI 10.1016/S0190-9622(87)70252-7; FERMIN CD, UNPUB; GARRY RF, UNPUB; GOTTLIEB A A, 1979, Wakayama Medical Reports, V21, P107; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HART DT, UNPUB; HERMANN M, 1989, MOL CELLULAR MECHANI; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; KOWALSKI M, 1989, P NATL ACAD SCI USA, V86, P3346, DOI 10.1073/pnas.86.9.3346; KRIEG AM, 1988, VIROLOGY, V162, P274, DOI 10.1016/0042-6822(88)90422-9; KUFF EL, 1968, CANCER RES, V28, P2137; KUFF EL, 1988, ADV CANCER RES, V51, P184; LEITER EH, 1986, J EXP MED, V163, P87, DOI 10.1084/jem.163.1.87; LEVY JA, 1975, J VIROL, V16, P844, DOI 10.1128/JVI.16.4.844-853.1975; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; RASHEED S, 1986, VIROLOGY, V154, P395, DOI 10.1016/0042-6822(86)90465-4; ROBERTSON DL, 1975, J VIROL, V15, P407, DOI 10.1128/JVI.15.2.407-415.1975; RUCHETON M, 1985, VIROLOGY, V144, P468, DOI 10.1016/0042-6822(85)90287-9; SARNGADHARAN MG, 1978, BIOCHIM BIOPHYS ACTA, V516, P419, DOI 10.1016/0304-419X(78)90019-7; SCHIODT M, 1989, AIDS, V3, P819, DOI 10.1097/00002030-198912000-00006; STRICKER RB, 1987, NATURE, V327, P710, DOI 10.1038/327710a0; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; TALAL N, 1990, ARTHRITIS RHEUM, V33, P774, DOI 10.1002/art.1780330603; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; WAITE MRF, 1975, J VIROL, V16, P872, DOI 10.1128/JVI.16.4.872-879.1975; WILSON SH, 1972, P NATL ACAD SCI USA, V69, P1531, DOI 10.1073/pnas.69.6.1531; WONGSTAAL F, 1975, J VIROL, V16, P887, DOI 10.1128/JVI.16.4.887-896.1975; YANG SS, 1973, J VIROL, V11, P287, DOI 10.1128/JVI.11.2.287-298.1973; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2	35	224	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 23	1990	250	4984					1127	1129		10.1126/science.1701273	http://dx.doi.org/10.1126/science.1701273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701273				2022-12-24	WOS:A1990EJ58100033
J	ALVAREZBUYLLA, A; KIRN, JR; NOTTEBOHM, F				ALVAREZBUYLLA, A; KIRN, JR; NOTTEBOHM, F			BIRTH OF PROJECTION NEURONS IN ADULT AVIAN BRAIN MAY BE RELATED TO PERCEPTUAL OR MOTOR LEARNING	SCIENCE			English	Article											ALVAREZBUYLLA, A (corresponding author), ROCKEFELLER UNIV,FIELD RES CTR,TYRREL RD,RR2,BOX 38B,MILLBROOK,NY 12545, USA.			Alvarez-Buylla, Arturo/0000-0003-4426-8925	NIMH NIH HHS [MH18343] Funding Source: Medline; NINDS NIH HHS [NS28478, NS08340] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018343, R37MH018343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028478, R01NS028478, F32NS008340, R37NS028478] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1988, J NEUROSCI METH, V25, P165, DOI 10.1016/0165-0270(88)90155-0; ALVAREZBUYLLA A, 1988, P NATL ACAD SCI USA, V85, P8722, DOI 10.1073/pnas.85.22.8722; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BOTTJER SW, 1986, NEUROSCI LETT, V67, P263, DOI 10.1016/0304-3940(86)90319-8; BOTTJER SW, 1989, J COMP NEUROL, V279, P312, DOI 10.1002/cne.902790211; EALES LA, 1985, ANIM BEHAV, V33, P1293, DOI 10.1016/S0003-3472(85)80189-5; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; HINDE RA, 1969, BIRD VOCALIZATIONS, P61; Jacobson M., 2013, DEV NEUROBIOL; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KIRN JR, 1989, J NEUROSCI, V9, P3176; KONISHI M, 1985, NATURE, V315, P145, DOI 10.1038/315145a0; KORDOWER JH, 1990, J COMP NEUROL, V291, P637, DOI 10.1002/cne.902910410; MARGOLIASH D, 1986, J NEUROSCI, V6, P1643; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; NORDEEN EJ, 1990, TRENDS NEUROSCI, V13, P31, DOI 10.1016/0166-2236(90)90060-N; NORDEEN KW, 1988, NATURE, V334, P149, DOI 10.1038/334149a0; NORDEEN KW, 1989, J NEUROBIOL, V20, P651, DOI 10.1002/neu.480200705; NOTTEBOHM F, 1984, CONDOR, V86, P227, DOI 10.2307/1366988; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; NOTTEBOHM F, 1981, BRAIN RES, V213, P99, DOI 10.1016/0006-8993(81)91250-6; NOTTEBOHM F, 1986, BEHAV NEURAL BIOL, V46, P445, DOI 10.1016/S0163-1047(86)90485-1; NOTTEBOHM F, 1978, Z TIERPSYCHOL, V46, P298; NOTTEBOHM F, 1982, J COMP NEUROL, V207, P344, DOI 10.1002/cne.902070406; Nottebohm F., 1980, PROGR PSYCHOBIOLOGY, V9, P85; NOTTEBOHM F, IN PRESS PHILOS T B; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; PATON JA, 1985, J NEUROSCI, V5, P3088; REH TA, 1989, J NEUROSCI, V9, P4179; SIMPSON HB, 1990, J NEUROSCI, V10, P1541; WILLIAMS H, 1985, SCIENCE, V229, P279, DOI 10.1126/science.4012321	34	223	229	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 21	1990	249	4975					1444	1446		10.1126/science.1698312	http://dx.doi.org/10.1126/science.1698312			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ451	1698312				2022-12-24	WOS:A1990DZ45100049
J	SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS				SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS			A CASE CONTROL STUDY OF SCREENING SIGMOIDOSCOPY AND MORTALITY FROM COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL-CANCER; FOLLOW-UP; EFFICACY; DEFINITION; POLYPS	Background. The efficacy of sigmoidoscopic screening in reducing mortality from colorectal cancer remains uncertain. A randomized trial would be ideal for clarifying this issue but is very difficult to conduct. Case-control studies provide an alternative method of estimating the efficacy of screening sigmoidoscopy. Methods. Using data on the 261 members of the Kaiser Permanente Medical Care Program who died of cancer of the rectum or distal colon from 1971 to 1988, we examined the use of screening by rigid sigmoidoscopy during the 10 years before the diagnosis and compared it with the use of screening in 868 control subjects matched with the case subjects for age and sex. Results. Only 8.8 percent of the case subjects had undergone screening by sigmoidoscopy, as compared with 24.2 percent of the controls (matched odds ratio, 0.30; 95 percent confidence interval, 0.19 to 0.48). Adjustment for potential confounding factors increased the odds ratio to 0.41 (95 percent confidence interval, 0.25 to 0.69). The negative association was as strong when the most recent sigmoidoscopy was 9 to 10 years before diagnosis as it was when examinations were more recent. By contrast, for 268 subjects with fatal colon cancer above the reach of the sigmoidoscope and for 268 controls, the adjusted odds ratio was 0.96 (95 percent confidence interval, 0.61 to 1.50). The specificity of the negative association for cancer within the reach of the sigmoidoscope is consistent with a true efficacy of screening rather than a confounding by unmeasured selection factors. Conclusions. Screening by sigmoidoscopy can reduce mortality from cancer of the rectum and distal colon. Screening once every 10 years may be nearly as efficacious as more frequent screening.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3451 PIEDMONT AVE, OAKLAND, CA 94611 USA.				NATIONAL CANCER INSTITUTE [R35CA049761, R01CA046569] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46569, R35 CA49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; BOHLMAN TW, 1977, GASTROENTEROLOGY, V72, P644; CLARKE EA, 1979, LANCET, V2, P1; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; GLICK SN, 1989, AM J ROENTGENOL, V152, P513, DOI 10.2214/ajr.152.3.513; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; KOZUKA S, 1975, DIS COLON RECTUM, V18, P494, DOI 10.1007/BF02587218; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; MACGREGOR JE, 1985, BMJ-BRIT MED J, V290, P1543, DOI 10.1136/bmj.290.6481.1543; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P108; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1989, AM J EPIDEMIOL, V130, P827; RHOADS GG, 1984, AM J EPIDEMIOL, V120, P803, DOI 10.1093/oxfordjournals.aje.a113952; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SCHAPIRO M, 1984, DIGEST DIS SCI, V29, P159, DOI 10.1007/BF01317058; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VERBEEK ALM, 1984, LANCET, V1, P1222; VERNON SW, 1990, J OCCUP ENVIRON MED, V32, P46, DOI 10.1097/00043764-199001000-00013; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; WILLIAMS CB, 1990, J GASTROEN HEPATOL, V5, P144, DOI 10.1111/j.1440-1746.1990.tb01787.x; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; 1987, GASTROINTEST ENDOSC, V33, P167; 1979, CAN MED ASS J, V121, P1193	29	1422	1445	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					653	657		10.1056/NEJM199203053261001	http://dx.doi.org/10.1056/NEJM199203053261001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736103				2022-12-24	WOS:A1992HG11700001
J	NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H				NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H			LOW-DOSE SPLENIC IRRADIATION IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA IN HIV-INFECTED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Note						PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; HUMAN IMMUNODEFICIENCY VIRUS; PREDNISONE; THROMBOCYTOPENIA; RADIOTHERAPY; SPLENECTOMY	RISK	Autoimmune thrombocytopenic purpura (AITP) can complicate the course of human immunodeficiency virus type-1 (HIV)-infected patients. Treatment of these patients with prednisone is problematic because the drug is immunosuppressive. Other modalities are available, but patients often must have splenectomy, which yields effective long-term control comparable to that seen in AITP that is not associated with HIV infection. Splenectomy, however, exposes the patient to substantial perioperative morbidity and mortality. We reasoned that low-dose splenic irradiation may be an effective alternative to splenectomy and obviate the invasive complications of surgery. We present three patients who had splenic irradiation instead of splenectomy and tolerated it well. Howell-Jolly bodies did not appear at any time after the radiation, and durable remission of the AITP was achieved. We conclude that low-dose splenic irradiation may be a safe and effective alternative to splenectomy in HIV-infected patients who suffer from AITP, and that it should be studied further.	UNIV MARYLAND HOSP, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	NEEDLEMAN, SW (corresponding author), BALTIMORE DEPT VET AFFAIRS MED CTR, MED SERV 111, 3900 LOCH RAVEN BLVD, BALTIMORE, MD 21218 USA.							ABOULAFIA DM, 1991, HEMATOL ONCOL CLIN N, V5, P195, DOI 10.1016/S0889-8588(18)30436-2; KARPATKIN S, 1990, HEMATOL ONCOL CLIN N, V4, P193, DOI 10.1016/S0889-8588(18)30513-6; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROBINETTE CD, 1977, LANCET, V2, P127; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SHAFER RW, 1985, LANCET, V1, P934; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; WALSH CM, 1984, NEW ENGL J MED, V311, P635, DOI 10.1056/NEJM198409063111004; WOLF BC, 1989, DISORDERS SPLEEN, P39; YU JR, 1986, J CLIN INVEST, V77, P1756, DOI 10.1172/JCI112498	10	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					310	311		10.7326/0003-4819-116-4-310	http://dx.doi.org/10.7326/0003-4819-116-4-310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733386				2022-12-24	WOS:A1992HD54600007
J	SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA				SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA			RISK-FACTORS FOR DELIRIUM IN HOSPITALIZED ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; BACTERIAL-MENINGITIS; DEMENTIA; AGE	Objective. - To determine risk factors for delirium in elderly hospitalized patients. Design. - Cohort analytic study. Using a reliable and valid instrument for detection of delirium, we prospectively followed up a cohort of elderly patients admitted to an acute care hospital. Using standardized criteria, we collected risk factor data from patient medical records. Setting. - General medical and surgical wards of a tertiary-care hospital. Patients. - Patients (n = 325) were 65 years of age or older, from either a geographically defined community or a long-term-care institution. We studied those patients (n = 291) not delirious on first evaluation. Fifty-seven patients or their families refused participation. Main Outcome Measures. - Incidence of delirium and risk factors calculated as adjusted odds ratios (ORs). Main Results. - Delirium developed in 91 patients. By stepwise logistic regression, the independent risk factors for in-hospital delirium included prior cognitive impairment (OR, 8.97; 95% confidence interval [Cl], 3.99 to 20.14), age over 80 years (OR, 5.22; 95% Cl, 2.60 to 10.46), fracture on admission (OR, 6.57; 95% Cl, 2.23 to 19.33), symptomatic infection (OR, 2.96; 95% Cl, 1.42 to 6.15), and male sex (OR, 2.40; 95% Cl, 1.19 to 4.84). Among medication groups, only neuroleptic use (OR, 4.48; 95% Cl, 1.82 to 10.45) and narcotic use (OR, 2.54; 955 Cl, 1.24 to 5.18) were independently associated with delirium. Anticholinergic use was not associated with delirium. Conclusions. - Delirium in hospitalized patients is most closely associated with factors already present on admission such as prior cognitive impairment, advanced age, and fracture. In the hospital, use of neuroleptics and narcotics and the presence of infection are less strongly associated with this syndrome.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CTR RES HLTH & AGING, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	Rush University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai			Cleary, Paul/AAF-7048-2019					ALBERT MS, IN PRESS J GERIATR P; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BERNSTEIN S, 1967, NEW ENGL J MED, V277, P638, DOI 10.1056/NEJM196709212771206; BILBERT VE, 1968, METABOLISM, V17, P943; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DJOKOVIC JL, 1979, JAMA-J AM MED ASSOC, V242, P2301, DOI 10.1001/jama.242.21.2301; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ENGEL G L, 1959, J Chronic Dis, V9, P260, DOI 10.1016/0021-9681(59)90165-1; ERKINJUNTTI T, 1986, ARCH INTERN MED, V146, P1923, DOI 10.1001/archinte.146.10.1923; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KADLECOVA O, 1974, J HYG EPID MICROB IM, V18, P472; LEVKOFF SE, IN PRESS ARCH INTERN; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; LIPOWSKI ZJ, 1990, DELIRIUM ACUTE CONFU, P229; NORMAN DC, 1983, J AM GERIATR SOC, V31, P677, DOI 10.1111/j.1532-5415.1983.tb04154.x; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; SIMON ALEXANDER, 1963, PSYCHIAT RES REPTS, V16, P8; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1988, BRAIN RES REV, V13, P371, DOI 10.1016/0165-0173(88)90013-6; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; VERGHESE A, 1983, MEDICINE, V62, P271, DOI 10.1097/00005792-198309000-00002; VERGHESE A, 1985, AM J MED, V79, P370, DOI 10.1016/0002-9343(85)90316-X; 1987, DIAGNOSTIC STATISTIC, P100	34	344	351	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					827	831		10.1001/jama.267.6.827	http://dx.doi.org/10.1001/jama.267.6.827			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732655				2022-12-24	WOS:A1992HC48400028
J	ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG				ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG			POTENTIALLY AMYLOIDOGENIC, CARBOXYL-TERMINAL DERIVATIVES OF THE AMYLOID PROTEIN-PRECURSOR	SCIENCE			English	Article							ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; IDENTIFICATION; PHOSPHORYLATION; BIOGENESIS; SULFATE; PEPTIDE	The 39- to 43-amino acid amyloid beta-protein (beta-AP), which is deposited as amyloid in Alzheimer's disease, is encoded as an internal peptide that begins 99 residues from the carboxyl terminus of a 695- to 770-amino acid glycoprotein referred to as the amyloid beta-protein precursor (beta-APP). To clarify the processing that produces amyloid, carboxyl-terminal derivatives of the beta-APP were analyzed. This analysis showed that the beta-APP is normally processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives. The two largest derivatives in human brain have the entire beta-AP at or near their amino terminus and are likely to be intermediates in the pathway leading to amyloid deposition.	NATL INST NEUROSCI,KODAIRA,TOKYO 187,JAPAN; UPJOHN CO,KALAMAZOO,MI 49001	National Center for Neurology & Psychiatry - Japan; Pfizer	ESTUS, S (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.			Lowery, David/0000-0001-5111-4719	NIA NIH HHS [AG06656, AG08012, AG08992] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006656, P50AG008012, R35AG008992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HARLOW E, 1988, ANTIBODIES LABORATOR; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	18	410	437	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					726	728		10.1126/science.1738846	http://dx.doi.org/10.1126/science.1738846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738846				2022-12-24	WOS:A1992HC50600041
J	GLIMCHER, PW; SPARKS, DL				GLIMCHER, PW; SPARKS, DL			MOVEMENT SELECTION IN ADVANCE OF ACTION IN THE SUPERIOR COLLICULUS	NATURE			English	Article							EYE-MOVEMENTS; BEHAVING MONKEY; DISCRIMINATION; NEURONS	THE primate superior colliculus contains a map of saccadic eye movements 1,2. Saccades are high-velocity eye movements to selected targets in the visual field, but little is known about the neural mechanisms responsible for target selection or the related problem of choosing a particular movement from the oculomotor repertoire. Two classes of neurons have been described in the superior colliculus which show bursts of activity before the saccade: discrete bursters display a vigorous pre-saccadic burst and prelude bursters 3 show low-frequency activity as a prelude to burst onset. We have designed experiments to test whether prelude activity is related to saccade selection. Our tasks use a cue to specify which of two physically identical visual stimuli is the goal of an impending saccade. This cue is spatially and temporally isolated from the potential targets as well as from visual cues signalling movement initiation. Our results show that prelude activity occurs shortly after information is available for correct saccade selection and, more importantly, the activity is predictive of saccade choice. The results thus suggest that the superior colliculus participates in the process of saccade selection.			GLIMCHER, PW (corresponding author), UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104, USA.			Glimcher, Paul/0000-0001-7872-3856				BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464, DOI 10.1152/jn.1991.65.6.1464; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAYS LE, 1980, SCIENCE, V208, P1163, DOI 10.1126/science.6769161; OTTES FP, 1985, VISION RES, V25, P849, DOI 10.1016/0042-6989(85)90193-2; OTTES FP, 1987, EXP BRAIN RES, V66, P465, DOI 10.1007/BF00270679; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1987, J NEUROPHYSIOL, V58, P300, DOI 10.1152/jn.1987.58.2.300; SPARKS DL, 1976, BRAIN RES, V113, P21, DOI 10.1016/0006-8993(76)90003-2; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	13	229	231	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					542	545		10.1038/355542a0	http://dx.doi.org/10.1038/355542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741032				2022-12-24	WOS:A1992HC52600057
J	COX, NH; WAGSTAFF, R; POPPLE, AW				COX, NH; WAGSTAFF, R; POPPLE, AW			USING CLINICOPATHOLOGICAL ANALYSIS OF GENERAL-PRACTITIONER SKIN SURGERY TO DETERMINE EDUCATIONAL REQUIREMENTS AND GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the impact of skin surgery in general practice on the workload of a pathology laboratory and to identify what further training might be helpful. Design - Analysis of skin biopsy specimens from general practitioners before and after their new contract to determine numbers of specimens, changes in diagnoses, adequacy of treatment of malignant tumours, and areas of low diagnostic accuracy. Setting - District general hospital. Subjects - All 1017 skin biopsy specimens from general practice for 15 months before and 12 months after the new general practitioner contract. Results - The number of pathology specimens received increased from 16 to 65 per month (median = 6 submitted by each general practitioner in the post-contract year). The proportion of the more common pathological diagnoses was unchanged between the two periods, but the proportion of correctly diagnosed naevi, cysts, and seborrhoeic keratoses increased in the second. Although few diagnoses were overtly incorrect, accurate diagnosis of dermatofibromas and malignancies decreased after the contract, and the overall correct diagnosis rate for seborrhoeic keratoses, dermatofibromas, rashes, and malignancies was below 30%. Only nine out of 21 squamous cell carcinomas were adequately excised with tumour free margins, and follow up of malignant tumours may have been inadequate. Conclusions - Skin surgery in general practice has advantages but matters of concern are the increase in laboratory workload, the excision of some benign lesions, and the inappropriateness of biopsy of rashes. Squamous cell carcinoma and other malignant tumours submitted for pathological examination were often unsuspected and inadequately excised, and heightened suspicion is recommended. Pathology request forms may need redesigning to encourage provision of clinical details.			COX, NH (corresponding author), CUMBERLAND INFIRM,CARLISLE CA2 7HY,ENGLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; DANDO P, 1991, J MED DEFENCE UNION, V1, P12; Godfrey E, 1990, Health Trends, V22, P57; HUNT AC, 1991, BMJ, V301, P495; MORGAN DR, 1991, BMJ, V300, P1379; NIXON RL, 1986, MED J AUSTRALIA, V144, P235, DOI 10.5694/j.1326-5377.1986.tb115884.x; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; PRINGLE M, 1991, BRIT MED J, V302, P830, DOI 10.1136/bmj.302.6780.830; RICHARDS T, 1991, BMJ, V301, P307; SHARMAN J, 1986, PRACTITIONER, V230, P27; SHRANK AB, 1990, HLTH TRENDS, V22, P181; SLATER DN, 1991, BMJ, V300, P1074; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; ZOLTIE N, 1991, BRIT MED J, V302, P941, DOI 10.1136/bmj.302.6782.941; 1989, GENERAL PRACTICE NAT	15	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					93	96		10.1136/bmj.304.6819.93	http://dx.doi.org/10.1136/bmj.304.6819.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737150	Green Published, Bronze			2022-12-24	WOS:A1992HA17100026
J	LINDEN, DJ; CONNOR, JA				LINDEN, DJ; CONNOR, JA			PARTICIPATION OF POSTSYNAPTIC PKC IN CEREBELLAR LONG-TERM DEPRESSION IN CULTURE	SCIENCE			English	Article							PROTEIN KINASE-C; PURKINJE-CELL DENDRITES; EXCITATORY AMINO-ACIDS; CLIMBING FIBER; GRANULE CELL; GLUTAMATE SENSITIVITY; CALCIUM; INDUCTION; INVITRO; POTENTIATION	Long-term depression (LTD) in the intact cerebellum is a decrease in the efficacy of the parallel fiber-Purkinje neuron synapse induced by coactivation of climbing fiber and parallel fiber inputs. In cultured Purkinje neurons, a similar depression can be induced by iontophoretic glutamate pulses and Purkinje neuron depolarization. This form of LTD is expressed as a depression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-mediated current, and its induction is dependent on activation of metabotropic quisqualate receptors. The effect of inhibitors of protein kinase C (PKC) on LTD induction was studied. Inhibitors of PKC blocked LTD induction, while phorbol-12,13-diacetate (PDA), a PKC activator, mimicked LTD. These results suggest that PKC activation is necessary for the induction of cerebellar LTD.			LINDEN, DJ (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110, USA.							AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; EKEROT CF, 1981, J PHYSIOL-LONDON, V318, P207; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1990, NEUROSCI LETT, V119, P141, DOI 10.1016/0304-3940(90)90818-T; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LINDEN DJ, UNPUB; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SANGAMESWARAN L, 1989, P NATL ACAD SCI USA, V86, P5651, DOI 10.1073/pnas.86.14.5651; SCHILLING K, IN PRESS NEURON; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; THOMASSET M, 1984, DEV PHARMACOL THERAP, V7, P6, DOI 10.1159/000457220; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519	38	266	272	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1656	1659		10.1126/science.1721243	http://dx.doi.org/10.1126/science.1721243			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721243				2022-12-24	WOS:A1991GV07300049
J	SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE				SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE			DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD BY MEANS OF REVERSE-TRANSCRIPTASE AND POLYMERASE CHAIN-REACTION	LANCET			English	Article							HUMAN MALIGNANT-MELANOMA; GENE; AMPLIFICATION; TYROSINASE; INSERTION; SEQUENCE; DNA	Only small numbers of cells from solid tumours are needed for haematogenous metastasis. Detection is difficult because existing techniques are not sensitive enough. We have used reverse transcriptase to make complementary DNA from peripheral blood messenger RNA, and the polymerase chain reaction (PCR) to amplify cDNA specific for a gene actively transcribed only in the tumour tissue type. We prepared cDNA from peripheral blood of seven patients with malignant melanoma, four patients with other metastatic cancers, and four healthy subjects, as well as from several melanoma-derived cell lines. PCR was used to amplify the gene for tyrosinase, a tissue-specific gene in melanocytes. Since normal melanocytes are not thought to circulate in peripheral blood, detection of tyrosinase transcription in peripheral blood should indicate the presence of circulating cancer cells. The method was highly sensitive and could detect a single melanoma cell from a cell line in 2 ml normal blood. Blood samples from four of the seven patients with malignant melanoma gave positive results, whereas all eight control subjects gave negative results. This method does not depend on the characterisation of cancer-specific genetic abnormalities and can be applied to any cancer for which tissue-specific genes can be identified, including epithelial cancers. It could prove useful in the diagnosis of primary or metastatic cancers, in assessing prognosis, and in detecting residual disease after treatment.	ST JAMES UNIV HOSP,INST CANC STUDIES,YORKSHIRE CANC RES CAMPAIGN,BECKETT ST,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Saint James's University Hospital; University of Leeds			Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LIAO SK, 1975, J NATL CANCER I, V54, P1037; LO YMD, 1989, LANCET, V2, P1363; LYONS J, 1990, PCR PROTOCOLS GUIDE, P386; MOSS TJ, 1990, J CLIN ONCOL, V8, P736, DOI 10.1200/JCO.1990.8.4.736; NAITO H, 1991, EUR J CANCER, V27, P762, DOI 10.1016/0277-5379(91)90184-F; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; TARIN D, 1984, BRIT MED J, V288, P749, DOI 10.1136/bmj.288.6419.749; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563	15	583	629	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1227	1229		10.1016/0140-6736(91)92100-G	http://dx.doi.org/10.1016/0140-6736(91)92100-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1719320				2022-12-24	WOS:A1991GQ16600002
J	DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ				DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ			REQUIREMENT FOR MAST-CELL GROWTH-FACTOR FOR PRIMORDIAL GERM-CELL SURVIVAL IN CULTURE	NATURE			English	Article							RECEPTOR TYROSINE KINASES; C-KIT; SI-LOCUS; LIGAND; MOUSE; IDENTIFICATION; PROGENITORS; EXPRESSION; CLONING; RAT	MAST-CELL growth factor (MGF) is encoded by the murine steel (Sl) locus and is a ligand for the tyrosine kinase receptor protein encoded by the proto-oncogene c-kit at the murine dominant white spotting (W) locus. Mutations at both these loci affect mast cells, primordial germ cells (PGCs), haemopoietic stem cells and melanocytes. In many Sl and W mutants, the rapid proliferation of PGC that normally occurs between day 7 and 13.5 of embryonic development fails to occur. As c-kit is expressed in PGCs 1,2 while MGF is expressed in the surrounding mesenchyme 2,3, MGF might promote the proliferation of PGCs. Here we report that MGF is essential for PGC survival in culture, but does not stimulate PGC proliferation. Moreover, whereas both the transmembrane and soluble proteolytic cleavage forms of MGF stimulate mast-cell proliferation, soluble MGF has a relatively limited ability to support survival of PGCs in culture, thus explaining the sterility in mice carrying the steel-dickie (Sl(d)) mutation, which encodes only a soluble form of MGF, and providing a functional role for a transmembrane growth factor.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CARCINOGENESIS LAB,FREDERICK,MD 21702; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; UNIV ROME TOR VERGATA 2,DIPARTIMENTO SANITA PUBBL & BIOL CELLULARE,I-00173 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Immunex Corporation; Immunex Corporation; Indiana University System; Indiana University-Purdue University Indianapolis; University of Rome Tor Vergata			dolci, susanna/B-8363-2013	dolci, susanna/0000-0002-6864-3673				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BOSWELL HS, 1987, EXP HEMATOL, V15, P46; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAIRNS L, 1987, THESIS U LOND; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KESHET E, IN PRESS EMBO J; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCCOSHEN JA, 1975, EXPERIENTIA, V31, P589, DOI 10.1007/BF01932475; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORR UA, 1990, DEVELOPMENT, V109, P911; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	26	437	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					809	811		10.1038/352809a0	http://dx.doi.org/10.1038/352809a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715518				2022-12-24	WOS:A1991GC96400062
J	LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL				LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL			CALCINEURIN IS A COMMON TARGET OF CYCLOPHILIN-CYCLOSPORINE-A AND FKBP-FK506 COMPLEXES	CELL			English	Article							T-CELL ACTIVATION; DEPENDENT PROTEIN PHOSPHATASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; LIMITED PROTEOLYSIS; MACROLIDES FK-506; CALCIUM-BINDING; CALMODULIN	Although the immediate receptors (immunophilins) of the immunosuppressants cyclosporin A (CsA) and FK506 are distinct, their similar mechanisms of inhibition of cell signaling suggest that their associated immunophilin complexes interact with a common target. We report here that the complexes cyclophilin-CsA and FKBP-FK506 (but not cyclophilin, FKBP, FKBP-rapamycin, or FKBP-506BD) competitively bind to and inhibit the Ca2+- and calmodulin-dependent phosphatase calcineurin, although the binding and inhibition of calcineurin do not require calmodulin. These results suggest that calcineurin is involved in a common step associated with T cell receptor and IgE receptor signaling pathways and that cyclophilin and FKBP mediate the actions of CsA and FK506, respectively, by forming drug-dependent complexes with and altering the activity of calcineurin-calmodulin.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Harvard University; Howard Hughes Medical Institute; Stanford University	LIU, J (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.				NCI NIH HHS [5T32 CA 09302] Funding Source: Medline; NIGMS NIH HHS [GM-40660, GM-38627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627, P01GM040660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, IN PRESS SCIENCE; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JOHANSSON A, 1990, TRANSPLANTATION, V50, P1001, DOI 10.1097/00007890-199012000-00021; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	43	3630	3852	12	239	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					807	815		10.1016/0092-8674(91)90124-H	http://dx.doi.org/10.1016/0092-8674(91)90124-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1715244				2022-12-24	WOS:A1991GC74500019
J	BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q				BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q			DEFECTIVE ACIDIFICATION OF INTRACELLULAR ORGANELLES IN CYSTIC-FIBROSIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CONDUCTANCE; GOLGI-APPARATUS; RAT-LIVER; GLYCOPROTEINS; GANGLIOSIDES; BIOSYNTHESIS; FIBROBLASTS; EPITHELIUM; CHANNELS	THE phenotype of cystic fibrosis (CF) includes abnormalities in transepithelial transport of Cl- (refs 1-5), decreased sialylation and increased sulphation and fucosylation of glycoproteins 6-9, and lung colonization with Pseudomonas. It is not apparent how these abnormalities are interrelated, nor how they result from loss of function of the CF gene-encoded transmembrane regulator (CFTR) 10. We have previously shown that that the pH of a secretory granule is regulated by the vesicular conductance for Cl- (ref. 11). Here we find defective acidification in CF cells of the trans-Golgi/trans-Golgi network, of prelysosomes and of endosomes as a result of diminished Cl- conductance. Sialylation of proteins and lipids is reduced and ligand traffic altered. These abnormalities can result from defective acidification because vacuolar pH regulates glycoprotein processing and ligand transport. The CF phenotype is similar to that of alkalinized cells 12 and acidification-defective mutatants 13.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143	Columbia University; Columbia University; University of California System; University of California San Francisco	BARASCH, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DICKSON RB, 1981, J CELL BIOL, V89, P29, DOI 10.1083/jcb.89.1.29; FISHMAN PH, 1976, J BIOL CHEM, V251, P4490; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.bi.55.070186.003311; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; Roseman S., 1966, METHOD ENZYMOL, V8, P354; ROSNER H, 1973, J NEUROCHEM, V21, P655, DOI 10.1111/j.1471-4159.1973.tb06010.x; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAATJES DJ, 1986, EUR J CELL BIOL, V42, P344; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WESLEY A, 1983, PEDIATR RES, V17, P65, DOI 10.1203/00006450-198301000-00013; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	36	466	469	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					70	73		10.1038/352070a0	http://dx.doi.org/10.1038/352070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712081				2022-12-24	WOS:A1991FV17800073
J	VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K				VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K			THE B-CELL SURFACE PROTEIN CD72/LYB-2 IS THE LIGAND FOR CD5	NATURE			English	Article							T-CELLS; DIFFERENTIATION ANTIGEN; LYMPHOCYTES-T; RECEPTORS; ACTIVATION; ADHESION; ANTIBODY; SYSTEM; IDENTIFICATION; EXPRESSION	THE glycoprotein CD5 is expressed on the surface membrane of all mature T cells 1 and a small proportion of B lymphocytes 1, 2. Its exact role in immune interactions is still unknown. Studies 3-10 indicate that CD5 functions both in mice and humans as a receptor, delivering co-stimulatory signals to T cells in a manner similar to CD2 (ref. 11) and CD28 (ref. 12). Anti-CD5 antibodies stimulate both T-cell proliferation mediated by CD3 in association with the T-cell receptor and secretion of interleukin-2 and expression of its receptor, as well as inducing an increase in intracellular Ca2+ concentration (refs 5-10). To identify the ligand for CD5 we purified the human CD5 protein, labelled it with biotin and used it as a probe. Here we report that CD5 specifically interacts with the cell-surface protein CD72 exclusive to B cells. This interaction is blocked by anti-CD72 antibodies, but not by any other anti-B-cell antibodies. Moreover, non-B cells (mouse L-cell fibroblasts and human Jurkat T cells) expressing a transfected human CD72 complementary DNA could bind to the CD5-biotin conjugate. The results demonstrate that the B-cell surface protein CD72 (Lyb-2 in mice) is the ligand for CD5.	VRIJE UNIV BRUSSELS, SCH MED, DIV HAEMATOL IMMUNOL, B-1090 BRUSSELS, BELGIUM; STANFORD UNIV, MED CTR, DEPT IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Stanford University								CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P15; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JA, 1990, CELL IMMUNOL, V126, P304, DOI 10.1016/0008-8749(90)90323-J; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KAMAL M, IN PRESS EUR J IMMUN; KAWAMURA N, 1986, J CLIN INVEST, V78, P1331, DOI 10.1172/JCI112719; KURZINGER K, 1982, J BIOL CHEM, V257, P2412; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCMICHAEL AJ, 1987, LEUCOCYTE TYPING, V3, P31; NAKAYAMA E, 1989, P NATL ACAD SCI USA, V86, P1352, DOI 10.1073/pnas.86.4.1352; NISHIMURA Y, 1988, EUR J IMMUNOL, V18, P747, DOI 10.1002/eji.1830180514; PEZZUTTO A, 1989, LEUCOCYTE TYPING, V4, P178; SCHWARTING R, 1989, LEUCOCYTE TYPING, V4, P100; SNOW EC, 1986, J IMMUNOL, V137, P1793; SPERTINI F, 1991, J IMMUNOL, V146, P47; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUBBARAO B, 1984, CURR TOP MICROBIOL, V113, P72; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1988, CELL IMMUNOL, V112, P329, DOI 10.1016/0008-8749(88)90302-4; Subbarao B, 1982, Immunol Rev, V69, P81; TAKI S, 1989, J IMMUNOL METHODS, V122, P33, DOI 10.1016/0022-1759(89)90331-1; VANDENBERGHE P, 1991, EUR J IMMUNOL, V21, P251, DOI 10.1002/eji.1830210203; VERWILGHEN J, 1990, CELL IMMUNOL, V131, P109, DOI 10.1016/0008-8749(90)90238-M; VONHOEGEN I, 1990, J IMMUNOL, V144, P4870; VONHOEGEN I, IN PRESS EUR J IMMUN; WANG CY, 1980, J EXP MED, V151, P1539, DOI 10.1084/jem.151.6.1539; YAKURA H, 1981, J EXP MED, V153, P129, DOI 10.1084/jem.153.1.129	32	311	315	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1991	351	6328					662	665						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1711157				2022-12-24	WOS:A1991FT11200070
J	EISEN, JS				EISEN, JS			DETERMINATION OF PRIMARY MOTONEURON IDENTITY IN DEVELOPING ZEBRAFISH EMBRYOS	SCIENCE			English	Article							GROWTH CONES; LINEAGE	The developmental determination of primary motoneurons was investigated by transplanting identified motoneurons in embryonic zebrafish to new spinal cord positions. Some cells moved from the new positions in which they were placed back to their original positions, thus it was difficult to evaluate whether they were determined. Among cells that remained in their new positions, those transplanted about 1 hour before axogenesis developed axonal trajectories that were appropriate for their original soma positions, whereas those transplanted 2 to 3 hours before axogenesis developed morphologies appropriate for their new soma positions. These results suggest that motoneuronal identity is determined before axogenesis.			EISEN, JS (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023915, R01NS023915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVEREZ IS, IN PRESS DEVELOPMENT; EISEN J, UNPUB; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; HANNEMAN E, 1988, DEVELOPMENT, V103, P49; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; KANDEL ER, 1976, CELLULAR BASIS BEHAV, P211; Kimble J., 1979, Cell lineage, stem cells and cell determination. (Proc. Internat. Workshop on cell lineage, stem cells and cell determination, Seillac, France, 20-24 May 1979. - Inserm Symposium No.10), P59; KIMMEL CB, 1990, MOL APPROACHES SUPRA, P137; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; PIKE SH, 1990, J NEUROSCI, V10, P44; SANES DH, 1989, NEURON, V2, P1237, DOI 10.1016/0896-6273(89)90308-5; STENT GS, 1985, PHILOS T R SOC B, V312, P3, DOI 10.1098/rstb.1985.0174; WESTERFIELD M, 1988, MESSAGE MIND, P110	17	106	107	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					569	572		10.1126/science.1708527	http://dx.doi.org/10.1126/science.1708527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708527				2022-12-24	WOS:A1991FJ12700048
J	ROBERTS, RG				ROBERTS, RG			CORRECTION	LANCET			English	Correction, Addition													Roberts, Roland G/C-3596-2009					ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					504	504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1704092				2022-12-24	WOS:A1991EY88700071
J	PHILLIPS, ML; NUDELMAN, E; GAETA, FCA; PEREZ, M; SINGHAL, AK; HAKOMORI, SI; PAULSON, JC				PHILLIPS, ML; NUDELMAN, E; GAETA, FCA; PEREZ, M; SINGHAL, AK; HAKOMORI, SI; PAULSON, JC			ELAM-1 MEDIATES CELL-ADHESION BY RECOGNITION OF A CARBOHYDRATE LIGAND, SIALYL-LEX	SCIENCE			English	Article									CYTEL CORP, 11099 N TORREY PINES RD, LA JOLLA, CA 92037 USA; BIOMEMBRANE INST, SEATTLE, WA 98119 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV WASHINGTON, DEPT PATHOBIOL & MICROBIOL, SEATTLE, WA 98195 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute			Paulson, James/AAG-3565-2019					ASADA M, IN PRESS BIOCHEMISTR; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HARLAN JM, 1987, ACTA MED SCAND, P123; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HOFF SD, 1989, CANCER RES, V49, P6883; HOFF SD, 1990, ARCH SURG-CHICAGO, V125, P206; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACHER BA, 1990, LEUKEMIA RES, V14, P119, DOI 10.1016/0145-2126(90)90040-G; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MIYAKE M, 1988, CANCER RES, V48, P7150; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; OHMORI K, 1989, BLOOD, V74, P255; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POBER JS, 1986, J IMMUNOL, V136, P1680; POTVIN B, 1990, J BIOL CHEM, V265, P1615; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAKAMOTO J, 1989, CANCER RES, V49, P745; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SINGHAL A, UNPUB; SINGHAL AK, 1990, CANCER RES, V50, P1375; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TAKI T, 1988, J BIOCHEM-TOKYO, V103, P998, DOI 10.1093/oxfordjournals.jbchem.a122400; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	54	1440	1526	4	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	1990	250	4984					1130	1132		10.1126/science.1701274	http://dx.doi.org/10.1126/science.1701274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701274				2022-12-24	WOS:A1990EJ58100034
J	WICTORIN, K; BRUNDIN, P; GUSTAVII, B; LINDVALL, O; BJORKLUND, A				WICTORIN, K; BRUNDIN, P; GUSTAVII, B; LINDVALL, O; BJORKLUND, A			REFORMATION OF LONG AXON PATHWAYS IN ADULT-RAT CENTRAL-NERVOUS-SYSTEM BY HUMAN FOREBRAIN NEUROBLASTS	NATURE			English	Article									UNIV LUND HOSP, DEPT OBSTET & GYNECOL, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT NEUROL, S-22185 LUND, SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital	WICTORIN, K (corresponding author), UNIV LUND, DEPT MED CELL RES, BISKOPSGATAN 5, S-22362 LUND, SWEDEN.		Björklund, Anders/ABA-1326-2020	Bjorklund, Anders/0000-0002-5676-6203				ALFONSI F, 1984, ROLE CELL INTERACTIO, P157; [Anonymous], 1959, DEGENERATION REGENER; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P9; BJORKLUND A, 1976, NATURE, V262, P787, DOI 10.1038/262787a0; BRUNDIN P, 1985, EXP BRAIN RES, V60, P204; CARBONETTO S, 1987, J NEUROSCI, V7, P610; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; CRUTCHER KA, 1989, EXP NEUROL, V104, P39, DOI 10.1016/0014-4886(89)90007-1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DOUCET G, 1989, EXP NEUROL, V106, P1, DOI 10.1016/0014-4886(89)90139-8; FOSTER GA, 1985, EXP BRAIN RES, V60, P427; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; MCLOON LK, 1985, NEURAL GRAFTING MAMM, P267; NORNES H, 1983, CELL TISSUE RES, V230, P15; OUIMET CC, 1984, J NEUROSCI, V4, P111; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; SOTELO C, 1987, NEUROSCIENCE, V20, P1, DOI 10.1016/0306-4522(87)90002-9; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WICTORIN K, 1989, NEUROSCIENCE, V30, P313, DOI 10.1016/0306-4522(89)90256-X; WICTORIN K, 1989, EUR J NEUROSCI, V1, P690, DOI 10.1111/j.1460-9568.1989.tb00375.x; ZHOU CF, 1989, NEUROSCIENCE, V32, P349, DOI 10.1016/0306-4522(89)90083-3	27	233	239	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 11	1990	347	6293					556	558		10.1038/347556a0	http://dx.doi.org/10.1038/347556a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC454	1699131				2022-12-24	WOS:A1990EC45400053
J	TWYCROSS, RG				TWYCROSS, RG			ASSISTED DEATH - A REPLY	LANCET			English	Editorial Material											TWYCROSS, RG (corresponding author), SIR MICHAEL SOBELL HOUSE, CHURCHILL HOUSE, OXFORD OX3 7LJ, ENGLAND.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; DRAIN G, 1990, LANCET, V2, P610; FENIGSEN R, 1989, HASTINGS CENT REP, V19, pS22; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; RAGLAN, 1972, CONTACT, V39, P9; Roy D J, 1990, J Palliat Care, V6, P3	6	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	1990	336	8718					796	798		10.1016/0140-6736(90)93253-L	http://dx.doi.org/10.1016/0140-6736(90)93253-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB077	1698235				2022-12-24	WOS:A1990EB07700016
J	HOPWOOD, ND; GURDON, JB				HOPWOOD, ND; GURDON, JB			ACTIVATION OF MUSCLE GENES WITHOUT MYOGENESIS BY ECTOPIC EXPRESSION OF MYOD IN FROG EMBRYO CELLS	NATURE			English	Article											HOPWOOD, ND (corresponding author), DEPT ZOOL,CANC RES CAMPAIGN,MOLEC EMBRYOL GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.			GURDON, JOHN/0000-0002-5621-3799; Hopwood, Nick/0000-0001-7069-7497				ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	27	114	114	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 13	1990	347	6289					197	200		10.1038/347197a0	http://dx.doi.org/10.1038/347197a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DY352	1697650				2022-12-24	WOS:A1990DY35200068
J	YATANI, A; OKABE, K; CODINA, J; BIRNBAUMER, L; BROWN, AM				YATANI, A; OKABE, K; CODINA, J; BIRNBAUMER, L; BROWN, AM			HEART-RATE REGULATION BY G-PROTEINS ACTING ON THE CARDIAC-PACEMAKER CHANNEL	SCIENCE			English	Article									BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor University	YATANI, A (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36930, HL39262] Funding Source: Medline; NIDDK NIH HHS [DK19318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P7; BERNE RM, 1988, PHYSIOLOGY, P451; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CARRIER GO, 1972, J PHARMACOL EXP THER, V180, P31; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; CODINA J, 1984, J BIOL CHEM, V259, P5871; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1987, PFLUG ARCH EUR J PHY, V410, P139, DOI 10.1007/BF00581906; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; GILES W, 1986, CARDIAC MUSCLE REGUL, P1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOHL CM, 1987, BIOCHIM BIOPHYS ACTA, V921, P356, DOI 10.1016/0005-2760(87)90037-3; KARDON MB, 1975, CIRC RES, V37, P41, DOI 10.1161/01.RES.37.1.41; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; Levy M., 1979, HDB PHYSL SECT 2 CAR, P581; MATTERA R, 1989, J BIOL CHEM, V264, P465; NAKAYAMA T, 1984, PFLUG ARCH EUR J PHY, V402, P248, DOI 10.1007/BF00585507; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NIEDERGERKE R, 1977, PROC R SOC SER B-BIO, V197, P333, DOI 10.1098/rspb.1977.0074; NOMA A, 1980, PFLUG ARCH EUR J PHY, V388, P1, DOI 10.1007/BF00582621; OKABE K, IN PRESS J BIOL CHEM; POWELL T, 1976, BIOCHEM BIOPH RES CO, V72, P1218, DOI 10.1016/S0006-291X(76)80260-4; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; YATANI A, 1990, AM J PHYSIOL, V258, pH1947, DOI 10.1152/ajpheart.1990.258.6.H1947; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	33	101	101	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 7	1990	249	4973					1163	1166		10.1126/science.1697697	http://dx.doi.org/10.1126/science.1697697			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DX399	1697697				2022-12-24	WOS:A1990DX39900035
J	GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG				GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG			PROCESSING OF THE AMYLOID PROTEIN-PRECURSOR TO POTENTIALLY AMYLOIDOGENIC DERIVATIVES	SCIENCE			English	Article							ALZHEIMERS-DISEASE	The approximately 120-kilodalton amyloid beta-protein precursor (beta-APP) is processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives that includes potentially amyloidogenic forms with the approximate 4-kilodalton amyloid beta-protein (beta-AP) at or near their amino terminus. In order to determine if these derivatives are processed in a secretory pathway or by the endosomal-lysosomal system, (i) deletion mutants that produce the normal set of carboxyl-terminal derivatives and shortened secreted derivatives were analyzed and (ii) the effect of inhibitors of endosomal-lysosomal processing was examined. In the secretory pathway, cleavage of the beta-APP occurs at a single site within the beta-AP to generate one secreted derivative and one nonamyloidogenic carboxyl-terminal fragment, whereas, in the endosomal-lysosomal system, a complex set of carboxyl-terminal derivatives is produced that includes the potentially amyloidogenic forms.	HARVARD UNIV,SCH MED,DEPT NEUROL NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GOLDE, TE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.							BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; COLE GM, 1990, MOL BIOL GENETICS AL, P113; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ESTUS S, 1992, SCIENCE, V248, P492; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAWAI M, IN PRESS AM J PATHOL; LUCOTTE G, 1991, NATURE, V351, P530, DOI 10.1038/351530b0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865	17	704	727	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					728	730		10.1126/science.1738847	http://dx.doi.org/10.1126/science.1738847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738847				2022-12-24	WOS:A1992HC50600042
J	LASIC, DD				LASIC, DD			MIXED MICELLES IN DRUG DELIVERY	NATURE			English	Article							AMPHOTERICIN-B				LASIC, DD (corresponding author), LIPOSOME TECHNOL INC,1050 HAMILTON COURT,MENLO PK,CA 94025, USA.							BRODIN A, 1982, ACTA PHARM SUEC, V19, P267; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; FIELDING RM, 1991, ANTIMICROB AGENTS CH, V35, P1208, DOI 10.1128/AAC.35.6.1208; FIELDING RM, IN PRESS ANTIMICROB; GUENTERT TW, 1987, BRIT J CLIN PHARMACO, V23, P569, DOI 10.1111/j.1365-2125.1987.tb03093.x; GUO LSS, 1991, INT J PHARM, V75, P45, DOI 10.1016/0378-5173(91)90249-N; JANOFF AS, 1988, P NATL ACAD SCI USA, V85, P6122, DOI 10.1073/pnas.85.16.6122; LASIC DD, 1982, BIOCHIM BIOPHYS ACTA, V692, P501, DOI 10.1016/0005-2736(82)90404-7; LASIC DD, 1988, BIOCHEM J, V256, P1; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1991, PERIOD BIOL, V93, P287; LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704; PAPAHADJOPOULOS P, 1991, P NATL ACAD SCI USA, V88, P11460; Prescott L.F., 1989, NOVEL DRUG DELIVERY; YOKOYAMA M, 1990, CANCER RES, V50, P1693	15	151	165	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					279	280		10.1038/355279a0	http://dx.doi.org/10.1038/355279a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731228				2022-12-24	WOS:A1992GZ69400077
J	MURRAY, RH; RUBEL, AJ				MURRAY, RH; RUBEL, AJ			PHYSICIANS AND HEALERS - UNWITTING PARTNERS IN HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICINE; CANCER; PRACTITIONERS; SURVIVAL; TRIAL		UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine	MURRAY, RH (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.							CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; FULDER SJ, 1985, LANCET, V2, P542; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; McGuire Meredith, 1988, RITUAL HEALING SUBUR; SHEKELLE PG, 1991, RAND R40252CCRFLER; SHIPLEY M, 1983, LANCET, V1, P97; SPIEGEL D, 1989, LANCET, V2, P888; WATT J, 1988, TALKING HLTH CONVENT; 1981, ALTERNATIVE MED NETH; 1986, ALTERNATIVE THERAPY; 1987, N Z MED J, V100, P110; 1986, AM MED NEWS     0411, P46; 1990, OTAH405 OFF TECHN AS; 1987, ENCY MED ORG AGENCIE, P93	19	104	105	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					61	64		10.1056/NEJM199201023260113	http://dx.doi.org/10.1056/NEJM199201023260113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX315	1727068				2022-12-24	WOS:A1992GX31500013
J	BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH				BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH			EPIDERMOLYSIS-BULLOSA SIMPLEX - EVIDENCE IN 2 FAMILIES FOR KERATIN GENE ABNORMALITIES	SCIENCE			English	Article							HUMAN TYPE-I; INTERMEDIATE FILAMENTS; SEQUENCE; EXPRESSION; LINKAGE; CYTOKERATIN-18; CHROMOSOME-12Q; MARKERS; CELLS	Epidermolysis bullosa simplex (EBS) is characterized by skin blistering due to basal keratinocyte fragility. In one family studied, inheritance of EBS is linked to the gene encoding keratin 14, and a thymine to cytosine mutation in exon 6 of keratin 14 has introduced a proline in the middle of an alpha-helical region. In a second family, inheritance of EBS is linked to loci that map near the keratin 5 gene. These data indicate that abnormalities of either of the components of the keratin intermediate filament heterodipolymer can impair the mechanical stability of these epithelial cells.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT DERMATOL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAMS NIH HHS [R01-AR39953, R01-AR28069] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR028069] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASAZS I, 1984, HUM GENET, V68, P57; BONIFAS JM, 1991, J INVEST DERMATOL, V96, P550; BONIFAS JM, UNPUB; CHIN S S M, 1990, Journal of Cell Biology, V111, p176A; FINE JD, 1988, ARCH DERMATOL, V124, P523, DOI 10.1001/archderm.124.4.523; HEATH P, 1990, HUM GENET, V85, P669; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUMPHRIES MM, 1990, GENOMICS, V7, P377, DOI 10.1016/0888-7543(90)90171-P; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUPPUSWAMY MN, 1991, P NATL ACAD SCI USA, V88, P1143, DOI 10.1073/pnas.88.4.1143; LATHROP GM, 1988, GENOMICS, V3, P361; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; MANN W, 1989, NUCLEIC ACIDS RES, V17, P5410, DOI 10.1093/nar/17.13.5410; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P3596, DOI 10.1093/nar/16.8.3596; MUTHA S, 1991, J INVEST DERMATOL, V97, P383, DOI 10.1111/1523-1747.ep12480948; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P779, DOI 10.1093/nar/16.2.779; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5223, DOI 10.1093/nar/16.11.5223; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P778, DOI 10.1093/nar/16.2.778; O'CONNELL P, 1987, Genomics, V1, P93, DOI 10.1016/0888-7543(87)90110-8; OLAISEN B, 1973, HUM HERED, V23, P189, DOI 10.1159/000152573; OTT J, 1985, ANAL HUMAN GENETIC L; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; Sambrook J., 1989, MOL CLONING LAB MANU; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SYKES B, 1986, LANCET, V2, P69; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WASSEEM A, 1990, GENOMICS, V7, P188; WEAVER EJ, 1989, CYTOGENET CELL GENET, V54, P1103	35	338	347	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1202	1205		10.1126/science.1720261	http://dx.doi.org/10.1126/science.1720261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1720261				2022-12-24	WOS:A1991GQ83400047
J	MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM				MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM			EFFECT OF STEEL FACTOR AND LEUKEMIA INHIBITORY FACTOR ON MURINE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; SI-LOCUS; PROTO-ONCOGENE; MOUSE; LIGAND; EXPRESSION; IDENTIFICATION	DESPITE the importance of germ cells to the survival of species, surprisingly little is known about their embryological origin, proliferation, migration and entry into mitotic arrest or meiosis 1-5. Mutations in the murine Dominant White Spotting (W) and Steel genes, which respectively encode the c-kit tyrosine kinase receptor and the c-kit ligand (or Steel factor), impair the development of primordial germ cells (PGCs) in vivo, as well as haematopoietic stem cells and neural crest-derived melanoblast 3,6-16. Here we use a monoclonal antibody against c-kit tyrosine kinase receptor and recombinant Steel factor to study the c-kit receptor-ligand system in cultured PGCs. In addition, we show that leukaemia inhibitory factor (also known as differentiation inhibitory activity) 17,18, a factor secreted by STO fibroblasts, can stimulate proliferation of primordial germ cells in vitro.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; KUMAMOTO UNIV,INST MED IMMUNOL,DEPT PATHOL,KUMAMOTO 860,JAPAN; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Kumamoto University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS L, 1988, NATURE, V336, P688; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	28	393	416	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					750	752		10.1038/353750a0	http://dx.doi.org/10.1038/353750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719421				2022-12-24	WOS:A1991GL69600067
J	TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP				TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP			DYSMYELINATION IN TRANSGENIC MICE RESULTING FROM EXPRESSION OF CLASS-I HISTOCOMPATIBILITY MOLECULES IN OLIGODENDROCYTES	NATURE			English	Article							PANCREATIC BETA-CELLS; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; MHC MOLECULES; SCHWANN-CELLS; ANTIGENS; TOLERANCE; GENE; TRANSCRIPTION; INTERFERON	MAJOR histocompatibility complex (MHC) molecules are not normally expressed in the central nervous system (CNS) 1-3. However, aberrant expression has been observed in multiple sclerosis lesions and could contribute to the destruction of myelin or the myelinating cells known as oligodendrocytes 4,5. The mechanism of cell damage associated with aberrant MHC molecule expression is unclear: for example, overexpression of class I (ref. 6) and class II (refs 7, 8) MHC molecules in pancreatic beta-cells in transgenic mice leads to nonimmune destruction of the cells and insulin-dependent diabetes mellitus. We have generated transgenic mice that express class I H-2K(b) MHC molecules, under the control of the myelin basic protein promoter, specifically in oligodendrocytes. Homozygous transgenic mice have a shivering phenotype, develop tonic seizures and die at 15-22 days. This phenotype, which we term 'wonky', is due to hypomyelination in the CNS, and not to involvement of the immune system. The primary defect appears to be a shortage of myelinating oligodendrocytes resulting from overexpression of the class I MHC molecules.	OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN	Osaka University	TURNLEY, AM (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA.		Bartlett, Perry/F-3813-2012; Okano, Hideyuki/I-7584-2019; Turnley, Ann/A-8125-2010; Morahan, Grant/T-7501-2019; Mikoshiba, Katsuhiko/N-7943-2015	Turnley, Ann/0000-0002-8442-127X				ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BARTLETT PF, 1983, J CLIN LAB IMMUNOL, V11, P1; BARTLETT PF, 1989, TRANSPLANT P, V21, P3166; DEROSBO NK, 1984, NEUROCHEM RES, V9, P1359, DOI 10.1007/BF00964663; GILFILLAN S, 1990, P NATL ACAD SCI USA, V87, P7319, DOI 10.1073/pnas.87.18.7319; GOULD RM, 1977, J CELL BIOL, V75, P326, DOI 10.1083/jcb.75.2.326; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KIDD GJ, 1990, J NEUROSCI RES, V26, P409, DOI 10.1002/jnr.490260403; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILLER J, 1990, J IMMUNOL, V144, P334; MITCHELL LS, 1990, J NEUROSCI RES, V27, P125, DOI 10.1002/jnr.490270202; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; PANITCH HS, 1987, LANCET, V1, P893; PERIER O, 1965, BRAIN, V88, P937, DOI 10.1093/brain/88.5.937; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHEN HZ, 1989, J NEUROSCI RES, V23, P425; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TRAUGOTT U, 1987, J NEUROIMMUNOL, V16, P283, DOI 10.1016/0165-5728(87)90082-8; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0	26	107	107	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					566	569		10.1038/353566a0	http://dx.doi.org/10.1038/353566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1717849				2022-12-24	WOS:A1991GJ64300070
J	KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D				KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D			NEOVASCULARIZATION IS ASSOCIATED WITH A SWITCH TO THE EXPORT OF BFGF IN THE MULTISTEP DEVELOPMENT OF FIBROSARCOMA	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CELL-GROWTH; TRANSGENIC MICE; ENDOTHELIAL-CELLS; HEPARIN AFFINITY; TRANSFORMING GENE; PURIFICATION; ANGIOGENESIS; SEQUENCE; PROTEIN	In a transgenic mouse model, dermal fibrosarcomas develop in a pathway comprised of at least three stages: mild fibromatosis, aggressive fibromatosis, and fibrosarcoma. The latter two stages are highly vascularized when compared with both the normal dermis and the initial mild lesion. Analysis of cell cultures derived from biopsies of these lesions has revealed that basic fibroblast growth factor (bFGF) is synthesized in all three stages and in normal dermal fibroblasts derived from the same mice. Unexpectedly, there is a change in the localization of bFGF from its normal cell-associated state to extracellular release in the latter two stages, which is concomitant both with the neovascularization seen in vivo and with the tumorigenicity of these cell lines. Thus, in this multistep tumorigenesis pathway there appears to be a discrete switch to the angiogenic phenotype that correlates with the export of bFGF, a known angiogenic factor.	HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, HORMONE RES INST, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	KANDEL, J (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA.			Radvanyi, Francois/0000-0002-5696-6424	NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37392, CA 70118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1986, J CELL BIOCHEM, V30, P79, DOI 10.1002/jcb.240300109; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IBERG N, 1989, J BIOL CHEM, V264, P19951; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLAGSBRUN M, 1977, EXP CELL RES, V105, P99, DOI 10.1016/0014-4827(77)90155-0; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; LOBB R, 1986, J BIOL CHEM, V261, P1924; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MARICS I, 1989, ONCOGENE, V4, P335; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; SENGER DR, 1990, CANCER RES, V50, P1774; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	48	501	527	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1095	1104		10.1016/0092-8674(91)90033-U	http://dx.doi.org/10.1016/0092-8674(91)90033-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717155				2022-12-24	WOS:A1991GG55200005
J	YU, XM; HALL, ZW				YU, XM; HALL, ZW			EXTRACELLULAR DOMAINS MEDIATING EPSILON SUBUNIT INTERACTIONS OF MUSCLE ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							ENDOPLASMIC-RETICULUM; ION CHANNELS; TRANSMEMBRANE; MUTAGENESIS; BINDING; CELLS	LIGAND-gated ion channels, a major class of cell-surface proteins, have a pseudosymmetric structure with five highly homologous subunits arranged around a central ion pore 1. The correct assembly of each channel, whose subunit composition varies with cell type and stage of development, requires specific recognition between the subunits 2-4. Assembly of the pentameric form of the acetylcholine receptor from adult muscle (AChR; alpha-2-beta-epsilon-delta) proceeds by a stepwise pathway starting with the formation of the heterodimers, alpha-epsilon and alpha-delta. The heterodimers then associate with the beta-subunit and with each other to form the complete receptor 5-7,21. We have now determined which parts of the subunits mediate the interactions during assembly of the adult form of the receptor from mouse muscle by using a chimaeric subunit in which the N-terminal and C-terminal extracellular domains are derived from the E subunit with the remainder from the beta-subunit. The epsilon and beta-subunits were chosen because the epsilon-subunit forms a heterodimer with the alpha-subunit in the pathway for assembly of the receptor, whereas the beta-subunit does not. The epsilon-beta chimaera can substitute for the epsilon but not the beta-subunit in the oligomeric receptor, indicating that the alpha-subunit specifically recognizes an extracellular domain of the epsilon-subunit.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GU Y, IN PRESS NEURON; GU Y, IN PRESS J CELL BIOL; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	21	80	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					64	67		10.1038/352064a0	http://dx.doi.org/10.1038/352064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712080				2022-12-24	WOS:A1991FV17800071
J	LAVORGNA, G; UEDA, H; CLOS, J; WU, C				LAVORGNA, G; UEDA, H; CLOS, J; WU, C			FTZ-F1, A STEROID-HORMONE RECEPTOR LIKE PROTEIN IMPLICATED IN THE ACTIVATION OF FUSHI-TARAZU	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; ESTROGEN-RECEPTOR; AMINO-ACIDS; GENE KNIRPS; SUPERFAMILY; DNA; SEGMENTATION; SEQUENCE; MEMBER; IDENTIFICATION	The Drosophila homeobox segmentation gene fushi tarazu (ftz) is expressed in a seven-stripe pattern during early embryogenesis. This characteristic pattern is largely specified by the zebra element located immediately upstream of the ftz transcriptional start site. The FTZ-F1 protein, one of multiple DNA binding factors that interacts with the zebra element, is implicated in the activation of ftz transcription, especially in stripes 1, 2, 3, and 6. An FTZ-F1 complementary DNA has been cloned by recognition site screening of a Drosophila expression library. The identity of the FTZ-F1 complementary DNA clone was confirmed by immunological cross-reaction with antibodies to FTZ-F1 and by sequence analysis of peptides from purified FTZ-F1 protein. The predicted amino acid sequence of FTZ-F1 revealed that the protein is a member of the nuclear hormone receptor superfamily. This finding raises the possibility that a hormonal ligand affects the expression of a homeobox segmentation gene early in embryonic development.	NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	LAVORGNA, G (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.		UEDA, Hitoshi/B-1455-2011; Lavorgna, Giovanni/AAN-2575-2020					AKAM M, 1987, DEVELOPMENT, V101, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOLLENBERG SM, 1985, NATURE, V318, P670; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LAVORGNA G, UNPUB; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SEAGRAVES WA, 1990, GENE DEV, V4, P204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	49	265	271	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					848	851		10.1126/science.1709303	http://dx.doi.org/10.1126/science.1709303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709303				2022-12-24	WOS:A1991FL12300048
J	DOUDNA, JA; COUTURE, S; SZOSTAK, JW				DOUDNA, JA; COUTURE, S; SZOSTAK, JW			A MULTISUBUNIT RIBOZYME THAT IS A CATALYST OF AND TEMPLATE FOR COMPLEMENTARY STRAND RNA-SYNTHESIS	SCIENCE			English	Article							GROUP-I INTRONS; DIRECTED SYNTHESIS; POLYMERASE; CONSERVATION; TETRAHYMENA; EVOLUTION	Derivatives of the sunY self-splicing intron efficiently catalyzed the synthesis of complementary strand RNA by template-directed assembly of oligonucleotides. These ribozymes were separated into three short RNA fragments that formed active catalytic complexes. One of the multisubunit sunY derivatives catalyzed the synthesis of a strand of RNA complementary to one of its own subunits. These results suggest that prebiotically synthesized oligonucleotides might have been able to assemble into a complex capable of self-replication.			DOUDNA, JA (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MICHEL F, IN PRESS J MOL BIOL; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; USMAN N, 1988, P NATL ACAD SCI USA, V85, P5764; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	21	101	104	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1605	1608		10.1126/science.1707185	http://dx.doi.org/10.1126/science.1707185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1707185				2022-12-24	WOS:A1991FD89000036
J	NEUGEBAUER, KM; REICHARDT, LF				NEUGEBAUER, KM; REICHARDT, LF			CELL-SURFACE REGULATION OF BETA-1-INTEGRIN ACTIVITY ON DEVELOPING RETINAL NEURONS	NATURE			English	Article							GLYCOPROTEIN; PROTEINS; COMPLEX; LAMININ; CSAT	INTEGRINS are a family of alpha-beta-heterodimeric receptors that mediate cell-cell and cell-substratum interactions. Integrin binding to extracellular ligands regulates cell adhesion, shape, motility, intracellular signalling and gene expression 1-3. Mechanisms that regulate integrin function are, therefore, central to the participation of integrins in a diverse set of cellular events. Here we report the identification of TASC, a monoclonal antibody to a novel epitope on the integrin beta-1 subunit, which inhibits cell adhesion to vitronectin but promotes adhesion to laminin and collagen types I and IV. We show that developing retinal neurons that have lost responsiveness to laminin 4 regain the ability to bind laminin in the presence of TASC. Thus, beta-1-class integrins are likely to occupy multiple affinity states that can be modulated at the cell surface.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS019090, R01 NS019090-14] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; COHEN J, 1989, DEVELOPMENT, V107, P381; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1990, J BIOL CHEM, V265, P9575; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ AF, 1984, MONOCLONAL ANTIBODIE, P103; KEIZER GD, 1988, J IMMUNOL, V140, P1393; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; NEUGEBAUER KM, IN PRESS NEURON; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REICHARDT LF, 1991, REV NEUROSCI, V14, P531; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	25	181	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					68	71		10.1038/350068a0	http://dx.doi.org/10.1038/350068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706071	Green Accepted			2022-12-24	WOS:A1991FA69300067
J	KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR				KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR			EXPRESSION OF THE CYSTIC-FIBROSIS GENE IN NONEPITHELIAL INVERTEBRATE CELLS PRODUCES A REGULATED ANION CONDUCTANCE	CELL			English	Article							HIGH-LEVEL EXPRESSION; INSECT CELLS; BACULOVIRUS VECTOR; COMPLEMENTARY-DNA; FOREIGN GENES; GLYCOPROTEIN; RECEPTOR; MEMBRANE; PROTEINS; CHANNEL	The nature of involvement of the cystic fibrosis gene product (CFTR) in epithelial anion transport is not yet understood. We have expressed CFTR in Sf9 insect cells using the baculovirus expression vector system. Reactivity with antibodies against 12 different epitopes spanning the entire sequence suggested that the complete polypeptide chain was synthesized. Immunogold labeling showed localization to both cell-surface and intracellular membranes. Concomitant with CFTR expression, these cells exhibited a new cAMP-stimulated anion permeability. This conductance, monitored both by radioiodide efflux and patch clamping, strongly resembled that present in several CFTR-expressing human epithelial cells. These findings demonstrate that CFTR can function in heterologous nonepithelial cells and lend support to the possibility that CFTR may itself be a regulated anion channel.	UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of Toronto; University of Toronto; University of Toronto; McGill University	KARTNER, N (corresponding author), HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA.		Tsui, Lap-chee/A-1081-2010; Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSENO, 1989, PFLUGERS ARCH, V415, P37; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1990, BIOPHYS J, V57, pA88; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON PW, 1989, GENE, V77, P287, DOI 10.1016/0378-1119(89)90076-0; KALIBER K, 1990, NEURON, V5, P221; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; POSSEE RD, 1986, VIRUS RES, V5, P43, DOI 10.1016/0168-1702(86)90064-X; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1990, IDENTIFICATION CF CY; RIORDAN JR, 1991, J PHARM THERAPEUT, V28, P51; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIERHOF YD, 1986, J ULTRA MOL STRUCT R, V97, P187, DOI 10.1016/S0889-1605(86)80017-9; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	40	517	533	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					681	691		10.1016/0092-8674(91)90498-N	http://dx.doi.org/10.1016/0092-8674(91)90498-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1705179				2022-12-24	WOS:A1991EZ47800004
J	HU, WS; TEMIN, HM				HU, WS; TEMIN, HM			RETROVIRAL RECOMBINATION AND REVERSE TRANSCRIPTION	SCIENCE			English	Article											HU, WS (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; JORGENSEN RA, 1979, MOL GEN GENET, V177, P65, DOI 10.1007/BF00267254; KAWAI S, 1972, VIROLOGY, V49, P37, DOI 10.1016/S0042-6822(72)80005-9; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; LINIAL M, 1979, J VIROL, V31, P257, DOI 10.1128/JVI.31.1.257-260.1979; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; RIGGS JL, 1974, J GEN VIROL, V25, P21, DOI 10.1099/0022-1317-25-1-21; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL FW, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0287-90; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TEMIN HM, IN PRESS TRENDS GENE; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; VOGT PK, 1971, VIROLOGY, V46, P947, DOI 10.1016/0042-6822(71)90093-6; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; Weiss R, 1982, RNA TUMOR VIRUSES; WEISS RA, 1973, VIROLOGY, V52, P535, DOI 10.1016/0042-6822(73)90349-8; WYKE JA, 1979, J GEN VIROL, V43, P349, DOI 10.1099/0022-1317-43-2-349; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YANG ST, UNPUB	27	522	533	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1227	1233		10.1126/science.1700865	http://dx.doi.org/10.1126/science.1700865			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700865				2022-12-24	WOS:A1990EK72300029
J	BACSKAI, BJ; FRIEDMAN, PA				BACSKAI, BJ; FRIEDMAN, PA			ACTIVATION OF LATENT CA-2+ CHANNELS IN RENAL EPITHELIAL-CELLS BY PARATHYROID-HORMONE	NATURE			English	Article									DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756; DARTMOUTH COLL,THAYER SCH ENGN,HANOVER,NH 03755	Dartmouth College; Dartmouth College			Bacskai, Brian/AAE-9583-2021					ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; BORKE JL, 1990, SEMIN NEPHROL, V10, P15; BORKE JL, 1989, BRAIN RES, V489, P355, DOI 10.1016/0006-8993(89)90870-6; BORKE JL, 1989, AM J PHYSIOL, V257, pC341, DOI 10.1152/ajpcell.1989.257.2.C341; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; EXTON JH, 1987, CALCIUM BINDING PROT, P137; FRIEDMAN PA, 1988, AM J PHYSIOL, V254, pF62, DOI 10.1152/ajprenal.1988.254.1.F62; FRIEDMAN PA, 1988, NEWS PHYSIOL SCI, V3, P17, DOI 10.1152/physiologyonline.1988.3.1.17; FRIEDMAN PA, 1982, J GEN PHYSIOL, V80, P683, DOI 10.1085/jgp.80.5.683; FRIEDMAN PA, 1989, J BONE MINER RES, V4, pS346; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GOLIGORSKY MS, 1986, AM J PHYSIOL, V251, pF938, DOI 10.1152/ajprenal.1986.251.5.F938; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANDLER JS, 1983, J EXP BIOL, V106, P55; HEBERT SC, 1984, J MEMBRANE BIOL, V80, P201, DOI 10.1007/BF01868439; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HRUSKA KA, 1987, J CLIN INVEST, V79, P230, DOI 10.1172/JCI112788; HURWITZ L, 1986, ANNU REV PHARMACOL, V26, P225; MARGOLIS RL, 1977, P NATL ACAD SCI USA, V74, P3466, DOI 10.1073/pnas.74.8.3466; MCKENNA E, 1990, BIOCHEM PHARMACOL, V39, P1145, DOI 10.1016/0006-2952(90)90255-J; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PFALLER W, 1989, RENAL PHYSIOL BIOCH, V12, P328; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; Taylor A., 1985, KIDNEY PHYSL PATHOPH, P1297; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; van Os C H, 1988, Prog Clin Biol Res, V252, P223; VILLEREAL ML, 1989, ANNU REV NUTR, V9, P347, DOI 10.1146/annurev.nu.09.070189.002023; WADE JB, 1980, CURR TOP MEMBR TRANS, V13, P123; Wasserman R H, 1989, Adv Exp Med Biol, V249, P45; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663	36	142	142	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					388	391		10.1038/347388a0	http://dx.doi.org/10.1038/347388a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699128				2022-12-24	WOS:A1990EA56400065
J	KYPTA, RM; GOLDBERG, Y; ULUG, ET; COURTNEIDGE, SA				KYPTA, RM; GOLDBERG, Y; ULUG, ET; COURTNEIDGE, SA			ASSOCIATION BETWEEN THE PDGF RECEPTOR AND MEMBERS OF THE SRC FAMILY OF TYROSINE KINASES	CELL			English	Article											KYPTA, RM (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X; Goldberg, Yves/0000-0001-7446-8595				BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1989, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1988, ONCOGENE, V3, P491; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	40	636	655	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 10	1990	62	3					481	492		10.1016/0092-8674(90)90013-5	http://dx.doi.org/10.1016/0092-8674(90)90013-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DU445	1696179				2022-12-24	WOS:A1990DU44500010
J	WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM				WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM			INFECTIONS DUE TO BETA-LACTAMASE-PRODUCING, HIGH-LEVEL GENTAMICIN-RESISTANT ENTEROCOCCUS-FAECALIS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECALIS; BETA-LACTAMASES; DRUG RESISTANCE, MICROBIAL; GENTAMICINS; CROSS INFECTION; DISEASE OUTBREAKS; COMMUNICABLE DISEASE CONTROL	STREPTOCOCCUS-FAECALIS; ENDOCARDITIS; STRAINS	Objective: To investigate the risk factors, clinical features, molecular epidemiology, and treatment outcomes associated with an outbreak of infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Design: Case-control and molecular genetics study. Setting: Tertiary care Veterans Affairs hospital. Patients: Sixty-five patients infected or colonized with beta-lactamase-producing high-level gentamicin-resistant E. faecalis (case patients) were matched and compared with 65 randomly selected patients infected or colonized with beta-lactamase-negative, gentamicin-susceptible E. faecalis. Measurements and Main Results: During the 20-month study period, 124 of 1506 isolates (8.2%) of E. faecalis from 70 patients were found to produce beta-lactamase. Univariate analysis showed older age, higher APACHE II score, nosocomial acquisition, recent surgical procedure, total parenteral nutrition, and antibiotic treatment to be significantly associated with the acquisition of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis. A multivariate analysis, done using stepwise multiple logistic regressions, showed that only two variables remained significant: an APACHE II score > 6 (odds ratio, 9.5; 95% Cl, 4.4 to 20.3) and antibiotic treatment (odds ratio, 10.2; Cl, 4.5 to 23.2). The mortality rate for case patients was 7.7% (5 of 65 patients; Cl, 1.2% to 14.2%); no control patient died. Of 23 infections occurring in case patients, 13 were treated with "inappropriate" antibiotics (regimens that included a beta-lactamase-unstable antibiotic); 2 patients improved and 11 had complete resolution of disease. "Appropriate" treatments (regimens that included a beta-lactamase-stable antibiotic) were used in 10 patients; 5 of 10 infections were fatal. Restriction enzyme digests of total chromosomal DNA showed nearly identical patterns for selected isolates of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis, suggesting dissemination through the hospital of a single strain of E. faecalis. Conclusions: Fatal infections were observed despite treatment with beta-lactamase-stable antibiotics. The risk for infection or colonization with beta-lactamase-producing, high-level gentamicin-resistant E. faecalis was strongly associated with severe underlying disease (acute physiology and chronic health evaluation [APACHE] II score, > 6) and previous antibiotic treatment. These results may be useful in targeting high-risk patients for infection-control interventions.	DEPT VET AFFAIRS MED CTR, INFECT DIS SECT 111C, 1201 BROAD ROCK BLVD, RICHMOND, VA 23249 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV INFECT DIS, RICHMOND, VA 23298 USA; UNIV TEXAS, HLTH SCI CTR, PROGRAM INFECT DIS & CLIN MICROBIOL, HOUSTON, TX 77225 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; University of Texas System; University of Texas Health Science Center Houston								BUSH LM, 1988, ANTIMICROB AGENTS CH, V32, P877, DOI 10.1128/AAC.32.6.877; DOUGHERTY SH, 1983, ARCH SURG-CHICAGO, V118, P232; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; INGERMAN M, 1987, J INFECT DIS, V155, P1226, DOI 10.1093/infdis/155.6.1226; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARKOWITZ SM, 1991, ANTIMICROB AGENTS CH, V35, P1075, DOI 10.1128/AAC.35.6.1075; MURRAY BE, 1986, ANTIMICROB AGENTS CH, V30, P861, DOI 10.1128/AAC.30.6.861; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; PATTERSON JE, 1988, ANTIMICROB AGENTS CH, V32, P122, DOI 10.1128/AAC.32.1.122; PATTERSON JE, 1990, ANTIMICROB AGENTS CH, V34, P302, DOI 10.1128/AAC.34.2.302; PATTERSON JE, 1989, ANTIMICROB AGENTS CH, V33, P251, DOI 10.1128/AAC.33.2.251; PATTERSON JE, 1988, J INFECT DIS, V158, P1144, DOI 10.1093/infdis/158.5.1144; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1983, MMWR S455, V32, P155; 1985, PROC IML VERSION 5	20	83	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					285	292		10.7326/0003-4819-116-4-285	http://dx.doi.org/10.7326/0003-4819-116-4-285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733382				2022-12-24	WOS:A1992HD54600003
J	CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW				CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW			EVOLUTION OF KING CRABS FROM HERMIT-CRAB ANCESTORS	NATURE			English	Article							DNA; PHYLOGENY; SIZE	KING crabs (Family Lithodidae) are among the world's largest arthropods, having a crab-like morphology and a strongly calcified exoskeleton 1-6. The hermit crabs, by contrast, have depended on gastropod shells for protection for over 150 million years 5,7. Shell living has constrained the morphological evolution of hermit crabs by requiring a decalcified asymmetrical abdomen capable of coiling into gastropod shells and by preventing crabs from growing past the size of the largest available shells 1-6. Whereas reduction in shell-living and acquisition of a crab-like morphology (carcinization) has taken place independently in several hermit crab lineages, and most dramatically in king crabs 1-6, the rate at which this process has occurred was entirely unknown 2,7. We present molecular evidence that king crabs are not only descended from hermit crabs, but are nested within the hermit crab genus Pagurus. We estimate that loss of the shell-living habit and the complete carcinization of king crabs has taken between 13 and 25 million years.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	Yale University; Yale University			Cunningham, Clifford/B-9807-2014	Cunningham, Clifford/0000-0002-5434-5122				ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; BLACKSTONE NW, 1986, BIOL BULL, V171, P379, DOI 10.2307/1541680; BLACKSTONE NW, 1989, J ZOOL, V217, P477, DOI 10.1111/j.1469-7998.1989.tb02503.x; BLACKSTONE NW, 1985, THESIS YALE U; Borradaile L. A., 1916, Nat Hist Rep Zool, VNo.3; CUNNINGHAM CW, 1991, EVOLUTION, V46, P1301; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GLAESSNER MF, 1969, ARTHROPODA, V4, pR400; Grabowski, 1991, SIMPLE FOOLS GUIDE P; Hart JFL, 1982, BC PROV MUS HDB, V40; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hillis David M., 1990, P502; Kafanov A. I., 1984, CANADIAN TRANSLATION, V5052, P1; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MACDONALD J. D., 1957, PROC ZOOL SOC LONDON, V128, P209; MARTIN AP, 1990, MOL BIOL EVOL, V7, P485; MARTIN JW, 1986, J CRUSTACEAN BIOL, V6, P576, DOI 10.2307/1548195; McLaughlin P. A., 1974, ZOOL VERHANDEL LEIDE, V130, P1; MCLAUGHLIN PA, 1983, J CRUSTACEAN BIOL, V3, P608, DOI 10.2307/1547956; PIKE R. B., 1960, PUBBL STAZ ZOOL NAPOLI, V31, P493; REESE ES, 1968, SCIENCE, V161, P385, DOI 10.1126/science.161.3839.385; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEVCIC Z, 1971, SYST ZOOL, V20, P331, DOI 10.2307/2412345; SWOFFORD DL, 1991, PAUP VERSION 3 0Q; Vermeij G.J., 1987, EVOLUTION ESCALATION; VERMEIJ GJ, 1991, SCIENCE, V253, P1099, DOI 10.1126/science.253.5024.1099; Williams A.B., 1984, SHRIMPS LOBSTERS CRA; Wolff T., 1961, Galathea Report, V4, P11	29	219	225	5	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					539	542		10.1038/355539a0	http://dx.doi.org/10.1038/355539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741031				2022-12-24	WOS:A1992HC52600056
J	SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E				SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E			RISK OF CANCER IN PATIENTS WITH DERMATOMYOSITIS OR POLYMYOSITIS - A POPULATION-BASED STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANCY; DISEASE	Background. An association between polymyositis and cancer was first proposed in 1916, but the existence of the association has been disputed. An association between dermatomyositis and cancer is better accepted, but its magnitude is not known. Methods. We undertook a study to provide accurate estimates of the risk of cancer in patients with dermatomyositis or polymyositis. We studied the incidence of cancer and the rate of mortality from cancer in a population-based cohort of 788 patients with dermatomyositis or polymyositis in Sweden from 1963 through 1983. The results were compared with those for the general population. Results. Among the 396 patients with polymyositis, 42 cancers were diagnosed at the same time or after polymyositis was diagnosed in 37 patients (9 percent). The relative risk of cancer was 1.8 (95 percent confidence interval, 1.1 to 2.7) in the male patients and 1.7 (95 percent confidence interval, 1.0 to 2.5) in the female patients. Eighty-four males and 85 females died, and in 24 of these cases (14 percent) cancer was the principal cause of death. The mortality ratio (the rate of mortality from cancer in these patients as compared with that in the general population) was 0.90 (95 percent confidence interval, 0.6 to 1.4). Among the 392 patients with dermatomyositis, 61 cancers were diagnosed at the same time or after dermatomyositis was diagnosed in 59 patients (15 percent). The relative risk of cancer was 2.4 (95 percent confidence interval, 1.6 to 3.6) in the male patients and 3.4 (95 percent confidence interval, 2.4 to 4.7) in the female patients. Fifty-seven males and 110 females died, and in 67 of these cases (40 percent) cancer was the principal cause of death (mortality ratio, 3.8; 95 percent confidence interval, 2.9 to 4.8). Conclusions. The risk of cancer is increased in patients with polymyositis or dermatomyositis. In patients with dermatomyositis there is also a higher rate of mortality from cancer.	HUDDINGE HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; NATL BOARD HLTH & WELF,STOCKHOLM,SWEDEN	National Board of Health & Welfare	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				BASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; BONNETBLANC JM, 1990, DERMATOLOGICA, V180, P212, DOI 10.1159/000248032; CALLEN JP, 1980, ARCH DERMATOL, V116, P295, DOI 10.1001/archderm.116.3.295; CARO I, 1989, MED CLIN N AM, V73, P1181; COX NH, 1990, ARCH DERMATOL, V126, P61, DOI 10.1001/archderm.126.1.61; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; Goh C L, 1983, Ann Acad Med Singap, V12, P6; HENRIKSSON KG, 1982, ACTA NEUROL SCAND, V65, P280, DOI 10.1111/j.1600-0404.1982.tb03087.x; HIDANO A, 1986, Journal of Dermatology (Tokyo), V13, P233; HOFFMAN GS, 1983, AM J MED, V75, P433, DOI 10.1016/0002-9343(83)90344-3; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MANCHUL LA, 1985, ARCH INTERN MED, V145, P1835, DOI 10.1001/archinte.145.10.1835; MATTSSON B, 1984, THESIS KAROLINSKA I; RICHARDSON JB, 1989, MED CLIN N AM, V73, P1211, DOI 10.1016/S0025-7125(16)30629-0; SIGURGEIRSSON B, 1991, COMPUT METH PROG BIO, V35, P193, DOI 10.1016/0169-2607(91)90121-9; Stertz G., 1916, BERL KLIN WOCHENSCHR, V53, P489; TYMMS KE, 1985, J RHEUMATOL, V12, P1140; VESTERAGER L, 1980, CLIN EXP DERMATOL, V5, P31, DOI 10.1111/j.1365-2230.1980.tb01661.x; 1960, CANCER INCIDENCE SWE; 1964, CAUSES DEATH SWEDEN	23	551	575	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					363	367		10.1056/NEJM199202063260602	http://dx.doi.org/10.1056/NEJM199202063260602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729618	Bronze			2022-12-24	WOS:A1992HC38600002
J	BRADLEY, CP				BRADLEY, CP			UNCOMFORTABLE PRESCRIBING DECISIONS - A CRITICAL INCIDENT STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To explore the discomfort experienced by general practitioners in relation to decisions about whether or not to prescribe. Design - Focused interviews of general practitioners about prescribing decisions that made them uncomfortable. Analysis based on the critical incident technique. Setting - One family practitioner committee area in the north of England. Respondents - 69 principals and five trainee general practitioners. Main outcome measures - Drugs and clinical problems associated with prescribing discomfort. Reasons given by doctors for making the prescribing decisions they did and reasons for feeling uncomfortable. Results - Antibiotics, tranquillisers, hypnotics, and symptomatic remedies were most often associated with discomfort, but any prescribeable item could be associated with discomfort. Respiratory diseases, musculoskeletal problems, and anxiety were most often associated with discomfort, but again any condition could be associated. The main reasons given for the decisions made were patient expectation, clinical appropriateness, factors related to the doctor-patient relationship, and precedents. The main reasons given for feeling uncomfortable were concern about drug toxicity, failure to live up to the general practitioner's own expectations, concern about the appropriateness of treatment, and ignorance or uncertainty. Conclusions - Many considerations, including medical, social, and logistic ones, influence the decision to prescribe in general practice. The final action taken depends on a complex interaction of these disparate influences.			BRADLEY, CP (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND.			Bradley, Colin/0000-0002-3595-9567				BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRADLEY CP, IN PRESS FAM PRACT; BRADLEY CP, 1990, THESIS U DUBLIN; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Glaser B. G., 1978, AWARENESS DYING; HARRIS CM, 1980, BRIT MED J, V281, P57; HEMMINKI E, 1975, MED CARE, V13, P150, DOI 10.1097/00005650-197502000-00006; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; PARISH PA, 1973, ROY SOC HEALTH J, V93, P213, DOI 10.1177/146642407309300414; 1986, 1981 1982 MORBIDITY; 1989, HLTH PERSONAL SOCIAL; 1987, BMA GUIDE LIVING RIS	12	145	146	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					294	296		10.1136/bmj.304.6822.294	http://dx.doi.org/10.1136/bmj.304.6822.294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739831	Green Published, Bronze			2022-12-24	WOS:A1992HC70800024
J	HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ				HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ			EXPERIMENTAL PHYLOGENETICS - GENERATION OF A KNOWN PHYLOGENY	SCIENCE			English	Article							PARSIMONY	Although methods of phylogenetic estimation are used routinely in comparative biology, direct tests of these methods are hampered by the lack of known phylogenies. Here a system based on serial propagation of bacteriophage T7 in the presence of a mutagen was used to create the first completely known phylogeny. Restriction-site maps of the terminal lineages were used to infer the evolutionary history of the experimental lines for comparison to the known history and actual ancestors. The five methods used to reconstruct branching pattern all predicted the correct topology but varied in their predictions of branch lengths; one method also predicts ancestral restriction maps and was found to bc greater than 98 percent accurate.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	HILLIS, DM (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.		Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019					ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; Brooks D.R., 1991, PHYLOGENY ECOLOGY BE; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Cochran W.G, 1957, STAT METHODS, V6th ed; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1985, SCIENCE, V228, P1169, DOI 10.1126/science.4001935; FITCH WM, 1987, MOL MORPHOLOGY EVOLU, P203; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HUELSENBECK JP, 1991, SYST ZOOL, V40, P257, DOI 10.2307/2992321; LAKE JA, 1987, MOL BIOL EVOL, V4, P167; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shennan SJ., 2009, INNOVATIONS CULTURAL, P53; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; STUDIER FW, 1980, CELLS BEHAVIOR VIEW, P72; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PHYLOGENETIC ANAL US; WHITE ME, 1991, 4TH P INT C SYST EV, P935; [No title captured]	21	214	215	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					589	592		10.1126/science.1736360	http://dx.doi.org/10.1126/science.1736360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736360				2022-12-24	WOS:A1992HB53100040
J	MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P				MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P			LIMBS GENERATED AT SITE OF TAIL AMPUTATION IN MARBLED BALLOON FROG AFTER VITAMIN-A TREATMENT	NATURE			English	Article							REGENERATING AXOLOTL LIMB; RETINOIC ACID; LOCAL APPLICATION; TADPOLES	NIAZI and Saxena 1 first observed that vitamin A has an inhibitory and modifying influence on tail regeneration in Bufo andersonii tadpoles. A positive relationship was later found between the inhibiting influence of vitamin A and the developmental stage of the regenerating tail in the same species 2. There have been several subsequent reports 3-7 on the effects of vitamin A and its derivatives on limb development and regeneration. Thus in regenerating amphibian limbs, application of retinoids produces pattern duplication in the proximodistal and anteroposterior axes of the limb 3,8,9, and local application of retinoic acid to the anterior side of developing chick limbs causes duplications in the anteroposterior axis of limb 10,11. Here we show that vitamin A can cause limb development when applied to amputated tail stumps of the tadpoles of the marbled balloon frog Uperodon systoma (Anura Microhylidae). This is the first report of homeotic transformation mediated through vitamin A in vertebrates.			MOHANTYHEJMADI, P (corresponding author), UTKAL UNIV, DEPT ZOOL, BHUBANESWAR 751004, ORISSA, INDIA.							DROBERTIS EM, 1990, SCI IT AM, P46; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1985, ROUX ARCH DEV BIOL, V194, P228, DOI 10.1007/BF00848251; MADEN M, 1983, J EMBRYOL EXP MORPH, V77, P273; Mohanty-Hejmadi P., 1977, Prakruti Utkal Univ J Sci, V11, P81; NIAZI IA, 1968, EXPERIENTIA, V24, P852, DOI 10.1007/BF02144915; NIAZI IA, 1984, ROUX ARCH DEV BIOL, V193, P111, DOI 10.1007/BF00848639; NIAZI IA, 1979, J EXP BIOL, V17, P866; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P35; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0	13	110	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					352	353		10.1038/355352a0	http://dx.doi.org/10.1038/355352a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731249				2022-12-24	WOS:A1992HA59100068
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - AIR-POLLUTION .2. ROAD TRAFFIC AND MODERN INDUSTRY	BRITISH MEDICAL JOURNAL			English	Article							DIESEL EXHAUST EXPOSURE; PARENTAL OCCUPATION; ASTHMATIC SUBJECTS; RAILROAD WORKERS; CHILDHOOD-CANCER; BLADDER-CANCER; LUNG-CANCER; ASSOCIATION; DIOXIDE											ANDERSON HR, 1987, ARCH DIS CHILD, V53, P295; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; BERCIANO FA, 1989, ANN ALLERGY, V62, P135; BLUMER M, 1977, ENVIRON SCI TECHNOL, V11, P1082, DOI 10.1021/es60135a002; BROWN LR, 1990, STATE WORLD 1990, P103; FERGUSSON M, 1989, ATMOSPHERIC EMISSION, V1; GARSHICK E, 1987, AM REV RESPIR DIS, V135, P1242; GARSHICK E, 1988, AM REV RESPIR DIS, V137, P820, DOI 10.1164/ajrccm/137.4.820; GILKS JML, 1989, CONCAWE889 REP; GUNNER G, 1991, Journal of Allergy and Clinical Immunology, V87, P185, DOI 10.1016/0091-6749(91)91469-A; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HOLMAN C, 1990, ROUTE AHEAD VEHICLE; HOWARD D, 1990, ENERGY TRANSPORT ENV; HUBER TE, 1954, AMA ARCH IND HYG OCC, V10, P399; JENSEN OM, 1987, SCAND J WORK ENV HEA, V13, P129, DOI 10.5271/sjweh.2070; KAPLAN I, 1959, JAMA-J AM MED ASSOC, V171, P97; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LINN WS, 1983, AM REV RESPIR DIS, V127, P234; MOHSENIN V, 1987, J TOXICOL ENV HEALTH, V22, P371, DOI 10.1080/15287398709531080; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; READ C, 1991, AIR POLLUTION CHILD; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360, DOI 10.5271/sjweh.1848; STEENLAND K, 1987, AM J EPIDEMIOL, V126, P247, DOI 10.1093/aje/126.2.247; VANDEHOUT KD, 1986, DIESEL EXHAUST AIR P; WILLIAMS RR, 1977, J NATL CANCER I, V59, P1147, DOI 10.1093/jnci/59.4.1147; 1988, TRANSPORT ENV; 1987, AIR QUALITY GUIDELIN; 1988, IARC MONOGRAPHS EVAL, V46; 1991, SOCIAL TRENDS, V20, P147; 1982, IARC MONOGRAPHS EVAL, V29; 1987, ENERGY CLEANER AIR C; 1984, REPORT SCI REV PANEL	33	17	17	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1539	1543		10.1136/bmj.303.6816.1539	http://dx.doi.org/10.1136/bmj.303.6816.1539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1723637	Green Published, Bronze			2022-12-24	WOS:A1991GV47600035
J	VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN				VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN			PROSPERO IS EXPRESSED IN NEURONAL PRECURSORS AND ENCODES A NUCLEAR-PROTEIN THAT IS INVOLVED IN THE CONTROL OF AXONAL OUTGROWTH IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; TRANSCRIPTION FACTOR; ZESTE GENE; ACTIVATION; EMBRYOS; LOCUS; MELANOGASTER; SEQUENCE; PRODUCT	Neurogenesis in Drosophila begins with the formation of neuronal precursors, which give rise to neurons of individual identity. To find out whether there are genes that are expressed in most or all neuronal precursors and are involved in controlling particular aspects of neuronal differentiation, we used the enhancer-trap method to screen for such "neuronal precursor genes." One gene of this group is prospero. Our mutant analysis indicates that prospero regulates other neuronal precursor genes and is essential for the axonal outgrowth and pathfinding of numerous central and peripheral neurons. prospero encodes a large nuclear protein with multiple homopolymeric amino acid stretches and is expressed in neuronal precursors early during their formation. It is probably generally required for proper neuronal differentiation.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VAESSIN, H (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1991, INT REV CYTOL, V124, P1; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FROHMAN MA, 1990, RACE RAPID AMPLIFICA, P28; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANSUKHANI A, 1988, MOL CELL BIOL, V8, P615, DOI 10.1128/MCB.8.2.615; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; POLLACK JA, 1985, CAL TECH BIOL ANN RE, V203; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; ROBERTSON HM, 1988, GENETICS, V118, P461; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	57	324	328	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					941	953		10.1016/0092-8674(91)90367-8	http://dx.doi.org/10.1016/0092-8674(91)90367-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720353				2022-12-24	WOS:A1991GT75500013
J	ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C				ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C			A MECHANOSENSITIVE CHANNEL IN WHOLE CELLS AND IN MEMBRANE PATCHES OF THE FUNGUS UROMYCES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; ESCHERICHIA-COLI; RUST FUNGUS; K+ CHANNEL; MUSCLE	Bean leaf stomata provide a topographical signal that induces germlings of the phytopathogen Uromyces appendiculatus to develop specialized infection structures. Protoplasts from germ tubes of this fungus, when examined with patch-clamp electrodes, displayed the Activities of a 600-picosiemen mechanosensitive ion channel. This channel passes a variety of cations, including Ca2+, and is blocked by Gd3+ at 50 micromolar. This channel could transduce the membrane stress induced by the leaf topography into an influx of ions, including Ca2+, that may trigger differentiation.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; CORNELL UNIV,NEW YORK STATE AGR EXPT STN,DEPT PLANT PATHOL,GENEVA,NY 14456	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cornell University								ALLEN EA, 1991, PHYTOPATHOLOGY, V81, P323, DOI 10.1094/Phyto-81-323; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; COLE GT, 1991, FUNGAL SPORE DISEASE, P25; EMMETT RW, 1975, ANNU REV PHYTOPATHOL, V13, P147, DOI 10.1146/annurev.py.13.090175.001051; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HOCH HC, 1987, ANNU REV PHYTOPATHOL, V25, P231, DOI 10.1146/annurev.py.25.090187.001311; HOCH HC, 1987, SCIENCE, V235, P1659, DOI 10.1126/science.235.4796.1659; HUANG D, 1990, PHYTOPATHOLOGY, V80, P81, DOI 10.1094/Phyto-80-81; KWON Y, IN PRESS CAN J BOT; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MORRIS CE, 1991, SCIENCE, V251, P246; Sachs F., 1986, P181; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; Spangler S G, 1972, Ala J Med Sci, V9, P218; STUMPF MPH, UNPUB; WYNN WK, 1976, PHYTOPATHOLOGY, V66, P136, DOI 10.1094/Phyto-66-136; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	21	151	153	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1415	1417		10.1126/science.1716786	http://dx.doi.org/10.1126/science.1716786			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716786				2022-12-24	WOS:A1991GF85100040
J	GOMEZ, N; COHEN, P				GOMEZ, N; COHEN, P			DISSECTION OF THE PROTEIN-KINASE CASCADE BY WHICH NERVE GROWTH-FACTOR ACTIVATES MAP KINASES	NATURE			English	Article							MYELIN BASIC-PROTEIN; OKADAIC ACID; PHOSPHORYLATION; INSULIN; CELLS; IDENTIFICATION; PHOSPHATASE-2A; LINE	MITOGEN activated protein (MAP) kinases (MAPKs) are a family of protein-serine/threonine kinases activated as an early intracellular response to a variety of hormones and growth factors 1-4. They are unique in requiring both serine/threonine and tyrosine phosphorylation to become active 5 and are the only examples of protein-serine/threonine kinases activated by tyrosine phosphorylation. Nerve growth factor (NGF) promotes differentiation of phaeochromocytoma (PC12) cells, which respond by conversion within hours from a chromaffin-like to a sympathetic neuron-like phenotype 6,7. NGF stimulation of PC12 cells increases the activity of two protein kinases by > 20-fold within minutes 8, both strikingly similar to MAPKs. They are inactivated by either protein-tyrosine phosphatases or the protein-serine/threonine phosphatase termed protein phosphatase 2A (ref. 8), they activate protein S6 kinase-II (refs 9, 10), and they phosphorylate identical threonine residues on myelin basic protein (our unpublished results) to those phosphorylated by other MAPKs 11,12. Immunological data 13 indicate that these protein kinases, termed peak-I and peak-II (Fig. 1a) are probably ERK2 and ERK1, respectively, two widely expressed MAPK isoforms 13. Here we identify the 'MAP kinase kinases' (MAPKKs) in PC12 cells which are activated by NGF and report that MAPKKs are dependent on serine/threonine phosphorylation for activity and promote phosphorylation of serine/threonine and tyrosine residues on MAPKs.			GOMEZ, N (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737				AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STREULI M, 1988, J EXP MED, V168, P1553; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001	30	564	571	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					170	173		10.1038/353170a0	http://dx.doi.org/10.1038/353170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1716348				2022-12-24	WOS:A1991GE73100055
J	MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS				MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS			A FUNCTIONAL C-MYB GENE IS REQUIRED FOR NORMAL MURINE FETAL HEPATIC HEMATOPOIESIS	CELL			English	Article							EMBRYONIC STEM-CELLS; DNA-BINDING DOMAIN; MOUSE ERYTHROLEUKEMIA-CELLS; AVIAN-MYELOBLASTOSIS VIRUS; HOMOLOGOUS RECOMBINATION; PROTO-ONCOGENE; LEUKEMIA-VIRUS; V-MYB; NUCLEOTIDE-SEQUENCE; INSERTIONAL MUTAGENESIS	The c-myb proto-oncogene encodes a sequence-specific DNA-binding protein. To better understand its normal biological function, we have altered the c-myb gene by homologous recombination in mouse embryonic stem cells. Resulting homozygous c-myb mutant mice displayed an interesting phenotype. At day 13 of gestation these mice appeared normal, suggesting that c-myb is not essential for early development. By day 15, however, the mutant mice were severely anemic. Analysis indicated that embryonic erythropoiesis, which occurs in the yolk sac, was not impaired by the c-myb alteration. Adult-type erythropoiesis, which first takes place in the fetal liver, was greatly diminished in c-myb mutants, however. Additional hematopoietic lineages were similarly affected. These results are compatible with a role for c-myb in maintaining the proliferative state of hematopoietic progenitor cells.	UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT HEMATOL ONCOL,CINCINNATI,OH 45229	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	MUCENSKI, ML (corresponding author), UNIV CINCINNATI,CHILDRENS HOSP,COLL MED,RES FDN,CINCINNATI,OH 45229, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P60HL015996] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496, HL15996] Funding Source: Medline; NICHD NIH HHS [HD24517] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; COLLINS MD, 1989, AM J PHYSIOL, V257, P542; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; CRAIG RW, 1984, CANCER RES, V44, P442; CUDENNEC LA, 1981, P NATL ACAD SCI USA, V78, P2412; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DYSON PJ, 1989, DIFFERENTIATION, V42, P24, DOI 10.1111/j.1432-0436.1989.tb00603.x; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FANTONI A, 1967, SCIENCE, V157, P1327, DOI 10.1126/science.157.3794.1327; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; HENRY JB, 1979, TS DAVIDSOHN CLIN DI; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUANG E, 1990, CELL, V63, P255; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; KRAKOWSKY JM, 1989, DNA-J MOLEC CELL BIO, V8, P715, DOI 10.1089/dna.1989.8.715; KUCZUK MH, 1984, TERATOLOGY, V29, P427, DOI 10.1002/tera.1420290314; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P115; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SHEHEE WR, 1989, J MOL BIOL, V205, P41, DOI 10.1016/0022-2836(89)90363-X; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SIRACUSA LD, 1987, GENETICS, V117, P85; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; Tavassoli M, 1983, BONE MARROW STRUCTUR; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WAHLS WP, 1990, MOL CELL BIOL, V10, P794, DOI 10.1128/MCB.10.2.794; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wilson J.G., 1965, TERATOLOGY PRINCIPLE, P251; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	100	924	951	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					677	689		10.1016/0092-8674(91)90099-K	http://dx.doi.org/10.1016/0092-8674(91)90099-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709592				2022-12-24	WOS:A1991FM03700017
J	ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F				ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F			HYALINE GLOBULES REACTING POSITIVELY WITH ZIDOVUDINE ANTIBODY IN BRAIN AND SPINAL-CORD OF AIDS PATIENTS	LANCET			English	Note							3'-AZIDO-3'-DEOXYTHYMIDINE; DIDEOXYNUCLEOSIDES	Histology of the central nervous system in nine AIDS patients who had been treated with zidovudine showed extracellular hyaline globules in the white matter of the brain and the spinal cord. In immunohistochemical studies with a battery of antibodies, the only positive reaction of these globules was with an antibody to zidovudine. High-performance liquid chromatography showed the presence of a zidovudine isomer in eluates of brain tissue from these patients.	AUGUSTE VIKTORIA KRANKENHAUS, DEPT MED, W-1000 BERLIN 41, GERMANY; AUGUSTE VIKTORIA KRANKENHAUS, DEPT CLIN BIOCHEM, W-1000 BERLIN 41, GERMANY		ARTIGAS, J (corresponding author), AUGUSTE VIKTORIA KRANKENHAUS, INST PATHOL, RUBENSTR 125, W-1000 BERLIN 41, GERMANY.							DAVTYAN DG, 1987, LANCET, V1, P919; ELLISON S, 1988, CLIN RES, V36, pA117; HAGLER DN, 1986, LANCET, V2, P1392; HARRIS PJ, 1988, NEW ENGL J MED, V318, P250, DOI 10.1056/NEJM198801283180412; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; SPEAR JB, 1988, ANN INTERN MED, V109, P76, DOI 10.7326/0003-4819-109-1-76; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; 1991, BIOCH ORGANIC COMPOU, P1204	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1127	1128		10.1016/0140-6736(91)92790-9	http://dx.doi.org/10.1016/0140-6736(91)92790-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1709247				2022-12-24	WOS:A1991FL12400007
J	AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J				AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J			IMMUNOMODULATION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY ANTIBODIES TO THE ANTIGEN-IA COMPLEX	NATURE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; CLASS-II; T-CELLS; HISTOCOMPATIBILITY MOLECULES; IMMUNE-RESPONSE; PEPTIDE; BINDING; VACCINATION; RECOGNITION	AUTOIMMUNE diseases occur when T lymphocytes become activated on recognizing self antigen linked to the autologous class II molecule of the major histocompatibility complex (MHC) 1,2. The resulting complex of antigen MHC T-cell receptor could be a target for treatment of autoimmune diseases. Studies in which each component is blocked separately 3-10 might be limited by interference in non-relevant immune responses that either use the same set of T-cell-receptor V gene segments or are linked to the same MHC. We report here an attack by a specific antibody on the unique antigenic site formed by the binding of two components of the trimolecular complex, the autoantigen bound to the self MHC 11-14. We tested its effect in experimental allergic encephalomyelitis, an acute neurological autoimmune disease which is widely regarded as a model for autoimmune disorders 15-17 and which is mediated by CD4+ T cells recognizing myelin basic protein (BP), or its peptides, in association with self Ia 18,19. We made monoclonal antibodies which bound only the complex of BP and I-A(s). These antibodies blocked the proliferative response in vitro to the encephalitogenic determinant of BP and reduced the response to intact BP, without affecting the response to a nonrelevant antigen-purified protein derivative of tuberculin presented on syngeneic macrophages. They also inhibited experimental allergic encephalomyelitis in H-2s mice. Hence, antibodies directed specifically to the autoantigen-Ia complex, may offer a highly selective and effective treatment in autoimmune diseases.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; DEMOTZ S, 1989, 7TH P INT C IMM, P60; ESHHAR Z, 1980, J IMMUNOL, V124, P775; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FRITZ RB, 1985, J IMMUNOL, V134, P2328; HIRSHFELD H, 1970, FEBS LETT, V7, P317, DOI 10.1016/0014-5793(70)80193-4; HOHFELD R, 1989, ANN NEUROL, V25, P532; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; OFFNER H, 1986, CELL IMMUNOL, V100, P364, DOI 10.1016/0008-8749(86)90036-5; PATERSON PY, 1977, AUTOIMMUNITY, P644; PURI J, 1980, EUR J IMMUNOL, V10, P273, DOI 10.1002/eji.1830100410; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SRIRAM S, 1987, J IMMUNOL, V139, P1485; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; URBAN JL, 1989, CELL, V59, P257, DOI 10.1016/0092-8674(89)90288-2; URBAN JL, 1980, CELL, V10, P273; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	25	90	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					147	150		10.1038/351147a0	http://dx.doi.org/10.1038/351147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709449				2022-12-24	WOS:A1991FL03500051
J	GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB				GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB			ACTIVATION OF EPSTEIN-BARR-VIRUS LATENT GENES PROTECTS HUMAN B-CELLS FROM DEATH BY APOPTOSIS	NATURE			English	Article							ENDEMIC BURKITTS-LYMPHOMA; DEPENDENCE; EXPRESSION; PHENOTYPE; LINES; EBV	EPSTEIN-Barr virus (EBV), a human herpesvirus, establishes a persistent asymptomatic infection of the circulating B-lymphocyte pool 1-3. The mechanism of virus persistence is not understood but, given the limited lifespan of most B cells in vivo, it seems most likely that EBV-infected cells must gain access to the long-lived memory B-cell pool. Here we show in an in vitro system that EBV, through expression of the full set of eight virus-coded 'latent' proteins, can protect human B cells from programmed cell death (apoptosis), the deletion mechanism which normally restricts entry into memory 4. We have found that EBV-positive Burkitt's lymphoma (BL) cell clones 5 retaining the original tumour cell phenotype and expressing only one of the virus latent proteins, the nuclear antigen EBNA 1, are extremely sensitive to apoptosis; in this respect they resemble the tumour's normal cell of origin found in the germinal centres of lymphoid tissue. By contrast, isogenic BL cell clones which have activated expression of all eight EBV latent proteins are resistant to the induction of apoptosis. The EBV latent proteins should therefore be seen not just as activators of B-cell proliferation but, perhaps more importantly, as mediators of enhanced B-cell survival.	UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BIRMINGHAM, DEPT ANAT, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV ASTON, INST PHARMACEUT SCI, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; Aston University	GREGORY, CD (corresponding author), UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.			Hope, Sheila/0000-0002-3608-4379; Williams, Gwyn/0000-0003-4556-9930; Dive, Caroline/0000-0002-1726-8850				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Berard C W, 1985, IARC Sci Publ, P31; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PENNELL CA, 1986, EUR J IMMUNOL, V16, P1577, DOI 10.1002/eji.1830161217; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	23	510	525	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					612	614		10.1038/349612a0	http://dx.doi.org/10.1038/349612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1705663				2022-12-24	WOS:A1991EX57000060
J	WILLIAMS, DE; EISENMAN, J; BAIRD, A; RAUCH, C; VANNESS, K; MARCH, CJ; PARK, LS; MARTIN, U; MOCHIZUKI, DY; BOSWELL, HS; BURGESS, GS; COSMAN, D; LYMAN, SD				WILLIAMS, DE; EISENMAN, J; BAIRD, A; RAUCH, C; VANNESS, K; MARCH, CJ; PARK, LS; MARTIN, U; MOCHIZUKI, DY; BOSWELL, HS; BURGESS, GS; COSMAN, D; LYMAN, SD			IDENTIFICATION OF A LIGAND FOR THE C-KIT PROTOONCOGENE	CELL			English	Article									IMMUNEX CORP,DEPT PROT CHEM,SEATTLE,WA 98101; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101; INDIANA UNIV,VET ADM HOSP,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46223	Immunex Corporation; Immunex Corporation; Immunex Corporation; Indiana University System; Indiana University-Purdue University Indianapolis	WILLIAMS, DE (corresponding author), IMMUNEX CORP,DEPT EXPTL HEMATOL,51 UNIV ST,SEATTLE,WA 98101, USA.							BERNSTEIN SE, 1968, ANN NY ACAD SCI, V149, P475, DOI 10.1111/j.1749-6632.1968.tb15186.x; BERNSTEIN SE, 1970, AM J SURG, V119, P448, DOI 10.1016/0002-9610(70)90148-0; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BOSWELL HS, 1987, EXP HEMATOL, V15, P46; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COCHET C, 1988, J BIOL CHEM, V263, P3290; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; ELIASON JF, 1988, EXP HEMATOL, V16, P307; FRIED W, 1973, BRIT J HAEMATOL, V24, P643, DOI 10.1111/j.1365-2141.1973.tb01690.x; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GUALTIERI RJ, 1987, EXP HEMATOL, V15, P883; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; LEBEAU MM, 1987, P NATL ACAD SCI USA, V84, P5913; LI CL, 1985, NATURE, V316, P633, DOI 10.1038/316633a0; LYMAN SD, 1989, ONCOGENE RES, V4, P149; Maniatis T., 1982, MOL CLONING; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURPHY ED, 1973, TRANSPLANTATION, V15, P526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; PARK LS, 1986, J BIOL CHEM, V261, P4177; PARK LS, 1986, J BIOL CHEM, V261, P205; PARK LS, 1989, J BIOL CHEM, V264, P5420; PRESTIDGE RL, 1984, J IMMUNOL, V133, P293; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1956, SCIENCE, V124, P1076, DOI 10.1126/science.124.3231.1076; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WILLIAMS DE, 1990, IN PRESS BLOOD; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	44	995	1032	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					167	174		10.1016/0092-8674(90)90297-R	http://dx.doi.org/10.1016/0092-8674(90)90297-R			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698553				2022-12-24	WOS:A1990EB46100017
J	PIRCHER, H; MOSKOPHIDIS, D; ROHRER, U; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM				PIRCHER, H; MOSKOPHIDIS, D; ROHRER, U; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM			VIRAL ESCAPE BY SELECTION OF CYTOTOXIC T-CELL-RESISTANT VIRUS VARIANTS INVIVO	NATURE			English	Article									SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz	PIRCHER, H (corresponding author), UNIV HOSP ZURICH, INST PATHOL, CH-8091 ZURICH, SWITZERLAND.							AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; ARALACHAVES MP, 1988, AM J VET RES, V49, P1955; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CATTANEO R, 1988, J VIROL, V62, P1388, DOI 10.1128/JVI.62.4.1388-1397.1988; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DENT PB, 1972, PROG MED VIROL, V14, P1; DESTGROTH SF, 1981, IMMUNE SYSTEM, V1, P155; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; FENYO EM, 1988, J VIROL, V62, P4414; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GLASGOW LA, 1971, FED PROC, V30, P1846; Gresser I, 1966, Prog Med Virol, V8, P62; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; JOSEPH BS, 1975, J EXP MED, V142, P864, DOI 10.1084/jem.142.4.864; KVIST S, 1978, P NATL ACAD SCI USA, V75, P5674, DOI 10.1073/pnas.75.11.5674; LAVER WG, 1973, VIROLOGY, V51, P383, DOI 10.1016/0042-6822(73)90437-6; LAVER WG, 1979, VIROLOGY, V98, P226, DOI 10.1016/0042-6822(79)90540-3; LEHMANNGRUBE F, 1977, J GEN VIROL, V37, P85, DOI 10.1099/0022-1317-37-1-85; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; MCCLURE HM, 1989, VET IMMUNOL IMMUNOP, V21, P13, DOI 10.1016/0165-2427(89)90126-8; MCINTYRE KW, 1985, ANTIVIR RES, V5, P299, DOI 10.1016/0166-3542(85)90044-0; MIMS CA, 1982, PATHOGENESIS INFECTI; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; MURRAY RJ, 1989, PROG IMMUN, V7, P939; NARAYAN O, 1977, SCIENCE, V197, P376, DOI 10.1126/science.195339; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO; OLDSTONE MBA, 1987, CURR TOP MICROBIOL, V133, P1; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PALESE P, 1982, SCIENCE, V215, P1468, DOI 10.1126/science.7038875; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; POPESCU M, 1976, J GEN VIROL, V30, P113, DOI 10.1099/0022-1317-30-1-113; POZSGAY JM, 1989, VIROLOGY, V173, P330, DOI 10.1016/0042-6822(89)90251-1; RIVIERE Y, 1987, CURR TOP MICROBIOL, V133, P59; RIVIERE Y, 1986, J VIROL, V59, P363, DOI 10.1128/JVI.59.2.363-368.1986; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377, DOI 10.1016/S0065-2776(08)60665-3; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SOUTHERN PJ, 1987, VIROLOGY, V157, P145, DOI 10.1016/0042-6822(87)90323-0; STEVENS JG, 1971, SCIENCE, V173, P843, DOI 10.1126/science.173.3999.843; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WHITE HD, 1990, J VIROL, V64, P2608, DOI 10.1128/JVI.64.6.2608-2619.1990; YEWDELL JW, 1979, NATURE, V279, P246, DOI 10.1038/279246a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZINKERNAGEL RM, 1976, J IMMUNOL, V117, P1495	59	511	518	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 16	1990	346	6285					629	633		10.1038/346629a0	http://dx.doi.org/10.1038/346629a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU728	1696684				2022-12-24	WOS:A1990DU72800051
J	ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D				ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D			THE USE OF TRANSCRANIAL ULTRASONOGRAPHY TO PREDICT STROKE IN SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; DOPPLER ULTRASOUND; CNS INFARCTION; ANEMIA; TRANSFUSION; CHILDREN	Background. Stroke, especially cerebral infarction, is a major cause of morbidity and mortality in children with sickle cell disease. Primary prevention of stroke by transfusion therapy may be feasible if there is a way to identify the patients at greatest risk. Transcranial Doppler ultrasonography can measure flow velocity in the large intracranial arteries, The narrowing of these arteries, which leads to cerebral infarction, is characterized by an increased velocity of flow. Methods. Using transcranial Doppler ultrasonography, we prospectively measured the velocity of cerebral blood flow in children and young adults being followed because of sickle cell disease. The results were classified as either normal or abnormal on the basis of the highest velocity of flow in the middle cerebral artery. Abnormal velocity was defined as a flow greater-than-or-equal-to 170 cm per second, a definition determined by post hoc analysis to maximize the predictive success of the test. The end point was a clinically apparent first cerebral infarction. Results. Two hundred eighty-three transcranial ultrasound examinations were performed in 190 patients with sickle cell disease (age at entry, 3 to 18 years). After an average follow-up of 29 months, cerebral infarction was diagnosed in seven patients. In 23 patients the results of the ultrasound examinations were abnormal, and in 167 patients they were normal. The clinical and hematologic characteristics of the two groups were similar, but six of the seven strokes occurred among the 23 patients with abnormal ultrasound results (P < 0.00001 by Fisher's exact test). In this group, the relative risk of stroke was 44 (95 percent confidence interval, 5.5 to 346). Conclusions. Transcranial ultrasonography can identify the children with sickle cell disease who are at highest risk for cerebral infarction. Periodic ultrasound examinations and the selective use of transfusion therapy could make the primary prevention of stroke an achievable goal.	MED COLL GEORGIA,DEPT PEDIAT,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT RADIOL,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT BIOSTAT,AUGUSTA,GA 30912	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	ADAMS, R (corresponding author), MED COLL GEORGIA,DEPT NEUROL,HB-2060,AUGUSTA,GA 30912, USA.				NHLBI NIH HHS [1PO1 HL 41544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1986, TRANSCRANIAL DOPPLER, P39; ADAMS R J, 1991, Neurology, V41, P182; ADAMS RJ, 1988, STROKE, V19, P518, DOI 10.1161/01.STR.19.4.518; ADAMS RJ, 1988, J CARDIOVASC ULTRAS, V7, P201; ADAMS RJ, 1989, J CARDIOVASC TECHNOL, V8, P97; ADAMS RJ, 1990, AM J PEDIAT HEMATOL, V12, P277; ADAMS RJ, 1988, NEUROLOGY, V38, P1012, DOI 10.1212/WNL.38.7.1012; ADAMS RJ, 1989, VASCULAR DISEASES 3, V55, P503; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BODE H, 1988, PEDIATRIC APPLICATIO; BOROS L, 1976, J NEUROL NEUROSUR PS, V39, P1236, DOI 10.1136/jnnp.39.12.1236; BRASS LM, 1991, STROKE, V22, P27, DOI 10.1161/01.STR.22.1.27; Bridgers WH, 1939, AM J PATHOL, V15, P353; CHARACHE S, 1989, DHHS NIH892117 PUBL, P22; GERALD B, 1980, AM J ROENTGENOL, V134, P1209, DOI 10.2214/ajr.134.6.1209; GREER M, 1962, NEUROLOGY, V12, P114, DOI 10.1212/WNL.12.2.114; HUISMAN THJ, 1977, CLIN BIOCH ANAL SERI, V6; JEFFRIES BF, 1980, SURG NEUROL, V14, P291; Koshy M, 1990, J Assoc Acad Minor Phys, V1, P71; LEYPOZO J, 1990, ANN NEUROL, V28, P640, DOI 10.1002/ana.410280507; LUSHER JM, 1976, AM J HEMATOL, V1, P265, DOI 10.1002/ajh.2830010210; MAEDA H, 1990, ULTRASOUND MED BIOL, V16, P9, DOI 10.1016/0301-5629(90)90080-V; MERKEL KHH, 1978, STROKE, V9, P45, DOI 10.1161/01.STR.9.1.45; Pavlakis S G, 1989, Adv Pediatr, V36, P247; PAVLAKIS SG, 1988, ANN NEUROL, V23, P125, DOI 10.1002/ana.410230204; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; PROHOVNIK I, 1989, NEUROLOGY, V39, P344, DOI 10.1212/WNL.39.3.344; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SARNAIK S, 1979, AM J DIS CHILD, V133, P1254, DOI 10.1001/archpedi.1979.02130120046009; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SERJEANT GR, 1985, SICKLE CELL DIS, P233; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; Sydenstricked VP, 1923, AM J DIS CHILD, V26, P132, DOI 10.1001/archpedi.1923.04120140031004; WILSON JB, 1983, J LAB CLIN MED, V102, P174; WIZNITZER M, 1990, J PEDIATR-US, V117, P551, DOI 10.1016/S0022-3476(05)80687-0; 1989, SAS STAT USERS GUIDE	39	452	458	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					605	610		10.1056/NEJM199202273260905	http://dx.doi.org/10.1056/NEJM199202273260905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734251				2022-12-24	WOS:A1992HF63300005
J	FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK				FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK			URINE FREE CORTISOL IN THE HIGH-DOSE DEXAMETHASONE SUPPRESSION TEST FOR THE DIFFERENTIAL-DIAGNOSIS OF THE CUSHING SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						DIAGNOSIS, DIFFERENTIAL; CUSHING SYNDROME; PITUITARY DISEASE; DEXAMETHASONE; HYDROCORTISONE	LABORATORY TESTS; UPDATE	Objective: To develop criteria for interpreting the high-dose dexamethasone suppression test using urine free cortisol as an end point for the differential diagnosis of the Cushing syndrome. Design: Retrospective review. Setting: Inpatient research ward. Patients: Patients (118) with surgically confirmed causes of the Cushing syndrome: 94 with pituitary disease, 14 with primary adrenal disease, and 10 with ectopic adrenocorticotropic hormone (ACTH) secretion. Main Outcome Measures: The sensitivity, specificity, and diagnostic accuracy were determined for the high-dose dexamethasone suppression test using urine free cortisol and using 17-hydroxysteroid excretion. For each analysis, patients with pituitary disease were considered to be "diseased" and patients with nonpituitary disease were considered to be "non-diseased". The level of suppression that gave 100% specificity was determined for each steroid. Results: The accuracy of urine free cortisol when used as an end point in the high-dose dexamethasone suppression test was equivalent to that of 17-hydroxysteroid excretion. At all levels of sensitivity and specificity, however, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease was greater than that of 17-hydroxysteroid excretion. The likelihood ratios for pituitary disease based on urine free cortisol suppression of > 50%, of > 80%, and of > 90% were 4.2, 10.1, and "infinite," respectively. Suppression of urine free cortisol greater than 90% or suppression of 17-hydroxysteroid excretion greater than 64% was associated with 100% specificity. When these criteria were combined, the percentage of correct predictions (102 of 118 [86%; 95% Cl, 78% to 92%]) was higher than that obtained using either steroid alone (89 of 118 [75%; Cl, 65% to 83%]) (P = 0.009) and higher than that obtained using the traditional criterion of 50% suppression for 17-hydroxysteroid excretion (95 of 118 [80%; Cl, 71% to 87%]) (P = 0.016). Conclusions: In the high-dose dexamethasone suppression test, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease is greater than that traditionally used for 17-hydroxysteroid excretion. The diagnostic performance of the test is improved by measuring both urine free cortisol and 17-hydroxysteroid excretion and by requiring greater suppression of both steroids.			FLACK, MR (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLD 10, ROOM 10N262, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							BEARDWELL CG, 1968, J ENDOCRINOL, V42, P79, DOI 10.1677/joe.0.0420079; BEISEL WR, 1964, J CLIN ENDOCR METAB, V24, P887, DOI 10.1210/jcem-24-9-887; BORUSHEK S, 1964, CLIN CHEM, V10, P41; BROWN RD, 1973, J CLIN ENDOCR METAB, V36, P445; BROWNLEE KA, 1965, STATISTICAL THEORY M, P262; BURKE CW, 1973, Q J MED, V42, P175; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; COPE CL, 1959, BR MED J        1128, P1117; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; EDDY RL, 1973, AM J MED, V55, P621, DOI 10.1016/0002-9343(73)90184-8; FORMAN DT, 1978, MANUAL PROCEDURES SE, P135; GOLD EM, 1979, ANN INTERN MED, V90, P829, DOI 10.7326/0003-4819-90-5-829; HANKIN ME, 1977, CLIN ENDOCRINOL, V6, P185, DOI 10.1111/j.1365-2265.1977.tb03314.x; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LORIAUX DL, 1986, CLIN ENDOCRINOL, P167; MARTIN MM, 1966, J CLIN ENDOCR METAB, V26, P257, DOI 10.1210/jcem-26-3-257; MORRISON DF, 1984, MULTIVARIATE STATIST, P34; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NICHOLS T, 1968, AM J MED, V45, P116, DOI 10.1016/0002-9343(68)90013-2; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; SHEELER LR, 1988, CLEV CLIN J MED, V55, P329, DOI 10.3949/ccjm.55.4.329; SILBER RH, 1950, J BIOL CHEM, V185, P923; SILBER RH, 1954, J BIOL CHEM, V21, P262; SINDLER BH, 1983, AM J MED, V74, P657, DOI 10.1016/0002-9343(83)91024-0; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; YOUNG DS, 1975, CLIN CHEM, V21, pD1; 1983, CAN MED ASSOC J, V129, P947	31	128	137	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					211	217		10.7326/0003-4819-116-3-211	http://dx.doi.org/10.7326/0003-4819-116-3-211			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728204				2022-12-24	WOS:A1992HB35600006
J	KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ				KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ			MORTALITY AND OCCUPATIONAL EXPOSURE TO RADIATION - 1ST ANALYSIS OF THE NATIONAL-REGISTRY-FOR-RADIATION-WORKERS	BRITISH MEDICAL JOURNAL			English	Article							EMPLOYEES; PROGRAM; COHORT; CANCER; PLANT; RISK	Objective - To study cause specific mortality of radiation workers with particular reference to associations between fatal neoplasms and level of exposure to radiation. Design - Cohort study. Setting - United Kingdom. Subjects - 95 217 radiation workers at major sites of the nuclear industry. Main outcome measure - Cause of death. Results - Most standardised mortality ratios were below 100: 83 unlagged, 85 with a 10 year lag for all causes; 84 unlagged, 86 lagged for all cancers; and 80 for all known other causes, indicating a "healthy worker effect." The deficit of lung cancer (75 unlagged, 76 lagged) was significant at the 0.1% level. Standardised mortality ratios were significantly raised (214 unlagged, 303 lagged) for thyroid cancer, but there was no evidence for any trend with external recorded radiation dose. Dose of external radiation and mortality from all cancers were weakly correlated (p = 0.10), and multiple myeloma was more strongly correlated (p = 0.06); for leukaemia, excluding chronic lymphatic, the trend was significant (p = 0.03; all tests one tailed). The central estimates of lifetime risk derived from these data were 10.0% per Sv (90% confidence interval < 0 to 24%) for all cancers and 0.76% per Sv (0.07 to 2.4%) for leukaemia (excluding chronic lymphatic leukaemia). These are, respectively, 2.5 times and 1.9 times the risk estimates recommended by the International Commission on Radiological Protection, but 90% confidence intervals are large and the commission's risk factors fall well within the range. The positive trend with dose for all cancers, from which the risk estimate was derived, was not significant. The positive association between leukaemia (except chronic lymphatic leukaemia) was significant and robust in subsidiary analyses. This study showed no association between radiation exposure and prostatic cancer. Conclusion - There is evidence for an association between radiation exposure and mortality from cancer, in particular leukaemia (excluding chronic lymphatic leukaemia) and multiple myeloma, although mortality from these diseases in the study population overall was below that in the general population. The central estimates of risk from this study lie above the most recent estimates of the International Commission on Radiological Protection for leukaemia (excluding chronic lymphatic leukaemia) and for all malignancies. However, the commission's risk estimates are well within the 90% confidence intervals from this study. Analysis of States indicated lower risk estimates than the commission recommends, and when the American data are combined with our analysis the overall risks are close to those estimated by the commission. This first analysis of the National Registry for Radiation Workers does not provide sufficient evidence to justify a revision in risk estimates for radiological protection purposes.			KENDALL, GM (corresponding author), NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND.			Muirhead, Colin/0000-0001-5394-1267; Butland, Barbara/0000-0001-9952-3108				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; BARRY SF, 1986, BRIT J IND MED, V43, P572; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BINKS K, 1989, RADIATION PROTECTION - THEORY AND PRACTICE, P49; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; Cox DR, 1974, THEORETICAL STATISTI; DARBY SC, 1981, J R STAT SOC A STAT, V144, P298, DOI 10.2307/2981797; DARBY SC, 1981, NRPBR116; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GILBERT E S, 1990, Radiation Research, V124, P348; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; GODWIN P, 1975, NATURE, V255, P517; KENDALL GM, 1992, NRPBR251; MUIRHEAD CR, 1991, RADIAT PROT DOSIM, V36, P321; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; 1971, DECENNIAL SUPPLEMENT; 1978, DS1 OFF POP CENS SUR; 1986, DS6 OFF POP CENS SUR; 1991, ICR PUBLICATION, V60, P1	21	152	161	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					220	225		10.1136/bmj.304.6821.220	http://dx.doi.org/10.1136/bmj.304.6821.220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739796	Green Published, Bronze			2022-12-24	WOS:A1992HA98000024
J	FERGUSON, BM; FANGMAN, WL				FERGUSON, BM; FANGMAN, WL			A POSITION EFFECT ON THE TIME OF REPLICATION ORIGIN ACTIVATION IN YEAST	CELL			English	Article							S-PHASE; DNA-REPLICATION; CELLS	The chromosomes of eukaryotes are characterized by the mosaic nature of their replication - large regions of DNA that replicate early in S phase are interspersed with regions that replicate late. This pattern of early and late synthesis appears to be the consequence of a temporal program that activates replication origins at different times. The basis of this temporal regulation in the yeast S. cerevisiae has been investigated by changing the chromosomal locations of two origins, one activated early in the S phase (ARS1) and one activated late (ARS501). We show that the cis-acting information controlling time of activation can be separated from the element that determines origin function. For the ARS501 origin, late activation appears to be a consequence of its proximity to the telomere.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM18926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; DUBEY DD, 1991, IN PRESS MOL CELL BI; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; HAND R, 1975, J CELL BIOL, V64, P89, DOI 10.1083/jcb.64.1.89; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARPEN GH, 1990, CELL, V63, P97; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	20	225	227	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					333	339		10.1016/0092-8674(92)90474-Q	http://dx.doi.org/10.1016/0092-8674(92)90474-Q			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733502				2022-12-24	WOS:A1992HB35300012
J	RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL				RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL			DEXFENFLURAMINE NEUROTOXICITY IN BRAINS OF NONHUMAN-PRIMATES	LANCET			English	Note							RAT-BRAIN; FENFLURAMINE	Dexfenfluramine, a drug prescribed for appetite suppression, was evaluated in non-human primates for its potential to produce toxic effects on brain serotonin (5-HT) neurons. Squirrel monkeys received dexfenfluramine subcutaneously twice daily for four days at doses of 1.25 or 5.00 mg/kg. Two weeks later, a dose-related depletion of 5-HT and 5-hydroxyindoleacetic acid was found, together with a reduced number of 5-HT uptake sites. Morphological studies showed acute pathological changes in 5-HT axons, followed by a persistent decrease in 5-HT axon density. Our findings indicate that dexfenfluramine damages central 5-HT neurons in monkeys and raise concern about the potential neurotoxicity of this drug in man.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; NIDA,ADDICT RES CTR,BALTIMORE,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	RICAURTE, GA (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,DEPT NEUROL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.			Katz, Jonathan/0000-0002-1068-1159	NIDA NIH HHS [DA05707, DA04431] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005707, R29DA005707, R01DA004431] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALPHIN RS, 1969, TOXICOL APPL PHARM, V14, P182, DOI 10.1016/0041-008X(69)90178-1; CACCIA S, 1982, ARCH INT PHARMACOD T, V258, P15; CAMPBELL DB, 1986, DEV DRUGS MODERN MED, P298; GARATTINI S, 1987, BODY WEIGHT CONTROL, P261; GUYGRAND B, 1989, LANCET, V2, P1142; KLEVEN MS, 1989, BRAIN RES, V505, P351, DOI 10.1016/0006-8993(89)91467-4; MOLLIVER DC, 1990, BRAIN RES, V511, P165, DOI 10.1016/0006-8993(90)90237-6; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; SANDLER M, 1991, 5 HYDROXYTRYPTAMINE; ZACZEK R, 1990, J PHARMACOL EXP THER, V253, P104	10	76	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1487	1488		10.1016/0140-6736(91)92301-H	http://dx.doi.org/10.1016/0140-6736(91)92301-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1720853				2022-12-24	WOS:A1991GV07700005
J	SETO, E; SHI, Y; SHENK, T				SETO, E; SHI, Y; SHENK, T			YY1 IS AN INITIATOR SEQUENCE-BINDING PROTEIN THAT DIRECTS AND ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							MAMMARY-TUMOR VIRUS; MAJOR LATE PROMOTER; LONG-TERMINAL REPEAT; RNA POLYMERASE-II; CONTROL REGION; GENE; BOX; TATA; IDENTIFICATION; PURIFICATION	REGULATION of eukaryotic messenger RNA transcription is governed by DNA sequence elements that serve as binding sites for sequence-specific transcription factors 1-3. These include upstream and downstream promoter-proximal elements, enhancers, repressors, and silencers, which modulate the rate of specific initiation by RNA polymerase II. In addition, the promoter-proximal region between -45 and +30 (relative to the start of initiation) contains two highly conserved motifs, the TATA sequence at around -30 and CA at +1 (ref. 4). Although the TATA element-binding factor TFIID has been purified and cloned from several organisms and has provided invaluable insight into the process of transcription initiation and its regulation, little is known about factors that interact at the +1 region. We have recently shown that the adeno-associated virus type 2 P5 promoter +1 region (P5 + 1 element) binds transcription factor YY1 (ref. 5). We report here that this sequence is necessary and sufficient for accurate basal transcription. Further, partially purified YY1 can restore basal level transcription from a P5 + 1 element in a HeLa extract depleted for YY1 or a Drosophila embryo extract devoid of YY1 activity, whereas a YY1-specific antibody can block the reactivation. Finally, using electrophoretic mobility shift assay, we have identified YY1-related factors that bind to two other transcription initiators in cellular genes.	PRINCETON UNIV,DEPT MOLEC BIOL,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University								BOYER TG, 1990, J BIOL CHEM, V265, P20524; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLANAGAN JR, IN PRESS P NATN ACAD; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HARIHARAN N, IN PRESS P NATN ACAD; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PARK K, IN PRESS P NATN ACAD; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; ULLRICH A, 1982, J MOL BIOL, V156, P467, DOI 10.1016/0022-2836(82)90261-3; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	34	393	402	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					241	245		10.1038/354241a0	http://dx.doi.org/10.1038/354241a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720509				2022-12-24	WOS:A1991GQ94800053
J	BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS				BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS			OLIGOCLONAL EXPANSION AND CD1 RECOGNITION BY HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES	SCIENCE			English	Article							T-CELL RECEPTOR; INTRA-THYMIC DIFFERENTIATION; VARIABLE REGION GENES; GAMMA-DELTA-CELLS; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; LEUKEMIC LYMPHOBLASTS; NORMAL THYMOCYTES; DISCRETE STAGES	A human intestinal intraepithelial lymphocyte (IEL) T cell line was established from jejunum to characterize the structure and function of the alpha-beta T cell antigen receptors (TCRs) expressed by this population. Single-sided polymerase chain reaction (PCR) amplification cloning and quantitative PCR amplification of the TCR chains from the cell line and from fresh IELs demonstrated that IELs were oligoclonal. The IEL T cell line exhibited CD1-specific cytotoxicity and a dominant IEL T cell clone was CD1c-specific. Thus, human jejunal intraepithelial lymphocytes are oligoclonal and recognize members of the CD1 gene family.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,MED RES BLDG,ROOM 013B,BOSTON,MA 02115; UNIV MED & DENT NEW JERSEY,DIV EBERT GASTROENTEROL,NEW BRUNSWICK,NJ 08903; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [K11CA001310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042166, K08DK001886] Funding Source: NIH RePORTER; NCI NIH HHS [CA-01310] Funding Source: Medline; NIDDK NIH HHS [5 KO8 DK01886, DK42166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; AMIOT M, 1986, J IMMUNOL, V136, P1752; ARUFFO A, 1989, J IMMUNOL, V143, P1723; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, UNPUB; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BENEDITA R, 1991, J EXP MED, V173, P483; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BLUMBERG RS, IN PRESS J IMMUNOL; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRANDTZAEG P, 1989, SCAND J IMMUNOL, V30, P123, DOI 10.1111/j.1365-3083.1989.tb01196.x; BROD SA, 1990, CELL IMMUNOL, V125, P426, DOI 10.1016/0008-8749(90)90096-A; BUCY RP, 1989, J IMMUNOL, V142, P3045; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; DRENO B, 1987, ACTA DERM-VENEREOL, V76, P406; DRIJKONINGEN M, 1986, BRIT J DERMATOL, V115, P511, DOI 10.1111/j.1365-2133.1986.tb06248.x; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; ERNST PB, 1985, IMMUNOL TODAY, V6, P50, DOI 10.1016/0167-5699(85)90047-7; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GROH V, 1989, P NATL ACAD SCI USA, V86, P5059, DOI 10.1073/pnas.86.13.5059; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAHNPERLES B, 1985, J IMMUNOL, V134, P1759; KIMURA N, 1986, J EXP MED, V164, P739, DOI 10.1084/jem.164.3.739; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TREJDOSIEWICZ LK, 1989, IMMUNOLOGY, V68, P7; VINEY JL, 1989, IMMUNOLOGY, V66, P583; WALSH LJ, 1988, J INVEST DERMATOL, V90, P13, DOI 10.1111/1523-1747.ep12462413; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	54	236	237	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1411	1415		10.1126/science.1716785	http://dx.doi.org/10.1126/science.1716785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716785				2022-12-24	WOS:A1991GF85100039
J	PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC				PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC			THE NEUTROPHIL SELECTIN LECAM-1 PRESENTS CARBOHYDRATE LIGANDS TO THE VASCULAR SELECTINS ELAM-1 AND GMP-140	CELL			English	Article							NODE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CELL-ADHESION; MONOCLONAL-ANTIBODY; INTERACTION DOMAINS; SIALYL-LEX; ENDOTHELIUM; EXPRESSION; PROTEINS; RECOGNITION	LECAM-1 (leukocyte-endothelial cell adhesion molecule 1), the lymphocyte lectin ("selectin") homing receptor for peripheral lymph nodes (PLNs), participates in the earliest interactions of polymorphonuclear neutrophilic leukocytes (PMNs) with inflamed venules. Here, we present evidence that LECAM-1 mediates this function through a novel mechanism - presentation of oligosaccharide ligands to the inducible vascular selectins endothelial-leukocyte adhesion molecule (ELAM-1) and granule membrane protein 140 (GMP-140). PMN, but not lymphocyte, LECAM-1 is modified with the vascular selectin ligand sialyl Lewis x (sLex) and specifically binds ELAM-1-transfected cells. Although only a small fraction of total cell surface sLex, LECAM-1-associated sLex appears to play a prominent role in PMN interactions with cell-associated ELAM-1 and GMP-140, as anti-LECAM-1 monoclonal antibodies or selective removal of cell surface LECAM-1 inhibits PMN binding to vascular selectin transfectants by up to 70%. The enhanced function of LECAM-1-associated sLex may reflect the striking concentration, shown here, of LECAM-1 on PMN surface microvilli, the site of initial cellular contact.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA; UNIV BRITISH COLUMBIA, ST PAULS HOSP, PULM RES LAB, VANCOUVER V6Z 1Y6, BC, CANADA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); St. Paul's Hospital; University of British Columbia; University of Saskatchewan	PICKER, LJ (corresponding author), UNIV TEXAS, DEPT PATHOL, MOLEC PATHOL LAB, SW MED CTR, DALLAS, TX 75235 USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014	Berg, Ellen/0000-0001-5149-6665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041965, R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957] Funding Source: Medline; NIGMS NIH HHS [GM37734, GM41965] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEESLEY JE, 1978, J CELL SCI, V33, P85; BEESLEY JE, 1979, J CELL SCI, V38, P237; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, IN PRESS J BIOL CHEM; BERG M, 1990, BLOOD, V76, P2381; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARLOS T, 1991, BLOOD, V77, P2266; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; EWIJK WV, 1980, CIBA F S, V71, P21; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1991, BLOOD, V78, P805; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MULLIGAN RC, 1981, MOL CELL BIOL, V1, P449, DOI 10.1128/MCB.1.5.449; MUNRO JM, 1989, AM J PATHOL, V135, P121; ORD DC, 1990, J BIOL CHEM, V265, P7760; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Richardson P D, 1980, Ciba Found Symp, V71, P313, DOI 10.1002/9780470720547.ch17; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Staehelin T, 1981, Methods Enzymol, V79, P589; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TOKUYASU KT, 1983, J HISTOCHEM CYTOCHEM, V31, P164, DOI 10.1177/31.1A_Suppl.6186722; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, IN PRESS P NATL ACAD; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WOOD GS, 1984, AM J CLIN PATHOL, V81, P176, DOI 10.1093/ajcp/81.2.176	65	579	612	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					921	933		10.1016/0092-8674(91)90438-5	http://dx.doi.org/10.1016/0092-8674(91)90438-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716182				2022-12-24	WOS:A1991GE46000011
J	SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL				SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL			COMPLETE HEPATIC REGENERATION AFTER SOMATIC DELETION OF AN ALBUMIN-PLASMINOGEN ACTIVATOR TRANSGENE	CELL			English	Article							GROWTH-HORMONE; MOLECULAR-GENETICS; LIVER NEOPLASIA; MAMMARY-GLAND; FUSION GENES; MOUSE MODEL; TGF-ALPHA; MICE; EXPRESSION; CELL	We previously demonstrated that expression of an albumin-urokinase-type plasminogen activator (Alb-uPA) fusion construct in transgenic mice resulted in elevated plasma uPA concentration, hypofibrinogenemia, and neonatal hemorrhaging. Two lines of Alb-uPA mice were established in which only one half of the transgenic pups died at birth; surprisingly, plasma uPA concentrations in survivors gradually returned to normal by 2 months of age. The basis for this phenomenon is DNA rearrangement within hepatocytes that affects the transgene tandem array and abolishes transgene expression. Transgene-deficient cells selectively proliferate relative to surrounding liver, and this process culminates in replacement of the entire liver by clonal hepatic nodules derived from transgene-deficient progenitor cells. In some cases as few as two nodules can reconstitute over 90% of liver mass, highlighting the remarkable regenerative capacity of individual liver cells.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	SANDGREN, EP (corresponding author), UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104, USA.			Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA044611, R01CA038635] Funding Source: NIH RePORTER; NCI NIH HHS [CA38635, CA44611] Funding Source: Medline; NICHD NIH HHS [HD09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; DANO K, 1985, ADV CANCER RES, V44, P149; DARRAS BT, 1987, NATURE, V329, P556, DOI 10.1038/329556a0; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; HAMMER RE, 1985, COLD SPRING HARB SYM, V50, P379, DOI 10.1101/SQB.1985.050.01.048; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HETHCOTE HW, 1978, P NATL ACAD SCI USA, V75, P2453, DOI 10.1073/pnas.75.5.2453; HIGGS DR, 1989, BLOOD, V73, P1081; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1984, CELL, V36, P869, DOI 10.1016/0092-8674(84)90036-9; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SELL S, 1990, CANCER RES, V50, P3811; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SODA R, 1984, BLOOD, V63, P270; STOLZ A, 1990, HEPATOLOGY TXB LIVER, P637; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WILKIE TM, 1991, GENE DEV, V5, P38, DOI 10.1101/gad.5.1.38; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	46	306	325	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					245	256		10.1016/0092-8674(91)90615-6	http://dx.doi.org/10.1016/0092-8674(91)90615-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713128				2022-12-24	WOS:A1991FY71200006
J	TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH				TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH			ACTIVATION OF THE BETA-1 ISOZYME OF PHOSPHOLIPASE-C BY ALPHA-SUBUNITS OF THE GQ CLASS OF G-PROTEINS	NATURE			English	Article							BOVINE BRAIN; TYROSINE PHOSPHORYLATION	MANY hormones, neurotransmitters and growth factors, on binding to G protein-coupled receptors or receptors possessing tyrosine kinase activity, increase intracellular levels of the second messengers inositol 1,4,5-trisphophate and 1,2-diacylglycerol. This is due to activation of phosphoinositide-specific phospholipase(s) C (PLC), the isozymes of which are classified into groups, alpha, beta, gamma and delta (refs 1, 2). The beta, gamma and delta-groups themselves contain PLC isozymes which have both common and unique structural domains 3. Only the gamma-1 isozyme has been implicated in a signal transduction mechanism 4. This involves association with, and tyrosine phosphorylation by, the ligand-bound epidermal growth factor and platelet-derived growth factor receptors 5-7, probably by means of the PLC-gamma-1-specific src homology (SH2) domain 8. Because EGF receptor-mediated tyrosine phosphorylation of PLC-gamma-1 stimulates catalytic activity in vitro 9 and G proteins have been implicated in the activation of PLC 10, we investigated which PLC isozymes are subject to G protein regulation. We have purified 11 an activated G protein alpha-subunit that stimulates partially purified phospholipase C and now report that this G protein specifically activates the beta-1 isozyme, but not the gamma-1 and delta-1 isozymes of phospholipase C. We also show that this protein is related to the G(q) class of G protein alpha-subunits 12.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; KRIZ R, 1990, CIBA F SYMP, V150, P112; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; ULLRICH A, 1990, J CELL, V61, P203; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	30	762	766	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					516	518		10.1038/350516a0	http://dx.doi.org/10.1038/350516a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1707501				2022-12-24	WOS:A1991FG14300056
J	FLANAGAN, JG; CHAN, DC; LEDER, P				FLANAGAN, JG; CHAN, DC; LEDER, P			TRANSMEMBRANE FORM OF THE KIT LIGAND GROWTH-FACTOR IS DETERMINED BY ALTERNATIVE SPLICING AND IS MISSING IN THE SI(D) MUTANT	CELL			English	Article							MOUSE AGGREGATION CHIMERAS; ANEMIC MICE; INVITRO DUPLICATION; PROTO-ONCOGENE; W-LOCUS; FIBROBLASTS; RECEPTOR; KINASE; CELLS; CURE	The ligand (KL) for the c-kit receptor is a growth factor encoded at the mouse steel (SI) locus. KL exists in both cell surface and soluble forms, though little is known of the regulation and functional significance of these forms. We show here that tissue-specific alternative splicing gives two types of KL mRNA. Both encode a transmembrane domain, but in transfected cells one produced the soluble form of KL at relatively high levels, whereas the other preferentially gave the cell surface form. Cell surface KL not only stimulated proliferation, but also mediated cell-cell adhesion. The SI(d) allele, which impairs development of hematopoietic cells, melanocytes, and germ cells, has a deletion in the KL gene removing the transmembrane and intracellular domains. Expression of a corresponding cDNA gave a soluble protein that stimulated cellular proliferation but was not associated with the cell surface. These results provide evidence that cell surface KL has a critical role in the intact organism.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	FLANAGAN, JG (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Chan, Doris/O-1227-2014; Flanagan, John/AAM-2995-2020	Chan, Doris/0000-0002-4990-986X; 				ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; LANDRETH KS, 1984, J IMMUNOL, V132, P2724; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NAKAYAMA H, 1988, DEVELOPMENT, V102, P107; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STANLEY ER, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P165; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	723	739	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1025	1035		10.1016/0092-8674(91)90326-T	http://dx.doi.org/10.1016/0092-8674(91)90326-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705866				2022-12-24	WOS:A1991FA94000019
J	YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K				YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K			ASSOCIATION OF B-CELL ANTIGEN RECEPTOR WITH PROTEIN TYROSINE KINASE LYN	SCIENCE			English	Article							IMMUNOGLOBULIN GAMMA-CHAINS; LYMPHOCYTES-B; MEMBRANE IGM; CD4 RECEPTOR; P56LCK; GENE; INVOLVEMENT; ACTIVATION; HYDROLYSIS; EXPRESSION	Antigen is thought to cross-link membrane-bound immunoglobulins (Igs) of B cells, causing proliferation and differentiation or the inhibition of growth. Protein tyrosine kinases are probably involved in signal transduction for cell proliferation and differentiation. The Src-like protein tyrosine kinase Lyn is expressed preferentially in B cells. The Lyn protein and its kinase activity could be coimmunoprecipitated with IgM from detergent lysates. Cross-linking of membrane-bound IgM induced a rapid increase in tyrosine phosphorylation of at least ten distinct proteins of B cells. Thus, Lyn is physically associated with membrane-bound IgM, and is suggested to participate in antigen-mediated signal transduction.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; NATL INST HLTH,DEPT APPL IMMUNOL,SHINAGAWA KU,TOKYO 141,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ALLERGOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOYD AW, 1981, J IMMUNOL, V126, P2466; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GOLD MR, 1987, J IMMUNOL, V139, P3604; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, ANNU REV IMMUNOL, V342, P385; GRUBER MF, 1989, J IMMUNOL, V142, P1444; GRUPP SA, 1985, J IMMUNOL, V134, P4087; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HARNETT MM, 1988, J IMMUNOL, V140, P3135; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KIM KJ, 1979, J IMMUNOL, V122, P549; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MONROE JG, 1989, BIOCHIM BIOPHYS ACTA, V1013, P273, DOI 10.1016/0167-4889(89)90146-8; NOSSAL GJV, 1989, ANNU REV IMMUNOL, V342, P340; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEMBA K, 1990, GENES CANCER, P73; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8697; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASILOV RG, 1982, EUR J IMMUNOL, V12, P804, DOI 10.1002/eji.1830121003; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, UNPUB; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	39	479	484	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					192	194		10.1126/science.1702903	http://dx.doi.org/10.1126/science.1702903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1702903				2022-12-24	WOS:A1991ET17300039
J	BAE, HR; VERKMAN, AS				BAE, HR; VERKMAN, AS			PROTEIN KINASE-A REGULATES CHLORIDE CONDUCTANCE IN ENDOCYTIC VESICLES FROM PROXIMAL TUBULE	NATURE			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARTHELSON R, 1987, J CLIN INVEST, V80, P1799, DOI 10.1172/JCI113274; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; HOPKINS CR, 1990, NATURE, V5346, P335; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MARUNAKA Y, 1990, J GEN PHYSIOL, V95, P773, DOI 10.1085/jgp.95.5.773; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.bi.55.070186.003311; OGRADY SM, 1988, AM J PHYSIOL, V254, pC115, DOI 10.1152/ajpcell.1988.254.1.C115; PEARCE D, 1989, BIOPHYS J, V55, P1251, DOI 10.1016/S0006-3495(89)82920-0; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SABOLIC I, 1985, AM J PHYSIOL, V248, pF835, DOI 10.1152/ajprenal.1985.248.6.F835; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SHI LB, 1989, J GEN PHYSIOL, V94, P1101, DOI 10.1085/jgp.94.6.1101; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1990, AM J PHYSIOL, V259, pC375, DOI 10.1152/ajpcell.1990.259.3.C375; YE R, 1989, J GEN PHYSIOL, V93, P885, DOI 10.1085/jgp.93.5.885	24	118	118	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 13	1990	348	6302					637	639		10.1038/348637a0	http://dx.doi.org/10.1038/348637a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM760	1701220				2022-12-24	WOS:A1990EM76000061
J	FREEDMAN, AS; MUNRO, JM; RICE, GE; BEVILACQUA, MP; MORIMOTO, C; MCINTYRE, BW; RHYNHART, K; POBER, JS; NADLER, LM				FREEDMAN, AS; MUNRO, JM; RICE, GE; BEVILACQUA, MP; MORIMOTO, C; MCINTYRE, BW; RHYNHART, K; POBER, JS; NADLER, LM			ADHESION OF HUMAN B-CELLS TO GERMINAL-CENTERS INVITRO INVOLVES VLA-4 AND INCAM-110	SCIENCE			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT IMMUNOL,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center	FREEDMAN, AS (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115, USA.				NCI NIH HHS [CA40216] Funding Source: Medline; NHLBI NIH HHS [5T32HL07627-03] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON AO, 1976, IMMUNOLOGY, V31, P731; BOYD AW, 1985, J IMMUNOL, V134, P1516; BOYD AW, 4TH INT WORKSH LEUK; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; COSSMAN J, 1984, AM J PATHOL, V115, P117; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FOSSUM S, 1985, HISTOPATHOLOGY, V9, P469, DOI 10.1111/j.1365-2559.1985.tb02830.x; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; FREEDMAN AM, UNPUB; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; HARRIS NL, 1984, AM J PATHOL, V117, P262; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEINEN E, 1984, EUR J IMMUNOL, V14, P267, DOI 10.1002/eji.1830140312; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; INABA K, 1984, J EXP MED, V160, P858, DOI 10.1084/jem.160.3.858; JAFFE ES, 1974, NEW ENGL J MED, V290, P814; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; KRAAL G, 1986, EUR J IMMUNOL, V16, P829, DOI 10.1002/eji.1830160718; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MINOWADA J, 1978, J NATL CANCER I, V60, P1269, DOI 10.1093/jnci/60.6.1269; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MUNRO M, UNPUB; NIEUWENHUIS P, 1974, IMMUNOLOGY, V26, P509; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICKER LJ, 1989, J IMMUNOL, V142, P2046; PISCHEL KD, 1987, J IMMUNOL, V138, P226; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1344; SCHNIZLEIN CT, 1985, J IMMUNOL, V134, P1360; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STEIN H, 1982, CLIN HAEMATOL, V11, P531; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; SZAKAL AK, 1988, J IMMUNOL, V140, P341; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TEDDER TF, 1990, J IMMUNOL, V144, P532; THORBECKE GJ, 1962, J EXP MED, V116, P295, DOI 10.1084/jem.116.3.295; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; [No title captured]	65	288	295	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 31	1990	249	4972					1030	1033		10.1126/science.1697696	http://dx.doi.org/10.1126/science.1697696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DX004	1697696				2022-12-24	WOS:A1990DX00400043
J	ATKIN, WS; MORSON, BC; CUZICK, J				ATKIN, WS; MORSON, BC; CUZICK, J			LONG-TERM RISK OF COLORECTAL-CANCER AFTER EXCISION OF RECTOSIGMOID ADENOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYPS; PROCTOSIGMOIDOSCOPY; NEOPLASMS; CARCINOMA	Background and Methods. Surveillance by repeated colonoscopy is currently recommended for patients with colorectal adenomas. We assessed the long-term risk of colorectal cancer after rigid-instrument sigmoidoscopy and polypectomy in 1618 patients with rectosigmoid adenomas (tumors of the rectum or distal sigmoid colon) who did not undergo surveillance. A total of 22,462 person-years of observation were accrued (mean, 14 years per patient). Results. The incidence of subsequent rectal cancer in these patients was similar to that in the general population (standardized incidence ratio, 1.2; 95 percent confidence interval, 0.7 to 2.1). Most rectal cancers developed in patients whose adenomas had been inadequately removed; the risk was very low after complete removal. The risk of subsequent colon cancer depended on the histologic type, size, and number of adenomas in the rectosigmoid. Among 842 patients with a rectosigmoid adenoma that was tubulovillous, villous, or large (greater-than-or-equal-to 1 cm), colon cancer developed in 31 patients. The standardized incidence ratio was 3.6 overall (95 percent confidence interval, 2.4 to 5.0) and 6.6 (95 percent confidence interval, 3.3 to 11.8) if there were multiple rectosigmoid adenomas. Among the remaining 776 patients with only small, tubular adenomas (whether single or multiple), colon cancer developed in only 4 patients. The standardized incidence ratio in this group was 0.5 (95 percent confidence interval, 0.1 to 1.3). Conclusions. Follow-up colonoscopic examinations may be warranted in patients with tubulovillous, villous, or large adenomas in the rectosigmoid, particularly if the adenomas are also multiple. In patients with only a single, small tubular adenoma that is only mildly or moderately dysplastic (43 percent of our series), however, surveillance may not be of value because the risk of cancer is so low.	IMPERIAL CANC RES FUND,DEPT MATH STAT & EPIDEMIOL,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; ST MARKS HOSP,DEPT PATHOL,LONDON EC1V 2PS,ENGLAND	Cancer Research UK; Imperial College London				Atkin, Wendy/0000-0001-9073-9658				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BRAHME F, 1974, DIS COLON RECTUM, V17, P166, DOI 10.1007/BF02588099; BRESLOW NE, 1987, IARC SCI PUBLICATION, V32; CASTRO AF, 1951, SURG GYNECOL OBSTET, V92, P164; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLVERT JR, 1948, AM J MED SCI, V215, P24, DOI 10.1097/00000441-194801000-00004; COX DR, 1972, J R STAT SOC B, V34, P187; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FUNG CHK, 1970, AM J CLIN PATHOL, V53, P21; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; KONISHI F, 1982, J CLIN PATHOL, V35, P830, DOI 10.1136/jcp.35.8.830; LOFTI AM, 1986, MAYO CLIN P, V61, P337; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MORSON BC, 1976, INT HISTOLOGICAL CLA, V15; PRAGER ED, 1974, DIS COLON RECTUM, V17, P322, DOI 10.1007/BF02586974; QUAN SHQ, 1971, DIS COLON RECTUM, V14, P267, DOI 10.1007/BF02553199; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SOUTHWOOD W F, 1962, Ann R Coll Surg Engl, V30, P23; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; THOMSON JPS, 1977, DIS COLON RECTUM, V20, P467, DOI 10.1007/BF02586582; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; WILKING N, 1986, CANCER, V57, P669, DOI 10.1002/1097-0142(19860201)57:3<669::AID-CNCR2820570345>3.0.CO;2-W; WILSON GS, 1955, AM J SURG, V90, P834, DOI 10.1016/0002-9610(55)90707-8; WINAWER SJ, 1986, FRONT GASTROINTEST R, V10, P216; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806	25	893	914	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					658	662		10.1056/NEJM199203053261002	http://dx.doi.org/10.1056/NEJM199203053261002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736104				2022-12-24	WOS:A1992HG11700002
J	OSHEA, EK; RUTKOWSKI, R; KIM, PS				OSHEA, EK; RUTKOWSKI, R; KIM, PS			MECHANISM OF SPECIFICITY IN THE FOS-JUN ONCOPROTEIN HETERODIMER	CELL			English	Article							LEUCINE ZIPPER; COILED-COIL; PROTEIN; COMPLEXES; ONCOGENE; AP-1; GENE	Fos and Jun, the protein products of the nuclear proto-oncogenes c-fos and c-jun, associate preferentially to form a heterodimer that binds to DNA and modulates transcription of a wide variety of genes in response to mitogenic stimuli. Both Fos and Jun contain a single leucine zipper region. Previous studies have shown that the leucine zippers of Fos and Jun are necessary and sufficient to mediate preferential heterodimer formation. The leucine zipper regions from Fos and Jun are also known to fold autonomously, most likely as two-stranded, parallel coiled coils. We show here that 8 amino acids from Fos and from Jun are sufficient to mediate preferential heterodimer formation in a background of the GCN4 leucine zipper sequence. Using pH titration and amino acid replacements, we also show that destabilization of the Fos homodimer by acidic residues provides a major thermodynamic driving force for preferential heterodimer formation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	OSHEA, EK (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [GM 44162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Cantor C.R., 1980, BIOPHYS CHEM; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRANZA BR, 1987, ONCOGENE, V1, P213; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1991, SCIENCE, V30, P5682; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183	24	412	438	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					699	708		10.1016/0092-8674(92)90145-3	http://dx.doi.org/10.1016/0092-8674(92)90145-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739975				2022-12-24	WOS:A1992HF44000010
J	ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW				ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW			CAVEOLIN, A PROTEIN-COMPONENT OF CAVEOLAE MEMBRANE COATS	CELL			English	Article							ROUS-SARCOMA VIRUS; ENDOTHELIAL PLASMALEMMAL VESICLES; LOW-DENSITY LIPOPROTEIN; CAPILLARY ENDOTHELIUM; SARCOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SMOOTH-MUSCLE; MA104 CELLS; RECEPTOR; SURFACE	Caveolae have been implicated in the transcytosis of macromolecules across endothelial cells and in the receptor-mediated uptake of 5-methyltetrahydrofolate. Structural studies indicate that caveolae are decorated on their cytoplasmic surface by a unique array of filaments or strands that form striated coatings. To understand how these nonclathrin-coated pits function, we performed structural analysis of the striated coat and searched for the molecular component(s) of the coat material. The coat cannot be removed by washing with high salt; however, exposure of membranes to cholesterol-binding drugs caused invaginated caveolae to flatten and the striated coat to disassemble. Antibodies directed against a 22 kd substrate for v-src tyrosine kinase in virus-transformed chick embryo fibroblasts decorated the filaments, suggesting that this molecule is a component of the coat. We have named the molecule caveolin. Caveolae represent a third type of coated membrane specialization that is involved in molecular transport.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV KENTUCKY, COLL MED, MARKEY CANC CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	Washington University (WUSTL); University of Kentucky	ROTHBERG, KG (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.		Heuser, John/H-5940-2012; Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647, R01GM043169] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43169, GM 29647] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; BUNDGAARD M, 1983, MICROVASC RES, V25, P358, DOI 10.1016/0026-2862(83)90025-0; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; IZUMI T, 1989, J ELECTRON MICROSC, V38, P47; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; NICOL A, 1987, EUR J CELL BIOL, V43, P348; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1961, CIRCULATION, V24, P368; PALADE GE, 1953, J APPL PHYS, V24, P1424; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU M, 1982, J CELL BIOL, V94, P406, DOI 10.1083/jcb.94.2.406; SIMIONESCU N, 1972, J CELL BIOL, V53, P365, DOI 10.1083/jcb.53.2.365; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SOMLYO AP, 1971, J CELL BIOL, V51, P722, DOI 10.1083/jcb.51.3.722; Steer C.J., 1991, INTRACELLULAR TRAFFI, P47; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	50	1883	1931	4	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					673	682		10.1016/0092-8674(92)90143-Z	http://dx.doi.org/10.1016/0092-8674(92)90143-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739974				2022-12-24	WOS:A1992HF44000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING AND PATIENT PACKAGE INSERT FOR TRIAZOLAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-24	WOS:A1992HC48400006
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - ENVIRONMENTAL RADIATION - A CAUSE FOR CONCERN	BRITISH MEDICAL JOURNAL			English	Article							X-RAYS; NUCLEAR INSTALLATIONS; MORTALITY; CANCER; EMPLOYEES; LEUKEMIA											BEEBE GW, 1978, RADIAT RES, V75, P136; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BOWIE C, 1991, LANCET, V337, P409, DOI 10.1016/0140-6736(91)91177-V; BRANSBYZACHARY MAP, 1989, BRIT MED J, V298, P1294, DOI 10.1136/bmj.298.6683.1294; Caufield Catherine, 1989, MULTIPLE EXPOSURES C; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI P, 1987, STUDIES MED POPULATI, V51; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; ISHIMARU T, 1981, RERF1181 RAD EFF RES; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1977, THERAPEUTIC RADIOLOG, V123, P741; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; RON E, 1980, J NATL CANCER I, V65, P7; ROSCOE RJ, 1989, JAMA-J AM MED ASSOC, V262, P629, DOI 10.1001/jama.262.5.629; SHIMIZU Y, 1987, RAD EFFECTS RES F TE, V12, P1; SMITH PG, 1982, BRIT MED J, V284, P449, DOI 10.1136/bmj.284.6314.449; STAPHER FK, 1988, NRPBR215 NAT RAD PRO; STEWART A, 1970, LANCET, V1, P1185; Sumner D, 1990, Med War, V6, P112, DOI 10.1080/07488009008408915; SUMNER DJ, 1991, RAD RISKS EVALUATION; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; WALL BF, 1980, NRPBR105; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; YOSHIMOTO Y, 1990, RERF490 RAD EFF RES; 1991, DOCUMENTS NATIONAL R; 1988, HLTH RISKS RADON OTH; 1988, 2ND REPORT INVESTIGA; 1990, RECOMMENDATIONS ICRP; 1984, RADIOLOGICAL PROTECT, V57, P11; 1987, ICRP PUBLICATION 50, V17; 1990, REPORT ROYAL COLLEGE, P1; 1989, LIVING RAD; 1990, PATIENT DOSE REDUCTI, V1; 1990, HOUSEHOLDERS GUIDE R; 1986, REPORT HLTH MINISTER; 1984, INVESTIGATION POSSIB; 1990, DOCUMENTS NATIONAL R, P1; 1989, 3RD REPORT REPORT IN; 1978, RECOMMENDATIONS ICRP, P1	45	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					299	304		10.1136/bmj.304.6822.299	http://dx.doi.org/10.1136/bmj.304.6822.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739833	Green Published, Bronze			2022-12-24	WOS:A1992HC70800026
J	BAIER, H; BONHOEFFER, F				BAIER, H; BONHOEFFER, F			AXON GUIDANCE BY GRADIENTS OF A TARGET-DERIVED COMPONENT	SCIENCE			English	Article							RETINAL AXONS; RETINOTECTAL MAP; TECTAL MEMBRANES; GROWTH; NEURITES; XENOPUS; REGENERATION; PROJECTION; AVOIDANCE; ADHESION	Spatial gradients of axon guiding molecules have long been suspected to provide positional and directional cues for retinal ganglion cell axons growing within the optic tectum. With the identification of a guiding activity from tectal cell membranes, it has become possible to investigate the potential physiological significance of molecular gradients for retinal growth cone behavior in vitro. A subset of retinal growth cones, those from the temporal half, were highly sensitive to small concentration changes of the guiding component. The degree of response was correlated with the strength of the gradient. These findings demonstrate that the neural growth cone can read gradients of surface-associated information.			BAIER, H (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,PHYS BIOL LAB,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ADLER J, 1976, SCI AM, V234, P40, DOI 10.1038/scientificamerican0476-40; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; DAVIES JA, 1990, NEURON, V2, P11; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; FRASER SE, 1980, DEV BIOL, V79, P453, DOI 10.1016/0012-1606(80)90130-X; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; GIERER A, 1987, DEVELOPMENT, V101, P479; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; HALFTER W, 1981, NATURE, V292, P67, DOI 10.1038/292067a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HEACOCK AM, 1977, SCIENCE, V198, P64, DOI 10.1126/science.897684; HEFNER CD, 1990, SCIENCE, V247, P217; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; LETOURNEAU PC, 1983, TRENDS NEUROSCI, V6, P451, DOI 10.1016/0166-2236(83)90217-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MCNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, COLD SH Q B, V55, P351; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J COMP NEUROL, V267, P55, DOI 10.1002/cne.902670105; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	32	269	272	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					472	475		10.1126/science.1734526	http://dx.doi.org/10.1126/science.1734526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734526				2022-12-24	WOS:A1992HA59000044
J	SCHELLING, TC				SCHELLING, TC			ADDICTIVE DRUGS - THE CIGARETTE EXPERIENCE	SCIENCE			English	Article								Cigarettes are among the most addictive substances of abuse and by far the most deadly. In this country smokers know it and try to stop. Their success has been dramatic but partial and excruciatingly slow, and until recently quite uncoerced by government. Cigarettes and nicotine have characteristics distinct among addictive drugs, and some of these help explain why efforts to quit smoking are so often frustrated. Nicotine itself is the most interesting chemical in the treatment of addiction and, in some forms, can pose a dilemma: compromise by settling for pure nicotine indefinitely, or stay with cigarettes and keep trying to quit. Nicotine is not alone among addictive drugs in becoming increasingly identified with the poorer classes.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park	SCHELLING, TC (corresponding author), UNIV MARYLAND,DEPT ECON,COLLEGE PK,MD 20742, USA.							JOHNSTON LD, 1984, DRUGS AM HIGH SCH ST, P12; 1983, HLTH CONSEQUENCES SM; 1982, HLTH CONSEQUENCES SM; 1985, NEWS            1205; 1989, REDUCING HLTH CONSEQ, P465; 1982, HLTH CONSEQUENCES SM, P372; 1985, HLTH CONSEQUENCES SM, P25; 1984, HLTH CONSEQUENCES SM	8	46	49	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					430	433		10.1126/science.1734519	http://dx.doi.org/10.1126/science.1734519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734519				2022-12-24	WOS:A1992HA59000030
J	DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J				DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J			STATIONARY AND DRIFTING SPIRAL WAVES OF EXCITATION IN ISOLATED CARDIAC-MUSCLE	NATURE			English	Article							EXCITABLE MEDIA; CELLULAR AUTOMATON; TACHYCARDIA; MYOCARDIUM; MECHANISM; VORTEX	EXCITABLE media can support spiral waves rotating around an organizing centre 1-7. Spiral waves have been discovered in different types of autocatalytic chemical reactions 8,9 and in biological systems 10-12. The so-called 're-entrant excitation' of myocardial cells 13, causing the most dangerous cardiac arrhythmias, including ventricular tachycardia and fibrillation, could be the result of spiral waves 1,2. Here we use a potentiometric dye 14,15 in combination with CCD (charge-coupled device) imaging technology 16,17 to demonstrate spiral waves in the heart muscle. The spirals were elongated and the rotation period, T(s), was about 180 ms (3-5 times faster than normal heart rate). In most episodes, the spiral was anchored to small arteries or bands of connective tissue, and gave rise to stationary rotations. In some cases, the core drifted away from its site of origin and dissipated at a tissue border. Drift was associated with a Doppler shift in the local excitation period, T, with T ahead of the core being about 20% shorter than T behind the core.			DAVIDENKO, JM (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,750 E ADAMS ST,SYRACUSE,NY 13210, USA.		Jalife, Jose/L-4833-2015; Jalife, Jose/AAJ-9156-2021	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BURES J, 1983, J NEUROBIOL, V14, P353; CARDINAL R, 1984, CIRCULATION, V70, P136, DOI 10.1161/01.CIR.70.1.136; DAVIDENKO JM, 1990, P NATL ACAD SCI USA, V87, P8785, DOI 10.1073/pnas.87.22.8785; DELGADO C, 1990, CIRC RES, V67, P97, DOI 10.1161/01.RES.67.1.97; DOWNAR E, 1984, J AM COLL CARD, V7, P403; ERMAKOVA EA, 1986, BIOFIZIKA+, V31, P855; FAST VG, 1990, BIOFIZIKA+, V35, P478; FRAZIER DW, 1989, J CLIN INVEST, V83, P1039, DOI 10.1172/JCI113945; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; Gerisch G, 1968, Curr Top Dev Biol, V3, P157; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KRINSKII VI, 1968, PROBL KIBERN, V20, P59; Krinsky V.I., 1984, SPRINGER SERIES SYNE, VVolume 28, P9; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LI T, 1985, J PHARMACOL EXP THER, V232, P688; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MULLER SC, 1985, SCIENCE, V230, P661, DOI 10.1126/science.230.4726.661; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINREE AT, 1989, J THEOR BIOL, V1388, P353; YAMAGUCHI T, 1991, PHYSICA D, V49, P40, DOI 10.1016/0167-2789(91)90191-B; ZHABOTINSKY A. M, 1971, OSCILLATORY PROCESSE, VII, P279; ZYKOV VS, 1987, SIMULATION WAVE PROC, P93	27	988	1016	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					349	351		10.1038/355349a0	http://dx.doi.org/10.1038/355349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731248				2022-12-24	WOS:A1992HA59100067
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FINAL RULE ELIMINATES USE OF 111 WEIGHT-CONTROL INGREDIENTS FROM OVER-THE-COUNTER DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0808, V56, P37792	1	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-24	WOS:A1992GY43700009
J	JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S				JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S			SIDE OF ORIGIN OF EPITHELIAL OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							OVULATION		UNIV PENN,SCH MED,DEPT MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNAECOL SERV,NEW YORK,NY 10021; NEW YORK HOSP,CANC CARE & RES PROGRAM,NEW YORK,NY 10021	University of Pennsylvania; Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital	JOHANNES, CB (corresponding author), BOSTON UNIV,SCH MED,SLONE EPIDEMIOL UNIT,BROOKLINE,MA 02146, USA.			Rosenberg, Lynn/0000-0003-2760-2987; Kaufman, David/0000-0002-2150-5070; Palmer, Julie/0000-0002-6534-335X	NCI NIH HHS [5 R37 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082, UO1 FD01222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CRUICKSHANK DJ, 1990, BMJ-BRIT MED J, V301, P524, DOI 10.1136/bmj.301.6751.524; FATHALLA MF, 1971, LANCET, V2, P163; POTASHNIK G, 1987, BRIT MED J, V294, P219, DOI 10.1136/bmj.294.6566.219; Slone D, 1977, EPIDEMIOLOGICAL EVAL, P59; SNEDECOR GW, 1967, STATISTICAL METHODS, P211	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					27	28		10.1136/bmj.304.6818.27	http://dx.doi.org/10.1136/bmj.304.6818.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734989	Bronze, Green Published			2022-12-24	WOS:A1992GY90900030
J	CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA				CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA			IDENTIFICATION OF A COMPETITIVE HGF ANTAGONIST ENCODED BY AN ALTERNATIVE TRANSCRIPT	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS; BIOLOGICAL CHARACTERIZATION; SCATTER FACTOR; PURIFICATION; EXPRESSION; PROTEIN; CDNA	We identified a naturally occurring hepatocyte growth factor (HGF) variant, whose predicted sequence extends only through the second kringle domain of this plasminogen-related molecule. This smaller molecule, derived from an alternative HGF transcript, lacked mitogenic activity but specifically inhibited HGF-induced mitogenesis. Cross-linking studies demonstrated that the truncated molecule competes with HGF for binding to the HGF receptor, which has been identified as the c-met proto-oncogene product. Thus, the same gene encodes both a growth factor and its direct antagonist.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Bottaro, Donald P/AAF-3853-2020; Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/F-8550-2010	Chan, Andrew Man-Lok/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOPINATH E, 1989, P NATL ACAD SCI USA, V86, P3045; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Maniatis T., 1982, MOL CLONING; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; ROSEN EM, 1990, EXP CELL RES, V186, P22, DOI 10.1016/0014-4827(90)90205-O; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314	37	209	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1382	1385		10.1126/science.1720571	http://dx.doi.org/10.1126/science.1720571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720571				2022-12-24	WOS:A1991GR77700058
J	WHARTON, RP; STRUHL, G				WHARTON, RP; STRUHL, G			RNA REGULATORY ELEMENTS MEDIATE CONTROL OF DROSOPHILA BODY PATTERN BY THE POSTERIOR MORPHOGEN NANOS	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; MATERNAL-EFFECT MUTATIONS; RECEPTOR TYROSINE KINASE; BICOID MESSENGER-RNA; ABDOMINAL SEGMENTATION; UNTRANSLATED REGION; SECONDARY STRUCTURE; ANTERIOR PATTERN; EMBRYO; PROTEIN	In Drosophila embryos, graded activity of the posterior determinant nanos (nos) generates abdominal segmentation by blocking protein expression from maternal transcripts of the hunchback (hb) gene. When active inappropriately at the anterior pole, nos can also block expression of the anterior determinant bicoid (bcd). We show that both regulatory interactions are mediated by similar sequences in the 3' untranslated region of each transcript. These nos response elements (NREs) are both necessary and sufficient to confer nos-dependent regulation, the degree of regulation determined by the number and quality of the elements and the level of nos in vivo. Based on these and other results, we argue that nos acts as a morphogen, controlling hb expression (and hence abdominal pattern) as a function of its concentration-dependent interaction with the NREs.			WHARTON, RP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.							BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHLER J, 1986, GENETICS, V112, P803; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	46	331	332	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					955	967		10.1016/0092-8674(91)90368-9	http://dx.doi.org/10.1016/0092-8674(91)90368-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720354				2022-12-24	WOS:A1991GT75500014
J	AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P				AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P			INOSITOL TRISPHOSPHATE-DEPENDENT PERIODIC ACTIVATION OF A CA2+ - ACTIVATED K+ CONDUCTANCE IN GLUCOSE-STIMULATED PANCREATIC BETA-CELLS	NATURE			English	Article							B-CELLS; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; CHANNELS; SECRETION; CURRENTS; TOLBUTAMIDE; CALCIUM; APAMIN; SMOOTH	GLUCOSE-STIMULATED insulin secretion is associated with the appearance of electrical activity in the pancreatic beta-cell. At intermediate glucose concentrations, beta-cell electrical activity follows a characteristic pattern of slow oscillations in membrane potential on which bursts of action potentials are superimposed 1. The electrophysiological background of the bursting pattern remains unestablished. Activation of Ca2+-activated large-conductance K+ channels (K(Ca) channel 12) has been implicated in this process 3 but seems unlikely in view of recent evidence demonstrating that the beta-cell electrical activity is unaffected by the specific K(Ca) channel blocker charybdotoxin 4. Another hypothesis postulates that the bursting arises as a consequence of two components of Ca2+-current inactivation 5. Here we show that activation of a novel Ca2+-dependent K+ current in glucose-stimulated-beta-cells produces a transient membrane repolarization. This interrupts action potential firing so that action potentials appear in bursts. Spontaneous activity of this current was seen only rarely but could be induced by addition of compounds functionally related to hormones and neurotransmitters present in the intact pancreatic islet. K+ currents of the same type could be evoked by intracellular application of GTP, the effect of which was mediated by mobilization of Ca2+ from inositol 1,4,5-trisphosphate (InsP3)-sensitive intracellular Ca2+ stores. These observations suggest that oscillatory glucose-stimulated electrical activity, which is correlated with pulsatile release of insulin 6, results from the interaction between the beta-cell and intraislet hormones and neurotransmitters. Our data also provide evidence for a close interplay between ion channels in the plasma membrane and InsP3-induced mobilization of intracellular Ca2+ in an excitable cell.	GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN	University of Gothenburg; Karolinska Institutet			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; COOK DL, 1989, DIABETES, V38, P416, DOI 10.2337/diabetes.38.4.416; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HENQUIN JC, 1988, BIOCHEM BIOPH RES CO, V156, P769, DOI 10.1016/S0006-291X(88)80910-0; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; KUKULJAN M, 1991, J MEMBRANE BIOL, V119, P187, DOI 10.1007/BF01871418; LEBRUN P, 1983, FEBS LETT, V161, P41, DOI 10.1016/0014-5793(83)80726-1; LUND PE, 1991, BIOCHEM BIOPH RES CO, V177, P777, DOI 10.1016/0006-291X(91)91856-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PENNER R, 1988, J EXP BIOL, V139, P329; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; ROSARIO LM, 1987, ADV EXP MED BIOL, V211, P413; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0	31	125	126	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					849	852		10.1038/353849a0	http://dx.doi.org/10.1038/353849a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719424				2022-12-24	WOS:A1991GM73200061
J	SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N				SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N			THE ROLES OF THE SUBUNITS IN THE FUNCTION OF THE CALCIUM-CHANNEL	SCIENCE			English	Article							SKELETAL-MUSCLE; XENOPUS OOCYTES; DIHYDROPYRIDINE RECEPTOR; GAMMA-SUBUNIT; MESSENGER-RNA; ION CHANNELS; HEART-CELLS; RAT-HEART; EXPRESSION; INACTIVATION	Dihydropyridine-sensitive voltage-dependent L-type calcium channels are critical to excitation-secretion and excitation-contraction coupling. The channel molecule is a complex of the main, pore-forming subunit alpha-1 and four additional subunits: alpha-2, delta, beta, and gamma (alpha-2 and delta are encoded by a single messenger RNA). The alpha-1 subunit messenger RNA alone directs expression of functional calcium channels in Xenopus oocytes, and coexpression of the alpha-2/delta and beta-subunits enhances the amplitude of the current. The alpha-2, delta, and gamma-subunits also have pronounced effects on its macroscopic characteristics, such as kinetics, voltage dependence of activation and inactivation, and enhancement by a dihydropyridine agonist. In some cases, specific modulatory functions can be assigned to individual subunits, whereas in other cases the different subunits appear to act in concert to modulate the properties of the channel.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL; TECH UNIV MUNICH, INST PHARMACOL & TOXIKOL, W-8000 MUNICH 40, GERMANY; UNIV SAARLAND, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY	Tel Aviv University; Sackler Faculty of Medicine; Technical University of Munich; Saarland University			Biel, Martin/G-1175-2014; Dascal, Nathan/O-3915-2015; Tuluc, Petronel/C-2527-2011	Biel, Martin/0000-0002-9974-3052; Dascal, Nathan/0000-0002-5397-4146; 				AARONSON PI, 1988, J PHYSIOL-LONDON, V405, P57, DOI 10.1113/jphysiol.1988.sp017321; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BIEL M, UNPUB; BIEL M, IN PRESS EUR J BIOCH; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1986, J PHYSIOL-LONDON, V379, P495, DOI 10.1113/jphysiol.1986.sp016266; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P287, DOI 10.1113/jphysiol.1988.sp017250; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANG FC, 1988, J BIOL CHEM, V263, P18929; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DASCAL N, UNPUB; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DONALDSON PL, 1983, J GEN PHYSIOL, V82, P449, DOI 10.1085/jgp.82.4.449; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERING S, 1989, PFLUG ARCH EUR J PHY, V414, P690, DOI 10.1007/BF00582137; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KASS RS, 1987, J GEN PHYSIOL, V89, P629, DOI 10.1085/jgp.89.4.629; KASS RS, 1984, J GEN PHYSIOL, V84, P705, DOI 10.1085/jgp.84.5.705; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; LEE KS, 1985, J PHYSIOL-LONDON, V364, P395, DOI 10.1113/jphysiol.1985.sp015752; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; LOTAN I, 1989, SCIENCE, V243, P666, DOI 10.1126/science.2464853; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; UMBACH JA, 1987, P NATL ACAD SCI USA, V84, P5464, DOI 10.1073/pnas.84.15.5464; WALSH KB, 1989, J GEN PHYSIOL, V93, P841, DOI 10.1085/jgp.93.5.841	43	470	482	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1553	1557		10.1126/science.1716787	http://dx.doi.org/10.1126/science.1716787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716787	Green Submitted			2022-12-24	WOS:A1991GG65100045
J	MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R				MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R			THE COMBINATION OF SYMBOLIC AND NUMERICAL COMPUTATION FOR 3-DIMENSIONAL MODELING OF RNA	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; HAMMERHEAD RNA; PREDICTION; PROTEIN; LOOP; CONFORMATION; SIMULATIONS; PSEUDOKNOTS; RESOLUTION; SEQUENCE	Three-dimensional (3-D) structural models of RNA are essential for understanding of the cellular roles played by RNA. Such models have been obtained by a technique based on a constraint satisfaction algorithm that allows for the facile incorporation of secondary and other structural information. The program generates 3-D structures of RNA with atomic-level resolution that can be refined by numerical techniques such as energy minimization. The precision of this technique was evaluated by comparing predicted transfer RNA loop and RNA pseudoknot structures with known or consensus structures. The root-mean-square deviation (2.0 to 3.0 angstroms before minimization) between predicted and control structures reveal this system to be an effective method in modeling RNA.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, QUEBEC, CANADA; UNIV MONTREAL, DEPT INFORMAT & RECH OPERAT, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal			Turcotte, Marcel/AAB-5397-2019	Turcotte, Marcel/0000-0002-4877-1029; Gautheret, Daniel/0000-0002-1508-8469				ABELSON H, 1989, COMMUN ACM, V32, P546, DOI 10.1145/63485.63486; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; FULLER W, 1967, NATURE, V215, P817, DOI 10.1038/215817a0; HANEEF I, 1989, J MOL GRAPHICS, V7, P186, DOI 10.1016/0263-7855(89)80001-3; HARALICK RM, 1980, ARTIF INTELL, V14, P263, DOI 10.1016/0004-3702(80)90051-X; HEUS HA, 1990, NUCLEIC ACIDS RES, V18, P1103, DOI 10.1093/nar/18.5.1103; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; Major F., 1991, Journal of Functional Programming, V1, P213; MALHOTRA A, 1990, P NATL ACAD SCI USA, V87, P1950, DOI 10.1073/pnas.87.5.1950; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MUTTER M, 1988, TRENDS BIOCHEM SCI, V13, P260, DOI 10.1016/0968-0004(88)90159-4; NILSSON L, 1990, BIOCHEMISTRY-US, V29, P10317, DOI 10.1021/bi00497a005; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHERAGA HA, 1968, ADV PHYS ORG CHEM, V6, P103; SKOLNICK J, 1990, SCIENCE, V250, P1121, DOI 10.1126/science.250.4984.1121; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TURNER DA, 1985, P FUNCTIONAL PROGRAM; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P	31	153	157	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1255	1260		10.1126/science.1716375	http://dx.doi.org/10.1126/science.1716375			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1716375				2022-12-24	WOS:A1991GE68900033
J	CYGLER, M; ROSE, DR; BUNDLE, DR				CYGLER, M; ROSE, DR; BUNDLE, DR			RECOGNITION OF A CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA BY AN ANTIBODY FAB FRAGMENT	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; COMBINING SITES; ANTIGEN COMPLEX; SEROGROUP-A; BINDING; PROTEINS; CONFORMATION; SPECIFICITY; LYSOZYME	The 2.05 angstrom (angstrom) resolution crystal structure of a dodecasaccharide-Fab complex revealed an unusual carbohydrate recognition site, defined by aromatic amino acids and a structured water molecule, rather than the carboxylic acid and amide side chains that are features of transport and other carbohydrate binding proteins. A trisaccharide epitope of a branched bacterial lipopolysaccharide fills this hydrophobic pocket (8 angstrom deep by 7 angstrom wide) in an entropy-assisted association (association constant = 2.05 x 10(5) liters per mole, enthalpy = -20.5 +/- 1.7 kilojoules per mole, and temperature times entropy = +10.0 +/- 2.9 kilojoules per mole). The requirement for the complementarity of van der Waals surfaces and the requirements of saccharide-saccharide and protein-saccharide hydrogen-bonding networks determine the antigen conformation adopted in the bound state.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA	National Research Council Canada	CYGLER, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANAND NN, IN PRESS GENE; ANAND NN, UNPUB J BIOL CHEM; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; BUNDLE DR, 1990, TOP CURR CHEM, V154, P1; BUNDLE DR, UNPUB; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES AT, 1978, J APPL CRYSTALLOGR, V11, P614; Kauffmann F, 1966, BACTERIOLOGY ENTEROB; Lemieux R. U., 1979, ACS SYM SER, V87, P17, DOI DOI 10.1021/BK-1979-0087.CH002; LEMIEUX RU, 1988, CAN J CHEM, V66, P3083, DOI 10.1139/v88-477; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; NASHED EM, 1990, J BIOL CHEM, V265, P20699; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PEREZ S, 1978, CARBOHYD RES, V65, P114, DOI 10.1016/S0008-6215(00)84218-4; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; ROBBINS JB, 1978, IMMUNOCHEMISTRY, V15, P839, DOI 10.1016/0161-5890(78)90117-7; ROSE DR, 1990, J MOL BIOL, V215, P489, DOI 10.1016/S0022-2836(05)80161-5; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; THURIN J, 1988, CURR TOP MICROBIOL, V139, P59	33	258	264	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					442	445		10.1126/science.1713710	http://dx.doi.org/10.1126/science.1713710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1713710				2022-12-24	WOS:A1991FY28800039
J	INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M				INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M			RETRONPHAGE-PHI-R73 - AN ESCHERICHIA-COLI PHAGE THAT CONTAINS A RETROELEMENT AND INTEGRATES INTO A TRANSFER-RNA GENE	SCIENCE			English	Article							SATELLITE BACTERIOPHAGE-P4; MUTANTS; DNA	Some strains of Escherichia coli contain retroelements (retrons) that encode genes for reverse transcriptase and branched, multicopy, single-stranded DNA (msDNA) linked to RNA. However, the origin of retrons is unknown. A P4-like cryptic prophage was found that contains a retroelement (retron Ec73) for msDNA-Ec73 in an E. coli clinical strain. The entire genome of this prophage, named phi-R73, is 12.7 kilobase pairs and is flanked by 29-base pair direct repeats derived from the 3' end of the selenocystyl transfer RNA gene (selC). P2 bacteriophage caused excision of the phi-R73 prophage and acted as a helper to package phi-R73 DNA into an infectious virion. The newly formed phi-R73 closely resembled P4 as a virion and in its lytic growth. Retronphage phi-R73 lysogenized a new host strain, reintegrating its genome into the selC gene of the host chromosome and enabling the newly formed lysogens to produce msDNA-Ec73. Hence, retron Ec73 can be transferred intercellularly as part of the genome of a helper-dependent retronphage.	RUTGERS STATE UNIV,UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa			Inouye, Sharon/R-7216-2019		NIAID NIH HHS [AI04043] Funding Source: Medline; NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertani LE, 1988, BACTERIOPHAGES, V2, P73; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; GIBBS W, 1973, VIROLOGY, V53, P24, DOI 10.1016/0042-6822(73)90462-5; INOUYE M, 1991, TRENDS BIOCHEM SCI, V16, P18, DOI 10.1016/0968-0004(91)90010-S; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; SIX EW, 1975, VIROLOGY, V67, P249, DOI 10.1016/0042-6822(75)90422-5; SUN J, IN PRESS J BACTERIOL; WALKER JT, 1983, J VIROL, V45, P1118, DOI 10.1128/JVI.45.3.1118-1139.1983	8	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					969	971		10.1126/science.1709758	http://dx.doi.org/10.1126/science.1709758			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1709758				2022-12-24	WOS:A1991FM04000037
J	SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W				SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W			ACTIVATION-INDEPENDENT BINDING OF HUMAN-MEMORY T-CELLS TO ADHESION MOLECULE ELAM-1	NATURE			English	Article							HELPER-INDUCER; ENDOTHELIAL-CELLS; LYMPHOCYTES; RECEPTOR; PROTEINS; LFA-1; ADHESIVENESS; ICAM-1	THE induction of an ensemble of adhesion molecules on endothelial cells by inflammatory cytokines is likely to be crucial to the differential migration of T-lymphocyte subsets into inflammatory sites. Two molecular pathways involving the VLA-4 and LFA-1 integrins are known to mediate T-cell adhesion to activated endothelium 1-4. Here we show that a third pathway involving the rapidly inducible endothelial cell-surface adhesion molecule ELAM-1 (refs 5, 6) contributes to the binding of resting CD4+ T cells to IL-1-induced human endothelial cells. All three pathways contribute to the greater adhesion to endothelium of memory T cells than naive T cells. There are two unique features of T-cell adhesion to purified ELAM-1: first, ELAM-1 exclusively mediates adhesion of memory T cells; second, memory T-cell binding to ELAM-1 is independent of acute activation events that regulate integrin-mediated adhesion 7,8. Thus, ELAM-1 may be of primary importance in the initial attachment of memory T cells to inflamed endothelium in vivo and to the preferential migration of memory T cells into tissue and inflammatory sites.	OTSUKA AMER PHARMACEUT INC,DEPT IMMUNOL,ROCKVILLE,MD 20850; OTSUKA AMER PHARMACEUT INC,DEPT MOLEC BIOL,ROCKVILLE,MD 20850		SHIMIZU, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.			Shimizu, Yoji/0000-0001-9760-0288; Horgan, Kevin/0000-0003-0647-9078				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAVENDER DE, 1988, CELL IMMUNOL, V117, P111, DOI 10.1016/0008-8749(88)90081-0; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DAMLE NK, 1990, J IMMUNOL, V144, P1233; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GRABER N, 1990, J IMMUNOL, V145, P819; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; JAMES SP, 1986, GASTROENTEROLOGY, V91, P1483, DOI 10.1016/0016-5085(86)90205-2; JANOSSY G, 1989, IMMUNOLOGY, V66, P517; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUNG TM, 1990, J IMMUNOL, V144, P3130; KINGSLEY G, 1988, SCAND J IMMUNOL, V28, P225, DOI 10.1111/j.1365-3083.1988.tb02435.x; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PITZALIS C, 1988, EUR J IMMUNOL, V18, P1397, DOI 10.1002/eji.1830180915; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEDDER TF, 1985, J IMMUNOL, V134, P2989; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	34	395	406	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					799	802		10.1038/349799a0	http://dx.doi.org/10.1038/349799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705667				2022-12-24	WOS:A1991EZ66600059
J	CHENG, SH; GREGORY, RJ; MARSHALL, J; PAUL, S; SOUZA, DW; WHITE, GA; ORIORDAN, CR; SMITH, AE				CHENG, SH; GREGORY, RJ; MARSHALL, J; PAUL, S; SOUZA, DW; WHITE, GA; ORIORDAN, CR; SMITH, AE			DEFECTIVE INTRACELLULAR-TRANSPORT AND PROCESSING OF CFTR IS THE MOLECULAR-BASIS OF MOST CYSTIC-FIBROSIS	CELL			English	Article											CHENG, SH (corresponding author), GENZYME CORP,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869				Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, AM J HUM GENET, V47, P213; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER PS, 1989, METABOLIC BASIS INHE, P2869; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P377; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; QUINTON PM, 1989, CLIN CHEM, V35, P726; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Sambrook J., 1989, MOL CLONING LAB MANU; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085	32	1467	1522	8	268	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 16	1990	63	4					827	834		10.1016/0092-8674(90)90148-8	http://dx.doi.org/10.1016/0092-8674(90)90148-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EJ590	1699669				2022-12-24	WOS:A1990EJ59000018
J	COPELAND, NG; GILBERT, DJ; CHO, BC; DONOVAN, PJ; JENKINS, NA; COSMAN, D; ANDERSON, D; LYMAN, SD; WILLIAMS, DE				COPELAND, NG; GILBERT, DJ; CHO, BC; DONOVAN, PJ; JENKINS, NA; COSMAN, D; ANDERSON, D; LYMAN, SD; WILLIAMS, DE			MAST-CELL GROWTH-FACTOR MAPS NEAR THE STEEL LOCUS ON MOUSE CHROMOSOME-10 AND IS DELETED IN A NUMBER OF STEEL ALLELES	CELL			English	Article									IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101	Immunex Corporation; Immunex Corporation	COPELAND, NG (corresponding author), FREDERICK CANC RES & DEV CTR,NCI,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; Beechey C.V., 1986, MOUSE NEWS LETT, V74, P92; BEECHEY CV, 1985, MOUSE NEWS LETT, V73, P17; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BERNSTEIN SE, 1968, ANN NY ACAD SCI, V149, P475, DOI 10.1111/j.1749-6632.1968.tb15186.x; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CACHEIRO NLA, 1975, GENET RES, V25, P193, DOI 10.1017/S0016672300015597; CATTANACH BM, 1988, MOUSE NEWS LETT, V80, P157; CATTANACH BM, 1980, MOUSE NEWS LETT, V80, P156; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FALCONER DS, 1965, MOUSE NEWS LETT, V32, P30; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GREEN EL, 1981, MOUSE BIOMEDICAL RES, V1, P91; HAYASHI C, 1985, DEV BIOL, V109, P234, DOI 10.1016/0012-1606(85)90363-X; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JUSTICE MJ, 1990, GENOMICS, V6, P341, DOI 10.1016/0888-7543(90)90575-F; JUSTICE MJ, 1990, GENETICS, V125, P855; KITAMURA Y, 1979, BLOOD, V53, P492; LEDLEY FD, 1988, CYTOGENET CELL GENET, V47, P125, DOI 10.1159/000132528; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MAYER TC, 1970, DEV BIOL, V23, P297, DOI 10.1016/0012-1606(70)90100-4; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCCUSKEY RS, 1973, AM J ANAT, V137, P187, DOI 10.1002/aja.1001370205; MITCHELL M, 1989, GENETICS, V121, P803; MORRISONGRAHAM K, 1990, DEV BIOL, V139, P308, DOI 10.1016/0012-1606(90)90300-8; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; MORRISONGRAHAM K, 1990, DEV BIOL, V139, P299, DOI 10.1016/0012-1606(90)90299-X; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; PETERS J, 1985, GENETICS, V110, P709; PETERS J, 1987, MOUSE NEWS LETT, V77, P125; POPP RA, 1983, GENETICS, V105, P157; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL LB, 1971, MUTAT RES, V11, P107, DOI 10.1016/0027-5107(71)90036-4; RUSSELL LB, 1989, MUTAT RES, V212, P23, DOI 10.1016/0027-5107(89)90019-5; RUSSELL WL, 1981, ENV MUTAGENS CARCINO, P59; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SCHAIBLE RH, 1961, MOUSE NEWS LETT, V24, P38; SCHAIBLE RH, 1963, MOUSE NEWS LETT, V29, P48; Silver W. K., 1979, COAT COLORS MICE MOD, P243; STEVENS LC, 1961, J NATL CANCER I, V27, P443; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WILLIAMS DE, 1990, CELL, V62, P167; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	53	603	622	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					175	183		10.1016/0092-8674(90)90298-S	http://dx.doi.org/10.1016/0092-8674(90)90298-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698554				2022-12-24	WOS:A1990EB46100018
J	ELLINGTON, AD; SZOSTAK, JW				ELLINGTON, AD; SZOSTAK, JW			INVITRO SELECTION OF RNA MOLECULES THAT BIND SPECIFIC LIGANDS	NATURE			English	Article									MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; COUTURE S, IN PRESS J MOL BIOL; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669	9	7097	7997	75	1258	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 30	1990	346	6287					818	822		10.1038/346818a0	http://dx.doi.org/10.1038/346818a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW488	1697402				2022-12-24	WOS:A1990DW48800045
J	ETLINGER, HM; GILLESSEN, D; LAHM, HW; MATILE, H; SCHONFELD, HJ; TRZECIAK, A				ETLINGER, HM; GILLESSEN, D; LAHM, HW; MATILE, H; SCHONFELD, HJ; TRZECIAK, A			USE OF PRIOR VACCINATIONS FOR THE DEVELOPMENT OF NEW VACCINES	SCIENCE			English	Article											ETLINGER, HM (corresponding author), F HOFFMANN LA ROCHE & CO LTD,CENT RES UNIT,CH-4002 BASEL,SWITZERLAND.							ADORINI L, 1979, J EXP MED, V150, P293, DOI 10.1084/jem.150.2.293; ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; ANDERSON P, 1985, J CLIN INVEST, V76, P52, DOI 10.1172/JCI111976; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BORRASCUESTA F, 1987, EUR J IMMUNOL, V17, P1213, DOI 10.1002/eji.1830170820; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELGIUDICE G, 1986, J IMMUNOL, V137, P2952; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; ETLINGER HM, 1988, IMMUNOLOGY, V64, P551; ETLINGER HM, 1988, J IMMUNOL, V140, P626; ETLINGER HM, UNPUB; FRANCIS MJ, 1987, NATURE, V330, P168, DOI 10.1038/330168a0; GEERLIGS HJ, 1989, J IMMUNOL METHODS, V124, P95, DOI 10.1016/0022-1759(89)90190-7; GOOD MF, 1986, J EXP MED, V164, P655, DOI 10.1084/jem.164.2.655; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HERZENBERG LA, 1982, J EXP MED, V155, P1741, DOI 10.1084/jem.155.6.1741; HERZENBERG LA, 1982, J EXP MED, V155, P1730, DOI 10.1084/jem.155.6.1730; JACOB CO, 1985, MOL IMMUNOL, V22, P1333, DOI 10.1016/0161-5890(85)90054-9; LEWIS GK, 1978, J EXP MED, V148, P915, DOI 10.1084/jem.148.4.915; LISE LD, 1987, INFECT IMMUN, V55, P2658, DOI 10.1128/IAI.55.11.2658-2661.1987; MITCHISON N A, 1971, European Journal of Immunology, V1, P10, DOI 10.1002/eji.1830010103; MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; RAJEWSKY K, 1969, J EXP MED, V129, P1131, DOI 10.1084/jem.129.6.1131; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SCHUTZE MP, 1987, CELL IMMUNOL, V104, P79, DOI 10.1016/0008-8749(87)90008-6; SCHUTZE MP, 1985, J IMMUNOL, V135, P2319; SERCARZ EE, 1978, IMMUNOL REV, V39, P108, DOI 10.1111/j.1600-065X.1978.tb00398.x; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; STUCHLER D, 1989, VACCINE, V7, P457; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	33	92	99	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 27	1990	249	4967					423	425		10.1126/science.1696030	http://dx.doi.org/10.1126/science.1696030			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ702	1696030				2022-12-24	WOS:A1990DQ70200045
J	ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I				ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I			INCREASED SYMPATHETIC NERVOUS ACTIVITY AND THE EFFECTS OF ITS INHIBITION WITH CLONIDINE IN ALCOHOLIC CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						SYMPATHETIC NERVOUS SYSTEM; CLONIDINE; LIVER CIRRHOSIS; HYPERTENSION; NOREPINEPHRINE	PLASMA NOREPINEPHRINE; SYSTEM ACTIVITY; DECOMPENSATED CIRRHOSIS; WATER-EXCRETION; SODIUM; RELEASE; HUMANS; PRESSURE; LIVER; DOG	Objective: To study disturbances in sympathetic nervous system function in patients with alcoholic cirrhosis and the effect of clonidine on such disturbances. Design: Cross-sectional physiologic and neurochemical evaluation of patients with cirrhosis and of healthy controls; an uncontrolled trial of intravenous clonidine in the cirrhotic patients. Patients: Forty-four hospitalized patients with biopsy-proven alcoholic cirrhosis and 31 healthy controls. Interventions: Intravenous clonidine. Main Outcome Measures: Radiotracer-derived measures of norepinephrine release to plasma, central hemodynamics, wedge hepatic vein pressure, and measures of renal function. Main Results: In patients with cirrhosis, clonidine reduced previously elevated norepinephrine overflow rates for the whole body, kidneys, and hepatomesenteric circulation. This sympathetic inhibition was accompanied by the following potentially clinically beneficial effects: the lowering of renal vascular resistance (median reduction, 24%; 95% CI, 14% to 31%), the elevation of glomerular filtration rate (median increase, 27%; CI, 14% to 39%), and the reduction of portal venous pressure (median reduction, 25%; CI, 18% to 32%). The norepinephrine and hemodynamic responses to graded clonidine dosing (1, 2, and 3-mu-g/kg body weight intravenously) indicated that the sympathetic outflow to the hepatomesenteric circulation was more sensitive to pharmacologic suppression with clonidine than was the sympathetic outflow to the systemic circulation. Conclusions: The sympathetic nerves to the kidneys, heart, and hepatomesenteric circulation are stimulated in patients with cirrhosis. Clonidine inhibits these activated sympathetic outflows differentially, which could possibly provide a basis for the selective pharmacologic treatment of portal hypertension in patients with cirrhosis.	ALFRED HOSP, GASTROENTEROL SERV, PRAHRAN, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health	ESLER, M (corresponding author), BAKER MED RES INST, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA.		Jennings, Garry/B-3914-2009; Lambert, Gavin/Q-4869-2017; Lambert, Gavin W/E-7384-2010	Lambert, Gavin/0000-0003-0315-645X; Lambert, Gavin W/0000-0003-0315-645X; Jennings, Garry/0000-0002-7865-5483				ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BOYER TD, 1977, GASTROENTEROLOGY, V72, P584; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DANCY M, 1985, LANCET, V1, P1122; DIBONA GF, 1977, AM J PHYSIOL, V233, pF73, DOI 10.1152/ajprenal.1977.233.2.F73; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; EISENHOFER G, 1988, J AUTONOM NERV SYST, V24, P1, DOI 10.1016/0165-1838(88)90130-0; EISENHOFER G, ENDOCRINOLOGY METABO, V24, pE505; EPSTEIN M, 1979, GASTROENTEROLOGY, V76, P622; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1982, CLIN SCI, V63, pS285, DOI 10.1042/cs063285s; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; ESLER M, 1984, J AUTONOM NERV SYST, V11, P125, DOI 10.1016/0165-1838(84)90071-7; ESLER M, 1988, PROGR CATECHOLAMIN C, P95; FLORAS JS, 1991, ANN INTERN MED, V114, P373, DOI 10.7326/0003-4819-114-5-373; FRIBERG P, 1990, HYPERTENSION, V16, P121, DOI 10.1161/01.HYP.16.2.121; GORESKY CA, 1989, AM J PHYSIOL, V256, pG107, DOI 10.1152/ajpgi.1989.256.1.G107; GREENWAY CV, 1971, PHYSIOL REV, V51, P23, DOI 10.1152/physrev.1971.51.1.23; HAUSLER G, 1978, N-S ARCH PHARMACOL, V295, P191; HAVEL PJ, 1988, J CLIN INVEST, V82, P1538, DOI 10.1172/JCI113763; HENRIKSEN JH, 1989, AM J PHYSIOL, V257, pE743, DOI 10.1152/ajpendo.1989.257.5.E743; HENRIKSEN JH, 1987, GUT, V28, P1637, DOI 10.1136/gut.28.12.1637; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; HENRIKSEN JH, 1981, CLIN PHYSIOL, V1, P293, DOI 10.1111/j.1475-097X.1981.tb00898.x; HORTNAGL H, 1984, LANCET, V1, P480; KIOSWKI W, 1985, J CARDIOVASC PHAR S6, V7, P144; MAEKAWA K, 1984, CIRCULATION, V70, P908, DOI 10.1161/01.CIR.70.5.908; MEREDITH IT, 1991, NEW ENGL J MED, V325, P618, DOI 10.1056/NEJM199108293250905; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SCHMITT H., 1967, EUR J PHARMACOL, V2, P147, DOI 10.1016/0014-2999(67)90041-6; SHERLOCK S, 1975, DISEASES LIVER BILIA, P66; TSYBENKO VA, 1991, J AUTONOM NERV SYST, V33, P255, DOI 10.1016/0165-1838(91)90026-Y; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; WILLETT IR, 1986, LANCET, V2, P939; YAMAGUCHI N, 1980, CAN J PHYSIOL PHARM, V58, P1347, DOI 10.1139/y80-204; ZOLLER RP, 1972, J CLIN INVEST, V51, P2967, DOI 10.1172/JCI107121	41	97	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					446	455		10.7326/0003-4819-116-6-446	http://dx.doi.org/10.7326/0003-4819-116-6-446			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739234				2022-12-24	WOS:A1992HJ59800003
J	BIRD, H				BIRD, H			AN AFFAIR OF THE HEART	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					487	488		10.1056/NEJM199202133260712	http://dx.doi.org/10.1056/NEJM199202133260712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732777				2022-12-24	WOS:A1992HD16400012
J	WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG				WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG			CIGARETTE ADVERTISING AND MAGAZINE COVERAGE OF THE HAZARDS OF SMOKING - A STATISTICAL-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; BAN	Background. Health professionals have charged that magazines that depend on revenues from cigarette advertising are less likely to publish articles on the dangers of smoking for fear of off ending cigarette manufacturers. Special concern has focused on magazines directed to women. Restricted coverage of smoking hazards could lead readers to underestimate the risks of smoking in relation to other health risks. Methods. Using logistic-regression analysis of a sample of 99 U.S. magazines published during 25 years (1959 through 1969 and 1973 through 1986), we analyzed the probability that the magazines would publish articles on the risks of smoking in relation to whether they carried advertisements for cigarettes and in relation to the proportion of their advertising revenues derived from cigarette advertisements. We controlled for other factors that might influence coverage. Results. The probability of publishing an article on the risks of smoking in a given year was 11.9 percent for magazines that did not carry cigarette advertisements, as compared with 8.3 percent for those that did publish such advertisements (adjusted odds ratio, 0.73; 95 percent confidence interval, 0.42 to 1.30). For women's magazines alone, the probabilities were 11.7 percent and 5.0 percent, respectively (adjusted odds ratio, 0.13; 95 percent confidence interval, 0.02 to 0.69). When the proportion of revenues derived from cigarette advertising was the independent variable, the probability of publishing an article on the risks of smoking in a given year was reduced by 38 percent (95 percent confidence interval, 18 percent to 55 percent) for magazines with the average proportion of total advertising revenues derived from cigarette advertising for the entire sample of magazines (6 percent) as compared with magazines with no cigarette advertising. This relation was particularly strong in the case of women's magazines. An increase of 1 percent in the share of advertising revenue derived from cigarette advertisements decreased the probability of covering the risks of smoking by three times as much as in other magazines. Conclusions. This study provides strong statistical evidence that cigarette advertising in magazines is associated with diminished coverage of the hazards of smoking. This is particularly true for magazines directed to women.			WARNER, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT PUBL HLTH POLICY & ADM,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004091] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04091] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; Bagdikian B., 1983, MEDIA MONOPOLY; BLUM A, 1986, WASHINGTON POST 0518, pF1; DALE KC, 1982, ACHS NEWS VIEWS, V3, P8; DOUGHERTY PH, 1988, NY TIMES        0406, P1; EMERY CE, 1986, PROVIDENCE J B  0423, pA1; ENGLANDER TJ, 1986, US TOBACCO CAND 0402, P46; GREENE W, 1990, ECONOMETRIC ANAL, P482; JACOBSON B, 1985, SMAOKE GETS YOUR EYE; KESSLER L, 1989, JOURNALISM QUART, V66, P316, DOI 10.1177/107769908906600207; MYERS ML, 1981, STAFF REPORT CIGARET; Seldes George, 1938, LORDS PRESS; SMITH RC, 1978, COLUMBIA JOURNAL REV, V16, P29; WARNER K E, 1989, Journal of Public Health Policy, V10, P32, DOI 10.2307/3342942; WARNER KE, 1979, POLICY ANAL, V5, P435; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1959, IN PRESS TOB CONTROL; Whelan E M, 1981, J Public Health Policy, V2, P28, DOI 10.2307/3342095; 1989, DHHS CDC898411 DEP H; 1964, DHEW PHS1103 PUBL, V1103; 1990, MMWR, V39, P261	21	59	60	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					305	309		10.1056/NEJM199201303260505	http://dx.doi.org/10.1056/NEJM199201303260505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA991	1728734				2022-12-24	WOS:A1992HA99100005
J	GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G				GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G			IRON OVERLOAD IN AFRICA - INTERACTION BETWEEN A GENE AND DIETARY IRON CONTENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; COMPLEX SEGREGATION; QUANTITATIVE TRAITS; PEDIGREES; MODEL; PREVALENCE; EXPRESSION; PATTERNS; DISEASE	Background and Methods. In contrast to hemochromatosis, which in white populations is inherited through a gene linked to the HLA locus, iron overload in sub-Saharan Africa is believed to result solely from increased dietary iron derived from traditional home-brewed beer. To examine the hypothesis that African iron overload also involves a genetic factor, we used likelihood analysis to test for an interaction between a gene (the hypothesized iron-loading locus) and an environmental factor (increased dietary iron) that determines transferrin saturation and unsaturated iron-binding capacity. We studied 236 members of 36 African families chosen because they contained index subjects with iron overload. Linkage to the HLA region was tested with use of lod scores. Results. In the index subjects, increased iron was present in both hepatocytes and cells of the mononuclear-phagocyte system. Among family members with increased dietary iron due to the consumption of traditional beer, transferrin saturation in serum was distributed bimodally, with 56 normal values (< 60 percent saturation) and 44 elevated values; the mean serum ferritin concentration was five times higher in the subjects with elevated transferrin saturation (P < 0.005). The pedigree analysis provided evidence of both a genetic effect (P < 0.005) and an effect of increased dietary iron (P < 0.005) on transferrin saturation and unsaturated iron-binding capacity. In the most likely model, increased dietary iron raised the mean transferrin saturation from 30 to 81 percent and lowered the mean unsaturated iron-binding capacity from 38 to 13-mu-mol per liter in subjects heterozygous for the iron-loading locus. The hypothesis of tight linkage to HLA was rejected. Conclusions. Iron overload in Africa may be caused by an interaction between the amount of dietary iron and a gene distinct from any HLA-linked gene.	BLOOD TRANSFUS SERV,HARARE,ZIMBABWE; SANYATI BAPTIST HOSP,SANYATI,ZIMBABWE; PROV LAB TISSUE IMMUNOL,CAPE TOWN,SOUTH AFRICA; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV ZIMBABWE,SCH MED,HARARE,ZIMBABWE; UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Case Western Reserve University; University of Zimbabwe; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Gordeuk, Victor/AAG-6577-2019; Chapanduka, zivanai/AAE-5631-2022	Chapanduka, zivanai/0000-0002-5489-8392	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD017463, R01HD017463] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 17463] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BLOCK M, 1958, IRON CLINICAL MEDICI, P115; BORECKI IB, 1989, AM J MED GENET, V134, P435; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTHWELL TH, 1964, AM J CLIN NUTR, V14, P47, DOI 10.1093/ajcn/14.1.47; BOTHWELL TH, 1984, S AFR MED J, V65, P601; BOTHWELL TH, 1989, METABOLIC BASIS INHE, V1, P1433; BOYLE CR, 1979, BIOMETRICS, V35, P55, DOI 10.2307/2529936; BRINK B, 1976, J LAB CLIN MED, V88, P725; BUCHANAN W M, 1970, South African Medical Journal, V44, P43; BUCHANAN WM, 1967, U COLLEGE RHODESIA F, V1, P5; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; GILL P, 1986, SOL862 STANF U TECH; GORDEUK VR, 1986, LANCET, V1, P1310; HASSTEDT SJ, 1982, COMPUT BIOMED RES, V15, P295, DOI 10.1016/0010-4809(82)90064-7; HENRY RJ, 1960, AM J CLIN PATHOL, V34, P381; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; ISAACSON C, 1961, J LAB CLIN MED, V58, P845; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LOWE R F, 1981, Central African Journal of Medicine, V27, P1; MACPHAIL AP, 1979, AM J CLIN NUTR, V32, P1272, DOI 10.1093/ajcn/32.6.1272; MORTON NE, 1974, AM J HUM GENET, V26, P489; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; Robins-Browne R M, 1979, Contrib Microbiol Immunol, V5, P277; ROSIN IV, 1982, TERAPEVT ARKH, V54, P80; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SEFTEL HC, 1961, J LAB CLIN MED, V58, P837; SEFTEL HC, 1966, BRIT MED J, V1, P642, DOI 10.1136/bmj.1.5488.642; SIMON M, 1987, AM J HUM GENET, V41, P89; SIMON M, 1977, CLIN GENET, V11, P327; SZASZ G, 1969, CLIN CHEM, V15, P124; YOUNG MR, 1988, AM J HUM GENET, V43, P705; 1978, BRIT J HAEMATOL, V38, P291; [No title captured]	38	241	240	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					95	100		10.1056/NEJM199201093260204	http://dx.doi.org/10.1056/NEJM199201093260204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727237				2022-12-24	WOS:A1992GY04500004
J	ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			NUCLEOSIDE TRIPHOSPHATES ARE REQUIRED TO OPEN THE CFTR CHLORIDE CHANNEL	CELL			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-BINDING FOLD; ADENYLATE KINASE; ATP-BINDING; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; TYROSINE KINASE; BETA-SUBUNIT	The CFTR Cl- channel contains two predicted nucleotide-binding domains (NBD1 and NBD2); therefore, we examined the effect of ATP on channel activity. Once phosphorylated by cAMP-dependent protein kinase (PKA), channels required cytosolic ATP to open. Activation occurred by a PKA-independent mechanism. ATP-gamma-S substituted for ATP in PKA phosphorylation, but it did not open the channel. Several hydrolyzable nucleotides (ATP > GTP > ITP almost-equal-to UTP > CTP) reversibly activated phosphorylated channels, but nonhydrolyzable analogs and Mg2+-free ATP did not. Studies of CFTR mutants indicated that ATP controls channel activity independent of the R domain and suggested that hydrolysis of ATP by NBD1 may be sufficient for channel opening. The finding that nucleoside triphosphates regulate CFTR begins to explain why CF-associated mutations in the NBDs block Cl- channel function.	GENZYME CORP,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.			Anderson, Matthew/0000-0003-4602-1811; Berger, Herbert/0000-0003-4383-2643; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, IN PRESS CELL; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GLYNN IM, 1971, PHYSIOLOGY, V218, P239; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KRUG F, 1973, J BIOL CHEM S, V24, P1203; LEMAIRE S, 1974, CAN J BIOCHEM CELL B, V52, P137, DOI 10.1139/o74-021; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	64	484	493	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					775	784		10.1016/0092-8674(91)90072-7	http://dx.doi.org/10.1016/0092-8674(91)90072-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1718606				2022-12-24	WOS:A1991GQ40700014
J	ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B				ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B			CD62/P-SELECTIN RECOGNITION OF MYELOID AND TUMOR-CELL SULFATIDES	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; ADHESIVE INTERACTION; MONOCLONAL-ANTIBODY; NEUTROPHIL ADHESION; SEQUENCE HOMOLOGY; HOMING RECEPTOR; SIALYL-LEX	CD62, also called PADGEM protein, GMP-140, or P-selectin, is a granule membrane protein of endothelial cells and platelets that is mobilized to the plasma membrane following exposure to mediators such as thrombin, histamine, complement components, or peroxides. Data presented to date suggest that one ligand of CD62 includes CD15 (Lewis x determinant) and sialic acid. We show here that sulfatides, heterogeneous 3-sulfated galactosyl ceramides, are an apparently unrelated ligand of CD62. Sulfatides are expressed on the plasma membrane of, and are excreted by, granulocytes, and constitute the principal ligand for CD62 on the plasma membrane of some tumor cells. CD62 binds to sulfatides adsorbed to plastic as avidly as it binds to myeloid or tumor cells. We find that granulocytes excrete sulfatides at a rate predicted to allow them to be rapidly released from CD62 once they have exited the bloodstream.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-40033 GOTHENBURG,SWEDEN; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Harvard University; Massachusetts General Hospital; University of Gothenburg; Bristol-Myers Squibb	ARUFFO, A (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DIETRICH CP, 1988, FASEB J, V2, P56, DOI 10.1096/fasebj.2.1.2961646; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hakomori S I, 1974, Methods Enzymol, V32, P345; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIRAIWA N, 1990, CANCER RES, V50, P2917; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; ISHIZUKA I, 1978, J BIOL CHEM, V253, P898; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PRENCE EM, 1986, BIOCHEM J, V237, P655, DOI 10.1042/bj2370655; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; SARLIEVE LL, 1984, BIOCHIM BIOPHYS ACTA, V795, P166, DOI 10.1016/0005-2760(84)90118-8; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	44	295	320	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					35	44		10.1016/0092-8674(91)90570-O	http://dx.doi.org/10.1016/0092-8674(91)90570-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717159				2022-12-24	WOS:A1991GJ32000005
J	LAWRENCE, MB; SPRINGER, TA				LAWRENCE, MB; SPRINGER, TA			LEUKOCYTES ROLL ON A SELECTIN AT PHYSIOLOGICAL FLOW-RATES - DISTINCTION FROM AND PREREQUISITE FOR ADHESION THROUGH INTEGRINS	CELL			English	Article							INCREASED SURFACE EXPRESSION; GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; NEUTROPHIL ADHERENCE; INTERCELLULAR-ADHESION; ENDOTHELIAL-CELLS; BLOOD-FLOW; TRANSENDOTHELIAL MIGRATION; VASCULAR ENDOTHELIUM; CULTURED ENDOTHELIUM	Rolling of leukocytes on vascular endothelial cells, an early event in inflammation, can be reproduced in vitro on artificial lipid bilayers containing purified CD62, a selectin also named PADGEM and GMP-140 that is inducible on endothelial cells. Neutrophils roll onthis selectin under flow conditions similar to those found in postcapillary venules. Adhesion of resting or activated neutrophils through the integrins LFA-1 and Mac-1 to ICAM-1 in a lipid bilayer does not occur at physiologic shear stresses; however, static incubation of activated neutrophils allows development of adhesion that is greater than 100-fold more shear resistant than found on CD62. Addition of a chemoattractant to activate LFA-1 and Mac-1 results in the arrest of neutrophils rolling on bilayers containing both CD62 and ICAM-1. Thus, at physiologic shear stress, rolling on a selectin is a prerequisite for activation-induced adhesion strengthening through integrins.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LAWRENCE, MB (corresponding author), HARVARD UNIV,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 31799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BUCHANAN MR, 1982, BLOOD, V60, P160; BUYON JP, 1988, J IMMUNOL, V140, P3156; Chien S, 1982, Adv Shock Res, V8, P71; COHNHEIM J, 1989, LECTURES GENERAL PAT; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FIEBIG E, 1991, INT J MICROCIRC, V10, P127; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GOLDSMITH HL, 1984, MICROVASC RES, V27, P204, DOI 10.1016/0026-2862(84)90054-2; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HARLAN JM, 1985, BLOOD, V66, P167; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Heisig N., 1968, ADV MICROCIRCULAT, V1, P89; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JUTILA MA, 1989, J IMMUNOL, V143, P3318; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1987, BLOOD, V70, P1284; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MARCHESI VT, 1961, Q J EXP PHYSIOL CMS, V46, P115, DOI 10.1113/expphysiol.1961.sp001522; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NOBIS U, 1985, MICROVASC RES, V29, P295, DOI 10.1016/0026-2862(85)90020-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; PRICE TH, 1987, J IMMUNOL, V139, P4174; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; Tanford C., 1961, PHYS CHEM MACROMOLEC; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	68	1984	2046	3	79	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					859	873		10.1016/0092-8674(91)90393-D	http://dx.doi.org/10.1016/0092-8674(91)90393-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710173				2022-12-24	WOS:A1991FP51600016
J	BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L				BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L			CHIMERIC GRNA MESSENGER-RNA MOLECULES WITH OLIGO(U) TAILS COVALENTLY LINKED AT SITES OF RNA EDITING SUGGEST THAT U-ADDITION OCCURS BY TRANSESTERIFICATION	CELL			English	Article							LEISHMANIA-TARENTOLAE; CYTOCHROME-OXIDASE; KINETOPLASTID MITOCHONDRIA; TRYPANOSOME MITOCHONDRIA; SUBUNIT-III; GUIDE RNAS; MODEL; SEQUENCES; ENZYME; INTRON	Chimeric RNA molecules were detected by polymerase chain reaction amplification of kinetoplast RNA using a 3' primer specific to mRNA and a 5' primer specific to guide RNA (gRNA), and directly by Northern analysis. Covalent linkage of the 3' oligo(U) tail of the gRNA to the mRNA occurs at editing sites. Chimeric molecules were isolated for NADH dehydrogenase subunit 7 and cytochrome oxidase subunits II and III. We propose that these molecules are intermediates in the editing process and that successive transesterifications result in the transfer of uridine residues from the gRNA 3' oligo(U) tail to an editing site, with the number of uridine residues determined by base pairing with adenine and guanine "guide" nucleotides in the gRNA.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BLUM, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MOUNT SM, 1983, CELL, V33, P209; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8	29	132	132	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					543	550		10.1016/0092-8674(91)90087-F	http://dx.doi.org/10.1016/0092-8674(91)90087-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709591				2022-12-24	WOS:A1991FM03700005
J	KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K				KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K			ASSOCIATION OF P60C-SRC WITH POLYOMA-VIRUS MIDDLE-T-ANTIGEN ABROGATING MITOSIS-SPECIFIC ACTIVATION	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSFORMING PROTEIN; REGULATORY DOMAIN; PP60C-SRC; SITES; KINASE; GENE; PRODUCT; INVIVO	POLYOMA middle-T antigen is required for tumorigenesis in animals and for viral transformation of a variety of cells in culture (reviewed in ref. 1). Middle-T associates with and thereby activates p60c-src, a cellular tyrosine kinase homologous to the oncogene product of Rous sarcoma virus 2,3. Activation of p60c-src by middle-T is accompanied both by dephosphorylation of tyrosine 527, a site which negatively regulates src kinase activity (reviewed in refs 4-6) and by autophosphorylation on tyrosine 416 (refs 7-10). Phosphoprotein p60c-src is subject to cell cycle-specific regulation. It is most active during mitosis and repressed in interphase 11. Here we report that mitotic p60c-src is dephosphorylated at tyrosine 527. We also show that in cells expressing middle-T, src kinase activity is high both in mitosis and during interphase. An oncogenic mutant src protein, p60c-src(527F), where tyrosine 527 is substituted by phenylalanine, is also highly active in all phases of the cell cycle.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990	27	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					431	433		10.1038/350431a0	http://dx.doi.org/10.1038/350431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1707141				2022-12-24	WOS:A1991FF04200053
J	KAPLAN, DR; MARTINZANCA, D; PARADA, LF				KAPLAN, DR; MARTINZANCA, D; PARADA, LF			TYROSINE PHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY OF THE TRK PROTOONCOGENE PRODUCT INDUCED BY NGF	NATURE			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELL LINE; ACETYLCHOLINE; ACTIVATION; INCREASE; RECEPTOR	NERVE growth factor (NGF) is a neurotrophic factor responsible for the differentiation and survival of sympathetic and sensory neurons as well as selective populations of cholinergic neurons 1,2. NGF binds to specific cell-surface receptors but the mechanism for transduction of the neurotrophic signal is unknown. Several experiments using the NGF-responsive pheochromocytoma cell line, PC12, have implicated tyrosine phosphorylation in NGF-mediated responses, although no NGF-specific tyrosine kinases have been identified 3. Here we show that NGF induces tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product, a tyrosine kinase receptor whose expression is restricted in vivo to neurons of the sensory spinal and cranial ganglia of neural crest origin 4. Tyrosine phosphorylation of trk by NGF is rapid, specific and occurs with picomolar quantities of factor, indicating that the response is mediated by physiological amounts of NGF. Activation of the trk tyrosine kinase receptor provides a possible mechanism for signal transduction by NGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KAPLAN, DR (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,EUKARYOT SIGNAL TRANSDUCT GRP,POB B,BETHESDA,MD 20892, USA.		Parada, luis F/B-9400-2014					ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; CHAO MV, 1990, HDB EXPT PHARM, V95, P135; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIM UH, IN PRESS J BIOL CHEM; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284	21	963	994	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					158	160		10.1038/350158a0	http://dx.doi.org/10.1038/350158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1706478				2022-12-24	WOS:A1991FB64500060
J	BASSET, P; BELLOCQ, JP; WOLF, C; STOLL, I; HUTIN, P; LIMACHER, JM; PODHAJCER, OL; CHENARD, MP; RIO, MC; CHAMBON, P				BASSET, P; BELLOCQ, JP; WOLF, C; STOLL, I; HUTIN, P; LIMACHER, JM; PODHAJCER, OL; CHENARD, MP; RIO, MC; CHAMBON, P			A NOVEL METALLOPROTEINASE GENE SPECIFICALLY EXPRESSED IN STROMAL CELLS OF BREAST CARCINOMAS	NATURE			English	Article									FAC MED STRASBOURG, INST CHIM BIOL,INSERM, UNITE BIOL MOLEC & GEN GENET 184,CNRS, F-67085 STRASBOURG, FRANCE; CHU STRASBOURG, SERV ANAT PATHOL GEN, F-67098 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Chenard, Marie-Pierre/O-2373-2016	podhajcer, osvaldo/0000-0002-6512-8553				Ahmed A, 1990, PATHOL ANNU 2, V25, P237; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS MM, 1984, P NATL ACAD SCI-BIOL, V81, P2194, DOI 10.1073/pnas.81.7.2194; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DEOME KB, 1978, CANCER RES, V38, P2103; ERICKSON HP, 1989, REV CELL BIOL, V5, P71; FERGUSON JE, 1990, J DIFFERENTIATION, V42, P199; FIDLER IJ, 1989, CYTOMETRY, V10, P673, DOI 10.1002/cyto.990100602; GARCIA M, 1987, J STEROID BIOCHEM, V27, P439, DOI 10.1016/0022-4731(87)90338-4; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NOWELL PC, 1986, CANCER RES, V46, P2203; PETTMANN B, 1985, FEBS LETT, V189, P102, DOI 10.1016/0014-5793(85)80851-6; PRESCOTT J, 1989, BIOCHEM INT, V19, P257; RHYNER TA, 1986, J NEUROSCI RES, V16, P167, DOI 10.1002/jnr.490160116; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RUBIN H, 1985, CANCER RES, V45, P2935; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAKAKURA T, 1979, DEV BIOL, V72, P201, DOI 10.1016/0012-1606(79)90111-8; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SALOMON DS, 1988, BREAST CANCER CELLUL, P363; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TREMBLAY G, 1979, EXP MOL PATHOL, V31, P248, DOI 10.1016/0014-4800(79)90026-1; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; ZIPORI D, 1990, CANCER J, V3, P164	50	1094	1134	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 20	1990	348	6303					699	704		10.1038/348699a0	http://dx.doi.org/10.1038/348699a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	1701851				2022-12-24	WOS:A1990EP04900047
J	JAVAHERIAN, K; LANGLOIS, AJ; LAROSA, GJ; PROFY, AT; BOLOGNESI, DP; HERLIHY, WC; PUTNEY, SD; MATTHEWS, TJ				JAVAHERIAN, K; LANGLOIS, AJ; LAROSA, GJ; PROFY, AT; BOLOGNESI, DP; HERLIHY, WC; PUTNEY, SD; MATTHEWS, TJ			BROADLY NEUTRALIZING ANTIBODIES ELICITED BY THE HYPERVARIABLE NEUTRALIZING DETERMINANT OF HIV-1	SCIENCE			English	Article									DUKE UNIV,SCH MED,DEPT SURG,DURHAM,NC 27710	Duke University	JAVAHERIAN, K (corresponding author), REPLIGEN CORP,CAMBRIDGE,MA 02139, USA.							EMINI E, UNPUB; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, UNPUB; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; KINNEYTHOMAS E, 1988, AIDS, V2, P25; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MATTHEWS TJ, UNPUB; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; NARA PL, 1990, J VIROL, V64, P3770; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989	20	376	396	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 14	1990	250	4987					1590	1593		10.1126/science.1703322	http://dx.doi.org/10.1126/science.1703322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM931	1703322				2022-12-24	WOS:A1990EM93100046
J	ROTZSCHKE, O; FALK, K; DERES, K; SCHILD, H; NORDA, M; METZGER, J; JUNG, G; RAMMENSEE, HG				ROTZSCHKE, O; FALK, K; DERES, K; SCHILD, H; NORDA, M; METZGER, J; JUNG, G; RAMMENSEE, HG			ISOLATION AND ANALYSIS OF NATURALLY PROCESSED VIRAL PEPTIDES AS RECOGNIZED BY CYTOTOXIC T-CELLS	NATURE			English	Article									MAX PLANCK INST BIOL,IMMUNOGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY	Max Planck Society; Eberhard Karls University of Tubingen			Roetzschke, Olaf/GXH-0012-2022					AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; DERES K, 1989, NATURE, V342, P516; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; ROTZSCHKE O, 1990, NATURE, V249, P283; SCHNORRENBERG G, 1989, TETRAHEDRON, V45, P7759, DOI 10.1016/S0040-4020(01)85791-4; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0	12	732	782	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 15	1990	348	6298					252	254		10.1038/348252a0	http://dx.doi.org/10.1038/348252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700304				2022-12-24	WOS:A1990EH79600063
J	CARMAN, WF; ZANETTI, AR; KARAYIANNIS, P; WATERS, J; MANZILLO, G; TANZI, E; ZUCKERMAN, AJ; THOMAS, HC				CARMAN, WF; ZANETTI, AR; KARAYIANNIS, P; WATERS, J; MANZILLO, G; TANZI, E; ZUCKERMAN, AJ; THOMAS, HC			VACCINE-INDUCED ESCAPE MUTANT OF HEPATITIS-B VIRUS	LANCET			English	Article									HOSP COTUGNO, DEPT INFECT DIS, NAPLES, ITALY; ROYAL FREE HOSP, SCH MED, DEPT MED MICROBIOL, LONDON, ENGLAND; UNIV MILAN, IST VIROL, I-20122 MILAN, ITALY	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Milan	CARMAN, WF (corresponding author), ST MARYS HOSP, SCH MED, DEPT MED, LONDON W2 1NY, ENGLAND.		Thomas, Howard C/A-3152-2009	Karayiannis, Peter/0000-0001-5195-7863	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHTONRICKARDT PG, 1989, J MED VIROL, V29, P196, DOI 10.1002/jmv.1890290310; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; BROWN SE, 1984, LANCET, V2, P184; BRUNETTO MR, 1989, VIRAL GASTROENTEROLO, V21, P151; CARMAN WF, 1989, LANCET, V2, P588; COURSAGET P, 1987, LANCET, V2, P1354; DREESMAN GR, 1982, NATURE, V295, P158, DOI 10.1038/295158a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KANEKO S, 1989, J INFECT DIS, V160, P903, DOI 10.1093/infdis/160.5.903; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMON SM, 1990, J INFECT DIS, V161, P7, DOI 10.1093/infdis/161.1.7; MCMAHON G, 1990, INT S VIRAL HEPATITI; MINOR PD, 1988, J GEN VIROL, V69, P1091, DOI 10.1099/0022-1317-69-5-1091; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; PORATH EB, 1985, TRANSFUSION, V25, P10, DOI 10.1046/j.1537-2995.1985.25185116491.x; STROFFOLINI T, 1988, PUBLIC HEALTH, V102, P329, DOI 10.1016/S0033-3506(88)80102-1; THIERS V, 1988, LANCET, V2, P1273; VYAS GN, 1972, SCIENCE, V178, P1300, DOI 10.1126/science.178.4067.1300; WANDS JR, 1986, P NATL ACAD SCI USA, V83, P6608, DOI 10.1073/pnas.83.17.6608; WU CTB, 1990, J VIROL, V64, P856, DOI 10.1128/JVI.64.2.856-863.1990	20	903	975	0	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 11	1990	336	8711					325	329		10.1016/0140-6736(90)91874-A	http://dx.doi.org/10.1016/0140-6736(90)91874-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU075	1697396				2022-12-24	WOS:A1990DU07500001
J	SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K				SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K			REGULATION OF THE G1-S TRANSITION IN POSTEMBRYONIC NEURONAL PRECURSORS BY AXON INGROWTH	NATURE			English	Article							DROSOPHILA CYCLIN-A; OPTIC-LOBES; NERVOUS-SYSTEM; CELL-DIVISION; MELANOGASTER; PATTERNS; NEUROGENESIS	IN the newly cellularized Drosophila embryo, progress through the cell cycle is regulated at the G2-M transition 1,2. We have examined cell-cycle regulation later in Drosophila development, in a group of postembryonic neuronal precursors. The S-phase precursor cells, which generate photoreceptor target neurons (lamina neurons) in the central nervous system, are not present in the absence of photoreceptor innervation 3. Here we report that axons selectively approach G1-phase precursors. Without axon ingrowth, lamina precursors do not enter their final S phase and by several criteria, arrest in the preceding G1 phase. These findings provide evidence that at this stage in development the control of cell division can occur at the G1-S transition.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SELLECK, SB (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.		Gonzalez, Cayetano/K-3055-2019; Gonzalez, Cayetano/K-3933-2019	Gonzalez, Cayetano/0000-0002-5259-3608; Glover, David/0000-0003-0956-0103				BAPTISTA CA, 1990, NATURE, V346, P855, DOI 10.1038/346855a0; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; FISCHBACH KF, 1983, DEV BIOL, V95, P1, DOI 10.1016/0012-1606(83)90002-7; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DI, 1968, CARNEGIE I PUBL, V627; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	16	90	90	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					253	255		10.1038/355253a0	http://dx.doi.org/10.1038/355253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731221				2022-12-24	WOS:A1992GZ69400068
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			ROLE OF NUCLEOSOMAL CORES AND HISTONE-H1 IN REGULATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							MINICHROMOSOMES ASSEMBLED INVITRO; INDUCIBLE MMTV PROMOTER; XENOPUS-LAEVIS OOCYTES; HIGH-SPEED SUPERNATANT; DNA-BINDING PROTEINS; CHROMATIN STRUCTURE; PREINITIATION COMPLEXES; IONIC-STRENGTH; MAJOR LATE; GENES	The relation between chromatin structure and transcriptional activity was examined by in vitro transcription analysis of chromatin reconstituted in the absence or presence of histone H1. To maintain well-defined template DNA, purified components were used in the reconstitution of chromatin. Reconstitution of nucleosomal cores to an average density of 1 nucleosome per 200 base pairs of DNA resulted in a mild reduction of basal RNA polymerase II transcription to 25 to 50 percent of that obtained with naked DNA templates. This nucleosome-mediated repression was due to nucleosomal cores located at the RNA start site and could not be counteracted by the sequence-specific transcription activators Sp1 and GAL4-VP16. When H1 was incorporated into the chromatin at 0.5 to 1.0 molecule per nucleosome (200 base pairs of DNA), RNA synthesis was reduced to 1 to 4 percent of that observed with chromatin containing only nucleosomal cores, and this H1-mediated repression could be counteracted by the addition of Sp1 or GAL4-VP16 (antirepression). With naked DNA templates, transcription was increased by a factor of 3 and 8 by Sp1 and GAL4-VP-16, respectively (true activation). With H1-repressed chromatin templates, however, the magnitude of transcriptional activation mediated by Sp1 and GAL4-VP16 was 90 and more than 200 times higher, respectively, because of the combined effects of true activation and antirepression. The data provide direct biochemical evidence that support and clarify previously proposed models in which there is depletion or reconfiguration of nucleosomal cores and histone H1 at the promoter regions of active genes.	UNIV CALIF SAN DIEGO, DEPT BIOL, 0322, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CAMERINIOTERO RD, 1977, NUCLEIC ACIDS RES, V4, P1159, DOI 10.1093/nar/4.5.1159-a; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, IN PRESS PROTIEN EXP, V2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALZMAN AG, 1989, FASEB J, V3, P1723; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1984, J MOL BIOL, V178, P341, DOI 10.1016/0022-2836(84)90148-7; STEIN A, 1983, NATURE, V302, P548, DOI 10.1038/302548a0; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; van Holde K.E., 1988, CHROMATIN; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	73	349	358	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					238	245		10.1126/science.1718039	http://dx.doi.org/10.1126/science.1718039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1718039				2022-12-24	WOS:A1991GJ64200031
J	LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D				LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D			MIK1 AND WEE1 COOPERATE IN THE INHIBITORY TYROSINE PHOSPHORYLATION OF CDC2	CELL			English	Article							CYCLE CONTROL GENE; YEAST SCHIZOSACCHAROMYCES-POMBE; P34CDC2 PROTEIN-KINASE; CELL-DIVISION CYCLE; FISSION YEAST; MITOTIC CONTROL; M-PHASE; SACCHAROMYCES-CEREVISIAE; MITOSIS; DNA	wee1 acts antagonistically to cdc25 in the tyrosine dephosphorylation and activation of cdc2, yet biochemical evidence suggests that wee1 is not required for tyrosine phosphorylation and its role is obscure. We show here that a related 66 kd kinase, called mik1, acts redundantly with wee1 in the negative regulation of cdc2 in S. pombe. A null allele of mik1 has no discernible phenotype, but a mik1 wee1 double mutant is hypermitotically lethal: all normal M phase checkpoints are bypassed, including the requirement for initiation of cell cycle "start," completion of S phase, and function of the cdc25+ mitotic activator. In the absence of mik1 and wee1 activity, cdc2 rapidly loses phosphate on tyrosine, both in strains undergoing mitotic lethality and in those that are viable owing to a compensating mutation within cdc2. The data suggest that mik1 and wee1 act cooperatively on cdc2, either directly as the inhibitory tyrosine kinase or as essential activators of that kinase.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LUNDGREN, K (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.			Walworth, Nancy/0000-0001-5940-8236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; CREANOR J, 1979, J GEN MICROBIOL, V112, P385, DOI 10.1099/00221287-112-2-385; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FANTES PA, 1981, J BACTERIOL, V146, P746, DOI 10.1128/JB.146.2.746-754.1981; FEATHERSTONE C, 1991, IN PRESS NATURE; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KOHLI J, 1977, GENETICS, V87, P471; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1765, DOI 10.1093/nar/14.4.1765; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MITCHISON JMM, 1974, CELL CYCLE CONTROLS; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1980, GENETICS, V96, P101; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	67	586	596	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1111	1122		10.1016/0092-8674(91)90266-2	http://dx.doi.org/10.1016/0092-8674(91)90266-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1706223				2022-12-24	WOS:A1991FD55800009
J	VANBLEEK, GM; NATHENSON, SG				VANBLEEK, GM; NATHENSON, SG			ISOLATION OF AN ENDOGENOUSLY PROCESSED IMMUNODOMINANT VIRAL PEPTIDE FROM THE CLASS-I H-2KB MOLECULE	NATURE			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	VANBLEEK, GM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461, USA.							BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BHAYANI H, 1989, J EXP MED, V170, P1609, DOI 10.1084/jem.170.5.1609; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CERUNDOLO V, 1990, NATURE, V345, P499; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEWAAL LP, 1983, J IMMUNOL, V130, P1090; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GALLIONE CJ, 1981, J VIROL, V39, P529, DOI 10.1128/JVI.39.2.529-535.1981; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHEIL JM, 1987, J IMMUNOL, V138, P3654; SHIMOJO N, 1989, J IMMUNOL, V143, P2939; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANDERZEE R, 1989, EUR J IMMUNOL, V19, P43; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	46	733	759	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 15	1990	348	6298					213	216						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700303				2022-12-24	WOS:A1990EH79600049
J	IMAMURA, T; ENGLEKA, K; ZHAN, X; TOKITA, Y; FOROUGH, R; ROEDER, D; JACKSON, A; MAIER, JAM; HLA, T; MACIAG, T				IMAMURA, T; ENGLEKA, K; ZHAN, X; TOKITA, Y; FOROUGH, R; ROEDER, D; JACKSON, A; MAIER, JAM; HLA, T; MACIAG, T			RECOVERY OF MITOGENIC ACTIVITY OF A GROWTH-FACTOR MUTANT WITH A NUCLEAR TRANSLOCATION SEQUENCE	SCIENCE			English	Article									AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,MOLEC BIOL LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross			Hla, Timothy/G-5873-2012; Maier, Jeanette AM/H-4820-2012	Hla, Timothy/0000-0001-8355-4065; Maier, Jeanette AM/0000-0002-6326-9221	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32348, HL 35627] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURGESS WH, IN PRESS J CELL BIOL; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ENGLEKA K, UNPUB; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOROUGH R, UNPUB; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GAY CG, 1990, J BIOL CHEM, V265, P3284; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GRUNZ H, 1988, CELL DIFFER DEV, V22, P183, DOI 10.1016/0045-6039(88)90010-3; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARCH CJ, 1985, NATURE, V315, P640; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENGART TK, 1988, J VASC SURG, V7, P311, DOI 10.1067/mva.1988.avs0070311; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SCHREIBER AB, 1985, J CELL BIOL, V101, P1623, DOI 10.1083/jcb.101.4.1623; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, IN PRESS METHODS ENZ; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YEH HJ, 1987, P NATL ACAD SCI USA, V84, P2317, DOI 10.1073/pnas.84.8.2317; Zhan X., UNPUB; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	55	365	398	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 28	1990	249	4976					1567	1570		10.1126/science.1699274	http://dx.doi.org/10.1126/science.1699274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA463	1699274				2022-12-24	WOS:A1990EA46300038
J	BLENOON, RJ; DONELAN, K; KNOX, RA				BLENOON, RJ; DONELAN, K; KNOX, RA			PUBLIC-OPINION AND AIDS - LESSONS FOR THE 2ND DECADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENOON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPINION & HLTH CARE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					ADAMS P, 1991, ADV DATA, V198, P1; BLENDON RJ, 1988, NEW ENGL J MED, V319, P1022, DOI 10.1056/NEJM198810133191522; BROWN ML, 1990, PUBLIC OPIN QUART, V54, P317, DOI 10.1086/269209; DAWSON DA, 1988, ADV DATA VITAL HLTH, V153, P1; DOWNS A, 1974, PUBLIC INTEREST, V4, P38; ROGERS DE, 1991, NY TIMES        0716, pA19; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Slovic P., 1980, SOC RISK ASSESSMENT, P181, DOI [10.1007/978-1-4899-0445-4_9, DOI 10.1007/978-1-4899-0445-4_9]; STORR C, 1969, SCIENCE, V165, P1232; 1990, NATIONAL ATTITUDES T; 1990, TIMES MIRROR     MAY; GENERAL SOCIAL SURVE; 1990, NY TIMES         OCT; 1990, WASHINGTON POST  JAN; 1984, NEWSWEEK         JUN; 1991, NEWSWEEK         JUN; 1988, NY TIMES         SEP; 1987, PEOPLE PRESS POLITIC; 1991, BOSTON GLOBE    0722; 1990, WALL STREET J    JUL; 1990, PUBLIC ATTITUDES PEO; 1991, LOS ANGELES TIM 1121; 1990, GENERAL SOCIAL SURVE; 1983, WASHINGTON POST  JUN; 1988, GALLUP REP       JAN	25	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					981	986		10.1001/jama.267.7.981	http://dx.doi.org/10.1001/jama.267.7.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734113				2022-12-24	WOS:A1992HD15500035
J	GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S				GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S			THE BENEFITS OF TREATING HYPERLIPIDEMIA TO PREVENT CORONARY HEART-DISEASE - ESTIMATING CHANGES IN LIFE EXPECTANCY AND MORBIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; COST-EFFECTIVENESS; CHOLESTEROL; MEN; HYPERCHOLESTEROLEMIA; GEMFIBROZIL; THERAPY; TRIAL	Objective. - To evaluate the lifetime benefits of reducing total serum cholesterol levels to prevent coronary heart disease (CHD). Design. - We developed a CHD primary prevention computer model to estimate the benefits associated with lifelong risk factor modification. We validated the model by comparing the computer estimates with the observed results of three primary CHD prevention trials. Patients. - Men and women age 35 to 65 years who are free of CHD, with total serum cholesterol levels ranging from 5.2 to 7.8 mmol/L (200 to 300 mg/dL), with or without additional CHD risk factors. Interventions. - Serum cholesterol reduction through dietary modification or diet and medications. Main Outcome Measures. - Changes in life expectancy and the delay of symptomatic CHD. Results. - The computer forecasts for CHD end points closely matched the observed results of the Lipid Research Clinics Trial, the Helsinki Heart Study, and MRFIT. We then applied the computer model to low-risk and high-risk men and women with total serum cholesterol levels between 5.2 and 7.8 mmol/L (200 and 300 mg/dL) and estimated that, after reducing serum cholesterol levels 5% to 33%, the average life expectancy would increase by 0.03 to 3.16 years. We also forecast that the average onset of symptomatic CHD would be delayed among these patient groups by 0.06 to 4.98 years. Conclusion. - We conclude that this computer model accurately estimates the results of clinical trials and can be used to forecast the changes in life expectancy and morbidity (the development of CHD) associated with specific CHD risk reduction interventions. The wide variation surrounding these estimates underscores the need to better define which groups of individuals will gain the most from cholesterol reduction.	MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL H3A 2T5, QUEBEC, CANADA; CTR CARDIOVASC RISK ASSESSMENT, MONTREAL, QUEBEC, CANADA; MONTREAL GEN HOSP, DIV GEN INTERNAL MED, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP, DIV CLIN EPIDEMIOL, 1650 CEDAR AVE, MONTREAL H3G 1A4, QUEBEC, CANADA.			Coupal, Louis/0000-0003-0828-9665; Abrahamowicz, Michal/0000-0002-3172-3952				ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BERWICK DM, 1980, CHOLESTEROL CHILDREN, P301; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1; GORDON T, 1971, FRAMINGHAM STUDY EPI; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; HJERMANN I, 1981, LANCET, V2, P1303; KANNEL WB, 1988, NIH882969 NAT HEART; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LEWIS B, 1987, EUR HEART J, V8, P77; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P607; OLIVER MF, 1986, CIRCULATION, V73, P1, DOI 10.1161/01.CIR.73.1.1; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; VEGA GL, 1989, JAMA-J AM MED ASSOC, V262, P3148; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, HLTH CANADIANS REPOR; 1973, CORONARY RISK HDB ES; 1989, LIFE TABLES CANADA P; 1987, LANCET, V1, P377	36	80	80	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					816	822						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732653				2022-12-24	WOS:A1992HC48400026
J	BECKER, S; HINTON, GE				BECKER, S; HINTON, GE			SELF-ORGANIZING NEURAL NETWORK THAT DISCOVERS SURFACES IN RANDOM-DOT STEREOGRAMS	NATURE			English	Article								THE standard form of back-propagation learning 1 is implausible as a model of perceptual learning because it requires an external teacher to specify the desired output of the network. We show how the external teacher can be replaced by internally derived teaching signals. These signals are generated by using the assumption that different parts of the perceptual input have common causes in the external world. Small modules that look at separate but related parts of the perceptual input discover these common causes by striving to produce outputs that agree with each other (Fig. 1a). The modules may look at different modalities (such as vision and touch), or the same modality at different times (for example, the consecutive two-dimensional views of a rotating three-dimensional object), or even spatially adjacent parts of the same image. Our simulations show that when our learning procedure is applied to adjacent patches of two-dimensional images, it allows a neural network that has no prior knowledge of the third dimension to discover depth in random dot stereograms of curved surfaces.			BECKER, S (corresponding author), UNIV TORONTO,DEPT COMP SCI,10 KINGS COLL RD,TORONTO M5S 1A4,ONTARIO,CANADA.		Becker, Suzanna/H-8197-2013	Becker, Suzanna/0000-0002-2645-070X				Hastie T.J., 1990, GEN ADDITIVE MODELS; LEHKY SR, 1990, J NEUROSCI, V10, P2281; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Zemel R.S., 1991, DISCOVERING VIEWPOIN	4	198	199	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					161	163		10.1038/355161a0	http://dx.doi.org/10.1038/355161a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729650				2022-12-24	WOS:A1992GY62900058
J	GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC				GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC			EFFECTS OF THE STEEL GENE-PRODUCT ON MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; EXPRESSION; LIGAND; RAT	MUTATIONS at the steel (sl) and dominant white spotting (W) loci in the mouse affect primordial germ cells (PGC), melanoblasts and haemopoietic stem cells 1. The W gene encodes a cell-surface receptor of the tyrosine kinase family 2,3, the proto-oncogene c-kit. In situ analysis has shown c-kit messenger RNA expression in PGC in the early genital ridges 4. The Sl gene encodes the ligand for this receptor, a peptide growth factor, called here stem cell factor (SCF) 5-7. SCF mRNA is expressed in many regions of the early mouse embryo, including the areas of migration of these cell types 8. It is important now to identify the role of the Sl-W interaction in the development of these migratory embryonic stem cell populations. Using an in vitro assay system 9, we show that SCF increases both the overall numbers and colony sizes of migratory PGC isolated from wild-type mouse embryos, and cultured on irradiated feeder layers of STO cells (a mouse embryonic fibroblast line). In the absence of feeder cells, SCF causes a large increase in the initial survival and apparent motility of PGC in culture. But labelling with bromodeoxyuridine shows that SCF is not, by itself, a mitogen for PGC. SCF does not exert a chemotropic effect on PGC in in vitro assays. These results suggest that SCF in vivo is an essential requirement for PGC survival. This demonstrates the control of the early germ-line population by a specific trophic factor.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Amgen	GODIN, I (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1990, DEVELOPMENT, V108, P357; MANIATIS T, 1987, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Silver W. K., 1979, COAT COLORS MICE MOD, P243; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	15	372	382	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					807	809		10.1038/352807a0	http://dx.doi.org/10.1038/352807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715517				2022-12-24	WOS:A1991GC96400061
J	VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J				VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J			ATOMIC-STRUCTURE OF FKBP-FK506, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; PROTEIN; FK506	The structure of the human FK506 binding protein (FKBP), complexed with the immunosuppressant FK506, has been determined to 1.7 angstroms resolution by x-ray crystallography. The conformation of the protein changes little upon complexation, but the conformation of FK506 is markedly different in the bound and unbound forms. The drug's association with the protein involves five hydrogen bonds, a hydrophobic binding pocket lined with conserved aromatic residues, and an unusual carbonyl binding pocket. The nature of this complex has implications for the mechanism of rotamase catalysis and for the biological actions of FK506 and rapamycin.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT CHEM,BAKER LAB,ITHACA,NY 14853	Harvard University; Cornell University; Cornell University			Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021	Standaert, Robert F/0000-0002-5684-1322; Karplus, Paul/0000-0001-8725-6292	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24487] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARUSO P, 1990, J AM CHEM SOC, V112, P9434, DOI 10.1021/ja00181a078; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083	23	615	636	6	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					839	842		10.1126/science.1709302	http://dx.doi.org/10.1126/science.1709302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709302				2022-12-24	WOS:A1991FL12300045
J	MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE				MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE			POINT MUTATION IN MENINGOCOCCAL POR-A GENE ASSOCIATED WITH INCREASED ENDEMIC DISEASE	LANCET			English	Article							OUTER-MEMBRANE PROTEIN; NEISSERIA-MENINGITIDIS; ANTIBODIES; SEROTYPES; EPITOPES; VACCINE	The por A gene, which encodes expression of meningococcal class 1 outer membrane protein, responsible for antigenic subtype specificity, has been cloned and sequenced in an isolate of Neisseria meningitidis (B:15:P1.7,16) from a patient in the Gloucester area with meningococcal meningitis. Comparison of the sequence with that of the equivalent gene from the P1.7,16 reference strain reveals a point mutation which generates a single amino acid change in the epitope responsible for P1.16 specificity. Monoclonal antibodies with P1.16 specificity do not react with synthetic peptides that correspond to the altered epitope, and do not promote complement-mediated bactericidal killing of the isolate. Analysis of other strains shows widespread distribution of infections due to B:15:P1.7,16 meningococci with the altered epitope (P1.16b) in England and Wales.	UNIV SOUTHAMPTON,SCH MED,DEPT MICROBIOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; RIJKSINST VOLKSGEZONDHEID MILIEUHYG,3720 BA BILTHOVEN,NETHERLANDS; WITHINGTON HOSP,PUBL HLTH LAB SERV,MENINGOCOCCAL REFERENCE LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	University of Southampton				Clarke, Ian/0000-0002-4938-1620				ABDILLAHI H, 1988, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P139, DOI 10.1016/0378-1097(88)90023-7; ABDILLAHI H, 1988, MICROB PATHOGENESIS, V4, P27, DOI 10.1016/0882-4010(88)90045-9; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; BARLOW AK, 1987, INFECT IMMUN, V55, P2734, DOI 10.1128/IAI.55.11.2734-2740.1987; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1986, CLIN INVEST MED, V9, P101; JONES DM, 1990, LANCET, V336, P53, DOI 10.1016/0140-6736(90)91566-S; KNIGHT, 1990, LANCET, V335, P1182; MANDRELL RE, 1989, INFECT IMMUN, V57, P1590, DOI 10.1128/IAI.57.5.1590-1598.1989; MCGUINNESS B, 1990, J EXP MED, V171, P1871, DOI 10.1084/jem.171.6.1871; POOLMAN JT, 1986, LANCET, V2, P555; POOLMAN JT, 1987, A VAN LEEUW J MICROB, V53, P261; SAUKKONEN K, 1989, VACCINE, V7, P325, DOI 10.1016/0264-410X(89)90194-1; VIRJI M, 1987, J GEN MICROBIOL, V133, P3393; WEDEGE E, 1986, INFECT IMMUN, V51, P571, DOI 10.1128/IAI.51.2.571-578.1986	16	168	183	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					514	517		10.1016/0140-6736(91)91297-8	http://dx.doi.org/10.1016/0140-6736(91)91297-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1705642				2022-12-24	WOS:A1991EZ87400004
J	GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R				GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R			ELFT - A GENE THAT DIRECTS THE EXPRESSION OF AN ELAM-1 LIGAND	CELL			English	Article							LEUKOCYTE-ENDOTHELIAL INTERACTIONS; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; MEMBRANE-PROTEIN; ANIMAL-CELLS; ADHESION; RECEPTOR; CDNA; NEUTROPHILS	The LECCAMs are a family of cell adhesion molecules implicated in certain inflammatory processes. ELAM-1, a LECCAM found on the surface of activated endothelial cells, can mediate adhesion of neutrophils, monocytes, and certain cell lines to endothelial cells in vitro. No ligand for any LECCAM has yet been fully characterized. Here we report the cloning of a cDNA, ELFT (ELAM-1 ligand fucosyltransferase), that can confer ELAM-1 binding activity when transfected into nonbinding cells lines. ELFT encodes a 46 kd protein that has alpha-(1,3)fucosyltransferase activity, suggesting that a fucosylated carbohydrate structure is an essential component of the ELAM-1 ligand. Furthermore, ELFT is expressed specifically in cell types that bind to ELAM-1, suggesting that this enzyme is an important regulator of inflammatory events in vivo.			GOELZ, SE (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARLOS T, 1990, IN PRESS BLOOD; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DAVIS MM, 1986, HDB EXPT IMMUNOLOGY, V2, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARLAN JM, 1985, BLOOD, V65, P513; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAXAM A, 1980, METHOD ENZYMOL, V68, P499; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OHMORI K, 1989, BLOOD, V74, P255; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, IN PRESS SCIENCE; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	44	305	324	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1349	1356		10.1016/0092-8674(90)90430-M	http://dx.doi.org/10.1016/0092-8674(90)90430-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1702034				2022-12-24	WOS:A1990EN92300025
J	ANDERSON, DM; LYMAN, SD; BAIRD, A; WIGNALL, JM; EISENMAN, J; RAUCH, C; MARCH, CJ; BOSWELL, HS; GIMPEL, SD; COSMAN, D; WILLIAMS, DE				ANDERSON, DM; LYMAN, SD; BAIRD, A; WIGNALL, JM; EISENMAN, J; RAUCH, C; MARCH, CJ; BOSWELL, HS; GIMPEL, SD; COSMAN, D; WILLIAMS, DE			MOLECULAR-CLONING OF MAST-CELL GROWTH-FACTOR, A HEMATOPOIETIN THAT IS ACTIVE IN BOTH MEMBRANE-BOUND AND SOLUBLE FORMS	CELL			English	Article									VET ADM MED CTR,INDIANAPOLIS,IN 46223; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT PROT CHEM,SEATTLE,WA 98101	US Department of Veterans Affairs; Veterans Health Administration (VHA); Immunex Corporation; Immunex Corporation	ANDERSON, DM (corresponding author), IMMUNEX CORP,DEPT MOLEC BIOL,51 UNIV ST,SEATTLE,WA 98101, USA.							ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; BERNSTEIN SE, 1970, AM J SURG, V119, P448, DOI 10.1016/0002-9610(70)90148-0; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CONLON PJ, 1987, J IMMUNOL, V139, P98; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOWER SK, 1989, J IMMUNOL, V142, P4314; FRIED W, 1973, BRIT J HAEMATOL, V24, P643, DOI 10.1111/j.1365-2141.1973.tb01690.x; FUJITA J, 1988, J CELL PHYSIOL, V134, P78, DOI 10.1002/jcp.1041340109; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HEARD JM, 1987, ONCOGENE RES, V1, P423; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LARSEN A, 1990, IN PRESS J EXP MED; LU L, 1985, EXP HEMATOL, V13, P989; Maniatis T., 1982, MOL CLONING; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY ED, 1973, TRANSPLANTATION, V15, P526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; PRICE V, 1987, GENE, V55, P287, DOI 10.1016/0378-1119(87)90288-5; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1956, SCIENCE, V124, P1076, DOI 10.1126/science.124.3231.1076; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1990, IN PRESS BLOOD; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	52	900	932	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					235	243		10.1016/0092-8674(90)90304-W	http://dx.doi.org/10.1016/0092-8674(90)90304-W			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698558				2022-12-24	WOS:A1990EB46100024
J	CITRON, M; SCHUSTER, H				CITRON, M; SCHUSTER, H			THE C4 REPRESSORS OF BACTERIOPHAGE-P1 AND BACTERIOPHAGE-P7 ARE ANTISENSE RNAS	CELL			English	Article											CITRON, M (corresponding author), MAX PLANCK INST MOLEC GENET, IHNESTR 73, W-1000 BERLIN 33, GERMANY.							APPLEYARD RK, 1954, GENETICS, V39, P440; BAGDASARIAN M, 1981, CURR TOP MICROBIOL, V96, P47; BAUMSTARK BR, 1987, VIROLOGY, V156, P197, DOI 10.1016/0042-6822(87)90398-9; CHESNEY RH, 1975, VIROLOGY, V67, P375, DOI 10.1016/0042-6822(75)90439-0; DEVLIN BH, 1982, VIROLOGY, V120, P360, DOI 10.1016/0042-6822(82)90037-X; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HANSEN EB, 1989, J MOL BIOL, V207, P135, DOI 10.1016/0022-2836(89)90445-2; HEISIG A, 1989, J MOL BIOL, V209, P525, DOI 10.1016/0022-2836(89)90591-3; HEISIG A, 1989, THESIS FREIE U BERLI; IIDA S, 1979, MOL GEN GENET, V173, P249, DOI 10.1007/BF00268635; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; LIAO SM, 1987, GENE DEV, V1, P197, DOI 10.1101/gad.1.2.197; MA C, 1990, EMBO J, V9, P1267, DOI 10.1002/j.1460-2075.1990.tb08235.x; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JR, 1977, VIROLOGY, V76, P39, DOI 10.1016/0042-6822(77)90279-3; SCOTT JR, 1968, VIROLOGY, V36, P564, DOI 10.1016/0042-6822(68)90188-8; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER DH, 1975, J VIROL, V16, P525, DOI 10.1128/JVI.16.3.525-534.1975; WANDERSMAN C, 1977, VIROLOGY, V77, P386, DOI 10.1016/0042-6822(77)90435-4; WU TH, 1987, GENE DEV, V1, P204, DOI 10.1101/gad.1.2.204; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	28	41	43	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 10	1990	62	3					591	598		10.1016/0092-8674(90)90023-8	http://dx.doi.org/10.1016/0092-8674(90)90023-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DU445	1696181				2022-12-24	WOS:A1990DU44500020
J	WEIHER, H; NODA, T; GRAY, DA; SHARPE, AH; JAENISCH, R				WEIHER, H; NODA, T; GRAY, DA; SHARPE, AH; JAENISCH, R			TRANSGENIC MOUSE MODEL OF KIDNEY-DISEASE - INSERTIONAL INACTIVATION OF UBIQUITOUSLY EXPRESSED GENE LEADS TO NEPHROTIC SYNDROME	CELL			English	Article									MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			/U-3554-2018	/0000-0002-8634-4984	NCI NIH HHS [R35CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; COVARRUBIAS L, 1986, P NATL ACAD SCI USA, V83, P6020, DOI 10.1073/pnas.83.16.6020; FRIES JWU, 1989, LAB INVEST, V60, P205; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GRIDLEY T, 1987, TRENDS GENET, V3, P162, DOI 10.1016/0168-9525(87)90218-6; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAENISCH R, 1983, CELL, V32, P209, DOI 10.1016/0092-8674(83)90511-1; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; MACKAY K, 1987, KIDNEY INT, V32, P827, DOI 10.1038/ki.1987.283; MAHON KA, 1988, P NATL ACAD SCI USA, V85, P1165, DOI 10.1073/pnas.85.4.1165; Maniatis T., 1982, MOL CLONING; MARK W, 1985, COLD SPRING HARB SYM, V50, P447; MCNEISH JD, 1988, SCIENCE, V241, P837, DOI 10.1126/science.3406741; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; RENNKE HG, 1989, AM J KIDNEY DIS, V13, P443, DOI 10.1016/S0272-6386(89)80001-0; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS, P991; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SELIGER B, 1986, MOL CELL BIOL, V6, P286, DOI 10.1128/MCB.6.1.286; Sheehan D.C., 1980, THEORY PRACTICE HIST; SORIANO P, 1987, GENE DEV, V1, P366, DOI 10.1101/gad.1.4.366; SPENCE SE, 1989, MOL CELL BIOL, V9, P177, DOI 10.1128/MCB.9.1.177; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; WEIHER H, 1987, J VIROL, V61, P2742, DOI 10.1128/JVI.61.9.2742-2746.1987; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0	34	150	153	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 10	1990	62	3					425	434		10.1016/0092-8674(90)90008-3	http://dx.doi.org/10.1016/0092-8674(90)90008-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DU445	1696177				2022-12-24	WOS:A1990DU44500005
J	BRITTIS, PA; CANNING, DR; SILVER, J				BRITTIS, PA; CANNING, DR; SILVER, J			CHONDROITIN SULFATE AS A REGULATOR OF NEURONAL PATTERNING IN THE RETINA	SCIENCE			English	Article							OPTIC AXONS; PROTEOGLYCANS; GROWTH; INVITRO; CULTURE; INVIVO; NERVE; CELLS	Highly sulfated proteoglycans are correlated with axon boundaries in the developing central nervous system which suggests that these molecules affect neural pattern formation. In the developing mammalian retina, gradual regression of chondroitin sulfate may help control the onset of ganglion cell differentiation and initial direction of their axons. Changes induced by the removal of chondroitin sulfate from intact retinas in culture confirm the function of chondroitin sulfate in retinal histogenesis.			BRITTIS, PA (corresponding author), CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106, USA.							CARBONETTO S, 1983, J NEUROSCI, V3, P2324; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; GOLDBERG S, 1977, EXP EYE RES, V25, P399, DOI 10.1016/0014-4835(77)90107-5; HALFTER W, 1987, J NEUROSCI, V7, P3712; HALFTER W, 1985, J COMP NEUROL, V232, P466, DOI 10.1002/cne.902320405; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; MANN I, 1969, DEV HUMAN EYE; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MORRIS JE, 1987, ARCH BIOCHEM BIOPHYS, V258, P206, DOI 10.1016/0003-9861(87)90337-7; NEWGREEN DF, 1986, CELL TISSUE RES, V244, P299; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sidman RL, 1961, STRUCTURE EYE, P487; SILVER J, 1979, DEV BIOL, V68, P175, DOI 10.1016/0012-1606(79)90252-5; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; THRELKELD A, 1989, DEV BIOL, V132, P559, DOI 10.1016/0012-1606(89)90251-0; WATANABE M, 1991, J NEUROBIOL, V22, P85, DOI 10.1002/neu.480220109; ZAREMBA S, 1990, J NEUROSCI, V10, P2985	21	389	397	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					733	736		10.1126/science.1738848	http://dx.doi.org/10.1126/science.1738848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738848				2022-12-24	WOS:A1992HC50600044
J	SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ			LACTOSE BINDING TO HEAT-LABILE ENTEROTOXIN REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							TOXIN B-SUBUNIT; CHOLERA-TOXIN; ESCHERICHIA-COLI; BACTERIAL TOXINS; GANGLIOSIDE GM1; RECEPTOR; PROTEINS; MEMBRANE; ASSOCIATION; REFINEMENT	RECOGNITION of the oligosaccharide portion of ganglioside G(M1) in membranes of target cells by the heat-labile enterotoxin from Escherichia coli is the crucial first step in its pathogenesis, as it is for the closely related cholera toxin 1-3. These toxins have five B subunits, which are essential for G(M1) binding, and a single A subunit, which needs to be nicked by proteolysis and reduced, yielding an A1-'enzyme' and an A2-'linker' peptide. A1 is translocated across the membrane of intestinal epithelial cells, possibly after endocytosis 4,5, upon which it ADP-ribosylates the G protein G(s-alpha) (reviewed in refs 2, 3, 6). The mechanism of binding and translocation of these toxins has been extensively investigated 1,2,7-20, but how the protein is orientated on binding is still not clear 10-12,18. Knowing the precise arrangement of the ganglioside binding sites of the toxins will be useful for designing drugs against the diarrhoeal diseases caused by organisms secreting these toxins and in the development of oral vaccines against them 21,22. We present here the three-dimensional structure of the E. coli heat-labile enterotoxin complexed with lactose. This reveals the location of the binding site of the terminal galactose of G(M1), which is consistent with toxin binding to the target cell with its A1 fragment pointing away from the membrane. A small helix is identified at the carboxy terminus of A2 which emerges through the central pore of the B subunits and probably comes into contact with the membrane upon binding, whereas the A1 subunit is flexible with respect to the B pentamer.			SIXMA, TK (corresponding author), UNIV GRONINGEN, BIOSON RES INST, DEPT CHEM, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X; Sixma, Titia K/0000-0001-6180-0632				ARNONE A, 1971, J BIOL CHEM, V246, P2302; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLEMENTS JD, 1979, INFECT IMMUN, V24, P760, DOI 10.1128/IAI.24.3.760-769.1979; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRIFFITHS SL, 1986, BIOCHEM J, V238, P313, DOI 10.1042/bj2380313; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; JANICOT M, 1991, J BIOL CHEM, V266, P12858; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LESK AM, 1985, METHOD ENZYMOL, V115, P381; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRONK SE, 1985, J BIOL CHEM, V260, P3580; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANCHEZ J, 1988, GENE, V64, P265, DOI 10.1016/0378-1119(88)90341-1; SATTLER J, 1977, H-S Z PHYSIOL CHEM, V358, P159, DOI 10.1515/bchm2.1977.358.1.159; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SVENNERHOLM AM, 1982, LANCET, V1, P305; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	36	185	192	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 6	1992	355	6360					561	564		10.1038/355561a0	http://dx.doi.org/10.1038/355561a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741035				2022-12-24	WOS:A1992HC52600064
J	BULLOCK, KD; REED, RJ; GRANT, I				BULLOCK, KD; REED, RJ; GRANT, I			REDUCED MORTALITY RISK IN ALCOHOLICS WHO ACHIEVE LONG-TERM ABSTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; FOLLOW-UP; 1ST ADMISSION; LATE 30S; MEN; SUICIDE	Objectives. - To determine if alcoholic men who achieved stable abstinence experienced fewer deaths than those who relapsed and to develop a model predictive of premature mortality. Design. - A cohort of alcoholic men recruited into a prospective study of neurocognitive effects of alcoholism was followed up from 1 through 11 years. A demographically equated group of nonalcoholic men was also followed up, Alcoholics were classified as stable abstainers or relapsers. Setting. - Alcoholics were patients or ex-patients from a Department of Veterans Affairs Alcoholism Treatment Program and/or members of local chapters of Alcoholics Anonymous. Participants. - There were 234 alcoholic men who met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, criteria for alcohol dependence. Follow-up status regarding relapse and mortality was obtained for 199 alcoholic subjects (85%). Of these, 1 01 had relapsed and 98 had abstained. Ninety-eight nonalcoholic controls equated for age, education, and sex also participated. Mortality status was obtained for 92 subjects in this group (94%). Exclusions. - Major medical and psychiatric illness and history of nonalcoholic drug abuse. Main Outcome Measure. - Death during a follow-up period of 1 through 11 years. Death was ascertained through the National Death index, the California State Department of Health and Vital Statistics, the State Department of Motor Vehicles, and through personal contact with informants. relatives, and significant others of the subjects. Results. - There were 19 deaths among relapsed alcoholics compared with the expected number of 3.83 (99% confidence interval (CI), 9.64 to 33.38). Among abstinent alcoholics there were four deaths (expected = 3.21; 99% CI, 0.67 to 12.59). The standardized mortality ratio for relapsed alcoholics was 4.96, which significantly exceeded the expected ratio (P < .001), whereas the standardized mortality ratio for abstinent alcoholics (1.25) was indistinguishable from the expected. Cox proportional hazards analysis was used to determine if any of several demographic, medical, cognitive, or drinking history variables (in addition to relapse) helped predict mortality among alcoholics. Only relapse was significantly related to increased mortality (chi-2 = 9. 15, P = .003). Conclusions. - Alcoholic men who achieve stable abstinence do not differ from nonalcoholic men in mortality experience; however, alcoholics who relapse die at a rate 4.96 times that of an age-, sex-, and race-matched representative sample from the US Bureau of the Census.	DEPT VET AFFAIRS MED CTR,PSYCHIAT SERV 116,3350 LA JOLLA VILLAGE DR,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,RES SERV,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego								ADAMS KM, 1980, AM J PSYCHIAT, V137, P928; ADAMS KM, 1981, AM J PSYCHIAT, V138, P445; BERGLUND M, 1985, ALCOHOL CLIN EXP RES, V9, P153, DOI 10.1111/j.1530-0277.1985.tb05541.x; BERGLUND M, 1984, ARCH GEN PSYCHIAT, V41, P888; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; BERGLUND M, 1985, ACTA PSYCHIAT SCAND, V71, P141, DOI 10.1111/j.1600-0447.1985.tb01264.x; COMBSORME T, 1985, J STUD ALCOHOL, V46, P443, DOI 10.15288/jsa.1985.46.443; COX DR, 1972, J R STAT SOC B, V34, P187; de Lint J, 1975, Can Med Assoc J, V113, P385; DIXON WJ, 1988, BMDP STATISTICAL SOF; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDWARDS G, 1978, J STUD ALCOHOL, V39, P1607, DOI 10.15288/jsa.1978.39.1607; GORWITZ R, 1966, PUBLIC HLTH REP, V81, P1095; GRANT I, 1984, ARCH GEN PSYCHIAT, V41, P710; GRANT I, 1978, ARCH GEN PSYCHIAT, V35, P1063; GRANT I, 1979, AM J PSYCHIAT, V136, P1263; IMAIZUMI Y, 1986, ALCOHOL ALCOHOLISM, V21, P159; KINNEY EL, 1989, ANGIOLOGY, V40, P270, DOI 10.1177/000331978904000405; Lachar D., 1974, MMPI CLIN ASSESSMENT; LEE ET, 1980, STATISTICAL METHODS; LINDBERG S, 1988, BRIT J ADDICT, V83, P1193; MACKENZIE A, 1986, INT J ADDICT, V21, P865, DOI 10.3109/10826088609027400; MACMAHON B, 1983, AM J PUBLIC HEALTH, V78, P1247; MURPHY GE, 1979, ARCH GEN PSYCHIAT, V36, P65; NICHOLLS P, 1974, Q J STUD ALCOHOL, V35, P841; Pell S, 1973, J Occup Med, V15, P120; Reitan RM, 1974, CLIN NEUROPSYCHOLOGY; ROGOT E, 1983, AM J PUBLIC HEALTH, V73, P1265, DOI 10.2105/AJPH.73.11.1265; SCHMIDT E, 1970, BR J ADDICT, V64, P327; SCHMIDT W, 1972, Q J STUD ALCOHOL, V33, P171; SCHUCKIT MA, 1974, Q J STUD ALCOHOL, V35, P856; SMITH EM, 1983, ALCOHOL CLIN EXP RES, V7, P237, DOI 10.1111/j.1530-0277.1983.tb05449.x; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; TAYLOR JR, 1983, BIOL ALCOHOL, V6, P17; THORARINSSON AA, 1979, J STUD ALCOHOL, V40, P704, DOI 10.15288/jsa.1979.40.704; VAILLANT GE, 1983, NATURAL HIST ALCOHOL, P161; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; 1987, DIAGNOSTIC STATISTIC; 1987, CURRENT POPULATION P, V25; 1980, MORTALITY, V2, P7; 1984, TECHNICAL APPENDIX A, V2	41	39	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					668	672		10.1001/jama.267.5.668	http://dx.doi.org/10.1001/jama.267.5.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731133				2022-12-24	WOS:A1992HB35400023
J	ELBRECHT, A; SMITH, RG				ELBRECHT, A; SMITH, RG			AROMATASE ENZYME-ACTIVITY AND SEX DETERMINATION IN CHICKENS	SCIENCE			English	Article							MULLERIAN INHIBITING SUBSTANCE; DETERMINING REGION; ESTROGEN; OVARY; CHROMOSOME; ANDROGEN; EMBRYO; GENE	During development, the genotype of the zygote determines the nature of the gonad, which then determines the male or female phenotype. The molecular events underlying this process are just beginning to be defined. A single treatment of chicken embryos with an aromatase inhibitor (which blocks the synthesis of estrogen from testosterone) at a stage when their gonads were bipotential caused genetic females to develop a permanent male phenotype. These sex-reversed females developed bilateral testes that were capable of complete spermatogenesis and had the physical appearance and behavior of normal males. This result identifies aromatase as a key developmental switch in the sex determination of chickens.			ELBRECHT, A (corresponding author), MERCK SHARP & DOHME LTD,DEPT ANIM BIOCHEM & MOLEC BIOL,RAHWAY,NJ 07065, USA.							BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BELL DJ, 1971, MALE REPRODUCTION PH, V3, P1411; BROWNE LJ, 1988, Patent No. 4728645; GEORGE FW, 1978, NATURE, V274, P172, DOI 10.1038/274172a0; GEORGE FW, 1978, J CLIN ENDOCR METAB, V47, P550, DOI 10.1210/jcem-47-3-550; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Haffen K., 1970, Adv Morphogen, V8, P285; HUTSON JM, 1985, GEN COMP ENDOCR, V57, P88, DOI 10.1016/0016-6480(85)90204-7; HUTSON JM, 1983, INT REV PHYSIOL, V27, P177; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; LAKE PE, 1956, Q J MICROSC SCI, V97, P487; Masui K, 1933, SEXING BABY CHICKS; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MILEWICH L, 1977, ENDOCRINOLOGY, V100, P187, DOI 10.1210/endo-100-1-187; SCHUMACHER M, 1991, J NEUROENDOCRINOL, V3, P221, DOI 10.1111/j.1365-2826.1991.tb00266.x; SCHWARZEL WC, 1973, ENDOCRINOLOGY, V92, P866, DOI 10.1210/endo-92-3-866; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RE, UNPUB, P54011; STEELE R E, 1987, Steroids, V50, P147, DOI 10.1016/0039-128X(83)90068-5; TENG CS, 1987, DEV BIOL, V123, P255, DOI 10.1016/0012-1606(87)90447-7; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; WOUTERS W, 1989, J STEROID BIOCHEM, V32, P781, DOI 10.1016/0022-4731(89)90453-6; YANG Y, COMMUNICATION	24	423	444	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					467	470		10.1126/science.1734525	http://dx.doi.org/10.1126/science.1734525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734525				2022-12-24	WOS:A1992HA59000042
J	AMON, A; SURANA, U; MUROFF, I; NASMYTH, K				AMON, A; SURANA, U; MUROFF, I; NASMYTH, K			REGULATION OF P34CDC28 TYROSINE PHOSPHORYLATION IS NOT REQUIRED FOR ENTRY INTO MITOSIS IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							CDC2 PROTEIN-KINASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ACTIVATION; DEPHOSPHORYLATION	PROGRESSION from G2 to M phase in eukaryotes requires activation of a protein kinase composed of p34cdc2/CDC28 associated with G1-specific cyclins (reviewed in ref. 1). In some organisms the activation of the kinase at the G2/M boundary is due to dephosphorylation of a highly conserved tyrosine residue at position 15 (Y15) of the cdc2 protein 2-6. Here we report that in the budding yeast Saccharomyces cervisiae, p34CDC28 also undergoes cell-cycle regulated dephosphorylation on an equivalent tyrosine residue (Y19). However, in contrast to previous observations in S. pombe 6, Xenopus 2,3 and mammalian cells 4,5, dephosphorylation of Y19 is not required for the activation of the CDC28/cyclin kinase. Furthermore, mutation of this tyrosine residue does not affect dependence of mitosis on DNA synthesis nor does it abolish G2 arrest induced by DNA damage. Our data imply that regulated phosphorylation of this tyrosine residue is not the 'universal' means by which the onset of mitosis is determined. We propose that there are other unidentified controls that regulate entry into mitosis.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Surana, Uttam/H-1142-2011	Surana, Uttam/0000-0002-4785-6514; Muroff, Ivor/0000-0003-3721-5278; Nasmyth, Kim/0000-0001-7030-4403; Amon, Angelika/0000-0001-9837-0314				COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GAULTIER J, 1991, CELL, V67, P197; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Rubin G M, 1975, Methods Cell Biol, V12, P45; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	23	257	261	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					368	371		10.1038/355368a0	http://dx.doi.org/10.1038/355368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731251				2022-12-24	WOS:A1992HA59100074
J	STORY, RM; WEBER, IT; STEITZ, TA				STORY, RM; WEBER, IT; STEITZ, TA			THE STRUCTURE OF THE ESCHERICHIA-COLI RECA PROTEIN MONOMER AND POLYMER	NATURE			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DUPLEX DNA; CONSTITUTIVE MUTANTS; ELECTRON-MICROSCOPY; FUNCTIONAL REGIONS; SEQUENCE ANALYSIS; BINDING PROTEIN; TRANSFER-RNA; COMPLEXES	The crystal structure of the recA protein from Escherichia coli at 2.3-angstrom resolution reveals a major domain that binds ADP and probably single- and double-stranded DNA. Two smaller subdomains at the N and C termini protrude from the protein and respectively stabilize a 6(1) helical polymer of protein subunits and interpolymer bundles. This polymer structure closely resembles that of recA/DNA filaments determined by electron microscopy. Mutations in recA protein that enhance coprotease, DNA-binding and/or strand-exchange activity can be explained if the interpolymer interactions in the crystal reflect a regulatory mechanism in vivo.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	STORY, RM (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009					BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BLANAR MA, 1983, COLD SPRING HARB SYM, V49, P507; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; BRYANT FR, 1986, J BIOL CHEM, V261, P2988; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KIRBY EP, 1967, P NATL ACAD SCI USA, V58, P1903, DOI 10.1073/pnas.58.5.1903; KNIGHT KL, 1984, J BIOL CHEM, V259, P1279; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCKAY DB, 1980, J BIOL CHEM, V255, P6662; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MORAND P, 1977, J BACTERIOL, V131, P572, DOI 10.1128/JB.131.2.572-582.1977; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MUENCH KA, 1991, J BIOL CHEM, V266, P844; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PUGH BF, 1988, J BIOL CHEM, V263, P76; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SALLES B, 1983, P NATL ACAD SCI-BIOL, V80, P65, DOI 10.1073/pnas.80.1.65; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WILSON DH, 1990, J BIOL CHEM, V265, P7351; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050; ZLOTNICK A, 1989, J MOL BIOL, V206, P133	57	693	710	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					318	325		10.1038/355318a0	http://dx.doi.org/10.1038/355318a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731246				2022-12-24	WOS:A1992HA59100055
J	BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV				BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV			FOLATE-DEFICIENCY AND CERVICAL DYSPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ORAL-CONTRACEPTIVES; LYMPHOCYTE CULTURE; ASCORBIC-ACID; FRAGILE SITES; FOLIC-ACID; CANCER; RISK; NEOPLASIA; PLASMA	Objective. - To test the hypothesis that nutritional deficiency affects the incidence of cervical dysplasia in young women. Design and Setting. - Case-control study. Participants were derived from community family-planning clinics and referrals to a colposcopy center. Participants. - A total of 726 subjects were screened, yielding 294 cases of dysplasia and 170 controls defined by coexistent cytologic and colposcopic evidence. Main Outcome Measures. - Planned prior to data collection. Odds ratios were computed using logistic regression models to evaluate association between cervical dysplasia and sociodemographic, sexual, and reproductive factors; smoking; oral contraceptive use; human papillomavirus (HPV) infection; and 12 nutritional indices determined by blind analysis of nonfasting blood specimens. Results. - The number of sexual partners, parity, oral contraceptive use, and HPV-16 infection were significantly associated with cervical dysplasia. Plasma nutrient levels were generally not associated with risk. However, red blood cell folate levels at or below 660 nmol/L interacted with HPV-16 infection. The adjusted odds ratio for HPV-16 was 1.1 among women with folate levels above 660 nmol/L but 5.1 (95% confidence interval, 2.3 to 11) among women with lower levels. Interactions of red blood cell folate levels with cigarette smoking and parity were also present but were not statistically significant. Conclusion. - Low red blood cell folate levels enhance the effect of other risk factors for cervical dysplasia and, in particular, that of HPV-16 infection.	UNIV ALABAMA, SCH MED, DEPT OBSTET & GYNECOL, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, SCH HLTH RELATED PROFESS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, DEPT BIOSTAT & BIOMATH, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH PUBL HLTH, DEPT EPIDEMIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BUTTERWORTH, CE (corresponding author), UNIV ALABAMA, SCH MED, DEPT NUTR SCI, UAB STN, BIRMINGHAM, AL 35294 USA.		Macaluso, Maurizio/J-2076-2015	Macaluso, Maurizio/0000-0002-2977-9690	NCI NIH HHS [5 P01-CA 28103] Funding Source: Medline; NICHD NIH HHS [N01-HD-5-2927] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052927] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BORST M, 1991, J REPROD MED, V36, P95; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; Breslow NE, 1980, IARC SCI PUBL, V1, P1; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; BROCK KE, 1988, J NATL CANCER I, V80, P580, DOI 10.1093/jnci/80.8.580; BUTTERWORTH CE, 1982, AM J CLIN NUTR, V35, P73, DOI 10.1093/ajcn/35.1.73; BUTTERWORTH CE, IN PRESS AM J OBSTET; BUTTERWORTH CE, 1991, MICRONUTRIENTS HLTH, P165; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DAS KC, 1980, CLIN CHEM, V26, P72; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Eto I, 1986, Adv Exp Med Biol, V206, P313; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; GARRY PJ, 1970, CLIN CHEM, V16, P766; HEATH CW, 1966, BLOOD-J HEMATOL, V27, P800, DOI 10.1182/blood.V27.6.800.800; HEIMBURGER DC, 1988, JAMA-J AM MED ASSOC, V259, P1525; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; JASKIEWICZ K, 1988, ANTICANCER RES, V8, P711; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P11; JONES CJ, 1990, CANCER RES, V50, P3657; KUTNINK MA, 1985, J LIQ CHROMATOGR, V8, P31, DOI 10.1080/01483918508067061; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MEANWELL CA, 1987, LANCET, V1, P703; MELCHERS WJG, 1989, J CLIN MICROBIOL, V27, P106, DOI 10.1128/JCM.27.1.106-110.1989; MUIR CS, 1990, CANCER RES, V50, P6441; OLSON AD, 1969, CLIN CHEM, V15, P438; ORR JW, 1985, AM J OBSTET GYNECOL, V151, P632, DOI 10.1016/0002-9378(85)90153-X; PALAN PR, 1991, NUTR CANCER, V15, P13, DOI 10.1080/01635589109514106; PALAN PR, 1988, J NATL CANCER I, V80, P454, DOI 10.1093/jnci/80.6.454; POPESCU NC, 1987, J VIROL, V61, P1682, DOI 10.1128/JVI.61.5.1682-1685.1987; POTISCHMAN N, 1991, CANCER RES, V51, P4785; RAN JY, 1990, BLOOD S, V76, pA114; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; ROMNEY SL, 1987, ANN NY ACAD SCI, V498, P132, DOI 10.1111/j.1749-6632.1987.tb23757.x; SCHNEIDER A, 1989, ARCH GYNECOL OBSTET, V246, P1, DOI 10.1007/BF00933072; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SHOJANIA AM, 1968, LANCET, V1, P1376; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27; STREIFF RR, 1970, J AMER MED ASSOC, V214, P105, DOI 10.1001/jama.214.1.105; SUNDERMAN FW, 1973, HUM PATHOL, V4, P549, DOI 10.1016/S0046-8177(73)80066-8; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; VESSEY MP, 1983, LANCET, V2, P930; WASSERTHEILSMOL.S, 1983, NUTRITIONAL FACTORS, P289; WHITEHEAD N, 1973, JAMA-J AM MED ASSOC, V226, P1421, DOI 10.1001/jama.226.12.1421; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZIEGLER RG, 1990, AM J EPIDEMIOL, V132, P432, DOI 10.1093/oxfordjournals.aje.a115678	54	179	184	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					528	533		10.1001/jama.267.4.528	http://dx.doi.org/10.1001/jama.267.4.528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729576				2022-12-24	WOS:A1992GZ43900029
J	SCHWOB, E; MARTIN, RP				SCHWOB, E; MARTIN, RP			NEW YEAST ACTIN-LIKE GENE REQUIRED LATE IN THE CELL-CYCLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SEQUENCE; DISRUPTION; TUBULIN; PROTEIN	ACTIN, a major cytoskeletal component of all eukaryotic cells, is one of the most highly conserved proteins. It is involved in various cellular processes such as motility, cytoplasmic streaming, chromosome segregation and cytokinesis 1,2. The actin from the yeast Saccharomyces cerevisiae, encoded by the essential ACT1 gene 3-5, is 89% identical to mouse cytoplasmic actin and is involved in the organization and polarized growth of the cell surface 6-8. We report here the characterization of ACT2, a previously undescribed yeast split gene encoding a putative protein (391 amino acids, relative molecular mass (M(r)) 44,073) that is 47% identical to yeast actin. The requirement of the ACT2 gene for vegetative growth of yeast cells and the existence of related genes in other eukaryotes indicate an important and conserved role for these actin-like proteins. Superimposition of the Act2 polypeptide onto the three-dimensional structure 9,10 of known actins reveals that most of the divergence occurred in loops involved in actin polymerization, DNase I and myosin binding, leaving the core domain mainly unaffected. To our knowledge, the Act2 protein from S. cerevisiae is the first highly divergent actin molecule described. Structural and physiological data suggest that the Act2 protein might have an important role in cytoskeletal reorganization during the cell cycle.	CNRS,INST BIOL MOLEC & CELLULAIRE,BIOCHIM LAB,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Schwob, Etienne/AAC-3050-2020; Schwob, Etienne/H-4678-2015	Schwob, Etienne/0000-0002-9369-6419				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEGRAIN P, 1991, MOL GEN GENET, V225, P199, DOI 10.1007/BF00269848; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SOLOMON LR, 1987, J BIOL CHEM, V262, P11382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x	31	115	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					179	182		10.1038/355179a0	http://dx.doi.org/10.1038/355179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729653				2022-12-24	WOS:A1992GY62900064
J	CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM				CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM			LONG-TERM IMPROVEMENT OF HYPERCHOLESTEROLEMIA AFTER EXVIVO GENE-THERAPY IN LDLR-DEFICIENT RABBITS	SCIENCE			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN RECEPTORS; LIVER-TRANSPLANTATION; ALBUMIN	Familial hypercholesterolemia (FH) is an inherited disorder in humans that is caused by a deficiency of low density lipoprotein receptors (LDLRs). An animal model for FH, the Watanabe Heritable Hyperlipidemic rabbit, was used to develop an approach for liver-directed gene therapy based on transplantation of autologous hepatocytes that were genetically corrected ex vivo with recombinant retroviruses. Animals transplanted with LDLR-transduced autologous hepatocytes demonstrated a 30 to 50 percent decrease in total serum cholesterol that persisted for the duration of the experiment (122 days). Recombinant-derived LDLR RNA was harvested from tissues with no diminution for up to 6.5 months after transplantation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	WILSON, JM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042193, R01DK034357, P01DK042718] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK-42718, R01-DK-34357, R01-DK42193-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; Cochran WG, 1957, EXPT DESIGNS, P127; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GROSSMAN MI, UNPUB; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PINTAR JE, 1987, IN SITU HYBRIDIZATIO, P179; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; STARZL TE, 1984, LANCET, V1, P1382; TRINDER P, 1974, ANN CLIN BIOCHEM, V12, P226; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P843; WILSON JM, 1991, CLIN BIOTECHNOL, V3, P21	18	323	423	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1802	1805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722351				2022-12-24	WOS:A1991GW31600047
J	FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW				FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW			RISK-FACTORS FOR PANCREATIC CELLULAR INJURY AFTER CARDIOPULMONARY BYPASS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL REVASCULARIZATION; DISCRIMINANT-ANALYSIS; LABORATORY TESTS; CARDIAC-SURGERY; BLOOD-FLOW; HYPERAMYLASEMIA; HYPERCALCEMIA; AMYLASE; SERUM; MORTALITY	Background. Pancreatitis is a known complication of cardiac surgery with cardiopulmonary bypass. Although ischemia is believed to be a factor, the cause of pancreatitis after cardiopulmonary bypass remains unknown. Methods. We prospectively studied 300 consecutive patients undergoing cardiac surgery with cardiopulmonary bypass. Serum amylase, pancreatic isoamylase, and serum lipase were measured on postoperative days 1, 2, 3, 7, and 10. Pancreatic cellular injury was defined as the presence of hyperamylasemia (> 123 U per liter) with an increase in either the serum level of lipase (> 24 U per liter) or the peak level of pancreatic isoamylase. Trypsinogen-activation peptides, which indicate intrapancreatic enzyme activation, were measured in the urine of the last 101 patients studied. Results. Evidence of pancreatic cellular injury was detected in 80 patients (27 percent), of whom 23 had associated abdominal signs or symptoms and 3 had severe pancreatitis (2 with pancreatic abscess and 1 with necrotizing hemorrhagic pancreatitis). Two of 19 postoperative deaths were secondary to pancreatitis. In multivariate analyses, the development of pancreatic cellular injury was significantly associated with preoperative renal insufficiency, valve surgery, postoperative hypotension, and perioperative administration of calcium chloride. The administration of more than 800 mg of calcium chloride per square meter of body-surface area was an independent predictor of pancreatic cellular injury, and the increase in risk was dose-related. No differences were found in the level of trypsinogen-activation peptides between patients who had pancreatic cellular injury and those who did not. Conclusions. Pancreatic cellular injury, as indicated by hyperamylasemia of pancreatic origin, is common after cardiac surgery. The administration of large doses of calcium chloride is an independent predictor of pancreatic cellular injury and may be a cause of it.	MASSACHUSETTS GEN HOSP, DEPT SURG, ACC337, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University			Castillo, Carlos Fenandez-del/AAO-2602-2020					AVRAM RM, 1982, NEPHRON, V32, P60, DOI 10.1159/000182804; AZIZ S, 1985, SURGERY, V97, P653; CATES MC, 1988, SURGERY, V104, P137; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; DEWAELE B, 1989, PANCREAS, V4, P378, DOI 10.1097/00006676-198906000-00017; DROP LJ, 1985, ANESTH ANALG, V64, P432; ECKFELDT JH, 1989, CLIN LAB MED, V9, P731, DOI 10.1016/S0272-2712(18)30601-2; FRICK TW, 1987, AM J SURG, V154, P487, DOI 10.1016/0002-9610(87)90260-1; FRICK TW, 1990, GASTROENTEROLOGY, V98, P1675, DOI 10.1016/0016-5085(90)91106-G; GAFTER U, 1976, JAMA-J AM MED ASSOC, V235, P2004, DOI 10.1001/jama.235.18.2004; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HAAS GS, 1985, AM J SURG, V149, P508, DOI 10.1016/S0002-9610(85)80048-9; HURLEY PR, 1988, J IMMUNOL METHODS, V111, P195, DOI 10.1016/0022-1759(88)90127-5; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; KAZMIERCZAK SC, 1988, CLIN CHEM, V34, P916; KOLARS JC, 1984, DIGEST DIS SCI, V29, P289, DOI 10.1007/BF01318510; Koski G, 1988, J Cardiothorac Anesth, V2, P570, DOI 10.1016/0888-6296(88)90239-6; LEFER AM, 1974, ANN SURG, V179, P868, DOI 10.1097/00000658-197406000-00009; Leijala M, 1988, Eur J Cardiothorac Surg, V2, P324; MCCORMICK PA, 1985, BRIT MED J, V290, P1472, DOI 10.1136/bmj.290.6480.1472-a; MCGRATH LB, 1990, ANN THORAC SURG, V49, P410, DOI 10.1016/0003-4975(90)90245-2; MELTZER LE, 1962, ANN INTERN MED, V57, P1008, DOI 10.7326/0003-4819-57-6-1008; MILLER DC, 1983, J THORAC CARDIOV SUR, V85, P197; MISSAVAGE AE, 1984, AM SURGEON, V50, P297; MIXTER CG, 1962, NEW ENGL J MED, V266, P265, DOI 10.1056/NEJM196202082660601; MORI A, 1988, JPN CIRC J, V52, P219, DOI 10.1253/jcj.52.219; NAUNHEIM KS, 1988, ANN THORAC SURG, V46, P666, DOI 10.1016/S0003-4975(10)64731-5; Panebianco A C, 1970, Ann Thorac Surg, V9, P562; PANTEGHINI M, 1989, CLIN CHEM, V35, P417; RATTNER DW, 1989, ANN SURG, V209, P279, DOI 10.1097/00000658-198903000-00005; ROBERT JH, 1988, INT J PANCREATOL, V3, P283; ROSE DM, 1984, ANN SURG, V199, P168, DOI 10.1097/00000658-198402000-00006; SANFEY H, 1985, AM J SURG, V150, P297, DOI 10.1016/0002-9610(85)90064-9; SCOTT WC, 1985, J THORAC CARDIOV SUR, V89, P400; SVENSSON LG, 1985, ANN THORAC SURG, V39, P409, DOI 10.1016/S0003-4975(10)61945-5; TIETZ NW, 1986, CLIN CHEM, V32, P301; TRAVERSO LW, 1977, AM J SURG, V133, P298, DOI 10.1016/0002-9610(77)90532-3; WALLWORK J, 1980, BRIT J SURG, V67, P410, DOI 10.1002/bjs.1800670609; WARSHAW AL, 1978, ANN SURG, V188, P197, DOI 10.1097/00000658-197808000-00012; WARSHAW AL, 1977, J SURG RES, V22, P362, DOI 10.1016/0022-4804(77)90158-5; 1990, 1990 HEART STROKE FA	42	148	150	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1991	325	6					382	387						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ804	1712076				2022-12-24	WOS:A1991FZ80400002
J	PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR				PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR			PAIN IN SICKLE-CELL DISEASE - RATES AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FETAL HEMOGLOBIN; CRISIS; ANEMIA; THALASSEMIA; SEVERITY; GELATION; MODELS	Background and Methods. Acute episodes of pain are the principal symptom of sickle cell disease, but little is known about the epidemiologic features of these episodes or risk factors for them, nor is it known whether patients with high rates of such episodes die prematurely. We prospectively studied the natural history of sickle cell disease in 3578 patients ranging from newborns to persons up to 66 years old who were followed at clinical centers across the United States. Results. There were 12,290 episodes of pain in 18,356 patient-years. The average rate was 0.8 episode per patient-year in sickle cell anemia, 1.0 episode per patient-year in sickle beta-0-thalassemia, and 0.4 episode per patient-year in hemoglobin SC disease and sickle beta+-thalassemia. The rate varied widely within each of thesefour groups - e.g., 39 percent of patients with sickle cell anemia had no episodes of pain, and 1 percent had more than six episodes per year. The 5.2 percent of patients with 3 to 10 episodes per year had 32.9 percent of all episodes. Among patients with sickle cell anemia who were more than 20 years old, those with high rates of pain episodes tended to die earlier than those with low rates. High rates were associated with a high hematocrit and low fetal hemoglobin levels. Alpha-Thalassemia had no effect on pain apart from its association with an increased hematocrit. Conclusions. The "pain rate" (episodes per year) is a measure of clinical severity and correlates with early death in patients with sickle cell anemia over the age of 20. Even when the fetal hemoglobin level is low, one can predict that small increments in the level may have an ameliorating effect on the pain rate and may ultimately improve survival. This outcome is particularly encouraging to investigators studying hydroxyurea and other treatments designed to increase the fetal hemoglobin level.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; NEW ENGLAND RES INST, WATERTOWN, MA USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA; OAKLAND CHILDRENS MED CTR, OAKLAND, CA USA	Harvard University; Harvard Medical School; HealthCore, Inc; University System of Georgia; Augusta University; Duke University	PLATT, OS (corresponding author), CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DIV HEMATOL ONCOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				AITKIN M, 1989, STATISTICAL MODELLIN; BAKER RJ, 1978, GLIM SYSTEM; BALLAS SK, 1988, BLOOD, V72, P1216; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; BILLETT HH, 1986, BLOOD, V68, P301; BRESLOW N, 1990, J AM STAT ASSOC, V85, P565, DOI 10.2307/2289799; BRESLOW NE, 1984, J R STAT SOC C-APPL, V33, P38; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1987, BLOOD, V69, P109; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; FARBER MD, 1985, J CHRON DIS, V38, P495, DOI 10.1016/0021-9681(85)90033-5; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; KONOTEYA.FI, 1974, ARCH INTERN MED, V133, P611, DOI 10.1001/archinte.133.4.611; LANDE WM, 1988, BLOOD, V72, P2056; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MANKAD VN, 1990, BLOOD, V75, P274; Powars D R, 1987, Prog Clin Biol Res, V240, P393; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Seber G.A., 1977, LINEAR REGRESSION AN; STEINBERG MH, 1984, BLOOD, V63, P1353; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; VICHINSKY EP, 1982, AM J PEDIAT HEMATOL, V4, P328	26	1145	1160	1	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					11	16		10.1056/NEJM199107043250103	http://dx.doi.org/10.1056/NEJM199107043250103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710777				2022-12-24	WOS:A1991FU34200003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SCIENTIFIC-DATA SOUGHT ON HEALTH CLAIMS ON FOODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-24	WOS:A1991FJ95500008
J	MACKINNON, R				MACKINNON, R			DETERMINATION OF THE SUBUNIT STOICHIOMETRY OF A VOLTAGE-ACTIVATED POTASSIUM CHANNEL	NATURE			English	Article							CHARYBDOTOXIN BLOCK; K+ CHANNELS; DROSOPHILA; INHIBITOR; JUNCTION	The voltage-activated K+, Na+ and Ca2+ channels are responsible for the generation and propagation of electrical signals in cell membranes. The K+ channels are multimeric membrane proteins formed by the aggregation of an unknown number of independent subunits 1-3. By studying the interaction of a scorpion toxin with coexpressed wild-type and toxin-insensitive mutant Shaker K+ channels, the subunit stoichiometry can be determined. The Shaker K+ channel is found to have a tetrameric structure. This is consistent with the sequence relationship between a K+ channel and each of the four internally homologous repeats of Na+ and Ca2+ channels 4-6.			MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115, USA.							AGNEW WS, 1988, NATURE, V331, P114, DOI 10.1038/331114a0; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V2, P405; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Hille B, 1984, IONIC CHANNELS EXCIT, P426; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MASSEFSKI W, 1990, SCIENCE, V249, P449; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OLIVA C, 1991, Biophysical Journal, V59, p450A; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3	23	808	825	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					232	235		10.1038/350232a0	http://dx.doi.org/10.1038/350232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706481				2022-12-24	WOS:A1991FC77900058
J	AHRINGER, J; KIMBLE, J				AHRINGER, J; KIMBLE, J			CONTROL OF THE SPERM-OOCYTE SWITCH IN CAENORHABDITIS-ELEGANS HERMAPHRODITES BY THE FEM-3 3' UNTRANSLATED REGION	NATURE			English	Article							SEX-DETERMINATION GENE; C-ELEGANS; SPERMATOGENESIS; SEQUENCES	IN the Caenorhabditis elegans hermaphrodite germ line, sperm and then oocytes are made from a common pool of germ-cell precursors. The decision to differentiate as a sperm or an oocyte is regulated by the sex-determining gene, fem-3. Expression of fem-3 in the hermaphrodite germ line directs spermatogenesis and must be negatively regulated to allow the switch to oogenesis1,2. In adult hermaphrodites (which are producing oocytes), most fem-3 RNA is found in the germ line3, consistent with both the requirement for fem-3 in hermaphrodite spermatogenesis and the maternal effects of fem-3 on embryonic sex determination1,2. Whereas loss-of-function mutants in fem-3 produce only oocytes, hermaphrodites carrying any of nine fem-3 gain-of-function (gf) mutations make none; instead sperm are produced continuously and in vast excess over wild-type amounts1. Genetic analyses suggest that fem-3(gf) mutations have escaped a negative control required for the switch to oogenesis1. Here we report that all nine fem-3(gf) mutants carry sequence alterations in the fem-3 3' untranslated region (3' UTR). There is no increase in the steady-state level of fem-3(gf) RNA over wild-type, but there is an increase in the polyadenylation of fem-3(gf) RNA that is coincident with the unregulated fem-3 activity. Results of a titration experiment support the hypothesis that a regulatory factory may bind the fem-3 3' UTR. We speculate that fem-3 RNA is regulated through its 3' UTR by binding a factor that inhibits translation, and discuss the idea that this control may be part of a more general regulation of maternal RNAs.	UNIV WISCONSIN, GRAD SCH, MOLEC BIOL LAB, 1525 LINDEN DR, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Ahringer, Julie/0000-0002-7074-4051				BARTON MK, 1987, GENETICS, V115, P107; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DONIACH T, 1986, GENETICS, V114, P53; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HODGKIN J, 1986, GENETICS, V114, P15; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; SCHEDL T, 1988, GENETICS, V119, P43; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4	16	193	198	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					346	348		10.1038/349346a0	http://dx.doi.org/10.1038/349346a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702880				2022-12-24	WOS:A1991EU50100058
J	SHIBUKI, K; OKADA, D				SHIBUKI, K; OKADA, D			ENDOGENOUS NITRIC-OXIDE RELEASE REQUIRED FOR LONG-TERM SYNAPTIC DEPRESSION IN THE CEREBELLUM	NATURE			English	Article							PURKINJE-CELLS; ACTIVATION; RAT	CONJUNCTIVE stimulation of climbing and parallel fibres in the cerebellum evokes a long-term depression of parallel-fibre Purkinje-cell transmission 1,2, a phenomenon implicated as the cellular mechanism for cerebellar motor learning 3. It is suspected that the increase in cyclic GMP concentration that occurs after activation of climbing fibres 4 is required to evoke long-term depression 3. Excitatory amino acids are known to cause the release of nitric oxide (NO), resulting in elevation of the cGMP level in the cerebellum 5. Here we report that endogenous NO is released after stimulation of climbing fibres, that long-term depression evoked by conjunctive stimulation of parallel and climbing fibres is blocked by haemoglobin (which strongly binds NO) or L-N(G)-monomethyl-arginine (an inhibitor of NO synthase), and that exogenous NO or cGMP can substitute for the stimulation of climbing fibres to cause long-term depression in rat cerebellar slices. These results demonstrate that the release of endogenous NO is essential for the induction of synaptic plasticity in the cerebellum.			SHIBUKI, K (corresponding author), INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL NETWORKS LAB,WAKO,SAITAMA 35101,JAPAN.							BIGGIO G, 1976, BRAIN RES, V107, P365, DOI 10.1016/0006-8993(76)90233-X; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; DEVENTE J, 1989, BRAIN RES, V504, P332, DOI 10.1016/0006-8993(89)91380-2; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; KARACHOT L, 1987, EXP BRAIN RES, V66, P229; KNOPFEL T, 1990, EUR J NEUROSCI, V2, P726, DOI 10.1111/j.1460-9568.1990.tb00463.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; SHIBUKI K, 1990, NEUROSCI LETT, V113, P34, DOI 10.1016/0304-3940(90)90490-Z	18	837	849	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					326	328		10.1038/349326a0	http://dx.doi.org/10.1038/349326a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702879				2022-12-24	WOS:A1991EU50100051
J	YOUNG, LHY; JOAG, SV; ZHENG, LM; LEE, CP; LEE, YS; YOUNG, JDE				YOUNG, LHY; JOAG, SV; ZHENG, LM; LEE, CP; LEE, YS; YOUNG, JDE			PERFORIN-MEDIATED MYOCARDIAL DAMAGE IN ACUTE MYOCARDITIS	LANCET			English	Article									ROCKEFELLER UNIV,NEW YORK,NY 10021; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114; CHANG GUNG MEM HOSP,TAIPEI,TAIWAN	Rockefeller University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Chang Gung Memorial Hospital				Young, Lucy/0000-0001-8634-7512	NATIONAL CANCER INSTITUTE [R01CA047307] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47307] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aretz T., 1986, AM J CARDIOVASC PATH, V1, P3; BOWLES NE, 1986, LANCET, V1, P1120; GODENY EK, 1987, AM J PATHOL, V129, P267; GRAVANIS MB, 1987, ARCH PATHOL LAB MED, V111, P915; JOAG S, 1989, J CELL BIOCHEM, V39, P239, DOI 10.1002/jcb.240390304; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; WOODRUFF JF, 1980, AM J PATHOL, V101, P426; YOUNG JDE, 1987, ADV IMMUNOL, V41, P269, DOI 10.1016/S0065-2776(08)60033-4; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3; YOUNG JDE, 1986, SCIENCE, V233, P184, DOI 10.1126/science.2425429	13	75	76	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 27	1990	336	8722					1019	1021		10.1016/0140-6736(90)92486-2	http://dx.doi.org/10.1016/0140-6736(90)92486-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF076	1699101				2022-12-24	WOS:A1990EF07600001
J	HOUMAN, F; DIAZTORRES, MR; WRIGHT, A				HOUMAN, F; DIAZTORRES, MR; WRIGHT, A			TRANSCRIPTIONAL ANTITERMINATION IN THE BGL OPERON OF ESCHERICHIA-COLI IS MODULATED BY A SPECIFIC RNA-BINDING PROTEIN	CELL			English	Article											HOUMAN, F (corresponding author), TUFTS UNIV,DEPT MOLEC BIOL & BIOCHEM,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038035] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; BACKMAN K, 1976, P NATL ACAD SCI USA, V73, P4174, DOI 10.1073/pnas.73.11.4174; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DECKMAN IC, 1987, J MOL BIOL, V196, P323, DOI 10.1016/0022-2836(87)90693-0; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FOX CF, 1968, P NATL ACAD SCI USA, V59, P988, DOI 10.1073/pnas.59.3.988; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HENKIN TM, 1987, MOL GEN GENET, V209, P467, DOI 10.1007/BF00331151; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HSARLOW E, 1988, ANTIBODIES LABORATOR; INOUYE S, 1987, DNA RNA SYNTHESIS, P181; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JAURIN B, 1981, NATURE, V290, P221, DOI 10.1038/290221a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOPILATO J, 1990, BACTERIAL CHROMOSOME, P435; LOWERY C, 1977, J BIOL CHEM, V252, P1381; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; Miller J.H., 1972, EXPT MOL GENETICS; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROLAND KL, 1988, P NATL ACAD SCI USA, V85, P7149, DOI 10.1073/pnas.85.19.7149; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; RYAN T, 1983, J BIOL CHEM, V258, P4690; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SHAEFLER S, 1967, J BACTERIOL, V93, P254; SHIMOTSU H, 1986, J BACTERIOL, V168, P380, DOI 10.1128/jb.168.1.380-388.1986; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; Silhavy T.J., 1984, EXPT GENE FUSIONS; STEINMETZ M, 1988, GENETICS BIOTECHNOLO, V2, P11; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; WILLIAMS MG, 1987, J BACTERIOL, V169, P1644, DOI 10.1128/jb.169.4.1644-1650.1987; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; ZUKOWSKI M, 1988, GENETICS BIOTECHNOLO, V2, P17	57	166	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 21	1990	62	6					1153	1163		10.1016/0092-8674(90)90392-R	http://dx.doi.org/10.1016/0092-8674(90)90392-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EA117	1698125				2022-12-24	WOS:A1990EA11700013
J	HEALY, B				HEALY, B			HELPING CHILDREN INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							PROBER CG, 1991, PEDIATR INFECT DIS J, V10, P684, DOI 10.1097/00006454-199109000-00012; 1991, JAMA-J AM MED ASSOC, V266, P3439	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1319	1319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740841				2022-12-24	WOS:A1992HG67800004
J	GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J				GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J			VALVULAR HEART-DISEASE IN THE PRIMARY ANTIPHOSPHOLIPID SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						HEART VALVE DISEASE; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; CARDIOLIPINS; LUPUS ERYTHEMATOSUS, SYSTEMIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; THROMBOCYTOPENIC PURPURA; MITRAL REGURGITATION; ANTICOAGULANT; ASSOCIATION; NECROPSY; PATTERNS; PATIENT	Objective: To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. Design: Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 21 months. Setting: University-based tertiary medical center. Patients: Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. Measurements and Main Results: Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valve involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with mitral valve involvement was 7.0 +/- 1.6 mm, compared with 2.7 +/- 0.8 mm in patients with normal valves and 3.2 +/- 0.9 mm in the control group. The mean aortic valve thickness in patients with aortic valve involvement was 3.8 +/- 0.5 mm compared with 1.4 +/- 0.3 mm in patients with normal valves and 1.4 +/- 0.5 mm in the control group. Stenotic lesions were not found. Regurgitation was severe in two patients (one required surgery), moderate in three patients, and mild in three patients. Conclusions: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome. The lesions are left-sided, causing regurgitation that may be clinically important.			GALVE, E (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, SERV CARDIOL, PASEO VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Barquinero, Jordi/F-6979-2011	Barquinero, Jordi/0000-0002-1677-9851				ANDERSON D, 1987, J RHEUMATOL, V14, P839; ARROYO R A, 1989, Arthritis and Rheumatism, V32, pS73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CANOSO RT, 1987, BRIT J HAEMATOL, V65, P495, DOI 10.1111/j.1365-2141.1987.tb04157.x; CHARTASH EK, 1989, AM J MED, V86, P407, DOI 10.1016/0002-9343(89)90337-9; CONLEY CL, 1952, J CLIN INVEST, V31, P621; DALTON JG, 1985, STROKE, V16, P512, DOI 10.1161/01.STR.16.3.512; DELEZE M, 1988, J RHEUMATOL, V15, P611; EVANGELISTA A, 1989, European Heart Journal, V10, P404; EXNER T, 1978, BRIT J HAEMATOL, V40, P143, DOI 10.1111/j.1365-2141.1978.tb03648.x; FORD PM, 1988, J RHEUMATOL, V15, P597; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GALVE E, 1989, NEW ENGL J MED, V320, P740; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; HARRIS EN, 1985, BRIT J HAEMATOL, V59, P231, DOI 10.1111/j.1365-2141.1985.tb02989.x; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUGHES GRV, 1985, CLIN EXP RHEUMATOL, V3, P285; KEANE A, 1987, BRIT J RHEUMATOL, V26, P346; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; KOCHENOUR NK, 1987, OBSTET GYNECOL, V69, P460; KOZLOWSKI CL, 1987, POSTGRAD MED J, V63, P793, DOI 10.1136/pgmj.63.743.793; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MALIA RG, 1988, CLIN EXP IMMUNOL, V73, P456; MURPHY JJ, 1989, BRIT HEART J, V62, P61; NANDA NN, 1989, ATLAS COLOR DOPPLER; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; OROURKE RA, 1990, CIRCULATION, V82, P636, DOI 10.1161/01.CIR.82.2.636; PONSLLADO G, 1986, AM J CARDIOL, V57, P806, DOI 10.1016/0002-9149(86)90618-1; POPE JM, 1991, AM J MED, V90, P299, DOI 10.1016/0002-9343(91)90569-J; ROUGET JP, 1983, ANN MED INTERNE, V134, P111; SALVARANI C, 1989, CLIN EXP RHEUMATOL, V7, P329; SCHLEIDER MA, 1976, BLOOD, V48, P499; SONTHEIMER RD, 1987, ARCH DERMATOL, V123, P590, DOI 10.1001/archderm.123.5.590; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; THIAGARAJAN P, 1986, BLOOD, V68, P869; TIRRI G, 1990, CLIN EXP RHEMATOL, V8, P215; VAARALA O, 1986, CLIN IMMUNOL IMMUNOP, V41, P8, DOI 10.1016/0090-1229(86)90046-2	38	162	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					293	298		10.7326/0003-4819-116-4-293	http://dx.doi.org/10.7326/0003-4819-116-4-293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733383				2022-12-24	WOS:A1992HD54600004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MORATORIUM ON SILICONE GEL BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-24	WOS:A1992HC48400005
J	CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D				CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D			MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT CLAUDICATION; RISK-FACTORS; DEFINED POPULATION; PREVALENCE; REGRESSION; CESSATION; SMOKING; FATE; MEN	Background. Previous investigators have observed a doubling of the mortality rate among patients with intermittent claudication, and we have reported a fourfold increase in the overall mortality rate among subjects with large-vessel peripheral arterial disease, as diagnosed by noninvasive testing. In this study, we investigated the association of large-vessel peripheral arterial disease with rates of mortality from all cardiovascular diseases and from coronary heart disease. Methods. We examined 565 men and women (average age, 66 years) for the presence of large-vessel peripheral arterial disease by means of two noninvasive techniques measurement of segmental blood pressure and determination of flow velocity by Doppler ultrasound. We identified 67 subjects with the disease (11.9 percent), whom we followed prospectively for 10 years. Results. Twenty-one of the 34 men (61.8 percent) and 11 of the 33 women (33.3 percent) with large-vessel peripheral arterial disease died during follow-up, as compared with 31 of the 183 men (16.9 percent) and 26 of the 225 women (11.6 percent) without evidence of peripheral arterial disease. After multivariate adjustment for age, sex, and other risk factors for cardiovascular disease, the relative risk of dying among subjects with large-vessel peripheral arterial disease as compared with those with no evidence of such disease was 3.1 (95 percent confidence interval, 1.9 to 4.9) for deaths from all causes, 5.9 (95 percent confidence interval, 3.0 to 11.4) for all deaths from cardiovascular disease, and 6.6 (95 percent confidence interval, 2.9 to 14.9) for deaths from coronary heart disease. The relative risk of death from causes other than cardiovascular disease was not significantly increased among the subjects with large-vessel peripheral arterial disease. After the exclusion of subjects who had a history of cardiovascular disease at base line, the relative risks among those with large-vessel peripheral arterial disease remained significantly elevated. Additional analyses revealed a 15-fold increase in rates of mortality due to cardiovascular disease and coronary heart disease among subjects with large-vessel peripheral arterial disease that was both severe and symptomatic. Conclusions. Patients with large-vessel peripheral arterial disease have a high risk of death from cardiovascular causes.	UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV HLTH CARE SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV CARDIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT SURG,DIV GEN SURG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	CRIQUI, MH (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV EPIDEMIOL 0607,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022255, R01HL042973] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22255, HL 42973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768; CRIQUI MH, 1990, CIRCULATION, V82, P2246, DOI 10.1161/01.CIR.82.6.2246; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FRONEK A, 1973, AM J SURG, V126, P205, DOI 10.1016/S0002-9610(73)80154-0; FRONEK A, 1976, CIRCULATION, V53, P957, DOI 10.1161/01.CIR.53.6.957; FRONEK A, 1989, NONINVASIVE DIAGNOST, P88; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; HUGHSON WG, 1978, BRIT MED J, V1, P1377, DOI 10.1136/bmj.1.6124.1377; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; JONASON T, 1987, ACTA MED SCAND, V221, P253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PEABODY CN, 1974, ARCH SURG-CHICAGO, V109, P693; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STRANDNESS DE, 1969, PERIPHERAL ARTERIAL; WINSOR T, 1950, AM J MED SCI, V220, P117, DOI 10.1097/00000441-195008000-00001; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1975, DHEW NIH75628 PUBL, V1; 1989, DHHS PHS891260 DEP H; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1967, JAMA-J AM MED ASSOC, V202, P1028; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	30	1930	2012	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					381	386		10.1056/NEJM199202063260605	http://dx.doi.org/10.1056/NEJM199202063260605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729621				2022-12-24	WOS:A1992HC38600005
J	PISON, G; AABY, P; KNUDSEN, K				PISON, G; AABY, P; KNUDSEN, K			INCREASED RISK OF DEATH FROM MEASLES IN CHILDREN WITH A SIBLING OF OPPOSITE SEX IN SENEGAL	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRANSMISSION; INFECTION; EXPOSURE; PATTERN; AREA	Objective - To examine whether contracting measles from a sibling of the opposite sex affects mortality. Design - Prospective registration during 15-20 years of all births and deaths, including 243 measles related deaths. Measles infection was not registered; however, as in fatal cases measles was probably contracted from a maternal sibling the risk of dying during measles outbreaks was examined in families with two boys, two girls, or a boy and a girl. Setting - 31 small villages in two rural areas of eastern Senegal. Subjects - 766 children living in families with two children aged under 10 years during outbreaks of measles, 107 (14%) of whom died of measles. Main outcome measure - Deaths from measles, size of village, age and sex of maternal siblings. Results - The interval between outbreaks in the same village was greater than 10 years. The risk of dying of measles was significantly related to age, increasing with the age difference between siblings and decreasing with the size of village. In a multiple logistic regression analysis adjusting for these background factors, children in families with a boy and a girl had a significantly higher mortality than children in families with two boys or two girls (odds ratio = 1.81, 95% confidence interval 1.17 to 2.82). The increase in risk was the same for boys and girls in families with two children one of whom was a boy and one a girl. Conclusion - Cross sexual transmission may be an important determinant of severity of measles infection.	MUSEUM NATL HIST NAT,ANTHROPOL BIOL LAB,F-75231 PARIS 05,FRANCE; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK; UNIV COPENHAGEN,STAT RES UNIT,DK-1168 COPENHAGEN,DENMARK	Museum National d'Histoire Naturelle (MNHN); Statens Serum Institut; University of Copenhagen				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1989, DAN MED BULL, V36, P93; AABY P, 1990, J INFECT DIS, V161, P171, DOI 10.1093/infdis/161.2.171; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, IN PRESS ANN TROP PA; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1987, SOC SCI MED, V24, P439, DOI 10.1016/0277-9536(87)90217-6; FARGUES P, 1988, DOUZE ANS MORTALITE; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1988, REV INFECT DIS, V10, P468; PISON G, 1985, POP STUD-J DEMOG, V39, P387, DOI 10.1080/0032472031000141586; PISON G, 1982, DYNAMIQUE UNE POPULA	18	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					284	287		10.1136/bmj.304.6822.284	http://dx.doi.org/10.1136/bmj.304.6822.284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739828	Bronze, Green Published			2022-12-24	WOS:A1992HC70800020
J	BENRUBI, GI				BENRUBI, GI			EUTHANASIA - THE NEED FOR PROCEDURAL SAFEGUARDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KILL				BENRUBI, GI (corresponding author), UNIV FLORIDA,HLTH SCI CTR,JACKSONVILLE,FL 32209, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COLE JJ, 1989, DEATH STUD, V13, P393, DOI 10.1080/07481188908252317; Hunter S F, 1989, JAMA, V262, P3074, DOI 10.1001/jama.262.21.3074; JONSEN AR, 1988, WESTERN J MED, V149, P195; PARKER M, 1990, J MED ETHICS, V16, P28, DOI 10.1136/jme.16.1.28; REICHEL W, 1989, LANCET, V2, P1321; Schoonheim P L, 1989, J Cancer Educ, V4, P109; SINGER PA, 1988, CAN MED ASSOC J, V138, P1000; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610	10	54	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					197	199		10.1056/NEJM199201163260311	http://dx.doi.org/10.1056/NEJM199201163260311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727551				2022-12-24	WOS:A1992GZ21300011
J	SMITH, DL; JOHNSON, AD				SMITH, DL; JOHNSON, AD			A MOLECULAR MECHANISM FOR COMBINATORIAL CONTROL IN YEAST - MCM1 PROTEIN SETS THE SPACING AND ORIENTATION OF THE HOMEODOMAINS OF AN ALPHA-2 DIMER	CELL			English	Article							REPRESSOR-OPERATOR INTERACTIONS; MATING-TYPE LOCUS; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; DNA; BINDING; IDENTIFICATION; RESOLUTION; COMPLEX; GENES	DNA recognition sequences for dimeric proteins typically contain two types of information. The first is the DNA sequence of each half-site, and the second is the arrangement of these half-sites. We show that dimers of the yeast homeodomain protein alpha-2, although able to read the first type of information, lack the ability to assess the second type. Rather, alpha-2 dimers bind with equal affinity to artificial operators in which the two half-sites are arrayed as inverted repeats, as direct repeats, or as everted (inside-out) repeats. We show that a second protein - MCM1 - sets the exact spacing and orientation of the homeodomains in the alpha-2 dimer so that they accommodate only the geometry of the naturally occurring operators. These experiments show directly how the target specificity of a homeodomain protein is raised by an auxiliary protein, allowing it to distinguish the biologically correct operators from closely related sequences in the cell.			SMITH, DL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1990, ANN REV BIOCH, V59, P933; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Maniatis T., 1982, MOL CLONING; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller J.H., 1972, EXPT MOL GENETICS; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PERSIC O, 1989, CELL, V59, P797; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Sherman F, 1979, METHODS YEAST GENETI; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLBERGER C, 1991, J MOL BIOL, V217, P11, DOI 10.1016/0022-2836(91)90605-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	155	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					133	142		10.1016/0092-8674(92)90212-U	http://dx.doi.org/10.1016/0092-8674(92)90212-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732062				2022-12-24	WOS:A1992GZ58300015
J	BADING, H; GREENBERG, ME				BADING, H; GREENBERG, ME			STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION BY NMDA RECEPTOR ACTIVATION	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERINE-THREONINE KINASE; NERVOUS-SYSTEM; GENE-PRODUCT; MAP KINASE; INSULIN; ANTAGONIST; EXPRESSION; BLOCKADE; CORTEX	The N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays a key role in synaptic plasticity in the nervous system. After NMDA receptor activation, calcium entry into the postsynaptic neuron is a critical initial event. However, the subsequent mechanisms by which the NMDA receptor signal is processed are incompletely understood. Stimulation of cultured rat hippocampal cells with glutamate resulted in the rapid and transient tyrosine phosphorylation of a 39-kilodalton protein (p39). Tyrosine phosphorylation of p39 was triggered by the NMDA receptor and required an influx of Ca2+ from the extracellular medium. Because p39 was found to be highly related or identical to the microtubule-associated protein 2 kinase, the NMDA receptor signal may be processed by a sequential activation of protein kinases.			BADING, H (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 43855] Funding Source: Medline; NINDS NIH HHS [NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BADING H, UNPUB; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chung J.-H., UNPUB; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GREENGARD P, 1989, NATURE, V340, P554; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSAMONDO AJ, IN PRESS J BIOL CHEM; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Weber M., UNPUB	36	448	455	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					912	914		10.1126/science.1715095	http://dx.doi.org/10.1126/science.1715095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715095				2022-12-24	WOS:A1991GC15200048
J	PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A				PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A			RECOGNITION BY CLASS-II ALLOREACTIVE T-CELLS OF PROCESSED DETERMINANTS FROM HUMAN SERUM-PROTEINS	SCIENCE			English	Article							MHC CLASS-II; HLA PEPTIDE; ANTIGENS; BINDING; COMPLEXES; MOLECULE; EPITOPES	Alloreactive T cells recognize a complex composed of an allogeneic major histocompatibility complex (MHC) molecule and a peptide derived from the processing of nonpolymorphic proteins. A sizable fraction of MHC class II alloreactive T cells is shown to recognize peptides derived from constitutive processing of human serum proteins. One such epitope is a fragment of human serum albumin. This epitope bound selectively to the human class II molecule DRw11 and was constitutively present on antigen-presenting cells in vivo. These data indicate that, in the case of MHC class II, peptides involved in allorecognition may originate from exogenous proteins.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; CYTEL,LA JOLLA,CA 92037; UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne			Panina, Paola/AAO-4563-2020; Sette, Alessandro/AFO-8916-2022; Panina, Paola/AAC-2424-2021	Panina, Paola/0000-0001-9913-8568				BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; DEKOSTER HS, 1989, J EXP MED, V169, P1191, DOI 10.1084/jem.169.3.1191; DEMOTZ S, 1989, J IMMUNOL METHODS, V122, P67, DOI 10.1016/0022-1759(89)90335-9; ECKELS DD, 1988, P NATL ACAD SCI USA, V85, P8191, DOI 10.1073/pnas.85.21.8191; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LIN RH, 1989, EUR J IMMUNOL, V19, P105, DOI 10.1002/eji.1830190117; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1990, J IMMUNOL, V145, P1850; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PANINABORDIGNON P, UNPUB; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	20	73	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1548	1550		10.1126/science.1710827	http://dx.doi.org/10.1126/science.1710827			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1710827				2022-12-24	WOS:A1991FR04000047
J	MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL				MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL			SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC BINDING-PROTEIN; LAC REPRESSOR HEADPIECE; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; IMMUNOSUPPRESSANT FK506; CYCLOSPORIN-A; CONFORMATION; CYCLOPHILIN	Immunophilins, when complexed to immunosuppressive ligands, appear to inhibit signal transduction pathways that result in exocytosis and transcription. The solution structure of one of these, the human FK506 and rapamycin binding protein (FKBP), has been determined by nuclear magnetic resonance (NMR). FKBP has a previously unobserved antiparallel beta-sheet folding topology that results in a novel loop crossing and produces a large cavity lined by a conserved array of aromatic residues; this cavity serves as the rotamase active site and drug-binding pocket. There are other significant structural features (such as a protruding positively charged loop and an apparently flexible loop) that may be involved in the biological activity of FKBP.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NCRR NIH HHS [I-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM-38627, GM-30804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030804, R37GM038627, R37GM030804, R01GM038627] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALBERS MW, IN PRESS BIOMED CHEM; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHIRGADZE YN, 1987, ACTA CRYSTALLOGR A, V43, P405, DOI 10.1107/S0108767387099239; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; FISHER G, 1989, NATURE, V337, P476; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GOEBL MG, 1991, CELL, V64, P1051, DOI 10.1016/0092-8674(91)90258-Z; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; HULTSCH T, IN PRESS P NATL ACAD; JIN Y, UNPUB; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MORAS D, 1975, J BIOL CHEM, V250, P9137; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, IN PRESS COMPUTATION; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; ROSEN MK, IN PRESS BIOCHEMISTR; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402	42	291	303	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					836	839		10.1126/science.1709301	http://dx.doi.org/10.1126/science.1709301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709301				2022-12-24	WOS:A1991FL12300044
J	PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC				PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC			ELAM-1 IS AN ADHESION MOLECULE FOR SKIN-HOMING T-CELLS	NATURE			English	Article							LEUKOCYTE ADHESION; ENDOTHELIAL ACTIVATION; LYMPH-NODES; LYMPHOCYTES; RECEPTOR; PROTEINS; ANTIGEN; CD2	ENDOTHELIAL cell leukocyte adhesion molecule-1 (ELAM-1) has been described as an inducible endothelial cell-adhesion molecule for neutrophils, and is believed to have a key role in the extravasation of these cells at sites of acute inflammation 1-3. Here we report that ELAM-1-transfected COS cells also bind a unique skin-associated subset of circulating memory T cells defined by the expression of the cutaneous lymphocyte-associated antigen 4,5. T cells expressing this antigen bind at least as well as neutrophils to expressed ELAM-1, whereas other lymphocytes in the peripheral blood bind poorly, or not at all. Immunohistological survey of chronically inflamed tissue specimens revealed that vascular expression of ELAM-1 occurs at cutaneous sites in preference to noncutaneous sites. We conclude that at sites of chronic inflammation, ELAM-1 may function as a skin vascular addressin, a tissue-selective endothelial cell-adhesion molecule for skin-homing memory T lymphocytes.	VET ADM MED CTR,CTR MOLEC MED,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,CTR DIGEST DIS,STANFORD,CA 94305; BAYLOR UNIV,DEPT PEDIAT,LEUKOCYTE BIOL SECT,HOUSTON,TX 77030	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Baylor University	PICKER, LJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.							BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHIN W, 1980, GASTROENTEROLOGY, V79, P1231; CHIN YH, 1990, J INVEST DERMATOL, V94, P413, DOI 10.1111/1523-1747.ep12874486; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ISSEKUTZ TB, 1980, CELL IMMUNOL, V54, P79, DOI 10.1016/0008-8749(80)90191-4; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MUNRO JM, 1989, AM J PATHOL, V135, P121; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; SAKSTEIN R, 1988, J INVEST DERMATOL, V91, P423; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TERSTAPPEN WMM, 1990, J LEUKOCYTE BIOL, V48, P138; WELLICOME SM, 1990, J IMMUNOL, V144, P2558	23	812	840	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					796	799		10.1038/349796a0	http://dx.doi.org/10.1038/349796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705666				2022-12-24	WOS:A1991EZ66600058
J	INGBER, D; FUJITA, T; KISHIMOTO, S; SUDO, K; KANAMARU, T; BREM, H; FOLKMAN, J				INGBER, D; FUJITA, T; KISHIMOTO, S; SUDO, K; KANAMARU, T; BREM, H; FOLKMAN, J			SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH	NATURE			English	Article									BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; TAKEDA CHEM IND LTD,DIV RES & DEV,OSAKA 532,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Takeda Chemical Industries	INGBER, D (corresponding author), CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115, USA.		Ingber, Donald E/AAC-5894-2019					CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DIPAOLO JA, 1958, ANTIBIOT ANNU, P541; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KILLOUGH JH, 1952, SCIENCE, V115, P71, DOI 10.1126/science.115.2977.71; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; OIKAWA T, 1989, J ANTIBIOT, V42, P1202, DOI 10.7164/antibiotics.42.1202; TANAKA NG, 1989, CANCER RES, V49, P6727; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807	20	1221	1353	1	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 6	1990	348	6301					555	557		10.1038/348555a0	http://dx.doi.org/10.1038/348555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL760	1701033				2022-12-24	WOS:A1990EL76000069
J	WALZ, G; ARUFFO, A; KOLANUS, W; BEVILACQUA, M; SEED, B				WALZ, G; ARUFFO, A; KOLANUS, W; BEVILACQUA, M; SEED, B			RECOGNITION BY ELAM-1 OF THE SIALYL-LEX DETERMINANT ON MYELOID AND TUMOR-CELLS	SCIENCE			English	Article									MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	WALZ, G (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36028] Funding Source: Medline; NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRECHTSEN M, 1989, BRIT J HAEMATOL, V72, P312, DOI 10.1111/j.1365-2141.1989.tb07710.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BALL ED, 1983, J IMMUNOL, V130, P2937; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIOU D, 1987, BIOCHIM BIOPHYS ACTA, V913, P308, DOI 10.1016/0167-4838(87)90140-3; BOLSCHER JGM, 1989, CLIN EXP METASTAS, V7, P557, DOI 10.1007/BF01753815; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; FORSYTH KD, 1989, EUR J IMMUNOL, V19, P1331, DOI 10.1002/eji.1830190727; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GOOI HC, 1983, EUR J IMMUNOL, V13, P306, DOI 10.1002/eji.1830130407; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HANISCH FG, 1988, CARBOHYD RES, V178, P29, DOI 10.1016/0008-6215(88)80100-9; HUANG LC, 1983, BLOOD, V61, P1020; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAGNANI JL, 1984, ARCH BIOCHEM BIOPHYS, V233, P501, DOI 10.1016/0003-9861(84)90473-9; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MITSAKOS A, 1988, BIOL CHEM H-S, V369, P661, DOI 10.1515/bchm3.1988.369.2.661; MITSAKOS A, 1989, BIOL CHEM H-S, V370, P239, DOI 10.1515/bchm3.1989.370.1.239; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SYMINGTON FW, 1984, J BIOL CHEM, V259, P6008; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TETTEROO PAT, 1984, EUR J IMMUNOL, V14, P1089, DOI 10.1002/eji.1830141205; WALZ G, UNPUB; WIERUSZESKI JM, 1988, FEBS LETT, V238, P390, DOI 10.1016/0014-5793(88)80518-0	43	887	972	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	1990	250	4984					1132	1135		10.1126/science.1701275	http://dx.doi.org/10.1126/science.1701275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701275				2022-12-24	WOS:A1990EJ58100035
J	STEVENSON, H; GAZDAR, AF; PHELPS, R; LINNOILA, RI; IHDE, DC; GHOSH, B; WALSH, T; WOODS, EL; OIE, H; OCONNOR, T; MAKUCH, R; KRAMER, BS; MULSHINE, JL				STEVENSON, H; GAZDAR, AF; PHELPS, R; LINNOILA, RI; IHDE, DC; GHOSH, B; WALSH, T; WOODS, EL; OIE, H; OCONNOR, T; MAKUCH, R; KRAMER, BS; MULSHINE, JL			TUMOR-CELL LINES ESTABLISHED INVITRO - AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NON-SMALL-CELL LUNG-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article									NATL NAVAL MED CTR, NCI,MED ONCOL BRANCH,BIOTHERAPY SECT,BLDG 8, ROOM 5101, BETHESDA, MD 20814 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA; YALE UNIV, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; Yale University								AAPRO MS, 1987, J CLIN ONCOL, V5, P890, DOI 10.1200/JCO.1987.5.6.890; BERTONCELLO I, 1982, BRIT J CANCER, V45, P803, DOI 10.1038/bjc.1982.131; BROWER M, 1986, CANCER RES, V46, P798; CARNEY DN, 1985, CANCER RES, V45, P2913; COX DR, 1972, J R STAT SOC B, V34, P187; DITTRICH C, 1985, BRIT J CANCER, V52, P197, DOI 10.1038/bjc.1985.178; EAGAN RT, 1979, CANCER, V44, P1125, DOI 10.1002/1097-0142(197909)44:3<1125::AID-CNCR2820440348>3.0.CO;2-4; ERWIN TJ, 1982, P AN M AM SOC CLIN, V1, P195; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1986, CANCER RES, V46, P6011; GAZDAR AF, 1988, BIOL LUNG CANCER DIA, P1; HUG V, 1984, CONTROVERSIES BREAST, P553; IHDE DC, 1987, P AN M AM SOC CLIN, V6, P181; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAD T, 1988, J CLIN ONCOL, V6, P9; LEHMAN EL, 1975, STATISTICAL METHODS, P55; LONGEVAL E, 1982, CANCER, V50, P2751, DOI 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTINI N, 1977, J THORAC CARDIOV SUR, V74, P499; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MILLER OL, 1984, SURG ONCOL, V30, P435; MINNA J, 1988, ACCOMPLISHMENTS CANC, P155; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; MULSHINE J, 1987, P AN M AM SOC CLIN, V6, P713; MULSHINE JL, 1986, J CLIN ONCOL, V4, P1704, DOI 10.1200/JCO.1986.4.11.1704; MULSHINE JL, 1988, THORACIC ONCOLOGY, P220; NAKANISHI Y, 1988, BIOL LUNG CANCER DIA, P59; NOMURA Y, 1989, CANCER RES, V49, P5288; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Reynolds C P, 1980, Trans Assoc Am Physicians, V93, P203; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; STEVENSON HC, 1989, J CLIN ONCOL, V7, P923, DOI 10.1200/JCO.1989.7.7.923; SUTHERLAND CM, 1983, SURGERY, V94, P370; TWEEDDALE ME, 1987, BLOOD, V69, P1307; 1978, STAGING LUNG CANCER; 1989, CANCER FACTS FIGURES, P9	38	48	48	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1990	113	10					764	770		10.7326/0003-4819-113-10-764	http://dx.doi.org/10.7326/0003-4819-113-10-764			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH363	1700655				2022-12-24	WOS:A1990EH36300008
J	BLEICHER, PA; BALK, SP; HAGEN, SJ; BLUMBERG, RS; FLOTTE, TJ; TERHORST, C				BLEICHER, PA; BALK, SP; HAGEN, SJ; BLUMBERG, RS; FLOTTE, TJ; TERHORST, C			EXPRESSION OF MURINE CD1 ON GASTROINTESTINAL EPITHELIUM	SCIENCE			English	Article									MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MOLEC IMMUNOL LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT HEMATOL & ONCOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT GASTROENTEROL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	BLEICHER, PA (corresponding author), MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN LABS,BOSTON,MA 02114, USA.				NCI NIH HHS [CA 01310] Funding Source: Medline; NIAMS NIH HHS [AR 01805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; AMIOT M, 1987, BLOOD, V70, P676; ARUFFO A, 1989, J IMMUNOL, V143, P1723; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BLEICHER PA, UNPUB; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HAGEN SJ, 1988, J HISTOCHEM CYTOCHEM, V36, P717, DOI 10.1177/36.7.3290330; HAGEN SJ, 1987, CELL TISSUE RES, V248, P709, DOI 10.1007/BF00216503; HARLOW E, 1988, ANTIBODIES LAB MANUA, P367; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; KONING F, 1988, J IMMUNOL, V141, P2057; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LERCH PG, 1986, MOL IMMUNOL, V23, P131, DOI 10.1016/0161-5890(86)90034-9; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MCCONNELL TJ, 1989, J IMMUNOL, V142, P2924; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; Sambrook J., 1989, MOL CLONING LAB MANU; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SMALL TN, 1987, J IMMUNOL, V138, P2864; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STEINER G, 1988, EUR J IMMUNOL, V18, P1323, DOI 10.1002/eji.1830180904; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERHORST C, 1983, J IMMUNOL, V131, P851; VANDERIJN M, 1983, J IMMUNOL, V131, P851; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VINEY JL, 1989, IMMUNOLOGY, V66, P583; YU CY, 1989, EMBO J, V8, P3727, DOI 10.1002/j.1460-2075.1989.tb08548.x	42	220	229	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 2	1990	250	4981					679	682		10.1126/science.1700477	http://dx.doi.org/10.1126/science.1700477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EF904	1700477				2022-12-24	WOS:A1990EF90400037
J	BREDT, DS; HWANG, PM; SNYDER, SH				BREDT, DS; HWANG, PM; SNYDER, SH			LOCALIZATION OF NITRIC-OXIDE SYNTHASE INDICATING A NEURAL ROLE FOR NITRIC-OXIDE	NATURE			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								BRECT DS, 1989, P NATL ACAD SCI USA, V86, P9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; DOHI T, 1983, EUR J PHARMACOL, V94, P331, DOI 10.1016/0014-2999(83)90423-5; Ferrendelli J A, 1978, Adv Cyclic Nucleotide Res, V9, P453; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARJORIE AA, 1982, P NATL ACAD SCI USA, V79, P1316; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; NOVELLI A, 1987, J NEUROSCI, V7, P40; OSULLIVAN AJ, 1990, J NEUROCHEM, V54, P1805, DOI 10.1111/j.1471-4159.1990.tb01238.x; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; RAMAGOPAL MW, 1989, BRIT J PHARMACOL, V174, P297; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SCHMIDT HHHW, 1989, BIOCHEM BIOPH RES CO, V165, P284, DOI 10.1016/0006-291X(89)91067-X; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TODA N, 1990, JPN J PHARMACOL, V52, P170, DOI 10.1254/jjp.52.170; ZWILLER J, 1981, NEUROSCI LETT, V23, P31	28	2869	2924	0	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 25	1990	347	6295					768	770		10.1038/347768a0	http://dx.doi.org/10.1038/347768a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE659	1700301	Bronze			2022-12-24	WOS:A1990EE65900064
J	CAMPBELL, JL; KLECKNER, N				CAMPBELL, JL; KLECKNER, N			ESCHERICHIA-COLI ORIC AND THE DNAA GENE PROMOTER ARE SEQUESTERED FROM DAM METHYLTRANSFERASE FOLLOWING THE PASSAGE OF THE CHROMOSOMAL REPLICATION FORK	CELL			English	Article											CAMPBELL, JL (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [5 R01 GM25326-12] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAUN RE, 1986, MOL GEN GENET, V202, P246, DOI 10.1007/BF00331644; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CASE CC, 1988, GENE, V72, P219, DOI 10.1016/0378-1119(88)90147-3; COOPER S, 1968, J MOL BIOL, V31, P519, DOI 10.1016/0022-2836(68)90425-7; EBERLE H, 1968, J MOL BIOL, V31, P149, DOI 10.1016/0022-2836(68)90065-X; EBERLE H, 1982, MOL GEN GENET, V186, P57, DOI 10.1007/BF00422912; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; HANSEN FG, 1982, EMBO J, V1, P1043, DOI 10.1002/j.1460-2075.1982.tb01294.x; HELMSTETTER CE, 1987, J BACTERIOL, V169, P3489, DOI 10.1128/jb.169.8.3489-3494.1987; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HERMAN GE, 1981, J BACTERIOL, V145, P644, DOI 10.1128/JB.145.1.644-646.1981; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KOPPES LJH, 1987, J BACTERIOL, V169, P430, DOI 10.1128/jb.169.1.430-433.1987; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; LANDOULSI A, 1989, MOL GEN GENET, V216, P217, DOI 10.1007/BF00334359; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LYONS SM, 1984, J BACTERIOL, V159, P421, DOI 10.1128/JB.159.1.421-423.1984; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MARINUS MG, 1987, ANNU REV GENET, V21, P113, DOI 10.1146/annurev.genet.21.1.113; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; NAGATA T, 1968, COLD SPRING HARB SYM, V33, P553, DOI 10.1101/SQB.1968.033.01.062; NELSON M, 1984, NUCLEIC ACIDS RES, V12, P5165, DOI 10.1093/nar/12.13.5165; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PIERUCCI O, 1989, J BACTERIOL, V171, P3760, DOI 10.1128/jb.171.7.3760-3766.1989; PUKKILA PJ, 1983, GENETICS, V104, P571; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; ROBERTS JM, 1988, CELL, V52, P397, DOI 10.1016/S0092-8674(88)80032-1; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SCHAEFER C, 1989, EMBO J, V8, P1609, DOI 10.1002/j.1460-2075.1989.tb03545.x; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; SUEOKA N, 1965, GENETICS, V52, P747; SZYF M, 1982, NUCLEIC ACIDS RES, V10, P7247, DOI 10.1093/nar/10.22.7247; YAMAKI H, 1988, NUCLEIC ACIDS RES, V16, P5067, DOI 10.1093/nar/16.11.5067; YIN JCP, 1988, J MOL BIOL, V199, P35, DOI 10.1016/0022-2836(88)90377-4; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	48	383	390	2	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 7	1990	62	5					967	979		10.1016/0092-8674(90)90271-F	http://dx.doi.org/10.1016/0092-8674(90)90271-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DY100	1697508				2022-12-24	WOS:A1990DY10000015
J	ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW				ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW			EFFECT OF HIV POSTTEST COUNSELING ON STD INCIDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEXUALLY-TRANSMITTED DISEASES; VIRUS-INFECTION; CLINICS; AIDS; MEN	Objective. - To evaluate the effectiveness of human immunodeficiency virus (HIV) testing and posttest counseling in reducing subsequent high-risk behavior. Methods. - The incidence of sexually transmitted diseases (STDs) in the Baltimore, Md, public STD clinic population after HIV testing and counseling was determined by chart review and was compared in two groups, 868 HIV-seropositive patients and 1104 HIV-seronegative patients, matched by age, sex, and month in which HIV test was conducted. Patients were observed for incident STDs at intervals of 6 through 23 months. Patients with incident STDs were classified hierarchically after being notified of the HIV test result and receiving posttest counseling. Results. - Of HIV-seropositive patients, 615 (71%) returned for their test results and received posttest counseling; 694 HIV-seronegative patients (63%) returned. Of all those who returned for results and posttest counseling, 60 (9.7%) of 615 HIV-seropositive patients and 61 (8.8%) of 694 HIV-seronegative patients were diagnosed at least once with definite STD (syphilis, gonorrhea, or trichomoniasis) (P, not significant). Twenty-four HIV-seropositive patients (3.9%) and 71 HIV-seronegative patients (10.2%) returned with probable STD (nongonococcal urethritis or pelvic inflammatory disease) (P < .001). Nine HIV-seropositive patients (1.5%) and 23 HIV-seronegative patients (3.3%) returned having had an STD-infected sexual partner (P < .03). Age, sexual orientation, and drug use behavior did not predict return with STD. Conclusions. - Both HIV-seropositive and HIV-seronegative patients showed high rates of repeat STDs after posttest counseling, an important public health challenge in creating effective high-risk behavior prevention strategies.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD	Johns Hopkins University					NIAID NIH HHS [AI29508, AI27727] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029508, R01AI027727] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; HANDSFIELD HH, 1990, SEX TRANSM DIS, V17, P211, DOI 10.1097/00007435-199010000-00011; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; REICHART CA, 1990, SEX TRANSM DIS, V17, P147, DOI 10.1097/00007435-199007000-00007; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; 1991, HIV AIDS SURVEILLANC, P1; 1989, MMWR SS8, V38, P1	12	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					843	845		10.1001/jama.267.6.843	http://dx.doi.org/10.1001/jama.267.6.843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732658				2022-12-24	WOS:A1992HC48400031
J	TASAYCO, ML; CAREY, J				TASAYCO, ML; CAREY, J			ORDERED SELF-ASSEMBLY OF POLYPEPTIDE FRAGMENTS TO FORM NATIVE-LIKE DIMERIC TRP REPRESSOR	SCIENCE			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; DNA-BINDING; TROPONIN-C; NMR; APOREPRESSOR; RESOLUTION; INTERMEDIATE	Subdomain-size proteolytic fragments of Escherichia coli trp repressor have been produced that assemble in defined order to regenerate fully native dimers. By characterization of the secondary and tertiary structures of isolated and recombined fragments, the structure of assembly intermediates can be correlated with the kinetic folding pathway of the intact repressor deduced from spectroscopic measurement of folding rates. The nativelike structure of these intermediates provides further evidence that protein folding pathways reflect the stabilities of secondary structural units and assemblies found in the native state. The proteolytic method should be generally useful in adding structural detail to spectroscopically determined folding mechanisms.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043558, R29GM043558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CAREY J, 1989, J BIOL CHEM, V264, P1941; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HYDE EI, 1989, EUR J BIOCHEM, V183, P545, DOI 10.1111/j.1432-1033.1989.tb21083.x; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MMULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Taniuchi H, 1986, Methods Enzymol, V131, P185; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	27	96	96	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					594	597		10.1126/science.1736361	http://dx.doi.org/10.1126/science.1736361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736361				2022-12-24	WOS:A1992HB53100042
J	HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN				HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN			DNA-BINDING ACTIVITY OF RECOMBINANT SRY FROM NORMAL MALES AND XY FEMALES	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; SEX-DETERMINING REGION; DETERMINING GENE; PROTEINS; ENCODES; DIFFERENTIATION; EXPRESSION; HOMOLOGY; MUTATION; SEQUENCE	The protein encoded by the human testis determining gene, SRY, contains a high mobility group (HMG) box related to that present in the T cell-specific, DNA-binding protein TCF-1. Recombinant SRY protein was able to bind to the same core sequence AACAAAG recognized by TCF-1 in a sequence dependent manner. In five XY females point mutations were found in the region encoding the HMG box. In four cases DNA binding activity of mutant SRY protein was negligible; in the fifth case DNA binding was reduced. These results imply that the DNA binding activity of SRY is required for sex determination.	IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHNS HOPKINS CHILDREN CTR,DIV PEDIAT ENDOCRINOL,BALTIMORE,MD 21205; NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Cancer Research UK; Johns Hopkins University; Johns Hopkins Medicine; MRC National Institute for Medical Research			Harley, Vincent/B-8092-2018; Hawkins, Ross/M-7702-2014	Harley, Vincent/0000-0002-2405-1262; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER AP, 1985, J BIOL CHEM, V19, P10613; DELACHAPELLE A, 1987, DEVELOPMENT, V101, P33; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; FERGUSONSMITH MA, 1990, HUM GENET, V84, P198; FORD CE, 1959, LANCET, V1, P711; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, UNPUB; GUELLAEN G, 1984, NATURE, V307, P172, DOI 10.1038/307172a0; HAGGREN W, 1988, MOL CELL BIOL, V8, P1282, DOI 10.1128/MCB.8.3.1282; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS JR, IN PRESS HUM GENET; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PENTECOST BT, 1985, NUCLEIC ACIDS RES, V13, P4871, DOI 10.1093/nar/13.13.4871; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; ROTH SY, 1987, NUCLEIC ACIDS RES, V15, P8112, DOI 10.1093/nar/15.19.8112; SINCLAIR AG, UNPUB; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; SUMMERS M, 1987, TEX ASGR EXP STN B, V1555; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VERGNAUD G, 1986, AM J HUM GENET, V38, P172; WATERMAN M L, 1990, New Biologist, V2, P621; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; [No title captured]	44	392	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					453	456		10.1126/science.1734522	http://dx.doi.org/10.1126/science.1734522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734522				2022-12-24	WOS:A1992HA59000037
J	HOWSON, CP; FINEBERG, HV				HOWSON, CP; FINEBERG, HV			ADVERSE EVENTS FOLLOWING PERTUSSIS AND RUBELLA VACCINES - SUMMARY OF A REPORT OF THE INSTITUTE-OF-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In August 1991, the Institute of Medicine released a report entitled Adverse Effects of Pertussis and Rubella Vaccines, which examined 18 adverse events in relation to diphtheria-tetanus-pertussis (DTP) vaccine and four adverse events in relation to the currently used rubella vaccine strain, RA 27/3. The committee spent 20 months reviewing a wide range of information sources, including case series and individual case reports, both published and unpublished, epidemiologic studies, studies in animals, and other laboratory studies. The committee found that the evidence indicates a causal relation between DTP vaccine and anaphylaxis and between the pertussis component of DTP vaccine and extended periods of inconsolable crying or screaming. The committee also reported that the evidence indicates a causal relation between the rubella vaccine and acute arthritis in adult women. The committee found the available evidence weaker but still consistent with a causal relation between DTP vaccine and two conditions-acute encephalopathy and hypotonic, hyporesponsive episodes-and between rubella vaccine and chronic arthritis in adult women. Estimated incidence rates of these adverse events following vaccination are provided, where possible. The committee found that the evidence does not indicate a causal relation between the DTP vaccine and infantile spasms, hypsarrhythmia, Reye's syndrome, and sudden infant death syndrome. The committee found insufficient evidence to indicate either the presence or absence of a causal relation between DTP vaccine and chronic neurologic damage, aseptic meningitis, erythema multiforme or other rash, Guillain-Barre syndrome, hemolytic anemia, juvenile diabetes, learning disabilities and attention-deficit disorder, peripheral mononeuropathy, or thrombocytopenia, and between rubella vaccine and radiculoneuritis and other neuropathies or thrombocytopenic purpura. The committee's evaluative methods are briefly described and a summary of research needs is provided.	NATL ACAD SCI,INST MED,DIV HLTH PROMOT & DIS PREVENT,WASHINGTON,DC 20418; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	National Academies of Sciences, Engineering & Medicine; Harvard University; Harvard T.H. Chan School of Public Health								ALDERSLADE R, 1981, WHOOPING COUGH, P79; Howson CP, 1991, ADVERSE EFFECTS PERT	2	84	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					392	396		10.1001/jama.267.3.392	http://dx.doi.org/10.1001/jama.267.3.392			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727962				2022-12-24	WOS:A1992GY43700037
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW			OBESITY AT DIAGNOSIS OF BREAST-CARCINOMA INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						OBESITY; BREAST NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; BODY MASS INDEX; WOMENS HEALTH	POST-MENOPAUSAL WOMEN; BODY-WEIGHT; ESTROGEN-RECEPTORS; CANCER SURVIVAL; MENSTRUAL STATUS; BOUND ESTRADIOL; RISK-FACTORS; DIETARY-FAT; EPIDEMIOLOGY; ASSOCIATION	Objective: To study disease-free survival at 10 years in relation to obesity at the time of diagnosis. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Nine hundred twenty-three women treated by mastectomy and axillary dissection. Main Results: Women who were obese (25% or more over optimal weight for height) at the time of primary breast cancer treatment were at significantly greater risk for recurrence (42%) compared with nonobese patients (32%) 10 years after diagnosis (P < 0.01). In multivariate analyses, obesiTy remained a statistically significant prognostic factor after controLling for measured tumor size, number of positive axillary lymph nodes, age at diagnosis, and adjuvant chemotherapy with a hazard ratio of 1.29 (95% Cl, 1.0 to 1.67). When analyses were restricted to the 557 patients free of lymph node metastases, the hazard ratio of recurrence associated with obesity was 1.59 (CL, 1.06 to 2.39); 32% of obese patients developed recurrent disease compared with 19% of nonobese women. Conclusions: Obesity at the time of diagnosis is a significant prognostic factor that may Limit the reduction in breast cancer mortality attainable through detection at an early stage of disease. Because obesity and the risk for breast cancer increase with age, interventions that encourage weight controL may influence breast cancer survival rates.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, DIV REPROD HLTH, WOMENS HLTH & FERTIL BRANCH, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; CHANDRA RK, 1981, CANCER RES, V41, P3795; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1981, Nutr Cancer, V2, P237; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GRAY DS, 1991, J CLIN EPIDEMIOL, V44, P545, DOI 10.1016/0895-4356(91)90218-X; GREENBERG ER, 1985, BRIT J CANCER, V51, P691, DOI 10.1038/bjc.1985.104; GREGORIO DI, 1985, JNCI-J NATL CANCER I, V75, P37; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRSCHNER MA, 1982, CANCER RES, V42, P3281; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LESSER ML, 1982, SURGERY, V91, P234; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASON B, 1982, J SURG ONCOL, V19, P62, DOI 10.1002/jso.2930190116; MCNEE RK, 1987, BREAST CANCER RES TR, V9, P145, DOI 10.1007/BF01807367; MOHLEBOETANI JC, 1988, PREV MED, V17, P634, DOI 10.1016/0091-7435(88)90056-4; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; NEWBERNE PM, 1983, CANCER RES, V43, P2426; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; NOMURA Y, 1981, GANN, V72, P468; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; REED MJ, 1983, CANCER RES, V43, P3940; ROSE DP, 1986, DIET NUTRITION CANCE, P151; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; ROSEN PP, 1979, SURGERY, V85, P219; Rowland M L, 1989, Stat Bull Metrop Insur Co, V70, P2; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; SHERMAN BM, 1974, CANCER, V33, P1306, DOI 10.1002/1097-0142(197405)33:5<1306::AID-CNCR2820330515>3.0.CO;2-#; SOHRABI A, 1980, JAMA-J AM MED ASSOC, V244, P264, DOI 10.1001/jama.244.3.264; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; TRICHOPOULOS D, 1987, INT J CANCER, V40, P721, DOI 10.1002/ijc.2910400602; VERREAULT R, 1989, AM J EPIDEMIOL, V129, P260, DOI 10.1093/oxfordjournals.aje.a115131; WAARD FD, 1975, CANCER RES, V35, P3351; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; Zumoff B, 1988, Acta Med Scand Suppl, V723, P153; 1959, STAT B METROP INSUR, V40, P1	51	143	143	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					26	32		10.7326/0003-4819-116-1-26	http://dx.doi.org/10.7326/0003-4819-116-1-26			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727092				2022-12-24	WOS:A1992GX15700005
J	STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML				STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML			PREVALENCE OF MIGRAINE HEADACHE IN THE UNITED-STATES - RELATION TO AGE, INCOME, RACE, AND OTHER SOCIODEMOGRAPHIC FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY; SYMPTOMS; WOMEN	Objective. - To describe the magnitude and distribution of the public health problem posed by migraine in the United States by examining migraine prevalence, attack frequency, and attack-related disability by gender, age, race, household income, geographic region, and urban vs rural residence. Design. - In 1989, a self-administered questionnaire was sent to a sample of 15000 households. A designated member of each household initially responded to the questionnaire. Each household member with severe headache was asked to respond to detailed questions about symptoms, frequency, and severity of headaches. Setting. - A sample of households selected from a panel to be representative of the US population in terms of age, gender, household size, and geographic area. Participants. - After a single mailing, 20468 subjects (63.4% response rate) between 12 and 80 years of age responded to the survey. Respondents and nonrespondents did not differ by gender, household income, region of the country, urban vs rural status. Whites and the elderly were more likely to respond. Migraine headache cases were identified on the basis of reported symptoms using established diagnostic criteria. Results. - 17.6% of females and 5.7% of males were found to have one or more migraine headaches per year. The prevalence of migraine varied considerably by age and was highest in both men and women between the ages of 35 to 45 years. Migraine prevalence was strongly associated with household income; prevalence in the lowest income group (< $10 000) was more than 60% higher than in the two highest income groups (greater-than-or-equal-to $30 000). The proportion of migraine sufferers who experienced moderate to severe disability was not related to gender, age, income, urban vs rural residence, or region of the country. In contrast, the frequency of headaches was lower in higher-income groups. Attack frequency was inversely related to disability. Conclusions. - A projection to the US population suggests that 8.7 million females and 2.6 million males suffer from migraine headache with moderate to severe disability. Of these, 3.4 million females and 1.1 million males experience one or more attacks per month. Females between ages 30 to 49 years from lower-income households are at especially high risk of having migraines and are more likely than other groups to use emergency care services for their acute condition.	JOHNS HOPKINS UNIV,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; GLAXO INC,RES TRIANGLE PK,NC	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; GlaxoSmithKline	STEWART, WF (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019381, T32NS007153] Funding Source: NIH RePORTER; NINDS NIH HHS [5-T32 NSO-7153, NS19381] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen R, 1979, TOTAL SURVEY ERROR; ANDERSON RJ, 1984, CLIN CHIM ACTA, V138, P185, DOI 10.1016/0009-8981(84)90233-X; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P152; BRUYN GW, 1983, HEADACHE, V23, P127; CELENTANO DD, 1990, SOC SCI MED, V30, P1289, DOI 10.1016/0277-9536(90)90309-G; CELENTANO DD, 1990, J CLIN EPIDEMIOL, V43, P983, DOI 10.1016/0895-4356(90)90082-Z; CHEN TC, 1987, ARCH NEUROL-CHICAGO, V44, P1024, DOI 10.1001/archneur.1987.00520220030011; CLARKE GJR, 1974, EPIDEMIOLOGY MIGRAIN, P14; DALLESANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21; DEUBNER DC, 1977, HEADACHE, V17, P173, DOI 10.1111/j.1526-4610.1977.hed1704173.x; EATON WW, 1988, HDB SCHIZOPHRENIA, V3, P169; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; JOHANNES CB, 1989, THESIS J HOPKINS U A; KAPPIUS REK, 1987, HEADACHE, V27, P491, DOI 10.1111/j.1526-4610.1987.hed2709491.x; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LIPTON RB, 1991, CEPHALALGIA, V11, P89, DOI 10.1177/0333102491011S1148; MARKUSH RE, 1975, NEUROLOGY, V25, P430, DOI 10.1212/WNL.25.5.430; MCCULLUGH P, 1983, GENERALIZED LINEAR M, P142; MOSS G, 1974, EPIDEMIOLOGY MIGRAIN, P49; SCHNARCH DM, 1980, PSYCHOSOMATICS, V21, P314; SILBERSTEIN SD, 1991, NEUROLOGY, V41, P786, DOI 10.1212/WNL.41.6.786; WATERS W E, 1970, Headache, V9, P178, DOI 10.1111/j.1526-4610.1970.hed0904178.x; ZIEGLER DK, 1990, NEUROL CLIN, V8, P781, DOI 10.1016/S0733-8619(18)30316-5; 1988, NATIONAL DATA BOOK G	25	1264	1299	3	57	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					64	69		10.1001/jama.267.1.64	http://dx.doi.org/10.1001/jama.267.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727198				2022-12-24	WOS:A1992GW84800025
J	WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE				WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE			MOLECULAR ARCHITECTURE AND ELECTROSTATIC PROPERTIES OF A BACTERIAL PORIN	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; COLI OUTER MEMBRANES; X-RAY-ANALYSIS; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; ALPHA-HELIX; RESOLUTION; CRYSTALLIZATION; DIPOLES; PROGRAM	The integral membrane protein porin from Rhodobacter capsulatus consists of three tightly associated 16-stranded beta-barrels that give rise to three distinct diffusion channels for small solutes through the outer membrane. The x-ray structure of this porin has revealed details of its shape, the residue distributions within the pore and at the membrane-facing surface, and the location of calcium sites. The electrostatic potential has been calculated and related to function. Moreover, potential calculations were found to predict the Ca2+ sites.	INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY; INST BIOL 2,W-7800 FREIBURG,GERMANY; INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY		SCHULZ, GE (corresponding author), INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY.		Weiss, Manfred S/B-6857-2013	Weiss, Manfred S/0000-0002-2362-7047				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; KARSHIKOV A, 1989, PROTEINS, V5, P248, DOI 10.1002/prot.340050308; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KREUSCH A, 1991, J MOL BIOL, V217, P9, DOI 10.1016/0022-2836(91)90604-5; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; STAUFFER KA, 1990, J MOL BIOL, V211, P297, DOI 10.1016/0022-2836(90)90351-L; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WELTE W, IN PRESS BIOCH BIOPH; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	29	578	594	4	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1627	1630		10.1126/science.1721242	http://dx.doi.org/10.1126/science.1721242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721242				2022-12-24	WOS:A1991GV07300040
J	LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW				LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW			FUNCTIONAL CONTRIBUTION OF NEURONAL ACHR SUBUNITS REVEALED BY ANTISENSE OLIGONUCLEOTIDES	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS	Although multiple related genes encoding nicotinic acetylcholine receptor (AChR) subunits have been identified, how each of these subunits contributes to AChRs in neurons is not known. Sympathetic neurons express four classes of AChR channels and six AChR subunit genes (alpha-3, alpha-4, alpha-5, alpha-7, beta-2, and beta-4). The contribution of individual subunits to AChR channel subtypes in these neurons was examined by selective deletion with antisense oligonucleotides. An alpha-3 antisense oligonucleotide decreased the number and altered the properties of the normally expressed ACh-activated channels. The remaining AChR channels have distinct biophysical and pharmacological properties that indicate an important functional contribution of the alpha-7 subunit.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027680, P50NS027680, R01NS029071] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029071-14, NS27680, R01 NS029071-15, NS 29071, R01 NS029071-10, R01 NS029071-13S1, R01 NS029071, R01 NS029071-12, R01 NS029071-13, R01 NS029071-09, R01 NS029071-17, R01 NS029071-16, R01 NS029071-11] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD RT, 1988, NEURON, V1, P495; BRUSSAARD A, UNPUB; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; GARDETTE R, 1991, DEV BIOL, V147, P83, DOI 10.1016/S0012-1606(05)80009-0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; LEPRINCE P, 1983, BIOCHEMISTRY-US, V22, P5551, DOI 10.1021/bi00293a015; LUETJE CW, 1991, J NEUROSCI, V11, P837; MOSS BL, 1989, NEURON, V3, P597, DOI 10.1016/0896-6273(89)90270-5; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOEPFER R, 1989, FEBS LETT, V257, P393, DOI 10.1016/0014-5793(89)81580-7; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SNEDECOR GW, 1967, STATISTICAL METHODS, P329; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001	17	164	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1518	1521		10.1126/science.1720573	http://dx.doi.org/10.1126/science.1720573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720573	Green Accepted			2022-12-24	WOS:A1991GT90300044
J	JORGENSEN, WL				JORGENSEN, WL			RUSTING OF THE LOCK AND KEY MODEL FOR PROTEIN-LIGAND BINDING	SCIENCE			English	Editorial Material							3-DIMENSIONAL STRUCTURE; COMPLEX; ANTIBODY; RESOLUTION; ANTIGEN; PEPTIDE				JORGENSEN, WL (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.		/AAW-1187-2021					AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CRUMPTON MJ, 1966, BIOCHEM J, V100, P223, DOI 10.1042/bj1000223; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KIM PS, 1982, J MOL BIOL, V162, P187, DOI 10.1016/0022-2836(82)90168-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, SCIENCE, V252, P6574; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	16	178	186	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					954	955		10.1126/science.1719636	http://dx.doi.org/10.1126/science.1719636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719636				2022-12-24	WOS:A1991GP88300031
J	RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ				RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ			EFFECT OF DELETING THE R-DOMAIN ON CFTR-GENERATED CHLORIDE CHANNELS	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; PATCH-CLAMP; CELLS; IDENTIFICATION; EXPRESSION; MUTATIONS; INACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR), which forms adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, is defective in patients with cystic fibrosis. This protein contains two putative nucleotide binding domains (NBD1 and NBD2) and an R domain. CFTR in which the R domain was deleted (CFTR-DELTA-R) conducted chloride independently of the presence of cAMP. However, sites within CFTR other than those deleted also respond to cAMP, because the chloride current of CFTR-DELTA-R increased further in response to cAMP stimulation. In addition, deletion of the R domain suppressed the inactivating effect of a mutation in NBD2 (but not NBD1), a result which suggests that NBD2 interacts with the channel through the R domain.	GENZYME CORP, FRAMINGHAM, MA 01701 USA; MIT, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, CAMBRIDGE, MA 02142 USA	Sanofi-Aventis; Genzyme Corporation; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	RICH, DP (corresponding author), MIT, HOWARD HUGHES MED INST, DEPT INTERNAL MED, CAMBRIDGE, MA 02142 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BOAT TF, 1989, METABOLIC BASIS INHE; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, IN PRESS MOL CELL BI; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OSTEDGAARD LS, UNPUB; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	250	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					205	207		10.1126/science.1712985	http://dx.doi.org/10.1126/science.1712985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712985				2022-12-24	WOS:A1991FW16000040
J	PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP				PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP			ACH RECEPTOR RICH MEMBRANE DOMAINS ORGANIZED IN FIBROBLASTS BY RECOMBINANT 43-KILDALTON PROTEIN	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; MOUSE NEUROMUSCULAR-JUNCTIONS; TORPEDO-MARMORATA; ALKALINE TREATMENT; ELECTRIC ORGAN; MUSCLE FIBERS; BETA-SUBUNIT; BINDING; CELLS; CHANNELS	Neurotransmitter receptors are generally clustered in the postsynaptic membrane. The mechanism of clustering was analyzed with fibroblast cell lines that were stably transfected with the four subunits for fetal (alpha, beta, gamma, delta) or adult (alpha, beta, epsilon, delta) type mouse muscle nicotinic acetylcholine receptors (AChRs). Immunofluorescent staining indicated that AChRs were dispersed on the surface of these cells. When transiently transfected with an expression construct encoding a 43-kilodalton protein that is normally concentrated under the postsynaptic membrane, AChRs expressed in these cells became aggregated in large cell-surface clusters, colocalized with the 43-kilodalton protein. This suggests that 43-kilodalton protein can induce AChR clustering and that cluster induction involves direct contact between AChR and 43-kilodalton protein.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Washington University (WUSTL); Dartmouth College	PHILLIPS, WD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Phillips, William/0000-0002-5405-8422	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022356] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS022356] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BARRANTES FJ, 1980, FEBS LETT, V112, P73, DOI 10.1016/0014-5793(80)80131-1; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BREHM P, 1987, P NATL ACAD SCI USA, V84, P2550, DOI 10.1073/pnas.84.8.2550; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARTAUD J, 1981, J CELL BIOL, V90, P418, DOI 10.1083/jcb.90.2.418; COVARRUBIAS M, 1990, PFLUG ARCH EUR J PHY, V416, P385, DOI 10.1007/BF00370744; COVARRUBIAS M, 1989, J GEN PHYSIOL, V93, P765, DOI 10.1085/jgp.93.5.765; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FISCHBACH GD, 1973, DEV BIOL, V31, P147, DOI 10.1016/0012-1606(73)90326-6; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FROEHNER SC, 1986, TRENDS NEUROSCI, V9, P37, DOI 10.1016/0166-2236(86)90013-5; GARDNER PJ, UNPUB; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; KULLBERG R, 1990, P NATL ACAD SCI USA, V87, P2067, DOI 10.1073/pnas.87.6.2067; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LO MMS, 1980, FEBS LETT, V111, P407, DOI 10.1016/0014-5793(80)80838-6; MATTHEWSBELLINGER JA, 1983, J NEUROSCI, V3, P644; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; SCHUETZE SM, 1978, P NATL ACAD SCI USA, V75, P520, DOI 10.1073/pnas.75.1.520; SLATER CR, 1982, DEV BIOL, V94, P11, DOI 10.1016/0012-1606(82)90063-X; SOBEL A, 1978, P NATL ACAD SCI USA, V75, P510, DOI 10.1073/pnas.75.1.510; STEINBACH JH, 1981, DEV BIOL, V84, P367; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180	36	202	204	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					568	570		10.1126/science.1703661	http://dx.doi.org/10.1126/science.1703661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1703661				2022-12-24	WOS:A1991EV45900054
J	KATAYANAGI, K; MIYAGAWA, M; MATSUSHIMA, M; ISHIKAWA, M; KANAYA, S; IKEHARA, M; MATSUZAKI, T; MORIKAWA, K				KATAYANAGI, K; MIYAGAWA, M; MATSUSHIMA, M; ISHIKAWA, M; KANAYA, S; IKEHARA, M; MATSUZAKI, T; MORIKAWA, K			3-DIMENSIONAL STRUCTURE OF RIBONUCLEASE-H FROM ESCHERICHIA-COLI	NATURE			English	Article									PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; MITSUBISHI KASEI CORP,CENT RES LABS,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN									ARNI R, 1988, J BIOL CHEM, V263, P15358; ARNONE A, 1971, J BIOL CHEM, V246, P2302; CARLISLE CH, 1974, J MOL BIOL, V85, P1, DOI 10.1016/0022-2836(74)90125-9; Crouch R. J., 1982, NUCLEASES, P211; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; MATTHEWS BW, 1988, NATURE, V335, P294, DOI 10.1038/335294a0; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; RICHARDS FM, 1971, ENZYMES, V4, P647; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617	26	332	340	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 20	1990	347	6290					306	309		10.1038/347306a0	http://dx.doi.org/10.1038/347306a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ452	1698262				2022-12-24	WOS:A1990DZ45200068
J	CHEONG, CJ; VARANI, G; TINOCO, I				CHEONG, CJ; VARANI, G; TINOCO, I			SOLUTION STRUCTURE OF AN UNUSUALLY STABLE RNA HAIRPIN, 5'GGAC(UUCG)GUCC	NATURE			English	Article									UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CHEM BIODYNAM LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Cheong, Chaejoon/GWC-3135-2022					ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; BLOMMERS MJJ, 1989, BIOCHEMISTRY-US, V28, P7491, DOI 10.1021/bi00444a049; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHATTOPADHYAYA R, 1988, NATURE, V334, P175, DOI 10.1038/334175a0; CHEONG C, 1989, THESIS U CALIFORNIA; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FREY MH, 1985, BIOPOLYMERS, V24, P2371, DOI 10.1002/bip.360241214; GORENSTEIN D, 1984, 31P NMR PRINCIPLES A; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HARE DR, 1986, BIOCHEMISTRY-US, V25, P5341, DOI 10.1021/bi00366a053; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; KOLLMAN PA, 1981, BIOPOLYMERS, V20, P2583, DOI 10.1002/bip.1981.360201208; LANKHORST PP, 1984, J BIOMOL STRUCT DYN, V1, P1387, DOI 10.1080/07391102.1984.10507527; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SKLENAR V, 1986, FEBS LETT, V208, P94, DOI 10.1016/0014-5793(86)81539-3; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WILLIAMSON JR, 1989, BIOCHEMISTRY-US, V28, P2819, DOI 10.1021/bi00433a012; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; Wuthrich K., 1986, NMR PROTEINS NUCL AC	22	415	423	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 16	1990	346	6285					680	682		10.1038/346680a0	http://dx.doi.org/10.1038/346680a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU728	1696688				2022-12-24	WOS:A1990DU72800070
J	ANNAS, GJ				ANNAS, GJ			CHANGING THE CONSENT RULES FOR DESERT-STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P61; CURRIE DP, 1990, CONSTITUTION SUPREME, P280; HOWE EG, 1991, HASTINGS CENT REP, V21, P21, DOI 10.2307/3562332; JOHNSON WH, 1953, SCIENCE, V117, P212; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; 1990, FED REGISTER, V55, P52814; 1991, AM J HOSP PHARM, V48, P1525	7	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					770	773		10.1056/NEJM199203123261117	http://dx.doi.org/10.1056/NEJM199203123261117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738394	Green Published			2022-12-24	WOS:A1992HH06400032
J	BROOKOFF, D; POLOMANO, R				BROOKOFF, D; POLOMANO, R			TREATING SICKLE-CELL PAIN LIKE CANCER PAIN	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; ANEMIA; CRISIS; ANALGESICS; MANAGEMENT	Objective: To assess the effect of a structured analgesic regimen on hospital use by patients with sickle cell disease. Intervention: Intravenous and oral controlled-release morphine was used instead of intramuscular meperidine and short-acting oral opioids for the treatment of sickle cell pain. Design: Time series in which emergency and admission records for four 6-month periods before and two 6-month periods after the institution of the new analgesic protocol were reviewed. Setting: Inner-city university hospital providing care for adults with sickle cell disease. Patients: All patients (an average of 50) who used the emergency department or the inpatient medical service for treatment of sickle cell crisis during the study periods. Measurements and Main Results: The number of admissions for sickle cell pain decreased by 44%, total inpatient days by 57%, length of hospital stay by 23%, and the number of emergency department visits by 67% after initiation of the morphine protocol. Hospital use remained at these lower levels one year later. Similar declines were seen for a subset of 15 patients who had a history of frequent admissions for sickle cell pain and who used this hospital exclusively and accounted for more than half of the admissions for sickle cell disease. Conclusion: A pain-control program modeled on regimens used to treat chronic cancer pain reduced hospital use by adult patients with sickle cell pain.	HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine								ABBUHL S, 1986, ANN EMERG MED, V15, P433, DOI 10.1016/S0196-0644(86)80183-4; ALAVI JB, 1984, MED CLIN N AM, V68, P545, DOI 10.1016/S0025-7125(16)31115-4; BEAVER WT, 1980, JAMA-J AM MED ASSOC, V244, P2653; BROOKS I, 1989, J FAM PRACTICE, V28, P275; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1986, HOSP PRACT, V21, P173; CHARACHE S, 1981, ANNU REV MED, V32, P195, DOI 10.1146/annurev.me.32.020181.001211; COHEN M, 1981, HOSP PHARM, V16, P296; Conley CL, 1980, BLOOD PURE ELOQUENT, P319; Diggs LW, 1934, SOUTH MED J, V27, P839; FOLEY KM, 1989, CANCER-AM CANCER SOC, V63, P2257, DOI 10.1002/1097-0142(19890601)63:11<2257::AID-CNCR2820631134>3.0.CO;2-6; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FRIEDMAN EW, 1986, ANN EMERG MED, V15, P787, DOI 10.1016/S0196-0644(86)80373-0; GALLOWAY S J, 1988, Journal of Emergency Medicine, V6, P213, DOI 10.1016/0736-4679(88)90329-0; LANDE WM, 1988, BLOOD, V72, P2056; MACEIRARODRIGUE.L, 1985, HOSP PHYSICIAN, V3, P14; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MCGUIRE DB, 1988, INSTRUMENTS CLIN NUR, P333; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; PETERSON CM, 1974, ANN INTERN MED, V81, P152, DOI 10.7326/0003-4819-81-2-152; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POLOMANO R, 1988, J PAIN SYMPTOM MANAG, V3, pS15; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; PORTENOY RK, 1987, MED CLIN N AM, V71, P233, DOI 10.1016/S0025-7125(16)30867-7; Powars D R, 1987, Prog Clin Biol Res, V240, P393; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; RODGERS GP, 1991, PJAMA, V256, P2097; Schechter N L, 1988, J Pain Symptom Manage, V3, P109, DOI 10.1016/0885-3924(88)90169-8; SIRS JA, 1963, LANCET, V1, P971; Taub A., 1982, NARCOTIC ANALGESICS, P199; 1974, JAMA-J AM MED ASSOC, V228, P1125; 1986, CANCER PAIN RELIEF	33	68	68	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					364	368		10.7326/0003-4819-116-5-364	http://dx.doi.org/10.7326/0003-4819-116-5-364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736768				2022-12-24	WOS:A1992HF26800003
J	SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D				SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D			PNEUMOCYSTIS-CARINII PNEUMONIA AMONG PATIENTS WITHOUT AIDS AT A CANCER HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTIOUS COMPLICATIONS; MARROW TRANSPLANTATION; LYMPHOCYTIC-LEUKEMIA; NEOPLASTIC DISEASES; THERAPY; CHILDREN; CHEMOPROPHYLAXIS; CYCLOSPORINE; DIAGNOSIS	Objectives. - To determine the predisposing factors, attack rate by underlying disease, and outcome of Pneumocystis carinii pneumonia among patients without the acquired immunodeficiency syndrome (AIDS) at a cancer center. Data Source. - Twelve-year retrospective review from a tertiary-care cancer center. Study Selection. - One hundred forty patients, constituting 142 cases, with morphologically proved P carinii pneumonia. Data Synthesis. - Hematologic malignancy (47%) (including lymphoma [27%] and leukemia [18%]), solid tumor (31%), or bone marrow transplantation (18%) was the underlying condition in the majority of cases. Twenty-five cases (18%) were diagnosed at autopsy. All but seven patients had previously established predisposing factors for P carinii pneumonia, including corticosteroid use in 87%. The attack rate for hospitalized patients with primary or metastatic brain tumor increased during the 12-year interval. The attack rates for hospitalized patients with hematologic neoplasm or bone marrow transplantation were stable. The overall mortality rate did not change during the period reviewed, Conclusions. - Despite the availability of effective prophylaxis, P carinii pneumonia continues to occur among patients with neoplastic disease. In addition to patients with certain hematologic neoplasms, those with primary or metastatic brain neoplasm who receive corticosteroids are at risk for the development of P carinii pneumonia and should receive P carinii pneumonia prophylaxis.			SEPKOWITZ, KA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER; NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENOUSAN T, 1990, LANCET, P1066; BRAZINSKY JH, 1969, J AMER MED ASSOC, V209, P1527, DOI 10.1001/jama.209.10.1527; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; BURKE BA, 1973, MEDICINE, V52, P23, DOI 10.1097/00005792-197301000-00002; CAPITANI.MA, 1966, AMER J ROENTGENOL RA, V97, P174, DOI 10.2214/ajr.97.1.174; CHAVE JP, 1991, AIDS, V5, P927, DOI 10.1097/00002030-199108000-00002; CHUSID MJ, 1978, PEDIATRICS, V62, P1031; FOSSIECK BE, 1980, CHEST, V78, P721, DOI 10.1378/chest.78.5.721; FRANSON TR, 1987, ARCH SURG-CHICAGO, V122, P1034; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; GIRON JA, 1982, LANCET, V2, P46; GLATT AE, 1990, ARCH INTERN MED, V150, P271, DOI 10.1001/archinte.150.2.271; GOESCH TR, 1991, LANCET, P627; GRYZAN S, 1988, AM REV RESPIR DIS, V137, P1268, DOI 10.1164/ajrccm/137.6.1268; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HARDY R, 1987, J NATL MED ASSOC, V79, P1205; HARON E, 1988, LANCET, V2, P904; HENSON JW, 1991, ARCH NEUROL-CHICAGO, V48, P406, DOI 10.1001/archneur.1991.00530160074017; HIGGINS RM, 1989, TRANSPLANTATION, V47, P558, DOI 10.1097/00007890-198903000-00032; HUGHES WT, 1978, JOHNS HOPKINS MED J, V143, P184; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1984, J INFECT DIS, V150, P305, DOI 10.1093/infdis/150.2.305-a; HUGHES WT, 1977, NEW ENGL J MED, V297, P1381, DOI 10.1056/NEJM197712222972505; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1975, CANCER, V36, P2004, DOI 10.1002/cncr.2820360912; HUGHES WT, 1974, AM J DIS CHILD, V128, P44, DOI 10.1001/archpedi.1974.02110260046008; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; HUGHES WT, 1982, J INFECT DIS, V145, P767, DOI 10.1093/infdis/145.2.767; HUGHES WT, 1987, PNEUMOCYSTIS CARINII; IVADY G, 1967, LANCET, V1, P616; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; KOUIDES PA, 1988, BRIT J HAEMATOL, V70, P383, DOI 10.1111/j.1365-2141.1988.tb02500.x; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KRITZ A, 1991, NEW ENGL J MED, V325, P661; LECLAIR RA, 1969, AM REV RESPIR DIS, V99, P542; LEFF RL, 1990, ANN INTERN MED, V112, P716, DOI 10.7326/0003-4819-112-9-716_1; LUNA MA, 1989, SEMIN DIAGN PATHOL, V6, P262; LUNA MA, 1972, TEX REP BIOL MED, V30, P41; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1988, ANN INTERN MED, V109, P755, DOI 10.7326/0003-4819-109-9-755; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MILLIGAN DW, 1987, LANCET, V1, P867; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1582, DOI 10.1164/ajrccm/141.6.1582; NATALE RB, 1981, CANCER, V47, P2933, DOI 10.1002/1097-0142(19810615)47:12&lt;2933::AID-CNCR2820471233&gt;3.0.CO;2-G; PERERA DR, 1970, J AMER MED ASSOC, V214, P1074, DOI 10.1001/jama.214.6.1074; PETERS SG, 1987, AM J MED, V82, P73, DOI 10.1016/0002-9343(87)90380-9; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; ROSEN P, 1972, AM J MED, V53, P428, DOI 10.1016/0002-9343(72)90138-6; ROSEN PP, 1975, AM J MED, V58, P794, DOI 10.1016/0002-9343(75)90634-8; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; RUSKIN J, 1967, J AMER MED ASSOC, V202, P1070, DOI 10.1001/jama.202.12.1070; SANTIAGODELPIN EA, 1988, TRANSPLANT P, V20, P462; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SEDAGHATIAN MR, 1972, CANCER-AM CANCER SOC, V29, P772, DOI 10.1002/1097-0142(197203)29:3<772::AID-CNCR2820290333>3.0.CO;2-K; SELIK RM, 1987, AIDS, V1, P175; SINGER C, 1979, AM J MED, V66, P110, DOI 10.1016/0002-9343(79)90490-X; SINGER C, 1975, ANN INTERN MED, V82, P772, DOI 10.7326/0003-4819-82-6-722; TALSETH T, 1988, TRANSPLANT P, V20, P400; VOGEL CL, 1968, ANN INTERN MED, V68, P97, DOI 10.7326/0003-4819-68-1-97; WALLIS PJW, 1989, ANN RHEUM DIS, V48, P247, DOI 10.1136/ard.48.3.247; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WALZER PD, 1977, SCIENCE, V197, P177, DOI 10.1126/science.301657; WALZER PD, 1991, NEW ENGL J MED, V324, P263, DOI 10.1056/NEJM199101243240411; WALZER PD, 1973, J PEDIATR-US, V82, P416, DOI 10.1016/S0022-3476(73)80114-3; WATANABE JM, 1965, J AMER MED ASSOC, V193, P685, DOI 10.1001/jama.1965.03090080047017; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001	67	232	239	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					832	837		10.1001/jama.267.6.832	http://dx.doi.org/10.1001/jama.267.6.832			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732656				2022-12-24	WOS:A1992HC48400029
J	ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y				ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y			CHARACTERIZATION OF CDNA FOR THE LARGE SUBUNIT OF THE TRANSCRIPTION INITIATION-FACTOR TFIIF	NATURE			English	Article							RNA POLYMERASE-II; ACTIVATOR; SEQUENCES; GENE	AT least six chromatographically resolvable general transcription factors may participate in accurate initiation by RNA polymerase II in HeLa cell-derived systems 1-3. TFIIF (also termed FC, RAP30/74 and beta/gamma) can bind directly to RNA polymerase II in solution 4-6 and decrease the affinity of RNA polymerase II for nonspecific DNA 7. From studies on the kinetics of transcription initiation 1, on the composition of transcription initiation complexes fractionated by acrylamide gel electrophoresis 8, and on template competition experiments 9, TFIIF is known to act at an intermediate stage in initiation complex formation. It acts after TFIID firmly associates with DNA, but coincidentally with or immediately after RNA polymerase II binding to DNA, and before the recruitment of factor TFIIE. TFIIF may 6 or may not 4,5 have DNA helicase activity. The small subunit (RAP30) of TFIIF has been cloned 6 and shows some amino-acid sequence homology to bacterial-sigma-factors. We have partially sequenced the RAP74 protein from purified HeLa cells, cloned its complementary DNA and shown that its translation product can interact with RAP30 in vitro as well as in vivo. The cDNA predicts an amino-acid sequence that lacks obvious DNA or RNA helicase motifs. It has regions rich in charged amino acids, including segments containing a higher content of acidic amino acids than are found in strong transcriptional activators such as VP16 (ref. 10).	YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510; TOKYO MED & DENT UNIV,MED RES INST,DEPT MED,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOLEC GENET,BUNKYO KU,TOKYO 113,JAPAN	Yale University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BURTOWSKI S, 1989, CELL, V56, P549; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; FLORES O, 1990, J BIOL CHEM, V265, P5629; GANGULY S, 1989, P NATL ACAD SCI USA, V86, P5247, DOI 10.1073/pnas.86.14.5247; HORIKOSHI M, 1991, NUCLEIC ACIDS RES, V19, P5436, DOI 10.1093/nar/19.19.5436; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1989, P NATL ACAD SCI USA, V86, P6106, DOI 10.1073/pnas.86.16.6106; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9159; SWAROOP A, 1988, NUCLEIC ACIDS RES, V16, P8739, DOI 10.1093/nar/16.17.8739; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VASAVADA H, IN PRESS P NATN ACAD	19	73	74	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					461	464		10.1038/355461a0	http://dx.doi.org/10.1038/355461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734283				2022-12-24	WOS:A1992HB53000074
J	MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C				MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C			TYPE-III RESTRICTION ENZYMES NEED 2 INVERSELY ORIENTED RECOGNITION SITES FOR DNA CLEAVAGE	NATURE			English	Article							BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; ENDONUCLEASE	TYPE III restriction/modification enzymes recognize short, non-palindromic sequences that can be methylated on only one strand, with the paradoxical consequence that during replication of what is in effect hemimethylated DNA totally unmodified sites arise 1. Why the unmodified sites are not subject to suicidal restriction was not clear. Here we show that restriction requires two unmodified recognition sites that can be separated by different distances but which must be in inverse orientation. All of the unmodified sites in newly replicated DNA are of course in the same orientation, which explains why they are not restricted. This result may be of relevance to other manifestations of anisotropy in double-stranded DNA, such as genetic imprinting 2.	UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; HUMBOLDT UNIV BERLIN,SCH MED CHARITE,INST VIROL,O-1040 BERLIN,GERMANY	University of Basel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Meisel, Andreas/0000-0001-7233-5342				BICKLE TA, 1983, NUCLEASES, P85; HADI SM, 1979, J MOL BIOL, V134, P655, DOI 10.1016/0022-2836(79)90372-3; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KUGER DH, 1990, NUCLEIC ACID METHYLA, P113; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; REISER J, 1977, J BIOL CHEM, V252, P451; Sambrook J., 1989, MOL CLONING LAB MANU; SCHROEDER C, 1986, GENE, V45, P77, DOI 10.1016/0378-1119(86)90134-4; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1	12	123	127	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					467	469		10.1038/355467a0	http://dx.doi.org/10.1038/355467a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734285				2022-12-24	WOS:A1992HB53000076
J	DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR				DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR			IMMUNIZATION OF HU-PBL-SCID MICE AND THE RESCUE OF HUMAN MONOCLONAL FAB FRAGMENTS THROUGH COMBINATORIAL LIBRARIES	NATURE			English	Article							HEPATITIS-B VIRUS; SEVERE COMBINED IMMUNODEFICIENCY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ANTIBODY-PRODUCTION; LYMPHOCYTES; ANTIGEN; EXPRESSION; GENERATION; MOUSE	ANTIBODIES are usually prepared from recently boosted animals and reflect ongoing immune responses 1-6. In humans, this is restrictive as ethical constraints generally prevent antigen-boosting. Therefore the rich memory compartment of human antibody responses remains largely untapped 7. Severe combined immune deficiency (SCID) mice 8 populated with human cells 9-11 allow the stimulation of human antibody memory without the usual constraints. Here we show how peripheral blood lymphocytes can be stimulated by antigen to produce large secondary responses after transfer to SCID mice. Specific monoclonal human Fab fragments can then be isolated from the mice by repertoire cloning even when the human donor's last contact with antigen was more than 17 years ago.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; UNIV SHEFFIELD, KREBS INST, DEPT MOLEC BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; University of Sheffield	DUCHOSAL, MA (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Thornton, George/0000-0002-8744-4987				BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BURTON DR, 1991, TRENDS BIOTECHNOL, V9, P169, DOI 10.1016/0167-7799(91)90055-M; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Hansen T. H., 1989, Fundamental immunology., P445; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JAMES K, 1987, J IMMUNOL METHODS, V100, P5, DOI 10.1016/0022-1759(87)90170-0; KRAMS SM, 1989, J EXP MED, V170, P1919, DOI 10.1084/jem.170.6.1919; LERNER RA, 1991, P NATL ACAD SCI USA, V88, P9705, DOI 10.1073/pnas.88.21.9705; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SEPPALA IJT, 1984, EUR J IMMUNOL, V14, P868, DOI 10.1002/eji.1830140918; STAHL S, 1982, P NATL ACAD SCI-BIOL, V79, P1606, DOI 10.1073/pnas.79.5.1606; TIGHE H, 1990, EUR J IMMUNOL, V20, P1843, DOI 10.1002/eji.1830200832; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0; WILLIAMSON RA, 1991, BIOCHEM J, V277, P561, DOI 10.1042/bj2770561; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	30	139	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					258	262		10.1038/355258a0	http://dx.doi.org/10.1038/355258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731222				2022-12-24	WOS:A1992GZ69400070
J	MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD				MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD			THE FREQUENCY OF FAMILIAL DILATED CARDIOMYOPATHY IN A SERIES OF PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; POPULATION; HEART; EPIDEMIOLOGY; FEATURES; HISTORY; ADULT	Background. Dilated cardiomyopathy is characterized by an increase in ventricular size and impairment of ventricular function. Most cases are believed to be sporadic, and familial dilated cardiomyopathy is usually considered to be a rare and distinct disorder. We studied the proportion of cases of idiopathic dilated cardiomyopathy that were familial in a large sequential series of patients whose first-degree relatives were investigated regardless of whether these relatives had cardiac symptoms. Methods. We studied the relatives of 59 index patients with idiopathic dilated cardiomyopathy by obtaining a family history and performing a physical examination, electrocardiography, and two-dimensional, M-mode, and Doppler echocardiography. A total of 315 relatives were examined. Results. Eighteen relatives from 12 families were shown to have dilated cardiomyopathy. Thus, 12 of the 59 index patients (20.3 percent) had familial disease. There was no difference in age, sex, severity of disease, exposure to selected environmental factors, or electrocardiographic or echocardiographic features between the index patients with familial disease and those with nonfamilial disease. A noteworthy finding was that 22 of 240 healthy relatives (9.2 percent) with normal ejection fractions had increased left ventricular diameters during systole or diastole (or both), as compared with 2 of 112 healthy control subjects (1.8 percent) who were studied separately. Conclusions. Dilated cardiomyopathy was found to be familial in at least one in five of the patients in this study, a considerably higher percentage than in previous reports. This finding has important implications for family screening and provides direction for further investigation into the causes and natural history of dilated cardiomyopathy.	MAYO CLIN & MAYO FDN, DEPT PEDIAT, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL, CARDIOL SECT, ROCHESTER, MN 55905 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MICHELS, VV (corresponding author), MAYO CLIN & MAYO FDN, DEPT MED GENET, ROCHESTER, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036879] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; ARETZ HT, 1986, MED CLIN N AM, V70, P1215; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COUGHLIN SS, 1990, AM J EPIDEMIOL, V131, P48, DOI 10.1093/oxfordjournals.aje.a115484; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; FRAGOLA PV, 1988, AM HEART J, V115, P912, DOI 10.1016/0002-8703(88)90900-3; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; HONEY M, 1986, BRIT HEART J, V55, P114; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KEREN A, 1985, CIRCULATION, V72, P302, DOI 10.1161/01.CIR.72.2.302; KHANDHERIA BK, 1986, MAYO CLIN PROC, V61, P623, DOI 10.1016/S0025-6196(12)62026-6; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P165; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; NISHIMURA RA, 1985, MAYO CLIN PROC, V60, P321, DOI 10.1016/S0025-6196(12)60540-0; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PERRAULT H, 1982, INT J SPORTS MED, V3, P141, DOI 10.1055/s-2008-1026077; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; SCHMITZ A, 1983, CAN J AGR ECON, V31, P135, DOI 10.1111/j.1744-7976.1983.tb01193.x; SUGRUE DD, 1989, BRIT HEART J, V61, P88; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; URIE PM, 1988, AM J CARDIOL, V62, P325, DOI 10.1016/0002-9149(88)90238-X; VALANTINE HA, 1989, AM J CARDIOL, V63, P959, DOI 10.1016/0002-9149(89)90148-3	27	509	522	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					77	82		10.1056/NEJM199201093260201	http://dx.doi.org/10.1056/NEJM199201093260201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727235				2022-12-24	WOS:A1992GY04500001
J	HEBELL, T; AHEARN, JM; FEARON, DT				HEBELL, T; AHEARN, JM; FEARON, DT			SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B	SCIENCE			English	Article							EPSTEIN-BARR-VIRUS; MONOCLONAL-ANTIBODY; CR-2 CD21; PROLIFERATION; BINDING; C3D; DEFICIENCIES; ACTIVATION; INVIVO; CELLS	The CD19-CR2 complex of B lymphocytes contains proteins that participate in two host-defense systems, the immune and complement systems. The ligand for the subunit of the immune system, CD19, is not known, but the complement receptor subunit, CR2 (CD21), binds activation fragments of the C3 component of the complement system and may mediate immunopotentiating effects of complement. A recombinant, soluble CR2 was prepared by fusing the C3-binding region of the receptor to immunoglobulin G1 (IgG1). The (CR2)2-IgG1 chimera competed with cellular CR2 for C3 binding and suppressed the antibody response to a T cell-dependent antigen when administered to mice at the time of immunization. This inhibitory effect of (CR2)2-IgG1 demonstrates the B cell-activating function of the CD19-CR2 complex and suggests a new method for humoral immunosuppression.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-22833, AI-28191] Funding Source: Medline; NIGMS NIH HHS [GM-43803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028191, R01AI022833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BIRD P, 1988, EUR J IMMUNOL, V18, P1217, DOI 10.1002/eji.1830180811; BOTTGER EC, 1985, J IMMUNOL, V135, P4100; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARTER R, UNPUB; CARTER RH, 1989, J IMMUNOL, V143, P1755; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; COULIE PG, 1985, EUR J IMMUNOL, V15, P793, DOI 10.1002/eji.1830150810; FINGEROTH JD, 1989, IMMUNOL LETT, V21, P291, DOI 10.1016/0165-2478(89)90022-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1984, J IMMUNOL METHODS, V68, P193, DOI 10.1016/0022-1759(84)90150-9; JACKSON CG, 1979, NEW ENGL J MED, V300, P1124, DOI 10.1056/NEJM197905173002002; KALLI KR, 1991, J IMMUNOL, V147, P590; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MARTINELLI GP, 1978, J IMMUNOL, V121, P2043; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MOORE MD, 1989, J BIOL CHEM, V264, P20576; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047	30	232	248	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1991	254	5028					102	105		10.1126/science.1718035	http://dx.doi.org/10.1126/science.1718035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718035				2022-12-24	WOS:A1991GH60500038
J	HALL, DH; HEDGECOCK, EM				HALL, DH; HEDGECOCK, EM			KINESIN-RELATED GENE UNC-104 IS REQUIRED FOR AXONAL-TRANSPORT OF SYNAPTIC VESICLES IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTION; CELL; MIGRATIONS; EXPRESSION; SYNAPSIN; NEURONS; MUTANTS; GROWTH	unc-104 encodes a novel kinesin paralog that may act as a microtubule-based motor in the nervous system. Neuronal cell lineages and axonogenesis are normal in unc-104 null mutants, but axons have few synaptic vesicles and make only a few small synapses. By contrast, neuron cell bodies have surfeits of similar vesicles tethered together within the cytoplasm. Based on behavioral and cellular phenotypes, we suggest that UNC-104 is a neuron-specific motor used for anterograde translocation of synaptic vesicles along axonal microtubules. Other membrane-bounded organelles are transported normally.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	HALL, DH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026295, R37NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295, NS07512] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHENG TPO, 1988, J NEUROSCI, V8, P3190; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; HALL DH, 1991, J NEUROSCI, V11, P1; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MORI I, 1988, GENETICS, V120, P397; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROGALSKI TM, 1988, GENETICS, V118, P61; ROSE M, 1991, GUIDE CYTOSKELETAL S; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHUBERT D, 1991, TRENDS NEUROSCI, V14, P127, DOI 10.1016/0166-2236(91)90078-9; SIGURDSON DC, 1984, GENETICS, V108, P331; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS JH, 1990, GENETICS, V124, P855; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VENOLIA L, 1990, GENETICS, V126, P345; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; [No title captured]	43	441	449	2	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					837	847		10.1016/0092-8674(91)90391-B	http://dx.doi.org/10.1016/0092-8674(91)90391-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710172				2022-12-24	WOS:A1991FP51600014
J	SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM				SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM			ENDOTHELIN IMMUNOREACTIVITY OF AIRWAY EPITHELIUM IN ASTHMATIC-PATIENTS	LANCET			English	Article							SMOOTH-MUSCLE CELLS; VASOCONSTRICTOR PEPTIDE; VASOACTIVE PEPTIDE; GUINEA-PIG	There is extensive pharmacological and physiological evidence that endothelin-1 influences airway calibre. In mammals, endothelin receptors occur on airway smooth muscle, local storage and release of the peptide have been demonstrated, and inhalation of endothelin-1 induces bronchoconstriction. To investigate the relation between endothelins and asthma the expression of this peptide in endobronchial biopsy specimens was examined immunohistochemically with an antiserum against endothelin-1. Biopsy specimens from 17 asthmatic patients and 11 atopic and non-atopic healthy controls revealed striking differences, with endothelin expression being evident in airways epithelium and vascular endothelium in 11 of the 17 asthmatic patients but in only 1 of 11 controls. These results suggest that endothelins may play a part in the exaggerated bronchomotor tone of asthma.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	SPRINGALL, DR (corresponding author), ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND.			Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612				BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; CARDELL LO, 1990, ACTA PHYSIOL SCAND, V139, P103, DOI 10.1111/j.1748-1716.1990.tb08902.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSKA T, 1989, FEBS LETT, V249, P42; LAGENTE V, 1989, BIOCHEM BIOPH RES CO, V158, P625, DOI 10.1016/0006-291X(89)92767-8; MAGGI CA, 1989, EUR J PHARMACOL, V160, P179; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; NAGASE T, 1990, BIOCHEM BIOPH RES CO, V168, P485, DOI 10.1016/0006-291X(90)92347-3; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NOMURA A, 1989, LANCET, V2, P747; Pepys J., 1975, BR J HOSP MED, V14, P412; POEER RF, 1989, J CARDIOVASC PHARM, V13, pS50; ROCHE WR, 1989, LANCET, V1, P520; ROZENGURT N, 1990, J PATHOL, V160, P5, DOI 10.1002/path.1711600104; SAKATA K, 1989, BRIT J PHARMACOL, V98, P483, DOI 10.1111/j.1476-5381.1989.tb12621.x; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SPRINGALL DR, 1990, AM REV RESPIR DIS, V141, P1538, DOI 10.1164/ajrccm/141.6.1538; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; SUNNERGREN KP, 1990, MOL CELL ENDOCRINOL, V68, P7; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TURNER NC, 1989, BRIT J PHARMACOL, V98, P361, DOI 10.1111/j.1476-5381.1989.tb12605.x; WATANABE A, 1990, 13TH WORLD C ASTHM G, P4; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	30	280	282	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					697	701		10.1016/0140-6736(91)90279-X	http://dx.doi.org/10.1016/0140-6736(91)90279-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706044				2022-12-24	WOS:A1991FD36700009
J	ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A				ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A			ENHANCEMENT OF T-CELL RESPONSIVENESS BY THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD4 RECEPTOR; SURFACE-ANTIGENS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; EXPRESSION; DOMAIN; LINES	LYMPHOCYTE-specific tyrosine protein kinase p56lck is physically associated with CD4 and CD8 T-cell surface molecules, suggesting that it may transduce CD4/CD8-triggered tyrosine phosphorylation signals during antigen stimulation 1,2. Indeed, antibody-mediated aggregation of CD4 (to mimic interaction with its ligand, major histocompatibility complex (MHC) class II molecules), rapidly elevates the kinase activity of p56lck (refs 3, 4) and is associated with marked changes in tyrosine protein phosphorylation 4-6. Genetic analyses suggest that the interaction of CD4/CD8 with p56lck results in a positive signal during antigen-induced T-cell activation 7-10. To evaluate directly the role of p56lck in T-cell activation, we introduced a constitutively activated form of Lck protein (tyrosine 505 to phenylalanine 505 mutant; refs 11-13) in a CD4-negative, MHC-class II restricted mouse T-cell hybridoma 14. We report here that, as for transfection of CD4 10,15,16, expression of the Lck mutant enhanced T-lymphocyte responsiveness. The finding provides direct evidence that p56lck can positively regulate T-cell functions and that it mediates at least some of the effects of CD4 and CD8 on T-cell activation.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA; STANFORD UNIV,MED CTR,DEPT MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305	McGill University; McGill University; Stanford University			Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, COLD SPRING HARB SYM, V54, P649; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WILDE DB, 1983, J IMMUNOL, V131, P2178; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	37	315	321	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					62	66		10.1038/350062a0	http://dx.doi.org/10.1038/350062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706070				2022-12-24	WOS:A1991FA69300065
J	STANWORTH, DR; JONES, VM; LEWIN, IV; NAYYAR, S				STANWORTH, DR; JONES, VM; LEWIN, IV; NAYYAR, S			ALLERGY TREATMENT WITH A PEPTIDE VACCINE	LANCET			English	Article											STANWORTH, DR (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,RHEUMATOL & ALLERGY RES UNIT,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BURT DS, 1986, MOL IMMUNOL, V23, P181, DOI 10.1016/0161-5890(86)90041-6; COOPER PH, 1976, METHOD CELL BIOL, P365; JASANI B, 1979, J IMMUNOL METHODS, V30, P55, DOI 10.1016/0022-1759(79)90273-4; Noon L, 1911, LANCET, V1, P1572; SHEPPARD RC, 1986, SCI TOOLS, V33, P9; STANWORTH DR, 1984, MOL IMMUNOL, V21, P1183, DOI 10.1016/0161-5890(84)90008-7; STANWORTH DR, IN PRESS MOL IMMUNOL; 1989, LANCET, V1, P259	9	48	59	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 24	1990	336	8726					1279	1281		10.1016/0140-6736(90)92963-I	http://dx.doi.org/10.1016/0140-6736(90)92963-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ943	1700248				2022-12-24	WOS:A1990EJ94300004
J	KONARSKA, MM; SHARP, PA				KONARSKA, MM; SHARP, PA			STRUCTURE OF RNAS REPLICATED BY THE DNA-DEPENDENT T7 RNA-POLYMERASE	CELL			English	Article									MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Massachusetts Institute of Technology (MIT); Rockefeller University	KONARSKA, MM (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Konarska, Maria M./AAT-2572-2021	Konarska, Maria M./0000-0001-9235-1702	NCI NIH HHS [CA14051] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARON MH, 1982, J BIOL CHEM, V257, P2351; BAUSCH JN, 1983, J BIOL CHEM, V258, P1978; BIEBRICH.CK, 1973, P NATL ACAD SCI USA, V70, P934, DOI 10.1073/pnas.70.3.934; CAVALIERSMITH T, 1987, COLD SPRING HARB SYM, V52, P805, DOI 10.1101/SQB.1987.052.01.089; CECH TR, 1988, HARVEY LECT, V82, P123; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GUERRIERTAKADA C, 1988, CELL, V53, P267, DOI 10.1016/0092-8674(88)90388-1; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HAENNI AL, 1982, PROG NUCLEIC ACID RE, V27, P85, DOI 10.1016/S0079-6603(08)60598-X; HAENNI AL, 1973, NATURE-NEW BIOL, V241, P166, DOI 10.1038/newbio241166a0; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANE CM, 1985, BIOCHEMISTRY-US, V24, P2254, DOI 10.1021/bi00330a020; KOHL RJ, 1974, J GEN VIROL, V25, P257, DOI 10.1099/0022-1317-25-2-257; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; Maniatis T., 1982, MOL CLONING; MARSH LE, 1987, COLD SPRING HARB SYM, V52, P331, DOI 10.1101/SQB.1987.052.01.038; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MINKLEY EG, 1973, J MOL BIOL, V77, P255, DOI 10.1016/0022-2836(73)90335-5; PINCK M, 1978, VIROLOGY, V88, P281, DOI 10.1016/0042-6822(78)90285-4; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; PROCHIANTZ A, 1973, NATURE-NEW BIOL, V241, P168, DOI 10.1038/newbio241168a0; RACKWITZ HR, 1981, NATURE, V291, P297, DOI 10.1038/291297a0; Randerath K, 1980, Methods Enzymol, V65, P638; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; SEMANCIK JS, 1984, P NATL ACAD SCI-BIOL, V81, P4429, DOI 10.1073/pnas.81.14.4429; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR JM, 1990, CELL, V61, P371, DOI 10.1016/0092-8674(90)90516-H; VANBELKUM A, 1987, BIOCHEMISTRY-US, V26, P1144, DOI 10.1021/bi00378a024; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383	43	51	80	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	1990	63	3					609	618		10.1016/0092-8674(90)90456-O	http://dx.doi.org/10.1016/0092-8674(90)90456-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699668				2022-12-24	WOS:A1990EG68700018
J	HUANG, E; NOCKA, K; BEIER, DR; CHU, TY; BUCK, J; LAHM, HW; WELLNER, D; LEDER, P; BESMER, P				HUANG, E; NOCKA, K; BEIER, DR; CHU, TY; BUCK, J; LAHM, HW; WELLNER, D; LEDER, P; BESMER, P			THE HEMATOPOIETIC GROWTH FACTOR-KL IS ENCODED BY THE SI-LOCUS AND IS THE LIGAND OF THE C-KIT RECEPTOR, THE GENE-PRODUCT OF THE W-LOCUS	CELL			English	Article									CORNELL UNIV,SCH MED,DEPT BIOCHEM,NEW YORK,NY 10021; SLOAN KETTERING MEM CANC CTR,IMMUNOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; F HOFFMANN LAROCHE LTD,CH-4005 BASEL,SWITZERLAND	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	HUANG, E (corresponding author), SLOAN KETTERING MEM CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.		Huang, Eric J./AAH-7997-2019	Huang, Eric J./0000-0002-5381-3801; Chu, Tang-Yuan/0000-0003-2717-2681	NATIONAL CANCER INSTITUTE [R37CA032926, P01CA016599, R01CA032926] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32926, CA 16599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BARKER JE, 1988, J CELL PHYSIOL, V135, P533, DOI 10.1002/jcp.1041350324; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUI DHK, 1978, BLOOD, V51, P539; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1988, J CELL PHYSIOL, V134, P78, DOI 10.1002/jcp.1041340109; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; GREGORY CJ, 1978, BLOOD, V51, P527; HARRISON DE, 1980, BLOOD, V55, P77; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1989, BIOESSAYS, V10, P193, DOI 10.1002/bies.950100604; KITAMURA Y, 1979, BLOOD, V53, P492; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MANOVA K, 1990, IN PRESS DEVELOPMENT; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCCULLOCH EA, 1970, REGULATION HEMATOPOI, P649; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARK LS, 1986, J BIOL CHEM, V261, P4177; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5206; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1970, REGULATION HEMATOPOI, P649; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silvers W.K., 1979, COAT COLORS MICE, P206; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TSUJI K, 1990, BLOOD, V75, P421; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUNG YP, 1982, J IMMUNOL, V129, P1256; YUNG YP, 1981, J IMMUNOL, V127, P794	57	1160	1204	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 5	1990	63	1					225	233		10.1016/0092-8674(90)90303-V	http://dx.doi.org/10.1016/0092-8674(90)90303-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EB461	1698557				2022-12-24	WOS:A1990EB46100023
J	WEBB, DSA; SHIMIZU, Y; VANSEVENTER, GA; SHAW, S; GERRARD, TL				WEBB, DSA; SHIMIZU, Y; VANSEVENTER, GA; SHAW, S; GERRARD, TL			LFA-3, CD44, AND CD45 - PHYSIOLOGICAL TRIGGERS OF HUMAN MONOCYTE TNF AND IL-1 RELEASE	SCIENCE			English	Article									US FDA, CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA; NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Shimizu, Yoji/0000-0001-9760-0288				BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHU E, 1984, J IMMUNOL, V132, P1311; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; DENNING SM, 1990, J IMMUNOL, V144, P7; DONNELLY RP, 1990, J IMMUNOL, V145, P569; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; GERRARD TL, 1987, J IMMUNOL, V138, P2535; GILBERT CW, 1988, J IMMUNOL, V140, P2821; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HALE LP, 1989, J IMMUNOL, V143, P3944; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HUET S, 1989, J IMMUNOL, V143, P798; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JANICKE R, 1990, J IMMUNOL, V144, P1144; LE JM, 1987, LAB INVEST, V56, P234; LEVIN J, 1970, J LAB CLIN MED, V75, P903; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAW S, 1988, CURR OPIN IMMUNOL, V1, P92, DOI 10.1016/0952-7915(88)90058-1; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; TIEFENTHALER G, 1987, EUR J IMMUNOL, V17, P1847, DOI 10.1002/eji.1830171227; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WEBB DJ, UNPUB; WEBB DSA, 1990, J IMMUNOL, V144, P3643; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT SD, 1988, J CELL SCI, P99	38	319	330	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 14	1990	249	4974					1295	1297		10.1126/science.1697984	http://dx.doi.org/10.1126/science.1697984			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DY351	1697984				2022-12-24	WOS:A1990DY35100038
J	HOLLENBECK, PJ; SWANSON, JA				HOLLENBECK, PJ; SWANSON, JA			RADIAL EXTENSION OF MACROPHAGE TUBULAR LYSOSOMES SUPPORTED BY KINESIN	NATURE			English	Article											HOLLENBECK, PJ (corresponding author), HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Swanson, Joel A/P-4362-2014	Swanson, Joel A/0000-0003-0900-8212				BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HOLLENBECK PJ, 1988, PROTOPLASMA, V145, P145, DOI 10.1007/BF01349352; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOLLENBECK PJ, 1984, J CELL BIOL, V99, P1251, DOI 10.1083/jcb.99.4.1251; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SHEETZ MP, 1987, BIOESSAYS, V7, P165, DOI 10.1002/bies.950070406; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1989, J CELL SCI, V94, P135; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	22	245	245	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 30	1990	346	6287					864	866		10.1038/346864a0	http://dx.doi.org/10.1038/346864a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW488	1697403				2022-12-24	WOS:A1990DW48800062
J	LU, X; LANE, EB				LU, X; LANE, EB			RETROVIRUS-MEDIATED TRANSGENIC KERATIN EXPRESSION IN CULTURED FIBROBLASTS - SPECIFIC DOMAIN FUNCTIONS IN KERATIN STABILIZATION AND FILAMENT FORMATION	CELL			English	Article											LU, X (corresponding author), IMPERIAL COUNCIL RES FUND, CLARE HALL LABS, CELL STRUCT LAB, BLANCHE LANE, S MIMMS, POTTERS BAR EN6 3LD, HERTS, ENGLAND.			Lu, Xin/0000-0002-6587-1152				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; AUBIN JE, 1980, EXP CELL RES, V129, P149, DOI 10.1016/0014-4827(80)90340-7; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BARTEK J, 1985, J CELL SCI, V75, P17; BOWDEN PE, 1984, J SUBMICR CYTOL PATH, V16, P21; BROWN AMC, 1987, DNA CLONING, V3, P189; DARMON M, 1984, EMBO J, V3, P961, DOI 10.1002/j.1460-2075.1984.tb01914.x; DENK H, 1987, EXP CELL RES, V173, P137, DOI 10.1016/0014-4827(87)90339-9; DOMENJOUD L, 1988, EXP CELL RES, V179, P352, DOI 10.1016/0014-4827(88)90274-1; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; FERRETTI P, 1989, DEV BIOL, V133, P415, DOI 10.1016/0012-1606(89)90045-6; GAO Z, 1988, J ORAL PATHOL MED, V17, P178, DOI 10.1111/j.1600-0714.1988.tb01521.x; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GIUDICE GJ, 1987, CELL, V48, P453, DOI 10.1016/0092-8674(87)90196-6; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HATZFELD M, 1987, J MOL BIOL, V197, P237, DOI 10.1016/0022-2836(87)90122-7; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; JAHN L, 1987, DIFFERENTIATION, V36, P234, DOI 10.1111/j.1432-0436.1987.tb00198.x; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KARSTEN U, 1985, EUR J CANCER CLIN ON, V21, P733, DOI 10.1016/0277-5379(85)90271-8; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KLYMKOWSKY MW, 1983, J CELL BIOL, V96, P494, DOI 10.1083/jcb.96.2.494; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KREIS TE, 1983, CELL, V32, P1125, DOI 10.1016/0092-8674(83)90296-9; KRIMPENFORT PJ, 1988, EMBO J, V7, P941, DOI 10.1002/j.1460-2075.1988.tb02899.x; KUBOTA Y, 1981, IN VITRO, V17, P965; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LANE EB, 1981, COLD SPRING HARB SYM, V46, P387; LAUEROVA L, 1988, HYBRIDOMA, V7, P495, DOI 10.1089/hyb.1988.7.495; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; PURKIS PE, 1990, IN PRESS J CELL SCI; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; QUINLAN RA, 1989, J CELL SCI, V93, P71; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; RAMAEKERS F, 1987, EXP CELL RES, V170, P235, DOI 10.1016/0014-4827(87)90133-9; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SMEDTS F, 1990, AM J PATHOL, V136, P657; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1985, NATURE, V316, P767, DOI 10.1038/316767a0; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1985, ANN NY ACAD SCI, V455, P451, DOI 10.1111/j.1749-6632.1985.tb50428.x; STEVEN AC, 1985, ANN NY ACAD SCI, V455, P371, DOI 10.1111/j.1749-6632.1985.tb50423.x; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; SUNDSTROM BE, 1989, J HISTOCHEM CYTOCHEM, V37, P1845, DOI 10.1177/37.12.2479674; TOLLE HG, 1985, EUR J CELL BIOL, V38, P234; TRAUB P, 1983, J CELL SCI, V63, P43; VANDENHEUVEL RMM, 1987, J CELL SCI, V88, P475; WASEEM A, 1990, New Biologist, V2, P464; WASEEM A, 1990, GENOMICS, V7, P188, DOI 10.1016/0888-7543(90)90540-B; WILLARD M, 1981, J CELL BIOL, V89, P198, DOI 10.1083/jcb.89.2.198	75	168	168	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 24	1990	62	4					681	696		10.1016/0092-8674(90)90114-T	http://dx.doi.org/10.1016/0092-8674(90)90114-T			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DW306	1696851				2022-12-24	WOS:A1990DW30600009
J	RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL				RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL			USING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS TO CONTROL VARICEAL BLEEDING BEFORE LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article						PORTOSYSTEMIC SHUNT, SURGICAL; LIVER TRANSPLANTATION; ESOPHAGEAL AND GASTRIC VARICES; HEMORRHAGE, GASTROINTESTINAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT	PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; HEMORRHAGE; STENTS; MANAGEMENT	Objective: To determine the safety and efficacy of transjugular intrahepatic portosystemic shunts (TIPS) in controlling bleeding from esophageal varices in patients awaiting liver transplantation. Design: Prospective, uncontrolled trial. Setting: University medical center with an active liver transplant program. Patients: Thirteen patients referred for liver transplantation with either active variceal hemorrhage or recurrent variceal hemorrhage despite sclerotherapy; four patients had been previously treated with surgical portosystemic shunts. Intervention: An intrahepatic portosystemic shunt created via a transjugular approach to the hepatic veins using expandable, flexible metallic stents. Measurements: Portal pressures before and after the creation of the shunt, the direction of portal blood flow at differing diameters of the shunts, procedure-related complications, and outcome in terms of survival, liver transplantation, and recurrent variceal bleeding. Main Results: The transjugular intrahepatic portosystemic shunt was placed successfully in 13 patients, and bleeding was controlled acutely in all 13. After the procedure, the mean portal pressure decreased from 34 +/- 8.9 cm H2O to 22.4 +/- 5.4 cm H2O (P < 0.001). No complications were associated with the procedure; however, two patients died of causes unrelated to the procedure. Seven patients subsequently underwent liver transplantation and are doing well, and three patients are being managed conservatively. Bleeding recurred in one patient 102 days after the procedure secondary to shunt occlusion caused by neointimal proliferation. Conclusion: Placement of a transjugular intrahepatic portosystemic shunt is apparently safe and effective therapy for variceal hemorrhage in patients referred for liver transplantation.			RING, EJ (corresponding author), UNIV CALIF SAN FRANCISCO, BOX 0628, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528				CELLO JP, 1984, NEW ENGL J MED, V311, P1589, DOI 10.1056/NEJM198412203112501; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; CRASS RA, 1989, AM J SURG, V157, P476, DOI 10.1016/0002-9610(89)90638-7; DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983; IWATSUKI S, 1988, SURGERY, V104, P697; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; ROBERTS JP, 1991, TRANSPLANTATION, V52, P160, DOI 10.1097/00007890-199107000-00036; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RYPINS EB, 1990, SURG CLIN N AM, V70, P395; SARFEH IJ, 1986, SURGERY, V100, P52; TURRION VS, 1991, TRANSPLANT P, V23, P1570; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; ZEMEL G, 1991, JAMA-J AM MED ASSOC, V266, P390, DOI 10.1001/jama.266.3.390	17	230	229	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					304	309		10.7326/0003-4819-116-4-304	http://dx.doi.org/10.7326/0003-4819-116-4-304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733385				2022-12-24	WOS:A1992HD54600006
J	WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH				WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH			TOWARD A DYNAMIC STRUCTURE OF DNA - COMPARISON OF THEORETICAL AND EXPERIMENTAL NOE INTENSITIES	SCIENCE			English	Article							DOUBLE HELIX; MOLECULAR-DYNAMICS; IMINO PROTONS; BASE-PAIR; KINETICS; EXCHANGE; D(CGCGAATTCGCG); SEQUENCE; GEOMETRY	Comparisons of experimental and calculated interproton nuclear Overhauser effect (NOE) buildup curves for duplex d(CGCGAATTCGCG)2 have been made. The calculated NOEs are based on molecular dynamics simulations including counterions and water and on the single-structure canonical A, B, and crystal forms. The calculated NOE effects include consideration of the motions of individual interproton vectors and the anisotropic tumbling of the DNA. The effects due to inclusion of anisotropic tumbling are much larger than those due to the local motion, and both improve the agreement between calculated and experimental results. The predictions based on the dynamical models agree significantly better with experiment than those based on either of the canonical forms or the crystal structure.			WITHKA, JM (corresponding author), WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008271, R37GM037909, R01GM037909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37909, 1T32 GM-08271] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON PH, 1990, PROG NUCL MAG RES SP, V22, P423, DOI 10.1016/0079-6565(90)80006-4; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DICKERSON RE, 1990, STRUCTURE METHOD, V3; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; GOCHIN M, 1990, BIOCHEMISTRY-US, V29, P11172, DOI 10.1021/bi00503a004; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; KONING TMG, 1991, BIOCHEMISTRY-US, V30, P3787, DOI 10.1021/bi00229a028; McCammon A. J., 1986, DYNAMICS PROTEINS NU; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; PARDI A, 1982, BIOCHEMISTRY-US, V21, P6567, DOI 10.1021/bi00268a038; PARDI A, 1982, BIOCHEMISTRY-US, V21, P4686, DOI 10.1021/bi00262a026; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; Saenger W., 1983, PRINCIPLES NUCL ACID; SRINIVASAN J, 1990, BIOPHYS J, V58, P533, DOI 10.1016/S0006-3495(90)82397-3; SWAMINATHAN S, 1991, J AM CHEM SOC, V113, P5027, DOI 10.1021/ja00013a043; Van Gunsteren W F, 1986, Ann N Y Acad Sci, V482, P287; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WITHKA JM, 1991, J AM CHEM SOC, V113, P5041, DOI 10.1021/ja00013a044; WITHKA JM, 1990, J MAGN RESON, V89, P386, DOI 10.1016/0022-2364(90)90246-6; WITHKA JM, 1991, P NATO ADV RES WORKS, P409; WITHKA JM, UNPUB; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	61	61	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					597	599		10.1126/science.1736362	http://dx.doi.org/10.1126/science.1736362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736362				2022-12-24	WOS:A1992HB53100043
J	MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA				MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA			ANGIOSCOPIC EVALUATION OF CORONARY-ARTERY THROMBI IN ACUTE CORONARY SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNSTABLE ANGINA-PECTORIS; PLACEBO-CONTROLLED TRIAL; TISSUE PLASMINOGEN-ACTIVATOR; ANGIOGRAPHIC MORPHOLOGY; INTRACORONARY THROMBUS; THROMBOLYTIC THERAPY; DOUBLE-BLIND; PATHOGENESIS; INFARCTION; DISEASE	Background. Disruption of an atherosclerotic plaque in a coronary artery followed by the formation of a thrombus is believed to be the cause of both unstable angina and acute myocardial infarction. Although thrombolytic therapy is efficacious in patients with acute myocardial infarction, for unknown reasons it is far less effective in patients with unstable angina. We postulated that there might be differences in the composition of the coronary-artery thrombi in unstable angina and acute myocardial infarction. Methods. To investigate the appearance of coronary-artery thrombi, we performed percutaneous transluminal coronary angioscopy in 15 patients with unstable angina and 16 with acute myocardial infarction. Angioscopy was performed within 48 hours after an episode of pain at rest in the patients with unstable angina and within 8 hours of onset in those with acute myocardial infarction. per Results. Angioscopy revealed coronary thrombi in all but two patients (one in each group). Of the 29 patients with thrombi, those with unstable angina were frequently observed to have grayish-white thrombi (10 of 14, 71 percent), but none were seen in the 15 patients with acute myocardial infarction (P < 0.01). By contrast, reddish thrombi were observed in all 15 patients with acute myocardial infarction who had thrombi, but in only 4 of the 14 patients with unstable angina and thrombi (P < 0.01). As assessed by coronary angiography, occlusive thrombi occurred frequently in patients with acute myocardial infarction (13 of 16 patients) but were not seen in any of the 15 patients with unstable angina (P < 0.01). Conclusions. Coronary-artery thrombi play an important part in the pathogenesis of unstable angina and acute myocardial infarction. However, the appearance of the thrombi is different in the two conditions, possibly reflecting differences in the composition or age of the thrombi or the presence or absence of blood flow in the artery. This difference may account for the contrasting results of thrombolytic therapy.	NATL DEF MED COLL,DEPT MED ENGN,TOKOROZAWA,SAITAMA 359,JAPAN; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,NEW YORK,NY 10029	National Defense Medical College - Japan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MIZUNO, K (corresponding author), NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN.							AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; AMBROSE JA, 1987, J AM COLL CARDIOL, V9, P1156, DOI 10.1016/S0735-1097(87)80321-2; AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; AMBROSE JA, 1989, J AM COLL CARDIOL, V13, P1661; ANDERSON JR, 1985, MUIRS TXB PATHOLOGY, P1012; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CAPONE G, 1985, AM J CARDIOL, V56, P403, DOI 10.1016/0002-9149(85)90875-6; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEZWAAN C, 1988, J AM COLL CARDIOL, V12, P301, DOI 10.1016/0735-1097(88)90398-1; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FORRESTER JS, 1987, CIRCULATION, V75, P505, DOI 10.1161/01.CIR.75.3.505; FREEMAN MR, 1989, CIRCULATION, V80, P17, DOI 10.1161/01.CIR.80.1.17; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOLD HK, 1987, CIRCULATION, V75, P1192, DOI 10.1161/01.CIR.75.6.1192; GOTOH K, 1988, CIRCULATION, V77, P526, DOI 10.1161/01.CIR.77.3.526; HOLMES DR, 1981, BRIT HEART J, V45, P411; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; Neri Serneri G G, 1990, Lancet, V335, P615, DOI 10.1016/0140-6736(90)90407-V; NERISERNERI GG, 1990, LANCET, V335, P868; NICKLAS JM, 1989, J AM COLL CARDIOL, V13, P434, DOI 10.1016/0735-1097(89)90524-X; PASTERNAK RC, 1988, HEART DISEASE TXB CA, V2, P1222; RAMEE SR, 1991, J AM COLL CARDIOL, V17, P100, DOI 10.1016/0735-1097(91)90710-Q; REHR R, 1989, J AM COLL CARDIOL, V14, P1429, DOI 10.1016/0735-1097(89)90376-8; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1987, CIRCULATION, V75, P156, DOI 10.1161/01.CIR.75.1.156; TOPOL EJ, 1988, AM J CARDIOL, V62, P368, DOI 10.1016/0002-9149(88)90960-5; UCHIDA Y, 1986, AM HEART J, V112, P691, DOI 10.1016/0002-8703(86)90462-X; VETROVEC GW, 1981, AM HEART J, V102, P1201; WILLIAMS DO, 1990, CIRCULATION, V82, P376, DOI 10.1161/01.CIR.82.2.376; YANAGIDA S, 1989, CIRCULATION S2, V80, P376	35	462	470	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					287	291		10.1056/NEJM199201303260502	http://dx.doi.org/10.1056/NEJM199201303260502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728732				2022-12-24	WOS:A1992HA99100002
J	WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C				WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C			QUALITY-OF-LIFE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - MEASUREMENT BY THE MEDICAL OUTCOMES STUDY INSTRUMENT	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; HIV INFECTIONS; OUTCOME ASSESSMENT (HEALTHY CARE); ACQUIRED IMMUNODEFICIENCY SYNDROME; HEALTH STATUS	AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; CARE	Objective: To assess the reliability and validity of the Medical Outcomes Study (MOS) Short Form Health Survey as an indicator for quality of life in patients infected with the human immunodeficiency virus (HIV). Design: Patient interview survey. Setting: The AIDS Health Services Program in seven sites: Newark and Jersey City, New Jersey; Nassau County, New York; Atlanta, Georgia; Dallas, Texas; Fort Lauderdale and Miami, Florida; New Orleans, Louisiana; and Seattle, Washington. Patients: Patients (520) with HIV infection receiving health services at one of the above sites. Measurements: All components of the MOS Short Form Health Survey were included in the interview. Minor modifications were made to adapt the survey to the particular circumstances of the study. Measured sociodemographic characteristics included age, sex, race, intravenous drug use, and education. Symptoms were assessed by closed-ended questions concerning memory, seizure, weakness or numbness, fever, chills, diaphoreses, dyspnea, diarrhea, and weight loss. Information on the frequency of symptoms was also collected. History of Pneumocystis carinii pneumonia and Kaposi sarcoma was noted. Main Results: The sociodemographic characteristics resemble those of patients with the acquired immunodeficiency syndrome (AIDS) reported to the Centers for Disease Control (CDC): mean age, 36; men, 89%; nonwhite, 31%; intravenous drug use, 34%. Neurologic symptoms (memory trouble, seizures, weakness or numbness) occurred in 71% of patients; constitutional symptoms (fever, chills, night sweats, weight loss) in 69%; dyspnea in 50%; and diarrhea in 47%. Although older age, female sex, nonwhite race, and intravenous drug use were associated with lower MOS scores in several areas, the strongest single or adjusted indicator of lower MOS scores was the presence of symptoms. Finally, patients with HIV infection had significantly lower scores than did previously reported patients with other chronic medical conditions (P < 0.001). Conclusions: The MOS survey is a reliable measure of quality of life for patients with HIV infection. These patients tend to have low scores, suggesting validity of the survey. The MOS survey is extremely sensitive to the effect of symptoms, which suggests that it might be useful as a quality-of-life indicator for AIDS clinical drug trails.			WACHTEL, T (corresponding author), RHODE ISL HOSP, DIV GEN INTERNAL MED, 593 EDDY ST, PROVIDENCE, RI 02903 USA.							BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BARKER S, 1990, LANCET, V335, P1045, DOI 10.1016/0140-6736(90)91117-S; BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHMAN J, DHHS PHS893447 PUB; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; MOR V, 1989, HEALTH AFFAIR, V8, P139, DOI 10.1377/hlthaff.8.4.139; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; PIETTE J, 1991, HEALTH SERV RES, V26, P75; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RAGSDALE D, 1990, NURS RES, V39, P355; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHROEDER SA, 1987, NEW ENGL J MED, V316, P160, DOI 10.1056/NEJM198701153160309; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; 1990, MMWR, V39, P81	26	283	286	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					129	137		10.7326/0003-4819-116-2-129	http://dx.doi.org/10.7326/0003-4819-116-2-129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727616				2022-12-24	WOS:A1992GZ35600005
J	PAN, T; GUTELL, RR; UHLENBECK, OC				PAN, T; GUTELL, RR; UHLENBECK, OC			FOLDING OF CIRCULARLY PERMUTED TRANSFER-RNAS	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; ESCHERICHIA-COLI; CLEAVAGES; SEQUENCE; ENZYME; INVIVO; ACID; GENE	All of the ribose-phosphate linkages in yeast tRNA(Phe) that could be cleaved without affecting the folding of the molecule have been determined in a single experiment. Circular permutation analysis subjects circular tRNA molecules to limited alkaline hydrolysis in order to generate one random break per molecule. Correctly folded tRNAs were identified by lead cleavage at neutral pH, a well-characterized reaction that requires proper folding of tRNA(Phe). Surprisingly, most of the circularly permuted tRNA molecules folded correctly. This result suggests that the tRNA folding motif could occur internally within other RNA sequences, and a computer search of Genbank entries has identified many examples of such motifs.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT MOLEC & CELLULAR DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM37552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BEHLEN LS, UNPUB; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DREHER TW, 1989, J MOL BIOL, V206, P425, DOI 10.1016/0022-2836(89)90491-9; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; GAUTHERET D, 1990, COMPUT APPL BIOSCI, V6, P325; GRAY MW, 1990, RIBOSOME, P589; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; KIM SH, 1978, TRANSFER RNA, P248; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, UNPUB; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P368, DOI DOI 10.1007/978-1-4612-5190-3_17; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WERNER C, 1976, BIOCHIM BIOPHYS ACTA, V432, P161, DOI 10.1016/0005-2787(76)90158-1; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	24	103	105	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1361	1364		10.1126/science.1720569	http://dx.doi.org/10.1126/science.1720569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720569				2022-12-24	WOS:A1991GR77700051
J	HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ				HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ			REGULATION OF TRANSENDOTHELIAL NEUTROPHIL MIGRATION BY ENDOGENOUS INTERLEUKIN-8	SCIENCE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ACTIVATING PEPTIDE NAP/IL-8; MGSA-GRO PROTEIN; MONOCLONAL-ANTIBODIES; POLYMORPHONUCLEAR LEUKOCYTES; BIOCHEMICAL-CHARACTERIZATION; RECOMBINANT EXPRESSION; BIOLOGICAL-ACTIVITIES; GENE-EXPRESSION	Movement of neutrophils from the bloodstream to inflamed tissue depends on the activation of both the neutrophil and the endothelial cell. Endothelial cells lining the postcapillary venule respond to proinflammatory mediators by expressing adhesion molecules and synthesizing a variety of neutrophil-activating factors. Endothelial cell production of a 77-amino acid variant of interleukin-8 (IL-8) was found to be a requirement for the invasion of neutrophils through a vessel wall model. IL-8 secreted by cytokine- or lipopolysaccharide-stimulated endothelial cells induced the rapid shedding of neutrophil lectin adhesion molecule-1, the up-regulation of leukocyte beta-2 integrins, and the attachment and transmigration of the neutrophils. Thus, endogenous endothelial IL-8 regulates transvenular traffic during acute inflammatory responses.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Todd, Robert/GWM-4486-2022		NATIONAL CANCER INSTITUTE [R01CA039064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39064] Funding Source: Medline; NHLBI NIH HHS [HL 28024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREVIARIO F, 1988, J IMMUNOL, V141, P3391; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11586; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FURIE MB, 1989, J IMMUNOL, V143, P3309; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUBER AM, UNPUB; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MOVAT HZ, 1987, J LAB CLIN MED, V110, P668; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SICA A, 1990, J IMMUNOL, V144, P3034; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STICHERLING M, 1989, J IMMUNOL, V143, P1628; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; TEDDER TF, 1990, J IMMUNOL, V144, P532; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WANG JM, 1987, IMMUNOLOGY, V60, P439; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	40	742	770	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					99	102		10.1126/science.1718038	http://dx.doi.org/10.1126/science.1718038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718038				2022-12-24	WOS:A1991GH60500037
J	SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V				SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V			A NOVEL CELL-SURFACE TRANS-SIALIDASE OF TRYPANOSOMA-CRUZI GENERATES A STAGE-SPECIFIC EPITOPE REQUIRED FOR INVASION OF MAMMALIAN-CELLS	CELL			English	Article							ALTERNATIVE COMPLEMENT PATHWAY; MONOCLONAL-ANTIBODIES; SIALYL-LEX; ACID; ADHESION; TRYPOMASTIGOTES; NEURAMINIDASE; RECOGNITION; FORMS; GLYCOSYLTRANSFERASES	When trypomastigotes of T. cruzi emerge from cells of the mammalian host, they contain little or no sialic acids on their surfaces. However, rapidly upon entering the circulation, they express a unique cell surface trans-sialidase activity. This enzyme specifically transfers alpha(2-3)-linked sialic acid from extrinsic host-derived macromolecules to parasite surface molecules, leading to the assembly of Ssp-3, a trypomastigote-specific epitope. The T. cruzi trans-sialidase does not utilize cytidine 5' monophospho-N-acetylneuraminic acid as a donor substrate, but readily transfers sialic acid from exogenously supplied alpha(2-3)-sialyllactose. Monoclonal antibodies that recognize sialic acid residues of Ssp-3 inhibit attachment of trypomastigotes to host cells, suggesting that the unusual trans-sialidase provides Ssp-3 with structural features required for target cell recognition.	NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; JOHNS HOPKINS UNIV,DEPT BIOL CHEM,BALTIMORE,MD 21218	New York University; Johns Hopkins University	SCHENKMAN, S (corresponding author), NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Schenkman, Sergio/A-9227-2013	Schenkman, Sergio/0000-0001-9353-8480; Hart, Gerald/0000-0001-7812-4351	NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUIN G, 1989, MOL BIOCHEM PARASIT, V35, P229, DOI 10.1016/0166-6851(89)90209-0; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CROWELL RL, 1986, VIRAL ATTACHMENT ENT; DEARAUJOJORGE TC, 1989, MEM I OSWALDO CRUZ, V84, P441, DOI 10.1590/S0074-02761989000400001; DEARRUDA MV, 1989, EUR J BIOCHEM, V182, P413, DOI 10.1111/j.1432-1033.1989.tb14847.x; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DETITTO EH, 1987, ACTA TROP, V44, P273; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; HADLEY LH, 1987, ANNU REV MICROBIOL, V40, P415; HARTH G, 1987, P NATL ACAD SCI USA, V84, P8320, DOI 10.1073/pnas.84.23.8320; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KIPNIS TL, 1981, P NATL ACAD SCI-BIOL, V78, P602, DOI 10.1073/pnas.78.1.602; Kirchhoff L. V., 1990, Principles and practice of infectious diseases., P2077; LEY V, 1988, J EXP MED, V168, P649, DOI 10.1084/jem.168.2.649; Marsden P. D., 1988, The biology of parasitism. A molecular and immunological approach., P77; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; PASSANITI A, 1988, J BIOL CHEM, V263, P7591; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; RIMOLDI MT, 1989, J CLIN INVEST, V84, P1982, DOI 10.1172/JCI114388; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	46	385	393	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1117	1125		10.1016/0092-8674(91)90008-M	http://dx.doi.org/10.1016/0092-8674(91)90008-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712251				2022-12-24	WOS:A1991FU89900005
J	KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG				KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG			PDGF STIMULATION OF INOSITOL PHOSPHOLIPID HYDROLYSIS REQUIRES PLC-GAMMA-1 PHOSPHORYLATION ON TYROSINE RESIDUES 783 AND 1254	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-GAMMA; FACTOR RECEPTOR; KINASES INVIVO; BOVINE BRAIN; SUBSTRATE; CALCIUM; INVITRO	PDGF binding to its receptor promotes the association with and stimulates the phosphorylation of PLC-gamma-1 at tyrosine and serine residues. Also, PDGF induces an increase in the hydrolysis of inositol phospholipids by PLC. How PDGF activates PLC was investigated by substituting phenylalanine for tyrosine at PLC-gamma-1 phosphorylation sites 771, 783, and 1254 and expressing the mutant enzymes in NIH 3T3 cells. Phenylalanine substitution at Tyr-783 completely blocked the activation of PLC by PDGF, whereas mutation at Tyr-1254 inhibited and mutation at Tyr-771 enhanced the response. Like the wild type, PLC-gamma-1 substituted with phenylalanine at Tyr-783 became associated with the PDGF receptor and underwent phosphorylation at serine residues in response to PDGF. These results suggest that PLC-gamma-1 is the PLC isozyme that mediates PDGF-induced inositol phospholipid hydrolysis, that phosphorylation on Tyr-783 is essential for PLC-gamma-1 activation. These results provide direct evidence that growth factor receptors activate the function of intracellular protein by tyrosine phosphorylation.	NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892; RORER BIOTECHNOL INC,KING OF PRUSSIA,PA 19406; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); New York University	KIM, HK (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KIM JW, 1990, J BIOL CHEM, V265, P3940; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	33	530	539	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					435	441		10.1016/0092-8674(91)90461-7	http://dx.doi.org/10.1016/0092-8674(91)90461-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1708307				2022-12-24	WOS:A1991FK18200010
J	GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD				GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD			A SMALL CHLOROPLAST RNA MAY BE REQUIRED FOR TRANSSPLICING IN CHLAMYDOMONAS-REINHARDTII	CELL			English	Article							NUCLEAR; INTRONS; GENE; DNA; TRANSFORMATION; MUTATIONS; STABILITY	In C. reinhardtii, the mature psaA mRNA is assembled by a process involving trans-splicing of three separate transcripts encoded at three widely scattered loci of the chloroplast genome. At least one additional chloroplast locus (tscA) is required for trans-splicing of exons 1 and 2. We have mapped this gene by transformation of a deletion mutant with a particle gun. The 0.7 kb region of the chloroplast genome that is sufficient to rescue tscA function has been subjected to insertion mutagenesis, showing that it does not contain significant open reading frames. We suggest from these experiments that the products of the tscA gene may be a small chloroplast RNA that acts in trans in the first trans-splicing reaction of psaA. A model for the mode of action of this RNA is presented, in which the characteristic structure of group II introns is assembled from three separate transcripts.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND; INST BIOL PHYS CHIM,F-75005 PARIS,FRANCE; CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	GOLDSCHMIDTCLERMONT, M (corresponding author), UNIV GENEVA,DEPT PLANT BIOL,30 QUAI E ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.		Choquet, Yves/M-5533-2019; Choquet, Yves/ABE-3084-2020; Rochaix, Jean-David/ABC-5243-2020	Choquet, Yves/0000-0003-4760-3397; 				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLOWERS AD, 1989, PLANT CELL, V1, P123, DOI 10.1105/tpc.1.1.123; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRIN DL, 1988, J BIOL CHEM, V263, P14601; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P1025; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; OZEKI H, 1987, COLD SPRING HARB SYM, V52, P791, DOI 10.1101/SQB.1987.052.01.088; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SAMBROOK KJ, 1989, MOL CLONING LABORATO; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204	30	148	155	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					135	143		10.1016/0092-8674(91)90415-U	http://dx.doi.org/10.1016/0092-8674(91)90415-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707343				2022-12-24	WOS:A1991FF77300016
J	DILLON, N; GROSVELD, F				DILLON, N; GROSVELD, F			HUMAN GAMMA-GLOBIN GENES SILENCED INDEPENDENTLY OF OTHER GENES IN THE BETA-GLOBIN LOCUS	NATURE			English	Article							TRANSGENIC MICE; EXPRESSION	ERYTHROPOIESIS during human development is characterized by switches in expression of beta-like globin genes during the transition from the embryonic through fetal to adult stages. Activation and high-level expression of the genes is directed by the locus control region (LCR), located 5' to the epsilon-gene 1-3. The location of the LCR and its role in directing high-level expression of the globin genes has led to the suggestion that competition from the beta-gene for interaction with the LCR has a major role in silencing the fetal gamma-genes during adult life 4,5. We have now constructed lines of transgenic mice containing the human A-gamma-globin gene linked to the LCR. We observe high-level expression of the transgene in the embryonic stages but silencing of the gene in adult animals. We conclude that the gamma-gene is not deregulated by the presence of the LCR and that competition from the beta-gene is not required for silencing of the gamma-genes in adult life. The silencing is therefore likely to be mediated by stage-specific factors binding to sequences immediately flanking the genes.			DILLON, N (corresponding author), NATL INST MED RES,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FEINGOLD EA, 1989, BLOOD, V74, P2178; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, GLOBIN GENE EXPRESSI; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	19	165	167	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					252	254		10.1038/350252a0	http://dx.doi.org/10.1038/350252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706482	Green Submitted			2022-12-24	WOS:A1991FC77900065
J	NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K				NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K			CUTANEOUS HYPERSENSITIVITY REACTIONS DUE TO THIACETAZONE IN HIV-1 SEROPOSITIVE PATIENTS TREATED FOR TUBERCULOSIS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ASSOCIATION; INFECTION; VIRUS	The effects of the human immunodeficiency virus (HIV) on tuberculosis management was investigated in 227 patients initially treated with a regimen containing streptomycin, isoniazid, and thiacetazone (STH). 93 of these 227 were HIV-seropositive. 60 patients, of whom 18 were HIV-seropositive, received a regimen consisting of streptomycin, isoniazid, rifampicin, and pyrazinamide (SHRZ) in the initial phase, and thiacetazone and isoniazid (TH) in the continuation phase. Cutaneous hypersensitivity reactions occurred in 22 of 111 (20%) HIV-seropositive patients, and in 2 of 176 (1%) HIV-seronegative patients (RR = 18, 95% CI 4.4-76, p < 10(-7). During the first 8 weeks of treatment 18 reactions occurred among the 93 HIV-seropositive patients on STH, whereas no reaction occurred in 17 HIV-seropositive patients during the initial phase of SHRZ/TH (p = 0.04). None of the 18 HIV-seropositive patients with cutaneous reactions who were subsequently challenged with isoniazid reacted, nor did any of the 10 tested with streptomycin, but 6 of the 7 challenged with thiacetazone reacted. 3 patients (all HIV-positive and with toxic epidermal necrolysis) died as a result of the cutaneous reaction. These results have major implications for tuberculosis control programmes in Africa.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; UNIV COLL & MIDDLESEX HOSP MED SCH LONDON,LONDON,ENGLAND; NUFFIELD DEPT MED,OXFORD,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB,OXFORD,ENGLAND	Kenya Medical Research Institute; University of London; University College London; University of Oxford; Kenyatta National Hospital; University of London; London School of Hygiene & Tropical Medicine			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN A, 1987, DIFFERENTIAL DIAGNOS, P28; BRICE SL, 1989, J INVEST DERMATOL, V93, P183, DOI 10.1111/1523-1747.ep12277397; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chonde T M, 1989, Bull Int Union Tuberc Lung Dis, V64, P37; CITRON KM, 1983, OXFORD TXB MED, V1; FERGUSON G C, 1971, Tubercle, V52, P166, DOI 10.1016/0041-3879(71)90040-7; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P451, DOI 10.1016/S0190-9622(88)70197-8; Kadende P, 1988, Med Trop (Mars), V48, P19; KIBUGA D, 4TH INT C AIDS ASS C, P99; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; Miller A B, 1966, Tubercle, V47, P33; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; SEN PK, 1974, INDIAN J MED RES, V62, P557; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; SUGARMAN J, 1990, 4TH INT C AIDS SAN F, V1, P249; WILLAME JC, 1988, ANN SOC BELG MED TR, V68, P165; 1973, TUBERCLE, V54, P169	19	176	177	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					627	630						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1705647				2022-12-24	WOS:A1991FB73000001
J	WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P				WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P			ACTIVATION OF CHLORIDE CHANNELS IN NORMAL AND CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS BY MULTIFUNCTIONAL CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							PHOSPHORYLATION; IDENTIFICATION; CONDUCTANCE; GENE	CYSTIC fibrosis is associated with defective regulation of apical membrane chloride channels in airway epithelial cells. These channels in normal cells are activated by cyclic AMP-dependent protein kinase 1,2 and protein kinase C 3,4. In cystic fibrosis these kinases fail to activate otherwise normal Cl- channels 1-4. But Cl- flux in cystic fibrosis cells, as in normal cells, can be activated by raising intracellular Ca2+ (refs 5-10). We report here whole-cell patch clamp studies of normal and cystic fibrosis-derived airway epithelial cells showing that Cl- channel activation by Ca2+ is mediated by multifunctional Ca2+/calmodulin-dependent protein kinase. We find that intracellular application of activated kinase and ATP activates a Cl- current similar to that activated by a Ca2+ ionophore, that peptide inhibitors of either the kinase or calmodulin block Ca2+-dependent activation of Cl- channels, and that a peptide inhibitor of protein kinase C does not block Ca2+-dependent activation. Ca2+/calmodulin activation of Cl- channels presents a pathway with therapeutic potential for circumventing defective regulation of Cl- channels in cystic fibrosis.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,FALK CVRC,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University; University of California System; University of California San Francisco; Stanford University								CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COZENS AL, IN PRESS IDENTIFICAT; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GORMAN ALF, 1982, BIOPHYS J, V38, P319, DOI 10.1016/S0006-3495(82)84565-7; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRUENERT DC, 1988, PEDIATR PULMONOL S2, V17, P100; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	24	194	194	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					793	796		10.1038/349793a0	http://dx.doi.org/10.1038/349793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705665				2022-12-24	WOS:A1991EZ66600057
J	SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ				SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ			A POTENT NONPEPTIDE ANTAGONIST OF THE SUBSTANCE-P (NK1) RECEPTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SELECTIVE AGONISTS; TACHYKININS; ACTIVATION; SECRETION; NEURONS; BINDING; TISSUE	CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]octan-3-amine] is a potent neopeptide antagonist of the substance P (NK1) receptor. CP-96,345 inhibited H-3-labeled substance P binding and was a classical competitive antagonist in the NK1 monoreceptor dog carotid artery preparation. CP-96,345 inhibited substance P-induced salivation in the rat, a classical in vivo bioassay, but did not inhibit NK2, NK3, or numerous other receptors; it is thus a selective NK1 antagonist. This compound may prove to be a powerful tool for investigation of the physiological properties of substance P and exploration of its role in diseases.			SNIDER, RM (corresponding author), PFIZER INC,CENT RES DIV,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340, USA.							ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG MM, 1970, J BIOL CHEM, V245, P4784; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONSTANTINE JW, IN PRESS NAUNYNSCHMI; ENBERG G, 1981, NATURE, V293, P222; GIULIANI S, 1988, EUR J PHARMACOL, V150, P377, DOI 10.1016/0014-2999(88)90022-2; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MELCHIORRI P, 1977, NOBEL S, V37, P311; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; NILSSON G, 1974, MED BIOL, V52, P424; PAYAN DG, 1984, J CLIN INVEST, V74, P1532, DOI 10.1172/JCI111567; PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P520, DOI 10.1016/0006-291X(89)92630-2; PERNOW B, 1975, ACTA PHYSIOL SCAND, V93, P139, DOI 10.1111/j.1748-1716.1975.tb05800.x; PERNOW B, 1983, PHARMACOL REV, V35, P85; PERNOW B, 1953, Acta Physiol Scand Suppl, V29, P1; PERRONE MH, 1983, EUR J PHARMACOL, V95, P131, DOI 10.1016/0014-2999(83)90277-7; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SNIDER RS, UNPUB; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P392, DOI 10.1073/pnas.86.1.392; VOGLER K, 1963, ANN NY ACAD SCI, V104, P378, DOI 10.1111/j.1749-6632.1963.tb17682.x; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WARAWA EJ, 1974, J MED CHEM, V17, P479; WOMACK MD, 1988, NATURE, V334, P351, DOI 10.1038/334351a0	29	925	947	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					435	437		10.1126/science.1703323	http://dx.doi.org/10.1126/science.1703323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703323				2022-12-24	WOS:A1991EU50400043
J	VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E				VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E			MUTANT KERATIN EXPRESSION IN TRANSGENIC MICE CAUSES MARKED ABNORMALITIES RESEMBLING A HUMAN GENETIC SKIN-DISEASE	CELL			English	Article							EPIDERMOLYSIS BULLOSA SIMPLEX; INTERMEDIATE-SIZED FILAMENTS; CULTURED EPIDERMAL-CELLS; CYTOKERATIN EXPRESSION; DOWLING-MEARA; MOLECULAR MARKERS; NORMAL EPITHELIA; DIFFERENTIATION; COMPLEX; FAMILY	To explore the relationship between keratin gene mutations and genetic disease, we made transgenic mice expressing a mutant keratin in the basal layer of their stratified squamous epithelia. These mice exhibited abnormalities in epidermal architecture and often died prematurely. Blistering occurred easily, and basal cell cytolysis was evident at the light and electron microscopy levels. Keratin filament formation was markedly altered, with keratin aggregates in basal cells. In contrast, terminally differentiating cells made keratin filaments and formed a stratum corneum. Recovery of outer layer cells was attributed to down-regulation of mutant keratin expression and concomitant induction of differentiation-specific keratins as cells terminally differentiate, and the fact that these cells arose from basal cells developing at a time when keratin expression was relatively low. Collectively, the pathobiology and biochemistry of the transgenic mice and their cultured keratinocytes bore a resemblance to a group of genetic disorders known as epidermolysis bullosa simplex.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago	VASSAR, R (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Albers, Kathryn/0000-0003-4597-9323	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBINDER LH, 1986, ARCH DERMATOL, V122, P190, DOI 10.1001/archderm.122.2.190; BURGE SM, 1989, J ROY SOC MED, V82, P673, DOI 10.1177/014107688908201113; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1990, IN PRESS J CELL BIOL; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; FINE JD, 1986, INT J DERMATOL, V25, P143, DOI 10.1111/j.1365-4362.1986.tb02206.x; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL, V1; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1978, CELL, V15, P887, DOI 10.1016/0092-8674(78)90273-8; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; JACKSON BW, 1981, DIFFERENTIATION, V20, P203, DOI 10.1111/j.1432-0436.1981.tb01177.x; KERO M, 1986, INT J DERMATOL, V25, P75, DOI 10.1111/j.1365-4362.1986.tb04542.x; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KOPAN R, 1989, GENE DEV, V3, P1, DOI 10.1101/gad.3.1.1; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; NAGLE RB, 1985, DIFFERENTIATION, V30, P130, DOI 10.1111/j.1432-0436.1985.tb00524.x; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1961, J INVEST DERMATOL, V36, P213, DOI 10.1038/jid.1961.35; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; STROMER MH, 1988, CELL MOTIL CYTOSKEL, V11, P117, DOI 10.1002/cm.970110205; Sun TT, 1984, CANCER CELLS, V1, P169; TIDMAN MJ, 1988, ACTA DERM-VENEREOL, V68, P15; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VENETIANER A, 1983, NATURE, V305, P730, DOI 10.1038/305730a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	54	368	370	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					365	380		10.1016/0092-8674(91)90645-F	http://dx.doi.org/10.1016/0092-8674(91)90645-F			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1703046				2022-12-24	WOS:A1991EV33600013
J	WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K				WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K			CD4 EXPRESSED ON EARLIEST T-LINEAGE PRECURSOR CELLS IN THE ADULT MURINE THYMUS	NATURE			English	Article							HOMING PROGENITOR CELLS; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; PGP-1 GLYCOPROTEIN; MOUSE THYMUS; STEM-CELLS; THYMOCYTES; SURFACE; ANTIGEN; SUBPOPULATIONS	A CONTINUOUS but low input of stem cells or 'prothymocytes' is necessary to maintain T-cell development in the adult thymus1, but the colonizing cell has not been characterized. Precursors of T cells have been found in the minor CD4-8- population2 of thymocytes, but even the earliest cells of this population already have partially rearranged T-cell antigen receptor (TCR) genes3. We now demonstrate that the thymus contains a minute population of lymphoid cells similar in some but not all respects to bone marrow-derived haemopoietic stem cells. This population has TCR genes in a germline state. It gives a slow but extensive reconstitution of both alpha-beta and gamma-delta-lineages on transfer into an irradiated thymus, with kinetics indicating that it includes the earliest intrathymic precursor cells so far isolated. Surprisingly, these cells express low surface levels of the mature T-cell marker CD4.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute				Shortman, Ken/0000-0002-9107-3007				CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; Coffman R L, 1982, Immunol Rev, V69, P5; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P3301, DOI 10.1073/pnas.86.9.3301; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HOLMES KL, 1986, J IMMUNOL, V137, P679; HYMAN R, 1986, CELL IMMUNOL, V101, P320, DOI 10.1016/0008-8749(86)90145-0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LESLEY J, 1985, CELL IMMUNOL, V91, P397, DOI 10.1016/0008-8749(85)90237-0; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MIESCHER GC, 1989, IMMUNOL LETT, V23, P113, DOI 10.1016/0165-2478(89)90122-3; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PEARSE MJ, 1988, IMMUNOL LETT, V18, P219, DOI 10.1016/0165-2478(88)90022-3; QUIN S, 1987, EUR J IMMUNOL, V17, P1159; SCOLLAY R, 1986, IMMUNOL REV, V91, P129, DOI 10.1111/j.1600-065X.1986.tb01487.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, EXP HEMATOL, V18, P920; SPANGRUDE GJ, IN PRESS J IMMUN; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WILSON A, 1988, J IMMUNOL, V140, P1461; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	30	339	345	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					71	74		10.1038/349071a0	http://dx.doi.org/10.1038/349071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1702186				2022-12-24	WOS:A1991EQ60100054
J	SIMPSON, L				SIMPSON, L			RNA EDITING - A NOVEL GENETIC PHENOMENON	SCIENCE			English	Article									UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	SIMPSON, L (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.							ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ALTMAN S, 1989, GENE, V82, P63, DOI 10.1016/0378-1119(89)90030-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHEN SH, 1990, J BIOL CHEM, V265, P6811; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; MAHENDRAN R, IN PRESS CELL; POLLARD VW, IN PRESS CELL; RIOU G, 1969, P NATL ACAD SCI USA, V62, P210, DOI 10.1073/pnas.62.1.210; SIMPSON A, UNPUB; SIMPSON L, 1971, J MOL BIOL, V56, P443, DOI 10.1016/0022-2836(71)90394-9; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8	26	77	77	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 26	1990	250	4980					512	513		10.1126/science.1700474	http://dx.doi.org/10.1126/science.1700474			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE660	1700474				2022-12-24	WOS:A1990EE66000026
J	PETERSON, CA; GORDON, H; HALL, ZW; PATERSON, BM; BLAU, HM				PETERSON, CA; GORDON, H; HALL, ZW; PATERSON, BM; BLAU, HM			NEGATIVE CONTROL OF THE HELIX-LOOP-HELIX FAMILY OF MYOGENIC REGULATORS IN THE NFB MUTANT	CELL			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	PETERSON, CA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305, USA.				NICHD NIH HHS [HD18179, HD20203] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179, R01HD020203] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKHURST RJ, 1988, MOL CELL BIOL, V8, P2335, DOI 10.1128/MCB.8.6.2335; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DEMARINI DM, 1989, MUTAT RES, V220, P11, DOI 10.1016/0165-1110(89)90006-7; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Esko J D, 1986, Methods Enzymol, V129, P237; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GORDON H, 1989, DEV BIOL, V135, P1, DOI 10.1016/0012-1606(89)90152-8; GRAHAM F, 1973, VIROLOGY, V52, P452; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARDEMAN EC, 1988, J CELL BIOL, V106, P1027, DOI 10.1083/jcb.106.4.1027; HARDEMAN EC, 1986, CELL, V47, P123, DOI 10.1016/0092-8674(86)90373-9; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAWRENCE JB, 1984, DEV BIOL, V101, P463, DOI 10.1016/0012-1606(84)90160-X; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER SC, 1988, GENE DEV, V2, P330, DOI 10.1101/gad.2.3.330; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; PAVLATH GK, 1986, J CELL BIOL, V102, P124, DOI 10.1083/jcb.102.1.124; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RINGERTZ NR, 1978, EXP CELL RES, V113, P233, DOI 10.1016/0014-4827(78)90363-4; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEISBLUM B, 1974, CHROMOSOMA, V46, P255; WRIGHT WE, 1984, EXP CELL RES, V151, P55, DOI 10.1016/0014-4827(84)90355-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1984, J CELL BIOL, V98, P427, DOI 10.1083/jcb.98.2.427; WRIGHT WE, 1983, CELL DIFFER DEV, V12, P299, DOI 10.1016/0045-6039(83)90026-X; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	75	68	68	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 10	1990	62	3					493	502		10.1016/0092-8674(90)90014-6	http://dx.doi.org/10.1016/0092-8674(90)90014-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	DU445	1696180				2022-12-24	WOS:A1990DU44500011
J	HIGGINSON, I; WADE, A; MCCARTHY, M				HIGGINSON, I; WADE, A; MCCARTHY, M			PALLIATIVE CARE - VIEWS OF PATIENTS AND THEIR FAMILIES	BRITISH MEDICAL JOURNAL			English	Article											HIGGINSON, I (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT COMMUNITY MED,LONDON WC1E 6EA,ENGLAND.		McCarthy, Mark/C-1117-2009; Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				BARNETT M, 1987, INT C S SERIES, V123, P78; CARTWRIGHT A, 1973, LIFE DEATH; COPPERMAN H, 1988, J ROY COLL GEN PRACT, V38, P411; DOYLE D, 1989, INT C S SERIES, V149, P165; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; GILLEY J, 1988, J ROY COLL GEN PRACT, V38, P121; HAINES A, 1986, BRIT MED J, V292, P1051, DOI 10.1136/bmj.292.6527.1051; HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507; HIGGINSON I, 1988, SAFER DEATH, P205; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIGGINSON I, 1989, INT C S SERIES, V149, P217; HINTON J, 1979, LANCET, V1, P29; LUNT B, 1985, SOC SCI MED, V20, P753, DOI 10.1016/0277-9536(85)90066-8; MAGUIRE P, 1988, BRIT MED J, V297, P972, DOI 10.1136/bmj.297.6654.972; MOR V, 1988, HOSPICE EXPT; MOUNT BM, 1987, J CHRON DIS, V40, P545; Parkes C M, 1978, J R Coll Gen Pract, V28, P19; PARKES CM, 1984, POSTGRAD MED J, V60, P120, DOI 10.1136/pgmj.60.700.120; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; SPRENT P, 1989, APPLIED NONPARAMETRI; 1986, LANCET, V1, P1013; 1980, J R COLL GEN PRACT, V30, P466	23	194	196	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 4	1990	301	6746					277	281		10.1136/bmj.301.6746.277	http://dx.doi.org/10.1136/bmj.301.6746.277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT797	1697189	Green Published, Bronze			2022-12-24	WOS:A1990DT79700025
J	POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ				POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ			NOSOCOMIAL TRANSMISSION OF HEPATITIS-B VIRUS ASSOCIATED WITH THE USE OF A SPRING-LOADED FINGERSTICK DEVICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMON-SOURCE OUTBREAK; HEMODIALYSIS UNIT; ANTIGEN	Background and Methods. From June 1989 through March 1990, 26 patients, of whom 23 had diabetes, contracted acute hepatitis B virus (HBV) infection in a hospital in California. All 26 patients and one HBV carrier (also a diabetic) had been admitted to a single medical ward during the six months before the case patients became infected with HBV. To determine the source of the infection, we conducted a retrospective cohort study of the 72 patients with diabetes who had been admitted to the ward from January through December 1989 and a case-control study comparing the 3 nondiabetic patients who contracted hepatitis with 20 nondiabetic controls. Results. The retrospective cohort study of all the patients with diabetes who were admitted to the ward during 1989 found that those who underwent capillary blood sampling by finger stick with a spring-loaded lancet device were more likely to contract HBV infection than those who did not have finger sticks (attack rate, 42 percent vs. 0 percent; P = 0.08). In addition, a dose-response relation was observed between the number of finger sticks received and the frequency of hepatitis B (P = 0.002). The case-control study found that all 3 of the nondiabetic patients who contracted hepatitis underwent finger-stick blood sampling with the device, as compared with none of the 20 nondiabetic controls (P = 0.0006). A review of nursing procedures indicated that the platform of the device was not routinely changed after each use; this finding suggested that contamination of the platform by HBV-infected blood was the mechanism of percutaneous transmission of HBV. Conclusions. Proper use of finger-stick devices as well as strict adherence to universal precautions to avoid contamination by blood are required to decrease the possibility of transmission of blood-borne pathogens among hospitalized patients.	FRESNO VET AFFAIRS HOSP,FRESNO,CA; CALIF DEPT HLTH & HUMAN SERV,BERKELEY,CA	California Health & Human Services Agency	POLISH, LB (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; BIRNIE GG, 1983, GUT, V24, P171, DOI 10.1136/gut.24.2.171; BOND WW, 1981, LANCET, V1, P550; CANTER J, 1990, ARCH INTERN MED, V150, P1923; CARL M, 1983, DIALYSIS TRANSPLANT, V12, P222; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; DOUVIN C, 1990, NEW ENGL J MED, V322, P57, DOI 10.1056/NEJM199001043220112; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; NATH N, 1985, AM J EPIDEMIOL, V122, P218, DOI 10.1093/oxfordjournals.aje.a114092; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J	11	111	116	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					721	725		10.1056/NEJM199203123261101	http://dx.doi.org/10.1056/NEJM199203123261101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738376	Bronze			2022-12-24	WOS:A1992HH06400001
J	RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ				RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ			INCIDENCE OF LYMPHOMAS AND OTHER CANCERS IN HIV-INFECTED AND HIV-UNINFECTED PATIENTS WITH HEMOPHILIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RENAL-TRANSPLANT RECIPIENTS; NON-HODGKIN LYMPHOMA; KAPOSIS-SARCOMA; DISEASE; AIDS; RISK; PAPILLOMAVIRUS	Objective. - To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1). Design. - Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years. Setting. - Fifteen hemophilia treatment centers. Patients. - A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive. Main Outcome Measures. -Morphologic classification and incidence rates of cancers. Main Results. - The incidence of non-Hodgkin's lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [Cl], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P <.05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi's sacroma was increased 200-fold (95% Cl, 20 to 700). The incidence of cancers other than non-Hodgkin's lymphoma and Kaposi's sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% Cl, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence. Conclusions. - HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIV-associated lymphoma.	NCI,VIRAL EPIDEMIOL SECT,BETHESDA,MD 20892; CORNELL UNIV,MED CTR,DEPT PEDIAT HEMATOL ONCOL,NEW YORK,NY 10021; CARDEZA FDN HEMOPHILIA CTR,PHILADELPHIA,PA; MT SINAI MED CTR,DEPT HEMATOL,NEW YORK,NY 10029; NATL RETROVIRUS REFERENCE CTR,ATHENS,GREECE; UNIV ATHENS,SCH MED,ATHENS,GREECE; UNIV VIENNA,DEPT INTERNAL MED,A-1010 VIENNA,AUSTRIA; PENN STATE UNIV,MILTON S HERSHEY MED CTR,SCH MED,DIV HEMATOL,HERSHEY,PA 17033; UNIV N CAROLINA,SCH MED,DIV HEMATOL,CHAPEL HILL,NC 27514; GEORGE WASHINGTON UNIV,MED CTR,DIV HEMATOL ONCOL,WASHINGTON,DC 20037; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; UNIV GENEVA,HEMOSTASIS UNIT,CH-1211 GENEVA 4,SWITZERLAND; HOP CANTONAL GENEVA,CH-1211 GENEVA 4,SWITZERLAND; CHILDRENS HOSP,NATL MED CTR,DEPT HEMATOL,WASHINGTON,DC 20010; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA; TULANE UNIV,SCH MED,HEMATOL SECT,NEW ORLEANS,LA 70112; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT HEMATOL,DENVER,CO 80262; UNIV MUNICH,MED CLIN,DIV HEMOSTASIS,W-8000 MUNICH 2,GERMANY; RES TRIANGLE INST,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; Jefferson University; Icahn School of Medicine at Mount Sinai; Athens Medical School; National & Kapodistrian University of Athens; University of Vienna; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; George Washington University; Case Western Reserve University; University of Geneva; University of Geneva; Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Tulane University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munich; Research Triangle Institute				, M. Elaine Eyster/0000-0001-8248-6793	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095663, N01CP085649] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-85649, N01-CO-74102, N01-CP-95663] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BLUMBERG N, 1989, ARCH PATHOL LAB MED, V113, P246; BREEN EC, 1990, J IMMUNOL, V144, P480; Breslow N. E., 1987, STATISTICAL METHODS, VII; DEVESA SS, IN PRESS CANCER RES; FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896; FILIPOVICH AH, 1980, PREV MED, V9, P252, DOI 10.1016/0091-7435(80)90083-3; Freter C E, 1990, J Natl Cancer Inst Monogr, P45; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; HARWOOD AR, 1979, AM J MED, V67, P759, DOI 10.1016/0002-9343(79)90731-9; HOOVER R, 1973, LANCET, V2, P55; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; LIFF JM, 1990, 30TH INT C ANT AG CH; MEEKER TC, 1991, AIDS, V5, P669, DOI 10.1097/00002030-199106000-00005; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NERI A, 1991, BLOOD, V77, P1092; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RABKIN CS, 1991, AIDS RES HUM RETROV, V7, P223; ROBERT NJ, 1984, ANN INTERN MED, V101, P142, DOI 10.7326/0003-4819-101-1-142_2; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SELIK RM, 1987, AIDS, V1, P175; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1989, ACTA ONCOL, V28, P637, DOI 10.3109/02841868909092284; 1990, NCI NIH902789 PUBL	32	112	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1090	1094		10.1001/jama.267.8.1090	http://dx.doi.org/10.1001/jama.267.8.1090			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735926				2022-12-24	WOS:A1992HE39100024
J	MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C				MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C			HOSPITALIZATION IN AN URBAN HOMELESS POPULATION - THE HONOLULU URBAN HOMELESS PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article						HOMELESS PERSONS; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; COSTS AND COST ANALYSIS; SUBSTANCE ABUSE	MENTAL-HEALTH	Objective: To determine the rate and estimate the cost of hospitalization in a defined urban homeless population. Design: Retrospective chart review. Setting: Kalihi-Palama Health Clinic Health Care for the Homeless Project, Hawaii State Hospital, and seven acute care hospitals in Honolulu, Hawaii. Patients: A total of 1751 homeless clients contacted between 1 December 1988 and 30 November 1990. Measurements and Main Results: A total of 1751 individuals were studied for an aggregate of 871.3 person-years. Five hundred sixty-four hospitalizations were identified: ninety-two to the state psychiatric hospital and 472 to acute care hospitals. The age- and sex-adjusted hospitalization rate for acute care hospitals was 542/1000 person-years (compared with the state rate of 96/1000 person-years). Homeless persons were admitted to acute care hospitals for 4766 days compared with a predicted 640 days. The age- and sex-adjusted rate of admission to the state psychiatric hospital was 105/1000 person-years (compared with the state rate of 0.8/1000 person-years). Homeless persons were admitted to the state psychiatric hospital for 3837 days compared with a predicted 139 days. Conclusions: Homeless individuals in this study were hospitalized in acute care and psychiatric hospitals far more frequently than were members of the general population.	UNIV HAWAII, JOHN A BURNS SCH MED, OFF STUDENT AFFAIRS, HONOLULU, HI 96822 USA	University of Hawaii System								BAHR HM, 1971, PUBLIC OPIN QUART, V35, P374, DOI 10.1086/267922; BASSUK EL, 1984, SCI AM, V251, P40, DOI 10.1038/scientificamerican0784-40; BORLAND A, 1989, HOSP COMMUNITY PSYCH, V40, P369; Bowdler J E, 1989, Nurse Pract, V14, P50; BOWDLER JE, 1989, NURSE PRACTITIONER, V14, P47; BOWDLER JE, 1989, NURSE PRACT, V14, P50; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1972, ANN INTERN MED, V77, P565, DOI 10.7326/0003-4819-77-4-565; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; CHRIST WR, 1989, SOC WORK HEALTH CARE, V14, P33, DOI 10.1300/J010v14n01_03; COHEN CI, 1988, J GERONTOL, V43, pS121, DOI 10.1093/geronj/43.4.S121; FISCHER PJ, 1986, AM J PUBLIC HEALTH, V76, P519, DOI 10.2105/AJPH.76.5.519; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; LAMB HR, 1986, JAMA-J AM MED ASSOC, V256, P498, DOI 10.1001/jama.256.4.498; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P1232, DOI 10.1001/jama.253.9.1232; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P3217, DOI 10.1001/jama.253.22.3217; MORRIS W, 1989, WESTERN J MED, V151, P472; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; TORREY EF, 1990, HOSP COMMUNITY PSYCH, V41, P526; WLODARCZYK D, 1988, WESTERN J MED, V148, P717; 1990, DHHS901232 US DEP HL, P184; 1990, HOSPITAL STATISTICS, P62; 1990, STATE HAWAII DATA BO, P37	25	65	65	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					299	303		10.7326/0003-4819-116-4-299	http://dx.doi.org/10.7326/0003-4819-116-4-299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733384				2022-12-24	WOS:A1992HD54600005
J	DESWIET, M; FAYERS, P; SHINEBOURNE, EA				DESWIET, M; FAYERS, P; SHINEBOURNE, EA			BLOOD-PRESSURE IN 1ST 10 YEARS OF LIFE - THE BROMPTON STUDY	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS; CHILDHOOD; AGE	Objectives - To determine the normal range of blood pressure and its pattern of change in the first 10 years of life. To estimate at what age (if any) children consistently appear in one part of the blood pressure distribution and at what age familial correlations in blood pressure become significant. Design - Longitudinal cohort study. Setting - South east England. Subjects - 2088 children of both sexes born consecutively in Farnborough Hospital, Kent, and their parents. Main outcome measure - Blood pressure measured by Doppler ultrasonography and sphygmomanometry. Results - Systolic blood pressure rose from a mean of 88.5 mm Hg at age 6 months to 96-2 mm Hg at 8 years measured with a 8 cm cuff and from 89.1 mm Hg at age 5 years to 94.3 mm Hg at age 10 years measured with a 12 cm cuff. The larger cuff gave blood pressure readings about 6 mm Hg lower. This effect was independent of body weight and arm circumference. Diastolic blood pressure rose from 57.8 mm Hg at 5 years to 61.8 mm Hg at 10 years (12 cm cuff). There was only about 1 mm Hg difference between sexes. Blood pressure was correlated with weight, weight adjusted for height, height, and arm circumference at all ages studied. The correlation coefficient of repeated yearly measurements increased steadily with age from 0.28 at 2 years to 0.59 at 10 years. The correlation coefficients between child's blood pressure and mother's average blood pressure increased from 0.1 at age 1 year to 0.23 at age 10. Conclusions - Blood pressure changes relatively little between the ages of 6 months and 10 years. Yet because of the increasing strength of between occasion and family correlations, children are more consistently occupying a specific part of the blood pressure distribution as they grow older. Studies in children should help determine why some adults have hypertension and others do not.	BROMPTON HOSP,NATL HEART & LUNG INST,DEPT PAEDIAT,LONDON SW3 6LY,ENGLAND	Imperial College London; Royal Brompton Hospital			Fayers, Peter M/A-5999-2010	Fayers, Peter/0000-0003-4778-1513				[Anonymous], 1987, PEDIATRICS, V79, P1; BURKE GL, 1987, PEDIATRICS, V80, P784; CLARKE WR, 1986, AM J EPIDEMIOL, V123, P67, DOI 10.1093/oxfordjournals.aje.a114225; COLE TJ, 1986, ANN HUM BIOL, V13, P433, DOI 10.1080/03014468600008621; de Swiet M, 1984, J Hypertens, V2, P501; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DESWIET M, 1980, PEDIATRICS, V65, P1028; DESWIET M, 1980, BMJ-BRIT MED J, V280, P1567, DOI 10.1136/bmj.280.6231.1567; DESWIET M, 1975, CLIN SCI MOL MED, V49, P557, DOI 10.1042/cs0490557; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SHEAR CL, 1986, PEDIATRICS, V77, P862; VERSMOLD HT, 1981, PEDIATRICS, V67, P607; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILSON PD, 1988, AM J EPIDEMIOL, V127, P946, DOI 10.1093/oxfordjournals.aje.a114898	15	79	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					23	26		10.1136/bmj.304.6818.23	http://dx.doi.org/10.1136/bmj.304.6818.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734987	Bronze, Green Published			2022-12-24	WOS:A1992GY90900028
J	ANSARI, AZ; CHAEL, ML; OHALLORAN, TV				ANSARI, AZ; CHAEL, ML; OHALLORAN, TV			ALLOSTERIC UNDERWINDING OF DNA IS A CRITICAL STEP IN POSITIVE CONTROL OF TRANSCRIPTION BY HG-MERR	NATURE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ANGLE; MERCURIC ION; PROTEIN; PROMOTER; COMPLEX; SEQUENCE; BINDING; TN501	POSITIVE control of transcription often involves stimulatory protein-protein interactions between regulatory factors and RNA polymerase 1. Critical steps in the activation process itself are seldom ascribed to protein-DNA distortions. Activator-induced DNA bending is typically assigned a role in binding-site recognition 2, alterations in DNA loop structures 3 or optimal positioning of the activator for interaction with polymerase 4. Here we present a transcriptional activation mechanism that does not require a signal-induced DNA bend but rather a receptor-induced untwisting of duplex DNA. The allosterically modulated transcription factor MerR is a repressor and an Hg(II)-responsive activator of bacterial mercury-resistance genes 5-7. Escherichia coli RNA polymerase binds to the MerR-promoter complex but cannot proceed to a transcriptionally active open complex until Hg(II) binds to MerR (ref. 6). Chemical nuclease studies show that the activator form, but not the repressor, induces a unique alteration of the helical structure localized at the centre of the DNA-binding site 6. Data presented here indicate that this Hg-MerR-induced DNA distortion corresponds to a local underwinding of the spacer region of the promoter by about 33-degrees relative to the MerR-operator complex. The magnitude and the direction of the Hg-MerR-induced change in twist angle are consistent with a positive control mechanism involving reorientation of conserved, but suboptimally phased, promoter elements and are consistent with a role for torsional stress in formation of an open complex.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2145 SHERIDAN RD,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University; Northwestern University			Ansari, Aseem/AAF-4945-2019; O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [R01 GM038784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BROWN NL, 1986, MOL GEN GENET, V202, P143, DOI 10.1007/BF00330531; BUCH H, 1987, RNA POLYM REGULATION, P115; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KOLB A, 1982, NUCLEIC ACIDS RES, V10, P473, DOI 10.1093/nar/10.2.473; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LUND P, 1989, NUCLEIC ACIDS RES, V17, P5517, DOI 10.1093/nar/17.14.5517; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	30	157	160	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					87	89		10.1038/355087a0	http://dx.doi.org/10.1038/355087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1731201				2022-12-24	WOS:A1992GY22800058
J	MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A				MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A			REVERSE-TRANSCRIPTASE ENCODED BY A HUMAN TRANSPOSABLE ELEMENT	SCIENCE			English	Article							SITE-SPECIFIC MUTAGENESIS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; EUKARYOTIC GENOME; SPT3 GENE; RETROTRANSPOSONS; SEQUENCES; PROTEIN; DNA	L1 elements are highly repeated mammalian DNA sequences whose structure suggests dispersal by retrotransposition. A consensus L1 clement encodes a protein with sequence similarity to known reverse transcriptases. The second open reading frame from the human L1 element L1.2A was expressed as a fusion protein targeted to Tyl virus-like particles in Saccharomyces cerevisiae and shown to have reverse transcriptase activity. This activity was eliminated by a missense mutation in the highly conserved amino acid motif Y/F-X-D-D. Thus, L1 represents a potential source of the reverse transcriptase activity necessary for dispersion of the many classes of mammalian retroelements.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	GABRIEL, A (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.			Boeke, Jef/0000-0001-5322-4946	NCI NIH HHS [CA16519] Funding Source: Medline; NIAID NIH HHS [AI00803] Funding Source: Medline; NIGMS NIH HHS [GM28931] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028931] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1989, MOBILE DNA, P335; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; GARFINKEL DJ, 1991, J VIROL, V65, P4573, DOI 10.1128/JVI.65.9.4573-4581.1991; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JACOBS E, 1988, GENE, V67, P259, DOI 10.1016/0378-1119(88)90402-7; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINSEY J, COMMUNICATION; KINSEY JA, 1990, GENETICS, V126, P317; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LAWRENCE W, 1978, METHODS YEAST GENETI; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, UNPUB; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; NATSOULIS G, 1989, GENETICS, V123, P269; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU H, 1991, MOL CELL BIOL, V11, P2736, DOI 10.1128/MCB.11.5.2736; XU H, 1990, Proceedings of the National Academy of Sciences of the United States of America, V87, P8360, DOI 10.1073/pnas.87.21.8360; [No title captured]	41	586	597	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1808	1810		10.1126/science.1722352	http://dx.doi.org/10.1126/science.1722352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722352				2022-12-24	WOS:A1991GW31600049
J	WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA				WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA			STRUCTURE OF THE CALCIUM-DEPENDENT LECTIN DOMAIN FROM A RAT MANNOSE-BINDING PROTEIN DETERMINED BY MAD PHASING	SCIENCE			English	Article							MULTIWAVELENGTH ANOMALOUS DIFFRACTION; LIVER ASIALOGLYCOPROTEIN RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; AREA-DETECTOR DIFFRACTOMETER; PROTEOGLYCAN CORE PROTEIN; CARTILAGE PROTEOGLYCAN; SYNCHROTRON RADIATION; CONCANAVALIN-A; MACROMOLECULAR CRYSTALLOGRAPHY	Calcium-dependent (C-type) animal lectins participate in many cell surface recognition events mediated by protein-carbohydrate interactions. The C-type lectin family includes cell adhesion molecules, endocytic receptors, and extracellular matrix proteins. Mammalian mannose-binding proteins are C-type lectins that function in antibody-independent host defense against pathogens. The crystal structure of the carbohydrate-recognition domain of a rat mannose-binding protein, determined as the holmium-substituted complex by multiwavelength anomalous dispersion (MAD) phasing, reveals an unusual fold consisting of two distinct regions, one of which contains extensive nonregular secondary structure stabilized by two holmium ions. The structure explains the conservation of 32 residues in all C-type carbohydrate-recognition domains, suggesting that the fold seen here is common to these domains. The strong anomalous scattering observed at the Ho L(III) edge demonstrates that traditional heavy atom complexes will be generally amenable to the MAD phasing method.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; CNRS, UTILISAT RAYONNEMENT ELECTROMAGNET LAB, F-91405 ORSAY, FRANCE; UNIV PARIS 11, F-91405 ORSAY, FRANCE	Columbia University; Howard Hughes Medical Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	WEIS, WI (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R01GM042628, R37GM034102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42628, GM34102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; BRUNGER AT, 1990, X PLOR MANUAL; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EZEKOWITZ R A B, 1991, Current Biology, V1, P60; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FANCHON E, 1990, ACTA CRYSTALLOGR A, V46, P809, DOI 10.1107/S0108767390005967; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAHN R, 1985, FEBS LETT, V179, P133, DOI 10.1016/0014-5793(85)80207-6; KAHN R, 1986, NUCL INSTRUM METH A, V246, P596, DOI 10.1016/0168-9002(86)90158-0; KRAULIS P, IN PRESS J APPL CRYS; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOEB JA, 1987, J BIOL CHEM, V262, P3022; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; QUESENBERRY MS, UNPUB; QUESENBERRY MS, IN PRESS GLYCOBIOLOG; REEKE GN, 1975, J BIOL CHEM, V250, P1525; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1989, LANCET, V2, P1236; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; TEMPLETON LK, 1982, ACTA CRYSTALLOGR A, V38, P74, DOI 10.1107/S056773948200014X; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	57	508	530	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1608	1615		10.1126/science.1721241	http://dx.doi.org/10.1126/science.1721241			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721241				2022-12-24	WOS:A1991GV07300035
J	THOMAS, JE; SORIANO, P; BRUGGE, JS				THOMAS, JE; SORIANO, P; BRUGGE, JS			PHOSPHORYLATION OF C-SRC ON TYROSINE-527 BY ANOTHER PROTEIN TYROSINE KINASE	SCIENCE			English	Article							MIDDLE TUMOR-ANTIGEN; ATP-BINDING SITE; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; CARBOXY TERMINUS; PP60C-SRC; ACTIVATION; DEPHOSPHORYLATION; FIBROBLASTS; P60C-SRC	The protein tyrosine kinase activity of the cellular Src protein is negatively regulated by phosphorylation at tyrosine residue 527 (Tyr527). It has not been established whether this regulatory modification of Src is mediated by autophosphorylation or by another cellular protein kinase. The phosphorylation of a modified form of c-Src that lacks kinase activity was examined in mouse cells that do not express endogenous Src (because of the targeted disruption of both src alleles). Phosphorylation of the inactive form of Src on Tyr527 occurred to a similar extent in cells lacking endogenous Src as it did in cells expressing Src. Therefore, Tyr527 phosphorylation, and thus negative control of Src kinase activity, is mediated by another cellular protein tyrosine kinase.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN J, COMMUNICATION; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SCHMIDT J, UNPUB; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O	32	94	96	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1991	254	5031					568	571		10.1126/science.1719633	http://dx.doi.org/10.1126/science.1719633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1719633				2022-12-24	WOS:A1991GL79900048
J	DRYER, SE; HENDERSON, D				DRYER, SE; HENDERSON, D			A CYCLIC GMP-ACTIVATED CHANNEL IN DISSOCIATED CELLS OF THE CHICK PINEAL-GLAND	NATURE			English	Article							SINGLE ION CHANNELS; ROD INNER SEGMENTS; PHOTOENDOCRINE TRANSDUCTION; CONCENTRATION-DEPENDENCE; MELATONIN RHYTHM; LIGHT	PHOTOTRANSDUCTION in the vertebrate retina is dependent in part on a cyclic GMP-activated ionic channel in the plasma membrane of rods and cones 1,2. But other vertebrate cells are also photosensitive. Cells of the chick pineal gland have a photosensitive circadian rhythm in melatonin secretion that persists in dissociated cell culture 3,4. Exposure to light causes inhibition of melatonin secretion, and entrainment of the intrinsic circadian oscillator 5,6. Chick pinealocytes express several 'retinal' proteins, including arrestin 7, transducin 8 and a protein similar to the visual pigment rhodopsin 9. Pinealocytes of lower vertebrates display hyperpolarizing responses to brief pulses of light 10,11. Thus it is possible that some of the mechanisms of phototransduction are similar in retinal and pineal photoreceptors. We report here the first recordings of cyclic GMP-activated channels in an extraretinal photoreceptor. Application of GMP, but not cyclic AMP, to excised inside-out patches caused activation of a 15-25 pS cationic channel. These channels may be essential for phototransduction in the chick pineal gland.			DRYER, SE (corresponding author), FLORIDA STATE UNIV, DEPT BIOL SCI B157, PROGRAM PSYCHOBIOL & NEUROSCI, TALLAHASSEE, FL 32306 USA.							COLLIN JP, 1986, NEUROSCIENCE, V19, P657, DOI 10.1016/0306-4522(86)90288-5; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; HARRISON NL, 1989, J NEUROSCI, V9, P2462; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; KAUPP UB, 1988, COLD SPRING HARB SYM, V53, P407, DOI 10.1101/SQB.1988.053.01.048; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MENINI A, 1990, J PHYSIOL-LONDON, V424, P167, DOI 10.1113/jphysiol.1990.sp018061; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAMOTSU S, 1986, J COMP PHYSIOL A, V159, P1, DOI 10.1007/BF00612489; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WAINWRIGHT SD, 1988, J NEUROCHEM, V413, P358; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X	19	97	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					756	758		10.1038/353756a0	http://dx.doi.org/10.1038/353756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719422				2022-12-24	WOS:A1991GL69600069
J	MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D				MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE 5HT3 RECEPTOR, A SEROTONIN-GATED ION CHANNEL	SCIENCE			English	Article							5-HT3 RECOGNITION SITES; NEURO-BLASTOMA CELLS; NICOTINIC ACETYLCHOLINE-RECEPTOR; CAPSAICIN-SENSITIVE FIBERS; NEUROBLASTOMA-GLIOMA CELLS; H-3 QUIPAZINE BINDING; RAT-BRAIN MEMBRANES; RADIOLIGAND BINDING; GLYCINE RECEPTOR; GABAA RECEPTOR	The neurotransmitter serotonin (5HT) activates a variety of second messenger signaling systems and through them indirectly regulates the function of ion channels. Serotonin also activates ion channels directly, suggesting that it may also mediate rapid, excitatory responses. A complementary DNA clone containing the coding sequence of one of these rapidly responding channels, a 5HT3 subtype of the serotonin receptor, has been isolated by screening a neuroblastoma expression library for functional expression of serotonin-gated currents in Xenopus oocytes. The predicted protein product has many of the features shared by other members of the ligand-gated ion channel family. The pharmacological and electrophysiological characteristics of the cloned receptor are largely consistent with the properties of native 5HT3 receptors. Messenger RNA encoding this receptor is found in the brain, spinal cord, and heart. This receptor defines a new class of excitatory ligand-gated channels.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM44298] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044298] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; BRANCHEK T, 1984, BRAIN RES, V324, P107, DOI 10.1016/0006-8993(84)90627-9; BUNCE K, 1991, TRENDS PHARMACOL SCI, V12, P46, DOI 10.1016/0165-6147(91)90493-C; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGEUX JP, 1990, TRENDS PHARM SCI; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COSTALL B, 1988, REV NEUROSCI, V2, P41; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DANI JA, 1989, TRENDS NEUROSCI, V12, P125, DOI 10.1016/0166-2236(89)90049-0; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; FRAZER A, 1990, ANNU REV PHARMACOL, V30, P307; GADDUM JH, 1957, BRIT J PHARM CHEMOTH, V12, P323, DOI 10.1111/j.1476-5381.1957.tb00142.x; GORDON JC, 1989, J PHARMACOL EXP THER, V251, P962; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V330, P25, DOI 10.1038/330025b0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMON M, 1989, EUR J PHARMACOL, V164, P315, DOI 10.1016/0014-2999(89)90472-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOYER D, 1987, EUR J PHARMACOL, V143, P291, DOI 10.1016/0014-2999(87)90547-4; HOYER D, 1988, MOL PHARMACOL, V33, P303; HOYER D, 1989, N-S ARCH PHARMACOL, V340, P396, DOI 10.1007/BF00167040; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KILPATRICK GJ, 1990, EUR J PHARMACOL, V182, P193, DOI 10.1016/0014-2999(90)90513-6; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT JJ, 1989, BRIT J PHARMACOL, V97, P27, DOI 10.1111/j.1476-5381.1989.tb11920.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MCKERNAN RM, 1990, J NEUROCHEM, V54, P924, DOI 10.1111/j.1471-4159.1990.tb02339.x; MCKERNAN RM, 1990, J BIOL CHEM, V265, P13572; MILBURN CM, 1989, J NEUROCHEM, V52, P1787, DOI 10.1111/j.1471-4159.1989.tb07258.x; MINNA JD, 1975, GENETICS, V79, P372; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NEIJT HC, 1988, NEUROPHARMACOLOGY, V27, P301, DOI 10.1016/0028-3908(88)90048-2; NEIJT HC, 1989, J PHYSIOL-LONDON, V411, P257, DOI 10.1113/jphysiol.1989.sp017572; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NUMA S, 1989, HARVEY LECT, V83, P121; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PEROUTKA SJ, 1988, ANNU REV NEUROSCI, V11, P45, DOI 10.1146/annurev.ne.11.030188.000401; PETERS JA, 1988, EUR J PHARMACOL, V151, P491, DOI 10.1016/0014-2999(88)90550-X; RAPPORT MM, 1948, J BIOL CHEM, V176, P1243; RICHARDSON BP, 1986, TRENDS NEUROSCI, V9, P424, DOI 10.1016/0166-2236(86)90137-2; RICHARDSON BP, 1985, NATURE, V316, P126, DOI 10.1038/316126a0; Richardson BP, 1988, NEURONAL SEROTONIN, P465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHAO XM, 1991, J NEUROPHYSIOL, V65, P630, DOI 10.1152/jn.1991.65.3.630; TUTTON PJM, 1987, ANTICANCER RES, V7, P1; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177	62	891	917	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					432	437		10.1126/science.1718042	http://dx.doi.org/10.1126/science.1718042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1718042				2022-12-24	WOS:A1991GK72900050
J	NUGENT, JM; PALMER, JD				NUGENT, JM; PALMER, JD			RNA-MEDIATED TRANSFER OF THE GENE COXII FROM THE MITOCHONDRION TO THE NUCLEUS DURING FLOWERING PLANT EVOLUTION	CELL			English	Article							OXIDASE SUBUNIT-II; CHLOROPLAST DNA; STRUCTURAL ORGANIZATION; OENOTHERA MITOCHONDRIA; RIBOSOMAL-PROTEIN; COMPLETE SEQUENCE; MESSENGER-RNAS; NO INTRON; EXPRESSION; GENOME	The gene coxII, normally present in the mitochondrion, was functionally transferred to the nucleus during flowering plant evolution. coxII transfer is estimated to have occurred between 60 and 200 million years ago, whereas loss of coxII from the mitochondrion occurred much more recently, being restricted to a single genus of legumes. Most legumes have coxII in both the nucleus and the mitochondrion; however, no evidence is found for simultaneous coxII expression in both compartments. The nuclear coxII sequence more closely resembles edited mitochondrial coxII transcripts than the genes encoding these RNAs. Hence, gene transfer appears to have involved reverse transcription of an edited RNA intermediate. The nuclear gene contains an intron at the junction of the transit peptide sequence and the mature protein-coding sequence; exon shuffling may have played a role in assembling a functional coxII gene in the nucleus.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	NUGENT, JM (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48104 USA.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1988, PLANT MOL BIOL REPOR, DOI DOI 10.1007/BF02669591; BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BARTNIK E, 1986, NUCLEIC ACIDS RES, V14, P2407, DOI 10.1093/nar/14.5.2407; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; CREPET WL, 1985, SCIENCE, V228, P1087, DOI 10.1126/science.228.4703.1087; Cronquist A., 1988, EVOLUTION CLASSIFICA; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DONOGHUE MJ, 1989, INT CONGR SER, V824, P181; Doyle JJ., 1987, PHYTOCHEM B, V19, P11, DOI DOI 10.2307/2419362; DROUIN G, 1987, NATURE, V328, P557, DOI 10.1038/328557a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROMAN BE, 1989, MOL GEN GENET, V217, P126, DOI 10.1007/BF00330951; GANTT JS, IN PRESS EMBO J; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRABAU EA, 1987, CURR GENET, V11, P287, DOI 10.1007/BF00355402; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUALBERTO JM, 1990, NUCLEIC ACIDS RES, V18, P3771, DOI 10.1093/nar/18.13.3771; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1983, EMBO J, V2, P2173, DOI 10.1002/j.1460-2075.1983.tb01719.x; HIESEL R, 1990, CURR GENET, V18, P371, DOI 10.1007/BF00318219; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IZUCHI S, 1990, CURR GENET, V18, P239, DOI 10.1007/BF00318387; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAO TH, 1984, NUCLEIC ACIDS RES, V12, P7305, DOI 10.1093/nar/12.19.7305; KIM YH, 1990, J BIOL CHEM, V265, P848; KOLODNER R, 1972, P NATL ACAD SCI USA, V69, P1830, DOI 10.1073/pnas.69.7.1830; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MOON E, 1985, NUCLEIC ACIDS RES, V13, P3195, DOI 10.1093/nar/13.9.3195; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; NUGENT JM, 1988, CURR GENET, V14, P501, DOI 10.1007/BF00521276; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; Polhill R.M., 1981, ADV LEGUME SYSTEMATI, P191; PRUITT KD, 1989, CURR GENET, V16, P281, DOI 10.1007/BF00422115; Sambrook J., 1982, MOL CLONING; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1990, MOL CELL BIOL, V10, P2428, DOI 10.1128/MCB.10.5.2428; SCHUSTER W, 1987, EMBO J, V6, P2857, DOI 10.1002/j.1460-2075.1987.tb02587.x; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Stern D. B., 1988, METHODS PLANT MOL BI, P309; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WAHLEITHNER JA, 1988, NUCLEIC ACIDS RES, V16, P6897, DOI 10.1093/nar/16.14.6897; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	66	284	291	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					473	481		10.1016/0092-8674(81)90011-8	http://dx.doi.org/10.1016/0092-8674(81)90011-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1714355	Green Published			2022-12-24	WOS:A1991GA94100009
J	HEUS, HA; PARDI, A				HEUS, HA; PARDI, A			STRUCTURAL FEATURES THAT GIVE RISE TO THE UNUSUAL STABILITY OF RNA HAIRPINS CONTAINING GNRA LOOPS	SCIENCE			English	Article							SECONDARY STRUCTURE; CONFORMATIONAL-ANALYSIS; RIBOSOMAL-RNA; SRP RNA; ACID; REGION; DNA	The most frequently occurring RNA hairpins in 16S and 23S ribosomal RNA contain a tetranucleotide loop that has a GNRA consensus sequence. The solution structures of the GCAA and GAAA hairpins have been determined by nuclear magnetic resonance spectroscopy. Both loops contain an unusual G-A base pair between the first and last residue in the loop, a hydrogen bond between a G base and a phosphate, extensive base stacking, and a hydrogen bond between a sugar 2'-end OH and a base. These interactions explain the high stability of these hairpins and the sequence requirements for the variant and invariant nucleotides in the GNRA tetranucleotide loop family.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027026, R37AI030726, R01AI030726] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI 27026, AI 30726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHIN MR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P110, DOI 10.1016/0167-4781(90)90150-Z; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; ENDO Y, 1988, J BIOL CHEM, V263, P7917; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HANEY J, COMMUNICATION; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HEUS HA, UNPUB; JAQUIR A, 1987, CELL, V54, P17; LANKHORST PP, 1984, J BIOMOL STRUCT DYN, V1, P1387, DOI 10.1080/07391102.1984.10507527; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LIAO X, 1989, P NATL ACAD SCI USA, V86, P4837; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; van Knippenberg PH, 1986, STRUCTURE FUNCTION G, P412; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44	23	613	631	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					191	194		10.1126/science.1712983	http://dx.doi.org/10.1126/science.1712983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712983				2022-12-24	WOS:A1991FW16000035
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW THERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P793	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-24	WOS:A1991FU89600004
J	LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM				LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM			ENHANCEMENT OF HIV-1 CYTOCIDAL EFFECTS IN CD4+ LYMPHOCYTES BY THE AIDS-ASSOCIATED MYCOPLASMA	SCIENCE			English	Article							INFECTIOUS AGENT VLIA; HTLV-III/LAV ENVELOPE; CELL-FUSION; VIRUS; IDENTIFICATION; INCOGNITUS; INDUCTION	Coinfection with Mycoplasma fermentans (incognitus strain) enhances the ability of human immunodeficiency virus type-1 (HIV-1) to induce cytopathic effects on human T lymphocytes in vitro. Syncytium formation of HIV-infected T cells was essentially eliminated in the presence of M. fermentans (incognitus strain), despite prominent cell death. However, replication and production of HIV-1 particles continued during the coinfection. Furthermore, the supernatant from cultures coinfected with HIV-1 and the mycoplasma contained a factor that inhibited the standard reverse transcriptase enzyme assay. The modification of the biological properties of HIV-1 by coinfection with mycoplasma may be involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS).	BIOTECH RES LABS INC,ROCKVILLE,MD 20852; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	LO, SC (corresponding author), ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306, USA.							BALTIMORE D, 1971, P NATL ACAD SCI USA, V68, P1507, DOI 10.1073/pnas.68.7.1507; CHOWDHURY MIH, 1990, LANCET, V336, P247; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; LEMAITRE M, 1990, RES VIROLOGY, V141, P5, DOI 10.1016/0923-2516(90)90052-K; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LO SC, 1986, AM J TROP MED HYG, V35, P675, DOI 10.4269/ajtmh.1986.35.675; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1989, AM J TROP MED HYG, V41, P586, DOI 10.4269/ajtmh.1989.41.586; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO ST, UNPUB; MARCUS JI, 1990, J CELL PHYSL, V143, P416; SAILLARD C, 1990, RES VIROLOGY, V141, P385, DOI 10.1016/0923-2516(90)90010-G; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; VASNDEVACHARI MB, 1990, AIDS RES HUM RETROV, V6, P411; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1989, 5 INT C AIDS MONTR	20	141	145	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1074	1076		10.1126/science.1705362	http://dx.doi.org/10.1126/science.1705362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1705362				2022-12-24	WOS:A1991EZ66500051
J	ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS				ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS			A CONSENSUS MOTIF COMMON TO ALL RHO-DEPENDENT PROKARYOTIC TRANSCRIPTION TERMINATORS	CELL			English	Article							ESCHERICHIA-COLI K-12; RIBOSOMAL-RNA TRANSCRIPTION; SALMONELLA-TYPHIMURIUM; HISTIDINE OPERON; BACTERIOPHAGE-LAMBDA; INTERCISTRONIC REGION; REGULATORY REGION; GENE-EXPRESSION; BINDING DOMAIN; SITES	We have characterized at the molecular level several polar mutations in four different cistrons of the his operon of S. typhimurium. An analysis of the his-specific transcripts produced in vivo in the mutant strains, together with in vitro transcription assays, led to the identification of several cryptic Rho-dependent transcription termination elements within the his operon that are activated by the uncoupling of transcription and translation. Common features of these elements were sought and found with a computer program. We have identified a consensus motif, consisting of a cytosine-rich and guanosine-poor region, that is located upstream of the heterogeneous 3' endpoints of the prematurely terminated in vivo transcripts and that is present in all the Rho-dependent transcription terminators described thus far.			ALIFANO, P (corresponding author), NAPLES UNIV,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY.							ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; AKSOY S, 1984, J BACTERIOL, V159, P260, DOI 10.1128/JB.159.1.260-264.1984; ALIFANO P, 1988, CELL, V55, P351, DOI 10.1016/0092-8674(88)90058-X; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRUNI CB, 1980, J BACTERIOL, V142, P32, DOI 10.1128/JB.142.1.32-42.1980; BURGIN AB, 1990, CELL, V60, P405, DOI 10.1016/0092-8674(90)90592-3; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CARLOMAGNO MS, 1985, J BACTERIOL, V163, P362, DOI 10.1128/JB.163.1.362-368.1985; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CIAMPI MS, 1989, J BACTERIOL, V171, P4472, DOI 10.1128/JB.171.8.4472-4478.1989; CIAMPI MS, 1988, GENETICS, V218, P193; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; Favaloro J, 1980, Methods Enzymol, V65, P718; FINK GR, 1967, J MOL BIOL, V30, P97, DOI 10.1016/0022-2836(67)90246-X; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GARRICKS.L, 1970, GENETICS, V66, P231; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOODMAN HM, 1980, METHOD ENZYMOL, V75, P63; GOTTESMAN M, 1982, CELL, V29, P727, DOI 10.1016/0092-8674(82)90434-2; GRISOLIA V, 1982, J BACTERIOL, V151, P692, DOI 10.1128/JB.151.2.692-700.1982; HARTMAN PE, 1971, ADV GENET, V16, P1, DOI 10.1016/S0065-2660(08)60352-1; HIGGINS CF, 1986, SOC GENERAL MICROBIO, V39, P179; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HOPPE I, 1979, GENETICS, V92, P17; HYMAN HC, 1986, J MOL BIOL, V189, P131, DOI 10.1016/0022-2836(86)90386-4; JOHNSTON HM, 1979, GENETICS, V92, P1; KASAI T, 1974, NATURE, V249, P523, DOI 10.1038/249523a0; KIESER T, 1988, GENE, V65, P83, DOI 10.1016/0378-1119(88)90419-2; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1966, J MOL BIOL, V21, P357, DOI 10.1016/0022-2836(66)90104-5; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NEWTON WA, 1965, J MOL BIOL, V14, P290, DOI 10.1016/S0022-2836(65)80250-9; RECHLER MM, 1972, J MOL BIOL, V69, P427, DOI 10.1016/0022-2836(72)90256-2; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENTHAL ER, 1987, J MOL BIOL, V194, P443, DOI 10.1016/0022-2836(87)90673-5; ROSSI J, 1981, CELL, V26, P305, DOI 10.1016/0092-8674(81)90199-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STITT BL, 1988, J BIOL CHEM, V263, P11130; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERDE P, 1981, NUCLEIC ACIDS RES, V9, P2075, DOI 10.1093/nar/9.9.2075; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; VOLL MJ, 1967, J MOL BIOL, V30, P109, DOI 10.1016/0022-2836(67)90247-1; WEK RC, 1987, J BIOL CHEM, V262, P15256; WHITFIELD HJ, 1966, J MOL BIOL, V21, P335, DOI 10.1016/0022-2836(66)90103-3; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1987, ESCHERICHIA COLI SAL, V1, P1241; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0	72	123	124	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					553	563						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1703923				2022-12-24	WOS:A1991EX36100011
J	GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H				GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H			INVITRO EFFECTS ON MICROTUBULE DYNAMICS OF PURIFIED XENOPUS M-PHASE-ACTIVATED MAP KINASE	NATURE			English	Article							SERINE-THREONINE KINASE; PROTEIN-KINASE; PHOSPHORYLATION; INSULIN; OOCYTES; EGGS; CENTROSOMES; MATURATION; TYROSINE; EXTRACTS	THE protein kinase MAP kinase, also called MAP2 kinase, is a serine/threonine kinase whose activation and phosphorylation are induced by a variety of mitogens 1-6, and which is thought to have a critical role in a network of protein kinases in mitogenic signal transduction 1-7. A burst in kinase activation 8,9 and protein phosphorylation 10 may also be important in triggering the dramatic reorganization of the cell during the transition from interphase to mitosis. The interphase-metaphase transition of microtubule arrays is under the control of p34cd2 kinase 11, a central control element in the G2-M transition of the cell cycle 12. Here we show that a Xenopus kinase, closely related to the mitogen-activated mammalian MAP kinase, is phosphorylated and activated during M phase of meiotic and mitotic cell cycles, and that the interphase-metaphase transition of microtubule arrays can be induced by the addition of purified Xenous M phase-activated MAP kinase or mammalian mitogen-activated MAP kinase to interphase extracts in vitro.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,INST ZOOL,TOKYO 113,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; University of Tokyo; Osaka University				Shiina, Nobuyuki/0000-0002-1854-4239				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; STITH BJ, 1984, DEV BIOL, V102, P79, DOI 10.1016/0012-1606(84)90176-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0	26	424	430	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					251	254		10.1038/349251a0	http://dx.doi.org/10.1038/349251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1702878				2022-12-24	WOS:A1991ET51900060
J	OCONNELL, AM; KOEPPE, RE; ANDERSEN, OS				OCONNELL, AM; KOEPPE, RE; ANDERSEN, OS			KINETICS OF GRAMICIDIN CHANNEL FORMATION IN LIPID BILAYERS - TRANSMEMBRANE MONOMER ASSOCIATION	SCIENCE			English	Article									UNIV ARKANSAS,DEPT CHEM & BIOCHEM,FAYETTEVILLE,AR 72701	University of Arkansas System; University of Arkansas Fayetteville	OCONNELL, AM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021, USA.			Koeppe, Roger/0000-0003-0676-6413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034968, R01GM021342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34968, GM21342, R01 GM021342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMDUR I, 1965, CHEM KINETICS PRINCI, P16; ANDERSEN OS, 1990, BIOPHYS J, V57, pA100; ANDERSEN OS, 1982, J GEN PHYSIOL, V80, P403, DOI 10.1085/jgp.80.3.403; ARSENIEV AS, 1985, FEBS LETT, V186, P168, DOI 10.1016/0014-5793(85)80702-X; BANO MC, 1989, FEBS LETT, V250, P67, DOI 10.1016/0014-5793(89)80686-6; BUSTER DC, 1988, BIOPHYS J, V53, P145, DOI 10.1016/S0006-3495(88)83076-5; BYSTROV VF, 1988, TETRAHEDRON, V44, P925, DOI 10.1016/S0040-4020(01)86126-3; CIFU AS, 1989, BIOPHYS J, V55, pA503; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; DURKIN JT, 1987, BIOPHYS J, V51, pA451; DURKIN JT, 1990, J MOL BIOL, V211, P221, DOI 10.1016/0022-2836(90)90022-E; EASTON PL, 1989, THESIS U ARKANSAS FA; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HAWKES GE, 1987, EUR J BIOCHEM, V166, P437, DOI 10.1111/j.1432-1033.1987.tb13535.x; HLADKY SB, 1974, DRUGS TRANSPORT PROC, P193; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; KEMP G, 1976, ARCH BIOCHEM BIOPHYS, V176, P547, DOI 10.1016/0003-9861(76)90198-3; KILLIAN JA, 1988, BIOPHYS J, V53, P111, DOI 10.1016/S0006-3495(88)83072-8; KILLIAN JA, 1988, BIOCHEMISTRY-US, V27, P7295, DOI 10.1021/bi00419a018; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; LOGRASSO PV, 1988, BIOPHYS J, V54, P259, DOI 10.1016/S0006-3495(88)82955-2; MADDOCK AK, 1989, ICSU SHORT REP, V9, P24; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; PULLMAN A, 1988, TRANSPORT MEMBRANES; ROUX B, 1990, THESIS HARVARD U CAM; RUSSELL EWB, 1986, BIOPHYS J, V49, P673, DOI 10.1016/S0006-3495(86)83694-3; SALEMME FR, 1988, SCIENCE, V241, P145, DOI 10.1126/science.2455343; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; SAWYER DB, 1990, BIOPHYS J, V57, P515, DOI 10.1016/S0006-3495(90)82567-4; SAWYER DB, 1989, BIOCHEMISTRY-US, V28, P6571, DOI 10.1021/bi00442a007; SYCHEV SV, 1980, BIOORG CHEM, V9, P121, DOI 10.1016/0045-2068(80)90035-8; URRY DW, 1975, ANN NY ACAD SCI, V264, P203, DOI 10.1111/j.1749-6632.1975.tb31484.x; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5257, DOI 10.1021/bi00723a002; WALLACE BA, 1988, SCIENCE, V241, P181; WALLACE BA, 1987, ION TRANSPORT MEMBRA, P255	39	227	229	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1256	1259		10.1126/science.1700867	http://dx.doi.org/10.1126/science.1700867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700867				2022-12-24	WOS:A1990EK72300037
J	LARSEN, E; PALABRICA, T; SAJER, S; GILBERT, GE; WAGNER, DD; FURIE, BC; FURIE, B				LARSEN, E; PALABRICA, T; SAJER, S; GILBERT, GE; WAGNER, DD; FURIE, BC; FURIE, B			PADGEM-DEPENDENT ADHESION OF PLATELETS TO MONOCYTES AND NEUTROPHILS IS MEDIATED BY A LINEAGE-SPECIFIC CARBOHYDRATE, LNF-III (CD15)	CELL			English	Article									TUFTS UNIV,SCH MED,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Tufts University; Tufts Medical Center; Tufts University; Tufts University; Tufts University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007437, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443, HL07437, HL07574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTSEN M, 1989, BRIT J HAEMATOL, V72, P312, DOI 10.1111/j.1365-2141.1989.tb07710.x; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BRANDLEY BK, 1986, J LEUKOCYTE BIOL, V40, P97, DOI 10.1002/jlb.40.1.97; CALLOW AD, 1982, ARCH SURG-CHICAGO, V117, P1447; CARLSSON SR, 1986, J BIOL CHEM, V261, P1287; CHRISTIANSEN NP, 1988, BLOOD, V71, P1624; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HALL PA, 1987, J CLIN PATHOL, V40, P1298, DOI 10.1136/jcp.40.11.1298; HAMBURGER SA, 1990, BLOOD, V75, P550; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUANG LC, 1983, BLOOD, V61, P1020; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUNGI TW, 1986, BLOOD, V67, P629; KOBATA A, 1969, J BIOL CHEM, V244, P5496; KOLBER MA, 1988, J IMMUNOL METHODS, V108, P255, DOI 10.1016/0022-1759(88)90427-9; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LINDENBERG S, 1988, J REPROD FERTIL, V83, P149; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; NAUSEEF WM, 1983, BLOOD, V62, P636; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; SANDERS DSA, 1988, J PATHOL, V154, P255, DOI 10.1002/path.1711540308; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V1648, P1373; SKUBITZ KM, 1988, J IMMUNOL, V141, P4318; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1987, BLOOD, V70, P1842; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TEDDER TF, 1989, J IMMUNOL, V143, P712; YANG HJ, 1971, J BIOL CHEM, V246, P1192	40	345	384	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 2	1990	63	3					467	474		10.1016/0092-8674(90)90443-I	http://dx.doi.org/10.1016/0092-8674(90)90443-I			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699666				2022-12-24	WOS:A1990EG68700005
J	BIERER, BE; SOMERS, PK; WANDLESS, TJ; BURAKOFF, SJ; SCHREIBER, SL				BIERER, BE; SOMERS, PK; WANDLESS, TJ; BURAKOFF, SJ; SCHREIBER, SL			PROBING IMMUNOSUPPRESSANT ACTION WITH A NONNATURAL IMMUNOPHILIN LIGAND	SCIENCE			English	Article									HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; BRIGHAM & WOMENS HOSP,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-39542] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BIERER BE, IN PRESS P NATL ACAD; BLANCHETTE MA, 1984, TETRAHEDRON LETT, V25, P2183, DOI 10.1016/S0040-4039(01)80205-7; BURKE SD, 1987, TETRAHEDRON LETT, V28, P3905, DOI 10.1016/S0040-4039(00)96416-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; GILLIS S, 1978, J IMMUNOL, V120, P2027; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENTGES SG, 1980, J AM CHEM SOC, V102, P4263, DOI 10.1021/ja00532a050; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; NAKATA T, 1983, TETRAHEDRON LETT, V24, P2653, DOI 10.1016/S0040-4039(00)87969-1; NAKATSUKA M, 1990, J AM CHEM SOC, V112, P5583, DOI 10.1021/ja00170a024; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; WANDLESS TJ, UNPUB; WILLIAMS DR, 1988, J ORG CHEM, V53, P4643, DOI 10.1021/jo00254a060	24	340	359	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 26	1990	250	4980					556	559		10.1126/science.1700475	http://dx.doi.org/10.1126/science.1700475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE660	1700475				2022-12-24	WOS:A1990EE66000037
J	LEVI, S; GOODLAD, RA; LEE, CY; STAMP, G; WALPORT, MJ; WRIGHT, NA; HODGSON, HJF				LEVI, S; GOODLAD, RA; LEE, CY; STAMP, G; WALPORT, MJ; WRIGHT, NA; HODGSON, HJF			INHIBITORY EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON MUCOSAL CELL-PROLIFERATION ASSOCIATED WITH GASTRIC-ULCER HEALING	LANCET			English	Article									ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND; IMPERIAL CANC RES FUND,HISTOPATHOL UNIT,LONDON WC2A 3PX,ENGLAND	Imperial College London; Cancer Research UK			Wright, Nicholas/HHY-7227-2022	Walport, Mark/0000-0001-7220-5273; Goodlad, Robert/0000-0002-7660-4287; Wright, Nicholas/0000-0002-5525-3457				ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; GOODLAD RA, 1989, GUT, V30, P316, DOI 10.1136/gut.30.3.316; GOODLAD RA, IN PRESS GUT; GRAHAM DY, 1988, GASTROENTEROLOGY, V95, P327, DOI 10.1016/0016-5085(88)90487-8; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HANSEN OH, 1975, GUT, V16, P23, DOI 10.1136/gut.16.1.23; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; INAUEN W, 1988, GASTROENTEROLOGY, V95, P636, DOI 10.1016/S0016-5085(88)80009-X; ITO S, 1985, GASTROENTEROLOGY, V88, P250, DOI 10.1016/S0016-5085(85)80178-5; LAMY PP, 1987, SIDE EFFECTS ANTIINF, P151; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; LEUNG FW, 1985, GASTROENTEROLOGY, V88, P1948, DOI 10.1016/0016-5085(85)90024-1; OTTO AM, 1982, P NATL ACAD SCI-BIOL, V79, P4992, DOI 10.1073/pnas.79.16.4992; RICHARDSON CT, 1978, GASTROINTESTINAL DIS, P876; SOMERVILLE K, 1986, LANCET, V1, P462; WANG JY, 1989, GASTROENTEROLOGY, V96, P393, DOI 10.1016/0016-5085(89)91563-1; WHITTLE BJR, 1981, GASTROENTEROLOGY, V80, P94	17	183	191	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 6	1990	336	8719					840	843		10.1016/0140-6736(90)92341-E	http://dx.doi.org/10.1016/0140-6736(90)92341-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB901	1699093				2022-12-24	WOS:A1990EB90100005
J	RIDEOUT, WM; COETZEE, GA; OLUMI, AF; JONES, PA				RIDEOUT, WM; COETZEE, GA; OLUMI, AF; JONES, PA			5-METHYLCYTOSINE AS AN ENDOGENOUS MUTAGEN IN THE HUMAN LDL RECEPTOR AND P53 GENES	SCIENCE			English	Article									UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,UROL CANC RES LAB,LOS ANGELES,CA 90033	University of Southern California			coetzee, Gerhard/AAT-6203-2020; Coetzee, Gerhard/AAG-8439-2019	Coetzee, Gerhard/0000-0001-8820-8364	NATIONAL CANCER INSTITUTE [R35CA049758, T32CA009569] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA49758, T32 CA09569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BIRD AP, 1978, J MOL BIOL, V118, P49, DOI 10.1016/0022-2836(78)90243-7; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRIPPO P, 1968, J MOL BIOL, V36, P195, DOI 10.1016/0022-2836(68)90375-6; HO YK, 1976, J CLIN INVEST, V58, P1465, DOI 10.1172/JCI108603; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; LEITERSDORF E, 1989, J CLIN INVEST, V84, P954, DOI 10.1172/JCI114258; LINDAHL T, 1979, PROG NUCLEIC ACID RE, V22, P135; LUBBERT M, 1989, ONCOGENE, V4, P643; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RIDEOUT WM, UNPUB; SELKER EU, 1987, MOL CELL BIOL, V7, P1032, DOI 10.1128/MCB.7.3.1032; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; TSAI YC, 1990, CANCER RES, V50, P44; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	26	588	602	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 14	1990	249	4974					1288	1290		10.1126/science.1697983	http://dx.doi.org/10.1126/science.1697983			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DY351	1697983				2022-12-24	WOS:A1990DY35100035
J	FORSTER, AC; ALTMAN, S				FORSTER, AC; ALTMAN, S			EXTERNAL GUIDE SEQUENCES FOR AN RNA ENZYME	SCIENCE			English	Article									YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019422, R37GM019422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; [Anonymous], COMMUNICATION; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; FORSTER AC, 1988, NATURE, V334, P265, DOI 10.1038/334265a0; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; GUERRIERTAKADA C, 1988, CELL, V53, P267, DOI 10.1016/0092-8674(88)90388-1; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1989, GENE, V82, P43, DOI 10.1016/0378-1119(89)90028-0; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; MARSH TL, 1985, SCIENCE, V229, P79, DOI 10.1126/science.4012313; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; ORELLANA O, 1986, MOL CELL BIOL, V6, P525, DOI 10.1128/MCB.6.2.525; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; WALDER J, 1988, GENE DEV, V2, P502, DOI 10.1101/gad.2.5.502; WYATT JR, 1989, NUCLEIC ACIDS RES, V17, P7833, DOI 10.1093/nar/17.19.7833; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	36	248	321	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 17	1990	249	4970					783	786		10.1126/science.1697102	http://dx.doi.org/10.1126/science.1697102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV088	1697102				2022-12-24	WOS:A1990DV08800033
J	KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P				KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P			A FAR UPSTREAM ESTROGEN RESPONSE ELEMENT OF THE OVALBUMIN GENE CONTAINS SEVERAL HALF-PALINDROMIC 5'-TGACC-3' MOTIFS ACTING SYNERGISTICALLY	CELL			English	Article							RETINOIC ACID RECEPTOR; CHICKEN PROGESTERONE-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; MAMMARY-TUMOR VIRUS; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE BINDING; ENHANCER ELEMENTS; NUCLEAR RECEPTORS; STEROID-HORMONES; THYROID-HORMONE	We have identified an estrogen-responsive enhancer element (DH3 ERE) in the estrogen-induced DNAase I-hypersensitive region III of the chicken ovalbumin gene, which is located approximately 3.3 kb upstream from the mRNA start site and does not contain palindromic ERE. Four TGACC half-palindromic motifs, separated from each other by more than 100 bp, are responsible for conferring estrogen inducibility either to the proximal ovalbumin gene promoter or to heterologous promoters. Thus, widely spaced half-palindromic ERE motifs can act synergistically. Each half-palindromic motif was shown to bind the estrogen receptor (ER) with a low efficiency in vitro. However, two widely spaced half-palindromic motifs bound the ER cooperatively, much more efficiently than expected from binding to isolated half-ERE motifs. The ovalbumin promoter half-palindromic ERE motif located close to the TATA box was required for the activity of the distal DH3 ERE, but could be replaced by the binding sites of other transactivators.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	KATO, S (corresponding author), TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN.		Jansen, Heiko T./A-5770-2008; Tora, Laszlo/E-9999-2018	Jansen, Heiko T./0000-0003-0178-396X; Tora, Laszlo/0000-0001-7398-2250				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUB MP, 1987, EMBO J, V6, P2313, DOI 10.1002/j.1460-2075.1987.tb02506.x; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PALMITER RD, 1977, COLD SPRING HARB SYM, V42, P639, DOI 10.1101/SQB.1978.042.01.066; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	59	282	289	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					731	742		10.1016/0092-8674(92)90148-6	http://dx.doi.org/10.1016/0092-8674(92)90148-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739978				2022-12-24	WOS:A1992HF44000013
J	KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P				KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P			L-MONOCYTOGENES-INDUCED ACTIN ASSEMBLY REQUIRES THE ACTA GENE-PRODUCT, A SURFACE PROTEIN	CELL			English	Article							CELL-LINE CACO-2; LISTERIA-MONOCYTOGENES; SHIGELLA-FLEXNERI; INTRACELLULAR GROWTH; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; F-ACTIN; SPREAD; IDENTIFICATION; PLASMID	The intracellular pathogenic bacterium L. monocytogenes can spread directly from cell to cell without leaving the cytoplasm. The mechanism of this movement, generated through bacterially induced actin polymerization, is not understood. By analyzing an avirulent Tn917-lac mutant defective for actin polymerization, we have identified a bacterial component involved in this process. The transposon had inserted in actA, the second gene of an operon. Gene disruption of downstream genes and transformation of the mutant strain with actA showed that the actA gene encodes a surface protein necessary for bacterially induced actin assembly. Our results indicate that it is a 610 amino acid protein with an apparent molecular weight of 90 kd.	INST PASTEUR,CENT MICROSCOPIE ELECTR STN,F-75724 PARIS 15,FRANCE; UNIV PARIS 05,MICROBIOL LAB,F-75730 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	KOCKS, C (corresponding author), INST PASTEUR,GENET MOLEC LISTERIA LAB,25 & 28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			TABOURET, Marc/0000-0003-0499-2804				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRYAN J, 1989, J BIOL CHEM, V264, P13873; COSSART P, 1989, MOL BIOL MED, V6, P463; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DERYCKE J, 1989, J CLIN MICROBIOL, V27, P983, DOI 10.1128/JCM.27.5.983-988.1989; DOMANN E, 1991, INFECT IMMUN, V59, P65, DOI 10.1128/IAI.59.1.65-72.1991; FUZI M, 1962, NATURE, V13, P195; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAVELL EA, 1986, INFECT IMMUN, V54, P787, DOI 10.1128/IAI.54.3.787-792.1986; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; KUHN M, 1990, INFECT IMMUN, V58, P3477, DOI 10.1128/IAI.58.11.3477-3486.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; LUCAS RD, 1989, LETT APPL MICROBIOL, V9, P215, DOI 10.1111/j.1472-765X.1989.tb00329.x; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENGAUD J, 1991, MOL MICROBIOL, V5, P2273, DOI 10.1111/j.1365-2958.1991.tb02158.x; MENGAUD J, 1989, INFECT IMMUN, V57, P3695, DOI 10.1128/IAI.57.12.3695-3701.1989; MENGAUD J, 1991, INFECT IMMUN, V59, P1043, DOI 10.1128/IAI.59.3.1043-1049.1991; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PAL T, 1989, INFECT IMMUN, V57, P477; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; RACZ P, 1970, ACTA MICROBIOL HUNG, V17, P221; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW JH, 1985, J BACTERIOL, V164, P782, DOI 10.1128/JB.164.2.782-796.1985; SULLIVAN M, 1984, GENE, V29, P24; SUN AN, 1990, INFECT IMMUN, V58, P3770, DOI 10.1128/IAI.58.11.3770-3778.1990; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VICENTE MF, 1985, FEMS MICROBIOL LETT, V30, P77; WEST RR, 1991, J BIOL CHEM, V266, P21886; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	48	655	691	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					521	531		10.1016/0092-8674(92)90188-I	http://dx.doi.org/10.1016/0092-8674(92)90188-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739966				2022-12-24	WOS:A1992HD39800012
J	GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM				GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM			ESTABLISHMENT OF PREGNANCY AFTER REMOVAL OF SPERM ANTIBODIES INVITRO	BRITISH MEDICAL JOURNAL			English	Article									PRINCESS ROYAL HOSP,HULL,ENGLAND		GRUNDY, CE (corresponding author), UNIV HULL,DEPT APPL BIOL,HULL HU6 7RX,N HUMBERSIDE,ENGLAND.							BRONSON R, 1984, FERTIL STERIL, V42, P171; CLARKE GN, 1985, AM J REPROD IM MIC, V8, P62; GRUNDY CE, 1991, HUM REPROD, V6, P593, DOI 10.1093/oxfordjournals.humrep.a137385; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1988, J ANDROL, V9, P190	5	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					292	293		10.1136/bmj.304.6822.292-a	http://dx.doi.org/10.1136/bmj.304.6822.292-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739830	Green Published, Bronze			2022-12-24	WOS:A1992HC70800023
J	SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R				SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R			EVIDENCE THAT DYSLEXIA MAY REPRESENT THE LOWER TAIL OF A NORMAL-DISTRIBUTION OF READING-ABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETARDATION; PREVALENCE; BOYS	Background. Dyslexia is now widely believed to be a biologically based disorder that is distinct from other, less specific reading problems. According to this view, reading ability is considered to follow a bimodal distribution, with dyslexia as the lower mode. We hypothesized that, instead, reading ability follows a normal distribution, with dyslexia at the lower end of the continuum. Methods and Results. We used data from the Connecticut Longitudinal Study, a sample survey of 414 Connecticut children who entered kindergarten in 1983 and were followed as a longitudinal cohort. Dyslexia was defined in terms of a discrepancy score, which represents the difference between actual reading achievement and achievement predicted on the basis of measures of intelligence. Data were available from intelligence tests administered in grades 1, 3, and 5 and achievement tests administered yearly in grades 1 through 6. For each child there were 108 possible discrepancy scores ([3 x 3 years] x [2 x 6 years]) based on combinations of the ability scores (full-scale, verbal, and performance 10) in each of three years and two achievement scores (reading and mathematics) in each of six years. We demonstrated that each of the discrepancy scores followed a univariate normal distribution and that the interrelation of two different discrepancy scores followed a bivariate normal distribution. At most, only 9 of 108 discrepancy scores (8.3 percent) and 171 of 3402 pairs of discrepancy scores (5-0 percent) were significantly different (at the 5 percent level) from the expected scores - well within the expected values for data with univariate and bivariate normal distributions, respectively. We also examined the stability of dyslexia over time. The normal-distribution model predicted (and the data indicated) that only 7 of the 25 children (28 percent) classified as having dyslexia in grade 1 would also be classified as having dyslexia in grade 3. Conclusions. Reading difficulties, including dyslexia, occur as part of a continuum that also includes normal reading ability. Dyslexia is not an all-or-none phenomenon, but like hypertension, occurs in degrees. The variability inherent in the diagnosis of dyslexia can be both quantified and predicted with use of the normal-distribution model.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR CHILD STUDY,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DIV BIOSTAT,NEW HAVEN,CT 06510; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; UNIV TEXAS,DEPT PEDIAT,HOUSTON,TX 77025	Yale University; Yale University; Yale University; Carnegie Mellon University; University of Texas System	SHAYWITZ, SE (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 3333,NEW HAVEN,CT 06510, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NICHD NIH HHS [P01 HD21888, P50 HD25802] Funding Source: Medline; NIMH NIH HHS [MH15758] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD021888, P50HD025802] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BADIAN NA, 1982, J SPEC EDUC, V16, P309, DOI 10.1177/002246698201600306; BADIAN NA, 1988, PRESCHOOL PREVENTION, P78; CONE TE, 1981, LEARN DISABILITY Q, V4, P359, DOI 10.2307/1510737; CRITCHLEY M, 1970, DYSLEXIC CHILD; de Hirsch K., 1966, PREDICTING READING F; HOGG R, 1970, INTRO MATH STAT, P166; JANSKY JJ, 1989, ANN DYSLEXIA, V39, P227, DOI 10.1007/BF02656911; MAKUCH RW, 1989, STATISTICIAN, V38, P61; PRENTICE RL, 1986, J AM STAT ASSOC, V81, P321, DOI 10.2307/2289219; REYNOLDS CR, 1984, J SPEC EDUC, V18, P451, DOI 10.1177/002246698401800403; Reynolds CR, 1990, HDB PSYCHOL ED ASSES, P571; RODGERS B, 1983, BRIT J EDUC PSYCHOL, V53, P369, DOI 10.1111/j.2044-8279.1983.tb02570.x; RUTTER M, 1975, J CHILD PSYCHOL PSYC, V16, P181, DOI 10.1111/j.1469-7610.1975.tb01269.x; RUTTER M, 1981, ED HLTH BEHAVIOR; SATTLER JM, 1988, ASSESSMENT CHILDRENS; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SILVA PA, 1985, J CHILD PSYCHOL PSYC, V26, P407, DOI 10.1111/j.1469-7610.1985.tb01942.x; THORNDIKE RL, 1963, CONCEPTS OVER UNDER; VANDERWISSEL A, 1985, BRIT J DEV PSYCHOL, V3, P3; Wechsler DW., 1999, INTELLIGENCE SCALE C; Woodcock R.W., 1977, WOODCOCK JOHNSON PSY; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x; YULE W, 1985, CHILD ADOLESCENT PSY, P444; 1977, FED REGISTER, V42, P62082; 1989, JAMA-J AM MED ASSOC, V261, P2236	25	489	490	1	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					145	150		10.1056/NEJM199201163260301	http://dx.doi.org/10.1056/NEJM199201163260301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727544				2022-12-24	WOS:A1992GZ21300001
J	STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H				STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H			GPI-ANCHORED CELL-SURFACE MOLECULES COMPLEXED TO PROTEIN TYROSINE KINASES	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; CYTOPLASMIC DOMAINS; MEMBRANE; CD4; PHOSPHORYLATION; P56LCK	Binding of ligand or antibody to certain cell-surface proteins that are anchored to the membrane by glycophosphatidylinositol (GPI) can cause activation of leukocytes. However, it is not known how these molecules, which lack intracellular domains, can transduce signals. The GPI-linked human molecules CD59, CD55, CD48, CD24, and CD14 as well as the mouse molecules Thy-1 and Ly-6 were found to associate with protein tyrosine kinases, key regulators of cell activation and signal transduction. A protein tyrosine kinase associated with the GPI-linked proteins CD59, CD55, and CD48 in human T cells, and with Thy-1 in mouse T cells was identified as p56lck, a protein tyrosine kinase related to Src. This interaction of GPI-linked molecules with protein tyrosine kinases suggests a potential mechanism of signal transduction in cells.	CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-14220 PRAGUE 4, CZECHOSLOVAKIA; KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Karolinska Institutet	STEFANOVA, I (corresponding author), UNIV VIENNA, VIENNA INT RES COOPERAT CTR SFI, INST IMMUNOL, BRUNNER STR 59, A-1235 VIENNA, AUSTRIA.		Horejsi, Vaclav/G-3113-2014; Stockinger, Hannes/E-5173-2011	Horejsi, Vaclav/0000-0003-4925-0142; Stockinger, Hannes/0000-0001-6404-4430				ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FISCHER GF, 1990, J IMMUNOL, V144, P638; HOREJSI V, 1991, ADV IMMUNOL, V49, P75; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; STEFANOVA I, UNPUB; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2	17	871	887	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1016	1019		10.1126/science.1719635	http://dx.doi.org/10.1126/science.1719635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719635				2022-12-24	WOS:A1991GP88300048
J	SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH				SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH			RNA EDITING IN BRAIN CONTROLS A DETERMINANT OF ION FLOW IN GLUTAMATE-GATED CHANNELS	CELL			English	Article							B MESSENGER-RNA; ACID RECEPTOR CHANNELS; FUNCTIONAL EXPRESSION; NERVOUS-SYSTEM; DNA; CLONING; RAT; MITOCHONDRIA; SUBUNIT; NEURONS	L-glutamate, the principal excitatory transmitter in the brain, gates ion channels mediating fast neurotrans-mission. Subunit components of two related classes of glutamate receptor channels have been characterized by cDNA cloning and shown to carry either an arginine or a glutamine residue in a defined position of their putative channel-forming segment. The arginine residue in this segment profoundly alters, and dominates, the properties of ion flow, as demonstrated for one channel class. We now show that the genomic DNA sequences encoding the particular channel segment of all subunits harbor a glutamine codon (CAG), even though an arginine codon (CGG) is found in mRNAs of three subunits. Multiple genes and alternative exons were excluded as sources for the arginine codon; hence, we propose that transcripts for three subunits are altered by RNA editing. This process apparently edits subunit transcripts of the two glutamate receptor classes with different efficiency and selectivity.			SOMMER, B (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, W-6900 HEIDELBERG, GERMANY.							BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1991, IN PRESS J PHYSL; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; Olney J W, 1986, Adv Exp Med Biol, V203, P631; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; TENG BB, 1990, J BIOL CHEM, V265, P20616; VEWRYVERDOORN TA, 1991, SCIENCE, V252, P1715; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WU JH, 1990, J BIOL CHEM, V265, P12312; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	1187	1224	0	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					11	19		10.1016/0092-8674(91)90568-J	http://dx.doi.org/10.1016/0092-8674(91)90568-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717158				2022-12-24	WOS:A1991GJ32000003
J	VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST				VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST			IDENTIFICATION OF A GENE (FMR-1) CONTAINING A CGG REPEAT COINCIDENT WITH A BREAKPOINT CLUSTER REGION EXHIBITING LENGTH VARIATION IN FRAGILE-X SYNDROME	CELL			English	Article							SOMATIC-CELL HYBRIDS; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; SITE; DNA; CHROMOSOME; SEQUENCES; FRAGMENTS; CONSTRUCTION; METHYLATION	Fragile X syndrome is the most frequent form of inherited mental retardation and is associated with a fragile site at Xq27.3. We identified human YAC clones that span fragile X site-induced translocation breakpoints coincident with the fragile X site. A gene (FMR-1) was identified within a four cosmid contig of YAC DNA that expresses a 4.8 kb message in human brain. Within a 7.4 kb EcoRl genomic fragment, containing FMR-1 exonic sequences distal to a CpG island previously shown to be hypermethylated in fragile X patients, is a fragile X site-induced breakpoint cluster region that exhibits length variation in fragile X chromosomes. This fragment contains a lengthy CGG repeat that is 250 bp distal of the CpG island and maps within a FMR-1 exon. Localization of the brain-expressed FMR-1 gene to this EcoRl fragment suggests the involvement of this gene in the phenotypic expression of the fragile X syndrome.	BAYLOR UNIV,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322; SYLVIUS LAB,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Emory University; Emory University; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	VERKERK, AJMH (corresponding author), ERASMUS UNIV,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS.		Sutcliffe, James S/C-1348-2012; Warren, Stephen T/A-2498-2012; Reiner, Orly/E-9455-2010	Sutcliffe, James S/0000-0001-5200-6007; Reiner, Orly/0000-0001-7560-9599; Verkerk, Annemieke JMH/0000-0002-7523-3656; PIZZUTI, Antonio/0000-0003-3245-1925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KRAWCZUN MS, 1985, HUM GENET, V69, P209, DOI 10.1007/BF00293026; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; LEE CH, 1987, NUCLEIC ACIDS RES, V15, P7639, DOI 10.1093/nar/15.18.7639; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINPONTHIEU A, 1991, EUR J BIOCHEM, V195, P611, DOI 10.1111/j.1432-1033.1991.tb15744.x; NELSON DL, 1991, IN PRESS P NATL ACAD; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; NUSSBAUM RL, 1990, METABOLIC BASIS INHE, P327; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; Sambrook J., 1989, MOL CLONING LAB MANU; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; Smith C.L., 1988, P41; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTHERLAND GR, 1985, FRAGILE SITES HUMAN, P53; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VANOMMEN GJB, 1986, HUMAN GENETIC DISEAS, P113; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1988, AM J MED GENET, V30, P613, DOI 10.1002/ajmg.1320300162; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759; YU S, 1991, IN PRESS FRAGILE X G	40	2812	2895	4	152	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					905	914		10.1016/0092-8674(91)90397-H	http://dx.doi.org/10.1016/0092-8674(91)90397-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710175				2022-12-24	WOS:A1991FP51600020
J	CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD				CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD			ARGININE-MEDIATED RNA RECOGNITION - THE ARGININE FORK	SCIENCE			English	Article								Short peptides that contain the basic region of the HIV-1 Tat protein bind specifically to a bulged region in TAR RNA. A peptide that contained nine arginines (R9) also bound specifically to TAR, and a mutant Tat protein that contained R9 was fully active for transactivation. In contrast, a peptide that contained nine lysines (K9) bound TAR poorly and the corresponding protein gave only marginal activity. By starting with the K9 mutant and replacing lysine residues with arginines, a single arginine was identified that is required for specific binding and transactivation. Ethylation interference experiments suggest that this arginine contacts two adjacent phosphates at the RNA bulge. Model building suggests that the arginine eta-nitrogens and the epsilon-nitrogen can form specific networks of hydrogen bonds with adjacent pairs of phosphates and that these arrangements are likely to occur near RNA loops and bulges and not within double-stranded A-form RNA. Thus, arginine side chains may be commonly used to recognize specific RNA structures.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; MILLIGEN BIOSEARCH, NOVATO, CA 94949 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute				/0000-0002-3320-3969	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CALNAN BJ, UNPUB; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P17; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VLASSOV VV, 1981, EUR J BIOCHEM, V119, P51, DOI 10.1111/j.1432-1033.1981.tb05575.x; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	32	588	594	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1167	1171		10.1126/science.252.5009.1167	http://dx.doi.org/10.1126/science.252.5009.1167			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1709522				2022-12-24	WOS:A1991FN05600049
J	DIFRANCESCO, D; TORTORA, P				DIFRANCESCO, D; TORTORA, P			DIRECT ACTIVATION OF CARDIAC-PACEMAKER CHANNELS BY INTRACELLULAR CYCLIC-AMP	NATURE			English	Article							SINO-ATRIAL NODE; DEPENDENT PROTEIN-KINASE; CURRENT IF; PHOSPHORYLATION; MYOCYTES; MODULATION; NEURONS; HEART; ACETYLCHOLINE; CONDUCTANCE	CYCLIC AMP acts as a second messenger in the modulation of several ion channels 1-9 that are typically controlled by a phosphorylation process 10. In cardiac pacemaker cells, adrenaline and acetylcholine regulate the hyperpolarization-activated current (i(f)), but in opposite ways; this current is involved in the generation and modulation of pacemaker activity 11. These actions are mediated by cAMP and underlie control of spontaneous rate by neurotransmitters 12-17. Whether the cAMP modulation of i(f) is mediated by channel phosphorylation is, however, still unknown. Here we investigate the action of cAMP on i(f) in excised patches of cardiac pacemaker cells and find that cAMP activates i(f) by a mechanism independent of phosphorylation, involving a direct interaction with the channels at their cytoplasmic side. Cyclic AMP activates i(f) by shifting its activation curve to more positive voltages, in agreement with whole-cell results. This is the first evidence of an ion channel whose gating is dually regulated by voltage and direct cAMP binding.			DIFRANCESCO, D (corresponding author), UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,VIA CELORIA 26,I-20133 MILAN,ITALY.		DiFrancesco, Dario/G-8408-2017	DiFrancesco, Dario/0000-0002-7322-1790; Tortora, Paolo/0000-0001-5234-601X				BOBKER DH, 1989, NEURON, V2, P1535, DOI 10.1016/0896-6273(89)90041-X; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; CHANG F, 1990, BIOPHYS J, V57, pA141; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P477, DOI 10.1113/jphysiol.1988.sp017343; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1985, PROG BIOPHYS MOL BIO, V46, P163, DOI 10.1016/0079-6107(85)90008-2; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; JAYNES LW, 1986, NATURE, V317, P61; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TERESAKI WL, 1977, J BIOL CHEM, V252, P1041; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; TSIEN RW, 1974, J GEN PHYSIOL, V64, P293, DOI 10.1085/jgp.64.3.293; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	30	656	669	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					145	147		10.1038/351145a0	http://dx.doi.org/10.1038/351145a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709448				2022-12-24	WOS:A1991FL03500050
J	GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P				GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P			A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS	CELL			English	Article							INHIBITS EXPERIMENTAL METASTASIS; LYMPHOCYTE HOMING RECEPTOR; HUMAN-TUMOR CELLS; MONOCLONAL-ANTIBODIES; HIGH ENDOTHELIUM; MELANOMA-CELLS; SURFACE GLYCOPROTEINS; PLASMINOGEN-ACTIVATOR; EXPRESSION; GENE	Using a monoclonal antibody (MAb1.1ASML) raised against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, cDNA clones have been isolated that encode glycoproteins with partial homology to CD44, a presumed adhesion molecule. In one of the clones, pMeta-1, the epitope marks an additional extracellular domain of 162 amino acids inserted into the rat CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). The new variants are expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; they are not expressed in the nonmetastasizing tumor cell lines nor in most normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cells suffices to establish full metastatic behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology	GUNTHERT, U (corresponding author), UNIV KARLSRUHE,INST GENET,W-7500 KARLSRUHE 1,GERMANY.		Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; CARR I, 1981, Invasion and Metastasis, V1, P34; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1989, CANCER RES, V49, P5323; DENNING SM, 1990, J IMMUNOL, V144, P7; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FRISCH SM, 1990, ONCOGENE, V5, P75; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GARBISA S, 1987, CANCER RES, V47, P1523; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUET S, 1989, J IMMUNOL, V143, P798; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KANSAS GS, 1989, J IMMUNOL, V142, P3050; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MATZKU S, 1984, CANCER IMMUNOL IMMUN, V17, P106, DOI 10.1007/BF00200045; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAZ A, 1989, CANCER RES, V49, P3489; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; REICH R, 1988, CANCER RES, V48, P3307; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WONG YC, 1990, BIOCHEM BIOPH RES CO, V166, P984, DOI 10.1016/0006-291X(90)90908-6; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	65	1626	1716	1	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					13	24		10.1016/0092-8674(91)90403-L	http://dx.doi.org/10.1016/0092-8674(91)90403-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707342	Bronze			2022-12-24	WOS:A1991FF77300004
J	BALLOU, LM; LUTHER, H; THOMAS, G				BALLOU, LM; LUTHER, H; THOMAS, G			MAP2 KINASE AND 70K-S6 KINASE LIE ON DISTINCT SIGNALING PATHWAYS	NATURE			English	Article							RIBOSOMAL-PROTEIN S6; SERINE-THREONINE KINASE; SWISS MOUSE 3T3-CELLS; 3T3 CELLS; INSULIN; ACTIVATION; SERUM; PHOSPHORYLATION; PURIFICATION; IDENTIFICATION	ACTIVATION of protein synthesis is required for quiescent cells to transit the cell cycle1, and seems to be mediated in part by phosphorylation of the 40S ribosomal protein, S6 (ref. 2). A mitogen-activated S6 kinase of relative molecular mass 70,000 (70K) has been isolated from mouse fibroblasts3,4 as well as from avian, rat and rabbit tissues5-9. Comparison of complementary DNA sequences shows that this enzyme10 is distinct from S6 kinase II (92K)11 found in Xenopus eggs12 and fibroblasts13,14. Both kinases are activated by serine/threonine phosphorylation3,15-18, suggesting that at least one serine/threonine kinase links receptor tyrosine kinases with S6 kinases. A candidate for this link is MAP2 kinase, which is rapidly activated by tyrosine/threonine phosphorylation following mitogenic stimulation19-23. Incubation of MAP2 kinase from insulin-treated 3T3-L1 adipocytes with phosphatase-inactivated S6 kinase II from Xenopus leads to partial reactivation and phosphorylation of the enzyme17. These and other findings8 have led to the suggestion that MAP2 kinase also activates the 70K S6 kinase. Here we refute this idea by showing that the two kinases lie on distinct signalling pathways.	FRIEDRICH MIESCHER INST,POSTFACH 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BLENIS J, 1984, P NATL ACAD SCI-BIOL, V81, P6408, DOI 10.1073/pnas.81.20.6408; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOSHI M, 1988, J BIOL CHEM, V263, P5396; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANE HA, IN PRESS METH ENZYM; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, ARCH BIOCHEM BIOPHYS, V262, P307, DOI 10.1016/0003-9861(88)90193-2; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	28	204	204	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					348	350		10.1038/349348a0	http://dx.doi.org/10.1038/349348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702881				2022-12-24	WOS:A1991EU50100059
J	KASAI, H; AUGUSTINE, GJ				KASAI, H; AUGUSTINE, GJ			CYTOSOLIC CA-2+ GRADIENTS TRIGGERING UNIDIRECTIONAL FLUID SECRETION FROM EXOCRINE PANCREAS	NATURE			English	Article									MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Augustine, George James/J-9228-2013	Kasai, Haruo/0000-0003-2327-9027				AMSTERDAM A, 1972, P NATL ACAD SCI USA, V69, P3028, DOI 10.1073/pnas.69.10.3028; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRUZZONE R, 1986, BIOCHEM J, V235, P139, DOI 10.1042/bj2350139; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; HABARA Y, 1980, JPN J PHYSIOL, V30, P561; KANNO T, 1989, BIOMED RES-TOKYO, V10, P475; LAUGIER R, 1980, PFLUG ARCH EUR J PHY, V386, P147, DOI 10.1007/BF00584202; MARTY A, 1984, J PHYSIOL-LONDON, V357, P293, DOI 10.1113/jphysiol.1984.sp015501; MARTY A, 1987, TRENDS NEUROSCI, V10, P373, DOI 10.1016/0166-2236(87)90074-9; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1982, NATURE, V299, P159, DOI 10.1038/299159a0; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MERRITT JE, 1985, BIOCHEM J, V230, P151, DOI 10.1042/bj2300151; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; OSCIPCHUK YV, 1990, EMBO J, V9, P697; PETERSEN OH, 1970, EXPERIENTIA, V26, P1103, DOI 10.1007/BF02112700; PETERSEN OH, 1977, J PHYSIOL-LONDON, V264, P819, DOI 10.1113/jphysiol.1977.sp011696; PETERSEN OH, 1988, ANNU REV PHYSIOL, V50, P65; PETERSEN OH, 1980, ELECTROPHYSIOLOGY GL; RANDRIAMAMPITA C, 1988, PFLUG ARCH EUR J PHY, V411, P53, DOI 10.1007/BF00581646; RAPP PE, 1981, J EXP BIOL, V93, P119; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0	26	364	365	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 20	1990	348	6303					735	738		10.1038/348735a0	http://dx.doi.org/10.1038/348735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	1701852				2022-12-24	WOS:A1990EP04900061
J	HORAK, ID; POPOVIC, M; HORAK, EM; LUCAS, PJ; GRESS, RE; JUNE, CH; BOLEN, JB				HORAK, ID; POPOVIC, M; HORAK, EM; LUCAS, PJ; GRESS, RE; JUNE, CH; BOLEN, JB			NO T-CELL TYROSINE PROTEIN-KINASE SIGNALING OR CALCIUM MOBILIZATION AFTER CD4 ASSOCIATION WITH HIV-1 OR HIV-1 GP120	NATURE			English	Article									NCI,TUMOR VIRUS BIOL LAB,BLDG 41 ROOM D824,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; USN,MED RES INST,BETHESDA,MD 20814; NEW MEXICO STATE UNIV,DEPT VIROL,PRIMATE RES INST,HOLLOMAN AFB,NM 88330	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; New Mexico State University								BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; FOLKS T, 1986, J IMMUNOL, V136, P4049; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; NEUDORF SML, 1990, CELL IMMUNOL, V125, P301, DOI 10.1016/0008-8749(90)90086-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; ULLRICH A, 1990, CELL, V61, P212; VEILETTE A, 1989, J EXP MED, V170, P16710; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	19	92	93	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 6	1990	348	6301					557	560		10.1038/348557a0	http://dx.doi.org/10.1038/348557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL760	1701034				2022-12-24	WOS:A1990EL76000070
J	WANG, JH; YAN, YW; GARRETT, TPJ; LIU, JH; RODGERS, DW; GARLICK, RL; TARR, GE; HUSAIN, Y; REINHERZ, EL; HARRISON, SC				WANG, JH; YAN, YW; GARRETT, TPJ; LIU, JH; RODGERS, DW; GARLICK, RL; TARR, GE; HUSAIN, Y; REINHERZ, EL; HARRISON, SC			ATOMIC-STRUCTURE OF A FRAGMENT OF HUMAN CD4 CONTAINING 2 IMMUNOGLOBULIN-LIKE DOMAINS	NATURE			English	Article									UPJOHN CO, KALAMAZOO, MI 49007 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOL LAB, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Pfizer; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	WANG, JH (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BRUNGER A, XPLOR MANUAL VERSION; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GARLICK RL, 1990, AIDS RES HUM RETROV, V6, P465, DOI 10.1089/aid.1990.6.465; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HARRISON SC, UNPUB; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HUBER R, 1985, MOL REPLACEMENT, P58; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; Richardson JS., 1989, PREDICT PROTEIN STRU; RICHARDSON NE, 1988, P NATL ACAD SCI USA, V85, P6102, DOI 10.1073/pnas.85.16.6102; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SAYRE PH, 1985, EUR J IMMUNOL, V15, P291, DOI 10.1002/eji.1830150315; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; STUART D, 1984, ACTA CRYSTALLOGR A, V40, P713, DOI 10.1107/S0108767384001471; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637	68	563	577	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	1990	348	6300					411	418		10.1038/348411a0	http://dx.doi.org/10.1038/348411a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK697	1701030				2022-12-24	WOS:A1990EK69700052
J	SOMMER, B; KEINANEN, K; VERDOORN, TA; WISDEN, W; BURNASHEV, N; HERB, A; KOHLER, M; TAKAGI, T; SAKMANN, B; SEEBURG, PH				SOMMER, B; KEINANEN, K; VERDOORN, TA; WISDEN, W; BURNASHEV, N; HERB, A; KOHLER, M; TAKAGI, T; SAKMANN, B; SEEBURG, PH			FLIP AND FLOP - A CELL-SPECIFIC FUNCTIONAL SWITCH IN GLUTAMATE-OPERATED CHANNELS OF THE CNS	SCIENCE			English	Article									UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC ENDOCRINOL LAB, W-6900 HEIDELBERG, GERMANY; MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, W-6900 HEIDELBERG 1, GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Wisden, William/A-4071-2011; Keinanen, Kari/E-9122-2010; Burnashev, Nail/G-4056-2013	Wisden, William/0000-0003-4743-0334; 				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; Bayer S.A, 1985, RAT NERVOUS SYSTEM, V1, P335; BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BLAKE JF, 1989, BRIT J PHARMACOL, V97, P71, DOI 10.1111/j.1476-5381.1989.tb11925.x; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KISKIN NI, 1990, EUR J NEUROSCI, V2, P464; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V166, P386, DOI 10.1126/science.166.3903.386; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRIESTLEY T, 1989, BRIT J PHARMACOL, V97, P1315, DOI 10.1111/j.1476-5381.1989.tb12594.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WISDEN W, IN PRESS MOL NEUROBI, V2	43	1061	1087	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 28	1990	249	4976					1580	1585		10.1126/science.1699275	http://dx.doi.org/10.1126/science.1699275			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA463	1699275				2022-12-24	WOS:A1990EA46300042
J	FOX, JD; BRIGGS, M; WARD, PA; TEDDER, RS				FOX, JD; BRIGGS, M; WARD, PA; TEDDER, RS			HUMAN HERPESVIRUS-6 IN SALIVARY-GLANDS	LANCET			English	Article											FOX, JD (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,67 RIDINGHOUSE ST,LONDON W1P 7PN,ENGLAND.			Tedder, Richard/0000-0002-9672-5721	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASANO Y, 1989, LANCET, V2, P1391; BRIGGS M, 1988, LANCET, V1, P1058; BUCHBINDER A, 1988, J VIROL METHODS, V21, P191, DOI 10.1016/0166-0934(88)90065-1; COUMBE A, 1990, Pediatric Pathology, V10, P483; DOWNING RG, 1987, LANCET, V2, P390; EFSTATHIOU S, 1988, LANCET, V1, P63; EIZURU Y, 1989, LANCET, V1, P40; FOX JD, 1990, EPIDEMIOL INFECT, V104, P289, DOI 10.1017/S095026880005946X; GARSON JA, 1987, NUCLEIC ACIDS RES, V15, P4761, DOI 10.1093/nar/15.12.4761; HARNETT GB, 1990, J MED VIROL, V30, P128, DOI 10.1002/jmv.1890300209; JARRETT RF, 1988, LEUKEMIA, V2, P496; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; KNOWLES WA, 1988, LANCET, V2, P912; LAWRENCE GL, 1990, J VIROL, V64, P287, DOI 10.1128/JVI.64.1.287-299.1990; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LONGIN T, 1986, VIRCHOWS ARCH, V409, P777; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; STAMMERS TG, 1988, PRACTITIONER, V232, P541; TAKAHASHI K, 1988, LANCET, V1, P1463; TEDDER RS, 1987, LANCET, V2, P390; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIKAWA T, 1989, PEDIATRICS, V84, P675	23	163	172	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 8	1990	336	8715					590	593		10.1016/0140-6736(90)93392-3	http://dx.doi.org/10.1016/0140-6736(90)93392-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DX401	1697399				2022-12-24	WOS:A1990DX40100004
J	AXELROD, PI; LORBER, B; VONDERHEID, EC				AXELROD, PI; LORBER, B; VONDERHEID, EC			INFECTIONS COMPLICATING MYCOSIS-FUNGOIDES AND SEZARY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL-LYMPHOMAS; RAPID PULMONARY DISSEMINATION; MANAGEMENT; REGRESSION; VARICELLA; SURVIVAL; THERAPY	Objective. - To determine, in patients with mycosis fungoides and Sezary syndrome, the incidence of infections, the importance of nosocomial infections, and the epidemiologic factors associated with cutaneous and visceral infections. Design and Setting. - Retrospective inception cohort study at a university medical center referral clinic. Patients. - Three hundred fifty-six patients with mycosis fungoides or Sezary syndrome. Main Outcome Measures. - Incidence rates for specific infections, and multivariate risk ratios for demographic and clinical factors associated with infection. Results. - Cutaneous bacterial infection was most common (17.0 infections per 100 patient-years), followed by cutaneous herpes simplex virus and herpes zoster virus infection (3.8 infections per 100 patient-years), bacteremia (2.1 infections per 100 patient-years), bacterial pneumonia (1.7 infections per 100 patient-years), and urinary tract infection (1.4 infections per 100 patient-years). Twenty-seven percent of herpesvirus infections disseminated on the skin but none disseminated to internal organs. Pneumonia or bacteremia was present in 88% of patients who died of infection. Only three patients had invasive fungal or protozoal infection. Nosocomial infections accounted for 19% of cutaneous bacterial infections, 59% of bacteremias, 62% of pneumonias, and 88% of infections leading to death. By logistic and Cox regression, the presence of extracutaneous involvement with lymphoma was the most important independent risk factor for recurrent bacterial skin infection (risk ratio [RR], 12; 95% confidence interval [Cl], 1.2 to 120), disseminated herpesvirus infection (RR, 28; 95% Cl, 2.7 to 290), bloodstream infection (RR, 5.5; 95% Cl, 1.7 to 18), and death from infection (RR, 15; 95% Cl, 3.6 to 64). Conclusions. - Community-acquired bacterial skin infections are a common cause of morbidity in patients with mycosis fungoides and Sezary syndrome but are usually treated without hospital admission. Bacteremia and pneumonia, which are usually nosocomial, are the major infectious causes of death. Advanced disease stage, independent of corticosteroids and other therapies, is the most important risk factor for both cutaneous and systemic infections.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,INFECT DIS SECT,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ABEL EA, 1985, DERMATOL CLIN, V3, P647, DOI 10.1016/S0733-8635(18)30863-5; ALTERAS I, 1982, MYCOPATHOLOGIA, V80, P83; BLAYLOCK WK, 1966, CANCER-AM CANCER SOC, V19, P233, DOI 10.1002/1097-0142(196602)19:2<233::AID-CNCR2820190215>3.0.CO;2-3; BLOCK JB, 1963, AM J MED, V34, P228, DOI 10.1016/0002-9343(63)90056-1; BRODER S, 1980, SEMIN ONCOL, V7, P310; BUNN PA, 1979, CANCER TREAT REP, V63, P725; Casazza AR, 1966, JAMA-J AM MED ASSOC, V197, P118; CLENDENNING WE, 1965, CANCER RES, V25, P1844; COHEN SR, 1980, CANCER, V46, P2654, DOI 10.1002/1097-0142(19801215)46:12<2654::AID-CNCR2820461220>3.0.CO;2-1; COX DR, 1972, J R STAT SOC B, V34, P187; CYR DP, 1966, ARCH DERMATOL, V94, P558, DOI 10.1001/archderm.94.5.558; EPSTEIN EH, 1972, MEDICINE, V15, P61; FOSTER GH, 1985, CANCER, V56, P1197, DOI 10.1002/1097-0142(19850901)56:5<1197::AID-CNCR2820560538>3.0.CO;2-H; FUKS ZY, 1973, CANCER, V32, P1385, DOI 10.1002/1097-0142(197312)32:6<1385::AID-CNCR2820320617>3.0.CO;2-#; GAHLENSCHULTE S, 1982, Z HAUTKRANKHEITEN, V57, P1757; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GOLDGEIER MH, 1981, J AM ACAD DERMATOL, V4, P176, DOI 10.1016/S0190-9622(81)70021-5; GREEN DC, 1969, ANN THORAC SURG, V6, P561; HAYNES HA, 1975, NEW ENGL J MED, V293, P598; JACOBS JB, 1969, RADIOLOGY, V93, P525, DOI 10.1148/93.3.525; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; LEVI JA, 1975, MEDICINE, V54, P73, DOI 10.1097/00005792-197501000-00004; LUTZNER M, 1975, ANN INTERN MED, V83, P534, DOI 10.7326/0003-4819-83-4-534; MCGEE DL, 1986, AM J EPIDEMIOL, V124, P702, DOI 10.1093/oxfordjournals.aje.a114444; PINKUS H, 1968, ARCH DERMATOL, V98, P323; POSNER LE, 1981, AM J MED, V71, P210, DOI 10.1016/0002-9343(81)90107-8; RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E; RUBIN DL, 1985, CANCER, V56, P649, DOI 10.1002/1097-0142(19850801)56:3<649::AID-CNCR2820560335>3.0.CO;2-#; SCOTT TFM, 1971, DERMATOLOGY GENERAL, P1878; SEGAL RJ, 1978, ARCH DERMATOL, V114, P1067, DOI 10.1001/archderm.114.7.1067; SLEVIN NJ, 1987, BRIT J DERMATOL, V116, P47, DOI 10.1111/j.1365-2133.1987.tb05790.x; STOKAR LM, 1985, CANCER, V56, P2694, DOI 10.1002/1097-0142(19851201)56:11<2694::AID-CNCR2820561129>3.0.CO;2-B; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; Swartz MN, 1990, PRINCIPLES PRACTICES, V3rd, P796; VANSCOTT EJ, 1971, DERMATOLOGY GENERAL, P556; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P408, DOI 10.1001/archderm.116.4.408; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P1018; YOSHIDA T, 1975, J IMMUNOL, V114, P915; YOSHIKAW.TT, 1974, CHEST, V65, P105, DOI 10.1378/chest.65.1.105	39	150	150	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1354	1358		10.1001/jama.267.10.1354	http://dx.doi.org/10.1001/jama.267.10.1354			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740857				2022-12-24	WOS:A1992HG67800028
J	KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE				KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE			SEROPREVALENCE OF HTLV-I AND HTLV-II AMONG INTRAVENOUS-DRUG-USERS AND PERSONS IN CLINICS FOR SEXUALLY-TRANSMITTED DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-I; UNITED-STATES; INFECTION; TRANSMISSION; ABUSERS; PREVALENCE; AIDS; MEN	Background. The human T-cell lymphotropic virus Type I (HTLV-I) is associated with adult T-cell leukemia and myelopathy, whereas HTLV-II infection has uncertain clinical consequences. We assessed the seroprevalence of these retroviruses among intravenous drug users and among patients seen at clinics for sexually transmitted diseases (STD clinics). Methods. We used serum samples that were collected in eight cities in 1988 and 1989 during surveys of human immunodeficiency virus infection among intravenous drug users entering treatment and persons seen in STD clinics. The serum samples were tested for antibodies to HTLV, and positive specimens were tested further by a synthetic peptide-based enzyme-linked immunosorbent assay to differentiate between HTLV-I and HTLV-II. Results. Among 3217 intravenous drug users in 29 drug-treatment centers, the median seroprevalence rates of HTLV varied widely according to city (range, 0.4 percent in Atlanta to 17.6 percent in Los Angeles). Seroprevalence increased sharply with age, to 32 percent in persons over 44 years of age. HTLV infection was more common among blacks (15.5 percent) and Hispanics (10.7 percent) than among whites (4.1 percent), and it was strongly associated with a history of heroin injection (P less-than-or-equal-to 0.001). Among 5264 patients in 24 STD clinics, the median rates of HTLV infection were much lower (range, 0.1 percent in Atlanta and Newark to 2.0 percent in Los Angeles). Again, this infection was more common among intravenous drug users (7.6 percent) than among non-drug users (0.7 percent). Eighty-four percent of the seropositive samples from drug-treatment centers and 69 percent of those from STD clinics were due to HTLV-II infection (P = 0.03). Conclusions. HTLV infection is common among intravenous drug users and is primarily caused by HTLV-II. Among patients seen at STD clinics, HTLV is strongly associated with intravenous drug use, but the retrovirus is also prevalent among non-drug users.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV STD HIV PREVENT,ATLANTA,GA 30333; UNITED BIOMED INC,LAKE SUCCESS,NY	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,RETROVIRUS DIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,MS-A32,ATLANTA,GA 30333, USA.							BIGGAR RJ, 1991, J INFECT DIS, V163, P57, DOI 10.1093/infdis/163.1.57; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; CANTOR KP, 1991, J ACQ IMMUN DEF SYND, V4, P460; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P646, DOI 10.1128/JCM.28.4.646-650.1990; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P1491; HASELTINE WA, 1985, CURR TOP MICROBIOL, V115, P177; HJELLE B, 1990, BLOOD, V76, P450; KHABBAZ RF, 1990, J INFECT DIS, V162, P241, DOI 10.1093/infdis/162.1.241; KHABBAZ RF, 1991, J INFECT DIS, V163, P252, DOI 10.1093/infdis/163.2.252; KHABBAZ RF, 1990, JAMA-J AM MED ASSOC, V263, P60, DOI 10.1001/jama.263.1.60; KWOK S, 1990, AIDS RES HUM RETROV, V6, P561, DOI 10.1089/aid.1990.6.561; LAIRMORE MD, 1989, BLOOD, V74, P2596; LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1991, LANCET, V337, P1435, DOI 10.1016/0140-6736(91)93126-T; MANNS A, 1988, NEW ENGL J MED, V319, P516, DOI 10.1056/NEJM198808253190811; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; NAKANO S, 1986, J INFECTION, V12, P205, DOI 10.1016/S0163-4453(86)94086-7; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; WEISS SH, 1987, 3RD P INT C AIDS WAS, P211; 1990, MMWR, V39, P921; 1990, NATIONAL HIV SEROPRE; 1988, MMWR, V37, P736; 1990, MMWR, V39, P915; 1988, MMWR, V37, P745; 1989, MMWR S7, V38, P1	30	167	167	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					375	380		10.1056/NEJM199202063260604	http://dx.doi.org/10.1056/NEJM199202063260604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729620	Bronze			2022-12-24	WOS:A1992HC38600004
J	OCONNOR, M				OCONNOR, M			MEDICINE IN EUROPE .7. EUROPE AND NUTRITION - PROSPECTS FOR PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article											OCONNOR, M (corresponding author), CORONARY PREVENT GRP,102 GLOUCESTER PL,LONDON W1H 3DA,ENGLAND.							GARROW JS, 1991, OBESITY OVERWEIGHT; JAMES WPT, 1988, HLTH NUTRITION, P9; LANG T, 1990, FINAL REPORT STUDY D; OCONNOR M, 1992, HLTH ED J, V50; RICHARDS T, 1991, BRIT MED J, V303, P1319, DOI 10.1136/bmj.303.6813.1319; 1991, DIETARY REFERENCE VA; 1991, EUROPEAN CITIZEN SEP; 1991, DEV FUTURE COMMON AG; 1991, FOOD ADVISORY COMMIT; 1991, CMND1523; 1990, NUTRITION BANDING SC	11	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					178	180		10.1136/bmj.304.6820.178	http://dx.doi.org/10.1136/bmj.304.6820.178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA979	1737167	Bronze, Green Published			2022-12-24	WOS:A1992HA97900030
J	BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B				BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B			REASONS THAT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA DO NOT UNDERGO ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; 1ST COMPLETE REMISSION; CYTOSINE-ARABINOSIDE; INDUCTION THERAPY; CHEMOTHERAPY; DAUNORUBICIN; ADULTS; TRIAL	Background. Numerous reports suggest that allogeneic bone marrow transplantation prolongs the survival of adult patients with acute myelogenous leukemia (AML) in first remission. However, it is unclear how many such patients actually undergo this procedure. Methods. We reviewed the case records of 350 consecutive adult patients with AML treated with chemotherapy at a single institution from 1979 (when the policy of offering allogeneic transplantation to all such patients in first remission was introduced) through 1990. The criteria for exclusion before transplantation included age greater than 40 and, beginning in 1984, a diagnosis of acute promyelocytic leukemia. Results. One hundred forty-two patients (41 percent of the study population) were 40 years of age or younger. HLA testing was performed for 120 of these patients (85 percent). Sixty-seven patients (47 percent) had an HLA-identical sibling as a potential donor. One hundred three patients (73 percent) entered remission during treatment according to one of five chemotherapy protocols. Of the 52 patients who both entered remission and had an HLA match, 30 underwent transplantation while they were in first remission. These 30 patients constituted 21 percent of all study patients 40 years old or younger, 29 percent of all patients 40 or under who entered remission, 45 percent of all patients with an HLA match, 58 percent of all patients who had both a remission and a match, and 9 percent of all patients treated according to a protocol. Among patients with a match who did not undergo transplantation, those with primary refractory disease were the largest subgroup. Conclusions. These findings suggest that allogeneic bone marrow transplantation is performed in less than 60 percent of adult patients with AML who are potentially eligible for the procedure.	MEM SLOAN KETTERING CANC CTR, BONE MARROW TRANSPLANT SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	BERMAN, E (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							APPELBAUM FR, 1988, BLOOD, V72, P179; ARLIN Z, 1990, LEUKEMIA, V4, P177; BERMAN E, 1991, BLOOD, V77, P1666; BISHOP JF, 1990, BLOOD, V75, P27; BRINCKER H, 1985, CANCER TREAT REP, V69, P5; CASSILETH PA, 1984, BLOOD, V63, P843; CHAMPLIN RE, 1985, ANN INTERN MED, V102, P285, DOI 10.7326/0003-4819-102-3-285; CHAN KW, 1982, TRANSPLANTATION, V33, P613, DOI 10.1097/00007890-198206000-00009; CLARKSON B, 1990, UCLA SYM BI, V108, P231; CUNNINGHAM I, 1989, BLOOD, V73, P1116; FORMAN SJ, 1987, TRANSPLANTATION, V43, P650, DOI 10.1097/00007890-198705000-00009; GELLER RB, 1989, BLOOD, V73, P2209; GRATWOHL A, 1988, LANCET, V1, P1379; HERMANS J, 1989, EUR J CANCER CLIN ON, V25, P545, DOI 10.1016/0277-5379(89)90268-X; KANTARJIAN HM, 1987, CANCER-AM CANCER SOC, V59, P1258, DOI 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MCGLAVE PB, 1988, BLOOD, V72, P1512; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PREISLER HD, 1979, BLOOD, V53, P455; RAI KR, 1981, BLOOD, V58, P1203; STONE RM, 1988, BLOOD, V71, P690; WEINSTEIN HJ, 1980, NEW ENGL J MED, V303, P473, DOI 10.1056/NEJM198008283030901; YATES J, 1982, BLOOD, V60, P454; YOUNG JW, 1990, BLOOD S, V76, pA575; ZANDER AR, 1988, J CLIN ONCOL, V6, P1548, DOI 10.1200/JCO.1988.6.10.1548	25	54	54	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					156	160		10.1056/NEJM199201163260303	http://dx.doi.org/10.1056/NEJM199201163260303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727546				2022-12-24	WOS:A1992GZ21300003
J	TURNBULL, PJ; STIMSON, GV; DOLAN, KA				TURNBULL, PJ; STIMSON, GV; DOLAN, KA			PREVALENCE OF HIV-INFECTION AMONG EX-PRISONERS IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											TURNBULL, PJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CTR RES DRUGS & HLTH BEHAV,LONDON SW6 1RQ,ENGLAND.		Dolan, Kate/B-1901-2008; Dolan, Kate/G-7859-2017	Dolan, Kate/0000-0002-9848-807X				FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MADEN A, 1991, BRIT MED J, V302, P880, DOI 10.1136/bmj.302.6781.880; MADEN A, 1991, BRIT MED J, V301, P1133; TURNBULL PJ, 1991, PRISONS HIV AIDS RIS	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					90	91		10.1136/bmj.304.6819.90	http://dx.doi.org/10.1136/bmj.304.6819.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737147	Bronze, Green Published			2022-12-24	WOS:A1992HA17100023
J	SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL				SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL			MULTIPOTENT NEURAL CELL-LINES CAN ENGRAFT AND PARTICIPATE IN DEVELOPMENT OF MOUSE CEREBELLUM	CELL			English	Article							CHICKEN OPTIC TECTUM; CORTICAL-NEURONS; PRECURSOR CELLS; MONOCLONAL-ANTIBODIES; MIGRATION PATTERNS; COMMON PROGENITOR; NERVOUS-SYSTEM; C-MYC; DIFFERENTIATION; CORTEX	Multipotent neural cell lines were generated via retrovirus-mediated v-myc transfer into murine cerebellar progenitor cells. When transplanted back into the cerebellum of newborn mice, these cells integrated into the cerebellum in a nontumorigenic, cytoarchitecturally appropriate manner. Cells from the same clonal line differentiated into neurons or glia in a manner appropriate to their site of engraftment. Engrafted cells, identified by lacZ expression and PCR-mediated detection of a unique sequence arrangement, could be identified in animals up to 22 months postengraftment. Electron microscopic and immunohistochemical analysis demonstrated that some engrafted cells were similar to host neurons and glia. Some transplant-derived neurons received appropriate synapses and formed normal intercellular contacts. These data indicate that generating immortalized cell lines for repair of, or transport of genes into, the CNS may be feasible. Such lines may also provide a model for commitment and differentiation of cerebellar progenitor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)			Deitcher, David/K-6538-2019	Deitcher, David/0000-0002-8512-8868	NINDS NIH HHS [5-K08-NS01403-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001403] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman J., 1982, CEREBELLUM NEW VISTA, V47, P8; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARRY DI, 1987, P NATL ACAD SCI USA, V84, P8712, DOI 10.1073/pnas.84.23.8712; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUZSAKI G, 1988, P NATL ACAD SCI USA, V85, P9327, DOI 10.1073/pnas.85.23.9327; CEPKO C, 1988, NEURON, V1, P345, DOI 10.1016/0896-6273(88)90184-5; CEPKO C, 1989, NEUROMETHODS, V16, P177; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; Eccles JC, 1967, CEREBELLUM NEURONAL; EVRARD C, 1990, P NATL ACAD SCI USA, V87, P3062, DOI 10.1073/pnas.87.8.3062; FIELDSBERRY SC, 1992, IN PRESS P NATL ACAD; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FREUND TF, 1985, J NEUROSCI, V5, P603; GAGE FH, 1983, SCIENCE, V221, P966, DOI 10.1126/science.6879196; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GELLER HM, 1988, J CELL BIOL, V107, P1977, DOI 10.1083/jcb.107.5.1977; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GRAVEL C, 1987, J NEUROSCI METH, V21, P145, DOI 10.1016/0165-0270(87)90112-9; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUND RD, 1987, ANN NY ACAD SCI, V495, P227, DOI 10.1111/j.1749-6632.1987.tb23678.x; Maniatis T., 1982, MOL CLONING; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCHMAN H, 1988, GENETICS, V120, P621; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; Palay S. L., 1974, CEREBELLAR CORTEX CY; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; Peters A, 1991, FINE STRUCTURE NERVO; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Schaper A, 1897, SCIENCE, V5, P430; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; SOTELO C, 1986, P NATL ACAD SCI USA, V83, P1135, DOI 10.1073/pnas.83.4.1135; SOTELO C, 1987, NATURE, V327, P421, DOI 10.1038/327421a0; STANFIELD BB, 1985, NATURE, V313, P135, DOI 10.1038/313135a0; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913	68	735	784	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					33	51		10.1016/0092-8674(92)90204-P	http://dx.doi.org/10.1016/0092-8674(92)90204-P			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732063				2022-12-24	WOS:A1992GZ58300007
J	MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR				MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR			SCHOOL ATTENDANCE AS A FACTOR IN DELIBERATE SELF POISONING BY 12-15 YEAR OLD ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article											MCGIBBEN, L (corresponding author), WALSGRAVE GEN HOSP,DEPT PSYCHIAT,COVENTRY CV2 2DX,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				Christoffel K K, 1988, Pediatr Emerg Care, V4, P32, DOI 10.1097/00006565-198803000-00011; Durkheim E., 1952, SUICIDE; MASTERTON G, 1991, BRIT J PSYCHIAT, V158, P155, DOI 10.1192/bjp.158.2.155; PAPATHOMOPOULOS E, 1989, CAN J PSYCHIAT, V34, P205, DOI 10.1177/070674378903400309	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					28	28		10.1136/bmj.304.6818.28	http://dx.doi.org/10.1136/bmj.304.6818.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734990	Bronze, Green Published			2022-12-24	WOS:A1992GY90900031
J	BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ				BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ			MHC CLASS-I SURFACE EXPRESSION IN EMBRYO-DERIVED CELL-LINES INDUCIBLE WITH PEPTIDE OR INTERFERON	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CARCINOMA-CELLS; GENE-EXPRESSION; MOUSE; ANTIGEN; BETA-2-MICROGLOBULIN; TRANSCRIPTS; MOLECULES; PLACENTA; VECTOR	IT has long been recognized that the absence of expression of products of the major histocompatibility complex (MHC) during early development might allow the fetus to escape recognition by maternal lymphocytes. In addition to the MHC class I heavy chain and beta-2-microglobulin, antigenic peptide is an essential structural component of the class I molecule 1-5. Indeed, there is evidence that MHC-linked genes encoding peptide transporter molecules 6-10 and possibly components of a proteolytic complex 11,12 are necessary for MHC class I assembly and stability at the cell surface. Here we demonstrate that embryonic cells in general show a defect in MHC class I assembly. Surface expression was rescued in the presence of an appropriate antigenic peptide, or by treatment with interferon. Consistent with this, HAM1 (ref. 9) messenger RNA was not constitutively expressed, but was inducible by interferon, and during differentiation in vitro. Thus, tolerance of the fetal allograft may in part be controlled at the level of peptide-dependent MHC class I assembly.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University	BIKOFF, EK (corresponding author), CUNY MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY 10029, USA.		Ribaudo, Randall/AAH-7094-2021; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAFFE L, IN PRESS J IMMUN; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL A, 1984, NATURE, V310, P415, DOI 10.1038/310415a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SILVERMAN T, 1988, J IMMUNOL, V140, P4378; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	30	57	60	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					235	238		10.1038/354235a0	http://dx.doi.org/10.1038/354235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720508				2022-12-24	WOS:A1991GQ94800051
J	HEITMAN, J; MOVVA, NR; HALL, MN				HEITMAN, J; MOVVA, NR; HALL, MN			TARGETS FOR CELL-CYCLE ARREST BY THE IMMUNOSUPPRESSANT RAPAMYCIN IN YEAST	SCIENCE			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; CYCLOSPORIN-A; SACCHAROMYCES-CEREVISIAE; MACROLIDES FK-506; FK506; CYCLOPHILIN; ACTIVATION	FK506 and rapamycin are related immunosuppressive compounds that block helper T cell activation by interfering with signal transduction. In vitro, both drugs bind and inhibit the FK506-binding protein (FKBP) proline rotamase. Saccharomyces cerevisiae cells treated with rapamycin irreversibly arrested in the G1 phase of the cell cycle. An FKBP-rapamycin complex is concluded to be the toxic agent because (i) strains that lack FKBP proline rotamase, encoded by FPR1, were viable and fully resistant to rapamycin and (ii) FK506 antagonized rapamycin toxicity in vivo. Mutations that conferred rapamycin resistance altered conserved residues in FKBP that are critical for drug binding. Two genes other than FPR1, named TOR1 and TOR2, that participate in rapamycin toxicity were identified. Nonallelic noncomplementation between FPR1, TORI, and TOR2 alleles suggests that the products of these genes may interact as subunits of a protein complex. Such a complex may mediate nuclear entry of signals required for progression through the cell cycle.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	University of Basel; Novartis; Sandoz			Heitman, Joseph/ABC-6006-2021	Hall, Michael N/0000-0002-2998-0757				ATKINSON KD, 1985, GENETICS, V111, P1; ATKINSON KD, 1988, PLANT MEMBRANES STRU, P65; BAKER H, 1978, J ANTIBIOT, V31, P539, DOI 10.7164/antibiotics.31.539; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BIERER BE, 1990, SCIENCE, V250, P1948; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CIANCIOTTO NP, 1989, INFECT IMMUN, V57, P1255, DOI 10.1128/IAI.57.4.1255-1262.1989; COLLIER J, 1990, CURR OPIN IMMUNOL, V2, P854; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ENGLEBERG NC, 1989, INFECT IMMUN, V57, P1263, DOI 10.1128/IAI.57.4.1263-1270.1989; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, UNPUB; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOMYK T, 1988, GENETICS, V119, P105; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUSCH M, 1986, GENETICS, V113, P621; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; ROSE MD, 1988, LABORATORY COURSE MA; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEARNS T, 1988, GENETICS, V119, P249; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STEINMANN B, 1991, J BIOL CHEM, V266, P3630; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1990, IMMUNOL TODAY, V11, P35; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE SGD, 1991, NATURE, V351, P248; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	47	1450	1516	10	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					905	909		10.1126/science.1715094	http://dx.doi.org/10.1126/science.1715094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715094				2022-12-24	WOS:A1991GC15200046
J	SHELDON, TA; SIMPSON, J				SHELDON, TA; SIMPSON, J			APPRAISAL OF A NEW SCHEME FOR PRENATAL SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; DECISION-ANALYSIS; PREGNANCY	Objective - To appraise a new method of prenatal screening for Down's syndrome based on maternal serum concentrations of alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin combined with maternal age - the "triple test". Design - Examination of the cost effectiveness of the triple test relative to screening only by maternal age over a range of population detection rates. Setting - Leicestershire Health Authority. Main outcome measures - Costs per affected fetus detected. Results - The triple test is more cost effective than screening only by maternal age for risk cut off points for amniocentesis, resulting in a detection rate over 45%. The most efficient detection rate is around 60-65%, for which the cost per case detected is around L29 000, though screening with higher detection rates is still likely to be cost beneficial. Conclusions - Prenatal screening for Down's syndrome based on the triple test should replace screening based only on maternal age. Individual women's preferences should be elicited by the use of structured decision analysis in order to maximise utility and so increase the benefits of the screening programme.	LEICESTERSHIRE DIST HLTH AUTHOR,LEICESTER LE1 6TY,ENGLAND		SHELDON, TA (corresponding author), UNIV LEEDS,DEPT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				CALLAN J, 1988, 42 CTR HLTH EC DISC; CARTMILL RS, 1991, IN PRESS J PERINATAL; DOUBILET P, 1985, MED CARE, V23, P648, DOI 10.1097/00005650-198505000-00021; DOWIE J, 1987, PROFESSIONAL JUDGMEN, P9; Drummond Michael, 1988, Br Med J (Clin Res Ed), V296, P566; FERGUSONSMITH M, 1987, SCREENING FETAL GENE; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HAGARD S, 1976, BRIT MED J, V1, P753, DOI 10.1136/bmj.1.6012.753; HENDERSON JB, 1987, SCREENING FETAL GENE; MCGROTHER CW, 1990, J MENT DEFIC RES, V34, P49; McKeown Thomas, 1968, SCREENING MED CARE R; Pauker S P, 1987, Birth Defects Orig Artic Ser, V23, P151; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; RICHARDS M, 1987, SCREENING FETAL GENE; SADOVNICK AD, 1981, AM J MED GENET, V10, P367, DOI 10.1002/ajmg.1320100409; SCHWARTZ WB, 1979, NEW ENGL J MED, V300, P556, DOI 10.1056/NEJM197903083001011; THORNTON JG, 1990, PRENATAL DIAGNOSIS P; Torrance GW, 1987, METHODS EC EVALUATIO; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1987, BAILLIERE CLIN OB GY, V1, P649, DOI 10.1016/S0950-3552(87)80010-X; Weinstein MC, 1980, CLIN DECISION ANAL; 1987, SCREENING FETAL GENE	22	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1133	1136		10.1136/bmj.302.6785.1133	http://dx.doi.org/10.1136/bmj.302.6785.1133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1710520	Green Published, Bronze			2022-12-24	WOS:A1991FL43900023
J	PAGE, CP				PAGE, CP			ONE EXPLANATION OF THE ASTHMA PARADOX - INHIBITION OF NATURAL ANTIINFLAMMATORY MECHANISM BY BETA-2-AGONISTS	LANCET			English	Note							MAST-CELL; BRONCHIAL RESPONSIVENESS; TRACHEAL EPITHELIUM; HEPARIN; DRUGS; TERBUTALINE; PROVOCATION; HISTAMINE; PROTEIN; AIRWAY	Our understanding of the mechanisms contributing to the pathogenesis of bronchial asthma has increased substantially over the past decade. This has been accompanied by the introduction of a range of new drugs for the treatment of this disorder, and the usage of anti-asthma drugs is increasing. Despite these changes and an increased awareness of the disease, asthma remains the only "preventable" disease where the morbidity and mortality are still increasing in most parts of the world. This "asthma paradox" requires explanation, and this article is an attempt to provide a plausible scientific one. The hypothesis expresses concern that a long recognised, but little publicised, pharmacological property of the drug class most widely prescribed for the treatment of asthma, the beta-2-adrenoceptor agonists-namely, the inhibition of mast-cell degranulation-may be contributing to the world wide increase in morbidity and mortality from asthma via the inhibition of a natural anti-inflammatory mechanism.			PAGE, CP (corresponding author), UNIV LONDON,KINGS COLL,DEPT PHARMACOL,LONDON SW3 6LX,ENGLAND.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BLOCK PE, 1980, BIOCHEM J, V191, P769; BOWLER S, 1988, HEPARIN RELATED POLY; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BUTTERFIELD JH, 1990, LAB INVEST, V62, P72; CARR J, 1979, THROMB RES, V16, P507, DOI 10.1016/0049-3848(79)90097-5; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39, DOI 10.1152/ajplung.1989.257.2.L39; CHIHARA J, 1988, AM REV RESPIR DIS, V137, pA421; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COHEN S, 1967, J IMMUNOL, V98, P351; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CRANE J, 1989, LANCET, V1, P917; DAHL S, 1962, Z Tuberk Erkr Thoraxorg, V118, P255; DOLOWITZ DA, 1965, ANN ALLERGY, V23, P309; DOUTREMEPUICH C, 1987, J LEUKOCYTE BIOL, V42, P628, DOI 10.1002/jlb.42.6.628; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; FRIERI M, 1983, J IMMUNOL, V131, P1942; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P78; GRAHAM MF, 1987, GASTROENTEROLOGY, V93, P801, DOI 10.1016/0016-5085(87)90443-4; HALES CA, 1983, AM REV RESPIR DIS, V128, P747; HANSS J G, 1989, American Review of Respiratory Disease, V139, pA134; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JEFFREY PK, 1990, AM REV RESPIR DIS, pA500; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1987, AM REV RESPIR DIS, V140, P917; LASSER EC, 1987, ALLERGY, V42, P549, DOI 10.1111/j.1398-9995.1987.tb00381.x; LASSER EC, 1987, ALLERGY, V42, P619, DOI 10.1111/j.1398-9995.1987.tb00393.x; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LUNGREN R, 1988, EUR RESPIR J, V1, P883; MATZNER Y, 1984, THROMB HAEMOSTASIS, V52, P134; MCCLAIN E J, 1982, Journal of Allergy and Clinical Immunology, V69, P93; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; RASHAD S, 1989, LANCET, V2, P519; ROCHE WR, 1989, LANCET, V1, P520; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; STOKES TC, 1981, BR J DIS CHEST, V75, P11; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; Van de Carr FR, 1928, J IMMUNOL, V15, P13; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YAMASHITA Y, 1990, American Review of Respiratory Disease, V141, pA912; 1985, J ALLERGY CLIN IMMUN, V75, P443	48	95	99	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					717	720		10.1016/0140-6736(91)90289-2	http://dx.doi.org/10.1016/0140-6736(91)90289-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706045				2022-12-24	WOS:A1991FD36700019
J	MORRIS, CE; HORN, R				MORRIS, CE; HORN, R			FAILURE TO ELICIT NEURONAL MACROSCOPIC MECHANOSENSITIVE CURRENTS ANTICIPATED BY SINGLE-CHANNEL STUDIES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; MEMBRANE; CELLS; CALCIUM; VOLUME; STRESS; YEAST	Mechanosensitive channels can be observed in most cell types during single-channel recording and have been implicated in many cellular processes. Potassium-selective single-channel currents, both stretch-activated and stretch-inactivated, can be observed in growth cones and cell bodies of Lymnaea stagnalis neurons. Equivalent macroscopic mechanosensitive currents could not, however, be elicited while applying various mechanical stimuli. This discrepancy suggests that single-channel mechanosensitivity is an artifact of patch recording.	UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA; ROCHE INST MOLEC BIOL,DEPT NEUROSCI,NUTLEY,NJ 07110	University of Ottawa				Morris, Catherine/0000-0002-7401-6545				BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BELARDETTI F, 1987, NATURE, V325, P153, DOI 10.1038/325153a0; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; EDWARDS C, 1981, NEUROSCIENCE, V6, P1455, DOI 10.1016/0306-4522(81)90200-1; ERXLEBEN C, 1989, J GEN PHYSIOL, V94, P1071, DOI 10.1085/jgp.94.6.1071; FALKE LC, 1989, P NATL ACAD SCI USA, V86, P3919, DOI 10.1073/pnas.86.10.3919; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; KIMITSUKI T, 1990, AM J PHYSIOL, V258, pH247, DOI 10.1152/ajpheart.1990.258.1.H247; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MEDINA IR, 1988, PROC R SOC SER B-BIO, V235, P95, DOI 10.1098/rspb.1988.0064; MILLS LR, 1988, NEUR SOC ABSTR, V14, P583; MILTON RL, 1990, PFLUG ARCH EUR J PHY, V416, P758, DOI 10.1007/BF00370626; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1990, THESIS U OTTAWA; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SUGRDSON WJ, 1989, J NEUROSCI, V9, P2801; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; VANDORPE D, UNPUB; [No title captured]	26	157	161	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1246	1249		10.1126/science.1706535	http://dx.doi.org/10.1126/science.1706535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1706535				2022-12-24	WOS:A1991FA69100046
J	LOWE, JB; STOOLMAN, LM; NAIR, RP; LARSEN, RD; BERHEND, TL; MARKS, RM				LOWE, JB; STOOLMAN, LM; NAIR, RP; LARSEN, RD; BERHEND, TL; MARKS, RM			ELAM-1-DEPENDENT CELL-ADHESION TO VASCULAR ENDOTHELIUM DETERMINED BY A TRANSFECTED HUMAN FUCOSYL-TRANSFERASE CDNA	CELL			English	Article									UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	LOWE, JB (corresponding author), UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA049256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038482] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA49256] Funding Source: Medline; NIDDK NIH HHS [DK38482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; Battey, 1986, BASIC METHODS MOL BI; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIA D, 1985, CANCER RES, V45, P435; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUNSTAN RA, 1986, BRIT J HAEMATOL, V62, P301, DOI 10.1111/j.1365-2141.1986.tb02933.x; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FOX N, 1983, CANCER RES, V43, P669; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALTON J, 1985, ANTIBODIES PROTECTIV, P117; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, TRANSPLANTATION, V48, P727, DOI 10.1097/00007890-198911000-00001; KANNAGI R, 1986, CANCER RES, V46, P2619; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PARHAM P, 1979, J IMMUNOL, V123, P342; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; VANKEUREN ML, 1986, AM J HUM GENET, V38, P793; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059; YASUYUKI I, 1990, IN PRESS J CELL BIOL; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	70	754	800	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	1990	63	3					475	484		10.1016/0092-8674(90)90444-J	http://dx.doi.org/10.1016/0092-8674(90)90444-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699667	Green Published			2022-12-24	WOS:A1990EG68700006
J	GREEN, JBA; SMITH, JC				GREEN, JBA; SMITH, JC			GRADED CHANGES IN DOSE OF A XENOPUS ACTIVIN-A HOMOLOG ELICIT STEPWISE TRANSITIONS IN EMBRYONIC-CELL FATE	NATURE			English	Article											GREEN, JBA (corresponding author), NATL INST MED RES,EMBRYOGENESIS LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620; Smith, Jim/0000-0003-2413-9392				COOKE J, 1983, J EMBRYOL EXP MORPH, V76, P95; COOKE J, 1989, DEVELOPMENT, V105, P549; DIXON JE, 1989, DEVELOPMENT, V106, P749; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Ruiz i Altaba A, 1989, Nature, V341, P33; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; Smith JC, 1989, CURR OPIN CELL BIOL, V1, P1061, DOI 10.1016/S0955-0674(89)80051-1; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1989, DEVELOPMENT S, P149; SYMES K, 1988, DEVELOPMENT, V104, P609; VANDENEIJNDENVA.AJ, 1990, NATURE, V345, P732; WOLPERT L, 1989, DEVELOPMENT S, P3	23	452	467	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					391	394		10.1038/347391a0	http://dx.doi.org/10.1038/347391a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699129				2022-12-24	WOS:A1990EA56400066
J	PERARNAU, B; SIEGRIST, CA; GILLET, A; VINCENT, C; KIMURA, S; LEMONNIER, FA				PERARNAU, B; SIEGRIST, CA; GILLET, A; VINCENT, C; KIMURA, S; LEMONNIER, FA			BETA-2-MICROGLOBULIN RESTRICTION OF ANTIGEN PRESENTATION	NATURE			English	Article									MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; INSERM,U80,F-69374 LYONS 8,FRANCE	Memorial Sloan Kettering Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	PERARNAU, B (corresponding author), CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,CASE 906,F-13288 MARSEILLE 9,FRANCE.							ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; FAHLMANN M, 1985, P NATL ACAD SCI USA, V68, P8634; FELLOUS M, 1977, IMMUNOGENETICS, V5, P423, DOI 10.1007/BF01570501; FIERZ W, 1982, IMMUNOGENETICS, V16, P593, DOI 10.1007/BF00372028; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASSER DL, 1985, IMMUNOGENETICS, V22, P413, DOI 10.1007/BF00430925; GERMAIN RN, 1987, NATURE, V329, P512; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; KURTZ ME, 1987, J IMMUNOL, V138, P87; MARGULIES DH, 1983, P NATL ACAD SCI-BIOL, V80, P2328, DOI 10.1073/pnas.80.8.2328; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; PERARNAU BM, 1988, J IMMUNOL, V141, P1383; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; RAMAMURTHY V, 1982, PRAMANA, V19, P435, DOI 10.1007/BF02847377; RAMMENSEE HG, 1986, NATURE, V319, P268; ROBINSON PJ, 1984, IMMUNOGENETICS, V20, P655, DOI 10.1007/BF00430324; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; YAMADA A, 1985, J EXP MED, V162, P1720, DOI 10.1084/jem.162.5.1720	25	66	68	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 23	1990	346	6286					751	754		10.1038/346751a0	http://dx.doi.org/10.1038/346751a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV652	1697039				2022-12-24	WOS:A1990DV65200064
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LICENSING OF G-CSF AND GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-24	WOS:A1991FJ95500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NUTRITION LABELING AND EDUCATION ACT OF 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P2995	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-24	WOS:A1991FJ95500007
